
<html lang="en"     class="pb-page"  data-request-id="6eb884d4-b037-44dc-848d-3b0aeb32be16"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b00196;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-16;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthetic Approaches to the New Drugs Approved During 2017" /></meta><meta name="dc.Creator" content="Andrew&#xA;C.  Flick" /></meta><meta name="dc.Creator" content="Carolyn A.  Leverett" /></meta><meta name="dc.Creator" content="Hong X.  Ding" /></meta><meta name="dc.Creator" content="Emma  McInturff" /></meta><meta name="dc.Creator" content="Sarah J.  Fink" /></meta><meta name="dc.Creator" content="Christopher J.  Helal" /></meta><meta name="dc.Creator" content="Christopher J.  O’Donnell" /></meta><meta name="dc.Description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while ..." /></meta><meta name="Description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 2, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00196" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00196" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00196" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00196" /></link>
        
    
    

<title>Synthetic Approaches to the New Drugs Approved During 2017 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00196" /></meta><meta property="og:title" content="Synthetic Approaches to the New Drugs Approved During 2017" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0065.jpeg" /></meta><meta property="og:description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 31 new chemical entities approved for the first time globally in 2017." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00196"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00196">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00196&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00196&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00196&amp;href=/doi/10.1021/acs.jmedchem.9b00196" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 7340-7382</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00175" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00030" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthetic Approaches to the New Drugs Approved During 2017</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Andrew C. Flick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew C. Flick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Seattle Genetics, Inc. 21823 30th Drive SE, Bothell, Washington 98021, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew%0AC.++Flick">Andrew C. Flick</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carolyn A. Leverett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carolyn A. Leverett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carolyn+A.++Leverett">Carolyn A. Leverett</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong X. Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong X. Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacodia (Beijing) Co., Ltd., Beijing, 100085, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong+X.++Ding">Hong X. Ding</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emma McInturff</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emma McInturff</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emma++McInturff">Emma McInturff</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah J. Fink</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah J. Fink</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BioDuro, 11011 Torreyana Road, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+J.++Fink">Sarah J. Fink</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher J. Helal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. Helal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Helal">Christopher J. Helal</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9091-2091" title="Orcid link">http://orcid.org/0000-0002-9091-2091</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Christopher J. O’Donnell</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. O’Donnell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (860)405-4976. E-mail: <a href="/cdn-cgi/l/email-protection#5a39322833292e352a323f28743074353e3534343f36361a2a3c33203f2874393537"><span class="__cf_email__" data-cfemail="600308120913140f100805124e0a4e0f040f0e0e050c0c201006091a05124e030f0d">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++O%E2%80%99Donnell">Christopher J. O’Donnell</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link">http://orcid.org/0000-0003-1004-7139</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00196&amp;href=/doi/10.1021%2Facs.jmedchem.9b00196" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 7340–7382</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 2, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 January 2019</li><li><span class="item_label"><b>Published</b> online</span>2 April 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 August 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00196" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00196</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7340%26pageCount%3D43%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndrew%250AC.%2BFlick%252C%2BCarolyn%2BA.%2BLeverett%252C%2BHong%2BX.%2BDing%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D16%26contentID%3Dacs.jmedchem.9b00196%26title%3DSynthetic%2BApproaches%2Bto%2Bthe%2BNew%2BDrugs%2BApproved%2BDuring%2B2017%26numPages%3D43%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7382%26publicationDate%3DAugust%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00196"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">14772</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00196" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthetic Approaches to the New Drugs Approved During 2017&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andrew\nC.&quot;,&quot;last_name&quot;:&quot;Flick&quot;},{&quot;first_name&quot;:&quot;Carolyn&quot;,&quot;last_name&quot;:&quot;A. Leverett&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;X. Ding&quot;},{&quot;first_name&quot;:&quot;Emma&quot;,&quot;last_name&quot;:&quot;McInturff&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;J. Fink&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Helal&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. O’Donnell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;7340-7382&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00196&quot;},&quot;abstract&quot;:&quot;New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 31 new chemical entities approved for the first time globally in 2017.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00196&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00196" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00196&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00196" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00196&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00196" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00196&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00196&amp;href=/doi/10.1021/acs.jmedchem.9b00196" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00196" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00196" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (11 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00196%26sid%3Dliteratum%253Aachs%26pmid%3D30939001%26genre%3Darticle%26aulast%3DFlick%26date%3D2019%26atitle%3DSynthetic%2BApproaches%2Bto%2Bthe%2BNew%2BDrugs%2BApproved%2BDuring%2B2017%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D16%26spage%3D7340%26epage%3D7382%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291301" title="Salts">Salts</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/jmcmar.2019.62.issue-16/20190822/jmcmar.2019.62.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0065.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 31 new chemical entities approved for the first time globally in 2017.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48030" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48030" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="quote"><p class="first">The most fruitful basis for the discovery of a new drug is to start with an old drug.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></p><div class="attrib">Sir James Whyte Black, Winner of the 1988 Nobel Prize in Medicine</div></div><div class="NLM_p">Because drugs can have structural homology across similar biological targets, it is widely believed that the knowledge of new chemical entities and approaches to their construction will enhance the ability to discover new drugs more efficiently. This annual review, which is now in its 17th installment,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> presents synthetic routes for 31 new molecular entities that were approved for the first time by a governing body anywhere in the world during the 2017 calendar year (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> For each drug, a description of the most likely process-scale synthetic approach, or in some cases the only publicly disclosed synthetic approach, is prefaced by a brief introduction summarizing the relevant pharmacology or differentiating features of the medicine.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In all cases, descriptions of the syntheses begin with commercially available starting materials. New indications for previously launched medications, new combinations or formulations of existing drugs, and drugs synthesized entirely by biological processes or peptide synthesizers have been excluded from coverage. For organizational purposes, drugs presented in this review are categorized into the following eight therapeutic areas: anti-infective, CNS (neuroscience), gastrointestinal, hematologic, metabolic, musculoskeletal, oncology, and ophthalmology. Within each of these therapeutic areas, drugs are ordered alphabetically by generic name. It is important to note that a drug’s process-scale synthetic approach is often not explicitly disclosed at the time of this review’s publication. In some cases, only a discovery-scale or a general synthetic approach capable of delivering the active pharmaceutical ingredient (API) has been made available. Nonetheless, the synthetic sequences presented in this review have all been previously reported either in patent or public chemical literature and, to the best of our assessment, represent scalable routes originating from commercially available starting materials (determined by explicit statement or inferred by experimental detail).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0001.jpeg" id="gr60" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0002.jpeg" id="GRAPHIC-d7e271-autogenerated" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0003.jpeg" id="GRAPHIC-d7e272-autogenerated" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0004.jpeg" id="GRAPHIC-d7e273-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 31 NCEs approved in 2017.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0001.jpeg jm-2019-00196t_0002.jpeg jm-2019-00196t_0003.jpeg jm-2019-00196t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Anti-Infective Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80273" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80273" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Amenamevir (Amenalief)</h3><div class="NLM_p">Originally discovered by Astellas and codeveloped with Maruho Co., Ltd., amenamevir is an antiviral agent approved for the first time in Japan in 2017 for the treatment of herpes zoster (shingles).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The non-nucleoside drug inhibits helicase-primase and offers an improved pharmacokinetic profile over existing therapies acyclovir and valacyclovir.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Researchers from Astellas attribute amenamevir’s differentiated profile to an improved absorption ratio (not hepatic availability) and slower rates of metabolism relative to acyclovir/valacyclovir.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Perhaps unsurprisingly, the primary metabolic pathway in rodents involves oxidation of the methyl groups affixed to the central aniline ring along with conversion of the oxadiazole to the corresponding amidine residue.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The half-life of the drug in human plasma was found to be 8 h, which translates into a once-daily dosing regimen, whereas acyclovir/valacyclovir have dosing regimens ranging from two to five doses per day.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">While three separate patent applications describe preparative approaches to amenamevir, only general synthetic approaches to the drug structure have been reported to date.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Although yields, spectral characterization, or crystallization conditions of intermediates or API were not detailed, a representative synthetic approach was reported, and this route is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'cit7a ref8'); return false;" href="javascript:void(0);" class="ref cit7a ref8">(7a,8)</a> Aniline <b>1</b> was alkylated with ethyl bromoacetate, and the resulting product <b>2</b> was immediately subjected to acid chloride <b>3</b> and pyridine giving rise to aniline <b>4</b>. Ester saponification of <b>4</b> followed by activation with EDCI and coupling with aniline <b>5</b><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> resulted in amenamevir (<b>I</b>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Amenamevir (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2.  Benznidazole (Rochagan)</h3><div class="NLM_p">Benznidazole was first disclosed almost 50 years ago in a patent<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> by Hoffman-La Roche demonstrating anti-infective properties. It was subsequently found to be particularly effective at treating Chagas disease (aka American trypanosomiasis), which is caused by the parasite <i>Trypanosoma cruzi</i>. In 2017, benznidazole was approved for the first time by the United States Food and Drug Administration (USFDA) under its accelerated approval program to treat Chagas disease in children ages 2–12 years old; its registration was led by Chemo Research. While Chagas disease is predominantly found in rural Latin America, it is estimated that up to 300000 people may be infected in the United States. Chronic infection can lead to heart damage.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Benznidazole oxidizes nucleotides incorporated into the parasite’s DNA, resulting in lethality.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">The original two-step synthesis of benznidazole has been improved upon in a recent patent that discloses a highly efficient one-pot process route that avoids isolating intermediates and introduces a procedure to cleanly crystallize the product on gram scale (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Alkylation of 2-nitroimidazole (<b>6</b>) was affected with ethyl bromoacetate using potassium carbonate as base in anhydrous ethanol at 70 °C. These conditions minimized hydrolysis, afforded <b>7</b> in good conversion, and represent an improvement over the originally reported protocol which required DMF and sodium methoxide at temperatures exceeding 100 °C. The mixture was directly treated with benzylamine (3.0 equiv) and warmed to 50 °C, followed by addition of water and filtration to yield benznidazole in 87% yield over two steps. Recrystallization by first solubilizing in acetone–methanol–water (1:1:0.1), distilling at atmospheric pressure, adding water, cooling to 0 to 5 °C while stirring, and filtration conveniently yielded benznidazole (<b>II</b>) in 91% yield. The simplicity of the method suggests that larger scale application would be viable.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benznidazole (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.3.  Delafloxacin Meglumine (Baxdela)</h3><div class="NLM_p">Delafloxacin meglumine is a fluoroquinolone antibiotic that targets DNA topoisomerase. It was approved by the USFDA in 2017 for the treatment of acute bacterial and skin structure infections.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Delafloxacin was discovered at Wakunaga Pharmaceutical Co. and licensed to Abbott Laboratories for further development. It was acquired by Rib-X (later renamed to Melinta Therapeutics), which completed its development and launch. Delafloxacin is currently in phase III clinical studies for the treatment of community-acquired pneumonia.</div><div class="NLM_p">The synthesis of delafloxacin is similar to that of other fluoroquinolone antibiotics but is unique in that the introduction of the chlorine to the C8 position of the quinolone occurred at a later stage of the synthetic sequence. Many routes have been published in the patent literature, and the multikilogram route disclosed by Abbott is described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Ketoester <b>8</b> (whose synthesis is described in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) was condensed with triethylorthoformate to give ethoxymethylene ester <b>9</b>. This intermediate was not isolated but was instead directly treated with 2,6-diamino-3,5-difluoropyridine (<b>10</b>, whose synthesis is described in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) to give vinylogous amide <b>11</b> in 93% yield. Complexation of <b>11</b> with lithium chloride in <i>N</i>-methylpyrrolidone (NMP) followed by reaction with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) effected cyclization to quinolone <b>12</b>. Intermediate <b>12</b> was not isolated but was treated with 3-hydroxyazetidine hydrochloride (<b>13</b>, <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>) and DBU, resulting in displacement of the fluorine in the 7-position of the quinolone. Exposure of the resulting alcohol to isobutyric anhydride followed by crystallization from citric acid gave quinolone <b>14</b> in 93% yield. Chlorination of the 8-position of the quinolone was effected by treatment with <i>N</i>-chlorosuccinimide (NCS) and sulfuric acid.<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> Hydrolysis of both the ester and the carbonate in the resulting product gave delafloxacin <b>15</b> in 90% yield. Salt formation with <i>N</i>-methyl-<i>d</i>-glycamine followed by crystallization provided delafloxacin meglumine (<b>III</b>) in 73% yield.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Delafloxacin Meglumine (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ketoester <b>8</b> was prepared in 94% yield from commercial 2,3,5-trifluorobenzoic acid (<b>16</b>) in two steps: reaction with thionyl chloride to generate the corresponding acid chloride and then treatment with the reagent derived from potassium ethyl malonate and magnesium chloride (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a></div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Delafloxacin Meglumine Ketoester Fragment <b>8</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Diamine <b>10</b> was prepared as described in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>.<a onclick="showRef(event, 'cit15c'); return false;" href="javascript:void(0);" class="ref cit15c">(15c)</a> 2,3,5,6-Tetrafluoropyridine (<b>17</b>) was reacted with benzylamine to give 2,6-dibenzylamino-3,5-difluoropyridine (<b>18</b>). Hydrogenolysis using catalytic palladium hydroxide on carbon and formic acid provided diamine <b>10</b> in 86% yield.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Delafloxacin Meglumine Diaminopyridine <b>10</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hydroxyazetidine <b>13</b> was prepared as described in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>.<a onclick="showRef(event, 'cit15c'); return false;" href="javascript:void(0);" class="ref cit15c">(15c)</a> Epichlorohydrin (<b>19</b>) was treated with benzylamine to give azetidine <b>20</b> in quantitative yield. Catalytic hydrogenation of <b>20</b> using palladium hydroxide on carbon followed by salt formation with hydrochloric acid gave 3-hydroxyazetidine hydrochloride (<b>13</b>) in 49% yield.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Delafloxacin Meglumine Azetidine Fragment <b>13</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.4.  Elsulfavirine (Elpida)</h3><div class="NLM_p">Elsulfavirine is an acyl sulfonamide prodrug of the non-nucleoside reverse-transcriptase (NNRT) inhibitor VM1500A (<b>28</b>, <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>), which is used for the treatment of HIV-AIDS. It was approved in Russia in June 2017 for use in combination with existing retroviral medications. Originally discovered by Roche,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> the rights for elsulfavirine were transferred to Viriom, which led its development. In efficacy trials, elsulfavirine demonstrated noninferiority to efavirenz in both viral load and HIV RNA reduction at 12 weeks with superior tolerability. An assessment of human pharmacokinetics showed that elsulfavirine was rapidly converted (<i>t</i><sub>1/2</sub> = ca. 2 h) to VM1500A, which has a very long half-life (<i>t</i><sub>1/2</sub> > 5 days).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Development of once-weekly elsulfavirine oral and subcutaneous once-monthly VM1500A dosage forms, presumably enabled by the long <i>t</i><sub>1/2</sub>, is underway to enhance patient compliance and efficacy.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Elsulfavirine (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Although the exact synthesis of elsulfavirine has not been reported, the synthesis of structurally similar compounds have been exemplified in a patent disclosed by Roche.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>, reactions with yields are those that have specifically been exemplified in the Roche patent. Reaction conditions for the last steps of the synthesis (<b>26</b> to <b>28</b> to elsulfavirine (<b>IV</b>)) were reported only in a generalized approach.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Because these final steps were not specifically exemplified with the bromine atom within elsulfavirine in place, no yields could be reported for these steps. The route is linear in nature and utilizes multiple site-selective nucleophilic aromatic substitution reactions to efficiently prepare the drug. The synthesis commenced with the interesting selective monochloride displacement reaction of <b>21</b> with sodium methoxide, likely facilitated by the electron-deficient nature of the aromatic system, followed by lithium iodide-mediated demethylation to afford phenol <b>22</b> in approximately 80% yield over two steps (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). A second S<sub>N</sub>Ar reaction of the sodium salt of <b>22</b> with 2,3,4-trifluoronitrobenzene (<b>23</b>) proceeded in an <i>ortho</i>-selective manner at low temperature to yield diaryl ether <b>24</b> in 82% yield. Introduction of the acetate unit was affected by a two-step process: S<sub>N</sub>Ar reaction of ethyl <i>tert</i>-butyl malonate at the position <i>para</i> to the nitro group followed by TFA-mediated Boc removal/decarboxylation, afforded <b>25</b> in 83% yield for the two steps. Conversion of the nitro group to the corresponding bromide was accomplished by iron-mediated reduction of <b>25</b> to the corresponding aniline (87% yield) and subsequent diazotization/bromination with <i>tert</i>-butyl nitrite in the presence of copper(I) bromide (53% yield) to give <b>26</b>. A reported general three-step sequence of (a) hydrolysis of ester <b>26</b> to acid, (b) conversion of acid to acid chloride, and (c) acylation of aniline <b>27</b>, without isolation of intermediates, was most likely used to convert <b>26</b> to <b>28</b> (VM1500A). Preparation of the acyl sulfonamide precursor likely used propionic anhydride (<b>29</b>) with catalytic DMAP, which afforded elsulfavirine (<b>IV</b>) upon treatment with a sodium base.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.5.  Glecaprevir/Pibrentasvir (Mavyret)</h3><div class="NLM_p">Discovered and developed in a joint effort between Abbvie and Enanta Pharmaceuticals, the combination of glecaprevir and pibrentasvir was approved by the USFDA in 2017 for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1–6 with no or mild cirrhosis, who have previously been treated with either an NS5A inhibitor or an NS3/4A inhibitor but not both.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Similar to Merck’s introduction of the HCV combination therapy Zepatier to the market in 2016, neither glecaprevir nor pibrentasvir have been previously approved as a separate medication prior to 2017.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Glecaprevir inhibits the serine protease NS3/4A, while pibrentasvir inhibits NS5A, which is a zinc-binding hydrophilic phosphoprotein involved in viral RNA replication.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In clinical trials, glecaprevir/pibrentasvir was found to be effective against all six known HCV genotypes.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The following side effects were commonly observed during clinical trials: headache, nausea, diarrhea, and hepatitis B reactivation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> For the purpose of this review, the synthesis of each component of the combination therapy will be discussed separately.</div><div class="NLM_p">No explicit report of a process-scale synthetic approach to glecaprevir has been published to date. However, a route capable of preparing milligram quantities of glecaprevir has been disclosed in a patent application from researchers at Enanta.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In this approach, glecaprevir’s macrocyclic structure was retrosynthetically divided into three subunits: quinoxaline <b>34</b>, allyl ether <b>38</b>, and cyclopropylamine <b>44</b>. The preparation of these subunits are described in <a class="ref internalNav" href="#sch8" aria-label="Schemes 8">Schemes 8</a>–<a class="ref internalNav" href="#sch10" aria-label="10">10</a>, and their final assembly to furnish the API is described in <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>.</div><div class="NLM_p">Allyl bromide <b>30</b> underwent a Barbier reaction with ethyl glyoxylate through activation with indium powder at room temperature,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and the resulting alcohol was subjected to a Ley–Griffith oxidation facilitating construction of oxopentanoate <b>31</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Condensation with 1,2-benzenediamine under mild conditions with base and subsequent treatment with phosphorus oxychloride converted <b>31</b> to chloroquinoxaline <b>32</b> in 45% yield from the starting allylic difluoride system <b>30</b>. Treatment of <b>32</b> with prolinol <b>33</b> in the presence of sodium <i>t</i>-butoxide resulted in ether formation to secure <b>34</b> in good yield.</div><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Glecaprevir Quinoxaline Subunit <b>34</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The construction of allyl ether <b>38</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>) began with monoacylation of <i>trans</i>-pentanediol (<b>35</b>), which was followed by a selective saponification by lipase resolution, allylation, and finally lithium hydroxide mediated removal of the acetyl protecting group to furnish enantiopure allyl ether <b>36</b>. Yields, specific lipase conditions, and enantioselectivities were not reported for this particular sequence but were instead described as a general procedure in the patent. Carbamate formation through initial exposure of <b>36</b> to phosgene and aminoester <b>37</b> in THF, followed by treatment with aqueous sodium hydroxide and subsequent acidification provided allyl ether <b>38</b>. This sequence was described as a general approach having no reported yields or stereoselectivity data.</div><figure id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0014.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Glecaprevir Allyl Ether <b>38</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A clever approach to cyclopropylamine <b>44</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>) has been described by researchers from Gilead in a 2014 patent.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Interestingly, this same structural subunit is incorporated into the structure of voxilaprevir (<b>X</b>), whose synthesis is described vide infra. Knoevenagel condensation of hemiacetal <b>39</b> with diethyl malonate utilizing cerium trichloride and sodium iodide followed by Corey–Chaykovsky cyclopropanation gave racemic cyclopropane diester <b>40</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Next, esterase resolution presumably delivered an enantioenriched carboxylic acid, which then underwent Curtius rearrangement, giving rise to aminoester <b>41</b>. This aminoester could be further resolved chromatographically to obtain the desired enantiomer in higher purity (exact purities and yields were not disclosed). Lastly, reaction of <b>41</b> with lithium hydroxide followed by mild acid quench and subsequent coupling of the resulting acid <b>42</b> with sulfonamide <b>43</b> furnished cyclopropylamine <b>44</b>.</div><figure id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0015.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Preparation of Glecaprevir Cyclopropylamine <b>44</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The final assembly of glecaprevir commenced with the union of quinoxaline <b>36</b> and allyl ether <b>40</b> through amide bond formation (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>). Acidic removal of the Boc group within <b>34</b> followed by HATU-mediated amide formation with acid <b>38</b> resulted in the diallyl species <b>45</b>. Next, a ring-closing metathesis involving the Zhan 1B catalyst (<b>46</b>) secured macrocycle <b>47</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Exposure of <b>47</b> to methanolic lithium hydroxide and subsequent amide bond formation with cyclopropylamine <b>44</b> ultimately furnished glecaprevir (<b>V</b>).</div><figure id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0016.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Glecaprevir (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthetic route to pibrentasvir has been reported in the patent literature and proceeded as shown in <a class="ref internalNav" href="#sch12" aria-label="Schemes 12">Schemes 12</a> and <a class="ref internalNav" href="#sch13" aria-label="13">13</a>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Substitution of 1,2,3-trifluoro-5-nitrobenzene (<b>48</b>) with 1,4-dioxa-8-azaspirol[4.5]decane (<b>49</b>) in the presence of potassium carbonate was followed by acid-mediated acetal removal to give the corresponding <i>N</i>-arylated 4-piperidone in 74% yield (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>). Deprotonation with LiHMDS followed by treatment with <i>N</i>-phenyl triflimide then delivered the corresponding enol triflate <b>50</b> in 81% yield. Suzuki coupling of triflate <b>50</b> with 4-fluorobenzeneboronic acid (<b>51</b>) furnished piperidine <b>52</b> in 54% yield. Hydrogenation of <b>52</b> reduced the olefin and the <i>p</i>-nitro group simultaneously to give the corresponding anilino piperidine in 99% yield. This compound was then reacted with bis-mesylate <b>53</b> (whose synthesis is described in <a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>) to form pyrrolidine <b>54</b> in 51% yield.</div><figure id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0017.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Pibrentasvir Pyrrolidine Core <b>54</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The final approach to pibrentasvir is outlined in <a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>. Buchwald amidation of bis-aryl chloride <b>54</b> with amide <b>55</b> generated the corresponding bis-amide <b>56</b> in 54% yield. Reduction of the nitro groups followed by acid-mediated benzimidazole formation and removal of the Boc groups furnished compound <b>57</b>. Bis-coupling with carboxylic acid <b>58</b> ultimately generated pibrentasvir (<b>VI</b>) in excellent yield.</div><figure id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0018.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Pibrentasvir (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Preparation of the bis-mesylate intermediate <b>53</b> (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>) began with conversion of benzoic acid <b>59</b> to the corresponding methyl ketone <b>60</b> via the intermediate acyl chloride. Bromination followed by a dimerization reaction utilizing conditions originally described by Kulinkovich gave 1,4-diketone <b>62</b> in 74% yield over two steps.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Asymmetric bis-reduction using the CBS reduction system provided diol <b>63</b> in 97% yield (ee not reported).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Finally, treatment of <b>63</b> with methanesulfonyl chloride in the presence of base delivered intermediate <b>53</b> in excellent yield.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0019.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Preparation of Pibrentasvir Dimesylate <b>53</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">2.6.  Letermovir (Prevymis)</h3><div class="NLM_p">Letermovir was approved in 2017 in the US and Canada for the treatment of cytomegalovirus (CMV) infection and disease in CMV-seropositive adults who have received an allogeneic hematopoietic stem cell transplant (HSCT).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Initially developed by the German firm AiCuris and later licensed to Merck, letermovir differs in mechanism of action relative to existing treatments for CMV.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> As such, the drug shows potent activity as a viral terminase inhibitor of CMV DNA-terminase complexes pUL51, pUL56, and pUL89, all of which play a role in processing and packaging viral DNA.<a onclick="showRef(event, 'cit32a'); return false;" href="javascript:void(0);" class="ref cit32a">(32a)</a> Existing medicines previously approved for CMV serve as DNA polymerase inhibitors and have been associated with drug resistance and significant adverse effects.<a onclick="showRef(event, 'cit32b ref33'); return false;" href="javascript:void(0);" class="ref cit32b ref33">(32b,33)</a> The drug demonstrates activity against viral populations resistant to existing standard of care treatments while exhibiting no cross-resistance.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> Letermovir received fast-track status by the USFDA and was approved based on the results of several clinical trials,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> including those where post-HSCT individuals receiving letermovir demonstrated significantly lower rates of clinically significant CMV infection than individuals on placebo.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The approval of letermovir, therefore, represents a significant advance for patients suffering from CMV, as the drug provides an alternative to other traditional DNA polymerase-based therapies. Letermovir has furthermore received a positive opinion from the European Medicines Agency (EMA) and is under review in several additional countries.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">Researchers at Merck have recently reported a scale-up route to letermovir, which also constitutes the first reported asymmetric route to the drug (<a class="ref internalNav" href="#sch15" aria-label="Schemes 15">Schemes 15</a>, <a class="ref internalNav" href="#sch16" aria-label="16">16</a>, and <a class="ref internalNav" href="#sch17" aria-label="17">17</a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This synthetic approach relies on the union of building blocks <b>74</b> and <b>75</b> and use of an asymmetric phase-transfer-catalyzed (PTC) aza-Michael reaction of an advanced guanidine intermediate (<b>74</b>) to install the necessary chiral center (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>). Toward this end, synthesis of guanidine <b>74</b> began with a Heck reaction involving 2-bromo-6-fluoroaniline (<b>64</b>) and methyl acrylate (<b>65</b>) on kilogram scale, providing acrylate <b>66</b> in an unisolated 99% yield. Acrylate <b>66</b> was then converted to phenyl carbamate <b>68</b> with phenyl chloroformate (<b>67</b>) under Schotten–Baumann conditions. This carbamate was immediately reacted with 2-methoxy-5-(trifluoromethyl)aniline (<b>69</b>) to afford urea <b>70</b>, which was isolated via crystallization in high yield (87% over the one-pot, 3-step sequence from <b>64</b>). Dehydration of urea <b>70</b> was achieved with PCl<sub>5</sub> and 2-picoline in warm toluene, giving rise to intermediate carbodiimide <b>71</b>, which was further reacted without isolation with piperazine <b>72</b> under basic conditions (Et<sub>3</sub>N, toluene/H<sub>2</sub>O), providing <b>74</b> in free base form. Subsequent treatment with salicyclic acid (<b>73</b>) enabled the isolation of the desired guanidine salicylate salt in 90% yield from <b>70</b>. The authors comment that utilization of toluene as a solvent in the guanidine formation reaction was essential for suppression of undesired cyclization products.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0020.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Preparation of Letermovir Guanidine <b>74</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The key step in the synthesis of letermovir relied upon on the intramolecular aza-Michael reaction of <b>74</b> to install the stereogenic acetate and dihydroquinazoline core present in the final drug target (<a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Subjection of salicylate salt <b>74</b> to biphasic basic conditions (K<sub>3</sub>PO<sub>4</sub> in toluene/H<sub>2</sub>O) and cinchona-alkaloid-based PTC <b>75</b> (prepared on multikilogram scale in two steps from cinchonidine (<b>79</b>, <a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>)) provided dihydroquinazoline <b>76</b> in nearly quantitative conversion and 76% ee as a solution in toluene. Optical enrichment of this solution was made possible by treatment with di-<i>p</i>-toluoyl-(<i>S</i>,<i>S</i>)-tartaric acid (DTTA, <b>77</b>), ultimately enabling production of <b>78</b> in 99.6% ee and 82% yield after filtration. Finally, free base formation (MTBE, Na<sub>2</sub>HPO<sub>4</sub>) and ester saponification (NaOH, 70 °C) converted intermediate <b>78</b> to the drug target letermovir (<b>VII</b>) after precipitation from acetone/H<sub>2</sub>O (94% yield over 2 steps).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0021.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Letermovir (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0022.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Preparation of Letermovir Auxiliary <b>75</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">2.7.  Secnidazole (Solosec)</h3><div class="NLM_p">Secnidazole is a nitroimidazole antimicrobial agent approved for the treatment of bacterial vaginosis (BV) in adult women.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Although the drug has been commercially available for more than three decades within Europe, Asia, South America, and Africa, the USFDA approved the drug for the first time in 2017 after it underwent priority review as an antibacterial agent intended to treat serious or life-threatening infections.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Structurally, secnidazole differs from other nitroimidazole antimicrobial agents metronidazole and tinidazole in <i>N</i>-1 substitution. The modest differences in structure likely account for physiochemical and biochemical differences (e.g., tissue distribution, metabolic pathways). Interestingly, the antimicrobial and antiprotozoal activity of this class of compounds is largely attributed to the nitro group attached directly to the 2-position of imidazole ring system, which is structurally conserved throughout this class of drugs.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Secnidazole and other 5-nitroimidazoles induce bactericidal activity by first diffusing into the organism, where the inactive parent compound (prodrug) undergoes nitro reduction to produce cytotoxic metabolites, which lead to DNA helix damage, disruption of bacterial protein synthesis and replication, and ultimately cytotoxicity.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">A single-step process-scale synthesis of secnidazole reported in the patent literature proceeded as depicted in <a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> 2-Methyl-5-nitroimidazole (<b>82</b>) was alkylated with 1-bromine-2-propanol (<b>83</b>) in the presence of base to give secnidazole (<b>VIII</b>) in 88% yield.<a onclick="showRef(event, 'cit37b'); return false;" href="javascript:void(0);" class="ref cit37b">(37b)</a></div><figure id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0023.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Secnidazole (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">2.8.  Vaborbactam (Vabomere, Vaborbactam/Meropenem Combination)</h3><div class="NLM_p">Discovered by Rempex Pharmaceuticals and subsequently developed and marketed by The Medicines Company, vaborbactam is an inhibitor of the carbapenem-deactivating serine protease <i>Klebsiella pneumoniae carbepenemase</i> (KPC). Intravenous dosing of vaborbactam in combination with the previously approved carbapenem antibiotic Meropenem was approved by the USFDA in 2017 for the treatment of complicated urinary tract infections including pyelonephritis.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Key in the design of vaborbactam is the use of a cyclic boronate to engender potent, reversible interactions with the catalytic serine hydroxyl group in KPC and also to reduce affinity to mammalian proteases that accommodate linear substrates.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In human trials, vaborbactam/meropenem demonstrated clinical efficacy superior to the best available treatment in addressing carbapenem-resistant <i>Enterobacteriaceae</i> (CRE) infections.<a onclick="showRef(event, 'ref16 ref40'); return false;" href="javascript:void(0);" class="ref ref16 ref40">(16,40)</a></div><div class="NLM_p">The main challenge in the synthesis of vaborbactam is construction of the relative <i>cis</i>-stereochemistry of the <i>N</i>-acyl and <i>N</i>-acetate groups at the 3- and 6-positions of the oxiborinane ring system in an asymmetric fashion. The absolute stereochemistry was established in an efficient 3-step process by enantioselective lipase resolution of the (<i>R</i>)-enantiomer of racemic ester <b>84</b>, base-mediated acetate hydrolysis, and hydroxyl silylation to afford <b>85</b> in 40% yield and >99% ee (<a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>). Iridium-catalyzed hydroboration gave boronate <b>86</b> in high yield followed by exchange of pinacol with pinanediol <b>87</b> to give pinene boronate <b>88</b>. Elegant utilization of a Matteson homologation (<b>88</b> to <b>89</b>) established the chiral center vicinal to boron. Originally reported as a batch step at −95 °C yielding an 85:15 ratio of desired to undesired diastereomers, a flow-based method has been reported at higher temperatures (−60 to −70 °C), resulting in improved dr (95:5), yield (>90%), and reaction reproducibility.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The flow approach has reportedly delivered more than 1000 kg of <b>89</b> under GMP conditions.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Conversion of the stereodefined chloride in <b>89</b> to acylated amine <b>90</b> was achieved with lithium hexamethyldisilazide followed by treatment of crude hexamethylsilazane with 2-thiopheneacetic acid and amide coupling reagents (EDCI, HOBT, NMM) in good yield.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Subjection of <b>90</b> to HCl in dioxane affected concomitant deprotection of the alcohol, hydrolysis of the boronate ester, and intramolecular cyclization to yield vaborbactam (<b>IX</b>) as a white solid.</div><figure id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0024.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Vaborbactam (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">2.9.  Voxilaprevir (Vosevi)</h3><div class="NLM_p">First approved by the USFDA and the EU in 2017, voxilaprevir was approved as part of a 3-fold combination therapy involving sofosbuvir and velpatisvir for the treatment of chronic HCV genotype 1–6 infection in adults, including those who have previously received direct-acting antiviral (DAA) therapy.<a onclick="showRef(event, 'cit2o ref42'); return false;" href="javascript:void(0);" class="ref cit2o ref42">(2o,42)</a> The drug, which is sold by Gilead, reversibly inhibits the HCV NS3/4A protease through noncovalent interactions. The approved treatment duration with sofosbuvir/velpatasvir/voxilaprevir in DAA-naive patients without compensated cirrhosis is shorter than sofosbuvir/velpatasvir (8 vs 12 weeks).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> This shorter treatment period may improve patient adherence to treatment. Furthermore, treatment with sofosbuvir/velpatasvir/voxilaprevir does not require ribavirin, a drug that is teratogenic and increases pill burden as well as the likelihood of mild anemia when used in combination with DAAs.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_p">A 2015 patent application published by workers at Gilead describes a process for the preparation of voxilaprevir and structurally related antiviral agents.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Although the Gilead patent exemplifies the reactions depicted in <a class="ref internalNav" href="#sch20" aria-label="Schemes 20">Schemes 20</a>–<a class="ref internalNav" href="#sch23" aria-label="23">23</a> in thorough detail on scales capable of supporting delivery of multigram quantities the API (and in many examples describe conditions for recrystallization or precipitative isolation of intermediates), no yields were reported in the patent. Voxilaprevir possesses significant structural homology to glecaprevir. Coincidentally, both HCV NS3/4A inhibitors utilize cyclopropylamine <b>44</b> for their preparation (see <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The macrocyclic structure of voxilaprevir was subdivided into four main subunits: pyrrolidinol <b>95</b>, cyclopropyl carbamate <b>100</b>, quinoxaline <b>105</b>, and cyclopropylamine <b>44</b>, and the synthesis hinged upon a critical ring-closing metathesis (RCM)-hydrogenation approach strategically similar to glecaprevir.<a onclick="showRef(event, 'ref22 ref25 cit27a ref45'); return false;" href="javascript:void(0);" class="ref ref22 ref25 cit27a ref45">(22,25,27a,45)</a></div><div class="NLM_p">The preparation of pyrrolidinol <b>95</b> began with subjection of pyrrolidinone <b>91</b> to DMF–DMA in warm dichloromethane. The resulting enaminone was treated with methylmagnesium bromide to furnish an unspecified mixture of <i>E</i>/<i>Z</i> enones <b>92</b> (<a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>). Hydrogenation of the olefin delivered excellent diastereoselectivity of the resulting product, presumably due to approach of the catalyst from the face opposite the preexisting <i>t</i>-butyl ester, allowing for arrival at ethylpyrrolidinone <b>93</b>. Next, stereoselective reduction of the carbonyl group was facilitated by treatment with zinc chloride, which likely biased delivery of hydride from the same face as the ester. Isolation of the product upon treatment with citric acid furnished alcohol <b>94</b> as the major product. No diastereoselectivity ratios were reported for this transformation. Transesterification through the use of tosic acid necessitated reinstallation of the Boc group to produce pyrrolidinol <b>95</b>.</div><figure id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0025.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Preparation of Voxilaprevir Pyrrolidinol <b>95</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cyclopropyl carbamate <b>100</b> was prepared by first converting cyclopropanol <b>96</b> to carbonate <b>98</b> using bis-succinimide reagent <b>97</b> (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>). Next, coupling with <i>tert</i>-leucine (<b>99</b>) proceeded in the presence of aqueous potassium phosphate. This step was followed by pH adjustment to allow for isolation of carbamate <b>100</b>.</div><figure id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0026.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Preparation of Voxilaprevir Cyclopropyl Carbamate <b>100</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Preparation of quinoxaline <b>105</b> started with acid <b>101</b>, which conveniently incorporated the difluoromethylene group into the molecule at a very early stage of the synthesis (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>). Subjection of this pentenoic acid to aniline in the presence of triphenylphosphine and CCl<sub>4</sub> converted <b>101</b> to the corresponding amide. This was followed by exposure to POCl<sub>3</sub> and subsequently potassium cyanide to form iminonitrile <b>102</b> (<i>E</i>/<i>Z</i> selectivity not reported). Reaction with <i>o</i>-phenylenediamine <b>103</b> in acetic acid followed by treatment with base established the quinoxaline core. Sandmeyer conditions were employed to transform the amine to the corresponding chloride, giving rise to quinoxalyl chloride <b>105</b>.</div><figure id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0027.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Preparation of Voxilaprevir Quinoxaline <b>105</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Final assembly of the voxilaprevir subunits is depicted in <a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>. Substitution of chloride <b>105</b> with alcohol <b>95</b> established the alkyl–aryl ether linkage. This was followed by tosic acid-mediated removal of the Boc group to give tosylate salt <b>106</b>. The amine salt was then immediately coupled with carboxylic acid <b>100</b> using EDCI as the activating reagent. Next, the key RCM reaction was facilitated by the Zhan IIa catalyst (<b>108</b>) to deliver the ring-closed product with impressive functional group tolerance.<a onclick="showRef(event, 'cit27b'); return false;" href="javascript:void(0);" class="ref cit27b">(27b)</a> Subsequent platinum-mediated hydrogenation secured macrocycle <b>109</b>.<a onclick="showRef(event, 'cit45b'); return false;" href="javascript:void(0);" class="ref cit45b">(45b)</a> Lastly, saponification of the methyl ester followed by amide bond formation with cyclopropylamine <b>44</b> delivered voxilaprevir (<b>X</b>). Although the Gilead patent exemplifies API isolation conditions as using chromatography,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> a separate patent application by the Chinese firm Sunshine Lake Pharma Co., Ltd. describes API solid form and crystallization conditions of macrocycles similar in structure to that of voxilaprevir.<a onclick="showRef(event, 'cit27a'); return false;" href="javascript:void(0);" class="ref cit27a">(27a)</a></div><figure id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0028.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Voxilaprevir (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">3.  CNS Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31304" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31304" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">3.1.  Deutetrabenazine (Austedo)</h3><div class="NLM_p">Deutetrabenazine, a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2), was approved by the USFDA for the treatment of chorea (abnormal involuntary movements) connected with Huntington’s disease.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> As the second drug approved in the U.S. for this indication, deutetrabenazine represents an improvement over its nondeuterated counterpart, tetrabenazine (<b>118</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which has been used for the same indication since its approval in 2008.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> While tetrabenazine provides effective treatment, the drug is quickly metabolized, necessitating frequent dosing, which contributes to issues with patient noncompliance.<a onclick="showRef(event, 'ref46 cit47b ref48'); return false;" href="javascript:void(0);" class="ref ref46 cit47b ref48">(46,47b,48)</a> The strategic incorporation of six deuterium atoms into tetrabenazine enables a more favorable pharmacokinetic profile due to the increased strength of C–D versus C–H bonds, lowering the rate of metabolism. This improves half-life and decreases dosage, and ultimately reduces adverse events compared to tetrabenazine.<a onclick="showRef(event, 'ref46 ref49'); return false;" href="javascript:void(0);" class="ref ref46 ref49">(46,49)</a> As the first deuterated drug approved by the USFDA, deutetrabenazine represents a successful incorporation of deuterium to modulate pharmacokinetic profile, establishing proof-of-concept for other deuterated compounds currently in clinical trials for a variety of indications.<a onclick="showRef(event, 'cit47a ref50'); return false;" href="javascript:void(0);" class="ref cit47a ref50">(47a,50)</a> The drug consists as a racemic mixture of <i>R</i>,<i>R</i> and <i>S</i>,<i>S</i> isomers, which are converted to two major active metabolites, α- and β-dihydrodeutetrabenazine.<a onclick="showRef(event, 'ref46 ref48'); return false;" href="javascript:void(0);" class="ref ref46 ref48">(46,48)</a> Even though the exact mechanism of action is unknown, the drug is believed to suppress levels of monoamines such as dopamine, serotonin, norepinephrine, and histamine, with the circulating active metabolites of the drug leading to decreased monoamine uptake into synaptic vesicles.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><figure id="fig2" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0005.jpeg" id="gr61" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of (±)-tetrabenazine <b>118</b>, <i>R</i>,<i>R</i>,<i>R</i>-DHTBZ <b>119</b>, and valbenazine (<b>XII</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While several synthetic routes to (±)-deutetrabenazine and (±)-tetrabenazine have been reported,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> the majority of these routes, including the route reported by Auspex Pharmaceuticals described herein,<a onclick="showRef(event, 'cit51c ref52'); return false;" href="javascript:void(0);" class="ref cit51c ref52">(51c,52)</a> rely on a single-step transformation to install the benzoquinoline core from the corresponding dihydroisoquinoline <b>114</b>.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> Synthesis of <b>114</b> is shown in <a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>, beginning with dopamine hydrochloride (<b>110</b>). Condensation of <b>110</b> with ethyl formate (<b>111</b>) in the presence of sodium <i>t</i>-butoxide provided formamide <b>112</b> in 85% yield. From <b>112</b>, phenol alkylation with CD<sub>3</sub>I provided the deuterated 3,4-bis-methoxy analogue <b>113</b>, which then underwent a Bischler–Napieralski cyclization to generate dihydroisoquinoline <b>114</b> in 44% yield over the two-step sequence.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The key step in the synthesis of deutetrabenazine is the final transformation, which was achieved by reaction of <b>114</b> and quaternary ammonium salt <b>115</b> (whose preparation is outline in <a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a>) with K<sub>2</sub>CO<sub>3</sub> under heating conditions.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> This transformation presumably proceeded through a tandem Mannich reaction–Hofmann elimination–Michael addition sequence,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> which has been previously employed in the synthesis of tetrabenazine<a onclick="showRef(event, 'cit51e ref55'); return false;" href="javascript:void(0);" class="ref cit51e ref55">(51e,55)</a> and has also been reported successfully on kilogram scale with similar substrates.<a onclick="showRef(event, 'cit54a'); return false;" href="javascript:void(0);" class="ref cit54a">(54a)</a> This cyclization sequence provided the racemic product as the cis-diastereomer<a onclick="showRef(event, 'cit55b ref56'); return false;" href="javascript:void(0);" class="ref cit55b ref56">(55b,56)</a> of deutetrabenazine (<b>XI</b>) in 67% yield after washing of the crude product with hot ethanol.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><figure id="sch24" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0029.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Deutetrabenazine (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Quaternary ammonium salt <b>115</b> can be synthesized on multikilogram scale starting from 5-methylhexan-2-one (<b>116</b>, <a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a>).<a onclick="showRef(event, 'cit51c'); return false;" href="javascript:void(0);" class="ref cit51c">(51c)</a> Treatment of <b>116</b> with paraformaldehyde and dimethylamine hydrochloride under refluxing conditions provided intermediate <b>117</b>, which was converted to the corresponding ammonium salt <b>115</b> in 87% yield via treatment with iodomethane.<a onclick="showRef(event, 'cit51c'); return false;" href="javascript:void(0);" class="ref cit51c">(51c)</a> Furthermore, an alternate approach to <b>XI</b> has recently been reported by reacting CD<sub>3</sub>OD with a catechol intermediate under Mitsunobu conditions.<a onclick="showRef(event, 'cit51e'); return false;" href="javascript:void(0);" class="ref cit51e">(51e)</a> This approach may offer a more cost-effective means of deuterium introduction relative to the CD<sub>3</sub>I displacement approach described in <a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>.</div><figure id="sch25" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0030.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Piperidone-Forming Reagent <b>115</b> for Deutetrabenazine (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">3.2.  Valbenazine (Ingrezza)</h3><div class="NLM_p">Valbenazine was developed by Neurocrine Biosciences and approved by the USFDA for treatment of adults with tardive dyskinesia, a movement disorder characterized by repetitive, purposeless, and involuntary movements caused by exposure to dopamine receptor-blocking agents that are prescribed as antipsychotics, some antidepressants, and antiemetics.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Valbenazine is a selective VMAT2 inhibitor that demonstrates superior potency over current standard of care, tetrabenazine (<b>118</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), requiring less frequent administration.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Valbenazine bears significant structural homology to tetrabenazine, deutetrabenazine (<b>XI</b>), and <i>R</i>,<i>R</i>,<i>R</i>-dihydrotetrabenazine (<i>R</i>,<i>R</i>,<i>R</i>-DHTBZ, <b>119</b>). It was found to have superior selectivity and potency relative to the other four possible hydroxyl metabolite isomers resulting from nonselective reduction of (±)-tetrabenazine by carbonyl reductase.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Valbenazine was designed as a valine ester prodrug of <i>R</i>,<i>R</i>,<i>R</i>-DHTBZ, enabling slower release of the active metabolite in the liver.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p">Patent literature from Neurocrine Biosciences suggests that valbenazine is accessed by a four-step synthetic route beginning with commercial (±)-tetrabenazine <b>118</b>, as shown in <a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a>. Although (±)-tetrabenazine is commercially available, a likely scale route has also been described which resembles the approach used for construction of deutetrabenazine (<a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> While deutetrabenazine is a mixture of cis-enantiomers, valbenazine’s construction requires tetrabenazine as a single enantiomer. Toward this end, a resolution of racemic <b>118</b> was developed using (<i>−</i>)-<i>O</i>,<i>O</i>′-di-<i>p</i>-toluoyl-<span class="smallcaps smallerCapital">l</span>-tartaric acid.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Treatment of the salt with aqueous ammonium hydroxide in ethanol provided resolved amine (+)-<b>120</b> in 67% yield and 97–98% chiral purity. Borane reduction of the ketone furnished the requisite (<i>R</i>,<i>R</i>,<i>R</i>)-alcohol <b>121</b>. This transformation can also be accomplished using a ruthenium-catalyzed transfer hydrogenation protocol, albeit in lower reported yields. Esterification of <b>121</b> with Boc-<span class="smallcaps smallerCapital">l</span>-valine followed by subjection to excess tosic acid resulted in bis-tosylate salt formation and arrival at valbenazine (<b>XII</b>). The precipitated product could be isolated via filtration,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> which represented an improvement over earlier patents describing an esterification using CBz-<span class="smallcaps smallerCapital">l</span>-valine, and relied upon column chromatography for isolation of final product.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><figure id="sch26" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0031.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Valbenazine (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">4.  Gastrointestinal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06753" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06753" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">4.1.  Naldemedine (Symproic)</h3><div class="NLM_p">Naldemedine was approved by the USFDA in March 2017 for the treatment of opioid-induced constipation in adult patients with chronic noncancer pain and, subsequently, in Japan for the treatment of opioid-induced constipation in patients with cancer and noncancer pain.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> It is a third-in-class, orally active, peripherally acting μ-opioid receptor antagonist (PAMORA) developed by Shionogi & Co., Ltd. Constipation is a common side effect of opioid treatment, occurring in 40–80% of patients;<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> naldemedine blocks the effect of opioids at peripheral μ-opioid receptors localized in the gastrointestinal tract tissue. Naldemedine is structurally similar to naltrexone, an opioid receptor antagonist approved for treatment of alcohol or opioid dependence, with a side chain designed to limit blood–brain barrier (BBB) penetration by increasing molecular weight and topological polar surface area. This structural modification results in minimal or no effect on CNS opioid activity (analgesia) and minimizes adverse effects associated with opioid withdrawal.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Naldemedine is also a permeability glycoprotein (P-gp) efflux substrate.</div><div class="NLM_p">The synthesis of naldemedine commenced with commercial naltrexone hydrochloride (<b>122</b>, <a class="ref internalNav" href="#sch27" aria-label="Scheme 27">Scheme 27</a>). Acylation of the phenol followed by CuCl<sub>2</sub>-mediated reaction with isocyanate <b>123</b> (whose synthesis is described in <a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>) generated carbamate <b>124</b> in 89% yield.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Subjection of <b>124</b> to KOH induced a 1,4-intramolecular acyl transfer reaction that proceeded with concomitant removal of the phenolic acetate. Treatment with tosic acid followed by crystallization from methanol and isopropyl acetate afforded naldemedine tosylate (<b>XIII</b>) in 66% yield from <b>124</b>.</div><figure id="sch27" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0032.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Naldemedine (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Isocyanate <b>123</b> was synthesized in fpur steps from <i>N</i>-Boc 2-amino-2-methylpropanoic acid (<b>125</b>, <a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Chloroformate-mediated oxadiazole formation with <b>126</b> and Boc deprotection proceeded in 93% yield over two steps. Carbamate formation with methyl chloroformate and subsequent treatment with boron trichloride and triethylamine gave isocyanate <b>123</b>, which was carried forward without isolation.</div><figure id="sch28" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0033.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Synthesis of Naldemedine Isocyanate Intermediate <b>123</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">5.  Hematologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61808" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61808" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47">5.1.  Betrixaban (Bevyxxa)</h3><div class="NLM_p">Discovered by Millenium Pharmaceuticals and later developed by Portola Pharmaceuticals, Inc. (originally in collaboration with Merck) as a selective serine protease factor Xa (FXa) inhibitor, betrixaban is an anticoagulant approved in 2017 by the USFDA for the treatment of thromboprophylaxis in hospitalized patients that have risk factors for venous thromboembolisms (such as deep vein thrombosis and pulmonary embolisms).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Some of these risk factors include acute medical illness, hospitalization, age, and a history of the condition.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Betrixaban binds to the active site of FXa thereby decreasing prothrombinase activity and thrombin generation.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Betrixaban belongs to a class of FXa inhibitors known as nonvitamin K antagonist oral anticoagulants (NOACs), which provide an alternative therapy to vitamin K antagonists, such as warfarin.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p">Researchers at Millennium Pharmaceuticals described the design and discovery of the anthranilamide-containing drug,<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> and a modular synthetic approach to the API has been reported in the patent literature.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Although alternative preparations have been available in the public literature, the route depicted in <a class="ref internalNav" href="#sch29" aria-label="Scheme 29">Scheme 29</a> was demonstrated on kilogram scale.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Starting from 5-methoxy-2-nitrobenzoic acid (<b>127</b>), conversion to the corresponding acid chloride then reaction with 5-chloropyridin-2-amine (<b>128</b>) formed amide <b>129</b>. Nitro group reduction followed by coupling with 4-cyanobenzoyl chloride (<b>131</b>) to <b>130</b> established the core structure <b>132</b>. Conversion of nitrile <b>132</b> to amidine <b>133</b> using dimethylamine and hexyl lithium completed the synthesis of the parent compound which was isolated as the maleate salt to arrive at betrixaban (<b>XIV</b>).</div><figure id="sch29" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0034.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Betrixaban (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">6.  Metabolic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50">6.1.  Ertugliflozin (Steglatro)</h3><div class="NLM_p">Ertugliflozin, an oral sodium glucose transporter type 2 (SGLT2) inhibitor discovered by Pfizer and codeveloped by Pfizer and Merck, was approved by the USFDA in 2017 and by the European Medicines Agency (EMA) in 2018 for the treatment of type II diabetes mellitus.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> SGLT2 inhibitors block glucose reabsorption in the kidney, resulting in increased glucose excretion and reduced glucose blood levels, body weight, and blood pressure.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Fixed-dosage forms of ertugliflozin/sitagliptin (DDP-IV inhibitor) and ertugliflozin/metformin (hepatic glucogenesis inhibitor) have also been approved. Four other SGLT2 inhibitors have been approved by the FDA and EMA: dapagliflozin, ipragliflozin, empagliflozin, and canagliflozin.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Ertugliflozin contains a bridged oxabicyclic ring system that presented synthetic challenges.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> A number of routes have been used over the course of ertugliflozin’s development,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> with a commercially viable route recently reported.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The key challenge was the introduction of the hydroxymethyl group at the C1 position. The additional steric hindrance of this quaternary stereocenter led to reactivity patterns that required creative solutions and surveying multiple potential starting materials. Furthermore, ertugliflozin and most related intermediate carbohydrate structures are noncrystalline, which made nonchromatographic purification difficult, leading to a strategy of telescoping steps, screening intermediates that were structurally different yet equivalent in reactivity for desired solid form properties and developing a cocrystal of ertugliflozin as the final pharmaceutical form.</div><div class="NLM_p">The synthesis started with oxidation of benzylated glucose derivative <b>134</b> (<a class="ref internalNav" href="#sch30" aria-label="Scheme 30">Scheme 30</a>) with DMSO/acetic anhydride at ambient temperature to afford gluconolactone <b>135</b> in high yield. This intermediate was carried directly into an amidation with methylpiperazine (<b>136</b>), affording amide <b>137</b> as a solid that was readily isolated and also allowed for potential salt formation. Oxidation of the secondary alcohol of <b>137</b> under Parikh–Doering conditions with SO<sub>3</sub>-pyridine yielded ketone <b>138</b>, which could be directly reacted with different hydroxymethyl anion equivalents to generate the key C1 quaternary stereocenter within <b>142</b>. Two methods were identified from different organomagnesium reagents: (1) derived from (chloromethyl)(isopropoxy)dimethylsilane followed by Tamao–Fleming oxidation (KF, H<sub>2</sub>O<sub>2</sub>) (<b>140</b> as 3:2 mixture of diastereomers), and (2) derived from iodomethyl pivalate followed by methoxide-mediated pivalate removal (<b>141</b> as 95:5 mixture of diasteromers). Protection of the hindered diol in <b>142</b> was achieved with 2,2-dimethoxypropane and methanesulfonic acid. Formation of the oxalate salt <b>143</b> afforded an isolable solid. Importantly, the ratio of C1 diastereomers did not impact subsequent chemistry at this point.</div><figure id="sch30" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0035.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Amide <b>143</b> towards Ertugliflozin-<span class="smallcaps smallerCapital">l</span>-pyroglutamic Acid (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The free base of <b>143</b> was generated (toluene, aqueous NaHCO<sub>3</sub>) and the organic layer was concentrated, serving to azeotropically dry <b>143</b> in preparation for the addition of the aryl anion (<a class="ref internalNav" href="#sch31" aria-label="Scheme 31">Scheme 31</a>). The precursor to the aryl anion (<b>144</b>, <a class="ref internalNav" href="#sch32" aria-label="Scheme 32">Scheme 32</a>) was identified based upon both good yield in synthesis, physical properties (highest melting point), and performance in the subsequent chemistry. Another series of telescoped steps started with metalation of <b>144</b> (<i>n</i>-hexyl lithium, 2-MeTHF, toluene, −15 °C) to give ketone <b>145</b>. Concomitant removal of the acetonide protecting group and reductive hydrogenolysis of the benzhydryl ether led to <b>146</b> as a mixture of diastereomers. Hydrogenation under acidic conditions removed the benzyl protecting groups and catalyzed the convergence of the diastereomers to ertugliflozin. To enhance the purity of ertugliflozin for final cocrystal formation, peracetylation (acetic anhydride, pyridine) gave highly crystalline <b>147</b> that allowed for effective purging of impurities to low levels in good yield over five steps (58% average yield). Acetate removal with catalytic sodium methoxide in methanol provided an ertugliflozin solution of good purity that was concentrated, taken up in 2-propanol, heated to 60 °C, and treated with water followed by a solution of <span class="smallcaps smallerCapital">l</span>-pyroglutamic (L-PGA) in water to yield crystalline ertugliflozin-<span class="smallcaps smallerCapital">l</span>-pyroglutamic acid (<b>XV</b>) (MP = 142.5 °C) in high yield (88% average yield over two steps).</div><figure id="sch31" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0036.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Synthesis of Ertugliflozin-<span class="smallcaps smallerCapital">l</span>-pyroglutamic Acid (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Intermediate <b>144</b> was prepared as described in <a class="ref internalNav" href="#sch32" aria-label="Scheme 32">Scheme 32</a>. Addition of Grignard reagent <b>149</b> to aldehyde <b>148</b> followed by etherification of the resulting alcohol gave <b>144</b> in 75% yield.</div><figure id="sch32" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0037.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Benzyl Ether Intermediate <b>144</b> for Ertugliflozin-<span class="smallcaps smallerCapital">l</span>-pyroglutamic Acid</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54">6.2.  Pemafibrate (Parmodia)</h3><div class="NLM_p">Pemafibrate is an orally delivered peroxisome proliferator activated receptor agonist (PPAR)-α that was developed by Kowa Pharmaceuticals America, Ltd.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The drug, which is also named K-877 and (<i>R</i>)-K-13675, received approval for the treatment of hyperlipidemia from Japan’s Pharmaceutical and Medical Devices Agency in 2017.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Pemafibrate acts by binding to PPAR-α, which is a nuclear hormone receptor primarily expressed in the liver, thereby regulating the expression of target genes that modulate lipid metabolism, resulting in the increased amount of high-density lipoprotein cholesterol levels (HDL-C) and decreased plasma triglyceride levels.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Pemafibrate exhibits remarkable selectivity for PPAR-α (>2000×) over PPAR-δ and PPAR-β among other receptors, which likely contributes to its improved adverse-event (AE) profile over existing fibrate drugs such as bezafibrate, fenofibrate, and gemfibrozil which are weaker PPAR agonists with poor selectivity.<a onclick="showRef(event, 'cit80a ref81'); return false;" href="javascript:void(0);" class="ref cit80a ref81">(80a,81)</a></div><div class="NLM_p">Kowa has disclosed three different synthetic approaches to pemafibrate: an initial synthesis, an improved enantioselective approach, and a kilogram-scale procedure.<a onclick="showRef(event, 'cit80b ref82'); return false;" href="javascript:void(0);" class="ref cit80b ref82">(80b,82)</a> The kilogram scale route described in <a class="ref internalNav" href="#sch33" aria-label="Scheme 33">Scheme 33</a> relied upon a critical ethereal bond establishment between optically pure triflate ester <b>153</b> and phenol <b>152</b>.<a onclick="showRef(event, 'cit82a'); return false;" href="javascript:void(0);" class="ref cit82a">(82a)</a> Conjugate addition of 4-methoxyphenol (<b>150</b>) to acrylonitrile was followed by borane–THF reduction to arrive at amine <b>151</b> in good yield. Next, reductive amination with commercial 3-hydroxybenzaldehyde followed by substitution with 2-chlorobenzoxazole gave rise to 2-aminobenzoxazole <b>152</b> in 62% yield across the two-step sequence. After considerable study, the S<sub>N</sub>2 reaction between phenol <b>152</b> and triflate ester <b>153</b> (<a class="ref internalNav" href="#sch34" aria-label="Scheme 34">Scheme 34</a>) proceeded with complete inversion of configuration using potassium carbonate and acetonitrile at ambient temperature. The authors reason that the trifluoromethanesulfonate group is critical to ensuring an efficient alkylation reaction in this case; racemization of the α-carboxylate stereocenter was observed with other alkylsulfonate leaving groups such as mesylate and tosylate.<a onclick="showRef(event, 'cit82b'); return false;" href="javascript:void(0);" class="ref cit82b">(82b)</a> Finally, saponification of the <i>n</i>-butyl ester proceeded in good yield to give pemafibrate (<b>XVI</b>) in 75% yield from <b>152</b>.</div><figure id="sch33" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0038.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Pemafibrate (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch34" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0039.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Pemafibrate Triflate <b>153</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The preparation of triflate <b>153</b> began from enantiopure (<i>S</i>)-2-hydroxybutyrolactone <b>154</b>.<a onclick="showRef(event, 'cit82b'); return false;" href="javascript:void(0);" class="ref cit82b">(82b)</a> An interesting ring-opening reaction involving trimethylsilyl iodide converted <b>154</b> to iodide <b>155</b>. The authors speculate that the mechanism of this reaction first involved activation of the ester carbonyl by the trimethylsilyl group to form an intermediate oxonium species which then underwent attack by a stoichiometric equivalent of <i>n</i>-butanol. The resulting tetrahedral intermediate participated in S<sub>N</sub>2 displacement by the iodide ion, and this was followed by ejection of trimethylsilanol, resulting in <i>n</i>-butyl ester <b>155</b>.<a onclick="showRef(event, 'cit82b'); return false;" href="javascript:void(0);" class="ref cit82b">(82b)</a> Hydrogenative reduction of the iodide followed by triflate formation through the use of 2,6-lutidine allowed for conversion of <b>155</b> to triflate <b>153</b> with complete stereocontrol and no loss of stereointegrity across the three-step sequence.<a onclick="showRef(event, 'cit82b'); return false;" href="javascript:void(0);" class="ref cit82b">(82b)</a></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">7.  Musculoskeletal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58">7.1.  Baricitinib (Olumiant)</h3><div class="NLM_p">Baricitinib is an inhibitor of Janus family tyrosine kinase (JAK)-1 and -2 approved by the USFDA in 2017 as monotherapy or in combination with methotrexate for the treatment of adults with moderate to severe active rheumatoid arthritis.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Baricitinib was discovered by Incyte and codeveloped with Eli Lilly. It is also in clinical trials for the treatment of atopic dermatitis, systemic lupus erythematosus, and giant cell arteritis.</div><div class="NLM_p">Numerous synthetic routes to baricitinib have been reported in the patent literature.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The largest scale synthesis was reported by Incyte and is described in <a class="ref internalNav" href="#sch35" aria-label="Schemes 35">Schemes 35</a>–<a class="ref internalNav" href="#sch37" aria-label="37">37</a>.<a onclick="showRef(event, 'cit28a'); return false;" href="javascript:void(0);" class="ref cit28a">(28a)</a> Horner–Emmons reaction between <i>tert</i>-butyl 3-oxoazetidine-1-carboxylate (<b>156</b>) and diethyl cyanomethyl phosphonate (<b>157</b>) gave cyanomethylene azetidine <b>158</b> in 61% yield (<a class="ref internalNav" href="#sch35" aria-label="Scheme 35">Scheme 35</a>). Acidic removal of the Boc protecting group was followed by treatment with ethanesulfonyl chloride to give the sulfonamide subunit of baricitinib <b>159</b> in 91% yield.</div><figure id="sch35" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0040.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Baricitinib Azetidine Sulfonamide <b>159</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of baricitinib was completed as described in <a class="ref internalNav" href="#sch36" aria-label="Scheme 36">Scheme 36</a>. Deprotonation of chloropyrrolopyrimidine <b>160</b> with sodium hydride followed by treatment with trimethylsilylethoxymethyl chloride gave the SEM protected chloropyrrolopyrimidine <b>161</b> in 89% yield. Suzuki coupling with commercially available boronic ester <b>162</b> followed by acidic removal of the ethoxyethyl protecting group gave pyrazole <b>163</b> in 87% yield. 1,4-Addition of pyrazole <b>163</b> to cyanomethylazetidine <b>159</b> was accomplished in the presence of DBU to give SEM-protected baricitinib <b>164</b> in high yield. Finally, treatment of <b>164</b> with lithium tetrafluoroborate followed by ammonium hydroxide gave baricitinib (<b>XVII</b>) in 81% yield. An alternative synthesis of baricitinib that avoids the use of the ethoxylethyl and SEM protecting groups and changes the order of the 1,4-addition and Suzuki coupling steps has also been reported on large scale and is described in <a class="ref internalNav" href="#sch37" aria-label="Scheme 37">Scheme 37</a>.<a onclick="showRef(event, 'cit28b ref84'); return false;" href="javascript:void(0);" class="ref cit28b ref84">(28b,84)</a></div><figure id="sch36" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0041.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 36. Synthesis of Baricitinib (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch37" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Scheme 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0042.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 37. Alternative Synthesis of Baricitinib (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch37"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">8.  Oncology Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63">8.1.  Abemaciclib (Verzenio)</h3><div class="NLM_p">Abemaciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor developed by Eli Lilly & Company for the treatment of breast cancer. CDK4/6 inhibitors impact signaling mechanisms for cell cycle progression by inhibiting phosphorylation of retinoblastoma 1 (RB1) gene that prompts transition from G1 to S phase in cell growth.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Abemaciclib has shown greater efficacy than other chemotherapeutic agents in multidrug resistant hormone receptor (HR) positive breast cancer cells.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The USFDA awarded approval for abemaciclib in combination with fulvestrant (a selective estrogen receptor degrader) in patients with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that had progressed while receiving endocrine therapy,<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> as well as in combination with a nonsteroidal aromatase inhibitor for postmenopausal patients with advanced HR-positive, HER2-negative breast cancer.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><div class="NLM_p">A convergent approach to the assembly of abemaciclib was disclosed in a 2014 patent application from Lilly.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> In the sequence shown in <a class="ref internalNav" href="#sch38" aria-label="Schemes 38">Schemes 38</a> and <a class="ref internalNav" href="#sch39" aria-label="39">39</a>, in which some reactions were exemplified on kilogram scale, the molecule was subdivided synthetically into three distinct subunits: aminopyridine <b>170</b>, chloropyrimidine <b>176</b>, and benzimidazole <b>175</b>. This efficient synthetic strategy avoids the use of protecting groups and chromatographic purification across the entire sequence, which is particularly noteworthy considering the use of palladium in the final three steps of the sequence. Aminopyridine <b>170</b> was accessed in two steps, beginning with the reductive amination of 6-bromonicotinaldehyde (<b>168</b>) with ethylpiperizine <b>167</b> to form bromopyridine <b>169</b> (<a class="ref internalNav" href="#sch38" aria-label="Scheme 38">Scheme 38</a>). This compound was then converted to aminopyridine <b>170</b> through an Ullman coupling employing ammonia and copper oxide.</div><figure id="sch38" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0043.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 38. Synthesis of Abemaciclib Aminopyridine <b>170</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A Vilsmeier-type reagent was formed by the addition of <i>N</i>-isopropylacetamide (<b>172</b>) to phosphorus oxychloride (<a class="ref internalNav" href="#sch39" aria-label="Scheme 39">Scheme 39</a>). Upon exposure to 4-bromo-2–5-fluoroaniline <b>171</b>, amidine <b>173</b> was formed, which then underwent base-induced intramolecular cyclization in warm DMF to form benzamidazole <b>174</b>. Miyaura borylation converted <b>174</b> to the corresponding boronic ester <b>175</b>, which then underwent Suzuki coupling with commercial aryl dichloride <b>176</b>, giving rise to the penultimate chloropyrimidine <b>177</b>. Finally, a palladium catalyzed Buchwald–Hartwig amination with aminopyridine <b>170</b> using Pd<sub>2</sub>(dba)<sub>3</sub> in combination with Xantphos completed the synthesis of abemaciclib (<b>XVIII</b>) in five steps in the longest linear sequence, with seven steps overall.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><figure id="sch39" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0044.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 39. Synthesis of Abemaciclib (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch39"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66">8.2.  Acalabrutinib (Calquence)</h3><div class="NLM_p">Acalabrutinib is a small molecule drug developed by Netherlands-based Acerta Pharma (now a subsidiary of AstraZeneca) for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The drug, which received approval in October 2017 from the USFDA, is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and achieves a half-maximal inhibitory concentration (IC<sub>50</sub>) of 3 nM against purified BTK in vitro.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The drug exhibited a higher selectivity for BTK than ibrutinib in a competitive binding assay and, in contrast to ibrutinib, does not inhibit EGFR, ITK, or TXK.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Acalabrutinib was designated by the USFDA as a breakthrough therapy and clinical trials for chronic lymphocytic leukemia (CLL) are currently underway.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><div class="NLM_p">Several small-scale synthetic approaches to the synthesis of acalabrutinib have been reported.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> An efficient and creative process preparation has been reported in two 2017 patents by the Chinese firm Suzhou Mingrui Pharmaceutical Technology Co., Ltd. and is described in <a class="ref internalNav" href="#sch40" aria-label="Scheme 40">Scheme 40</a>.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Conversion of 4-bromobenzoic acid (<b>178</b>) to the corresponding acid chloride preceded amide-bond formation with 2-aminopyridine. This step was immediately followed by Miyaura borylation with catalytic Pd(dppf)Cl<sub>2</sub>. Subsequent hydrolysis through the use of hydrochloric acid with sodium periodate in aqueous THF furnished boronic acid <b>179</b>. Next, a clever use of a Petasis reaction involving commercial pyrazinyl aldehyde <b>180</b> in the presence of ammonia in aqueous 1,4-dioxane yielded racemic branched amine <b>181</b> in 81% overall yield from <b>178</b>.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> At this stage, establishment of the core heterocycle took place through a modified Filmier cyclization. Although typically this reaction encompasses the preparation of imidazopyridines, the approach in this case has been extended to the construction of imidazopyrazine <b>183</b>.<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95,96)</a> To this end, amidation of amine <b>181</b> and proline derivative <b>182</b> proceeded via the corresponding acid chloride. Exposure of the resulting product to phosphorus oxychloride in acetonitrile at elevated temperatures gave rise to chloroimidazopyrazine <b>183</b>. Lastly, treatment of <b>183</b> with ammonia in 2-propanol facilitated a S<sub>N</sub>Ar reaction to furnish acalabrutinib (<b>XIX</b>) in 86% overall yield from <b>181</b>.</div><figure id="sch40" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Scheme 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0045.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 40. Synthesis of Acalabrutinib (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch40"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68">8.3.  Brigatinib (Alunbri)</h3><div class="NLM_p">Brigatinib, an oral anaplastic lymphoma kinase (ALK) inhibitor developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company, was granted accelerated approval by the USFDA in April 2017 for the treatment of patients with metastatic ALK-positive nonsmall cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> A majority of patients treated with first-generation ALK inhibitors like crizotinib develop disease progression within one to two years post-treatment and acquire resistance.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Brigatinib has demonstrated in vitro activity against a panel of 17 ALK mutants that confer resistance to first-generation inhibitors, as well as substantial and durable responses in phase I/II and ALTA clinical trials after progression on crizotinib. Unique to brigatinib’s architecture is its dimethylphosphine oxide moiety, which serves as a hydrogen-bond acceptor designed to drive potency, selectivity, and favorable ADME properties.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><div class="NLM_p">Brigatinib was readily synthesized in five steps, with an assembly strategy consisting of a metal-catalyzed reaction to introduce the phosphine oxide functional group and three S<sub>N</sub>Ar reactions.<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99,100)</a> Although reaction yields were not reported, the largest scale route was exemplified in a patent published by Ariad in 2017 and this sequence is depicted in <a class="ref internalNav" href="#sch41" aria-label="Scheme 41">Scheme 41</a>.<a onclick="showRef(event, 'cit100e'); return false;" href="javascript:void(0);" class="ref cit100e">(100e)</a> Phosphine oxide <b>185</b> was prepared from 2-iodoaniline (<b>184</b>) and dimethylphosphine oxide under modified Hirao conditions employing palladium acetate and Xantphos. Remarkably, this reaction represents one of the few reported examples of <i>P</i>-arylation of aryl halides involving a dialkyl- or diaryl-phosphine oxide in the presence of an unsubstituted aniline.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Trichloropyrimidine <b>186</b> next underwent sequential nucleophilic aromatic substitution reactions, first with aniline <b>185</b> to give intermediate <b>187</b>, and then with aniline <b>188</b> (preparation in <a class="ref internalNav" href="#sch42" aria-label="Scheme 42">Scheme 42</a>) to afford brigatinib (<b>XX</b>).</div><figure id="sch41" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0046.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 41. Synthesis of brigatinib (<b>XX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Aniline <b>188</b> was prepared in two steps via an S<sub>N</sub>Ar displacement of fluoronitroarene <b>189</b> with piperidine <b>190</b> followed by hydrogenative nitro reduction (<a class="ref internalNav" href="#sch42" aria-label="Scheme 42">Scheme 42</a>). No yields were reported.</div><figure id="sch42" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Scheme 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0047.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 42. Synthesis of Brigatinib Aniline <b>188</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch42"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71">8.4.  Copanlisib Hydrochloride (Aliqopa)</h3><div class="NLM_p">Copanlisib is an inhibitor of pan-class I phosphoinositide 3-kinase (PI3K) approved by the USFDA for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> The drug was developed and launched by Bayer in 2017. It is also currently in phase III trials for the treatment of relapsed/refractory diffuse large B-cell lymphoma, and it is under evaluation in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma in combination with rituximab or rituximab-based chemotherapy or standard immunochemotherapy.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The drug is administered as an intravenous infusion on a weekly but intermittent schedule (3 weeks on and 1 week off) and is currently approved only in the United States.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">Although multiple synthetic approaches to copanlisib have been reported in the patent literature,<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> the most likely large scale synthesis of copanlisib follows a linear sequence disclosed in a patent from Bayer and is described in <a class="ref internalNav" href="#sch43" aria-label="Scheme 43">Scheme 43</a>.<a onclick="showRef(event, 'cit104a'); return false;" href="javascript:void(0);" class="ref cit104a">(104a)</a> Nitration of 4-formyl-2-methoxyphenyl acetate (<b>191</b>) gave nitroarene <b>192</b>. Next, saponification of the acetate within <b>192</b> followed by acidic pH adjustment and last benzylation furnished aldehyde <b>193</b>, which then underwent condensation with ethylene diamine (<b>194</b>) to arrive at imidazoline <b>195</b>. Selective nitro reduction of <b>196</b> followed by treatment with cyanogen bromide in base secured the key tricyclic core of the drug’s substructure <b>197</b>. Interestingly, the catalytic hydrogenation conditions which reduced the nitro group did not remove the benzyl ether protecting group, presumably necessitating resubjection of <b>197</b> to a second hydrogenation to liberate phenol <b>198</b>. Next, base-mediated alkylation installed the morpholine side chain. This was followed by coupling with acid <b>201</b> to ultimately provide copanlisib (<b>XXI</b>) in 96% yield.</div><figure id="sch43" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Scheme 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0048.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 43. Synthesis of Copanlisib (<b>XXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch43"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73">8.5.  Enasidenib (Idhifa)</h3><div class="NLM_p">Enasidenib is a selective inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) that was developed by Agios and later licensed to Celgene. The drug was approved by the USFDA for the treatment of patients with relapsed or refractory acute myeloid leukemia with IDH2 mutation.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> IDH2 catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG) in the citric acid cycle.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> The mutant enzyme reduces α-KG further to <i>R</i>-2-hydroxyglutarate (2-HG), which leads to hypermethylation of histones and DNA.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Elevated levels of 2-HG have been used as a biomarker for IDH1 or IDH2 mutated cells.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Likely due to enasidenib’s high selectivity for mutant IDH2, the drug was well-tolerated in clinical trials and did not exhibit significant off-target cytotoxicity.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><div class="NLM_p">The only reported synthesis of enasidenib was described in a 2015 patent application filed by Agios which involves a linear seven-step process to construct the API (no yields were reported for any of the transformations in this disclosure).<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Although it is possible that this route could have been one of the first-generation approaches to the drug, the procedure avoids the use of protecting groups. 2-(Trifluoromethyl)pyridine <b>202</b> (<a class="ref internalNav" href="#sch44" aria-label="Scheme 44">Scheme 44</a>) underwent metalation with <i>n</i>-BuLi followed by carbon dioxide quench to prepare the carboxylic acid intermediate, which was converted to methyl ester <b>203</b> using acetyl chloride in methanol. Next, triazine dione <b>205</b> was formed by condensation of <b>203</b> with carbamyl urea <b>204</b> in the presence of sodium ethoxide in ethanol. This reaction was followed by chlorination using phosphorus pentachloride and phosphorus oxychloride to generate <b>206</b>. Dichlorotriazine <b>206</b> underwent two sequential S<sub>N</sub>Ar reactions, first with aminopyridine <b>207</b> and then with ethanolamine <b>209</b> to access enasidenib <b>210</b> as the free base. Subjection of this compound to methanesulfonic acid in acetone yielded enasidenib mesylate (<b>XXII</b>).</div><figure id="sch44" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Scheme 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0049.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 44. Synthesis of Enasidenib (<b>XXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch44"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75">8.6.  Inotuzumab Ozogamicin (Besponsa)</h3><div class="NLM_p">Inotuzumab ozogamicin is an antibody drug conjugate (ADC) approved by the USFDA for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Inotuzumab ozogamicin consists of a conjugate of an anti-CD22 monoclonal antibody with the potent DNA double-strand cleaving payload, <i>N</i>-acetyl-γ-calicheamicin.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> The payload is linked through lysines on the antibody using a hydrolytically cleavable linker that releases the payload in the acidic environment of the lysosome after internalization of the ADC. There are approximately six payload molecules/antibody. Inotuzumab ozogamicin was discovered in the Lederle laboratories of American Cyanamid. After the merger between American Cyanamid and American Home Products, the combined company was eventually renamed Wyeth. In 2009, Wyeth was acquired by Pfizer, where the development and launch of inotuzumab ozogamicin was completed. Pfizer also completed the relaunch of Mylotag (gemtuzumab ozogamicin), an ADC that incorporates the same calicheamicin based linker-payload conjugated to an anti-CD33 antibody and is approved to treat a certain type of acute myeloid leukemia (AML).<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">The synthesis of the linker of inotuzumab ozogamicin began with the 1,4-addition of (4-methoxyphenyl)methanethiol (<b>211</b>) to methyl 3-methylbut-2-enoate (<b>212</b>) followed by basic hydrolysis of the resulting ester to give thioether <b>213</b> in 89% yield (<a class="ref internalNav" href="#sch45" aria-label="Scheme 45">Scheme 45</a>).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Activation of the acid with 1,1′-carbonyldiimidazole (CDI) followed by treatment with hydrazine monohydrate gave hydrazide <b>214</b> in 97% yield. Condensation of hydrazide <b>214</b> and ketone <b>215</b> using acetic acid provided hydrazone <b>216</b>, which was treated with trifluoroacetic acid and anisole to give thiol <b>217</b> in 94% yield. The mixed anhydride of the carboxylic acid group of <b>217</b> was generated by treatment with pivaloyl chloride and triethyl amine and the resulting anhydride was reacted with <i>N</i>-hydroxysuccinimide (NHS) to give the NHS ester <b>218</b> in 92% yield.</div><figure id="sch45" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Scheme 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0050.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 45. Synthesis of the Inotuzumab Ozogamicin Linker Fragment <b>218</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The completion of the synthesis of inotuzumab ozogamicin is described in <a class="ref internalNav" href="#sch46" aria-label="Scheme 46">Scheme 46</a>. Calicheamicin (<b>219</b>) was obtained from the fermentation of <i>Micromonospora echinospora</i> ssp. <i>calichenis</i><a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> and was aceylated to give <i>N</i>-acetyl-calicheamicin <b>220</b> in 80% yield.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> The linker <b>218</b> was coupled to <b>220</b> in the presence of EDCI and triethylamine to give the disulfide containing linker-payload <b>221</b> in 60% yield.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The linker-payload was conjugated to the anti-CD22 mAb G-544 using the conditions described in <a class="ref internalNav" href="#sch46" aria-label="Scheme 46">Scheme 46</a> to give inotuzumab ozogamicin (<b>XXIII</b>) in 60% yield based on the amount of protein with approximately six linker/payloads per antibody.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div><figure id="sch46" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Scheme 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0051.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 46. Synthesis of Inotuzumab Ozogamicin (<b>XXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch46"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78">8.7.  Midostaurin (Rydapt)</h3><div class="NLM_p">Midostaurin is a natural product-based multitargeted kinase inhibitor approved in 2017 for the treatment of FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukemia (AML).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The approval includes use as a combination therapy with standard chemotherapy treatments such as daunorubicin and cytarabine.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Midostaurin represents the first multikinase inhibitor therapy approved for FTL3 mutant AML.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Although originally studied as an inhibitor of protein kinase C, in 2001, midostaurin became the topic of collaborations between Novartis and the Dana-Farber Cancer Institute to identify inhibitors of mutant FLT3-positive AML.<a onclick="showRef(event, 'cit116b'); return false;" href="javascript:void(0);" class="ref cit116b">(116b)</a> In clinical trials, combination therapy of midostaurin with chemotherapy resulted in 80% complete response among patients and led to significantly increased survival time versus placebo.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> The activity of midostaurin against AML relies on a reversible binding event with a variety of kinases, including stem cell factor receptors (c-KIT) and mutated and wild-type FLT3 kinases, overall resulting in inhibition of cell signaling pathways and leading to diminished cell growth and apoptosis.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></div><div class="NLM_p">While the drug was approved as a combination therapy for FLT3-positive AML, midostaurin was also approved as a monotherapy for more rare blood disorders such as aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).<a onclick="showRef(event, 'ref116 ref118'); return false;" href="javascript:void(0);" class="ref ref116 ref118">(116,118)</a></div><div class="NLM_p">Midostaurin was generated via semisynthesis<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> from the natural product staurosporine,<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> which can be produced via a variety of fermentation processes.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Acylation of staurosporine <b>222</b> (<a class="ref internalNav" href="#sch47" aria-label="Scheme 47">Scheme 47</a>) with benzoic anhydride (<b>223</b>) provided midostaurin (<b>XXIV</b>) in 82% yield.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div><figure id="sch47" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Scheme 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0052.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 47. Synthesis of Midostaurin (<b>XXIV</b>) from Staurosporine (<b>222</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch47"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80">8.8.  Neratinib (Zykadia)</h3><div class="NLM_p">Neratinib was approved by the USFDA in 2017 for the extended adjuvant treatment of HER2-positive breast cancer following adjuvant treatment with trastuzumab, a humanized HER2 monoclonal antibody, based upon a statistically significant impact on invasive disease free survival.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Discovered by Wyeth and currently marketed by Puma Biotechnology, Inc., neratinib is an irreversible inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) kinases, the latter being overexpressed in 20–25% of breast cancer patients.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> An interesting feature of the neratibib structure involves the terminal dimethylamino functionality in proximity to a 2-butenoyl group. By design, the terminal amine functions as a base to deprotonate a nucleophilic active-site cysteine residue (Cys773 (EGFR) and Cys805 (HER2)), thereby catalyzing a 1,4-addition to the 2-butenoyl group, resulting in covalent linkage between the inhibitor and the kinase.</div><div class="NLM_p">Three patents were published by Wyeth detailing the process-scale approach to the drug: two focusing on various routes to neratinib<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> and one emphasizing methods to introduce the 4-dimethylamino-2-butenoyl side chain.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Starting with aniline <b>224</b>, an addition–elimination reaction with ethyl 2-cyano-3-ethoxyacrylate (<b>225</b>) in warm toluene afforded vinylogous amide <b>226</b> in high yield (<a class="ref internalNav" href="#sch48" aria-label="Scheme 48">Scheme 48</a>). Subsequent heating of <b>226</b> at elevated temperature (approximately 250 °C) led to a cyclization reaction providing quinolone <b>227</b> in modest efficiency (42% yield). Treatment of <b>227</b> with POCl<sub>3</sub> at reflux converted the hydroxyl group to the corresponding chloride <b>228</b>, thereby completing the synthesis of the cyanoquinoline core. The anilino-side chain <b>229</b> (which is synthesized as described in <a class="ref internalNav" href="#sch49" aria-label="Scheme 49">Scheme 49</a>) was introduced via S<sub>N</sub>Ar reaction with <b>228</b>. As scale increased for this transformation, catalytic methanesulfonic acid was found to be important for optimal yields of <b>230</b>. Intermediate <b>230</b> was carried directly into the acetyl hydrolysis step (2.7 N HCl in water, reflux) and subsequent neutralization (K<sub>2</sub>CO<sub>3</sub>, MeOH) to afford <b>231</b> in 86% conversion from <b>228</b>. Lastly, introduction of the 4-dimethylamino-2-butenoyl side chain required significant optimization due to stability issues of the acid chloride on scale. One method that proved highly effective involved conversion of the commercial acid <b>232</b> to the acid chloride-HCl salt <b>233</b> with oxalyl chloride and catalytic DMF. The selection of isopropyl acetate as solvent was critical in promoting precipitation of <b>233</b> as an isolable solid. Addition of aniline <b>231</b> to acid chloride <b>233</b> in chilled NMP afforded neratinib in improved yield (85–98% vs 60–75%) and purity (96–98% vs 85–90%) when compared to using a solvent such as THF. Dissolving neratinib and malic acid (1:1) in <i>n</i>-propanol/water (9:1) with heating provided neratinib maleate (<b>XXV</b>) following isolation.</div><figure id="sch48" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Scheme 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0053.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 48. Synthesis of Neratinib Maleate (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Side chain <b>229</b> arose from exposure of fluoroarene <b>234</b> to 2-pyridyl methanol (<b>235</b>) with flake KOH in acetonitrile followed by platinum-mediated hydrogenation (<a class="ref internalNav" href="#sch49" aria-label="Scheme 49">Scheme 49</a>). <b>229</b> was carried forward as a solution.</div><figure id="sch49" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Scheme 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0054.jpeg" id="gr49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 49. Synthesis of Neratinib Anilino Side Chain <b>229</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch49"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83">8.9.  Niraparib (Zejula)</h3><div class="NLM_p">Niraparib was approved by the USFDA in March 2017 for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Niraparib is an oral poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor discovered by Merck and developed by Tesaro and is the first approved PARP inhibitor that does not require BRCA or other biomarker testing. PARP-1 and PARP-2 play a role in DNA repair, with inhibition resulting in DNA damage, apoptosis, and cell death.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div><div class="NLM_p">Researchers from Merck have published several approaches to niraparib.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The route in <a class="ref internalNav" href="#sch50" aria-label="Schemes 50">Schemes 50</a> and <a class="ref internalNav" href="#sch51" aria-label="51">51</a>, while not the largest scale reported in the patent literature, is potentially the most scalable, relying upon a late stage C–N bond coupling between aryl bromide <b>244</b> and indazole <b>246</b>, along with a key transaminase-mediated asymmetric synthesis of the piperidine substructure within <b>244</b>.<a onclick="showRef(event, 'cit129b'); return false;" href="javascript:void(0);" class="ref cit129b">(129b)</a> An earlier, fit-for-purpose process chemistry route, which was reportedly used to provide kilogram-scale material to support early development work, was deemed unsuitable for further development due to the use of chiral chromatography and azide-containing reagents.<a onclick="showRef(event, 'cit129c'); return false;" href="javascript:void(0);" class="ref cit129c">(129c)</a> Details associated with the asymmetric transaminase reaction to establish chirality within piperidine <b>244</b> along with the merits and challenges of various routes to niraparib (as well as other PARP inhibitors) have been nicely reviewed by Hughes.<a onclick="showRef(event, 'cit129d'); return false;" href="javascript:void(0);" class="ref cit129d">(129d)</a></div><div class="NLM_p">Bearing a challenging chiral center at the 3-position, piperidine <b>244</b> was prepared asymmetrically in nine steps and an impressive 44% overall yield (<a class="ref internalNav" href="#sch50" aria-label="Scheme 50">Scheme 50</a>).<a onclick="showRef(event, 'cit129b cit129d cit129g cit129h'); return false;" href="javascript:void(0);" class="ref cit129b cit129d cit129g cit129h">(129b,d,g,h)</a> Solvent-free Friedel–Crafts acylation of bromobenzene (<b>237</b>) with succinic anhydride (<b>238</b>) and subsequent esterification afforded isopropyl ester <b>239</b>. The choice of the isopropyl group proved important as the corresponding methyl and ethyl esters were prone to hydrolysis during the transaminase step. One-carbon homologation was next affected by an epoxidation/rearrangement sequence involving the subjection of <b>239</b> to Me<sub>3</sub>SOI followed by ZnBr<sub>2</sub> that gave aldehyde <b>240</b> as a solution in toluene. As this aldehyde was unstable and not crystalline, it was converted to bisulfite adduct <b>241</b>, which could be partitioned into the aqueous layer and was used directly without isolation. Optimized conditions for the transaminase reaction were found to employ enzyme ATA-302, pyridoxal-5-phosphate (PLP, <b>242</b>) as cocatalyst, and isopropylamine as an amine donor at pH 10.5 in aqueous DMSO. After filtration and solvent switch to isopropyl acetate, γ-arylvalerolactam <b>243</b> was crystallized in 84% yield. Reduction of the carboxyl group (NaBH<sub>4</sub>, BF<sub>3</sub>·THF) followed by Boc <i>N</i>-protection afforded coupling partner <b>244</b>.</div><figure id="sch50" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Scheme 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0055.jpeg" id="gr50" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 50. Synthesis of Niraparib Piperidinyl Aryl Bromide <b>244</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Aryl bromide <b>244</b> was then coupled to indazole <b>246</b>, which was synthesized from indazole-7-carboxylic acid (<b>245</b>) by amidation with <i>t</i>-butylamine (<a class="ref internalNav" href="#sch51" aria-label="Scheme 51">Scheme 51</a>). The C–N coupling of <b>244</b> and <b>246</b> was the focus of extensive optimization. The conditions ultimately identified (CuBr, K<sub>2</sub>CO<sub>3</sub>, DMA, 8-hydroxyquinoline at 110 °C) afforded product <b>247</b> in 94% yield. The <i>t</i>-butyl amide within <b>246</b> was designed to influence regiochemical <i>N</i>-arylation at the desired <i>N</i>-2 position, and indeed excellent selectivity over the undesired <i>N</i>-1 counterpart (<0.5%) was observed. The desired product could be crystallized from the reaction mixture by addition of 10% aqueous citric acid. Concomitant removal of the Boc and <i>t</i>-butyl groups in <b>247</b> was facilitated by use of MeSO<sub>3</sub>H in <i>o</i>-xylene. Cleverly, the choice of <i>o</i>-xylene as solvent accelerated the <i>t</i>-Bu amide deprotection, presumably by scavenging the <i>t</i>-Bu cation. Following addition of water, niraparib partitioned into the acidic aqueous layer where, due to significant solubility differences between the mesylate and tosylate salts, the tosylate salt could be crystallized by addition of 1.5 equiv of <i>p</i>-TsOH monohydrate to afford niraparib tosylate monohydrate (<b>XXVI</b>).</div><figure id="sch51" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Scheme 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0056.jpeg" id="gr51" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 51. Synthesis of Niraparib Tosylate Monohydrate (<b>XXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch51"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86">8.10.  Ribociclib Succinate (Kisqa)</h3><div class="NLM_p">Ribociclib is a CDK4/6 inhibitor indicated for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Both CDK4 and CDK6 are thought to be involved in the signaling pathway for growth and proliferation of breast cancer cells, thus their inhibition causes cell cycle arrest.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The drug is also undergoing evaluation in phase I/II trials for various solid tumor types and hematological malignancies.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Ribociclib, which is marketed by Novartis, was approved by the USFDA and European Medicines Agency (EMA).</div><div class="NLM_p">Although numerous synthetic approaches to ribociclib have been reported in the patent literature,<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> an efficient approach exemplified on large scale has been reported by researchers at Tsingtao Chenda Biological Technology Co., Ltd., as detailed in <a class="ref internalNav" href="#sch52" aria-label="Schemes 52">Schemes 52</a> and <a class="ref internalNav" href="#sch53" aria-label="53">53</a>.<a onclick="showRef(event, 'cit131b'); return false;" href="javascript:void(0);" class="ref cit131b">(131b)</a> Reaction of dichloropyrimidine (<b>248</b>) and cyclopentylamine (<b>249</b>) furnished pyrimidine <b>250</b> in 92% yield.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> This was followed by treatment with bromooxylate <b>251</b> (whose preparation involved converting 2-oxopropanoic acid (<b>254</b>) to the corresponding dimethyl amide, followed by bromination (<a class="ref internalNav" href="#sch53" aria-label="Scheme 53">Scheme 53</a>)) to give rise to the key pyrrolopyrimidine fragment <b>252</b> in 78% yield. Lastly, subjection of <b>252</b> to <i>tert</i>-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate <b>253</b> in the presence of Pd(OAc)<sub>2</sub>, BINAP, and Cs<sub>2</sub>CO<sub>3</sub> followed by acidic Boc removal secured ribociclib (<b>XXVII</b>) in 84% across the two-step sequence.</div><figure id="sch52" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Scheme 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0057.jpeg" id="gr52" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 52. Synthesis of Ribociclib (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch53" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Scheme 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0058.jpeg" id="gr53" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 53. Synthesis of Ribociclib Bromooxylate <b>251</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch53"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89">8.11.  Telotristat Ethyl (Xermelo)</h3><div class="NLM_p">Telotristat ethyl is a first-in-class peripheral oral tryptophan hydroxylase (TPH) inhibitor developed by Lexicon Pharmaceuticals.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The drug was approved for the first time in February 2017 in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy and has been filed for regulatory approval in the EU and Switzerland for treatment of carcinoid syndrome.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Patients treated with telotristat ethyl exhibited a reduction in serotonin (5-HT) levels (via inhibition of TPH, which mediates the rate limiting step in 5-HT production), thereby decreasing the frequency of carcinoid syndrome symptoms.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Telotristat ethyl is sold as the hippurate salt (telotristat etiprate) and functions as a prodrug of the corresponding carboxylic acid.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><div class="NLM_p">Several patents have been published by Lexicon describing the synthesis of structurally related analogues of telotristat ethyl.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> The approach described in <a class="ref internalNav" href="#sch54" aria-label="Schemes 54">Schemes 54</a> and <a class="ref internalNav" href="#sch55" aria-label="55">55</a> represents the most likely scalable approach to the drug, including its hippurate salt formation.<a onclick="showRef(event, 'cit135a cit135b'); return false;" href="javascript:void(0);" class="ref cit135a cit135b">(135a,b)</a> Beginning with <i>N</i>-Boc-tyrosine methyl ester (<b>255</b>), triflation of the phenol preceded Miyaura installation of the pinacol borane. Careful saponification of the methyl ester to arrive at pinacol boronate <b>256</b> was achieved through the use of lithium hydroxide followed by acidic pH adjustment. Next, palladium-catalyzed cross-coupling of borane <b>256</b> with pyrimidyl chloride <b>257</b> was followed by aqueous citric acid quench. Control of pH (∼4) was critical for isolation of crude product which required no chromatographic purification to give amino acid <b>258</b>. Ether formation involving trifluoroalcohol <b>259</b> (whose synthesis is described in <a class="ref internalNav" href="#sch55" aria-label="Scheme 55">Scheme 55</a>) and pyrimidyl chloride <b>258</b> was affected by means of cesium carbonate in dioxane at elevated temperatures, but these conditions also partially removed the Boc group. Because the Boc group allowed for purification and isolation from any unreacted alcohol <b>259</b>, the crude reaction mixture was subjected to Boc anhydride followed by pH adjustment using 6 N HCl to allow for the construction of <b>260</b> in good overall yield. At this stage, the Boc group was deliberately removed with concentrated HCl in warm THF. This was followed by adjustment of pH to ∼6.1 using a buffer consisting of sodium hydroxide and phosphoric acid to furnish telotristat (<b>261</b>). Treatment of amino acid <b>261</b> with thionyl chloride and ethanol secured the ethyl ester, and subsequent subjection to hippuric acid in warm isopropyl acetate and ethanol furnished telotristat ethyl as the hippurate salt (<b>XXVIII</b>).</div><figure id="sch54" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Scheme 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0059.jpeg" id="gr54" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 54. Synthesis of Telotristat Ethyl (<b>XXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preparation of telotristat trifluoroalcohol fragment <b>259</b> is described in <a class="ref internalNav" href="#sch55" aria-label="Scheme 55">Scheme 55</a>.<a onclick="showRef(event, 'cit135a cit135b'); return false;" href="javascript:void(0);" class="ref cit135a cit135b">(135a,b)</a> 3-Methylpyrazole <b>262</b> participated in an aromatic substitution reaction with aryl fluoride <b>263</b> in the presence of potassium <i>t</i>-butoxide in DMSO. The reaction went to completion but gave a 5:1 distribution of arylated pyrazole regioisomers which could be separated by recrystallization. The major product, which was recovered in 83% yield, was pyrazole <b>264</b>. Next, Grignard formation was followed by quench with ethyl trifluoroacetate, providing ketone <b>265</b>. An asymmetric transfer hydrogenation utilizing an iridium catalyst and ligand <b>266</b> converted ketone <b>265</b> into trifluoroalcohol <b>259</b> in remarkable yield and purity: 99% ee and 94% yield. None of the steps in the sequence described in <a class="ref internalNav" href="#sch55" aria-label="Scheme 55">Scheme 55</a> required silica gel chromatography.</div><figure id="sch55" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Scheme 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0060.jpeg" id="gr55" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 55. Preparation of Trifluoroalcohol Fragment <b>259</b> for Telotristat Ethyl</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch55"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92">8.12.  Tivozanib (Fotivda)</h3><div class="NLM_p">Tivozanib was approved in the European Union, Norway, and Iceland during 2017 for the treatment of patients with renal cell carcinoma (RCC), both as first-line treatment and for vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naïve patients showing progression after previous cytokine therapy for RCC.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> As a highly selective, potent VEGFR tyrosine kinase inhibitor (VEGFR-TKI), tivozanib, was designed to target all three VEGF receptors, resulting in inhibition of angiogenesis and vascular permeability, thereby leading to decreased tumor growth.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Clinically, a phase 3 trial of tivozanib showed an improved progression-free survival profile compared to other standard VEGFR-TKI treatment for RCC (sorafenib).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> However, it ultimately demonstrated an inferior overall survival rate, resulting in approval by the EMA but rejection by the USFDA.<a onclick="showRef(event, 'cit137a'); return false;" href="javascript:void(0);" class="ref cit137a">(137a)</a> Tivozanib was discovered by Kyowa Hakko Kirin and later licensed to Aveo Pharmaceuticals. In Europe, further licensing agreements have been made between Aveo and Eusa Pharma.<a onclick="showRef(event, 'cit136a'); return false;" href="javascript:void(0);" class="ref cit136a">(136a)</a></div><div class="NLM_p">While a number of routes to various forms of tivozanib have been reported in recent years,<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> a scale synthesis of tivozanib hydrochloride monohydrate has been reported by Matsunaga and co-workers,<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> beginning with kilogram quantities of 3,4-dimethoxyacetophenone (<b>267</b>, <a class="ref internalNav" href="#sch56" aria-label="Scheme 56">Scheme 56</a>). Nitration of <b>267</b> under standard conditions (HNO<sub>3</sub>, NaNO<sub>2</sub>) and subsequent nitro reduction (H<sub>2</sub>, Pd/C) provided aniline <b>268</b> in 53% over the two-step sequence.<a onclick="showRef(event, 'cit140b ref141'); return false;" href="javascript:void(0);" class="ref cit140b ref141">(140b,141)</a> Quinolone <b>269</b> could be readily accessed in 82% yield by reaction of ethyl formate with a prestirred solution of <b>268</b> and sodium methoxide, providing a means for synthesis of 4-chloroquinolone <b>270</b> via chlorination with POCl<sub>3</sub> in toluene (88% yield). Reaction of chloroquinoline <b>270</b> with phenol <b>271</b>, facilitated by <i>t</i>-BuOK in warm DMA, provided aniline <b>272</b> in 70% yield.<a onclick="showRef(event, 'cit140b'); return false;" href="javascript:void(0);" class="ref cit140b">(140b)</a> Finally, the urea functionality was installed via reaction of <b>272</b> with the phenyl carbamate of 3-amino-5-methylisoxazole <b>273</b> and benzyl chloroformate, providing the free base form of tivozanib in 86% yield after precipitation from a methanol and water mixture. The hydrochloride monohydrate salt of tivozanib was generated by subjection of tivozanib free base to hot ethanolic HCl and subsequent precipitation to provide the final drug target tivozanib hydrochloride (<b>XXIX</b>) in 75% yield (1 kg scale).<a onclick="showRef(event, 'cit140b'); return false;" href="javascript:void(0);" class="ref cit140b">(140b)</a></div><figure id="sch56" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Scheme 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0061.jpeg" id="gr56" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 56. Synthesis of Tivozanib Hydrochloride (<b>XXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch56"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">9.  Ophthalmologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27030" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27030" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95">9.1.  Latanoprostene Bunod (Vyzulta)</h3><div class="NLM_p">Latanoprostene bunod is a dual acting nitric oxide donating prostaglandin F2a analogue approved by the USFDA for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> The drug is thought to lower IOP by increasing aqueous humor outflow through the uveoscleral pathway (mediated by latanoprost acid) and increasing the facility of aqueous humor outflow through the trabecular meshwork pathway (mediated by NO).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Latanoprostene bunod was discovered by NicOx in collaboration with Pfizer and licensed to Bausch & Lomb, which completed its development and commercialization.</div><div class="NLM_p">The synthesis of latanoprostene bunod has only been reported on small scale in the patent literature.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Tetrahydrofuran (<b>274</b>) was treated with hydrogen bromide to give 4-bromobutanol in 77% yield (<a class="ref internalNav" href="#sch57" aria-label="Scheme 57">Scheme 57</a>). Reaction of 4-bromobutanol with fuming nitric acid in sulfuric acid gave 4-bromobutyl nitrate (<b>275</b>) in 96% yield. Commercial latanoprost acid (<b>276</b>) was treated with bromide <b>275</b> in the presence of potassium iodide and potassium carbonate to give latanoprostene bunod (<b>XXX</b>). No yield was provided for the esterification.</div><figure id="sch57" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Scheme 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0062.jpeg" id="gr57" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 57. Synthesis of Latanoprostene Vunod (<b>XXX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch57"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97">9.2.  Netarsudil (Rhopressa)</h3><div class="NLM_p">Developed by Aerie Pharmaceuticals, netarsudil received USFDA approval for the treatment of open-angle glaucoma or ocular hypertension. The drug is dosed topically as a 0.02% opthamalic solution.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Netarsudil’s biological activity is due to inhibition of Rho-associated protein kinase (ROCK) and norepinephrine transporter (NET).<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> ROCK inhibition relaxes the trabecular meshwork cells, increases aqueous humor outflow, and ultimately lowers IOP.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Inhibition of NET results in decreased aqueous humor production.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p">A process for the synthesis of netarsudil has been described in both a patent application and a recent publication from Aerie, which featured a linear sequence beginning from (2-<i>p</i>-tolyl)acetic acid (<b>277</b>), as described in <a class="ref internalNav" href="#sch58" aria-label="Schemes 58">Schemes 58</a> and <a class="ref internalNav" href="#sch59" aria-label="59">59</a>.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> The key step hinged upon an asymmetric alkylation influenced by the economical and readily available Evans oxazolidinone auxiliary. Bromination of (2-<i>p</i>-tolyl)acetic acid (<b>277</b>) with NBS furnished the corresponding benzyl bromide which underwent displacement by hydroxide and subsequent acid-mediated esterification to generate benzyl alcohol <b>278</b>. Esterification with 2,4-dimethylbenzoic acid (<b>279</b>) provided <b>280</b>. Saponification of the methyl ester followed by generation of the corresponding acid chloride and reaction of the lithium amide of <b>281</b> provided oxazolidinone <b>282</b>, which was set for the key asymmetric alkylation step.</div><figure id="sch58" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Scheme 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0063.jpeg" id="gr58" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 58. Preparation of Netarsudil Oxazolidinone Fragment <b>282</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Enolization of <b>282</b> with LiHMDS at low temperature followed by introduction of commercial <b>283</b> in THF produced α-chiral amide <b>284</b> in 68% yield and 96:4 diastereomeric ratio (<a class="ref internalNav" href="#sch59" aria-label="Scheme 59">Scheme 59</a>). Although the minor diastereomer could be removed chromatographically, the authors could carry the mixture forward through hydrogen peroxide-mediated removal of the oxazolidinone to produce acid <b>285</b>. A series of recrystallizations eventually provided the product with excellent enantiomeric excess (>99% ee). After considerable optimization, carboxylic acid <b>285</b> was then carefully converted to isoquinoline amide <b>288</b> through unusual conditions involving 6-aminoisoquinoline (<b>286</b>), collidine, and 2,2,2-trichloro-1,1-dimethylethylchloroformate (<b>287</b>). The authors claim that the use of dimethyl chloroformate <b>287</b> in this reaction is the first report of its use as an amide coupling reagent (although other chloroformates have been utilized as coupling reagents). In this case, <b>287</b> was particularly effective at minimizing epimerization of the α-carboxylate stereocenter relative to other reagents and other chloroformates.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The final dimesylate salt of the drug substance was generated upon the removal of the Boc group in <b>288</b> using methanesulfonic acid at ambient temperature. The final product netarsudil (<b>XXXI</b>) was purified by recrystallization from 2-propanol and heptane.</div><figure id="sch59" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Scheme 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0064.jpeg" id="gr59" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 59. Synthesis of Netarsudil (<b>XXXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch59"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">10.  Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, the industry at large enjoyed a productive year during 2017, as evidenced by the substantial number of small molecules comprising the overall total: 46 new drugs were approved by the USFDA in 2017 including antibodies and other modalities. Noteworthy contributions this year include the first-ever approved deuterated compound, a chiral alkyl boronate, a dozen oncology medicines (including the fourth antibody drug conjugate), and two separate nitroimidazole prodrugs. Structural complexity continued to increase (highly functionalized macrocycles, asymmetric centers, and complex heterocyclic systems can be found in many of the structures of these important new medicines), and we can expect that trend to persist within future approvals. The development of innovative and creative chemistry was certainly required not only to deliver these 31 medicines on scale but ostensibly during the initial discovery stages as well. As opportunities for new targets, medicines, and modalities continue to increase, so will the synthetic obstacles facing organic chemists become more challenging and complex, prompting the continuing demand for development of innovative and efficient synthetic technologies.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00196" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. O’Donnell</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link">http://orcid.org/0000-0003-1004-7139</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ccafa4bea5bfb8a3bca4a9bee2a6e2a3a8a3a2a2a9a0a08cbcaaa5b6a9bee2afa3a1"><span class="__cf_email__" data-cfemail="4e2d263c273d3a213e262b3c602460212a2120202b22220e3e2827342b3c602d2123">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew
C. Flick</span> - <span class="hlFld-Affiliation affiliation">Seattle
Genetics, Inc. 21823 30th Drive SE, Bothell, Washington 98021, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolyn A. Leverett</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong X. Ding</span> - <span class="hlFld-Affiliation affiliation">Pharmacodia
(Beijing) Co., Ltd., Beijing, 100085, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emma McInturff</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah J. Fink</span> - <span class="hlFld-Affiliation affiliation">BioDuro, 11011 Torreyana Road, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Helal</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9091-2091" title="Orcid link">http://orcid.org/0000-0002-9091-2091</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">For A.C.F: phone, 425-527-4755; E-mail, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="aecfc8c2c7cdc5eeddcbcfc9cbc080cdc1c3">[email protected]</a></p><br /></br><p class="inlineNote">For C.A.L.: phone 860-441-3936; E-mail, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a8cbc9dac7c4d1c686c986c4cddecddacddcdce8d8cec1d2cdda86cbc7c586">[email protected]</a></p><br /></br><p class="inlineNote">For H.X.D.: phone, 8610-8282-6195; E-mail, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e89b808d9a9184c68c81868fa89880899a85898b878c8189c68b8785c6">[email protected]</a></p><br /></br><p class="inlineNote">For E.M.: phone, 860-441-3276; E-mail, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="f590989894db98969c9b8180879393b585939c8f9087db969a98db">[email protected]</a></p><br /></br><p class="inlineNote">For S.J.F.: phone, 631-635-0516; E-mail, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="98ebf9eaf9f0b6fef1f6f3d8faf1f7fcedeaf7b6fbf7f5b6">[email protected]</a></p><br /></br><p class="inlineNote">For C.J.H.: phone, 860-715-5064; E-mail: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="76151e041f05581c581e131a171a3606101f0c13045815191b58">[email protected]</a></p></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Andrew
C. Flick</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=BIO-d7e4145-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andrew C. Flick</b> earned a B.A. in Chemistry from Lake Forest College. After brief appointments at Abbott Laboratories and Array BioPharma, he joined Professor Albert Padwa’s laboratory at Emory University. After obtaining his Ph.D. in organic chemistry in 2008, he joined Pfizer, where he was involved with numerous medicinal chemistry projects within the neurosciences, rare diseases, and inflammation and immunology therapeutic areas. As a team leader, his contributions led to the discovery of the transcription factor inhibitor PF-06763809, which is currently undergoing phase I trials for the treatment of psoriasis. Andy has recently joined Seattle Genetics’ Chemistry Research group, and he has authored over 40 peer-reviewed publications and patents.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Carolyn A. Leverett</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=BIO-d7e4150-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Carolyn A. Leverett</b> began her career at Pfizer in 2012, focusing on the development of microtubule inhibitor-based payloads for use as antibody–drug conjugates. She currently works in the Discovery Sciences research group, exploring the use of protein degrader-based therapies for treating a variety of disease areas. Carolyn is a native of North Carolina and obtained her B.Sc. in chemistry from North Carolina State University. She completed her doctoral studies with Professor Albert Padwa at Emory University in Atlanta, GA, working on total synthesis of several piperidine-based natural products and the alkaloid minfiensine. Prior to joining Pfizer, she was a postdoctoral fellow working with Professor Daniel Romo at Texas A&M University, exploring new applications of nucleophile-catalyzed aldol lactonization reactions.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Hong X. Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=BIO-d7e4155-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong X. (Sheryl) Ding</b> obtained a B.Sc. in Pharmaceutics in 2001 and a Ph.D. in medicinal chemistry in 2006 from Zhejiang University in Hangzhou, China. Hongxia is the cofounder and Chief Executive Officer of PHARMACODIA, a company founded in 2013, which is an online platform (<a href="http://www.pharmacodia.com" class="extLink">http://www.pharmacodia.com</a>) providing big data and information service in pharmaceutical R&D field. In 2010–2013, Hongxia joined Shenogen Pharma Group, a China-based biotech company. As senior director of R&D department, Hongxia is responsible for the CMC development of a novel ER-α36 targeted phase II candidates drugs, named Icaritin (SNG162), and the discovery and development of second-generation small molecular based on the structure optimization of SNG162. Before Shenogen, Hongxia worked at BioDuro since 2006 as senior group leader and senior research scientist.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Emma McInturff</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=BIO-d7e4163-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Emma McInturff</b> obtained a B.Sc. in chemistry from Boise State University and a Ph.D. from the University of Texas at Austin, working in the laboratory of Professor Mike Krische on ruthenium catalyzed carbonyl addition methodology development. She joined Pfizer process chemistry in Groton, CT, in 2014.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Sarah J. Fink</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=BIO-d7e4168-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sarah J. Fink</b> is a Senior Manager for Integrated Programs at BioDuro and is based in the Boston area. She obtained a B.A. in chemistry and English literature from Williams College, followed by a Ph.D. in organic chemistry from the University of Cambridge with Professor Ian Paterson. Her thesis work focused on the total synthesis of aplyronine C. After a fellowship for young international scientists at Shanghai Institute of Materia Medica, Sarah joined BioDuro in Shanghai in 2014, where she was a scientist and chemistry group leader for integrated drug discovery projects in multiple therapeutic areas. She relocated to Boston in early 2017; in her current role, she provides medicinal chemistry and scientific project management support for collaborations with pharma and biotech.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Christopher J. Helal</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=BIO-d7e4173-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher J. Helal</b> received his B.Sc. in chemistry at the Ohio State University in 1991 and carried out his doctoral studies at Harvard University with Professor Elias J. Corey. He joined Pfizer in 1997 in Groton, CT, working in neuroscience medicinal chemistry. He currently is Senior Director of Medicinal Chemistry, supporting the metabolic disease research area and leading an enabling technologies team that includes biocatalysis, flow chemistry, single-electron chemistry, reaction optimization, and parallel synthesis.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Christopher J. O’Donnell</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=BIO-d7e4178-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher J. O’Donnell</b> obtained a B.Sc. in chemistry from the University of Illinois in Urbana/Champaign and a Ph.D. in Organic Chemistry from the University of Wisconsin—Madison. After postdoctoral research at the University of California—Irvine, he joined Pfizer’s Neuroscience Medicinal Chemistry group in 1999. As a scientist, project leader, and manager in these areas, he has led project teams to the nomination of over 10 clinical candidates. In 2010, Chris moved to the Oncology Medicinal Chemistry group to build the Antibody Drug Conjugate chemistry group, and his team has nominated 11 conjugates for clinical development. In 2018, Chris moved to the Pfizer Ventures team, where he makes and manages equity investments for Pfizer. Chris is an author/inventor of 75 peer-reviewed journal articles and patent applications.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetyl</p></td></tr><tr><td class="NLM_term">Ad</td><td class="NLM_def"><p class="first last">adamantyl</p></td></tr><tr><td class="NLM_term">AIBN</td><td class="NLM_def"><p class="first last">2,2′-azobis(isobutyronitrile)</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">BINAP</td><td class="NLM_def"><p class="first last">2,2′-bis(diphenylphosphino)-1,1′-binaphthalene</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>N</i>-<i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">Bu, <i>n</i>-Bu</td><td class="NLM_def"><p class="first last">butyl, <i>n</i>-butyl</p></td></tr><tr><td class="NLM_term">cat</td><td class="NLM_def"><p class="first last">catalytic</p></td></tr><tr><td class="NLM_term">Cbz</td><td class="NLM_def"><p class="first last">benzyloxycarbonyl</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CDMT</td><td class="NLM_def"><p class="first last">2-chloro-4,6-dimethoxy-1,3,5-triazine</p></td></tr><tr><td class="NLM_term">conc</td><td class="NLM_def"><p class="first last">concentrated</p></td></tr><tr><td class="NLM_term">CPME</td><td class="NLM_def"><p class="first last">cyclopentyl methyl ether</p></td></tr><tr><td class="NLM_term">CSA</td><td class="NLM_def"><p class="first last">camphorsulfonic Acid</p></td></tr><tr><td class="NLM_term">Cy</td><td class="NLM_def"><p class="first last">cyclohexyl</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">1,3-dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DDQ</td><td class="NLM_def"><p class="first last">2,3-dichloro-5,6-dicyano-1,4-benzoquinone</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N,N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMF-DMA</td><td class="NLM_def"><p class="first last">dimethylformamide–dimethylacetal</p></td></tr><tr><td class="NLM_term">DMPA</td><td class="NLM_def"><p class="first last">dimethylolpropionic acid</p></td></tr><tr><td class="NLM_term">DMPU</td><td class="NLM_def"><p class="first last">1,3-dimethyl-3,4,5,6-tetrahydro-2(1<i>H</i>)-pyrimidinone</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DPPA</td><td class="NLM_def"><p class="first last">diphenyl phosphoryl azide</p></td></tr><tr><td class="NLM_term">dppb</td><td class="NLM_def"><p class="first last">1,4-bis(diphenylphosphino)butane</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-ferrocenediyl-bis(diphenylphosphine)</p></td></tr><tr><td class="NLM_term">dr</td><td class="NLM_def"><p class="first last">diastereomeric ratio</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropal)-<i>N</i>-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">ee</td><td class="NLM_def"><p class="first last">enantiomeric excess</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last">(2-(1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">Hex, <i>n</i>-Hex</td><td class="NLM_def"><p class="first last">hexyl</p></td></tr><tr><td class="NLM_term">HMDS</td><td class="NLM_def"><p class="first last">hexamethyldisilazane</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole hydrate</p></td></tr><tr><td class="NLM_term">HWE</td><td class="NLM_def"><p class="first last">Horner–Wadsworth–Emmons</p></td></tr><tr><td class="NLM_term"><i>I</i>-Pr</td><td class="NLM_def"><p class="first last">isopropyl</p></td></tr><tr><td class="NLM_term">L-PGA</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-pyroglutamic acid</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">methyl ethyl ketone</p></td></tr><tr><td class="NLM_term">Moc</td><td class="NLM_def"><p class="first last">methoxycarbonyl</p></td></tr><tr><td class="NLM_term">Ms</td><td class="NLM_def"><p class="first last">methylsulfonyl, mesyl</p></td></tr><tr><td class="NLM_term">MTBE</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl ether</p></td></tr><tr><td class="NLM_term"><i>n</i>-Pr</td><td class="NLM_def"><p class="first last"><i>n</i>-propyl</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl morpholine</p></td></tr><tr><td class="NLM_term">NMO</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl morpholine-<i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">Ph</td><td class="NLM_def"><p class="first last">phenyl</p></td></tr><tr><td class="NLM_term">PhCH<sub>3</sub></td><td class="NLM_def"><p class="first last">toluene</p></td></tr><tr><td class="NLM_term">Pin</td><td class="NLM_def"><p class="first last">pinacolato</p></td></tr><tr><td class="NLM_term">Piv</td><td class="NLM_def"><p class="first last">pivaloyl</p></td></tr><tr><td class="NLM_term">PLP</td><td class="NLM_def"><p class="first last">pyridoxal-5-phosphate</p></td></tr><tr><td class="NLM_term"><i>p</i>-TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">py</td><td class="NLM_def"><p class="first last">pyridine</p></td></tr><tr><td class="NLM_term">rac</td><td class="NLM_def"><p class="first last">racemic</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">2-(trimethylsilyl)ethoxymethyl</p></td></tr><tr><td class="NLM_term">TBAB</td><td class="NLM_def"><p class="first last">tetrabutylammonium bromide</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">TBAH</td><td class="NLM_def"><p class="first last">tetrabutylammonium hydroxide</p></td></tr><tr><td class="NLM_term">TBAI</td><td class="NLM_def"><p class="first last">tetrabutylammonium iodide</p></td></tr><tr><td class="NLM_term">TBS</td><td class="NLM_def"><p class="first last"><i>t</i>-butyldimethylsilyl</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>,<i>N</i>-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term"><i>t</i>-Bu</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TES</td><td class="NLM_def"><p class="first last">triethylsilane</p></td></tr><tr><td class="NLM_term">TEMPO</td><td class="NLM_def"><p class="first last">2,2,6,6-tetramethylpiperidine 1-oxyl</p></td></tr><tr><td class="NLM_term">Tf</td><td class="NLM_def"><p class="first last">triflic, trifluoromethanesulfonyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid anhydride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyranyl</p></td></tr><tr><td class="NLM_term">TMEDA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>′<i>,N</i>′-tetramethylethylenediamine</p></td></tr><tr><td class="NLM_term">TMS</td><td class="NLM_def"><p class="first last">trimethylsilyl</p></td></tr><tr><td class="NLM_term">TPAP</td><td class="NLM_def"><p class="first last">tetrapropylammonium perruthenate</p></td></tr><tr><td class="NLM_term">Tr</td><td class="NLM_def"><p class="first last">trityl, triphenylmethyl</p></td></tr><tr><td class="NLM_term">Ts</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonyl</p></td></tr><tr><td class="NLM_term">UHP</td><td class="NLM_def"><p class="first last">urea hydrogen peroxide</p></td></tr><tr><td class="NLM_term">Xantphos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i115">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54270" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54270" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 148 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raju, T. N. K.</span></span> <span> </span><span class="NLM_article-title">The Nobel Chronicles. 1988: James Whyte Black, (B 1924), Gertrude Elion (1918–99), and George H Hitchings (1905–98)</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1022</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)74775-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2FS0140-6736%2805%2974775-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10768469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=1022&author=T.+N.+K.+Raju&title=The+Nobel+Chronicles.+1988%3A+James+Whyte+Black%2C+%28B+1924%29%2C+Gertrude+Elion+%281918%E2%80%9399%29%2C+and+George+H+Hitchings+%281905%E2%80%9398%29&doi=10.1016%2FS0140-6736%2805%2974775-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span></div><div class="casAuthors">Raju T N</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9208</span>),
    <span class="NLM_cas:pages">1022</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTWLVzWjiD66qcneEtCi92fW6udTcc2earHZ8OQNoWlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D&md5=c89d64b40317d0d0cb4a76c1cceecb58</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974775-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974775-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DT.%2BN.%2BK.%26atitle%3DThe%2520Nobel%2520Chronicles.%25201988%253A%2520James%2520Whyte%2520Black%252C%2520%2528B%25201924%2529%252C%2520Gertrude%2520Elion%2520%25281918%25E2%2580%259399%2529%252C%2520and%2520George%2520H%2520Hitchings%2520%25281905%25E2%2580%259398%2529%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D1022%26doi%3D10.1016%2FS0140-6736%2805%2974775-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0ljyePAU-7nUDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0ljyePAU-7nUDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.-C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0ljyePAU-7nUDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0ljyePAU-7nUDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0ljaaxySvJAASQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0ljaaxySvJAASQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0liRsrjnkMzWEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2hR"><div class="casContent"><span class="casTitleNuber">2h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0liRsrjnkMzWEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0liRsrjnkMzWEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2jR"><div class="casContent"><span class="casTitleNuber">2j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0ljmN83iR6K7pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0ljmN83iR6K7pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2lR"><div class="casContent"><span class="casTitleNuber">2l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0ljmN83iR6K7pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2mR"><div class="casContent"><span class="casTitleNuber">2m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0lhlHAe8QsC3hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6480</span>– <span class="NLM_lpage">6515</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6480-6515&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2015&doi=10.1021%2Facs.jmedchem.7b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2nR"><div class="casContent"><span class="casTitleNuber">2n</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2015</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K. -C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6480-6515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 29 new chem. entities (NCEs) that were approved for the first time in 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5OCn9h-Lu07Vg90H21EOLACvtfcHk0lhlHAe8QsC3hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D&md5=b10c1f677c2f4a216b11a4c89e8b3683</span></div><a href="/servlet/linkout?suffix=cit2n&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6480%26epage%3D6515%26doi%3D10.1021%2Facs.jmedchem.7b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to New Drugs Approved During 2016</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7004</span>– <span class="NLM_lpage">7031</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2o&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7004-7031&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+New+Drugs+Approved+During+2016&doi=10.1021%2Facs.jmedchem.8b00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2oR"><div class="casContent"><span class="casTitleNuber">2o</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to New Drugs Approved During 2016</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7004-7031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review discusses the published syntheses of the nineteen new chem. entities approved for the first time by a governing body anywhere in the world in 2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr16l1kfs1KlbVg90H21EOLACvtfcHk0lj5S_RA4F5wtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D&md5=183bbabe40dbfd7b7cfbcd94fd55f0d0</span></div><a href="/servlet/linkout?suffix=cit2o&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00260%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520New%2520Drugs%2520Approved%2520During%25202016%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7004%26epage%3D7031%26doi%3D10.1021%2Facs.jmedchem.8b00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graul, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, M.</span></span> <span> </span><span class="NLM_article-title">The Year’s New Drugs and Biologics 2018: Part I</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1358/dot.2018.54.1.2766396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1358%2Fdot.2018.54.1.2766396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktFGluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=35-84&author=A.+I.+Graulauthor=P.+Pinaauthor=M.+Stringer&title=The+Year%E2%80%99s+New+Drugs+and+Biologics+2018%3A+Part+I&doi=10.1358%2Fdot.2018.54.1.2766396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The year's new drugs and biologics 2017: Part I</span></div><div class="casAuthors">Graul A I; Pina P; Stringer M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-84</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">This review presents the 113 new drugs and biologics that were approved or launched for the first time globally in 2017.  Fifty-two new drugs and biologics reached their first markets worldwide in 2017.  Seven of the new launches were first-in-class agents, meaning the first drug with a novel mechanism of action to be approved and launched anywhere in the world.  In addition, 36 notable line extensions (i.e., new indications, new combinations and new formulations of previously marketed products) were introduced last year.  The remaining 25 products discussed in this article were approved for the first time during the year just passed, but had not yet been launched as of December 31, 2017.  The United States was the most active market for new drugs, and oncology was the most active therapeutic group.  Information on these new arrivals is covered in depth in part I of our annual review of the pharma and biotech industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDuiEw0Baa1AWRJ3OJdH_qfW6udTcc2eaqzSLvay-7q7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktFGluw%253D%253D&md5=9bfdac91095ed398ab8ae5561595699c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1358%2Fdot.2018.54.1.2766396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2018.54.1.2766396%26sid%3Dliteratum%253Aachs%26aulast%3DGraul%26aufirst%3DA.%2BI.%26aulast%3DPina%26aufirst%3DP.%26aulast%3DStringer%26aufirst%3DM.%26atitle%3DThe%2520Year%25E2%2580%2599s%2520New%2520Drugs%2520and%2520Biologics%25202018%253A%2520Part%2520I%26jtitle%3DDrugs%2520Today%26date%3D2018%26volume%3D54%26spage%3D35%26epage%3D84%26doi%3D10.1358%2Fdot.2018.54.1.2766396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span>For
a more detailed description of the medicinal chemistry strategy, preclinical
and clinical pharmacology of these drugs, see: <span> </span><span class="NLM_article-title">To Market, To Market—2017</span>. In  <i>2018
Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">ACS Division of Medicinal Chemistry</span>, <span class="NLM_year">2018</span>; Vol.  <span class="NLM_volume">53</span>, pp  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">693</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=587-693&author=J.+J.+Bronson&title=2018%0AMedicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTo%2520Market%252C%2520To%2520Market%25E2%2580%25942017%26btitle%3D2018%250AMedicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DACS%2520Division%2520of%2520Medicinal%2520Chemistry%26date%3D2018%26volume%3D53%26spage%3D587%26epage%3D693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, K.</span></span> <span> </span><span class="NLM_article-title">Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (Asp2151), in Rodents</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1007/s13318-018-0481-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs13318-018-0481-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29748821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVWmsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=693-706&author=Y.+Ohtsuauthor=Y.+Susakiauthor=K.+Noguchi&title=Absorption%2C+Distribution%2C+Metabolism%2C+and+Excretion+of+the+Novel+Helicase-Primase+Inhibitor%2C+Amenamevir+%28Asp2151%29%2C+in+Rodents&doi=10.1007%2Fs13318-018-0481-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents</span></div><div class="casAuthors">Ohtsu, Yoshiaki; Susaki, Yoko; Noguchi, Kiyoshi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">693-706</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">Background and Objectives: The helicase-primase inhibitor amenamevir (ASP2151) is a novel therapeutic agent which has been approved for the treatment of herpes zoster.  The present study examd. the pharmacokinetic profile of amenamevir in rodents and compared it with data from the literature of past and current established therapies (acyclovir and valaciclovir) to provide addnl. data to facilitate drug discovery and proper drug use.  Methods: In situ absorption, blood and plasma radioactivity concns., tissue distribution, and excretion were detd. using liq. scintillation counting.  Plasma amenamevir concns. were measured using a validated chromatog. method.  Chem. structures of in vivo metabolites were investigated using liq. chromatog.-mass spectrometry and NMR spectroscopy.  Results: Amenamevir, after single i.v. administration to mice, had an elimination half-life of 2 h.  Bioavailability was 40% after single oral administration.  In situ absorption data indicated that amenamevir is mainly absorbed in the small intestine.  The main component in mouse plasma was amenamevir, accounting for 87.9% of amenamevir-derived components.  Our results suggest that the main elimination pathway in mice is oxidative metab. at a Me group and a 1,2,3-trisubstituted benzene ring followed by biliary and fecal excretion.  Following oral administration of 14C-amenamevir to mice, 100.63% of the dose (10.06% in urine and 90.46% in feces) was excreted by 96 h post-dose.  Conclusions: The underlying mechanism of the improved pharmacokinetic profile of amenamevir was linked to an improved absorption ratio (not hepatic availability) compared to acyclovir, and qual. differences in elimination (slow metab. of amenamevir vs rapid urinary excretion of acyclovir/valaciclovir).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLaNJnfDGlkrVg90H21EOLACvtfcHk0lj5S_RA4F5wtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVWmsbzO&md5=3516e3d9aa2e0a7435f47e3d5c0b1286</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs13318-018-0481-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-018-0481-y%26sid%3Dliteratum%253Aachs%26aulast%3DOhtsu%26aufirst%3DY.%26aulast%3DSusaki%26aufirst%3DY.%26aulast%3DNoguchi%26aufirst%3DK.%26atitle%3DAbsorption%252C%2520Distribution%252C%2520Metabolism%252C%2520and%2520Excretion%2520of%2520the%2520Novel%2520Helicase-Primase%2520Inhibitor%252C%2520Amenamevir%2520%2528Asp2151%2529%252C%2520in%2520Rodents%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2018%26volume%3D43%26spage%3D693%26epage%3D706%26doi%3D10.1007%2Fs13318-018-0481-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusawake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keirns, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Adel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenendaal-van
de Meent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katashima, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2625</span>– <span class="NLM_lpage">2637</span>, <span class="refDoi"> DOI: 10.1007/s12325-017-0642-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs12325-017-0642-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29134426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSmsrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=2625-2637&author=T.+Kusawakeauthor=J.+J.+Keirnsauthor=D.+Kowalskiauthor=M.+den+Adelauthor=D.+Groenendaal-van%0Ade+Meentauthor=A.+Takadaauthor=Y.+Ohtsuauthor=M.+Katashima&title=Pharmacokinetics+and+Safety+of+Amenamevir+in+Healthy+Subjects%3A+Analysis+of+Four+Randomized+Phase+1+Studies&doi=10.1007%2Fs12325-017-0642-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies</span></div><div class="casAuthors">Kusawake, Tomohiro; Keirns, James J.; Kowalski, Donna; den Adel, Martin; Groenendaal-van de Meent, Dorien; Takada, Akitsugu; Ohtsu, Yoshiaki; Katashima, Masataka</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2625-2637</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Introduction: Amenamevir (ASP2151) is a nonnucleoside antiherpesvirus compd. available for the treatment of varicella-zoster virus infections.  In this article we summarize the findings of four phase 1 studies in healthy participants.  Methods: Four randomized phase 1 studies investigated the safety and pharmacokinetics of single and multiple doses of amenamevir, including the assessment of age group effect (nonelderly vs elderly), food effect, and the relative bioavailability of two formulations.  Amenamevir was administered orally at various doses as a single dose (5-2400 mg) or daily (300 or 600 mg/day) for 7 days.  Results: Following single and multiple oral doses, amenamevir demonstrated a less than dose proportional increase in the pharmacokinetic parameters area under the plasma drug concn. vs. time curve from time zero to infinity (AUCinf) and Cmax.  After single and multiple oral 300-mg doses of amenamevir, no apparent differences in pharmacokinetics were obsd. between nonelderly and elderly participants.  In contrast, with the amenamevir 600-mg dose both the area under the plasma drug concn. vs. time curve from time zero to 24 h and Cmax were slightly increased and renal clearance was decreased in elderly participants.  The pharmacokinetics of amenamevir was affected by food, with AUCinf increased by about 90%.  In the bioavailability study, AUCinf and Cmax were slightly lower following tablet vs. capsule administration (decreased by 14 and 12%, resp.), with relative bioavailability of 86%.  The different amenamevir doses and formulations were safe and well tolerated; no deaths or serious adverse events were reported.  Conclusion: Amenamevir had less than dose proportional pharmacokinetic characteristics.  Age may have an influence on amenamevir pharmacokinetics; however, the effect was considered minimal.  The pharmacokinetics of amenamevir were affected by food, with AUCinf almost doubling when amenamevir was administered with food.  The concn. vs. time profile of the tablet was slightly lower than that of the capsule; the relative bioavailability of the tablet vs. the capsule was 86%.  Amenamevir was safe and well tolerated in the dose range investigated.  Funding: Astellas Pharma.  Trial registration: ClinicalTrials.gov identifiers NCT02852876 (15L-CL-002) and NCT02796118 (15L-CL-003).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpziv1dPHTvMbVg90H21EOLACvtfcHk0lhXpJKjw_H42w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSmsrvF&md5=899c34c5e3bbb28c25fbe18980a015bd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0642-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0642-4%26sid%3Dliteratum%253Aachs%26aulast%3DKusawake%26aufirst%3DT.%26aulast%3DKeirns%26aufirst%3DJ.%2BJ.%26aulast%3DKowalski%26aufirst%3DD.%26aulast%3Dden%2BAdel%26aufirst%3DM.%26aulast%3DGroenendaal-van%2Bde%2BMeent%26aufirst%3DD.%26aulast%3DTakada%26aufirst%3DA.%26aulast%3DOhtsu%26aufirst%3DY.%26aulast%3DKatashima%26aufirst%3DM.%26atitle%3DPharmacokinetics%2520and%2520Safety%2520of%2520Amenamevir%2520in%2520Healthy%2520Subjects%253A%2520Analysis%2520of%2520Four%2520Randomized%2520Phase%25201%2520Studies%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26spage%3D2625%26epage%3D2637%26doi%3D10.1007%2Fs12325-017-0642-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span>; <span class="NLM_string-name">Sudo, K.</span></span> <span> </span><span class="NLM_article-title">Preventive or Therapeutic Agent for Herpesvirus-Related Disease</span>. <span class="NLM_patent">WO 2006082821A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=H.+Suzuki&author=K.+Sudo&title=Preventive+or+Therapeutic+Agent+for+Herpesvirus-Related+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DPreventive%2520or%2520Therapeutic%2520Agent%2520for%2520Herpesvirus-Related%2520Disease%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span>; <span class="NLM_string-name">Chono, K.</span>; <span class="NLM_string-name">Sudo, K.</span></span> <span> </span><span class="NLM_article-title">Agent for Prevention/Treatment of Disease Caused by Acyclovir-Resistant Herpesvirus</span>. <span class="NLM_patent">WO 2006082822A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=H.+Suzuki&author=K.+Chono&author=K.+Sudo&title=Agent+for+Prevention%2FTreatment+of+Disease+Caused+by+Acyclovir-Resistant+Herpesvirus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DAgent%2520for%2520Prevention%252FTreatment%2520of%2520Disease%2520Caused%2520by%2520Acyclovir-Resistant%2520Herpesvirus%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kontani, T.</span>; <span class="NLM_string-name">Miyata, J.</span>; <span class="NLM_string-name">Hamaguchi, W.</span>; <span class="NLM_string-name">Kawano, T.</span>; <span class="NLM_string-name">Kamikawa, A.</span>; <span class="NLM_string-name">Suzuki, H.</span>; <span class="NLM_string-name">Sudo, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of Tetrahydro-2H-thiopyran-4-carboxamides as Anti-Herpesvirus Agents</span>. <span class="NLM_patent">US 20050032855A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Kontani&author=J.+Miyata&author=W.+Hamaguchi&author=T.+Kawano&author=A.+Kamikawa&author=H.+Suzuki&author=K.+Sudo&title=Preparation+of+Tetrahydro-2H-thiopyran-4-carboxamides+as+Anti-Herpesvirus+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKontani%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Tetrahydro-2H-thiopyran-4-carboxamides%2520as%2520Anti-Herpesvirus%2520Agents%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span>; <span class="NLM_string-name">Salituro, F. G.</span>; <span class="NLM_string-name">Saunders, J. O.</span>; <span class="NLM_string-name">Travins, J.</span>; <span class="NLM_string-name">Yan, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Cycloalkylheteroarylacetylphenylaminophenylacetamide Derivatives and Analogs for Use as Antitumor Agents</span>. <span class="NLM_patent">WO 2012009678A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+Popovici-Muller&author=F.+G.+Salituro&author=J.+O.+Saunders&author=J.+Travins&author=S.+Yan&title=Preparation+of+Cycloalkylheteroarylacetylphenylaminophenylacetamide+Derivatives+and+Analogs+for+Use+as+Antitumor+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520Cycloalkylheteroarylacetylphenylaminophenylacetamide%2520Derivatives%2520and%2520Analogs%2520for%2520Use%2520as%2520Antitumor%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Zhou, H.</span>; <span class="NLM_string-name">Xie, J.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of 4-(1,2,4-Oxadiazole-3-yl)aniline</span>. <span class="NLM_patent">CN 108484522A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Zhen&author=J.+Chen&author=Z.+Zhang&author=H.+Zhou&author=J.+Xie&title=Preparation+Method+of+4-%281%2C2%2C4-Oxadiazole-3-yl%29aniline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhen%26aufirst%3DY.%26atitle%3DPreparation%2520Method%2520of%25204-%25281%252C2%252C4-Oxadiazole-3-yl%2529aniline%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span>Biocidal (2-Nitroimidazolyl)
Alkanoic Acids and Derivatives. <span class="NLM_patent">GB1138529</span>, <span class="NLM_year">1969</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Biocidal+%282-Nitroimidazolyl%29%0AAlkanoic+Acids+and+Derivatives.+GB1138529%2C+1969."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D1969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span> <i>FDA Approves First U.S. Treatment for Chagas Disease</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administraqtion</span>, August 29, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573942.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573942.htm</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+First+U.S.+Treatment+for+Chagas+Disease%3B+U.S.+Food+and+Drug+Administraqtion%2C+August+29%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm573942.htm+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520First%2520U.S.%2520Treatment%2520for%2520Chagas%2520Disease%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administraqtion%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajao, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passos-Silva, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Moura, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamber-Reis, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunrath-Lima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuma, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-da-Rocha, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, S. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza-Pinto, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Medeiros, M. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motta, M. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, S. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, C. R.</span></span> <span> </span><span class="NLM_article-title">Unveiling Benznidazoles Mechanism of Action through Overexpression of DNA Repair Proteins in Trypanosoma Cruzi</span>. <i>Environ. Mol. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1002/em.21839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fem.21839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=24347026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCjtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=309-321&author=M.+A.+Rajaoauthor=C.+Furtadoauthor=C.+L.+Alvesauthor=D.+G.+Passos-Silvaauthor=M.+B.+de+Mouraauthor=B.+L.+Schamber-Reisauthor=M.+Kunrath-Limaauthor=A.+A.+Zumaauthor=J.+P.+Vieira-da-Rochaauthor=J.+B.+F.+Garciaauthor=I.+C.+Mendesauthor=S.+D.+J.+Penaauthor=A.+M.+Macedoauthor=G.+R.+Francoauthor=N.+C.+de+Souza-Pintoauthor=M.+H.+G.+de+Medeirosauthor=A.+K.+Cruzauthor=M.+C.+M.+Mottaauthor=S.+M.+R.+Teixeiraauthor=C.+R.+Machado&title=Unveiling+Benznidazoles+Mechanism+of+Action+through+Overexpression+of+DNA+Repair+Proteins+in+Trypanosoma+Cruzi&doi=10.1002%2Fem.21839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Unveiling Benznidazoles mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi</span></div><div class="casAuthors">Rajao, Matheus Andrade; Furtado, Carolina; Alves, Ceres Luciana; Passos-Silva, Danielle Gomes; Moura, Michelle Barbi; Schamber-Reis, Bruno Luiz; Kunrath-Lima, Marianna; Zuma, Aline Araujo; Vieira-da-Rocha, Joao Pedro; Garcia, Juliana Borio Ferreira; Mendes, Isabela Cecilia; Pena, Sergio Danilo Junho; Macedo, Andrea Mara; Franco, Gloria Regina; Souza-Pinto, Nadja Cristhina; Medeiros, Marisa Helena Gennari; Cruz, Angela Kaysel; Motta, Maria Cristina Machado; Teixeira, Santuza Maria Ribeiro; Machado, Carlos Renato</div><div class="citationInfo"><span class="NLM_cas:title">Environmental and Molecular Mutagenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-321</span>CODEN:
                <span class="NLM_cas:coden">EMMUEG</span>;
        ISSN:<span class="NLM_cas:issn">0893-6692</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Benznidazole (BZ) is the most commonly used drug for the treatment of Chagas disease.  Although BZ is known to induce the formation of free radicals and electrophilic metabolites within the parasite Trypanosoma cruzi, its precise mechanisms of action are still elusive.  Here, the authors analyzed the survival of T. cruzi exposed to BZ using genetically modified parasites overexpressing different DNA repair proteins.  The authors' results indicate that BZ induces oxidn. mainly in the nucleotide pool, as heterologous expression of the nucleotide pyrophosphohydrolase MutT (but not overexpression of the glycosylase TcOgg1) increased drug resistance in the parasite.  In addn., electron microscopy indicated that BZ catalyzes the formation of double-stranded breaks in the parasite, as its genomic DNA undergoes extensive heterochromatin unpacking following exposure to the drug.  Furthermore, the overexpression of proteins involved in the recombination-mediated DNA repair increased resistance to BZ, reinforcing the idea that the drug causes double-stranded breaks.  The authors' results also show that the overexpression of mitochondrial DNA repair proteins increase parasite survival upon BZ exposure, indicating that the drug induces lesions in the mitochondrial DNA as well.  These findings suggest that BZ preferentially oxidizes the nucleotide pool, and the extensive incorporation of oxidized nucleotides during DNA replication leads to potentially lethal double-stranded DNA breaks in T. cruzi DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipqLqr5XxpbVg90H21EOLACvtfcHk0lgo0J5taDduwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCjtr3L&md5=ebb14fc101937d18e805a687f6ba84a7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fem.21839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fem.21839%26sid%3Dliteratum%253Aachs%26aulast%3DRajao%26aufirst%3DM.%2BA.%26aulast%3DFurtado%26aufirst%3DC.%26aulast%3DAlves%26aufirst%3DC.%2BL.%26aulast%3DPassos-Silva%26aufirst%3DD.%2BG.%26aulast%3Dde%2BMoura%26aufirst%3DM.%2BB.%26aulast%3DSchamber-Reis%26aufirst%3DB.%2BL.%26aulast%3DKunrath-Lima%26aufirst%3DM.%26aulast%3DZuma%26aufirst%3DA.%2BA.%26aulast%3DVieira-da-Rocha%26aufirst%3DJ.%2BP.%26aulast%3DGarcia%26aufirst%3DJ.%2BB.%2BF.%26aulast%3DMendes%26aufirst%3DI.%2BC.%26aulast%3DPena%26aufirst%3DS.%2BD.%2BJ.%26aulast%3DMacedo%26aufirst%3DA.%2BM.%26aulast%3DFranco%26aufirst%3DG.%2BR.%26aulast%3Dde%2BSouza-Pinto%26aufirst%3DN.%2BC.%26aulast%3Dde%2BMedeiros%26aufirst%3DM.%2BH.%2BG.%26aulast%3DCruz%26aufirst%3DA.%2BK.%26aulast%3DMotta%26aufirst%3DM.%2BC.%2BM.%26aulast%3DTeixeira%26aufirst%3DS.%2BM.%2BR.%26aulast%3DMachado%26aufirst%3DC.%2BR.%26atitle%3DUnveiling%2520Benznidazoles%2520Mechanism%2520of%2520Action%2520through%2520Overexpression%2520of%2520DNA%2520Repair%2520Proteins%2520in%2520Trypanosoma%2520Cruzi%26jtitle%3DEnviron.%2520Mol.%2520Mutagen.%26date%3D2014%26volume%3D55%26spage%3D309%26epage%3D321%26doi%3D10.1002%2Fem.21839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watson, L.</span></span> <span> </span><span class="NLM_article-title">Making Benznidazole</span>. <span class="NLM_patent">WO 2017205622A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Watson&title=Making+Benznidazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DL.%26atitle%3DMaking%2520Benznidazole%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mealy, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, J.</span></span> <span> </span><span class="NLM_article-title">Abt-492: Quinolone Antibacterial</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1358/dof.2002.027.11.707859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1358%2Fdof.2002.027.11.707859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFelt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=1033-1038&author=N.+E.+Mealyauthor=J.+Castaner&title=Abt-492%3A+Quinolone+Antibacterial&doi=10.1358%2Fdof.2002.027.11.707859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-492: Quinolone antibacterial</span></div><div class="casAuthors">Mealy, N. E.; Castaner, J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1033-1038</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  ABT-492/WQ-3034 (I) is a novel fluoroquinolone that targets bacterial DNA topoisomerases and is undergoing clin. evaluation for the treatment of respiratory and urinary tract infections.  In numerous in vitro studies, the new antibiotic has demonstrated excellent, broad-spectrum antibacterial and bactericidal activity, with particularly good activity against respiratory tract pathogens.  ABT-492/WQ-3034 was generally more active than other quinolones and its spectrum included quinolone-sensitive and -resistant staphylococci and streptococci, vancomycin-sensitive and -resistant enterococci, anaerobic bacteria, Pseudomonas aeruginosa, Enterobacteriaceae, Legionella, mycobacteria and the causative organism of anthrax, Bacillus anthracis.  ABT-492/WQ-3034 has also been tested in rodent infection models, including systemic, respiratory tract and thigh infections.  The new fluoroquinolone proved to be generally at least as active as the ref. antibiotics following s.c. or p.o. administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNJbieb5vtsrVg90H21EOLACvtfcHk0lgo0J5taDduwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFelt7w%253D&md5=dc0e65564bac4e6cda533b395a57bcd1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.11.707859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.11.707859%26sid%3Dliteratum%253Aachs%26aulast%3DMealy%26aufirst%3DN.%2BE.%26aulast%3DCastaner%26aufirst%3DJ.%26atitle%3DAbt-492%253A%2520Quinolone%2520Antibacterial%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D1033%26epage%3D1038%26doi%3D10.1358%2Fdof.2002.027.11.707859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Haight, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariman, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueffier, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willcox, D. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the Quinolone Abt-492: Crystallizations for Optimal Processing</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1021/op060054e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op060054e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt12mt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=751-756&author=A.+R.+Haightauthor=S.+Z.+Arimanauthor=D.+M.+Barnesauthor=N.+J.+Benzauthor=F.+X.+Gueffierauthor=R.+F.+Henryauthor=M.+C.+Hsuauthor=E.+C.+Leeauthor=L.+Morinauthor=K.+B.+Pearlauthor=M.+J.+Petersonauthor=D.+J.+Plataauthor=D.+R.+Willcox&title=Synthesis+of+the+Quinolone+Abt-492%3A+Crystallizations+for+Optimal+Processing&doi=10.1021%2Fop060054e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the Quinolone ABT-492: Crystallizations for Optimal Processing</span></div><div class="casAuthors">Haight, Anthony R.; Ariman, Sema Z.; Barnes, David M.; Benz, Nancy J.; Gueffier, Francoix X.; Henry, Rodger F.; Hsu, Margaret C.; Lee, Elaine C.; Morin, Larry; Pearl, Kurt B.; Peterson, Matthew J.; Plata, Daniel J.; Willcox, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">751-756</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ABT-492 was under development at Abbott Labs. as a quinolone antibiotic.  A convergent syntheses was utilized to prep. the compd. on a multi-kilogram scale.  Difficulties in isolation of intermediates were overcome by developing control of the phys. forms.  Examples of controlling the agglomeration, crystal habit, and polymorphism of intermediates and the API are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnTZJO1LdporVg90H21EOLACvtfcHk0lgo0J5taDduwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt12mt7s%253D&md5=09459d3c4a8aa714dd311ff6d96ffa92</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Fop060054e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop060054e%26sid%3Dliteratum%253Aachs%26aulast%3DHaight%26aufirst%3DA.%2BR.%26aulast%3DAriman%26aufirst%3DS.%2BZ.%26aulast%3DBarnes%26aufirst%3DD.%2BM.%26aulast%3DBenz%26aufirst%3DN.%2BJ.%26aulast%3DGueffier%26aufirst%3DF.%2BX.%26aulast%3DHenry%26aufirst%3DR.%2BF.%26aulast%3DHsu%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DMorin%26aufirst%3DL.%26aulast%3DPearl%26aufirst%3DK.%2BB.%26aulast%3DPeterson%26aufirst%3DM.%2BJ.%26aulast%3DPlata%26aufirst%3DD.%2BJ.%26aulast%3DWillcox%26aufirst%3DD.%2BR.%26atitle%3DSynthesis%2520of%2520the%2520Quinolone%2520Abt-492%253A%2520Crystallizations%2520for%2520Optimal%2520Processing%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2006%26volume%3D10%26spage%3D751%26epage%3D756%26doi%3D10.1021%2Fop060054e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christesen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haight, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedrow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagaw, S.</span></span> <span> </span><span class="NLM_article-title">Chlorination at the 8-Position of a Functionalized Quinolone and the Synthesis of Quinolone Antibiotic Abt-492</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1021/op0600557</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op0600557" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVSiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=803-807&author=D.+M.+Barnesauthor=A.+C.+Christesenauthor=K.+M.+Engstromauthor=A.+R.+Haightauthor=M.+C.+Hsuauthor=E.+C.+Leeauthor=M.+J.+Petersonauthor=D.+J.+Plataauthor=P.+S.+Rajeauthor=E.+J.+Stonerauthor=J.+S.+Tedrowauthor=S.+Wagaw&title=Chlorination+at+the+8-Position+of+a+Functionalized+Quinolone+and+the+Synthesis+of+Quinolone+Antibiotic+Abt-492&doi=10.1021%2Fop0600557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Chlorination at the 8-Position of a Functionalized Quinolone and the Synthesis of Quinolone Antibiotic ABT-492</span></div><div class="casAuthors">Barnes, David M.; Christesen, Alan C.; Engstrom, Kenneth M.; Haight, Anthony R.; Hsu, Margaret C.; Lee, Elaine C.; Peterson, Matthew J.; Plata, Daniel J.; Raje, Prasad S.; Stoner, Eric J.; Tedrow, Jason S.; Wagaw, Seble</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">803-807</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The total synthesis of quinolone antibiotic ABT-492 (I) has been achieved in 67% yield over nine steps from 2,4,5-trifluorobenzoic acid.  The highlights of this synthesis include a novel chemoselective chlorination at the 8-position of a highly elaborated quinolone core.  In addn., a Lewis acid promoted cyclization reaction to form the quinolone heterocycle was developed which was incorporated into a one-pot, three-step cyclization/coupling/protection sequence that proceeds in 93% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphXtd9jRc3TLVg90H21EOLACvtfcHk0lhaFgTWw-CoTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVSiu7c%253D&md5=d411e4afcaa965d5e389e253b511ea75</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fop0600557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0600557%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DD.%2BM.%26aulast%3DChristesen%26aufirst%3DA.%2BC.%26aulast%3DEngstrom%26aufirst%3DK.%2BM.%26aulast%3DHaight%26aufirst%3DA.%2BR.%26aulast%3DHsu%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DPeterson%26aufirst%3DM.%2BJ.%26aulast%3DPlata%26aufirst%3DD.%2BJ.%26aulast%3DRaje%26aufirst%3DP.%2BS.%26aulast%3DStoner%26aufirst%3DE.%2BJ.%26aulast%3DTedrow%26aufirst%3DJ.%2BS.%26aulast%3DWagaw%26aufirst%3DS.%26atitle%3DChlorination%2520at%2520the%25208-Position%2520of%2520a%2520Functionalized%2520Quinolone%2520and%2520the%2520Synthesis%2520of%2520Quinolone%2520Antibiotic%2520Abt-492%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2006%26volume%3D10%26spage%3D803%26epage%3D807%26doi%3D10.1021%2Fop0600557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Haight, A.</span>; <span class="NLM_string-name">Barnes, D.</span>; <span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of a 3-Quinolinecarboxylic Acid as an Antibacterial Agent</span>. <span class="NLM_patent">WO 2006015194</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=A.+Haight&author=D.+Barnes&author=G.+Zhang&title=Preparation+of+a+3-Quinolinecarboxylic+Acid+as+an+Antibacterial+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaight%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520a%25203-Quinolinecarboxylic%2520Acid%2520as%2520an%2520Antibacterial%2520Agent%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, J. P.</span>; <span class="NLM_string-name">Hirschfeld, D. R.</span>; <span class="NLM_string-name">Silva, T.</span>; <span class="NLM_string-name">Sweeney, Z. K.</span>; <span class="NLM_string-name">Vora, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Phenoxyphenylacetamides as Non-Nucleoside Reverse Transcriptase Inhibitors</span>. <span class="NLM_patent">US 20050239881A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+P.+Dunn&author=D.+R.+Hirschfeld&author=T.+Silva&author=Z.+K.+Sweeney&author=H.+Vora&title=Preparation+of+Phenoxyphenylacetamides+as+Non-Nucleoside+Reverse+Transcriptase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DJ.%2BP.%26atitle%3DPreparation%2520of%2520Phenoxyphenylacetamides%2520as%2520Non-Nucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span> <span> </span><span class="NLM_article-title">Elsulfavirine: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1811</span>– <span class="NLM_lpage">1816</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0820-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0820-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28940154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOitrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1811-1816&author=Z.+T.+Al-Salama&title=Elsulfavirine%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0820-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Elsulfavirine: First Global Approval</span></div><div class="casAuthors">Al-Salama, Zaina T.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1811-1816</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Elsulfavirine (Elpida) is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections.  It is the prodrug of the active compd. VM-1500A, a small mol. selective NNRTI, which prevents HIV replication.  In June 2017, elsulfavirine received its first global approval in Russia for the treatment of HIV-1 infections in combination with other antiretroviral medicines.  Other formulations of this drug are also being evaluated in preclin. and phase II studies for the treatment of HIV infections and/or pre-exposure and post-exposure prophylaxis.  This article summarizes the milestones in the development of elsulfavirine leading to this first approval in HIV-1 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWl64SuDGjZbVg90H21EOLACvtfcHk0lhaFgTWw-CoTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOitrnM&md5=f90acfd69a4867927c0cc287459e833f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0820-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0820-3%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26atitle%3DElsulfavirine%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1811%26epage%3D1816%26doi%3D10.1007%2Fs40265-017-0820-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J. P.</span>; <span class="NLM_string-name">Pang, F.</span>; <span class="NLM_string-name">Wong, M.</span>; <span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Polymorphs of Acyl Sulfonamides</span>. <span class="NLM_patent">US 20100063154A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+P.+Davidson&author=F.+Pang&author=M.+Wong&author=M.+Martin&title=Preparation+of+Polymorphs+of+Acyl+Sulfonamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DJ.%2BP.%26atitle%3DPreparation%2520of%2520Polymorphs%2520of%2520Acyl%2520Sulfonamides%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, L. E.</span>; <span class="NLM_string-name">Hegde, S.</span>; <span class="NLM_string-name">Kuo, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Stefanidis, D.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Concentrated Aqueous Micellar Solutions</span>. <span class="NLM_patent">WO 2009109476A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=L.+E.+Fisher&author=S.+Hegde&author=J.+Kuo&author=F.+Li&author=D.+Stefanidis&title=Process+for+Preparing+Concentrated+Aqueous+Micellar+Solutions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DL.%2BE.%26atitle%3DProcess%2520for%2520Preparing%2520Concentrated%2520Aqueous%2520Micellar%2520Solutions%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J. P.</span>; <span class="NLM_string-name">Pang, F.</span>; <span class="NLM_string-name">Wong, M.</span>; <span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Polymorphs of Acyl Sulfonamides</span>. <span class="NLM_patent">US 20100063154</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+P.+Davidson&author=F.+Pang&author=M.+Wong&author=M.+Martin&title=Preparation+of+Polymorphs+of+Acyl+Sulfonamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DJ.%2BP.%26atitle%3DPreparation%2520of%2520Polymorphs%2520of%2520Acyl%2520Sulfonamides%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Glecaprevir/Pibrentasvir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1804</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0817-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0817-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28929412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFant7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1797-1804&author=Y.+N.+Lamb&title=Glecaprevir%2FPibrentasvir%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0817-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Glecaprevir/Pibrentasvir: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1804</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; Maviret (EU); Mavyret (USA)] has been developed by AbbVie.  Oral glecaprevir/pibrentasvir 300 mg/120 mg (three 100 mg/40 mg tablets) taken once daily has been approved by the EMA for the treatment of all major genotypes (genotypes 1-6) of chronic HCV infection in adults.  It has also been approved by the US FDA for the treatment of adult patients with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis, and for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen contg. either an HCV NS5A inhibitor or an NS3/4A PI, but not both.  This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlCoM88PgfTLVg90H21EOLACvtfcHk0ljDFlSA7XUyEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFant7bM&md5=52dc993b2fafc0256e6cfc0d3461da9f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0817-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0817-y%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DGlecaprevir%252FPibrentasvir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1797%26epage%3D1804%26doi%3D10.1007%2Fs40265-017-0817-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Leuw, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, C.</span></span> <span> </span><span class="NLM_article-title">Protease Inhibitor Therapy for Hepatitis C Virus-Infection</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1454428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F14656566.2018.1454428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29595065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsF2gt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=577-587&author=P.+de%0ALeuwauthor=C.+Stephan&title=Protease+Inhibitor+Therapy+for+Hepatitis+C+Virus-Infection&doi=10.1080%2F14656566.2018.1454428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Protease inhibitor therapy for hepatitis C virus-infection</span></div><div class="casAuthors">de Leuw, P.; Stephan, C.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: The hepatitis C virus (HCV) has affected an estd. of 80 million individuals worldwide and is a strain on public health.  Around 25-30% of patients in Europe and the US who are infected with HIV are coinfected with HCV.  Prior to 2013, treatment modalities contg. an NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin improved sustained virol. response (SVR) rates.  However, rates of severe side effects were high.  Nowadays, oral direct-acting antiviral (DAA) combination therapy offers excellent treatment efficacy, safety and tolerability.: This review focuses on the current literature and clin. evidence and their impact regarding NS3/4A protease inhibitors.  The pitfalls encountered in treating HIV- and HBV-coinfected patients are also discussed.: In the era of DAA treatment, third-generation pan-genotypic NS3/4A protease inhibitors (mainly glecaprevir and voxilaprevir) show high antiviral activity and a genetic resistance barrier with cure rates of over 95% when combined with an NS5A inhibitor, irresp. of baseline resistance assocd. variants (RASs) being present.  These new key components of DAA combination therapy are impressive options to eradicate HCV in the so-called difficult-to-treat population (e.g. compensated cirrhosis, end-stage renal disease and patients who failed previous DAA treatment).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhRlnsjOpKi7Vg90H21EOLACvtfcHk0ljDFlSA7XUyEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsF2gt7k%253D&md5=2b1ffd31d392a62a846004cbf46efc34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1454428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1454428%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLeuw%26aufirst%3DP.%26aulast%3DStephan%26aufirst%3DC.%26atitle%3DProtease%2520Inhibitor%2520Therapy%2520for%2520Hepatitis%2520C%2520Virus-Infection%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D577%26epage%3D587%26doi%3D10.1080%2F14656566.2018.1454428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Or, Y. S.</span>; <span class="NLM_string-name">Ma, J.</span>; <span class="NLM_string-name">Wang, G.</span>; <span class="NLM_string-name">Long, J.</span>; <span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocycles, Especially Proline-Containing Cyclic Peptides, as Hepatitis C Virus (Hcv) Ns3-Ns4a Protease Inhibitors</span>. <span class="NLM_patent">US 20120070416A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Y.+S.+Or&author=J.+Ma&author=G.+Wang&author=J.+Long&author=B.+Wang&title=Preparation+of+Macrocycles%2C+Especially+Proline-Containing+Cyclic+Peptides%2C+as+Hepatitis+C+Virus+%28Hcv%29+Ns3-Ns4a+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOr%26aufirst%3DY.%2BS.%26atitle%3DPreparation%2520of%2520Macrocycles%252C%2520Especially%2520Proline-Containing%2520Cyclic%2520Peptides%252C%2520as%2520Hepatitis%2520C%2520Virus%2520%2528Hcv%2529%2520Ns3-Ns4a%2520Protease%2520Inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luche, J.-L.</span>; <span class="NLM_string-name">Sarandeses, L. A.</span></span> <span> </span><span class="NLM_article-title">Zinc-Mediated Barbier Reactions</span>. In  <i>Organozinc Reagents: A Practical Approach</i>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Knochel, P.</span>, <span class="NLM_string-name">Jones, P.</span></span>, Eds.; <span class="NLM_publisher-name">Oxford University Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1999</span>; pp  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">323</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=307-323&author=J.-L.+Luche&author=L.+A.+Sarandesesauthor=P.+Knochel&author=P.+Jones&title=Organozinc+Reagents%3A+A+Practical+Approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLuche%26aufirst%3DJ.-L.%26atitle%3DZinc-Mediated%2520Barbier%2520Reactions%26btitle%3DOrganozinc%2520Reagents%253A%2520A%2520Practical%2520Approach%26aulast%3DKnochel%26aufirst%3DP.%26pub%3DOxford%2520University%2520Press%26date%3D1999%26spage%3D307%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Green, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollinshead, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, M.</span></span> <span> </span><span class="NLM_article-title">Oxo Complexes of Ruthenium(Vi) and (Vii) as Organic Oxidants</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.1039/P19840000681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2FP19840000681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaL2cXkvV2ru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1984&pages=681-686&author=G.+Greenauthor=W.+P.+Griffithauthor=D.+M.+Hollinsheadauthor=S.+V.+Leyauthor=M.+Schroder&title=Oxo+Complexes+of+Ruthenium%28Vi%29+and+%28Vii%29+as+Organic+Oxidants&doi=10.1039%2FP19840000681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Oxo complexes of ruthenium(VI) and (VII) as organic oxidants</span></div><div class="casAuthors">Green, Graham; Griffith, William P.; Hollinshead, David M.; Ley, Steven V.; Schroder, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1:  Organic and Bio-Organic Chemistry (1972-1999)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">681-6</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    </div><div class="casAbstract">The oxidn. of alcs. by [RuO4]2- (I), [RuO4]- (II), trans-Ba[Ru(OH)2O3] (III), [RuO2Cl3]- (IV), and [RuO2(bpy)Cl2] (V; bpy = 2,2'-bipyridyl) was examd.  Both I and II oxidize primary alcs. to carboxylic acids and secondary alcs. to ketones.  IV ( as its Ph4P+ salt) and V cleanly oxidize a wide range of alcs. to aldehydes and ketones without attack on double bonds.  III functions as a heterogeneous oxidant in CH2Cl2, oxidizing only reactive alcs. to aldehydes.  I catalyzed the oxidn. of alcs. by S2O82-.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4AIaM0NUQz7Vg90H21EOLACvtfcHk0lgiECU_telQKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvV2ru7o%253D&md5=cec8d0291a6c5e0bd67fb1fc47d2e773</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1039%2FP19840000681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FP19840000681%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DG.%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DHollinshead%26aufirst%3DD.%2BM.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DSchroder%26aufirst%3DM.%26atitle%3DOxo%2520Complexes%2520of%2520Ruthenium%2528Vi%2529%2520and%2520%2528Vii%2529%2520as%2520Organic%2520Oxidants%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1984%26spage%3D681%26epage%3D686%26doi%3D10.1039%2FP19840000681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolliffe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springhorn, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiffin, P. D.</span></span> <span> </span><span class="NLM_article-title">Oxidation of Activated Halides to Aldehydes and Ketones by N-Methylmorpholine N-Oxide</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1967</span>– <span class="NLM_lpage">1971</span>, <span class="refDoi"> DOI: 10.1080/00397919208021328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F00397919208021328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK38XkvV2qs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1992&pages=1967-1971&author=W.+P.+Griffithauthor=J.+M.+Jolliffeauthor=S.+V.+Leyauthor=K.+F.+Springhornauthor=P.+D.+Tiffin&title=Oxidation+of+Activated+Halides+to+Aldehydes+and+Ketones+by+N-Methylmorpholine+N-Oxide&doi=10.1080%2F00397919208021328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation of activated halides to aldehydes and ketones by N-methylmorpholine N-oxide</span></div><div class="casAuthors">Griffith, William P.; Jolliffe, Jenny M.; Ley, Steven V.; Springhorn, Karsten F.; Tiffin, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1967-71</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">N-methylmorpholine N-oxide (NMO) in acetonitrile soln. will oxidize activated primary halides to aldehydes and secondary halides to ketones in good yields at room temp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLhsYP3x4oqLVg90H21EOLACvtfcHk0lgiECU_telQKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XkvV2qs7w%253D&md5=ea5dd42526b5dbe970d33f54e17bcb85</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1080%2F00397919208021328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919208021328%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DJolliffe%26aufirst%3DJ.%2BM.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DSpringhorn%26aufirst%3DK.%2BF.%26aulast%3DTiffin%26aufirst%3DP.%2BD.%26atitle%3DOxidation%2520of%2520Activated%2520Halides%2520to%2520Aldehydes%2520and%2520Ketones%2520by%2520N-Methylmorpholine%2520N-Oxide%26jtitle%3DSynth.%2520Commun.%26date%3D1992%26volume%3D22%26spage%3D1967%26epage%3D1971%26doi%3D10.1080%2F00397919208021328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolliffe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. J.</span></span> <span> </span><span class="NLM_article-title">A New Ruthenium(Vi) Oxidant: Preparation, X-Ray Crystal Structure, and Properties of (Ph4p)[Ruo2(Oac)Cl2]</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1039/c39900001219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fc39900001219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK3MXhs1GmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&pages=1219-1221&author=W.+P.+Griffithauthor=J.+M.+Jolliffeauthor=S.+V.+Leyauthor=D.+J.+Williams&title=A+New+Ruthenium%28Vi%29+Oxidant%3A+Preparation%2C+X-Ray+Crystal+Structure%2C+and+Properties+of+%28Ph4p%29%5BRuo2%28Oac%29Cl2%5D&doi=10.1039%2Fc39900001219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24cR"><div class="casContent"><span class="casTitleNuber">24c</span><div class="casTitle"><span class="NLM_cas:atitle">A new ruthenium(VI) oxidant:  preparation, x-ray crystal structure, and properties of (Ph4P)[RuO2(OAc)Cl2]</span></div><div class="casAuthors">Griffith, William P.; Jolliffe, Jennifer M.; Ley, Steven V.; Williams, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1219-21</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Ph4P[RuO2(OAc)Cl2] (I), and butyrato and propionato analogs, were prepd.  I was characterized by elemental anal., IR and Raman spectroscopies, and (as I.2HOAc) x-ray crystallog.  Crystals are monoclinic, space group Cc, a 16.823(4), b 7.725(2), c 20.576(5) Å, β 98.93(2)°, Z = 4, R = 0.050, and Rw = 0.047.  I has a quasi-trigonal bipyramidal (or alternatively, distorted octahedral) structure with a sym. bound acetato ligand and cis-dioxo ligands in the trigonal plane, and is an effective oxidant for halides, alcs., sulfides, and phosphines, functioning catalytically in the presence of N-methylmorpholine-N-oxide as cooxidant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9p7kW3LsC8bVg90H21EOLACvtfcHk0lgiECU_telQKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhs1GmtA%253D%253D&md5=b0343b81e21c7e42d1282e558c698f54</span></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1039%2Fc39900001219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39900001219%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DJolliffe%26aufirst%3DJ.%2BM.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DWilliams%26aufirst%3DD.%2BJ.%26atitle%3DA%2520New%2520Ruthenium%2528Vi%2529%2520Oxidant%253A%2520Preparation%252C%2520X-Ray%2520Crystal%2520Structure%252C%2520and%2520Properties%2520of%2520%2528Ph4p%2529%255BRuo2%2528Oac%2529Cl2%255D%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1990%26spage%3D1219%26epage%3D1221%26doi%3D10.1039%2Fc39900001219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span> <span> </span><span class="NLM_article-title">TPAP: Tetra-N-Propylammonium Perruthenate, a Mild and Convenient Oxidant for Alcohols</span>. <i>Aldrichimica Acta</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1002/chin.199040362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fchin.199040362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK3MXotVKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1990&pages=13-19&author=W.+P.+Griffithauthor=S.+V.+Ley&title=TPAP%3A+Tetra-N-Propylammonium+Perruthenate%2C+a+Mild+and+Convenient+Oxidant+for+Alcohols&doi=10.1002%2Fchin.199040362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24dR"><div class="casContent"><span class="casTitleNuber">24d</span><div class="casTitle"><span class="NLM_cas:atitle">TRAP:  tetra-n-propylammonium perruthenate, a mild and convenient oxidant for alcohols</span></div><div class="casAuthors">Griffith, William P.; Ley, Steven V.</div><div class="citationInfo"><span class="NLM_cas:title">Aldrichimica Acta</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-19</span>CODEN:
                <span class="NLM_cas:coden">ALACBI</span>;
        ISSN:<span class="NLM_cas:issn">0002-5100</span>.
    </div><div class="casAbstract">A review with 19 refs. illustrating the use of the title compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqybUhLNpSCrLVg90H21EOLACvtfcHk0lgiECU_telQKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXotVKmsw%253D%253D&md5=02c84ebd8229aafdb72b84a76b53aea9</span></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=10.1002%2Fchin.199040362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchin.199040362%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DLey%26aufirst%3DS.%2BV.%26atitle%3DTPAP%253A%2520Tetra-N-Propylammonium%2520Perruthenate%252C%2520a%2520Mild%2520and%2520Convenient%2520Oxidant%2520for%2520Alcohols%26jtitle%3DAldrichimica%2520Acta%26date%3D1990%26volume%3D23%26spage%3D13%26epage%3D19%26doi%3D10.1002%2Fchin.199040362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitcombe, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. D.</span></span> <span> </span><span class="NLM_article-title">Preparation and Use of Tetrabutylammonium Perruthenate (Tbap Reagent) and Tetrapropylammonium Perruthenate (Tpap Reagent) as New Catalytic Oxidants for Alcohols</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1627</span>, <span class="refDoi"> DOI: 10.1039/c39870001625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fc39870001625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaL1cXktlOhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=1625-1627&author=W.+P.+Griffithauthor=S.+V.+Leyauthor=G.+P.+Whitcombeauthor=A.+D.+White&title=Preparation+and+Use+of+Tetrabutylammonium+Perruthenate+%28Tbap+Reagent%29+and+Tetrapropylammonium+Perruthenate+%28Tpap+Reagent%29+as+New+Catalytic+Oxidants+for+Alcohols&doi=10.1039%2Fc39870001625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24eR"><div class="casContent"><span class="casTitleNuber">24e</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and use of tetrabutylammonium perruthenate (TBAP reagent) and tetrapropylammonium perruthenate (TPAP reagent) as new catalytic oxidants for alcohols</span></div><div class="casAuthors">Griffith, William P.; Ley, Steven V.; Whitcombe, Gwynne P.; White, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1625-7</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Bu4NRuO4 or Pr4NRuO4 in combination with N-methylmorpholine N-oxide are mild catalytic oxidants for the high yield conversion of alcs. to aldehyde and ketones and are competitive with more conventional reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxf2jCOWaVh7Vg90H21EOLACvtfcHk0liQjiq_5mqWlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktlOhuro%253D&md5=19a661844cadf93bad8dc9ae9ba18477</span></div><a href="/servlet/linkout?suffix=cit24e&amp;dbid=16384&amp;doi=10.1039%2Fc39870001625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39870001625%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DWhitcombe%26aufirst%3DG.%2BP.%26aulast%3DWhite%26aufirst%3DA.%2BD.%26atitle%3DPreparation%2520and%2520Use%2520of%2520Tetrabutylammonium%2520Perruthenate%2520%2528Tbap%2520Reagent%2529%2520and%2520Tetrapropylammonium%2520Perruthenate%2520%2528Tpap%2520Reagent%2529%2520as%2520New%2520Catalytic%2520Oxidants%2520for%2520Alcohols%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1987%26spage%3D1625%26epage%3D1627%26doi%3D10.1039%2Fc39870001625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, S. P.</span></span> <span> </span><span class="NLM_article-title">Tetrapropylammonium Perruthenate, Pr4n+Ruo4-, Tpap: A Catalytic Oxidant for Organic Synthesis</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>1994</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1055/s-1994-25538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-1994-25538" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1994&publication_year=1994&pages=639-666&author=S.+V.+Leyauthor=J.+Normanauthor=W.+P.+Griffithauthor=S.+P.+Marsden&title=Tetrapropylammonium+Perruthenate%2C+Pr4n%2BRuo4-%2C+Tpap%3A+A+Catalytic+Oxidant+for+Organic+Synthesis&doi=10.1055%2Fs-1994-25538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24f&amp;dbid=16384&amp;doi=10.1055%2Fs-1994-25538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1994-25538%26sid%3Dliteratum%253Aachs%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DNorman%26aufirst%3DJ.%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DMarsden%26aufirst%3DS.%2BP.%26atitle%3DTetrapropylammonium%2520Perruthenate%252C%2520Pr4n%252BRuo4-%252C%2520Tpap%253A%2520A%2520Catalytic%2520Oxidant%2520for%2520Organic%2520Synthesis%26jtitle%3DSynthesis%26date%3D1994%26volume%3D1994%26spage%3D639%26epage%3D666%26doi%3D10.1055%2Fs-1994-25538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bjornson, K.</span>; <span class="NLM_string-name">Karki, K.
K.</span>; <span class="NLM_string-name">Link, J.
O.</span>; <span class="NLM_string-name">Pyun, H.-J.</span>; <span class="NLM_string-name">Schrier, A. J.</span>; <span class="NLM_string-name">Stevens, K. L.</span>; <span class="NLM_string-name">Taylor, J. G.</span>; <span class="NLM_string-name">Vivian, R. W.</span>; <span class="NLM_string-name">Zablocki, J.</span>; <span class="NLM_string-name">Zipfel, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocyclic and Bicyclic Derivatives of N-Prolyl-1-aminocyclopropanecarboxylic Acid Peptides as Inhibitors of Hepatitis C Virus</span>. <span class="NLM_patent">WO 2014145095A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+Bjornson&author=K.%0AK.+Karki&author=J.%0AO.+Link&author=H.-J.+Pyun&author=A.+J.+Schrier&author=K.+L.+Stevens&author=J.+G.+Taylor&author=R.+W.+Vivian&author=J.+Zablocki&author=S.+Zipfel&title=Preparation+of+Macrocyclic+and+Bicyclic+Derivatives+of+N-Prolyl-1-aminocyclopropanecarboxylic+Acid+Peptides+as+Inhibitors+of+Hepatitis+C+Virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBjornson%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Macrocyclic%2520and%2520Bicyclic%2520Derivatives%2520of%2520N-Prolyl-1-aminocyclopropanecarboxylic%2520Acid%2520Peptides%2520as%2520Inhibitors%2520of%2520Hepatitis%2520C%2520Virus%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, N. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furkert, D. P.</span></span> <span> </span><span class="NLM_article-title">Remarkable Influence of Cobalt Catalysis on Epoxide Ring-Opening with Sulfoxonium Ylides</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">3952</span>– <span class="NLM_lpage">3956</span>, <span class="refDoi"> DOI: 10.1055/s-0036-1588814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-0036-1588814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlyrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=3952-3956&author=M.+L.+Jamiesonauthor=N.+Z.+Brantauthor=M.+A.+Brimbleauthor=D.+P.+Furkert&title=Remarkable+Influence+of+Cobalt+Catalysis+on+Epoxide+Ring-Opening+with+Sulfoxonium+Ylides&doi=10.1055%2Fs-0036-1588814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Remarkable Influence of Cobalt Catalysis on Epoxide Ring-Opening with Sulfoxonium Ylides</span></div><div class="casAuthors">Jamieson, Megan L.; Brant, Nicola Z.; Brimble, Margaret A.; Furkert, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3952-3956</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Cobalt demonstrates a remarkable ability to catalytically divert the course of epoxide to oxetane ring expansion via reaction with a sulfoxonium ylide.  An expanded survey of transition-metal catalysts has confirmed that cobalt salts uniquely instead deliver homoallylic alc. products from epoxides, with retention of the original epoxide stereochem.  The reaction is an unusual example of cobalt-catalyzed epoxide ring-opening by a carbon nucleophile.  A tandem Corey-Chaykovsky/epoxide olefination sequence giving homoallylic alcs. from aldehydes is further demonstrated along with preliminary mechanistic anal.  This communication summarizes current understanding and ongoing studies into this intriguing new cobalt-mediated reactivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpodo_joTc5zLVg90H21EOLACvtfcHk0liQjiq_5mqWlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlyrtLY%253D&md5=7706b207f7896f2523d6ceb2745ad7af</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1055%2Fs-0036-1588814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0036-1588814%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DM.%2BL.%26aulast%3DBrant%26aufirst%3DN.%2BZ.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26aulast%3DFurkert%26aufirst%3DD.%2BP.%26atitle%3DRemarkable%2520Influence%2520of%2520Cobalt%2520Catalysis%2520on%2520Epoxide%2520Ring-Opening%2520with%2520Sulfoxonium%2520Ylides%26jtitle%3DSynthesis%26date%3D2017%26volume%3D49%26spage%3D3952%26epage%3D3956%26doi%3D10.1055%2Fs-0036-1588814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguloth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohapatra, D. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the Major Oxepane Segment of Zoapatanol</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1002/hlca.201200364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fhlca.201200364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls12rs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2013&pages=663-674&author=J.+S.+Yadavauthor=U.+Dashauthor=N.+Gugulothauthor=D.+K.+Mohapatra&title=Synthesis+of+the+Major+Oxepane+Segment+of+Zoapatanol&doi=10.1002%2Fhlca.201200364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the Major Oxepane Segment of Zoapatanol</span></div><div class="casAuthors">Yadav, Jhillu S.; Dash, Uttam; Guguloth, Nagesh; Mohapatra, Debendra K.</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">663-674</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta</span>)
        </div><div class="casAbstract">A linear synthesis of the major oxepane fragment (I) of zoapatanol, isolated from the leaves of Mexican zoapatle plant Montanoa tomentosa, is described from a known intermediate involving Sharpless asym. epoxidn., bis-epoxide opening reaction with Corey-Chaykovsky reagent, ring-closing metathesis reaction, and Horner-Wadsworth-Emmons olefination reaction as key steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqibindN9ROJ7Vg90H21EOLACvtfcHk0liNu5dcljNlNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls12rs7w%253D&md5=29e50a456b976c6c769d600f55882023</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1002%2Fhlca.201200364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.201200364%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DJ.%2BS.%26aulast%3DDash%26aufirst%3DU.%26aulast%3DGuguloth%26aufirst%3DN.%26aulast%3DMohapatra%26aufirst%3DD.%2BK.%26atitle%3DSynthesis%2520of%2520the%2520Major%2520Oxepane%2520Segment%2520of%2520Zoapatanol%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2013%26volume%3D96%26spage%3D663%26epage%3D674%26doi%3D10.1002%2Fhlca.201200364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span>; <span class="NLM_string-name">Chen, L.</span>; <span class="NLM_string-name">Shan, Y.</span>; <span class="NLM_string-name">Luo, H.</span>; <span class="NLM_string-name">Liang, J.</span>; <span class="NLM_string-name">Huang, J.</span>; <span class="NLM_string-name">Xiong, J.</span>; <span class="NLM_string-name">Zhang, D.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Salts of a Macrocyclic Peptidomimetic as HCV Inhibitors</span>. <span class="NLM_patent">WO 2018028634A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Q.+Ren&author=L.+Chen&author=Y.+Shan&author=H.+Luo&author=J.+Liang&author=J.+Huang&author=J.+Xiong&author=D.+Zhang&author=Y.+Zhang&author=J.+Zhang&title=Preparation+of+Salts+of+a+Macrocyclic+Peptidomimetic+as+HCV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520Salts%2520of%2520a%2520Macrocyclic%2520Peptidomimetic%2520as%2520HCV%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Z.-Y. J.</span></span> <span> </span><span class="NLM_article-title">Highly Active Metathesis Catalysts Selective for Romp and Rcm Reactions</span>. <span class="NLM_patent">WO 2011079439A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Z.-Y.+J.+Zhan&title=Highly+Active+Metathesis+Catalysts+Selective+for+Romp+and+Rcm+Reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DZ.-Y.%2BJ.%26atitle%3DHighly%2520Active%2520Metathesis%2520Catalysts%2520Selective%2520for%2520Romp%2520and%2520Rcm%2520Reactions%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span>; <span class="NLM_string-name">Shepard, S.</span>; <span class="NLM_string-name">Li, Y.-L.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Liu, P.</span>; <span class="NLM_string-name">Meloni, D.</span>; <span class="NLM_string-name">Xia, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Azetidine and Cyclobutane Derivatives as Jak Inhibitors</span>. <span class="NLM_patent">WO 2009114512</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+D.+Rodgers&author=S.+Shepard&author=Y.-L.+Li&author=J.+Zhou&author=P.+Liu&author=D.+Meloni&author=M.+Xia&title=Preparation+of+Azetidine+and+Cyclobutane+Derivatives+as+Jak+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26atitle%3DPreparation%2520of%2520Azetidine%2520and%2520Cyclobutane%2520Derivatives%2520as%2520Jak%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobierski, M. E.</span>; <span class="NLM_string-name">Kopach, M. E.</span>; <span class="NLM_string-name">Martinelli, J. R.</span>; <span class="NLM_string-name">Varie, D. L.</span>; <span class="NLM_string-name">Wilson, T. M.</span></span> <span> </span><span class="NLM_article-title">Processes and Intermediates for the Preparation of {1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile</span>. <span class="NLM_patent">WO 2016205487</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+E.+Kobierski&author=M.+E.+Kopach&author=J.+R.+Martinelli&author=D.+L.+Varie&author=T.+M.+Wilson&title=Processes+and+Intermediates+for+the+Preparation+of+%7B1-%28Ethylsulfonyl%29-3-%5B4-%287H-pyrrolo%5B2%2C3-D%5Dpyrimidin-4-yl%29-1H-pyrazol-1-yl%5Dazetidin-3-yl%7Dacetonitrile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKobierski%26aufirst%3DM.%2BE.%26atitle%3DProcesses%2520and%2520Intermediates%2520for%2520the%2520Preparation%2520of%2520%257B1-%2528Ethylsulfonyl%2529-3-%255B4-%25287H-pyrrolo%255B2%252C3-D%255Dpyrimidin-4-yl%2529-1H-pyrazol-1-yl%255Dazetidin-3-yl%257Dacetonitrile%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevar, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kel'in, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulinkovich, O. G.</span></span> <span> </span><span class="NLM_article-title">One Step Preparation of 1,4-Diketones from Methyl Ketones and A-Bromomethyl Ketones in the Presence of Zncl2·T-Buoh·Et2nr as a Condensation Agent</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2000</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1055/s-2000-6418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-2000-6418" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2000&publication_year=2000&pages=1259-1262&author=N.+M.+Nevarauthor=A.+V.+Kel%27inauthor=O.+G.+Kulinkovich&title=One+Step+Preparation+of+1%2C4-Diketones+from+Methyl+Ketones+and+A-Bromomethyl+Ketones+in+the+Presence+of+Zncl2%C2%B7T-Buoh%C2%B7Et2nr+as+a+Condensation+Agent&doi=10.1055%2Fs-2000-6418"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-6418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-6418%26sid%3Dliteratum%253Aachs%26aulast%3DNevar%26aufirst%3DN.%2BM.%26aulast%3DKel%2527in%26aufirst%3DA.%2BV.%26aulast%3DKulinkovich%26aufirst%3DO.%2BG.%26atitle%3DOne%2520Step%2520Preparation%2520of%25201%252C4-Diketones%2520from%2520Methyl%2520Ketones%2520and%2520A-Bromomethyl%2520Ketones%2520in%2520the%2520Presence%2520of%2520Zncl2%25C2%25B7T-Buoh%25C2%25B7Et2nr%2520as%2520a%2520Condensation%2520Agent%26jtitle%3DSynthesis%26date%3D2000%26volume%3D2000%26spage%3D1259%26epage%3D1262%26doi%3D10.1055%2Fs-2000-6418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Periasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seenivasaperumal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. D.</span></span> <span> </span><span class="NLM_article-title">Convenient Procedures for the Asymmetric Reduction of 1,4-Diphenylbutane-1,4-Dione and Synthesis of 2,5-Diphenylpyrrolidine Derivatives</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2510</span>, <span class="refDoi"> DOI: 10.1055/s-2003-42447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-2003-42447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsV2htb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=2507-2510&author=M.+Periasamyauthor=M.+Seenivasaperumalauthor=V.+D.+Rao&title=Convenient+Procedures+for+the+Asymmetric+Reduction+of+1%2C4-Diphenylbutane-1%2C4-Dione+and+Synthesis+of+2%2C5-Diphenylpyrrolidine+Derivatives&doi=10.1055%2Fs-2003-42447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">Convenient procedures for the asymmetric reduction of 1,4-diphenylbutane-1,4-dione and synthesis of 2,5-diphenylpyrrolidine derivatives</span></div><div class="casAuthors">Periasamy, Mariappan; Seenivasaperumal, Muthu; Rao, Vutukuri Dharma</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2507-2510</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Asym. redn. of 1,4-diphenylbutane-1,4-dione was carried out using the reducing agents NaBH4, BH3·THF, and PhNEt2·BH3 in combination with the chiral reagents (S)-(-)-α,α-diphenyl-2-pyrrolidinemethanol or (S)-proline, in the presence of TMSCl or B(OMe)3 under various conditions to obtain the corresponding 1,4-diol I in good yield and high enantiomeric excess.  I was converted to various C2-sym. (2S,5S)-2,5-diphenylpyrrolidines II (R = Ph, PhCH2, 2-MeOC6H4, HOCH2CH2, Bu) via the corresponding dimesylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYep2mvYWKbVg90H21EOLACvtfcHk0liNu5dcljNlNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsV2htb8%253D&md5=f2d2121da2144ef04acb518b86dab373</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1055%2Fs-2003-42447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2003-42447%26sid%3Dliteratum%253Aachs%26aulast%3DPeriasamy%26aufirst%3DM.%26aulast%3DSeenivasaperumal%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DV.%2BD.%26atitle%3DConvenient%2520Procedures%2520for%2520the%2520Asymmetric%2520Reduction%2520of%25201%252C4-Diphenylbutane-1%252C4-Dione%2520and%2520Synthesis%2520of%25202%252C5-Diphenylpyrrolidine%2520Derivatives%26jtitle%3DSynthesis%26date%3D2003%26spage%3D2507%26epage%3D2510%26doi%3D10.1055%2Fs-2003-42447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span>; <span class="NLM_string-name">Meyer, M. P.</span></span> <span> </span><span class="NLM_article-title">The Corey–Bakshi–Shibata Reduction: Mechanistic and Synthetic Considerations—Bifunctional Lewis Base Catalysis with Dual Activation</span>. In  <i>Lewis Base Catalysis in Organic Synthesis</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedejs, E.</span>, <span class="NLM_string-name">Denmark, S. E.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">1, 2</span> and  <span class="NLM_volume">3</span>, pp  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">456</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2F9783527675142.ch11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=387-456&author=C.+J.+Helal&author=M.+P.+Meyerauthor=E.+Vedejs&author=S.+E.+Denmark&title=Lewis+Base+Catalysis+in+Organic+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1002%2F9783527675142.ch11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527675142.ch11%26sid%3Dliteratum%253Aachs%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520Corey%25E2%2580%2593Bakshi%25E2%2580%2593Shibata%2520Reduction%253A%2520Mechanistic%2520and%2520Synthetic%2520Considerations%25E2%2580%2594Bifunctional%2520Lewis%2520Base%2520Catalysis%2520with%2520Dual%2520Activation%26btitle%3DLewis%2520Base%2520Catalysis%2520in%2520Organic%2520Synthesis%26aulast%3DVedejs%26aufirst%3DE.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2016%26volume%3D1%252C%25202%26volume%3D3%26spage%3D387%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Letermovir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0860-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0860-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29288370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=147-152&author=E.+S.+Kim&title=Letermovir%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0860-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Letermovir: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-152</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Letermovir (Prevymis) is an orally or i.v. administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH.  Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropos. recipients of an allogeneic haematopoietic stem cell transplant (HSCT).  In addn., letermovir has received a pos. opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan.  This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropos. recipients of an allogeneic HSCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd17YxqIzKurVg90H21EOLACvtfcHk0licTsLldwTP0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGrtQ%253D%253D&md5=f8119640200c6dcd24b78c6bf261b85e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0860-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0860-8%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DLetermovir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D147%26epage%3D152%26doi%3D10.1007%2Fs40265-017-0860-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goldner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewlett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettischer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruebsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lischka, P.</span></span> <span> </span><span class="NLM_article-title">The Novel Anticytomegalovirus Compound Aic246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">10884</span>– <span class="NLM_lpage">10893</span>, <span class="refDoi"> DOI: 10.1128/JVI.05265-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1128%2FJVI.05265-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=21752907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=10884-10893&author=T.+Goldnerauthor=G.+Hewlettauthor=N.+Ettischerauthor=H.+Ruebsamen-Schaeffauthor=H.+Zimmermannauthor=P.+Lischka&title=The+Novel+Anticytomegalovirus+Compound+Aic246+%28Letermovir%29+Inhibits+Human+Cytomegalovirus+Replication+through+a+Specific+Antiviral+Mechanism+That+Involves+the+Viral+Terminase&doi=10.1128%2FJVI.05265-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase</span></div><div class="casAuthors">Goldner, Thomas; Hewlett, Guy; Ettischer, Nicole; Ruebsamen-Schaeff, Helga; Zimmermann, Holger; Lschka, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10884-10893</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) remains the leading viral cause of birth defects and life-threatening disease in transplant recipients.  All approved antiviral drugs target the viral DNA polymerase and are assocd. with severe toxicity issues and the emergence of drug resistance.  Attempts to discover improved anti-HCMV drugs led to the identification of the small-mol.-wt. compd. AIC246 (Letermovir).  AIC246 exhibits outstanding anti-HCMV activity in vitro and in vivo and currently is undergoing a clin. phase IIb trial.  The initial mode-of-action studies suggested that the drug acts late in the HCMV replication cycle via a mechanism distinct from that of polymerase inhibitors.  Here, we extend our mode-of-action analyses and report that AIC246 blocks viral replication without inhibiting the synthesis of progeny HCMV DNA or viral proteins.  The genotyping of mutant viruses that escaped AIC246 inhibition uncovered distinct point mutations in the UL56 subunit of the viral terminase complex.  Marker transfer analyses confirmed that these mutations were sufficient to mediate AIC246 resistance.  The mapping of drug resistance to open reading frame UL56 suggests that viral DNA processing and/or packaging is targeted by AIC246.  In line with this, we demonstrate that AIC246 affects the formation of proper unit-length genomes from viral DNA concatemers and interferes with virion maturation.  However, since AIC246-resistant viruses do not exhibit cross-resistance to previously published terminase inhibitors, our data suggest that AIC246 interferes with HCMV DNA cleavage/packaging via a mol. mechanism that is distinct from that of other compd. classes known to target the viral terminase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswkV2gibRBbVg90H21EOLACvtfcHk0licTsLldwTP0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsbzI&md5=63602456ebfb1cf9c2509d26d260487d</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1128%2FJVI.05265-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.05265-11%26sid%3Dliteratum%253Aachs%26aulast%3DGoldner%26aufirst%3DT.%26aulast%3DHewlett%26aufirst%3DG.%26aulast%3DEttischer%26aufirst%3DN.%26aulast%3DRuebsamen-Schaeff%26aufirst%3DH.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DLischka%26aufirst%3DP.%26atitle%3DThe%2520Novel%2520Anticytomegalovirus%2520Compound%2520Aic246%2520%2528Letermovir%2529%2520Inhibits%2520Human%2520Cytomegalovirus%2520Replication%2520through%2520a%2520Specific%2520Antiviral%2520Mechanism%2520That%2520Involves%2520the%2520Viral%2520Terminase%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D10884%26epage%3D10893%26doi%3D10.1128%2FJVI.05265-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lischka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewlett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruebsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Activities of the Novel Anticytomegalovirus Compound Aic246</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1297</span>, <span class="refDoi"> DOI: 10.1128/AAC.01596-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1128%2FAAC.01596-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=20047911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFWqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=1290-1297&author=P.+Lischkaauthor=G.+Hewlettauthor=T.+Wunbergauthor=J.+Baumeisterauthor=D.+Paulsenauthor=T.+Goldnerauthor=H.+Ruebsamen-Schaeffauthor=H.+Zimmermann&title=In+Vitro+and+in+Vivo+Activities+of+the+Novel+Anticytomegalovirus+Compound+Aic246&doi=10.1128%2FAAC.01596-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of the novel anti-cytomegalovirus compound AIC246</span></div><div class="casAuthors">Lischka, Peter; Hewlett, Guy; Wunberg, Tobias; Baumeister, Judith; Paulsen, Daniela; Goldner, Thomas; Ruebsamen-Schaeff, Helga; Zimmermann, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1290-1297</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) remains a serious threat for immunocompromised individuals, including transplant recipients and newborns.  To date, all drugs licensed for the treatment of HCMV infection and disease target the viral DNA polymerase.  Although these drugs are effective, several drawbacks are assocd. with their use, including toxicity and emergence of drug resistance.  Hence, new and improved antivirals with novel mol. targets are urgently needed.  Here we report on the antiviral properties of AIC246, a representative of a novel class of low-mol.-wt. compds. that is currently undergoing clin. phase II studies.  The anti-HCMV activity of AIC246 was evaluated in vitro and in vivo using various cell culture assays and an engineered mouse xenograft model.  In addn., antiviral properties of the drug were characterized in comparison to the current gold std. ganciclovir.  We demonstrate that AIC246 exhibits excellent in vitro inhibitory activity against HCMV lab. strains and clin. isolates, retains activity against ganciclovir-resistant viruses, is well tolerated in different cell types (median selectivity index, 18,000), and exerts a potent in vivo efficacy in a mouse xenograft model.  Moreover, we show that the antiviral block induced by AIC246 is reversible and the efficacy of the drug is not significantly affected by cell culture variations such as cell type or multiplicity of infection.  Finally, initial mode-of-action analyses reveal that AIC246 targets a process in the viral replication cycle that occurs later than DNA synthesis.  Thus, AIC246 acts via a mode of action that differs from that of polymerase inhibitors like ganciclovir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYctCp0_IZsrVg90H21EOLACvtfcHk0liOcEKBLfB22A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFWqtro%253D&md5=5241b3ab03c28e9071c7e2ac7113d1c3</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1128%2FAAC.01596-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01596-09%26sid%3Dliteratum%253Aachs%26aulast%3DLischka%26aufirst%3DP.%26aulast%3DHewlett%26aufirst%3DG.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DBaumeister%26aufirst%3DJ.%26aulast%3DPaulsen%26aufirst%3DD.%26aulast%3DGoldner%26aufirst%3DT.%26aulast%3DRuebsamen-Schaeff%26aufirst%3DH.%26aulast%3DZimmermann%26aufirst%3DH.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Activities%2520of%2520the%2520Novel%2520Anticytomegalovirus%2520Compound%2520Aic246%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D1290%26epage%3D1297%26doi%3D10.1128%2FAAC.01596-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maffini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Festuccia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, B.</span></span> <span> </span><span class="NLM_article-title">Treatment of Cmv Infection after Allogeneic Hematopoietic Stem Cell Transplantation</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1080/17474086.2016.1174571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F17474086.2016.1174571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27043241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsValtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=585-596&author=E.+Maffiniauthor=L.+Giacconeauthor=M.+Festucciaauthor=L.+Brunelloauthor=A.+Buscaauthor=B.+Bruno&title=Treatment+of+Cmv+Infection+after+Allogeneic+Hematopoietic+Stem+Cell+Transplantation&doi=10.1080%2F17474086.2016.1174571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation</span></div><div class="casAuthors">Maffini, Enrico; Giaccone, Luisa; Festuccia, Moreno; Brunello, Lucia; Busca, Alessandro; Bruno, Benedetto</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">585-596</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Despite a remarkable redn. in the past decades, cytomegalovirus (CMV) disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients remains a feared complication, still assocd. with significant morbidity and mortality.  Today, first line treatment of CMV infection/reactivation is still based on dated antiviral compds. Ganciclovir (GCV), Foscarnet (FOS) and Cidofovir (CDF) with their burdensome wt. of side effects.  Maribavir (MBV), Letermovir (LMV) and Brincidofovir (BDF) are three new promising anti-CMV drugs without myelosuppressive properties or renal toxic effects that are under investigation in randomized phase II and III trials.  Adoptive T-cell therapy (ATCT) in CMV infection possesses a strong rationale, demonstrated by several proof of concept studies; its feasibility is currently under investigation by clin. trials.  ATCT from third-party and naive donors could meet the needs of HSCT recipients of seroneg. donors and cord blood grafts.  In selected patients such as recipients of T-cell depleted grafts, ATCT, based on CMV-specific host T-cells reconstitution kinetics, would be of value in the prophylactic and/or preemptive CMV treatment.  Vaccine-immunotherapy has the difficult task to reduce the incidence of CMV reactivation/infection in highly immunocompromised HSCT patients.  Newer notions on CMV biol. may represent the base to flush out the Troll of transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p3iqa8nYoLVg90H21EOLACvtfcHk0liOcEKBLfB22A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsValtbc%253D&md5=6202b81031dab3e5909b610b72f7cc9c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F17474086.2016.1174571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2016.1174571%26sid%3Dliteratum%253Aachs%26aulast%3DMaffini%26aufirst%3DE.%26aulast%3DGiaccone%26aufirst%3DL.%26aulast%3DFestuccia%26aufirst%3DM.%26aulast%3DBrunello%26aufirst%3DL.%26aulast%3DBusca%26aufirst%3DA.%26aulast%3DBruno%26aufirst%3DB.%26atitle%3DTreatment%2520of%2520Cmv%2520Infection%2520after%2520Allogeneic%2520Hematopoietic%2520Stem%2520Cell%2520Transplantation%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2016%26volume%3D9%26spage%3D585%26epage%3D596%26doi%3D10.1080%2F17474086.2016.1174571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R.
F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmann, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoelben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornhauser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolling, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stobernack, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lischka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehninger, G.</span></span> <span> </span><span class="NLM_article-title">Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1789</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1309533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1056%2FNEJMoa1309533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=24806159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXot12jtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1781-1789&author=R.%0AF.+Chemalyauthor=A.+J.+Ullmannauthor=S.+Stoelbenauthor=M.+P.+Richardauthor=M.+Bornhauserauthor=C.+Grothauthor=H.+Einseleauthor=M.+Silvermanauthor=K.+M.+Mullaneauthor=J.+Brownauthor=H.+Nowakauthor=K.+Kollingauthor=H.+P.+Stobernackauthor=P.+Lischkaauthor=H.+Zimmermannauthor=H.+Rubsamen-Schaeffauthor=R.+E.+Champlinauthor=G.+Ehninger&title=Letermovir+for+Cytomegalovirus+Prophylaxis+in+Hematopoietic-Cell+Transplantation&doi=10.1056%2FNEJMoa1309533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation</span></div><div class="casAuthors">Chemaly, Roy F.; Ullmann, Andrew J.; Stoelben, Susanne; Richard, Marie Paule; Bornhauser, Martin; Groth, Christoph; Einsele, Hermann; Silverman, Margarida; Mullane, Kathleen M.; Brown, Janice; Nowak, Horst; Kolling, Katrin; Stobernack, Hans P.; Lischka, Peter; Zimmermann, Holger; Rubsamen-Schaeff, Helga; Champlin, Richard E.; Ehninger, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1781-1789</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Cytomegalovirus (CMV) infection is a leading cause of illness and death in patients who have undergone allogeneic hematopoietic-cell transplantation.  Available treatments are restricted by clin. significant toxic effects and drug resistance.  METHODS In this phase 2 study, we evaluated the effect of letermovir (also known as AIC246), a new anti-CMV drug with a novel mechanism of action, on the incidence and time to onset of prophylaxis failure in CMV-seropos. recipients of allogeneic hematopoietic-cell transplants from matched related or unrelated donors.  From March 2010 through Oct. 2011, we randomly assigned 131 transplant recipients in a 3:1 ratio to three sequential study cohorts according to a double-blind design.  Patients received oral letermovir (at a dose of 60, 120, or 240 mg per day, or matching placebo) for 12 wk after engraftment.  The primary end point was all-cause prophylaxis failure, defined as discontinuation of the study drug because of CMV antigen or DNA detection, end-organ disease, or any other cause.  Patients underwent weekly surveillance for CMV infection.  RESULTS The redn. in the incidence of all-cause prophylaxis failure was dose-dependent.  The incidence of prophylaxis failure with letermovir, as compared with placebo, was 48% vs. 64% at a daily letermovir dose of 60 mg (P = 0.32), 32% at a dose of 120 mg (P = 0.01), and 29% at a dose of 240 mg (P = 0.007).  Kaplan-Meier time-to-onset profiles for prophylaxis failure showed a significant difference in the comparison of letermovir at a dose of 240 mg per day with placebo (P = 0.002).  The safety profile of letermovir was similar to placebo, with no indication of hematol. toxicity or nephrotoxicity.  CONCLUSIONS Letermovir, as compared with placebo, was effective in reducing the incidence of CMV infection in recipients of allogeneic hematopoietic-cell transplants.  The highest dose (240 mg per day) had the greatest anti-CMV activity, with an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_0Nxh6vCjW7Vg90H21EOLACvtfcHk0liOcEKBLfB22A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXot12jtLc%253D&md5=bdba7e2d625d8713e7224584b2f3adaf</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1309533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1309533%26sid%3Dliteratum%253Aachs%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DUllmann%26aufirst%3DA.%2BJ.%26aulast%3DStoelben%26aufirst%3DS.%26aulast%3DRichard%26aufirst%3DM.%2BP.%26aulast%3DBornhauser%26aufirst%3DM.%26aulast%3DGroth%26aufirst%3DC.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DSilverman%26aufirst%3DM.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DNowak%26aufirst%3DH.%26aulast%3DKolling%26aufirst%3DK.%26aulast%3DStobernack%26aufirst%3DH.%2BP.%26aulast%3DLischka%26aufirst%3DP.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DRubsamen-Schaeff%26aufirst%3DH.%26aulast%3DChamplin%26aufirst%3DR.%2BE.%26aulast%3DEhninger%26aufirst%3DG.%26atitle%3DLetermovir%2520for%2520Cytomegalovirus%2520Prophylaxis%2520in%2520Hematopoietic-Cell%2520Transplantation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1781%26epage%3D1789%26doi%3D10.1056%2FNEJMoa1309533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljungman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadwal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmann, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snydman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNubile, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teal, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartsonis, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badshah, C.</span></span> <span> </span><span class="NLM_article-title">Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2433</span>– <span class="NLM_lpage">2444</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1056%2FNEJMoa1706640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29211658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2433-2444&author=F.+M.+Martyauthor=P.+Ljungmanauthor=R.+F.+Chemalyauthor=J.+Maertensauthor=S.+S.+Dadwalauthor=R.+F.+Duarteauthor=S.+Haiderauthor=A.+J.+Ullmannauthor=Y.+Katayamaauthor=J.+Brownauthor=K.+M.+Mullaneauthor=M.+Boeckhauthor=E.+A.+Blumbergauthor=H.+Einseleauthor=D.+R.+Snydmanauthor=Y.+Kandaauthor=M.+J.+DiNubileauthor=V.+L.+Tealauthor=H.+Wanauthor=Y.+Murataauthor=N.+A.+Kartsonisauthor=R.+Y.+Leavittauthor=C.+Badshah&title=Letermovir+Prophylaxis+for+Cytomegalovirus+in+Hematopoietic-Cell+Transplantation&doi=10.1056%2FNEJMoa1706640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation</span></div><div class="casAuthors">Marty, F. M.; Ljungman, P.; Chemaly, R. F.; Maertens, J.; Dadwal, S. S.; Duart, R. F.; Haider, S.; Ullmann, A. J.; Katayama, Y.; Brown, J.; Mullane, K. M.; Boeckh, M.; Blumberg, E. A.; Einsele, H.; Snydman, D. R.; Kanda, Y.; Di Nubile, M. J.; Teal, V. L.; Wan, H.; Murata, Y.; Kartsonis, N. A.; Leavitt, R. Y.; Badshah, C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2433-2444</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation.  Letermovir is an antiviral drug that inhibits the CMV-terminase complex. methods In this phase 3, double-blind trial, we randomly assigned CMV-seropos. transplant recipients, 18 years of age or older, in a 2:1 ratio to receive letermovir or placebo, administered orally or i.v., through week 14 after transplantation; randomization was stratified according to trial site and CMV disease risk.  Letermovir was administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine).  Patients in whom clin. significant CMV infection (CMV disease or CMV viremia leading to preemptive treatment) developed discontinued the trial regimen and received anti-CMV treatment.  The primary end point was the proportion of patients, among patients without detectable CMV DNA at randomization, who had clin. significant CMV infection through week 24 after transplantation.  Patients who discontinued the trial or had missing end-point data at week 24 were imputed as having a primary end-point event.  Patients were followed through week 48 after transplantation. results From June 2014 to March 2016, a total of 565 patients underwent randomization and received letermovir or placebo beginning a median of 9 days after transplantation.  Among 495 patients with undetectable CMV DNA at randomization, fewer patients in the letermovir group than in the placebo group had clin. significant CMV infection or were imputed as having a primary end-point event by week 24 after transplantation (122 of 325 patients [37.5%] vs. 103 of 170 [60.6%], P<0.001).  The frequency and severity of adverse events were similar in the two groups overall.  Vomiting was reported in 18.5% of the patients who received letermovir and in 13.5% of those who received placebo; edema in 14.5% and 9.4%, resp.; and atrial fibrillation or flutter in 4.6% and 1.0%, resp.  The rates of myelotoxic and nephrotoxic events were similar in the letermovir group and the placebo group.  All-cause mortality at week 48 after transplantation was 20.9% among letermovir recipients and 25.5% among placebo recipients. conclusions Letermovir prophylaxis resulted in a significantly lower risk of clin. significant CMV infection than placebo.  Adverse events with letermovir were mainly of low grade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZcGkNwE_sAbVg90H21EOLACvtfcHk0lhXrNoJTYN2fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtLs%253D&md5=b474e8e6101f895a2b95bd4612e5954e</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706640%26sid%3Dliteratum%253Aachs%26aulast%3DMarty%26aufirst%3DF.%2BM.%26aulast%3DLjungman%26aufirst%3DP.%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DMaertens%26aufirst%3DJ.%26aulast%3DDadwal%26aufirst%3DS.%2BS.%26aulast%3DDuarte%26aufirst%3DR.%2BF.%26aulast%3DHaider%26aufirst%3DS.%26aulast%3DUllmann%26aufirst%3DA.%2BJ.%26aulast%3DKatayama%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DBoeckh%26aufirst%3DM.%26aulast%3DBlumberg%26aufirst%3DE.%2BA.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DSnydman%26aufirst%3DD.%2BR.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DDiNubile%26aufirst%3DM.%2BJ.%26aulast%3DTeal%26aufirst%3DV.%2BL.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DMurata%26aufirst%3DY.%26aulast%3DKartsonis%26aufirst%3DN.%2BA.%26aulast%3DLeavitt%26aufirst%3DR.%2BY.%26aulast%3DBadshah%26aufirst%3DC.%26atitle%3DLetermovir%2520Prophylaxis%2520for%2520Cytomegalovirus%2520in%2520Hematopoietic-Cell%2520Transplantation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D2433%26epage%3D2444%26doi%3D10.1056%2FNEJMoa1706640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzung, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschaen, D. M.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of Letermovir Using a Novel Phase-Transfer-Catalyzed Aza-Michael Reaction</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00076</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00076" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslOhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1097-1103&author=G.+R.+Humphreyauthor=S.+M.+Dalbyauthor=T.+Andreaniauthor=B.+Xiangauthor=M.+R.+Luzungauthor=Z.+J.+Songauthor=M.+Shevlinauthor=M.+Christensenauthor=K.+M.+Belykauthor=D.+M.+Tschaen&title=Asymmetric+Synthesis+of+Letermovir+Using+a+Novel+Phase-Transfer-Catalyzed+Aza-Michael+Reaction&doi=10.1021%2Facs.oprd.6b00076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Synthesis of Letermovir Using a Novel Phase-Transfer-Catalyzed Aza-Michael Reaction</span></div><div class="casAuthors">Humphrey, Guy R.; Dalby, Stephen M.; Andreani, Teresa; Xiang, Bangping; Luzung, Michael R.; Song, Zhiguo Jake; Shevlin, Michael; Christensen, Melodie; Belyk, Kevin M.; Tschaen, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1097-1103</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a concise asym. synthesis of the antiviral development candidate letermovir is reported, proceeding in >60% yield over a total of seven steps from com. available materials.  Key to the effectiveness of this process is a novel cinchonidine-based PTC-catalyzed aza-Michael reaction to configure the single stereocenter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSx6sMyAk_LVg90H21EOLACvtfcHk0lhXrNoJTYN2fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslOhs7g%253D&md5=b5ac61d9d4457c2a3dccefd78b0db80f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00076%26sid%3Dliteratum%253Aachs%26aulast%3DHumphrey%26aufirst%3DG.%2BR.%26aulast%3DDalby%26aufirst%3DS.%2BM.%26aulast%3DAndreani%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DLuzung%26aufirst%3DM.%2BR.%26aulast%3DSong%26aufirst%3DZ.%2BJ.%26aulast%3DShevlin%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26aulast%3DTschaen%26aufirst%3DD.%2BM.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520Letermovir%2520Using%2520a%2520Novel%2520Phase-Transfer-Catalyzed%2520Aza-Michael%2520Reaction%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1097%26epage%3D1103%26doi%3D10.1021%2Facs.oprd.6b00076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nyirjesy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwebke, J. R.</span></span> <span> </span><span class="NLM_article-title">Secnidazole: Next-Generation Antimicrobial Agent for Bacterial Vaginosis Treatment</span>. <i>Future Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.2217/fmb-2017-0270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2217%2Ffmb-2017-0270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29327947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVamur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=507-524&author=P.+Nyirjesyauthor=J.+R.+Schwebke&title=Secnidazole%3A+Next-Generation+Antimicrobial+Agent+for+Bacterial+Vaginosis+Treatment&doi=10.2217%2Ffmb-2017-0270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment</span></div><div class="casAuthors">Nyirjesy, Paul; Schwebke, Jane R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">507-524</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Secnidazole is a next-generation 5-nitroimidazole approved for more than three decades in Europe, Asia, South America and Africa and recently in the USA as a single-dose (2 g) treatment of bacterial vaginosis (BV).  Secnidazole is characterized by potent in vitro antimicrobial activity against BV-assocd. pathogens, as well as prolonged terminal elimination half-life and systemic exposure.  These characteristics form the basis of effective and safe treatment of BV with a 2-g single-dose secnidazole regimen, which was recently confirmed in double-blind, placebo-controlled clin. trials conducted in the USA.  The option to treat BV with single-dose secnidazole not only cures the primary infection but also may diminish risks of serious sequelae of untreated or undertreated infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0eIhix5Hck7Vg90H21EOLACvtfcHk0lhXrNoJTYN2fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVamur4%253D&md5=946d0e7a31c59499a112e6276b6ff24c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2217%2Ffmb-2017-0270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb-2017-0270%26sid%3Dliteratum%253Aachs%26aulast%3DNyirjesy%26aufirst%3DP.%26aulast%3DSchwebke%26aufirst%3DJ.%2BR.%26atitle%3DSecnidazole%253A%2520Next-Generation%2520Antimicrobial%2520Agent%2520for%2520Bacterial%2520Vaginosis%2520Treatment%26jtitle%3DFuture%2520Microbiol.%26date%3D2018%26volume%3D13%26spage%3D507%26epage%3D524%26doi%3D10.2217%2Ffmb-2017-0270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeanmart, C.</span>; <span class="NLM_string-name">Messer, M. N.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of 5-Nitroimidazole Derivatives</span>. <span class="NLM_patent">GB 1278758</span>, <span class="NLM_year">1972</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1972&author=C.+Jeanmart&author=M.+N.+Messer&title=Process+for+the+Preparation+of+5-Nitroimidazole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJeanmart%26aufirst%3DC.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%25205-Nitroimidazole%2520Derivatives%26date%3D1972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y. F.</span>; <span class="NLM_string-name">Yi, Z.
H.</span></span> <span> </span><span class="NLM_article-title">Method for Synthesizing Secnidazole and Secnidazole</span>. <span class="NLM_patent">CN 103772289</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Y.+F.+Zeng&author=Z.%0AH.+Yi&title=Method+for+Synthesizing+Secnidazole+and+Secnidazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DY.%2BF.%26atitle%3DMethod%2520for%2520Synthesizing%2520Secnidazole%2520and%2520Secnidazole%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avery, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, D. P.</span></span> <span> </span><span class="NLM_article-title">Investigational Drugs for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacteria</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1460354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F13543784.2018.1460354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29611447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlSmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=325-338&author=L.+M.+Averyauthor=D.+P.+Nicolau&title=Investigational+Drugs+for+the+Treatment+of+Infections+Caused+by+Multidrug-Resistant+Gram-Negative+Bacteria&doi=10.1080%2F13543784.2018.1460354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria</span></div><div class="casAuthors">Avery, Lindsay M.; Nicolau, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">325-338</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Infections caused by multidrug-resistant Gram-neg. bacteria (MDR-GNB) are assocd. with significant mortality and costs.  New drugs in development to combat these difficult-to-treat infections primarily target carbapenem-resistant Enterobacteriaceae, MDR Pseudomonas aeruginosa, and MDR Acinetobacter baumannii.: The authors summarize in vitro and in vivo efficacy studies, as well as available clin. trial findings, for new agents in development for treatment of infection caused by MDR-GNB.  Information regarding dosage regimens utilized in clin. trials and key pharmacokinetic and pharmacodynamic considerations are provided if available.  A summary of recently approved agents, delafloxacin and meropenem/vaborbactam, is also included.: The development of multiple novel agents to fight MDR-GNB is promising to help save the lives of patients who acquire infection, and judicious use of these agents is imperative once they come to market to prevent the development of resistance.  The other component paramount to this field of research is implementation of effective infection control policies and carbapenem-resistant Enterobacteriaceae (CRE) carrier screening protocols to mitigate the worldwide spread of MDR-GNB.  Further investigation of anti-infective synergistic combinations will also be important, as well as support for economic research to reveal the true cost-benefit of utilization of the new agents discussed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolNiho0hD-KLVg90H21EOLACvtfcHk0lhazBzRPGoeCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlSmtLo%253D&md5=7d904dfaafedfbd9137568fd5a58faa9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1460354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1460354%26sid%3Dliteratum%253Aachs%26aulast%3DAvery%26aufirst%3DL.%2BM.%26aulast%3DNicolau%26aufirst%3DD.%2BP.%26atitle%3DInvestigational%2520Drugs%2520for%2520the%2520Treatment%2520of%2520Infections%2520Caused%2520by%2520Multidrug-Resistant%2520Gram-Negative%2520Bacteria%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26spage%3D325%26epage%3D338%26doi%3D10.1080%2F13543784.2018.1460354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loutit, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Cyclic Boronic Acid B-Lactamase Inhibitor (Rpx7009) with Utility Vs Class a Serine Carbapenemases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3682</span>– <span class="NLM_lpage">3692</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3682-3692&author=S.+J.+Heckerauthor=K.+R.+Reddyauthor=M.+Totrovauthor=G.+C.+Hirstauthor=O.+Lomovskayaauthor=D.+C.+Griffithauthor=P.+Kingauthor=R.+Tsivkovskiauthor=D.+Sunauthor=M.+Sabetauthor=Z.+Taraziauthor=M.+C.+Cliftonauthor=K.+Atkinsauthor=A.+Raymondauthor=K.+T.+Pottsauthor=J.+Abendrothauthor=S.+H.+Boyerauthor=J.+S.+Loutitauthor=E.+E.+Morganauthor=S.+Dursoauthor=M.+N.+Dudley&title=Discovery+of+a+Cyclic+Boronic+Acid+B-Lactamase+Inhibitor+%28Rpx7009%29+with+Utility+Vs+Class+a+Serine+Carbapenemases&doi=10.1021%2Facs.jmedchem.5b00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span></div><div class="casAuthors">Hecker, Scott J.; Reddy, K. Raja; Totrov, Maxim; Hirst, Gavin C.; Lomovskaya, Olga; Griffith, David C.; King, Paula; Tsivkovski, Ruslan; Sun, Dongxu; Sabet, Mojgan; Tarazi, Ziad; Clifton, Matthew C.; Atkins, Kateri; Raymond, Amy; Potts, Kristy T.; Abendroth, Jan; Boyer, Serge H.; Loutit, Jeffrey S.; Morgan, Elizabeth E.; Durso, Stephanie; Dudley, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3682-3692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing dissemination of carbapenemases in Gram-neg. bacteria has threatened the clin. usefulness of the β-lactam class of antimicrobials.  A program was initiated to discover a new series of serine β-lactamase inhibitors contg. a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials.  Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases.  Promising candidate mols. were synthesized and evaluated in biochem. and whole-cell assays.  Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases.  Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains.  Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXpE5YX_dRNLVg90H21EOLACvtfcHk0lhazBzRPGoeCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D&md5=965fbf2b42f2e1b38eccc3b23dfa374f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00127%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DSabet%26aufirst%3DM.%26aulast%3DTarazi%26aufirst%3DZ.%26aulast%3DClifton%26aufirst%3DM.%2BC.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DRaymond%26aufirst%3DA.%26aulast%3DPotts%26aufirst%3DK.%2BT.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DS.%2BH.%26aulast%3DLoutit%26aufirst%3DJ.%2BS.%26aulast%3DMorgan%26aufirst%3DE.%2BE.%26aulast%3DDurso%26aufirst%3DS.%26aulast%3DDudley%26aufirst%3DM.%2BN.%26atitle%3DDiscovery%2520of%2520a%2520Cyclic%2520Boronic%2520Acid%2520B-Lactamase%2520Inhibitor%2520%2528Rpx7009%2529%2520with%2520Utility%2520Vs%2520Class%2520a%2520Serine%2520Carbapenemases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3682%26epage%3D3692%26doi%3D10.1021%2Facs.jmedchem.5b00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenitsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagace-Wiens, P. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denisuik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoban, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-B-Lactamase Inhibitor Combinations</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0851-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0851-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29230684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKmu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=65-98&author=G.+G.+Zhanelauthor=C.+K.+Lawrenceauthor=H.+Adamauthor=F.+Schweizerauthor=S.+Zelenitskyauthor=M.+Zhanelauthor=P.+R.+S.+Lagace-Wiensauthor=A.+Walktyauthor=A.+Denisuikauthor=A.+Goldenauthor=A.+S.+Ginauthor=D.+J.+Hobanauthor=J.+P.+Lynchauthor=J.+A.+Karlowsky&title=Imipenem-Relebactam+and+Meropenem-Vaborbactam%3A+Two+Novel+Carbapenem-B-Lactamase+Inhibitor+Combinations&doi=10.1007%2Fs40265-017-0851-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations</span></div><div class="casAuthors">Zhanel, George G.; Lawrence, Courtney K.; Adam, Heather; Schweizer, Frank; Zelenitsky, Sheryl; Zhanel, Michael; Lagace-Wiens, Philippe R. S.; Walkty, Andrew; Denisuik, Andrew; Golden, Alyssa; Gin, Alfred S.; Hoban, Daryl J.; Lynch, Joseph P., III; Karlowsky, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-98</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-lactamase inhibitor that is structurally related to avibactam, differing by the addn. of a piperidine ring to the 2-position carbonyl group.  Vaborbactam (formerly known as RPX7009) is a non-β-lactam, cyclic, boronic acid-based, β-lactamase inhibitor.  The structure of vaborbactam is unlike any other currently marketed β-lactamase inhibitor.  Both inhibitors display activity against Ambler class A [including extended-spectrum β-lactamases (ESBLs), Klebsiella pneumoniae carbapenemases (KPCs)] and class C β-lactamases (AmpC).  Little is known about the potential for relebactam or vaborbactam to select for resistance; however, inactivation of the porin protein OmpK36 in K. pneumoniae has been reported to confer resistance to both imipenem-relebactam and meropenem-vaborbactam.  The addn. of relebactam significantly improves the activity of imipenem against most species of Enterobacteriaceae [by lowering the min. inhibitory concn. (MIC) by 2- to 128-fold] depending on the presence or absence of β-lactamase enzymes.  Against Pseudomonas aeruginosa, the addn. of relebactam also improves the activity of imipenem (MIC reduced eightfold).  Based on the data available, the addn. of relebactam does not improve the activity of imipenem against Acinetobacter baumannii, Stenotrophomonas maltophilia and most anaerobes.  Similar to imipenem-relebactam, the addn. of vaborbactam significantly (2- to > 1024-fold MIC redn.) improves the activity of meropenem against most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzymes.  Limited data suggest that the addn. of vaborbactam does not improve the activity of meropenem against A. baumannii, P. aeruginosa, or S. maltophilia.  The pharmacokinetics of both relebactam and vaborbactam are described by a two-compartment, linear model and do not appear to be altered by the co-administration of imipenem and meropenem, resp.  Relebactam's approx. vol. of distribution (Vd) and elimination half-life (t1/2) of ∼ 18 L and 1.2-2.1 h, resp., are similar to imipenem.  Likewise, vaborbactam's Vd and t1/2 of ∼ 18 L and 1.3-2.0 h, resp., are comparable to meropenem.  Like imipenem and meropenem, relebactam and vaborbactam are both primarily renally excreted, and clearance correlates with creatinine clearance.  In vitro and in vivo pharmacodynamic studies have reported bactericidal activity for imipenem-relebactam and meropenem-vaborbactam against various Gram-neg. β-lactamase-producing bacilli that are not inhibited by their resp. carbapenems alone.  These data also suggest that pharmacokinetic-pharmacodynamic parameters correlating with efficacy include time above the MIC for the carbapenems and overall exposure for their companion β-lactamase inhibitors.  Phase II clin. trials to date have reported that imipenem-relebactam is as effective as imipenem alone for treatment of complicated intra-abdominal infections and complicated urinary tract infections, including acute pyelonephritis.  Imipenem-relebactam is currently in two phase III clin. trials for the treatment of imipenem-resistant bacterial infections, as well as hospital-assocd. bacterial pneumonia (HABP) and ventilator-assocd. bacterial pneumonia (VABP).  A phase III clin. trial has reported superiority of meropenem-vaborbactam over piperacillin-tazobactam for the treatment of complicated urinary tract infections, including acute pyelonephritis.  Meropenem-vaborbactam has recently demonstrated higher clin. cure rates vs. best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE), as well as for HABP and VABP.  The safety and tolerability of imipenem-relebactam and meropenem-vaborbactam has been reported in various phase I pharmacokinetic studies and phase II and III clin. trials.  Both combinations appear to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.  In conclusion, relebactam and vaborbactam serve to broaden the spectrum of imipenem and meropenem, resp., against β-lactamase-producing Gram-neg. bacilli.  The exact roles for imipenem-relebactam and meropenem-vaborbactam will be defined by efficacy and safety data from further clin. trials.  Potential roles in therapy for these agents include the treatment of suspected or documented infections caused by resistant Gram-neg. bacilli-producing ESBL, KPC, and/or AmpC β-lactamases.  The usage of these agents in patients with CRE infections will likely become the std. of care.  Finally, increased activity of imipenem-relebactam against P. aeruginosa may be of clin. benefit to patients with suspected or documented P. aeruginosa infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYBXUqPtdemrVg90H21EOLACvtfcHk0lhYJhZYL1FU-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKmu7bK&md5=a8506d493387208f8ac429057ca15a49</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0851-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0851-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DLawrence%26aufirst%3DC.%2BK.%26aulast%3DAdam%26aufirst%3DH.%26aulast%3DSchweizer%26aufirst%3DF.%26aulast%3DZelenitsky%26aufirst%3DS.%26aulast%3DZhanel%26aufirst%3DM.%26aulast%3DLagace-Wiens%26aufirst%3DP.%2BR.%2BS.%26aulast%3DWalkty%26aufirst%3DA.%26aulast%3DDenisuik%26aufirst%3DA.%26aulast%3DGolden%26aufirst%3DA.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DImipenem-Relebactam%2520and%2520Meropenem-Vaborbactam%253A%2520Two%2520Novel%2520Carbapenem-B-Lactamase%2520Inhibitor%2520Combinations%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D65%26epage%3D98%26doi%3D10.1007%2Fs40265-017-0851-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felfer, U.</span>; <span class="NLM_string-name">Stueckler, C.</span>; <span class="NLM_string-name">Steinhofer, S.</span>; <span class="NLM_string-name">Pelz, A.</span>; <span class="NLM_string-name">Hanacek, M.</span>; <span class="NLM_string-name">Pabst, T. H.</span>; <span class="NLM_string-name">Winkler, G.</span>; <span class="NLM_string-name">Poechlauer, P.</span>; <span class="NLM_string-name">Ritzen, B.</span>; <span class="NLM_string-name">Goldbach, M.</span></span> <span> </span><span class="NLM_article-title">Apparatus and Continuous Flow Process for Production of Boronic Acid Derivatives</span>. <span class="NLM_patent">WO 2016100043A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=U.+Felfer&author=C.+Stueckler&author=S.+Steinhofer&author=A.+Pelz&author=M.+Hanacek&author=T.+H.+Pabst&author=G.+Winkler&author=P.+Poechlauer&author=B.+Ritzen&author=M.+Goldbach&title=Apparatus+and+Continuous+Flow+Process+for+Production+of+Boronic+Acid+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFelfer%26aufirst%3DU.%26atitle%3DApparatus%2520and%2520Continuous%2520Flow%2520Process%2520for%2520Production%2520of%2520Boronic%2520Acid%2520Derivatives%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0895-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0895-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29546556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslGjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=577-587&author=Y.-A.+Heoauthor=E.+D.+Deeks&title=Sofosbuvir%2FVelpatasvir%2FVoxilaprevir%3A+A+Review+in+Chronic+Hepatitis+C&doi=10.1007%2Fs40265-018-0895-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C</span></div><div class="casAuthors">Heo, Young-A.; Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A fixed-dose combination of the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir, the HCV NS5A inhibitor velpatasvir and the HCV NS3/4A protease inhibitor voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir; Vosevi) is approved in the EU for the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in adults.  In the phase III POLARIS trials, in patients who had HCV genotype 1-6 infection with or without compensated cirrhosis, overall rates of sustained virol. response at 12 wk post-treatment (SVR12) with sofosbuvir/velpatasvir/voxilaprevir were high after 8 wk of treatment in direct-acting antiviral (DAA)-naive patients and 12 wk of treatment in DAA-experienced patients.  However, 8 wk of sofosbuvir/velpatasvir/voxilaprevir was inferior to 12 wk of sofosbuvir/velpatasvir in cirrhotic or non-cirrhotic DAA-naive patients with HCV genotype 1, 2, 4, 5 or 6 infection and non-cirrhotic DAA-naive patients with HCV genotype 3 infection, mostly due to an insufficient treatment period.  Sofosbuvir/velpatasvir/voxilaprevir was generally well tolerated, with most adverse events being of mild or moderate intensity.  The most common adverse events included headache, fatigue, nausea and diarrhoea.  In conclusion, sofosbuvir/velpatasvir/voxilaprevir is an important and effective option for the treatment of HCV genotype 1-6 infection in adults, esp. those who have previously failed a DAA therapy with or without an HCV NS5A inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpWFvjHRFxCLVg90H21EOLACvtfcHk0lhYJhZYL1FU-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslGjt7k%253D&md5=d4557e43a321ca3a9a30d996ac5f77ba</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0895-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0895-5%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DSofosbuvir%252FVelpatasvir%252FVoxilaprevir%253A%2520A%2520Review%2520in%2520Chronic%2520Hepatitis%2520C%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D577%26epage%3D587%26doi%3D10.1007%2Fs40265-018-0895-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grebely, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruneau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruggmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litwin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backmund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, G. J.</span></span> <span> </span><span class="NLM_article-title">Contradictory Advice for People Who Inject Drugs in the 2016 Easl Recommendations on Treatment of Hepatitis C</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2016.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.jhep.2016.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28167323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jslajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1101-1103&author=J.+Grebelyauthor=T.+Swanauthor=M.+Hickmanauthor=J.+Bruneauauthor=P.+Bruggmannauthor=O.+Dalgardauthor=A.+Litwinauthor=M.+Backmundauthor=G.+J.+Dore&title=Contradictory+Advice+for+People+Who+Inject+Drugs+in+the+2016+Easl+Recommendations+on+Treatment+of+Hepatitis+C&doi=10.1016%2Fj.jhep.2016.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C</span></div><div class="casAuthors">Grebely Jason; Swan Tracy; Hickman Matthew; Bruneau Julie; Bruggmann Philip; Dalgard Olav; Litwin Alain; Backmund Markus; Dore Gregory J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1101-1103</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRI8vVeL9xn7VQKX3ooHxWjfW6udTcc2eYNUMaTRxaA27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jslajuw%253D%253D&md5=5d8a96950ca2668ce4b876ee56854bf3</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DGrebely%26aufirst%3DJ.%26aulast%3DSwan%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DBruneau%26aufirst%3DJ.%26aulast%3DBruggmann%26aufirst%3DP.%26aulast%3DDalgard%26aufirst%3DO.%26aulast%3DLitwin%26aufirst%3DA.%26aulast%3DBackmund%26aufirst%3DM.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26atitle%3DContradictory%2520Advice%2520for%2520People%2520Who%2520Inject%2520Drugs%2520in%2520the%25202016%2520Easl%2520Recommendations%2520on%2520Treatment%2520of%2520Hepatitis%2520C%26jtitle%3DJ.%2520Hepatol.%26date%3D2017%26volume%3D66%26spage%3D1101%26epage%3D1103%26doi%3D10.1016%2Fj.jhep.2016.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cagulada, A.</span>; <span class="NLM_string-name">Chan, J.</span>; <span class="NLM_string-name">Chan, L.</span>; <span class="NLM_string-name">Colby, D. A.</span>; <span class="NLM_string-name">Karki, K. K.</span>; <span class="NLM_string-name">Kato, D.</span>; <span class="NLM_string-name">Keaton, K. A.</span>; <span class="NLM_string-name">Kondapally, S.</span>; <span class="NLM_string-name">Levins, C.</span>; <span class="NLM_string-name">Littke, A.</span>; <span class="NLM_string-name">Martinez, R.</span>; <span class="NLM_string-name">Pcion, D.</span>; <span class="NLM_string-name">Reynolds, T.</span>; <span class="NLM_string-name">Ross, B.</span>; <span class="NLM_string-name">Sangi, M.</span>; <span class="NLM_string-name">Schrier, A. J.</span>; <span class="NLM_string-name">Seng, P.</span>; <span class="NLM_string-name">Siegel, D.</span>; <span class="NLM_string-name">Shapiro, N.</span>; <span class="NLM_string-name">Tang, D.</span>; <span class="NLM_string-name">Taylor, J. G.</span>; <span class="NLM_string-name">Tripp, J.</span>; <span class="NLM_string-name">Waltman, A. W.</span>; <span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis of an Antiviral N-(3-Ethyl)prolyl-1-aminocyclopropanecarboxylic Acid Peptide and New Routes to Its Difluoromethylaminocyclopropanecarboxylic Acid Intermediate</span>. <span class="NLM_patent">US 20150175626A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+Cagulada&author=J.+Chan&author=L.+Chan&author=D.+A.+Colby&author=K.+K.+Karki&author=D.+Kato&author=K.+A.+Keaton&author=S.+Kondapally&author=C.+Levins&author=A.+Littke&author=R.+Martinez&author=D.+Pcion&author=T.+Reynolds&author=B.+Ross&author=M.+Sangi&author=A.+J.+Schrier&author=P.+Seng&author=D.+Siegel&author=N.+Shapiro&author=D.+Tang&author=J.+G.+Taylor&author=J.+Tripp&author=A.+W.+Waltman&author=L.+Yu&title=Synthesis+of+an+Antiviral+N-%283-Ethyl%29prolyl-1-aminocyclopropanecarboxylic+Acid+Peptide+and+New+Routes+to+Its+Difluoromethylaminocyclopropanecarboxylic+Acid+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCagulada%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520an%2520Antiviral%2520N-%25283-Ethyl%2529prolyl-1-aminocyclopropanecarboxylic%2520Acid%2520Peptide%2520and%2520New%2520Routes%2520to%2520Its%2520Difluoromethylaminocyclopropanecarboxylic%2520Acid%2520Intermediate%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G.</span>; <span class="NLM_string-name">Bluemling, G. R.</span>; <span class="NLM_string-name">De La Rosa, A.</span>; <span class="NLM_string-name">Liotta, D. C.</span>; <span class="NLM_string-name">Kuiper, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Nucleotide and Nucleoside Therapeutic Compounds. and Uses Related Thereto as Antiviral Agents</span>. <span class="NLM_patent">WO 2017155923A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Painter&author=G.+R.+Bluemling&author=A.+De+La+Rosa&author=D.+C.+Liotta&author=D.+Kuiper&title=Preparation+of+Nucleotide+and+Nucleoside+Therapeutic+Compounds.+and+Uses+Related+Thereto+as+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPainter%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Nucleotide%2520and%2520Nucleoside%2520Therapeutic%2520Compounds.%2520and%2520Uses%2520Related%2520Thereto%2520as%2520Antiviral%2520Agents%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ene, D.</span></span> <span> </span><span class="NLM_article-title">Olefin Metathesis in Drug Discovery and Development-Examples from Recent Patent Literature</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1962</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1938-1962&author=D.+Hughesauthor=P.+Wheelerauthor=D.+Ene&title=Olefin+Metathesis+in+Drug+Discovery+and+Development-Examples+from+Recent+Patent+Literature&doi=10.1021%2Facs.oprd.7b00319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Olefin Metathesis in Drug Discovery and Development-Examples from Recent Patent Literature</span></div><div class="casAuthors">Hughes, David; Wheeler, Philip; Ene, Doina</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1938-1962</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review that summarizes applications of the metathesis reactions in drug discovery and development in the pharmaceutical industry disclosed in the patent literature from Jan. 2016 to August 2017.  The olefin metathesis reaction is finding increasing use in drug discovery and process chem., with a no. of applications now implemented at com. manufg. scale.  Catalyst improvements over the past decade have allowed use of the metathesis reaction with highly functionalized substrates, allowing chemists to access increasingly diverse chem. space, including most notably macrocycles, constrained small ring spirocycles, and fused-ring systems.  For scientists employed in the pharmaceutical industry, the patent literature is the primary avenue for communication of synthetic routes to drug candidates.  While most examples of the metathesis reaction in the patent literature offer only sketchy exptl. details and provide little context on reaction development, the wide scope of substrates within the pharmaceutical patent literature provides a true indication of reaction scope and functional group compatibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwS-l_9Wgak7Vg90H21EOLACvtfcHk0lhYZbvfAmZK3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsrbP&md5=8fcebbc4105e77751d56724d758535ac</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00319%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%26aulast%3DWheeler%26aufirst%3DP.%26aulast%3DEne%26aufirst%3DD.%26atitle%3DOlefin%2520Metathesis%2520in%2520Drug%2520Discovery%2520and%2520Development-Examples%2520from%2520Recent%2520Patent%2520Literature%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1938%26epage%3D1962%26doi%3D10.1021%2Facs.oprd.7b00319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Deutetrabenazine: A Review in Chorea Associated with Huntington’s Disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0831-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0831-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29080203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslejtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1857-1864&author=Y.-A.+Heoauthor=L.+J.+Scott&title=Deutetrabenazine%3A+A+Review+in+Chorea+Associated+with+Huntington%E2%80%99s+Disease&doi=10.1007%2Fs40265-017-0831-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease</span></div><div class="casAuthors">Heo, Young-A.; Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Oral deutetrabenazine (Austedo), a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) that is structurally related to tetrabenazine is approved for the treatment of chorea symptoms assocd. with Huntington's disease (HD).  In the pivotal 12-wk phase III FIRST-HD trial (n = 90), deutetrabenazine, at doses titrated for optimal chorea control and tolerability (maintenance dosage range 12-48 mg/day), was significantly more effective for controlling chorea in HD patients than placebo.  In the ongoing phase III ARC-HD trial, a preliminary anal. demonstrated that deutetrabenazine treatment was assocd. with improvements in chorea control at 54 wk in patients who had completed FIRST-HD (i.e. ≤ 66 wk' treatment; rollover cohort) or switched overnight from tetrabenazine to deutetrabenazine.  The tolerability profile of deutetrabenazine is similar to that of placebo, with most treatment-emergent adverse events of mild or moderate severity.  In both trials, with the exception of somnolence, individual neuropsychiatric adverse events typically occurred in < 7% of deutetrabenazine recipients; in FIRST-HD, there was no significant difference in the incidence of individual neuropsychiatric events between the deutetrabenazine and placebo groups.  The favorable pharmacokinetic (PK) profile of deutetrabenazine permits a lower dosage than tetrabenazine, thereby potentially improving the safety profile of deutetrabenazine vs. tetrabenazine, while maintaining its efficacy.  Long-term clin. experience will assist in fully defining the safety profile of deutetrabenazine.  Current evidence, albeit relatively limited, indicates that deutetrabenazine provides an effective and potentially better tolerated option than tetrabenazine for controlling chorea symptoms assocd. with HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosFkE2-piB3rVg90H21EOLACvtfcHk0lhYZbvfAmZK3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslejtLfL&md5=aa25bb171c0b5ccb5edca1dcea6cc425</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0831-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0831-0%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DDeutetrabenazine%253A%2520A%2520Review%2520in%2520Chorea%2520Associated%2520with%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1857%26epage%3D1864%26doi%3D10.1007%2Fs40265-017-0831-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">DeWitt, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Deuterated Drug Molecules: Focus on Fda-Approved Deutetrabenazine</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=472-473&author=S.+H.+DeWittauthor=B.+E.+Maryanoff&title=Deuterated+Drug+Molecules%3A+Focus+on+Fda-Approved+Deutetrabenazine&doi=10.1021%2Facs.biochem.7b00765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine</span></div><div class="casAuthors">DeWitt, Sheila H.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">472-473</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The approval of Austedo (deutetrabenazine) as a new chem. entity (NCE) via the 505(b)(2) regulatory pathway established an important milestone for the development and marketing of deuterated drugs.  Its notable introduction into clin. medicine could well be the harbinger of a new era for the utility of deuterium-substituted drug mols.  This point of view is further supported by the sizable collection of other deuterated mols. that are currently in clin. trials, some of which will hopefully emerge successful for the benefit of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQcRjVCOoN5bVg90H21EOLACvtfcHk0ljwZsPpsNKYoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL&md5=a1aecdd9f8b539b9e3988d8b135d881a</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00765%26sid%3Dliteratum%253Aachs%26aulast%3DDeWitt%26aufirst%3DS.%2BH.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DDeuterated%2520Drug%2520Molecules%253A%2520Focus%2520on%2520Fda-Approved%2520Deutetrabenazine%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D472%26epage%3D473%26doi%3D10.1021%2Facs.biochem.7b00765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reilmann, R.</span></span> <span> </span><span class="NLM_article-title">Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease</span>. <i>JAMA Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1406</span>, <span class="refDoi"> DOI: 10.1001/jamaneurol.2016.3916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1001%2Fjamaneurol.2016.3916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27749952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC2srhtlWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=1404-1406&author=R.+Reilmann&title=Deutetrabenazine-Not+a+Revolution+but+Welcome+Evolution+for+Treating+Chorea+in+Huntington+Disease&doi=10.1001%2Fjamaneurol.2016.3916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease</span></div><div class="casAuthors">Reilmann Ralf</div><div class="citationInfo"><span class="NLM_cas:title">JAMA neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1406</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx4xCzs0XGFQvupmecNw_lfW6udTcc2eZAjpfsJrMbybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srhtlWmsg%253D%253D&md5=d0b2b593b977dcdf3e71cde1cac2961b</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1001%2Fjamaneurol.2016.3916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaneurol.2016.3916%26sid%3Dliteratum%253Aachs%26aulast%3DReilmann%26aufirst%3DR.%26atitle%3DDeutetrabenazine-Not%2520a%2520Revolution%2520but%2520Welcome%2520Evolution%2520for%2520Treating%2520Chorea%2520in%2520Huntington%2520Disease%26jtitle%3DJAMA%2520Neurol.%26date%3D2016%26volume%3D73%26spage%3D1404%26epage%3D1406%26doi%3D10.1001%2Fjamaneurol.2016.3916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span> <span> </span><span class="NLM_article-title">Investigational Agents for the Management of Huntington’s Disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1270266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F13543784.2017.1270266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27927041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFWnur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=175-185&author=T.+Mueller&title=Investigational+Agents+for+the+Management+of+Huntington%E2%80%99s+Disease&doi=10.1080%2F13543784.2017.1270266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational agents for the management of Huntington's disease</span></div><div class="casAuthors">Mueller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-185</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: An inherited, chronic progressive, neurodegenerative disorder is Huntington's disease, characterized by motor, cognitive, and psychiatric symptoms.  Predictive genetic testing allows earlier diagnosis and identification of gene carriers for Huntington's disease.  These individuals are ideal candidates for testing of therapeutic interventions for disease modification.: According to queries in Pubmed, Embase and clin. register databases, research and clin. studies emerge on symptomatic and neuroprotective therapies in Huntington's disease.  This review discusses novel agents for symptomatic therapy and disease modification.  They are currently in phase I and II of drug development: There are promising, safe and well tolerated compds. for amelioration of motor and neuropsychiatric symptoms, but their efficacy still needs to be proven in clin. trials.  Deterioration of mutant huntington expression, antiapoptotic or cell death inhibition as disease modifying concepts was efficacious in models of Huntington's disease.  However, the risk for clin. trial failures is high not only due to ineffectiveness of the tested agent.  Neg. study outcomes may also result from design misconceptions, underestimation of the heterogeneity of Huntington's disease, too short study durations and too small study cohorts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNKNqKfMkAprVg90H21EOLACvtfcHk0ljwZsPpsNKYoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFWnur3M&md5=981868e57326b021902e0dae282a3b0b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1270266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1270266%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DT.%26atitle%3DInvestigational%2520Agents%2520for%2520the%2520Management%2520of%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D175%26epage%3D185%26doi%3D10.1080%2F13543784.2017.1270266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snively, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whaley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Shahed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claassen, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clouse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Hilaire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criswell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racette, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revilla, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucifora, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mary, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brashers-Krug, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinsky, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Factor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eglow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samii, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmail, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, W. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colcher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackmyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudesblatt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fafard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graffitti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojcieszek, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Faver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson-Perez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shprecher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blindauer, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farbman, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feigin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edicola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, E.</span></span> <span> </span><span class="NLM_article-title">Effect of Deutetrabenazine on Chorea among Patients with Huntington Disease. A Randomized Clinical Trial</span>. <i>JAMA, J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1001/jama.2016.8655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1001%2Fjama.2016.8655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27380342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2016&pages=40-50&author=S.+Frankauthor=C.+M.+Testaauthor=D.+Stamlerauthor=E.+Kaysonauthor=C.+Davisauthor=M.+C.+Edmondsonauthor=S.+Kinelauthor=B.+Leavittauthor=D.+Oakesauthor=C.+O%E2%80%99Neillauthor=C.+Vaughanauthor=J.+Goldsteinauthor=M.+Herzogauthor=V.+Snivelyauthor=J.+Whaleyauthor=C.+Wongauthor=G.+Suterauthor=J.+Jankovicauthor=J.+Jimenez-Shahedauthor=C.+Hunterauthor=D.+O.+Claassenauthor=O.+C.+Romanauthor=V.+Sungauthor=J.+Smithauthor=S.+Janickiauthor=R.+Clouseauthor=M.+Saint-Hilaireauthor=A.+Hohlerauthor=D.+Turpinauthor=R.+C.+Jamesauthor=R.+Rodriguezauthor=K.+Rizerauthor=K.+E.+Andersonauthor=H.+Hellerauthor=A.+Carlsonauthor=S.+Criswellauthor=B.+A.+Racetteauthor=F.+J.+Revillaauthor=F.+Nuciforaauthor=R.+L.+Margolisauthor=J.+O.+Maryauthor=T.+Mendisauthor=N.+Mendisauthor=C.+Singerauthor=M.+Quesadaauthor=J.+S.+Paulsenauthor=T.+Brashers-Krugauthor=A.+Millerauthor=J.+Kerrauthor=R.+M.+Dubinskyauthor=C.+Grayauthor=S.+A.+Factorauthor=E.+Sperinauthor=E.+Molhoauthor=M.+Eglowauthor=S.+Evansauthor=R.+Kumarauthor=C.+Reevesauthor=A.+Samiiauthor=S.+Chouinardauthor=M.+Belandauthor=B.+L.+Scottauthor=P.+T.+Hickeyauthor=S.+Esmailauthor=W.+L.+A.+Fungauthor=C.+Gibbonsauthor=L.+Qiauthor=A.+Colcherauthor=C.+Hackmyerauthor=A.+McGarryauthor=K.+Klosauthor=M.+Gudesblattauthor=L.+Fafardauthor=L.+Graffittiauthor=D.+P.+Schneiderauthor=R.+Dhallauthor=J.+M.+Wojcieszekauthor=K.+La+Faverauthor=A.+Dukerauthor=E.+Neefusauthor=H.+Wilson-Perezauthor=D.+Shprecherauthor=P.+Wallauthor=K.+A.+Blindauerauthor=L.+Wheelerauthor=J.+T.+Boydauthor=E.+Houstonauthor=E.+S.+Farbmanauthor=P.+Agarwalauthor=S.+W.+Eberlyauthor=A.+Wattsauthor=P.+N.+Tariotauthor=A.+Feiginauthor=S.+Evansauthor=C.+Beckauthor=C.+Ormeauthor=J.+Edicolaauthor=E.+Christopher&title=Effect+of+Deutetrabenazine+on+Chorea+among+Patients+with+Huntington+Disease.+A+Randomized+Clinical+Trial&doi=10.1001%2Fjama.2016.8655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of deutetrabenazine on chorea among patients with Huntington disease. A randomized clinical trial</span></div><div class="casAuthors">Frank, Samuel; Testa, Claudia M.; Stamler, David; Kayson, Elise; Davis, Charles; Edmondson, Mary C.; Kinel, Shari; Leavitt, Blair; Oakes, David; O'Neill, Christine; Vaughan, Christina; Goldstein, Jody; Herzog, Margaret; Snively, Victoria; Whaley, Jacquelyn; Wong, Cynthia; Suter, Greg; Jankovic, Joseph; Jimenez-Shahed, Joohi; Hunter, Christine; Claassen, Daniel O.; Roman, Olivia C.; Sung, Victor; Smith, Jenna; Janicki, Sarah; Clouse, Ronda; Saint-Hilaire, Marie; Hohler, Anna; Turpin, Denyse; James, Raymond C.; Rodriguez, Ramon; Rizer, Kyle; Anderson, Karen E.; Heller, Hope; Carlson, Alexis; Criswell, Susan; Racette, Brad A.; Revilla, Fredy J.; Nucifora, Frederick; Margolis, Russell L.; Mary, Jane Ong; Mendis, Tilak; Mendis, Neila; Singer, Carlos; Quesada, Monica; Paulsen, Jane S.; Brashers-Krug, Thomas; Miller, Amanda; Kerr, Jane; Dubinsky, Richard M.; Gray, Carolyn; Factor, Stewart A.; Sperin, Elaine; Molho, Eric; Eglow, Mary; Evans, Sharon; Kumar, Rajeev; Reeves, Christina; Samii, Ali; Chouinard, Sylvain; Beland, Monica; Scott, Burton L.; Hickey, Patrick T.; Esmail, Sherali; Fung, Wai Lun Alan; Gibbons, Clare; Qi, Lina; Colcher, Amy; Hackmyer, Cory; McGarry, Andrew; Klos, Kevin; Gudesblatt, Mark; Fafard, Lori; Graffitti, Laura; Schneider, Daniel P.; Dhall, Rohit; Wojcieszek, Joanne M.; La Faver, Kathrin; Duker, Andrew; Neefus, Erin; Wilson-Perez, Hilary; Shprecher, David; Wall, Paola; Blindauer, Karen A.; Wheeler, Lynn; Boyd, James T.; Houston, Emily; Farbman, Eric S.; Agarwal, Pinky; Eberly, Shirley W.; Watts, Arthur; Tariot, Pierre N.; Feigin, Andrew; Evans, Scott; Beck, Chris; Orme, Constance; Edicola, Jon; Christopher, Emily</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-50</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">IMPORTANCE: Deutetrabenazine is a novel mol. contg. deuterium, which attenuates CYP2D6 metab. and increases active metabolite half-lives and may therefore lead to stable systemic exposure while preserving key pharmacol. activity.  OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea assocd. with Huntington disease.  DESIGN, SETTING, AND PARTICIPANTS: Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea score of 8 or higher (range, 0-28; lower score indicates less chorea) were enrolled from August 2013 to August 2014 and randomized to receive deutetrabenazine (n = 45) or placebo (n = 45) in a double-blind fashion at 34 Huntington Study Group sites.  INTERVENTIONS: Deutetrabenazine or placebo was titrated to optimal dose level over 8 wk and maintained for 4 wk, followed by a 1-wk washout.  MAIN OUTCOMES AND MEASURES: Primary end point was the total maximal chorea score change from baseline (the av. of values from the screening and day-0 visits) to maintenance therapy (the av. of values from the week 9 and 12 visits) obtained by in-person visits.  This study was designed to detect a 2.7-unit treatment difference in scores.  The secondary end points, assessed hierarchically, were the proportion of patients who achieved treatment success on the Patient Global Impression of Change (PGIC) and on the Clin. Global Impression of Change (CGIC), the change in 36-Item Short Form- phys. functioning subscale score (SF-36), and the change in the Berg Balance Test.  RESULTS: Ninety patients with Huntington disease (mean age, 53.7 years;40women [44.4%]) were enrolled.  In the deutetrabenazine group, the mean total maximal chorea scores improved from 12.1 (95%CI, 11.2-12.9) to 7.7 (95%CI, 6.5-8.9), whereas in the placebo group, scores improved from 13.2 (95%CI,12.2-14.3)to11.3(95%CI,10.0-12.5);themeanbetween-group difference was -2.5 units (95%CI, -3.7 to -1.3) (P <.001).  Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%)in the placebo group (P =.002).  As measured by the CGIC, treatment success occurred in 19 patients (42%) in the deutetrabenazine group vs 6(13%)in the placebo group(P =.002).  In the deutetrabenazine group, the mean SF-36 phys. functioning subscale scores decreased from 47.5 (95%CI, 44.3-50.8) to 47.4(44.3-50.5),whereasin the placebo group, scores decreased from 43.2 (95%CI,40.2-46.3) to 39.9(95%CI, 36.2-43.6), for a treatment benefit of 4.3 (95%CI,0.4to8.3) (P =.03).  There was no difference between groups (mean difference of 1.0unit; 95%CI, -0.3 to 2.3; P =.14), for improvement in the Berg Balance Test, which improved by 2.2 units (95%CI, 1.3-3.1) in the deutetrabenazine group and by 1.3 units (95%CI,0.4-2.2) in the placebo group. Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety, and akathisia.  CONCLUSIONS AND RELEVANCE: Among patients with chorea assocd. with Huntington disease, the use of deutetrabenazine compared with placebo resulted in improved motor signs at 12 wk.  Further research is needed to assess the clin. importance of the effect size and to det. longer-term efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09cwKO054C7Vg90H21EOLACvtfcHk0lgUc_FjxBbTQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlu77M&md5=d1c5aebdb74a312c3f19c184e4789747</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1001%2Fjama.2016.8655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2016.8655%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DS.%26aulast%3DTesta%26aufirst%3DC.%2BM.%26aulast%3DStamler%26aufirst%3DD.%26aulast%3DKayson%26aufirst%3DE.%26aulast%3DDavis%26aufirst%3DC.%26aulast%3DEdmondson%26aufirst%3DM.%2BC.%26aulast%3DKinel%26aufirst%3DS.%26aulast%3DLeavitt%26aufirst%3DB.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DC.%26aulast%3DVaughan%26aufirst%3DC.%26aulast%3DGoldstein%26aufirst%3DJ.%26aulast%3DHerzog%26aufirst%3DM.%26aulast%3DSnively%26aufirst%3DV.%26aulast%3DWhaley%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DSuter%26aufirst%3DG.%26aulast%3DJankovic%26aufirst%3DJ.%26aulast%3DJimenez-Shahed%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DC.%26aulast%3DClaassen%26aufirst%3DD.%2BO.%26aulast%3DRoman%26aufirst%3DO.%2BC.%26aulast%3DSung%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DJanicki%26aufirst%3DS.%26aulast%3DClouse%26aufirst%3DR.%26aulast%3DSaint-Hilaire%26aufirst%3DM.%26aulast%3DHohler%26aufirst%3DA.%26aulast%3DTurpin%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DR.%2BC.%26aulast%3DRodriguez%26aufirst%3DR.%26aulast%3DRizer%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DHeller%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DA.%26aulast%3DCriswell%26aufirst%3DS.%26aulast%3DRacette%26aufirst%3DB.%2BA.%26aulast%3DRevilla%26aufirst%3DF.%2BJ.%26aulast%3DNucifora%26aufirst%3DF.%26aulast%3DMargolis%26aufirst%3DR.%2BL.%26aulast%3DMary%26aufirst%3DJ.%2BO.%26aulast%3DMendis%26aufirst%3DT.%26aulast%3DMendis%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DC.%26aulast%3DQuesada%26aufirst%3DM.%26aulast%3DPaulsen%26aufirst%3DJ.%2BS.%26aulast%3DBrashers-Krug%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DKerr%26aufirst%3DJ.%26aulast%3DDubinsky%26aufirst%3DR.%2BM.%26aulast%3DGray%26aufirst%3DC.%26aulast%3DFactor%26aufirst%3DS.%2BA.%26aulast%3DSperin%26aufirst%3DE.%26aulast%3DMolho%26aufirst%3DE.%26aulast%3DEglow%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DSamii%26aufirst%3DA.%26aulast%3DChouinard%26aufirst%3DS.%26aulast%3DBeland%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DB.%2BL.%26aulast%3DHickey%26aufirst%3DP.%2BT.%26aulast%3DEsmail%26aufirst%3DS.%26aulast%3DFung%26aufirst%3DW.%2BL.%2BA.%26aulast%3DGibbons%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DL.%26aulast%3DColcher%26aufirst%3DA.%26aulast%3DHackmyer%26aufirst%3DC.%26aulast%3DMcGarry%26aufirst%3DA.%26aulast%3DKlos%26aufirst%3DK.%26aulast%3DGudesblatt%26aufirst%3DM.%26aulast%3DFafard%26aufirst%3DL.%26aulast%3DGraffitti%26aufirst%3DL.%26aulast%3DSchneider%26aufirst%3DD.%2BP.%26aulast%3DDhall%26aufirst%3DR.%26aulast%3DWojcieszek%26aufirst%3DJ.%2BM.%26aulast%3DLa%2BFaver%26aufirst%3DK.%26aulast%3DDuker%26aufirst%3DA.%26aulast%3DNeefus%26aufirst%3DE.%26aulast%3DWilson-Perez%26aufirst%3DH.%26aulast%3DShprecher%26aufirst%3DD.%26aulast%3DWall%26aufirst%3DP.%26aulast%3DBlindauer%26aufirst%3DK.%2BA.%26aulast%3DWheeler%26aufirst%3DL.%26aulast%3DBoyd%26aufirst%3DJ.%2BT.%26aulast%3DHouston%26aufirst%3DE.%26aulast%3DFarbman%26aufirst%3DE.%2BS.%26aulast%3DAgarwal%26aufirst%3DP.%26aulast%3DEberly%26aufirst%3DS.%2BW.%26aulast%3DWatts%26aufirst%3DA.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DFeigin%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DBeck%26aufirst%3DC.%26aulast%3DOrme%26aufirst%3DC.%26aulast%3DEdicola%26aufirst%3DJ.%26aulast%3DChristopher%26aufirst%3DE.%26atitle%3DEffect%2520of%2520Deutetrabenazine%2520on%2520Chorea%2520among%2520Patients%2520with%2520Huntington%2520Disease.%2520A%2520Randomized%2520Clinical%2520Trial%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2016%26volume%3D316%26spage%3D40%26epage%3D50%26doi%3D10.1001%2Fjama.2016.8655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span> <span> </span><span class="NLM_article-title">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/jm4007998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3595-3611&author=T.+G.+Gant&title=Using+Deuterium+in+Drug+Discovery%3A+Leaving+the+Label+in+the+Drug&doi=10.1021%2Fjm4007998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span></div><div class="casAuthors">Gant, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Deuterium, the stable isotope of hydrogen, is known to medicinal chemists for its utility in mechanistic, spectroscopic, and tracer studies.  In fact, well-known applications utilizing deuterium exist within every subdiscipline in pharmaceutical discovery and development.  Recent emphasis on incorporation of deuterium into the active pharmaceutical ingredient has come about as a result of inquiries into the potential for substantial benefits of the deuterium kinetic isotope effect on the safety and disposition of the drug substance.  This Perspective traces the author's experience in reviving and expanding this potential utility, first suggested many decades prior by the discoverer of this, the simplest of all isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4z14tbfBfBbVg90H21EOLACvtfcHk0ljxMS8NCeLsSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ&md5=3818a1dba9be431098ad9dd941dababc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm4007998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007998%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DUsing%2520Deuterium%2520in%2520Drug%2520Discovery%253A%2520Leaving%2520the%2520Label%2520in%2520the%2520Drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3595%26epage%3D3611%26doi%3D10.1021%2Fjm4007998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span>; <span class="NLM_string-name">Shahbaz, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Deuterated Benzoquinolizidine Inhibitors of Vesicular Monoamine Transporter 2</span>. <span class="NLM_patent">WO 2010044981</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=T.+G.+Gant&author=M.+Shahbaz&title=Preparation+of+Deuterated+Benzoquinolizidine+Inhibitors+of+Vesicular+Monoamine+Transporter+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DPreparation%2520of%2520Deuterated%2520Benzoquinolizidine%2520Inhibitors%2520of%2520Vesicular%2520Monoamine%2520Transporter%25202%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit51b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzoquinolines as for Treatment of Abnormal Muscular Activity</span>. <span class="NLM_patent">WO 2015077520</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Shah&title=Preparation+of+Benzoquinolines+as+for+Treatment+of+Abnormal+Muscular+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DP.%26atitle%3DPreparation%2520of%2520Benzoquinolines%2520as%2520for%2520Treatment%2520of%2520Abnormal%2520Muscular%2520Activity%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit51c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Stamler, D.</span></span> <span> </span><span class="NLM_article-title">Benzoquinolines as Inhibitors of Vesicular Monoamine Transporter 2</span>. <span class="NLM_patent">WO 2015112707</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+Stamler&title=Benzoquinolines+as+Inhibitors+of+Vesicular+Monoamine+Transporter+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStamler%26aufirst%3DD.%26atitle%3DBenzoquinolines%2520as%2520Inhibitors%2520of%2520Vesicular%2520Monoamine%2520Transporter%25202%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit51d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span>; <span class="NLM_string-name">Saks, S.</span></span> <span> </span><span class="NLM_article-title">Benzoquinolines as Inhibitors of Vesicular Monoamine Transporter 2 and Their Preparation</span>. <span class="NLM_patent">WO 2015077521</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Shah&author=S.+Saks&title=Benzoquinolines+as+Inhibitors+of+Vesicular+Monoamine+Transporter+2+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DP.%26atitle%3DBenzoquinolines%2520as%2520Inhibitors%2520of%2520Vesicular%2520Monoamine%2520Transporter%25202%2520and%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit51e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Despande, T. N.</span>; <span class="NLM_string-name">Singare, D. T.</span>; <span class="NLM_string-name">Pawar, Y. D.</span>; <span class="NLM_string-name">Chavan, Y. A.</span>; <span class="NLM_string-name">Ray, P. C.</span>; <span class="NLM_string-name">Singh, G. P.</span></span> <span> </span><span class="NLM_article-title">Novel Process for the Preparation of Tetrabenazine and Deutetrabenazine</span>. <span class="NLM_patent">WO 2017182916</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=T.+N.+Despande&author=D.+T.+Singare&author=Y.+D.+Pawar&author=Y.+A.+Chavan&author=P.+C.+Ray&author=G.+P.+Singh&title=Novel+Process+for+the+Preparation+of+Tetrabenazine+and+Deutetrabenazine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDespande%26aufirst%3DT.%2BN.%26atitle%3DNovel%2520Process%2520for%2520the%2520Preparation%2520of%2520Tetrabenazine%2520and%2520Deutetrabenazine%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Methods of Manufacturing Benzoquinoline Compounds as Inhibitors of Vesicular Monoamine Transporter 2 (Vmat2)</span>. <span class="NLM_patent">US 20150152099A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+Zhang&title=Methods+of+Manufacturing+Benzoquinoline+Compounds+as+Inhibitors+of+Vesicular+Monoamine+Transporter+2+%28Vmat2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DMethods%2520of%2520Manufacturing%2520Benzoquinoline%2520Compounds%2520as%2520Inhibitors%2520of%2520Vesicular%2520Monoamine%2520Transporter%25202%2520%2528Vmat2%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Brossi, A.</span>, <span class="NLM_string-name">Schnider, O.</span>, <span class="NLM_string-name">Walter, M.</span></span> <span> </span><span class="NLM_article-title">Quinolizine Derivatives</span>. <span class="NLM_patent">US 2830993</span>, <span class="NLM_year">1958</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1958&author=A.+Brossi&author=O.+Schnider&author=M.+Walter&title=Quinolizine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrossi%26aufirst%3DA.%26atitle%3DQuinolizine%2520Derivatives%26date%3D1958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit53b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Brossi, A.</span></span> <span> </span><span class="NLM_article-title">Substituted 2-Oxobenzoquinolizines</span>. <span class="NLM_patent">US 3045021</span>, <span class="NLM_year">1962</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1962&author=A.+Brossi&title=Substituted+2-Oxobenzoquinolizines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrossi%26aufirst%3DA.%26atitle%3DSubstituted%25202-Oxobenzoquinolizines%26date%3D1962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Openshaw, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, N.</span></span> <span> </span><span class="NLM_article-title">The Synthesis of Emetine and Related Compounds. Iv. A New Synthesis of 3-Substituted 1,2,3,4,6,7-Hexahydro-9,10-Dimethoxy-2-Oxo-11bh-Benzo[A]Quinolizines</span>. <i>J. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1460</span>, <span class="refDoi"> DOI: 10.1039/jr9630001449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fjr9630001449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaF3sXlvF2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1963&pages=1449-1460&author=H.+T.+Openshawauthor=N.+Whittaker&title=The+Synthesis+of+Emetine+and+Related+Compounds.+Iv.+A+New+Synthesis+of+3-Substituted+1%2C2%2C3%2C4%2C6%2C7-Hexahydro-9%2C10-Dimethoxy-2-Oxo-11bh-Benzo%5BA%5DQuinolizines&doi=10.1039%2Fjr9630001449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54aR"><div class="casContent"><span class="casTitleNuber">54a</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis of emetine and related compounds. IV. A new synthesis of 3-substituted 1,2,3,4,6,7-hexahydro-9,10-dimethoxy-2-oxo-11bH-benzo[α]quinolizines</span></div><div class="casAuthors">Openshaw, H. T.; Whittaker, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society</span>
        (<span class="NLM_cas:date">1963</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1449-60</span>CODEN:
                <span class="NLM_cas:coden">JCSOA9</span>;
        ISSN:<span class="NLM_cas:issn">0368-1769</span>.
    </div><div class="casAbstract">cf. CA 56, 8765h.  The title compds. (I) are produced by spontaneous cyclization of the 2-(2-alkyl-3-oxobutyl)-3,4-dihydroisoquinolinium cations which arise either by the mercuric acetate dehydrogenation of the related tetrahydroisoquinolines, prepd. by a Mannich reaction, or more simply by amine interchange between 3,4-dihydroisoquinoline (II) and a quaternized Mannich base.  The procedure has also been applied to the synthesis of 9,10-methylenedioxy- and 9,10-unsubstituted analogs of I, and, less satisfactorily, to the related indoloquinolizines (III).  When II was treated with formaldehyde and a methyl ketone, I was not produced, but a more complex product, assigned structure IV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8iz6VJ8CcbVg90H21EOLACvtfcHk0ljxMS8NCeLsSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3sXlvF2hsw%253D%253D&md5=406a2b48886650a0cceac54d78c4cf73</span></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=10.1039%2Fjr9630001449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fjr9630001449%26sid%3Dliteratum%253Aachs%26aulast%3DOpenshaw%26aufirst%3DH.%2BT.%26aulast%3DWhittaker%26aufirst%3DN.%26atitle%3DThe%2520Synthesis%2520of%2520Emetine%2520and%2520Related%2520Compounds.%2520Iv.%2520A%2520New%2520Synthesis%2520of%25203-Substituted%25201%252C2%252C3%252C4%252C6%252C7-Hexahydro-9%252C10-Dimethoxy-2-Oxo-11bh-Benzo%255BA%255DQuinolizines%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1963%26spage%3D1449%26epage%3D1460%26doi%3D10.1039%2Fjr9630001449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit54b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Openshaw, H.
T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Emetine and Related Compounds. X. Synthesis of Emetine Analogs, Including C(3)-Dinoremetine and C(3)-Noremetine. Correlation of Structure with Amebicidal Activity</span>. <i>J. Chem. Soc. C</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1039/j39690000101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fj39690000101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaF1MXkslKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1969&pages=101-105&author=H.%0AT.+Openshawauthor=N.+C.+Robsonauthor=N.+Whittaker&title=Synthesis+of+Emetine+and+Related+Compounds.+X.+Synthesis+of+Emetine+Analogs%2C+Including+C%283%29-Dinoremetine+and+C%283%29-Noremetine.+Correlation+of+Structure+with+Amebicidal+Activity&doi=10.1039%2Fj39690000101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54bR"><div class="casContent"><span class="casTitleNuber">54b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of emetine and related compounds.  X.  Synthesis of emetine analogs, including C(3)-dinoremetine and C(3)-noremetine.  Correlation of structure with amebicidal activity</span></div><div class="casAuthors">Openshaw, Harry T.; Robson, N. C.; Whittaker, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society [Section] C:  Organic</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-5</span>CODEN:
                <span class="NLM_cas:coden">JSOOAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-4952</span>.
    </div><div class="casAbstract">The (±)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxybenzo[a]quinolizin-2-one [(±)-I] was converted into (±)-C(3)-dinoremetine (II) via an N-(3,4-dimethoxyphenethyl) amide which had the same relative configuration as emetine at C-11b and C-2.  3-Methyl deriv. of [(-)-I] obtained by asymmetric transformation of the racemic compd. was converted into (-)-C(3)-noremetine (III).  (-)-1',8a'-Secoemetine (IV) and the (-)-analogs were also prepd.  Only II, III, and IV showed appreciable amebicidal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpah4VzG-gGtbVg90H21EOLACvtfcHk0liKTx1vsvm-Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkslKlsQ%253D%253D&md5=eaa452044183c57877d6f49b8b734999</span></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=10.1039%2Fj39690000101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fj39690000101%26sid%3Dliteratum%253Aachs%26aulast%3DOpenshaw%26aufirst%3DH.%2BT.%26aulast%3DRobson%26aufirst%3DN.%2BC.%26aulast%3DWhittaker%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520Emetine%2520and%2520Related%2520Compounds.%2520X.%2520Synthesis%2520of%2520Emetine%2520Analogs%252C%2520Including%2520C%25283%2529-Dinoremetine%2520and%2520C%25283%2529-Noremetine.%2520Correlation%2520of%2520Structure%2520with%2520Amebicidal%2520Activity%26jtitle%3DJ.%2520Chem.%2520Soc.%2520C%26date%3D1969%26spage%3D101%26epage%3D105%26doi%3D10.1039%2Fj39690000101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit54c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Emetine and Related Compounds. Vi. Improvements in the Synthesis of 3-Alkyl-1,3,4,6,7,11b-Hexahydro-9,10-Dimethoxybenzo[a]Quinolizin-2-Ones and 3-Alkyl-1,2,3,4,6,7,12,12b-Octahydroindolo[2,3-a]Quinolizin-2-Ones. Formation of Some Related Diazabicyclo[3.3.1]Nonanes</span>. <i>J. Chem. Soc. C</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1039/j39690000085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fj39690000085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaF1MXkslKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1969&pages=85-89&author=N.+Whittaker&title=Synthesis+of+Emetine+and+Related+Compounds.+Vi.+Improvements+in+the+Synthesis+of+3-Alkyl-1%2C3%2C4%2C6%2C7%2C11b-Hexahydro-9%2C10-Dimethoxybenzo%5Ba%5DQuinolizin-2-Ones+and+3-Alkyl-1%2C2%2C3%2C4%2C6%2C7%2C12%2C12b-Octahydroindolo%5B2%2C3-a%5DQuinolizin-2-Ones.+Formation+of+Some+Related+Diazabicyclo%5B3.3.1%5DNonanes&doi=10.1039%2Fj39690000085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54cR"><div class="casContent"><span class="casTitleNuber">54c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of emetine and related compounds.  VI.  Improvements in the synthesis of 3-alkyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxybenzo[a]quinolizin-2-ones and 3-alkyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-ones.  Formation of some related diazabicyclo[3.3.1]nonanes</span></div><div class="casAuthors">Whittaker, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society [Section] C:  Organic</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-9</span>CODEN:
                <span class="NLM_cas:coden">JSOOAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-4952</span>.
    </div><div class="casAbstract">A simplified procedure is reported for the almost quantitative conversion of 3,4-dihydro-6,7-di-methoxyisoquinoline (I) into benzo[a]quinolizines.  A byproduct formed in the prepn. of 1,3,4,6,7,11b-hexahydro-9,10-dimethoxybenzo[a]quinolizin-2-one is assigned the diisoquinopy-rimidine structure.  3,4-Dihydro-β-carboline condenses with Mannich bases in the presence of CO2 to give the indolo[2,3-a]quinolizines in good yield.  4-Dimethylamino-3-(dimethylaminomethyl)-2-butanone condenses with two mols. I to give 9,18-methanodiisoquino[2,1-a:1',2'-d][1,5]diazocine; similarly was prepd. the substituted 9,18-methanodiisoquino[2,1-a:2',1'-e]-[1,5]diazocine, together with a trace of a dipentacyclic ketone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7q6tHFtYe4LVg90H21EOLACvtfcHk0liKTx1vsvm-Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkslKmuw%253D%253D&md5=43ff9e3bddc72eb532bd4fc8e536ac93</span></div><a href="/servlet/linkout?suffix=cit54c&amp;dbid=16384&amp;doi=10.1039%2Fj39690000085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fj39690000085%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520Emetine%2520and%2520Related%2520Compounds.%2520Vi.%2520Improvements%2520in%2520the%2520Synthesis%2520of%25203-Alkyl-1%252C3%252C4%252C6%252C7%252C11b-Hexahydro-9%252C10-Dimethoxybenzo%255Ba%255DQuinolizin-2-Ones%2520and%25203-Alkyl-1%252C2%252C3%252C4%252C6%252C7%252C12%252C12b-Octahydroindolo%255B2%252C3-a%255DQuinolizin-2-Ones.%2520Formation%2520of%2520Some%2520Related%2520Diazabicyclo%255B3.3.1%255DNonanes%26jtitle%3DJ.%2520Chem.%2520Soc.%2520C%26date%3D1969%26spage%3D85%26epage%3D89%26doi%3D10.1039%2Fj39690000085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">McGee, K.</span>; <span class="NLM_string-name">Li, B.-F.</span></span> <span> </span><span class="NLM_article-title">Synthetic Methods for Preparation of (S)-(2r,3r,11br)-3-Isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-Pyrido[2,1-a]isoquinolin-2-yl 2-Amino-3-methylbutanoate Di(4-methylbenzenesulfonate)</span>. <span class="NLM_patent">WO 2017112857</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+McGee&author=B.-F.+Li&title=Synthetic+Methods+for+Preparation+of+%28S%29-%282r%2C3r%2C11br%29-3-Isobutyl-9%2C10-dimethoxy-2%2C3%2C4%2C6%2C7%2C11b-hexahydro-1H-Pyrido%5B2%2C1-a%5Disoquinolin-2-yl+2-Amino-3-methylbutanoate+Di%284-methylbenzenesulfonate%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcGee%26aufirst%3DK.%26atitle%3DSynthetic%2520Methods%2520for%2520Preparation%2520of%2520%2528S%2529-%25282r%252C3r%252C11br%2529-3-Isobutyl-9%252C10-dimethoxy-2%252C3%252C4%252C6%252C7%252C11b-hexahydro-1H-Pyrido%255B2%252C1-a%255Disoquinolin-2-yl%25202-Amino-3-methylbutanoate%2520Di%25284-methylbenzenesulfonate%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit55b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span> <span> </span><span class="NLM_article-title">A Concise Synthesis of Tetrabenazine and Its Crystal Structure</span>. <i>Mol. Cryst. Liq. Cryst.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>557</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1080/15421406.2011.627764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F15421406.2011.627764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC38XksV2nt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=557&publication_year=2012&pages=39-49&author=C.+Liuauthor=Z.+Chenauthor=X.+Liauthor=J.+Tang&title=A+Concise+Synthesis+of+Tetrabenazine+and+Its+Crystal+Structure&doi=10.1080%2F15421406.2011.627764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55bR"><div class="casContent"><span class="casTitleNuber">55b</span><div class="casTitle"><span class="NLM_cas:atitle">A Concise Synthesis of Tetrabenazine and Its Crystal Structure</span></div><div class="casAuthors">Liu, Chunyi; Chen, Zhengping; Li, Xiaomin; Tang, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Crystals and Liquid Crystals</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">557</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-49</span>CODEN:
                <span class="NLM_cas:coden">MCLCD8</span>;
        ISSN:<span class="NLM_cas:issn">1542-1406</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The synthesis of the target compd. (Tetrabenazine) was achieved using 3-[(dimethylamino)methyl]-5-methyl-2-heptanone and 6,7-dimethoxy-3,4-dihydroisoquinoline hydrochloride as reactants.  This approach provides an efficient and concise way to the synthesis of the marketed drug Tetrabenazine.  A colorless single crystal of Tetrabenazine suitable for X-ray anal. was obtained from a satd. methanol soln.  The X-ray results showed that tetrabenazine consists of (3R,11bR)-enantiomer (I) [i.e., (3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one] and (3S,11bS)-enantiomer (II) [(3S,11bS)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one].  Two terminal Me groups are disordered in the (3R,11bR) enantiomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFdRBfJ_fnbbVg90H21EOLACvtfcHk0lhA3StuaqHdSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksV2nt7k%253D&md5=4b7970ed498054204b9ec7e06a9003ef</span></div><a href="/servlet/linkout?suffix=cit55b&amp;dbid=16384&amp;doi=10.1080%2F15421406.2011.627764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15421406.2011.627764%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DA%2520Concise%2520Synthesis%2520of%2520Tetrabenazine%2520and%2520Its%2520Crystal%2520Structure%26jtitle%3DMol.%2520Cryst.%2520Liq.%2520Cryst.%26date%3D2012%26volume%3D557%26spage%3D39%26epage%3D49%26doi%3D10.1080%2F15421406.2011.627764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit55c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gano, K. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrido[2,1-a]isoquinoline Derivatives for Treating Hyperkinetic Disorders</span>. <span class="NLM_patent">WO 2008058261</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+W.+Gano&title=Preparation+of+Pyrido%5B2%2C1-a%5Disoquinoline+Derivatives+for+Treating+Hyperkinetic+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGano%26aufirst%3DK.%2BW.%26atitle%3DPreparation%2520of%2520Pyrido%255B2%252C1-a%255Disoquinoline%2520Derivatives%2520for%2520Treating%2520Hyperkinetic%2520Disorders%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilbourn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewett, D. M.</span></span> <span> </span><span class="NLM_article-title">Absolute Configuration of (+)-A-Dihydrotetrabenazine, an Active Metabolite of Tetrabenazine</span>. <i>Chirality</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1520-636X(1997)9:1<59::AID-CHIR11>3.0.CO;2-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2F%28SICI%291520-636X%281997%299%3A1%3C59%3A%3AAID-CHIR11%3E3.0.CO%3B2-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=9094204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK2sXit1aitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1997&pages=59-62&author=M.+R.+Kilbournauthor=L.+C.+Leeauthor=M.+J.+Heegauthor=D.+M.+Jewett&title=Absolute+Configuration+of+%28%2B%29-A-Dihydrotetrabenazine%2C+an+Active+Metabolite+of+Tetrabenazine&doi=10.1002%2F%28SICI%291520-636X%281997%299%3A1%3C59%3A%3AAID-CHIR11%3E3.0.CO%3B2-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Absolute configuration of (+)-α-dihydrotetrabenazine, an active metabolite of tetrabenazine</span></div><div class="casAuthors">Kilbourn, Michael R.; Lee, Lihsueh C.; Heeg, Mary J.; Jewett, Douglas M.</div><div class="citationInfo"><span class="NLM_cas:title">Chirality</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-62</span>CODEN:
                <span class="NLM_cas:coden">CHRLEP</span>;
        ISSN:<span class="NLM_cas:issn">0899-0042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss</span>)
        </div><div class="casAbstract">Chiral column liq. chromatog. and enantiospecific enzymic hydrolysis were utilized to sep. the enantiomers of α- and β-dihydrotetrabenazine and α-9-O-desmethyldihydrotetrabenazine, three benzo[a]quinolizines derived from the amine-depleting drug tetrabenazine.  An X-ray crystal structure anal. of (-)-α-9-O-desmethyldihydrotetrabenazine gave an abs. structure of that compd. as the 2S, 3S, 11bS isomer.  Therefore, (-)-α-dihydrotetrabenazine also has the 2S, 3S, 11bS abs. configuration.  (+)-α-Dihydrotetrabenazine, the single biol. active isomer from the metabolic redn. of tetrabenazine, thus has the abs. configuration of 2R, 3R, 11bR.  For further in vitro and in vivo studies of the vesicular monoamine transporter, it is now possible to use the single enantiomer of radiolabeled α-dihydrotetrabenazine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgn_jEbKw9U7Vg90H21EOLACvtfcHk0lhA3StuaqHdSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1aitro%253D&md5=bf708fc279b4850a9191035a82323a99</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291520-636X%281997%299%3A1%3C59%3A%3AAID-CHIR11%3E3.0.CO%3B2-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291520-636X%25281997%25299%253A1%253C59%253A%253AAID-CHIR11%253E3.0.CO%253B2-P%26sid%3Dliteratum%253Aachs%26aulast%3DKilbourn%26aufirst%3DM.%2BR.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DHeeg%26aufirst%3DM.%2BJ.%26aulast%3DJewett%26aufirst%3DD.%2BM.%26atitle%3DAbsolute%2520Configuration%2520of%2520%2528%252B%2529-A-Dihydrotetrabenazine%252C%2520an%2520Active%2520Metabolite%2520of%2520Tetrabenazine%26jtitle%3DChirality%26date%3D1997%26volume%3D9%26spage%3D59%26epage%3D62%26doi%3D10.1002%2F%28SICI%291520-636X%281997%299%3A1%3C59%3A%3AAID-CHIR11%3E3.0.CO%3B2-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citrome, L.</span></span> <span> </span><span class="NLM_article-title">Valbenazine for Tardive Dyskinesia: A Systematic Review of the Efficacy and Safety Profile for This Newly Approved Novel Medication—What Is the Number Needed to Treat, Number Needed to Harm and Likelihood to Be Helped or Harmed?</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">e12964</span>, <span class="refDoi"> DOI: 10.1111/ijcp.12964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1111%2Fijcp.12964" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=e12964&author=L.+Citrome&title=Valbenazine+for+Tardive+Dyskinesia%3A+A+Systematic+Review+of+the+Efficacy+and+Safety+Profile+for+This+Newly+Approved+Novel+Medication%E2%80%94What+Is+the+Number+Needed+to+Treat%2C+Number+Needed+to+Harm+and+Likelihood+to+Be+Helped+or+Harmed%3F&doi=10.1111%2Fijcp.12964"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fijcp.12964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fijcp.12964%26sid%3Dliteratum%253Aachs%26aulast%3DCitrome%26aufirst%3DL.%26atitle%3DValbenazine%2520for%2520Tardive%2520Dyskinesia%253A%2520A%2520Systematic%2520Review%2520of%2520the%2520Efficacy%2520and%2520Safety%2520Profile%2520for%2520This%2520Newly%2520Approved%2520Novel%2520Medication%25E2%2580%2594What%2520Is%2520the%2520Number%2520Needed%2520to%2520Treat%252C%2520Number%2520Needed%2520to%2520Harm%2520and%2520Likelihood%2520to%2520Be%2520Helped%2520or%2520Harmed%253F%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2017%26volume%3D71%26spage%3De12964%26doi%3D10.1111%2Fijcp.12964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, D.</span></span> <span> </span><span class="NLM_article-title">Tardive Dyskinesia: Out of the Shadows</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2018.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.jns.2018.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29449008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1MritFOntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2018&pages=1-3&author=R.+A.+Hauserauthor=D.+Truong&title=Tardive+Dyskinesia%3A+Out+of+the+Shadows&doi=10.1016%2Fj.jns.2018.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58aR"><div class="casContent"><span class="casTitleNuber">58a</span><div class="casTitle"><span class="NLM_cas:atitle">Tardive dyskinesia: Out of the shadows</span></div><div class="casAuthors">Hauser Robert A; Truong Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the neurological sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The approvals of the first two medications, valbenazine and deutetrabenazine, to treat tardive dyskinesia have ushered in a new era in neuropsychiatric care.  Tardive syndromes are defined as delayed onset, persistent movement disorders or sensory phenomena that occur in association with exposure to dopamine receptor blocking agents (DRBAs).  Their underlying pathophysiology remains to be fully elucidated, but clinicians can conceptualize tardive syndromes as persistent dopamine supersensitivity states.  Tardive syndromes can potentially cause distress, disfigurement, embarrassment, and dysfunction, and are often permanent.  Therefore, practitioners who prescribe DRBAs should be aware of this potential, carefully assess the risk/benefit ratio when considering the use of these medications, and be sure that patients are appropriately informed.  Patients on DRBAs should be monitored for the development of tardive syndromes, including through the use of regularly scheduled Abnormal Involuntary Movement Scale (AIMS) (or similar) examinations.  Clinicians prescribing DRBAs should be familiar with the diagnosis and management of tardive syndromes, and be able to institute treatment or refer patients when treatment is appropriate.  Future research may focus on the potential benefit of earlier introduction of VMAT2 inhibitors to delay onset or progression of tardive syndromes.  More effective treatments are still needed, as are effective, well-tolerated antipsychotics that do not cause tardive syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQl20610aearWHOrQ6qeX-mfW6udTcc2ebl3_ZDzMDz4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MritFOntQ%253D%253D&md5=6d7a984c6854f8df5ae4e983b6afad49</span></div><a href="/servlet/linkout?suffix=cit58a&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2018.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2018.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DR.%2BA.%26aulast%3DTruong%26aufirst%3DD.%26atitle%3DTardive%2520Dyskinesia%253A%2520Out%2520of%2520the%2520Shadows%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2018%26volume%3D389%26spage%3D1%26epage%3D3%26doi%3D10.1016%2Fj.jns.2018.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit58b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankovic, J.</span></span> <span> </span><span class="NLM_article-title">Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0874-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0874-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29484607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=525-541&author=N.+Niemannauthor=J.+Jankovic&title=Treatment+of+Tardive+Dyskinesia%3A+A+General+Overview+with+Focus+on+the+Vesicular+Monoamine+Transporter+2+Inhibitors&doi=10.1007%2Fs40265-018-0874-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58bR"><div class="casContent"><span class="casTitleNuber">58b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors</span></div><div class="casAuthors">Niemann, Nicki; Jankovic, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-541</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Tardive dyskinesia (TD) encompasses the spectrum of iatrogenic hyperkinetic movement disorders following exposure to dopamine receptor-blocking agents (DRBAs).  Despite the advent of atypical or second- and third-generation antipsychotics with a presumably lower risk of complications, TD remains a persistent and challenging problem.  Prevention is the first step in mitigating the risk of TD, but early recognition, gradual withdrawal of offending medications, and appropriate treatment are also crit.  As TD is often a persistent and troublesome disorder, specific antidyskinetic therapies are often needed for symptomatic relief.  The vesicular monoamine transporter 2 (VMAT2) inhibitors, which include tetrabenazine, deutetrabenazine, and valbenazine, are considered the treatment of choice for most patients with TD.  Deutetrabenazine-a deuterated version of tetrabenazine-and valbenazine, the purified parent product of one of the main tetrabenazine metabolites, are novel VMAT2 inhibitors and the only drugs to receive approval from the US FDA for the treatment of TD.  VMAT2 inhibitors deplete presynaptic dopamine and reduce involuntary movements in many hyperkinetic movement disorders, particularly TD, Huntington disease, and Tourette syndrome.  The active metabolites of the VMAT2 inhibitors have high affinity for VMAT2 and minimal off-target binding.  Compared with tetrabenazine, deutetrabenazine and valbenazine have pharmacokinetic advantages that translate into less frequent dosing and better tolerability.  However, no head-to-head studies have compared the various VMAT2 inhibitors.  One of the major advantages of VMAT2 inhibitors over DRBAs, which are still being used by some clinicians in the treatment of some hyperkinetic disorders, including TD, is that they are not assocd. with the development of TD.  We also briefly discuss other treatment options for TD, including amantadine, clonazepam, Gingko biloba, zolpidem, botulinum toxin, and deep brain stimulation.  Treatment of TD and other drug-induced movement disorders must be individualized and based on the severity, phenomenol., potential side effects, and other factors discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKvcuWVWOIJrVg90H21EOLACvtfcHk0lhweo2MnkmkMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKgurk%253D&md5=6865bade039dd5f6c3670a376de6160b</span></div><a href="/servlet/linkout?suffix=cit58b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0874-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0874-x%26sid%3Dliteratum%253Aachs%26aulast%3DNiemann%26aufirst%3DN.%26aulast%3DJankovic%26aufirst%3DJ.%26atitle%3DTreatment%2520of%2520Tardive%2520Dyskinesia%253A%2520A%2520General%2520Overview%2520with%2520Focus%2520on%2520the%2520Vesicular%2520Monoamine%2520Transporter%25202%2520Inhibitors%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D525%26epage%3D541%26doi%3D10.1007%2Fs40265-018-0874-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zai, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zai, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remington, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, J. L.</span></span> <span> </span><span class="NLM_article-title">Genetics of Tardive Dyskinesia: Promising Leads and Ways Forward</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2018.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.jns.2018.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29502799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGgtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2018&pages=28-34&author=C.+C.+Zaiauthor=M.+S.+Maesauthor=A.+K.+Tiwariauthor=G.+C.+Zaiauthor=G.+Remingtonauthor=J.+L.+Kennedy&title=Genetics+of+Tardive+Dyskinesia%3A+Promising+Leads+and+Ways+Forward&doi=10.1016%2Fj.jns.2018.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59aR"><div class="casContent"><span class="casTitleNuber">59a</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics of tardive dyskinesia: Promising leads and ways forward</span></div><div class="casAuthors">Zai, Clement C.; Maes, Miriam S.; Tiwari, Arun K.; Zai, Gwyneth C.; Remington, Gary; Kennedy, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">28-34</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tardive dyskinesia (TD) is a potentially irreversible and often debilitating movement disorder secondary to chronic use of dopamine receptor blocking medications.  Genetic factors have been implicated in the etiol. of TD.  We therefore have reviewed the most promising genes assocd. with TD, including DRD2, DRD3, VMAT2, HSPG2, HTR2A, HTR2C, and SOD2.  In addn., we present evidence supporting a role for these genes from preclin. models of TD.  The current understanding of the etiogenesis of TD is discussed in the light of the recent approvals of valbenazine and deutetrabenazine, VMAT2 inhibitors, for treating TD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWdvPQ0-XfM7Vg90H21EOLACvtfcHk0lhweo2MnkmkMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGgtb8%253D&md5=108bd106300c2fbcf96d8f02dc3c93e0</span></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2018.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2018.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DZai%26aufirst%3DC.%2BC.%26aulast%3DMaes%26aufirst%3DM.%2BS.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DZai%26aufirst%3DG.%2BC.%26aulast%3DRemington%26aufirst%3DG.%26aulast%3DKennedy%26aufirst%3DJ.%2BL.%26atitle%3DGenetics%2520of%2520Tardive%2520Dyskinesia%253A%2520Promising%2520Leads%2520and%2520Ways%2520Forward%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2018%26volume%3D389%26spage%3D28%26epage%3D34%26doi%3D10.1016%2Fj.jns.2018.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit59b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Skor, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozigian, H.</span></span> <span> </span><span class="NLM_article-title">Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine</span>. <i>Drugs R&amp;D</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1007/s40268-017-0202-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40268-017-0202-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28776237" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=449-459&author=H.+Skorauthor=E.+B.+Smithauthor=G.+Loewenauthor=C.+F.+O%E2%80%99Brienauthor=D.+E.+Grigoriadisauthor=H.+Bozigian&title=Differences+in+Dihydrotetrabenazine+Isomer+Concentrations+Following+Administration+of+Tetrabenazine+and+Valbenazine&doi=10.1007%2Fs40268-017-0202-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=10.1007%2Fs40268-017-0202-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40268-017-0202-z%26sid%3Dliteratum%253Aachs%26aulast%3DSkor%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DLoewen%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BF.%26aulast%3DGrigoriadis%26aufirst%3DD.%2BE.%26aulast%3DBozigian%26aufirst%3DH.%26atitle%3DDifferences%2520in%2520Dihydrotetrabenazine%2520Isomer%2520Concentrations%2520Following%2520Administration%2520of%2520Tetrabenazine%2520and%2520Valbenazine%26jtitle%3DDrugs%2520R%2526amp%253BD%26date%3D2017%26volume%3D17%26spage%3D449%26epage%3D459%26doi%3D10.1007%2Fs40268-017-0202-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harriott, N. D.</span>; <span class="NLM_string-name">Williams, J. P.</span>; <span class="NLM_string-name">Smith, E. B.</span>; <span class="NLM_string-name">Bozigian, H. P.</span>; <span class="NLM_string-name">Grigoriadis, D. E.</span></span> <span> </span><span class="NLM_article-title">Chapter Two—Vmat2 Inhibitors and the Path to Ingrezza (Valbenazine)</span>. In  <i>Progress in Medicinal Chemistry</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, D. R.</span>, <span class="NLM_string-name">Cox, B.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2018</span>; Vol.  <span class="NLM_volume">57</span>, pp  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">111</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=87-111&author=N.+D.+Harriott&author=J.+P.+Williams&author=E.+B.+Smith&author=H.+P.+Bozigian&author=D.+E.+Grigoriadisauthor=D.+R.+Witty&author=B.+Cox&title=Progress+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHarriott%26aufirst%3DN.%2BD.%26atitle%3DChapter%2520Two%25E2%2580%2594Vmat2%2520Inhibitors%2520and%2520the%2520Path%2520to%2520Ingrezza%2520%2528Valbenazine%2529%26btitle%3DProgress%2520in%2520Medicinal%2520Chemistry%26aulast%3DWitty%26aufirst%3DD.%2BR.%26pub%3DElsevier%26date%3D2018%26volume%3D57%26spage%3D87%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boldt, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggers, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phifer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brine, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehder, K. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (+)- and (−)-Tetrabenazine from the Resolution of A-Dihydrotetrabenazine</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">3574</span>– <span class="NLM_lpage">3585</span>, <span class="refDoi"> DOI: 10.1080/00397910902788125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F00397910902788125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2qs7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=3574-3585&author=K.+G.+Boldtauthor=M.+S.+Biggersauthor=S.+S.+Phiferauthor=G.+A.+Brineauthor=K.+S.+Rehder&title=Synthesis+of+%28%2B%29-+and+%28%E2%88%92%29-Tetrabenazine+from+the+Resolution+of+A-Dihydrotetrabenazine&doi=10.1080%2F00397910902788125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (+)- and (-)-tetrabenazine from the resolution of α-dihydrotetrabenazine</span></div><div class="casAuthors">Boldt, Karl G.; Biggers, Michael S.; Phifer, Sharnelle S.; Brine, George A.; Rehder, Ken S.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3574-3585</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">(±)-Tetrabenazine ((±)-I) was reduced with NaBH4 to (±)-α-dihydrotetrabenazine ((±)-II) and then resolved with di-4-toluoyl-L- and -D-tartrate to subsequently give (+)- and (-)-II.  The enantiomers were oxidized under Swern conditions to prep. samples of (+)- and (-)-I, which were optically pure by chiral HPLC anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTEb9wdKjbhrVg90H21EOLACvtfcHk0liOMZ8qBvp9YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2qs7%252FE&md5=8ff1d09981dd945f8c19b08e0d047e23</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1080%2F00397910902788125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910902788125%26sid%3Dliteratum%253Aachs%26aulast%3DBoldt%26aufirst%3DK.%2BG.%26aulast%3DBiggers%26aufirst%3DM.%2BS.%26aulast%3DPhifer%26aufirst%3DS.%2BS.%26aulast%3DBrine%26aufirst%3DG.%2BA.%26aulast%3DRehder%26aufirst%3DK.%2BS.%26atitle%3DSynthesis%2520of%2520%2528%252B%2529-%2520and%2520%2528%25E2%2588%2592%2529-Tetrabenazine%2520from%2520the%2520Resolution%2520of%2520A-Dihydrotetrabenazine%26jtitle%3DSynth.%2520Commun.%26date%3D2009%26volume%3D39%26spage%3D3574%26epage%3D3585%26doi%3D10.1080%2F00397910902788125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mittelman, A.</span>; <span class="NLM_string-name">Shachan-Tov, S.</span>; <span class="NLM_string-name">Masarwa, A.</span>; <span class="NLM_string-name">Sella-Erez, R.</span>; <span class="NLM_string-name">Enav, J.</span>; <span class="NLM_string-name">Erlich, M.</span>; <span class="NLM_string-name">Machtey, V.</span>; <span class="NLM_string-name">Piran, M.</span>; <span class="NLM_string-name">Yarovoy, M.</span>; <span class="NLM_string-name">Azran, S.</span>; <span class="NLM_string-name">Kisin-Finfer, E.</span>; <span class="NLM_string-name">Nidam, T.</span></span> <span> </span><span class="NLM_article-title">Solid State Forms of Valbenazine</span>. <span class="NLM_patent">WO 2018067945A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Mittelman&author=S.+Shachan-Tov&author=A.+Masarwa&author=R.+Sella-Erez&author=J.+Enav&author=M.+Erlich&author=V.+Machtey&author=M.+Piran&author=M.+Yarovoy&author=S.+Azran&author=E.+Kisin-Finfer&author=T.+Nidam&title=Solid+State+Forms+of+Valbenazine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMittelman%26aufirst%3DA.%26atitle%3DSolid%2520State%2520Forms%2520of%2520Valbenazine%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gano, K. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrido[2,1-a]isoquinoline Derivatives for Treating Hyperkinetic Disorders</span>. <span class="NLM_patent">WO2008058261A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+W.+Gano&title=Preparation+of+Pyrido%5B2%2C1-a%5Disoquinoline+Derivatives+for+Treating+Hyperkinetic+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGano%26aufirst%3DK.%2BW.%26atitle%3DPreparation%2520of%2520Pyrido%255B2%252C1-a%255Disoquinoline%2520Derivatives%2520for%2520Treating%2520Hyperkinetic%2520Disorders%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Naldemedine: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0750-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0750-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28466424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1crjsFSmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=923-927&author=A.+Markham&title=Naldemedine%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0750-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Naldemedine: First Global Approval</span></div><div class="casAuthors">Markham Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">923-927</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Naldemedine (Symproic(®)) is an orally active μ-opioid receptor antagonist being developed by Shionogi & Co., Ltd. that has been approved in the USA and Japan for the treatment of opioid-induced constipation.  The drug inhibits peripheral μ-opioid receptors such as those present in the gastrointestinal tract and has minimal or no effect on central opioid activity.  This article summarizes the milestones in the development of naldemedine leading to its first global approval in the USA for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4GzOCvvzBrO98rul4nhSdfW6udTcc2eahWjtM12arPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjsFSmtg%253D%253D&md5=6af1127aa3c094af82bbb5617a4dfcf2</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0750-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0750-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DNaldemedine%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D923%26epage%3D927%26doi%3D10.1007%2Fs40265-017-0750-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stern, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, D. M.</span></span> <span> </span><span class="NLM_article-title">Spotlight on Naldemedine in the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Noncancer Pain: Design, Development, and Place in Therapy</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.2147/JPR.S141322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2147%2FJPR.S141322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29391826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKltLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=195-199&author=E.+K.+Sternauthor=D.+M.+Brenner&title=Spotlight+on+Naldemedine+in+the+Treatment+of+Opioid-Induced+Constipation+in+Adult+Patients+with+Chronic+Noncancer+Pain%3A+Design%2C+Development%2C+and+Place+in+Therapy&doi=10.2147%2FJPR.S141322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy</span></div><div class="casAuthors">Stern, Emily K.; Brenner, Darren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-199</span>CODEN:
                <span class="NLM_cas:coden">JPROEV</span>;
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Opioid-induced constipation (OIC) is an increasingly prevalent problem in the USA due to the growing use of opioids.  A novel class of therapeutics, the peripherally acting μ-opioid receptor antagonists (PAMORAs), has been developed to mitigate the deleterious effects of opioids in the gastrointestinal tract while maintaining central analgesia and minimizing opioid withdrawal.  This review aimed to summarize the literature on naldemedine, the third PAMORA to gain US Food and Drug Administration (FDA) approval for the treatment of OIC in adults with chronic noncancer pain-related syndromes.  Naldemedine has a chem. structure similar to naltrexone, an opioid receptor antagonist, with chem. modifications that limit its ability to cross the blood-brain barrier.  Naldemedine was evaluated in two Phase II and three Phase III clin. trials prior to gaining FDA approval.  In two pivotal identical Phase III trials, COMPOSE-I (NCT 01965158) and COMPOSE-II (NCT 01993940), patients receiving naldemedine were significantly more likely to respond when compared with placebo (COMPOSE-I: 47.6 vs 34.6%, P=0.002 and COMPOSE-II: 52.5 vs 33.6%, P<0.0001).  The most frequent adverse events were abdominal pain (8%) and diarrhea (7%) - rates similar to the other PAMORAs.  Based on the available data, naldemedine appears to be an effective and safe drug for the treatment of OIC in adults with chronic noncancer pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3a5L_7P8WQ7Vg90H21EOLACvtfcHk0lgpatGxwbkybg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKltLvP&md5=0d15a9d564a22942aed2525a79d44d05</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2147%2FJPR.S141322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S141322%26sid%3Dliteratum%253Aachs%26aulast%3DStern%26aufirst%3DE.%2BK.%26aulast%3DBrenner%26aufirst%3DD.%2BM.%26atitle%3DSpotlight%2520on%2520Naldemedine%2520in%2520the%2520Treatment%2520of%2520Opioid-Induced%2520Constipation%2520in%2520Adult%2520Patients%2520with%2520Chronic%2520Noncancer%2520Pain%253A%2520Design%252C%2520Development%252C%2520and%2520Place%2520in%2520Therapy%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2018%26volume%3D11%26spage%3D195%26epage%3D199%26doi%3D10.2147%2FJPR.S141322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, Y.</span>; <span class="NLM_string-name">Noguchi, K.</span>; <span class="NLM_string-name">Inagaki, M.</span>; <span class="NLM_string-name">Morimoto, K.</span>; <span class="NLM_string-name">Haga, N.</span>; <span class="NLM_string-name">Oda, S.</span>; <span class="NLM_string-name">Omura, S.</span></span> <span> </span><span class="NLM_article-title">Crystal of 6,7-Unsaturated-7-carbamoyl Morphinan Derivative and Method for Producing the Same</span>. <span class="NLM_patent">US 9108975B2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Tamura&author=K.+Noguchi&author=M.+Inagaki&author=K.+Morimoto&author=N.+Haga&author=S.+Oda&author=S.+Omura&title=Crystal+of+6%2C7-Unsaturated-7-carbamoyl+Morphinan+Derivative+and+Method+for+Producing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DY.%26atitle%3DCrystal%2520of%25206%252C7-Unsaturated-7-carbamoyl%2520Morphinan%2520Derivative%2520and%2520Method%2520for%2520Producing%2520the%2520Same%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yee, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daaboul, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korjian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlKhalfan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerneis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhaber, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, C. M.</span></span> <span> </span><span class="NLM_article-title">Increased Benefit of Betrixaban among Patients with a History of Venous Thromboembolism: A Post-Hoc Analysis of the Apex Trial</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1007/s11239-017-1583-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs11239-017-1583-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29188425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1-8&author=M.+K.+Yeeauthor=T.+Nafeeauthor=Y.+Daaboulauthor=S.+Korjianauthor=F.+AlKhalfanauthor=M.+Kerneisauthor=C.+Wiestauthor=S.+Z.+Goldhaberauthor=A.+F.+Hernandezauthor=R.+D.+Hullauthor=A.+T.+Cohenauthor=R.+A.+Harringtonauthor=C.+M.+Gibson&title=Increased+Benefit+of+Betrixaban+among+Patients+with+a+History+of+Venous+Thromboembolism%3A+A+Post-Hoc+Analysis+of+the+Apex+Trial&doi=10.1007%2Fs11239-017-1583-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial</span></div><div class="casAuthors">Yee, Megan K.; Nafee, Tarek; Daaboul, Yazan; Korjian, Serge; Al Khalfan, Fahad; Kerneis, Mathieu; Wiest, Cara; Goldhaber, Samuel Z.; Hernandez, Adrian F.; Hull, Russell D.; Cohen, Alexander T.; Harrington, Robert A.; Gibson, C. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hospitalized acute medically ill patients with a history of venous thromboembolism (VTE) are at increased risk for recurrent VTE.  We characterized the efficacy and safety of betrixaban for prevention of recurrent VTE in these high risk patients.  The APEX trial randomized 7513 acutely ill hospitalized medical patients at risk for developing VTE to receive either betrixaban for 35-42 days or enoxaparin for 10 ± 4 days to prevent VTE.  This exploratory post-hoc anal. assessed the efficacy and safety of betrixaban vs. enoxaparin among subjects with and without prior VTE.  Time-to-multiple symptomatic VTE events was also calcd.  Approx. 8% of subjects in both arms had prior VTE, which was assocd. with a fourfold increase in adjusted risk of VTE [MV OR 4.03, 95% CI 3.06-5.30, p < 0.001].  Betrixaban reduced VTE compared with enoxaparin among subjects with prior VTE [32 (10.4%) vs. 55 (18.9%), RR 0.57, 95% CI 0.38-0.86, p = 0.006, ARR 8.5%, NNT 12] and without prior VTE [133 (3.9%) vs. 168 (4.9%), RR 0.79, 95% CI 0.64-0.99, p = 0.042, ARR 1.0%, NNT 100] (interaction p > 0.05).  Addnl., four subjects in the enoxaparin arm and one subject in the betrixaban arm experienced a recurrent VTE.  Compared with enoxaparin, betrixaban use was assocd. with redn. of recurrent VTE events through the active treatment period [36 vs. 57, HR 0.63, 95% CI 0.41-0.97, p = 0.045] and through the end of study [38 vs. 71, HR 0.54, 95% CI 0.36-0.81, p = 0.004].  Prior VTE is assocd. with a fourfold increase in the risk of VTE among hospitalized medically ill patients.  Only 12 such patients would need to be treated with betrixaban vs. enoxaparin to prevent an addnl. VTE endpoint.  Betrixaban reduced not only the first but also all recurrent VTE events in a time-to-any-event anal.  Trial registration: http://www.clinicaltrials.gov, Unique identifier: NCT01583218.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiFiuZS4tfhLVg90H21EOLACvtfcHk0lgpatGxwbkybg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejsr%252FP&md5=5cae40f3e164559cc7b36f713e5f788f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs11239-017-1583-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-017-1583-0%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DM.%2BK.%26aulast%3DNafee%26aufirst%3DT.%26aulast%3DDaaboul%26aufirst%3DY.%26aulast%3DKorjian%26aufirst%3DS.%26aulast%3DAlKhalfan%26aufirst%3DF.%26aulast%3DKerneis%26aufirst%3DM.%26aulast%3DWiest%26aufirst%3DC.%26aulast%3DGoldhaber%26aufirst%3DS.%2BZ.%26aulast%3DHernandez%26aufirst%3DA.%2BF.%26aulast%3DHull%26aufirst%3DR.%2BD.%26aulast%3DCohen%26aufirst%3DA.%2BT.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26aulast%3DGibson%26aufirst%3DC.%2BM.%26atitle%3DIncreased%2520Benefit%2520of%2520Betrixaban%2520among%2520Patients%2520with%2520a%2520History%2520of%2520Venous%2520Thromboembolism%253A%2520A%2520Post-Hoc%2520Analysis%2520of%2520the%2520Apex%2520Trial%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2018%26volume%3D45%26spage%3D1%26epage%3D8%26doi%3D10.1007%2Fs11239-017-1583-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkart, T.</span></span> <span> </span><span class="NLM_article-title">Advances in Oral Anticoagulation Therapy – What’s in the Pipeline?</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2017.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.blre.2017.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28185693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1Ciu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=205-211&author=P.+S.+S.+Raoauthor=T.+Burkart&title=Advances+in+Oral+Anticoagulation+Therapy+%E2%80%93+What%E2%80%99s+in+the+Pipeline%3F&doi=10.1016%2Fj.blre.2017.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68aR"><div class="casContent"><span class="casTitleNuber">68a</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in oral anticoagulation therapy - What's in the pipeline?</span></div><div class="casAuthors">Rao, P. S. S.; Burkart, T.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-211</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Approx. 900,000 people are affected by some sort of venous thromboembolic (VTE) event every year in the United States.  VTE diagnosis used to mean treatment with medications that required routine lab monitoring for safety and efficacy.  Activated factor X (FXa) inhibition has emerged as a convenient pathway for management of VTE and currently three FXa inhibitors are available for anticoagulation management - rivaroxaban, apixaban, and edoxaban.  Continued development of medications utilizing this pathway may offer advantages via novel pharmacokinetic or pharmacodynamic properties that may minimize the adverse effects assocd. with traditional anticoagulant therapy.  This review summarizes the available information regarding pharmacokinetic, pharmacodynamic, and early safety and efficacy data for three factor Xa inhibitors being developed - darexaban, betrixaban and nokxaban.  The studies reviewed in this article suggests that three newer agents possess the potential for promise based on early phase I and II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKxaHqAjVZmbVg90H21EOLACvtfcHk0lgpatGxwbkybg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1Ciu70%253D&md5=f506f70c09569727898309e3c0aecbca</span></div><a href="/servlet/linkout?suffix=cit68a&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2017.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2017.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DP.%2BS.%2BS.%26aulast%3DBurkart%26aufirst%3DT.%26atitle%3DAdvances%2520in%2520Oral%2520Anticoagulation%2520Therapy%2520%25E2%2580%2593%2520What%25E2%2580%2599s%2520in%2520the%2520Pipeline%253F%26jtitle%3DBlood%2520Rev.%26date%3D2017%26volume%3D31%26spage%3D205%26epage%3D211%26doi%3D10.1016%2Fj.blre.2017.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRemer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gums, J. G.</span></span> <span> </span><span class="NLM_article-title">Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1177/1060028018754383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1177%2F1060028018754383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29338293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt12ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2018&pages=554-561&author=S.+G.+Garlandauthor=C.+E.+DeRemerauthor=S.+M.+Smithauthor=J.+G.+Gums&title=Betrixaban%3A+A+New+Oral+Factor+Xa+Inhibitor+for+Extended+Venous+Thromboembolism+Prophylaxis+in+High-Risk+Hospitalized+Patients&doi=10.1177%2F1060028018754383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68bR"><div class="casContent"><span class="casTitleNuber">68b</span><div class="casTitle"><span class="NLM_cas:atitle">Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients</span></div><div class="casAuthors">Garland, Scott G.; De Remer, Christina E.; Smith, Steven M.; Gums, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">554-561</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., pharmacokinetics, efficacy, and safety of the factor Xa (FXa) inhibitor betrixaban for extended-duration prophylaxis of acute medically ill patients with venous thromboembolism (VTE) risk factors.  Data Sources: A MEDLINE/PubMed (Jan. 1990 to Oct. 2017) search was conducted using the following keywords: betrixaban, PRT054021, FXa inhibitor, novel oral anticoagulant, NOAC, direct oral anticoagulant, DOAC, and target specific oral anticoagulant, TSOAC.  Refs. of identified articles were searched by hand for addnl. relevant citations.  Study Selection and Data Extn.: We included English-language articles evaluating betrixaban pharmacol., pharmacokinetics, efficacy, or safety in human subjects for VTE prophylaxis.  Data Synthesis: Betrixaban is a FXa inhibitor that decreases prothrombinase activity and thrombin generation.  Betrixaban efficacy and safety has been compared with that of enoxaparin for prophylaxis of VTE in acutely ill medical patients.  In the APEX trial and substudies, extended-duration betrixaban was superior in efficacy to std.-duration enoxaparin in patients at high risk for VTE, including those with elevated D-dimer levels (≥2× upper limit of normal) and of older age (≥75 years).  Betrixaban is noninferior to enoxaparin in rates of major bleeding, but the former is assocd. with more clin. relevant nonmajor bleeding events.  Conclusion: Betrixaban is the first oral agent approved for extended-duration VTE prophylaxis in acutely ill hospitalized patients.  Extended-duration thromboprophylaxis with betrixaban reduces the risk of VTE compared with std.-duration thromboprophylaxis with enoxaparin but is assocd. with increased risk of bleeding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv8UZJFdksCrVg90H21EOLACvtfcHk0ljIaOIJaoOHPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt12ru7k%253D&md5=4e7e718093fdb2f2cbb1cdcfb7839112</span></div><a href="/servlet/linkout?suffix=cit68b&amp;dbid=16384&amp;doi=10.1177%2F1060028018754383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028018754383%26sid%3Dliteratum%253Aachs%26aulast%3DGarland%26aufirst%3DS.%2BG.%26aulast%3DDeRemer%26aufirst%3DC.%2BE.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DGums%26aufirst%3DJ.%2BG.%26atitle%3DBetrixaban%253A%2520A%2520New%2520Oral%2520Factor%2520Xa%2520Inhibitor%2520for%2520Extended%2520Venous%2520Thromboembolism%2520Prophylaxis%2520in%2520High-Risk%2520Hospitalized%2520Patients%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2018%26volume%3D52%26spage%3D554%26epage%3D561%26doi%3D10.1177%2F1060028018754383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Al Yami, M.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfayez, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsheikh, R.</span></span> <span> </span><span class="NLM_article-title">Direct Oral Anticoagulants for Extended-Duration Thromboprophylaxis in Hospitalized Medically Ill Patients: Are We There Yet?</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1007/s11239-017-1481-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs11239-017-1481-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28197755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVaqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=1-8&author=M.%0AS.+Al+Yamiauthor=O.+M.+Alfayezauthor=S.+M.+Kurdiauthor=R.+Alsheikh&title=Direct+Oral+Anticoagulants+for+Extended-Duration+Thromboprophylaxis+in+Hospitalized+Medically+Ill+Patients%3A+Are+We+There+Yet%3F&doi=10.1007%2Fs11239-017-1481-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69aR"><div class="casContent"><span class="casTitleNuber">69a</span><div class="casTitle"><span class="NLM_cas:atitle">Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?</span></div><div class="casAuthors">Al Yami, Majed S.; Alfayez, Osamah M.; Kurdi, Sawsan M.; Alsheikh, Razan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Despite a recommended 7-10 days of thromboprophylaxis, medically ill patients remain at increased risk of developing venous thromboembolism (VTE) after hospital discharge.  Here, we present a contemporary review on the efficacy and safety of extended-duration thromboprophylaxis with direct oral anticoagulants (DOACs) in hospitalized medically ill patients.  A search of publication and trial databases of controlled trials conducted from 2010 to 2016 using the key terms apixaban, rivaroxaban, and betrixaban showed three phase III trials that met our search criteria.  In the "ADOPT" trial, apixaban was not inferior to enoxaparin in preventing VTE events (relative risk [RR] of 0.87; 95% confidence interval [CI] 0.62-1.23; P = 0.44); however, major bleeding rate was significantly higher with apixaban (RR of 2.58; 95% CI 1.02-7.24; P = 0.04).  In the "MAGELLAN" trial, rivaroxaban was superior to enoxaparin in preventing VTE events (RR of 0.77; 95% CI 0.62-0.96; P = 0.02) but with higher clin. relevant bleeding rate (RR of 2.5; 95% CI 1.85-3.25; P < 0.001).  Finally, in the "APEX" trial, there were no differences between betrixaban and enoxaparin in preventing VTE events in patients with elevated D-dimer levels (RR of 0.81; 95% CI 0.65-1.00; P = 0.054) and no differences in major bleeding events in all patients (RR of 1.19; 95% CI 0.67-2.12; P = 0.55).  Compared with std.-duration thromboprophylaxis with enoxaparin, extended-duration thromboprophylaxis with DOACs in medically ill patients may provide an incremental benefit, although at the cost of increased bleeding events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplnxXCRi-BvrVg90H21EOLACvtfcHk0ljIaOIJaoOHPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVaqt74%253D&md5=a9e5e2906d598d17da002eb79f390844</span></div><a href="/servlet/linkout?suffix=cit69a&amp;dbid=16384&amp;doi=10.1007%2Fs11239-017-1481-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-017-1481-5%26sid%3Dliteratum%253Aachs%26aulast%3DAl%2BYami%26aufirst%3DM.%2BS.%26aulast%3DAlfayez%26aufirst%3DO.%2BM.%26aulast%3DKurdi%26aufirst%3DS.%2BM.%26aulast%3DAlsheikh%26aufirst%3DR.%26atitle%3DDirect%2520Oral%2520Anticoagulants%2520for%2520Extended-Duration%2520Thromboprophylaxis%2520in%2520Hospitalized%2520Medically%2520Ill%2520Patients%253A%2520Are%2520We%2520There%2520Yet%253F%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2017%26volume%3D44%26spage%3D1%26epage%3D8%26doi%3D10.1007%2Fs11239-017-1481-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit69b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douketis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz, J. I.</span></span> <span> </span><span class="NLM_article-title">Reversal Agents for Non-Vitamin K Antagonist Oral Anticoagulants</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2017.223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1038%2Fnrcardio.2017.223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29345686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=273-281&author=J.+H.+Levyauthor=J.+Douketisauthor=J.+I.+Weitz&title=Reversal+Agents+for+Non-Vitamin+K+Antagonist+Oral+Anticoagulants&doi=10.1038%2Fnrcardio.2017.223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69bR"><div class="casContent"><span class="casTitleNuber">69b</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal agents for non-vitamin K antagonist oral anticoagulants</span></div><div class="casAuthors">Levy, Jerrold H.; Douketis, James; Weitz, Jeffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">273-281</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit coagulation factor Xa.  Although clin. studies of NOACs were conducted without antidotes, patient outcomes with major bleeding when receiving NOACs were no worse than those in patients treated with a vitamin K antagonist.  Nonetheless, in patients with life-threatening bleeding or requiring urgent surgery, the capacity for rapid NOAC reversal is likely to increase patient safety.  Three NOAC reversal agents are in various stages of development: idarucizumab, a specific reversal agent for dabigatran; andexanet alfa, which reverses factor Xa inhibitors; and ciraparantag, which is purported to reverse all NOACs.  Idarucizumab is licensed in many countries, andexanet is under consideration by regulatory agencies, and ciraparantag is undergoing phase III evaluation.  In the absence of licensed reversal agents for the oral factor Xa inhibitors, prothrombin complex concs. are often used in patients taking these agents who present with life-threatening bleeding.  In this Review, we summarize the approved indications for the NOACs, outline how to measure their anticoagulant effects, describe the mechanism of action of the reversal strategies, assess the preclin. and clin. data supporting their use, provide guidance on potential indications for reversal, and offer a management approach for patients treated with NOACs who present with serious bleeding or require urgent surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQAKzCSQxfbVg90H21EOLACvtfcHk0ljIaOIJaoOHPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOju7g%253D&md5=9c75288fd177791f560d471f1014b84e</span></div><a href="/servlet/linkout?suffix=cit69b&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2017.223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2017.223%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DJ.%2BH.%26aulast%3DDouketis%26aufirst%3DJ.%26aulast%3DWeitz%26aufirst%3DJ.%2BI.%26atitle%3DReversal%2520Agents%2520for%2520Non-Vitamin%2520K%2520Antagonist%2520Oral%2520Anticoagulants%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2018%26volume%3D15%26spage%3D273%26epage%3D281%26doi%3D10.1038%2Fnrcardio.2017.223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probst, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolfrey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arfsten, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clizbe, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchaleelaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambing, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarborough, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Betrixaban (Prt054021), N-(5-Chloropyridin-2-Yl)-2-(4-(N,N-Dimethylcarbamimidoyl)Benzamido)-5-Methoxybenzamide, a Highly Potent, Selective, and Orally Efficacious Factor Xa Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2179</span>– <span class="NLM_lpage">2185</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.02.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmcl.2009.02.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=19297154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2179-2185&author=P.+Zhangauthor=W.+Huangauthor=L.+Wangauthor=L.+Baoauthor=Z.+J.+Jiaauthor=S.+M.+Bauerauthor=E.+A.+Goldmanauthor=G.+D.+Probstauthor=Y.+Songauthor=T.+Suauthor=J.+Fanauthor=Y.+Wuauthor=W.+Liauthor=J.+Woolfreyauthor=U.+Sinhaauthor=P.+W.+Wongauthor=S.+T.+Edwardsauthor=A.+E.+Arfstenauthor=L.+A.+Clizbeauthor=J.+Kanterauthor=A.+Pandeyauthor=G.+Parkauthor=A.+Hutchaleelahaauthor=J.+L.+Lambingauthor=S.+J.+Hollenbachauthor=R.+M.+Scarboroughauthor=B.-Y.+Zhu&title=Discovery+of+Betrixaban+%28Prt054021%29%2C+N-%285-Chloropyridin-2-Yl%29-2-%284-%28N%2CN-Dimethylcarbamimidoyl%29Benzamido%29-5-Methoxybenzamide%2C+a+Highly+Potent%2C+Selective%2C+and+Orally+Efficacious+Factor+Xa+Inhibitor&doi=10.1016%2Fj.bmcl.2009.02.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor</span></div><div class="casAuthors">Zhang, Penglie; Huang, Wenrong; Wang, Lingyan; Bao, Liang; Jia, Zhaozhong J.; Bauer, Shawn M.; Goldman, Erick A.; Probst, Gary D.; Song, Yonghong; Su, Ting; Fan, Jingmei; Wu, Yanhong; Li, Wenhao; Woolfrey, John; Sinha, Uma; Wong, Paul W.; Edwards, Susan T.; Arfsten, Ann E.; Clizbe, Lane A.; Kanter, James; Pandey, Anjali; Park, Gary; Hutchaleelaha, Athiwat; Lambing, Joseph L.; Hollenbach, Stanley J.; Scarborough, Robert M.; Zhu, Bing-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2179-2185</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Systematic SAR studies of in vitro factor Xa inhibitory activity around N-[(5-chloropyridin-2-yl)-2-(4-N,N-dimethylcarbamimidoyl)benzamido]benzamide were performed by modifying each of the three Ph rings.  A class of highly potent, selective, efficacious and orally bioavailable direct factor Xa inhibitors was discovered.  These compds. were screened in hERG binding assays to examine the effects of substitution groups on the hERG channel affinity.  From the leading compds., betrixaban (PRT054021) has been selected as the clin. candidate for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpd-1pBQ8QvLVg90H21EOLACvtfcHk0liW6GhtM_UZ5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjtr8%253D&md5=15697f13d2e0ab670db0a49135e3f6a1</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.02.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.02.111%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DJia%26aufirst%3DZ.%2BJ.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DGoldman%26aufirst%3DE.%2BA.%26aulast%3DProbst%26aufirst%3DG.%2BD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DT.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWoolfrey%26aufirst%3DJ.%26aulast%3DSinha%26aufirst%3DU.%26aulast%3DWong%26aufirst%3DP.%2BW.%26aulast%3DEdwards%26aufirst%3DS.%2BT.%26aulast%3DArfsten%26aufirst%3DA.%2BE.%26aulast%3DClizbe%26aufirst%3DL.%2BA.%26aulast%3DKanter%26aufirst%3DJ.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DHutchaleelaha%26aufirst%3DA.%26aulast%3DLambing%26aufirst%3DJ.%2BL.%26aulast%3DHollenbach%26aufirst%3DS.%2BJ.%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DDiscovery%2520of%2520Betrixaban%2520%2528Prt054021%2529%252C%2520N-%25285-Chloropyridin-2-Yl%2529-2-%25284-%2528N%252CN-Dimethylcarbamimidoyl%2529Benzamido%2529-5-Methoxybenzamide%252C%2520a%2520Highly%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520Factor%2520Xa%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2179%26epage%3D2185%26doi%3D10.1016%2Fj.bmcl.2009.02.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scarborough, R. M.</span>; <span class="NLM_string-name">Kanter, J. P.</span>; <span class="NLM_string-name">Sujino, K.</span>; <span class="NLM_string-name">Zuberi, S. S.</span></span> <span> </span><span class="NLM_article-title">Methods for Preparing Pharmaceutical Salts of a Factor Xa Inhibitor</span>. <span class="NLM_patent">WO 2008057972A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+M.+Scarborough&author=J.+P.+Kanter&author=K.+Sujino&author=S.+S.+Zuberi&title=Methods+for+Preparing+Pharmaceutical+Salts+of+a+Factor+Xa+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DMethods%2520for%2520Preparing%2520Pharmaceutical%2520Salts%2520of%2520a%2520Factor%2520Xa%2520Inhibitor%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span>; <span class="NLM_string-name">Leitao, E. P. T.</span>; <span class="NLM_string-name">Rato, J.</span>; <span class="NLM_string-name">Song, Z.
J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Betrixaban and Maleate Salt as Factor Xa Inhibitors</span>. <span class="NLM_patent">WO 2011084519A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Pandey&author=E.+P.+T.+Leitao&author=J.+Rato&author=Z.%0AJ.+Song&title=Process+for+Preparation+of+Betrixaban+and+Maleate+Salt+as+Factor+Xa+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Betrixaban%2520and%2520Maleate%2520Salt%2520as%2520Factor%2520Xa%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Ertugliflozin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0878-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0878-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29476348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=513-519&author=A.+Markham&title=Ertugliflozin%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0878-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Ertugliflozin: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">513-519</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ertugliflozin (Steglatro) is an orally active sodium glucose co-transporter type 2 inhibitor being developed by Merck and Pfizer as a treatment for type 2 diabetes mellitus (T2DM).  Ertugliflozin as monotherapy and in combination with various other antidiabetic drugs was assocd. with improvements in glycemic control and secondary outcome measures in the VERTIS phase III clin. trial program.  Ertugliflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet) and ertugliflozin and sitagliptin (Steglujan) have recently been approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.  These products have also received a pos. opinion from the EU Committee for Medicinal Products for Human Use (CHMP).  This article summarizes the milestones in the development of ertugliflozin leading to its first approval for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsUU0pdo7517Vg90H21EOLACvtfcHk0liW6GhtM_UZ5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKns7g%253D&md5=f23e3b58816b270fcb9b473e35993f6f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0878-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0878-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DErtugliflozin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D513%26epage%3D519%26doi%3D10.1007%2Fs40265-018-0878-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span> <span> </span><span class="NLM_article-title">Sodium Glucose Co-Transporter-2 (Sglt2) Inhibitors: A Review of Their Basic and Clinical Pharmacology</span>. <i>Diabetes Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1007/s13300-014-0089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs13300-014-0089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=25424969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCgt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=355-366&author=S.+Kalra&title=Sodium+Glucose+Co-Transporter-2+%28Sglt2%29+Inhibitors%3A+A+Review+of+Their+Basic+and+Clinical+Pharmacology&doi=10.1007%2Fs13300-014-0089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology</span></div><div class="casAuthors">Kalra, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">DTIHAP</span>;
        ISSN:<span class="NLM_cas:issn">1869-6961</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">A review.  Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action.  This review describes the biochem. and physiol. underlying the use of SGLT2 inhibitors, and their clin. pharmacol., including mechanism of action and posol.  The pragmatic placement of these mols. in the existing OAD arena is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbe5yB6I3cm7Vg90H21EOLACvtfcHk0lgqefz3BcAAMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCgt7jI&md5=e3aa0a1431f783accef94b17fd8108e8</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1007%2Fs13300-014-0089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13300-014-0089-4%26sid%3Dliteratum%253Aachs%26aulast%3DKalra%26aufirst%3DS.%26atitle%3DSodium%2520Glucose%2520Co-Transporter-2%2520%2528Sglt2%2529%2520Inhibitors%253A%2520A%2520Review%2520of%2520Their%2520Basic%2520and%2520Clinical%2520Pharmacology%26jtitle%3DDiabetes%2520Ther.%26date%3D2014%26volume%3D5%26spage%3D355%26epage%3D366%26doi%3D10.1007%2Fs13300-014-0089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aguillón, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segretti, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Azevedo, H. F. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimaraes, C. R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, L. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Souza, R. O. M. A.</span></span> <span> </span><span class="NLM_article-title">Synthetic Strategies toward Sglt2 Inhibitors</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1artLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=467-488&author=A.+R.+Aguill%C3%B3nauthor=A.+Mascarelloauthor=N.+D.+Segrettiauthor=H.+F.+Z.+de+Azevedoauthor=C.+R.+W.+Guimaraesauthor=L.+S.+M.+Mirandaauthor=R.+O.+M.+A.+de%0ASouza&title=Synthetic+Strategies+toward+Sglt2+Inhibitors&doi=10.1021%2Facs.oprd.8b00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Strategies toward SGLT2 Inhibitors</span></div><div class="casAuthors">Aguillon, Anderson R.; Mascarello, Alessandra; Segretti, Natanael D.; de Azevedo, Hatylas F. Z.; Guimaraes, Cristiano R. W.; Miranda, Leandro S. M.; de Souza, Rodrigo O. M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-488</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with refs.  Gliflozins are an important class of prescription drugs used to treat type II diabetes.  They reduce blood sugar levels by targeting the sodium-glucose transport protein 2 (SGLT2) and consequently inhibit glucose reabsorption in the kidney.  There are currently several FDA-approved gliflozins as well as others in the pipeline to be launched in the next few years.  This review describes the synthetic strategies used for manufg. SGLT2 inhibitors on both bench and industrial scales.  Moreover, the drawbacks to the strategies and the improvements made to obtain selected gliflozins and their glucose derivs. over the years are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpfFZiYkkQlbVg90H21EOLACvtfcHk0lgqefz3BcAAMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1artLY%253D&md5=0294cd48b1ee220fbde82a0b4abce3ea</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00017%26sid%3Dliteratum%253Aachs%26aulast%3DAguill%25C3%25B3n%26aufirst%3DA.%2BR.%26aulast%3DMascarello%26aufirst%3DA.%26aulast%3DSegretti%26aufirst%3DN.%2BD.%26aulast%3Dde%2BAzevedo%26aufirst%3DH.%2BF.%2BZ.%26aulast%3DGuimaraes%26aufirst%3DC.%2BR.%2BW.%26aulast%3DMiranda%26aufirst%3DL.%2BS.%2BM.%26aulast%3Dde%2BSouza%26aufirst%3DR.%2BO.%2BM.%2BA.%26atitle%3DSynthetic%2520Strategies%2520toward%2520Sglt2%2520Inhibitors%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26spage%3D467%26epage%3D488%26doi%3D10.1021%2Facs.oprd.8b00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boustany-Kari, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klenotic, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leininger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaiyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobol, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuma, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugnait, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Clinical Candidate from the Structurally Unique Dioxa-Bicyclo[3.2.1]Octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2952</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1021/jm200049r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200049r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVCntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2952-60&author=V.+Mascittiauthor=T.+S.+Maurerauthor=R.+P.+Robinsonauthor=J.+Bianauthor=C.+M.+Boustany-Kariauthor=T.+Brandtauthor=B.+M.+Collmanauthor=A.+S.+Kalgutkarauthor=M.+K.+Klenoticauthor=M.+T.+Leiningerauthor=A.+Loweauthor=R.+J.+Maguireauthor=V.+M.+Mastersonauthor=Z.+Miaoauthor=E.+Mukaiyamaauthor=J.+D.+Patelauthor=J.+C.+Pettersenauthor=C.+Previlleauthor=B.+Samasauthor=L.+Sheauthor=Z.+Sobolauthor=C.+M.+Steppanauthor=B.+D.+Stevensauthor=B.+A.+Thumaauthor=M.+Tugnaitauthor=D.+Zengauthor=T.+Zhu&title=Discovery+of+a+Clinical+Candidate+from+the+Structurally+Unique+Dioxa-Bicyclo%5B3.2.1%5DOctane+Class+of+Sodium-Dependent+Glucose+Cotransporter+2+Inhibitors&doi=10.1021%2Fjm200049r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors</span></div><div class="casAuthors">Mascitti, Vincent; Maurer, Tristan S.; Robinson, Ralph P.; Bian, Jianwei; Boustany-Kari, Carine M.; Brandt, Thomas; Collman, Benjamin M.; Kalgutkar, Amit S.; Klenotic, Michelle K.; Leininger, Michael T.; Lowe, Andre; Maguire, Robert J.; Masterson, Victoria M.; Miao, Zhuang; Mukaiyama, Emi; Patel, Jigna D.; Pettersen, John C.; Preville, Cathy; Samas, Brian; She, Li; Sobol, Zhanna; Steppan, Claire M.; Stevens, Benjamin D.; Thuma, Benjamin A.; Tugnait, Meera; Zeng, Dongxiang; Zhu, Tong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2952-2960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-04971729 (I) belongs to a new class of potent and selective sodium-dependent glucose cotransporter 2 inhibitors incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system.  In this paper we present the design, synthesis, preclin. evaluation, and human dose predictions related to I.  This compd. demonstrated robust urinary glucose excretion in rats and an excellent preclin. safety profile.  It is currently in phase 2 clin. trials and is being evaluated for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoytwz0hHDVmrVg90H21EOLACvtfcHk0lgqefz3BcAAMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVCntrY%253D&md5=80e156d19d3a6a87a61dca59cc1a0e99</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm200049r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200049r%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DBoustany-Kari%26aufirst%3DC.%2BM.%26aulast%3DBrandt%26aufirst%3DT.%26aulast%3DCollman%26aufirst%3DB.%2BM.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DKlenotic%26aufirst%3DM.%2BK.%26aulast%3DLeininger%26aufirst%3DM.%2BT.%26aulast%3DLowe%26aufirst%3DA.%26aulast%3DMaguire%26aufirst%3DR.%2BJ.%26aulast%3DMasterson%26aufirst%3DV.%2BM.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DMukaiyama%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DPettersen%26aufirst%3DJ.%2BC.%26aulast%3DPreville%26aufirst%3DC.%26aulast%3DSamas%26aufirst%3DB.%26aulast%3DShe%26aufirst%3DL.%26aulast%3DSobol%26aufirst%3DZ.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DThuma%26aufirst%3DB.%2BA.%26aulast%3DTugnait%26aufirst%3DM.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520Clinical%2520Candidate%2520from%2520the%2520Structurally%2520Unique%2520Dioxa-Bicyclo%255B3.2.1%255DOctane%2520Class%2520of%2520Sodium-Dependent%2520Glucose%2520Cotransporter%25202%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2952%26epage%3D60%26doi%3D10.1021%2Fjm200049r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span>; <span class="NLM_string-name">Collman, B. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol Derivatives as Antidiabetic Agents</span>. <span class="NLM_patent">WO 2010023594A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=V.+Mascitti&author=B.+M.+Collman&title=Preparation+of+Dioxa-bicyclo%5B3.2.1.%5Doctane-2%2C3%2C4-triol+Derivatives+as+Antidiabetic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26atitle%3DPreparation%2520of%2520Dioxa-bicyclo%255B3.2.1.%255Doctane-2%252C3%252C4-triol%2520Derivatives%2520as%2520Antidiabetic%2520Agents%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit77b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preville, C.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Synthesis of a Dioxa-Bicyclo[3.2.1]Octane Sglt2 Inhibitor</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2940</span>– <span class="NLM_lpage">2943</span>, <span class="refDoi"> DOI: 10.1021/ol100940w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol100940w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFyktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=2940-2943&author=V.+Mascittiauthor=C.+Preville&title=Stereoselective+Synthesis+of+a+Dioxa-Bicyclo%5B3.2.1%5DOctane+Sglt2+Inhibitor&doi=10.1021%2Fol100940w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77bR"><div class="casContent"><span class="casTitleNuber">77b</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective synthesis of a dioxa-bicyclo[3.2.1]octane SGLT2 inhibitor</span></div><div class="casAuthors">Mascitti, Vincent; Preville, Cathy</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2940-2943</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A promising class of SGLT2 inhibitors bearing a unique dioxa-bicyclo[3.2.1]octane motif I was recently disclosed.  An improved stereoselective synthesis providing efficient access to one of the most potent and selective compds. from this class is reported.  A one-pot deprotection/cyclization was used as the key step to form the dioxa-bicyclo[3.2.1]octane motif with full control of stereochem.  Using an appropriately substituted aryl group, the route enables the synthesis of any given compd. from the class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobDJBvQKnThrVg90H21EOLACvtfcHk0ljx7OLO1xjYCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFyktr0%253D&md5=e8106f180e5a652cd8a6d40c9a200419</span></div><a href="/servlet/linkout?suffix=cit77b&amp;dbid=16384&amp;doi=10.1021%2Fol100940w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol100940w%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DPreville%26aufirst%3DC.%26atitle%3DStereoselective%2520Synthesis%2520of%2520a%2520Dioxa-Bicyclo%255B3.2.1%255DOctane%2520Sglt2%2520Inhibitor%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D2940%26epage%3D2943%26doi%3D10.1021%2Fol100940w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit77c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulford, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagal, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Pierre, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuma, B.</span></span> <span> </span><span class="NLM_article-title">Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/op400289z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op400289z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=57-65&author=D.+Bernhardsonauthor=T.+A.+Brandtauthor=C.+A.+Hulfordauthor=R.+S.+Lehnerauthor=B.+R.+Prestonauthor=K.+Priceauthor=J.+F.+Sagalauthor=M.+J.+St.+Pierreauthor=P.+H.+Thompsonauthor=B.+Thuma&title=Development+of+an+Early-Phase+Bulk+Enabling+Route+to+Sodium-Dependent+Glucose+Cotransporter+2+Inhibitor+Ertugliflozin&doi=10.1021%2Fop400289z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77cR"><div class="casContent"><span class="casTitleNuber">77c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin</span></div><div class="casAuthors">Bernhardson, David; Brandt, Thomas A.; Hulford, Catherine A.; Lehner, Richard S.; Preston, Brian R.; Price, Kristin; Sagal, John F.; St. Pierre, Michael J.; Thompson, Peter H.; Thuma, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-65</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development and optimization of a scalable synthesis of sodium-dependent glucose cotransporter 2 inhibitor, ertugliflozin (I) , for the treatment of type-2 diabetes is described.  Highlights of the chem. are a concise, four-step synthesis of a structurally complex API from known intermediate II via persilylation-selective monodesilylation, primary alc. oxidn., aldol-crossed-Cannizzaro reaction, and solid-phase acid-catalyzed bicyclic ketal formation.  The final API was isolated as the L-pyroglutamic acid cocrystal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlgOpR9wfoBLVg90H21EOLACvtfcHk0ljx7OLO1xjYCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKjsg%253D%253D&md5=dfef0a029f4cd46ddd0c8179786a2042</span></div><a href="/servlet/linkout?suffix=cit77c&amp;dbid=16384&amp;doi=10.1021%2Fop400289z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop400289z%26sid%3Dliteratum%253Aachs%26aulast%3DBernhardson%26aufirst%3DD.%26aulast%3DBrandt%26aufirst%3DT.%2BA.%26aulast%3DHulford%26aufirst%3DC.%2BA.%26aulast%3DLehner%26aufirst%3DR.%2BS.%26aulast%3DPreston%26aufirst%3DB.%2BR.%26aulast%3DPrice%26aufirst%3DK.%26aulast%3DSagal%26aufirst%3DJ.%2BF.%26aulast%3DSt.%2BPierre%26aufirst%3DM.%2BJ.%26aulast%3DThompson%26aufirst%3DP.%2BH.%26aulast%3DThuma%26aufirst%3DB.%26atitle%3DDevelopment%2520of%2520an%2520Early-Phase%2520Bulk%2520Enabling%2520Route%2520to%2520Sodium-Dependent%2520Glucose%2520Cotransporter%25202%2520Inhibitor%2520Ertugliflozin%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D57%26epage%3D65%26doi%3D10.1021%2Fop400289z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenek, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljubicic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makowski, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustakis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Place, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salisbury, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanchina, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderplas, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weekly, R. M.</span></span> <span> </span><span class="NLM_article-title">Commercial Route Research and Development for Sglt2 Inhibitor Candidate Ertugliflozin</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1021/op4002802</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op4002802" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOnsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=66-81&author=P.+Bowlesauthor=S.+J.+Brenekauthor=S.+Caronauthor=N.+M.+Doauthor=M.+T.+Drexlerauthor=S.+Duanauthor=P.+Dub%C3%A9author=E.+C.+Hansenauthor=B.+P.+Jonesauthor=K.+N.+Jonesauthor=T.+A.+Ljubicicauthor=T.+W.+Makowskiauthor=J.+Mustakisauthor=J.+D.+Nelsonauthor=M.+Olivierauthor=Z.+Pengauthor=H.+H.+Perfectauthor=D.+W.+Placeauthor=J.+A.+Raganauthor=J.+J.+Salisburyauthor=C.+L.+Stanchinaauthor=B.+C.+Vanderplasauthor=M.+E.+Websterauthor=R.+M.+Weekly&title=Commercial+Route+Research+and+Development+for+Sglt2+Inhibitor+Candidate+Ertugliflozin&doi=10.1021%2Fop4002802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin</span></div><div class="casAuthors">Bowles, Paul; Brenek, Steven J.; Caron, Stephane; Do, Nga M.; Drexler, Michele T.; Duan, Shengquan; Dube, Pascal; Hansen, Eric C.; Jones, Brian P.; Jones, Kris N.; Ljubicic, Tomislav A.; Makowski, Teresa W.; Mustakis, Jason; Nelson, Jade D.; Olivier, Mark; Peng, Zhihui; Perfect, Hahdi H.; Place, David W.; Ragan, John A.; Salisbury, John J.; Stanchina, Corey L.; Vanderplas, Brian C.; Webster, Mark E.; Weekly, R. Matt</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-81</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical synthesis of SGLT2 inhibitor candidate ertugliflozin (1) has been developed for potential com. application.  The highly telescoped process involves only three intermediate isolations over a 12-step sequence.  The dioxa-bicyclo[3.2.1]-octane motif is prepd. from com. available 2,3,4,6-tetra-O-benzyl-D-glucose, with nucleophilic hydroxymethylation of a 5-ketogluconamide intermediate as a key step.  The aglycon moiety is introduced via aryl anion addn. to a methylpiperazine amide.  High chem. purity of the API is assured through isolation of the cryst. penultimate intermediate, tetraacetate 39.  A co-cryst. complex of the amorphous solid 1 with L-pyroglutamic acid has been prepd. in order to improve the phys. properties for manuf. and to ensure robust API quality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP6NFo2yUVILVg90H21EOLACvtfcHk0ljZemudObih1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOnsbbO&md5=bfbd79c5a79fd39dc6ad8f8081a56700</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fop4002802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop4002802%26sid%3Dliteratum%253Aachs%26aulast%3DBowles%26aufirst%3DP.%26aulast%3DBrenek%26aufirst%3DS.%2BJ.%26aulast%3DCaron%26aufirst%3DS.%26aulast%3DDo%26aufirst%3DN.%2BM.%26aulast%3DDrexler%26aufirst%3DM.%2BT.%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DDub%25C3%25A9%26aufirst%3DP.%26aulast%3DHansen%26aufirst%3DE.%2BC.%26aulast%3DJones%26aufirst%3DB.%2BP.%26aulast%3DJones%26aufirst%3DK.%2BN.%26aulast%3DLjubicic%26aufirst%3DT.%2BA.%26aulast%3DMakowski%26aufirst%3DT.%2BW.%26aulast%3DMustakis%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DJ.%2BD.%26aulast%3DOlivier%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DPerfect%26aufirst%3DH.%2BH.%26aulast%3DPlace%26aufirst%3DD.%2BW.%26aulast%3DRagan%26aufirst%3DJ.%2BA.%26aulast%3DSalisbury%26aufirst%3DJ.%2BJ.%26aulast%3DStanchina%26aufirst%3DC.%2BL.%26aulast%3DVanderplas%26aufirst%3DB.%2BC.%26aulast%3DWebster%26aufirst%3DM.%2BE.%26aulast%3DWeekly%26aufirst%3DR.%2BM.%26atitle%3DCommercial%2520Route%2520Research%2520and%2520Development%2520for%2520Sglt2%2520Inhibitor%2520Candidate%2520Ertugliflozin%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D66%26epage%3D81%26doi%3D10.1021%2Fop4002802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Pemafibrate: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1805</span>– <span class="NLM_lpage">1810</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0818-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0818-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28929345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFant7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1805-1810&author=H.+A.+Blair&title=Pemafibrate%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0818-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Pemafibrate: First Global Approval</span></div><div class="casAuthors">Blair, Hannah A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1805-1810</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Pemafibrate (Parmodia) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-α modulator (SPPARM).  It acts by binding to PPAR-α and regulating the expression of target genes that modulate lipid metab., thereby decreasing plasma triglyceride levels and increasing high-d. lipoprotein cholesterol levels.  Developed by Kowa Company, Ltd., oral pemafibrate has been approved in Japan for the treatment of hyperlipidemia (including familial hyperlipidemia).  This article summarizes the milestones in the development of pemafibrate leading to this first global approval for hyperlipidemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAtunrUMkTKLVg90H21EOLACvtfcHk0ljZemudObih1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFant7nL&md5=669b83e04a86005c951f2342451b696c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0818-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0818-x%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DPemafibrate%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1805%26epage%3D1810%26doi%3D10.1007%2Fs40265-017-0818-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokote, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suganami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of K-877, a Novel Selective Peroxisome Proliferator-Activated Receptor A Modulator (Spparmα), in Combination with Statin Treatment: Two Randomised, Double-Blind, Placebo-Controlled Clinical Trials in Patients with Dyslipidaemia</span>. <i>Atherosclerosis (Amsterdam, Neth.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.atherosclerosis.2017.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.atherosclerosis.2017.03.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFyrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=2017&pages=144-152&author=H.+Araiauthor=S.+Yamashitaauthor=K.+Yokoteauthor=E.+Arakiauthor=H.+Suganamiauthor=S.+Ishibashi&title=Efficacy+and+Safety+of+K-877%2C+a+Novel+Selective+Peroxisome+Proliferator-Activated+Receptor+A+Modulator+%28Spparm%CE%B1%29%2C+in+Combination+with+Statin+Treatment%3A+Two+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Clinical+Trials+in+Patients+with+Dyslipidaemia&doi=10.1016%2Fj.atherosclerosis.2017.03.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80aR"><div class="casContent"><span class="casTitleNuber">80a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia</span></div><div class="casAuthors">Arai, Hidenori; Yamashita, Shizuya; Yokote, Koutaro; Araki, Eiichi; Suganami, Hideki; Ishibashi, Shun</div><div class="citationInfo"><span class="NLM_cas:title">Atherosclerosis (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144-152</span>CODEN:
                <span class="NLM_cas:coden">ATHSBL</span>;
        ISSN:<span class="NLM_cas:issn">0021-9150</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Substantial residual cardiovascular risks remain despite intensive statin treatment.  Residual risks with high triglyceride and low high-d. lipoprotein cholesterol are not the primary targets of statins.  K-877 (pemafibrate) demonstrated robust efficacy on triglycerides and high-d. lipoprotein cholesterol and a good safety profile as a monotherapy.  The aim of these studies was to evaluate the efficacy and safety of K-877 add-on therapy to treat residual hypertriglyceridemia during statin treatment.  The objectives were investigated in two, multicentre, randomised, double-blind, placebo-controlled, parallel group comparison clin. trials: (A) K-877 0.1, 0.2, and 0.4 mg/day in combination with pitavastatin for 12 wk in 188 patients, (B) K-877 0.2 (fixed dose) and 0.2 (0.4) (conditional up-titrn.) mg/day in combination with any statin for 24 wk in 423 patients.  In both studies, we found a robust redn. in fasting triglyceride levels by approx. 50% in all combination therapy groups, which was significant compared to the statin-monotherapy (placebo) groups (p < 0.001).  High-performance liq. chromatog. anal. for lipoprotein subfractions revealed that atherogenic lipoprotein profiles were ameliorated by K-877 add-on therapy, i.e. small low-d. lipoproteins decreased whereas larger ones increased, and larger high-d. lipoproteins decreased whereas smaller ones increased.  The incidence rates of adverse events and adverse drug reactions in K-877 combination therapy groups were comparable to those in statin-monotherapy groups without any noteworthy event in both studies.  These results strongly support the favorable benefit-to-risk ratio of K-877 add-on therapy in combination with statin treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBX7qpzm9YrVg90H21EOLACvtfcHk0ljZemudObih1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFyrsr8%253D&md5=aaf3769f631e549dbc6225b130d2dd0e</span></div><a href="/servlet/linkout?suffix=cit80a&amp;dbid=16384&amp;doi=10.1016%2Fj.atherosclerosis.2017.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.atherosclerosis.2017.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DS.%26aulast%3DYokote%26aufirst%3DK.%26aulast%3DAraki%26aufirst%3DE.%26aulast%3DSuganami%26aufirst%3DH.%26aulast%3DIshibashi%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520K-877%252C%2520a%2520Novel%2520Selective%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520A%2520Modulator%2520%2528Spparm%25CE%25B1%2529%252C%2520in%2520Combination%2520with%2520Statin%2520Treatment%253A%2520Two%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Clinical%2520Trials%2520in%2520Patients%2520with%2520Dyslipidaemia%26jtitle%3DAtherosclerosis%2520%2528Amsterdam%252C%2520Neth.%2529%26date%3D2017%26volume%3D261%26spage%3D144%26epage%3D152%26doi%3D10.1016%2Fj.atherosclerosis.2017.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit80b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruchart, J.-C.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Highly Potent and Selective Human Peroxisome Proliferator-Activated Receptor A Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4689</span>– <span class="NLM_lpage">4693</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmcl.2007.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=17553678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFSiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4689-4693&author=Y.+Yamazakiauthor=K.+Abeauthor=T.+Tomaauthor=M.+Nishikawaauthor=H.+Ozawaauthor=A.+Okudaauthor=T.+Arakiauthor=S.+Odaauthor=K.+Inoueauthor=K.+Shibuyaauthor=B.+Staelsauthor=J.-C.+Fruchart&title=Design+and+Synthesis+of+Highly+Potent+and+Selective+Human+Peroxisome+Proliferator-Activated+Receptor+A+Agonists&doi=10.1016%2Fj.bmcl.2007.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80bR"><div class="casContent"><span class="casTitleNuber">80b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists</span></div><div class="casAuthors">Yamazaki, Yukiyoshi; Abe, Kazutoyo; Toma, Tsutomu; Nishikawa, Masahiro; Ozawa, Hidefumi; Okuda, Ayumu; Araki, Takaaki; Oda, Soichi; Inoue, Keisuke; Shibuya, Kimiyuki; Staels, Bart; Fruchart, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4689-4693</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aryloxyalkanoic acids substituted with aryloxyalkyl and benzoxazole-substituted aminoalkyl groups such as I are prepd. as human peroxisome proliferator-activated receptor α (PPAR-α) agonists for decreasing lipid levels; the binding of the compds. to PPAR-α, PPAR-δ, and PPA-γ and the decreases in liver wt. and triglyceride levels in rats upon administration of the sodium salts of three of the compds. are detd.  The racemate of I is prepd. and resolved by HPLC to provide I and its enantiomer; I inhibits PPAR-α with an EC50 value of 1 nM and approx. 1000-fold selectivity over PPAR-δ and PPAR-γ, while the sodium salt of I decreases triglyceride concns. in rats by approx. 49%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowBzT-9tjHnrVg90H21EOLACvtfcHk0lgz5hPxgLa91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFSiurg%253D&md5=212568f85768742693056e8f1fdce501</span></div><a href="/servlet/linkout?suffix=cit80b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DToma%26aufirst%3DT.%26aulast%3DNishikawa%26aufirst%3DM.%26aulast%3DOzawa%26aufirst%3DH.%26aulast%3DOkuda%26aufirst%3DA.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DS.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DShibuya%26aufirst%3DK.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DFruchart%26aufirst%3DJ.-C.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Highly%2520Potent%2520and%2520Selective%2520Human%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520A%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4689%26epage%3D4693%26doi%3D10.1016%2Fj.bmcl.2007.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takei, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arulmozhiraja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sladek, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokiwa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokiwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimano, H.</span></span> <span> </span><span class="NLM_article-title">Molecular Association Model of Pparα and Its New Specific and Efficient Ligand, Pemafibrate: Structural Basis for Spparmα</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>499</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.03.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bbrc.2018.03.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29567478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=499&publication_year=2018&pages=239-245&author=Y.+Yamamotoauthor=K.+Takeiauthor=S.+Arulmozhirajaauthor=V.+Sladekauthor=N.+Matsuoauthor=S.-i.+Hanauthor=T.+Matsuzakaauthor=M.+Sekiyaauthor=T.+Tokiwaauthor=M.+Shojiauthor=Y.+Shigetaauthor=Y.+Nakagawaauthor=H.+Tokiwaauthor=H.+Shimano&title=Molecular+Association+Model+of+Ppar%CE%B1+and+Its+New+Specific+and+Efficient+Ligand%2C+Pemafibrate%3A+Structural+Basis+for+Spparm%CE%B1&doi=10.1016%2Fj.bbrc.2018.03.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα</span></div><div class="casAuthors">Yamamoto, Yuta; Takei, Kenta; Arulmozhiraja, Sundaram; Sladek, Vladimir; Matsuo, Naoya; Han, Song-iee; Matsuzaka, Takashi; Sekiya, Motohiro; Tokiwa, Takaki; Shoji, Mitsuo; Shigeta, Yasuteru; Nakagawa, Yoshimi; Tokiwa, Hiroaki; Shimano, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">499</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-245</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Peroxisome proliferator-activated receptor-α (PPARα) is a ligand-activated transcription factor involved in the regulation of lipid homeostasis and improves hypertriglyceridemia.  Pemafibrate is a novel selective PPARα modulator (SPPARMα) that activates PPARα transcriptional activity.  Here, we computationally constructed the structure of the human PPARα in a complex with pemafibrate, along with that of hPPARα complexed with the classical fenofibrate, and studied their interactions quant. by using the first-principles calcns.-based fragment MO (FMO) method.  Comprehensive structural and protein-ligand binding elucidation along with the in vitro luciferase anal. let us to identify pemafibrate as a novel SPPARMα.  Unlike known fibrate ligands, which bind only with the arm I of the Y-shaped ligand binding pocket, the Y-shaped pemafibrate binds to the entire cavity region.  This lock and key nature causes enhanced induced fit in pemafibrate-ligated PPARα.  Importantly, this selective modulator allosterically changes PPARα conformation to form a brand-new interface, which in turn binds to PPARα co-activator, PGC-1α, resulting in the full activation of PPARα.  The structural basis for the potent effects of pemafibrate on PPARα transcriptional activity predicted by the in silico FMO methods was confirmed by in vitro luciferase assay for mutants.  The unique binding mode of pemafibrate reveals a new pattern of nuclear receptor ligand recognition and suggests a novel basis for ligand design, offering cues for improving the binding affinity and selectivity of ligand for better clin. consequences.  The findings explain the high affinity and efficacy of pemafibrate, which is expected to be in the clin. use soon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLVA8CZNSKTbVg90H21EOLACvtfcHk0lgz5hPxgLa91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOhs70%253D&md5=152c9cb80a81117a41c3bee909b11723</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.03.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.03.135%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DTakei%26aufirst%3DK.%26aulast%3DArulmozhiraja%26aufirst%3DS.%26aulast%3DSladek%26aufirst%3DV.%26aulast%3DMatsuo%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.-i.%26aulast%3DMatsuzaka%26aufirst%3DT.%26aulast%3DSekiya%26aufirst%3DM.%26aulast%3DTokiwa%26aufirst%3DT.%26aulast%3DShoji%26aufirst%3DM.%26aulast%3DShigeta%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DY.%26aulast%3DTokiwa%26aufirst%3DH.%26aulast%3DShimano%26aufirst%3DH.%26atitle%3DMolecular%2520Association%2520Model%2520of%2520Ppar%25CE%25B1%2520and%2520Its%2520New%2520Specific%2520and%2520Efficient%2520Ligand%252C%2520Pemafibrate%253A%2520Structural%2520Basis%2520for%2520Spparm%25CE%25B1%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D499%26spage%3D239%26epage%3D245%26doi%3D10.1016%2Fj.bbrc.2018.03.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, K.</span></span> <span> </span><span class="NLM_article-title">A Practical Synthesis of the Pparα Agonist, (R)-K-13675, Starting from (S)-2-Hydroxybutyrolactone</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">8155</span>– <span class="NLM_lpage">8158</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2008.06.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.tet.2008.06.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslensr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=8155-8158&author=Y.+Yamazakiauthor=T.+Arakiauthor=M.+Kouraauthor=K.+Shibuya&title=A+Practical+Synthesis+of+the+Ppar%CE%B1+Agonist%2C+%28R%29-K-13675%2C+Starting+from+%28S%29-2-Hydroxybutyrolactone&doi=10.1016%2Fj.tet.2008.06.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82aR"><div class="casContent"><span class="casTitleNuber">82a</span><div class="casTitle"><span class="NLM_cas:atitle">A practical synthesis of the PPARα agonist, (R)-K-13675, starting from (S)-2-hydroxybutyrolactone</span></div><div class="casAuthors">Yamazaki, Yukiyoshi; Araki, Takaaki; Koura, Minoru; Shibuya, Kimiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8155-8158</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A practical synthesis of optically pure PPARα agonist, (R)-K-13675, is described.  This process is based on the use of (S)-2-hydroxybutyrolactone, which can be transformed into the requisite Bu (S)-2-hydroxybutanoate in an efficient manner.  A key reaction is the etherification between the phenol and Bu (S)-2-trifluoromethanesulfonyloxybutanoate to give the Ph ether in excellent yield without loss of optical purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAPbfFv1MSfLVg90H21EOLACvtfcHk0lgBVB27jpcpNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslensr8%253D&md5=38e5140d3f23247fb7280629130d0abe</span></div><a href="/servlet/linkout?suffix=cit82a&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2008.06.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2008.06.049%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DKoura%26aufirst%3DM.%26aulast%3DShibuya%26aufirst%3DK.%26atitle%3DA%2520Practical%2520Synthesis%2520of%2520the%2520Ppar%25CE%25B1%2520Agonist%252C%2520%2528R%2529-K-13675%252C%2520Starting%2520from%2520%2528S%2529-2-Hydroxybutyrolactone%26jtitle%3DTetrahedron%26date%3D2008%26volume%3D64%26spage%3D8155%26epage%3D8158%26doi%3D10.1016%2Fj.tet.2008.06.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit82b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, K.</span></span> <span> </span><span class="NLM_article-title">Enantioselective Synthesis of the Pparα Agonist (R)-K-13675 Via (S)-2-Hydroxybutyrolactone</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2008</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1032123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-2008-1032123" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2008&publication_year=2008&pages=1017-1022&author=Y.+Yamazakiauthor=T.+Arakiauthor=M.+Kouraauthor=K.+Shibuya&title=Enantioselective+Synthesis+of+the+Ppar%CE%B1+Agonist+%28R%29-K-13675+Via+%28S%29-2-Hydroxybutyrolactone&doi=10.1055%2Fs-2008-1032123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82b&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1032123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1032123%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DKoura%26aufirst%3DM.%26aulast%3DShibuya%26aufirst%3DK.%26atitle%3DEnantioselective%2520Synthesis%2520of%2520the%2520Ppar%25CE%25B1%2520Agonist%2520%2528R%2529-K-13675%2520Via%2520%2528S%2529-2-Hydroxybutyrolactone%26jtitle%3DSynthesis%26date%3D2008%26volume%3D2008%26spage%3D1017%26epage%3D1022%26doi%3D10.1055%2Fs-2008-1032123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: A Review in Rheumatoid Arthritis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0908-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0908-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29687421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosFCrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=761-772&author=Z.+T.+Al-Salamaauthor=L.+J.+Scott&title=Baricitinib%3A+A+Review+in+Rheumatoid+Arthritis&doi=10.1007%2Fs40265-018-0908-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: A Review in Rheumatoid Arthritis</span></div><div class="casAuthors">Al-Salama, Zaina T.; Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Baricitinib (Olumiant) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA).  This novel, small mol. is approved for use as monotherapy, or in combination with methotrexate, for the treatment of adults with moderate to severe active RA who responded inadequately to or were intolerant of ≥ 1 DMARD.  In pivotal multinational trials, once-daily baricitinib 4 mg, with/without methotrexate (± another csDMARD), improved the signs and symptoms of RA, disease activity and phys. function in DMARD-naive patients and in patients with an inadequate response to methotrexate, csDMARDs or TNF inhibitors; baricitinib treatment also slowed structural joint damage in DMARD-naive patients and in those with an inadequate response to methotrexate and csDMARDs.  Baricitinib plus methotrexate was more effective than adalimumab plus methotrexate in patients with an inadequate response to methotrexate.  The onset of these benefits was generally rapid and sustained over time.  Baricitinib was generally well tolerated during up to 5.5 years' treatment; the most commonly reported adverse drug reactions were upper respiratory tract infections, increased LDL cholesterol, nausea and thrombocytosis.  Thus, once-daily baricitinib, as monotherapy or in combination with methotrexate, is an effective and generally well tolerated emerging treatment for patients with moderate to severe active RA who have responded inadequately to or are intolerant of ≥ 1 DMARD, and extends the options available for this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8sBLEBbET5bVg90H21EOLACvtfcHk0lgBVB27jpcpNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosFCrs7k%253D&md5=df956988c6927dd96c7fe5e547919dd3</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0908-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0908-4%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DBaricitinib%253A%2520A%2520Review%2520in%2520Rheumatoid%2520Arthritis%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D761%26epage%3D772%26doi%3D10.1007%2Fs40265-018-0908-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">An Efficient Synthesis of Baricitinib</span>. <i>J. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.3184/174751916X14569294811333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.3184%2F174751916X14569294811333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVers77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=205-208&author=J.+Xuauthor=J.+Caiauthor=J.+Chenauthor=X.+Zongauthor=X.+Wuauthor=M.+Jiauthor=P.+Wang&title=An+Efficient+Synthesis+of+Baricitinib&doi=10.3184%2F174751916X14569294811333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of baricitinib</span></div><div class="casAuthors">Xu, Jiaojiao; Cai, Jin; Chen, Junding; Zong, Xi; Wu, Xuan; Ji, Min; Wang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-208</span>CODEN:
                <span class="NLM_cas:coden">JCROA4</span>;
        ISSN:<span class="NLM_cas:issn">1747-5198</span>.
    
            (<span class="NLM_cas:orgname">Science Reviews 2000 Ltd.</span>)
        </div><div class="casAbstract">A highly efficient method for the synthesis of baricitinib was developed.  The starting material tert-Bu 3-oxoazetidine-1-carboxylate was converted to intermediate 2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile via the Horner-Emmons reaction, deprotection of the N-Boc-group and a final sulfonamidation reaction.  Then the nucleophilic addn. reaction was carried out smoothly to afford the borate intermediate in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene under reflux.  Finally, the desired compd. baricitinib was obtained by the Suzuki coupling reaction of 4-chloro-7-H-pyrrolo[2,3-d]pyrimidine with the above borate intermediate.  All compds. were characterised by IR, MS, 1H NMR and 13C NMR.  The overall yield in this synthetic route was as high as 49%.  Moreover, this procedure was straightforward to carry out, had low cost and was suitable for industrial prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmrkAF79V4r7Vg90H21EOLACvtfcHk0lgBVB27jpcpNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVers77F&md5=1028a8f75d586f7c99e984d187128efb</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.3184%2F174751916X14569294811333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3184%252F174751916X14569294811333%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZong%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DAn%2520Efficient%2520Synthesis%2520of%2520Baricitinib%26jtitle%3DJ.%2520Chem.%2520Res.%26date%3D2016%26volume%3D40%26spage%3D205%26epage%3D208%26doi%3D10.3184%2F174751916X14569294811333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shajahan-Haq, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, S. M.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 Inhibitors in Breast Cancer Therapy: Current Practice and Future Opportunities</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2018.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.pharmthera.2018.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29933034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFynu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2018&pages=65-73&author=F.+Lynceauthor=A.+N.+Shajahan-Haqauthor=S.+M.+Swain&title=Cdk4%2F6+Inhibitors+in+Breast+Cancer+Therapy%3A+Current+Practice+and+Future+Opportunities&doi=10.1016%2Fj.pharmthera.2018.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities</span></div><div class="casAuthors">Lynce, Filipa; Shajahan-Haq, Ayesha N.; Swain, Sandra M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Dysregulation of the cyclin dependent kinase pathway in luminal breast cancer creates a new therapeutic opportunity for estrogen receptor pos. breast cancer.  Initial pan-CDK inhibitors were assocd. with extensive toxicities but in recent years, the development of potent specific CDK inhibitors with favorable tolerability has driven renewed interests in this class of targeted therapies.  Palbociclib, ribociclib and abemaciclib are specific CDK4/6 inhibitors that have been approved by the U.S.  Food and Drug Administration for use in combination with endocrine therapy for women with advanced hormone receptor pos. breast cancer.  These three anticancer therapeutics were approved based on progression free survival benefit seen on phase III trials with the most common grade 3 treatment-related side effects being neutropenia, fatigue, nausea and diarrhea.  Except for estrogen receptor positivity, no biomarkers predictive of response to CDK4/6 inhibitors have been identified to date.  Based on mechanistic insights here described, CDK4/6 inhibitors are currently being explored in combination with other agents, including targeted therapies, immunotherapy and chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB4puZfFByuLVg90H21EOLACvtfcHk0lhBJR97UsMBOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFynu7vN&md5=0f2e1c7c5577569da9066af98768dfb4</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DLynce%26aufirst%3DF.%26aulast%3DShajahan-Haq%26aufirst%3DA.%2BN.%26aulast%3DSwain%26aufirst%3DS.%2BM.%26atitle%3DCdk4%252F6%2520Inhibitors%2520in%2520Breast%2520Cancer%2520Therapy%253A%2520Current%2520Practice%2520and%2520Future%2520Opportunities%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D191%26spage%3D65%26epage%3D73%26doi%3D10.1016%2Fj.pharmthera.2018.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Effect of Abemaciclib (Ly2835219) on Enhancement of Chemotherapeutic Agents in Abcb1 and Abcg2 Overexpressing Cells in Vitro and in Vivo</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bcp.2016.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27816545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslyjsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=29-42&author=T.+Wuauthor=Z.+Chenauthor=K.+K.+W.+Toauthor=X.+Fangauthor=F.+Wangauthor=B.+Chengauthor=L.+Fu&title=Effect+of+Abemaciclib+%28Ly2835219%29+on+Enhancement+of+Chemotherapeutic+Agents+in+Abcb1+and+Abcg2+Overexpressing+Cells+in+Vitro+and+in+Vivo&doi=10.1016%2Fj.bcp.2016.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo</span></div><div class="casAuthors">Wu, Tong; Chen, Zhen; To, Kenneth K. W.; Fang, Xiaona; Wang, Fang; Cheng, Bin; Fu, Liwu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-42</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is the major obstacle of the success in cancer chemotherapy.  The overexpression of ATP-binding cassette (ABC) transporters, particularly ABCB1 and ABCG2, play a significant role in mediating MDR by pumping anticancer drugs out of cancer cells.  Abemaciclib (LY2835219) is an orally bioavailable CDK4/6 inhibitor under phase III clin. trials.  Here, we found that LY2835219 remarkably enhanced the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 over-expressing cancer cells in vitro and in vivo.  Furthermore, LY2835219 significantly increased the intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells.  Mechanistically, LY2835219 is likely a competitive inhibitor of ABCB1 and ABCG2 for its competition with [125I]-iodoarylazidoprazosin for photo affinity labeling of the transporters.  On the other hand, at the transporters-inhibiting concns., LY2835219 did not alter the expression level of ABCB1 and ABCG2, and the phosphorylation status of retinoblastoma (Rb) pathway in both parental and their resistant cells.  In conclusion, these findings revealed a novel role of LY2835219 in reversing ABCB1 or ABCG2-mediated MDR, which may be benefit to the patients with MDR cancer for combinational therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvdnLDHAGV7bVg90H21EOLACvtfcHk0lhBJR97UsMBOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslyjsbvL&md5=3d6bd83fe2e6ece8660278efafe75e4c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DEffect%2520of%2520Abemaciclib%2520%2528Ly2835219%2529%2520on%2520Enhancement%2520of%2520Chemotherapeutic%2520Agents%2520in%2520Abcb1%2520and%2520Abcg2%2520Overexpressing%2520Cells%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D124%26spage%3D29%26epage%3D42%26doi%3D10.1016%2Fj.bcp.2016.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sledge, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pivot, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdaeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grischke, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourayou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart-Cussac, A.</span></span> <span> </span><span class="NLM_article-title">Monarch 2: Abemaciclib in Combination with Fulvestrant in Women with Hr+/Her2– Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2884</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.73.7585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1200%2FJCO.2017.73.7585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28580882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVemtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2875-2884&author=G.+W.+Sledgeauthor=M.+Toiauthor=P.+Nevenauthor=J.+Sohnauthor=K.+Inoueauthor=X.+Pivotauthor=O.+Burdaevaauthor=M.+Okeraauthor=N.+Masudaauthor=P.+A.+Kaufmanauthor=H.+Kohauthor=E.-M.+Grischkeauthor=M.+Frenzelauthor=Y.+Linauthor=S.+Barrigaauthor=I.+C.+Smithauthor=N.+Bourayouauthor=A.+Llombart-Cussac&title=Monarch+2%3A+Abemaciclib+in+Combination+with+Fulvestrant+in+Women+with+Hr%2B%2FHer2%E2%80%93+Advanced+Breast+Cancer+Who+Had+Progressed+While+Receiving+Endocrine+Therapy&doi=10.1200%2FJCO.2017.73.7585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy</span></div><div class="casAuthors">Sledge, George W., Jr.; Toi, Masakazu; Neven, Patrick; Sohn, Joohyuk; Inoue, Kenichi; Pivot, Xavier; Burdaeva, Olga; Okera, Meena; Masuda, Norikazu; Kaufman, Peter A.; Koh, Han; Grischke, Eva-Maria; Frenzel, Martin; Lin, Yong; Barriga, Susana; Smith, Ian C.; Bourayou, Nawel; Llombart-Cussac, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2875-2884</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose MONARCH 2 compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC).  Patients and Methods MONARCH 2 was a global, double-blind, phase III study of women with hormone receptor-pos. and human epidermal growth factor receptor 2-neg. ABC who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), ≤ 12 mo from the end of adjuvant ET, or while receiving first-line ET for metastatic disease.  Patients were randomly assigned 2:1 to receive abemaciclib or placebo (150 mg twice daily) on a continuous schedule and fulvestrant (500 mg, per label).  The primary end point was investigator-assessed progression-free survival (PFS), and key secondary end points included overall survival, objective response rate (ORR), duration of response, clin. benefit rate, quality of life, and safety.  Results Between August 2014 and Dec. 2015, 669 patients were randomly assigned to receive abemaciclib plus fulvestrant (n = 446) or placebo plus fulvestrant (n = 223).  Abemaciclib plus fulvestrant significantly extended PFS vs. fulvestrant alone (median, 16.4 v 9.3 mo; hazard ratio, 0.553; 95% CI, 0.449 to 0.681; P < .001).  In patients with measurable disease, abemaciclib plus fulvestrant achieved an ORR of 48.1% (95% CI, 42.6% to 53.6%) compared with 21.3% (95% CI, 15.1% to 27.6%) in the control arm.  The most common adverse events in the abemaciclib vs. placebo arms were diarrhea (86.4% v 24.7%), neutropenia (46.0% v 4.0%), nausea (45.1% v 22.9%), and fatigue (39.9% v 26.9%).  Conclusions Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-pos. and human epidermal growth factor receptor 2-neg. ABC who progressed while receiving ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv8MbtQF40ArVg90H21EOLACvtfcHk0lhBJR97UsMBOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVemtrrO&md5=fd0fc00a4402aa089a88db1420ff9beb</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.73.7585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.73.7585%26sid%3Dliteratum%253Aachs%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DNeven%26aufirst%3DP.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DPivot%26aufirst%3DX.%26aulast%3DBurdaeva%26aufirst%3DO.%26aulast%3DOkera%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DKaufman%26aufirst%3DP.%2BA.%26aulast%3DKoh%26aufirst%3DH.%26aulast%3DGrischke%26aufirst%3DE.-M.%26aulast%3DFrenzel%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DBarriga%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DI.%2BC.%26aulast%3DBourayou%26aufirst%3DN.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26atitle%3DMonarch%25202%253A%2520Abemaciclib%2520in%2520Combination%2520with%2520Fulvestrant%2520in%2520Women%2520with%2520Hr%252B%252FHer2%25E2%2580%2593%2520Advanced%2520Breast%2520Cancer%2520Who%2520Had%2520Progressed%2520While%2520Receiving%2520Endocrine%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D2875%26epage%3D2884%26doi%3D10.1200%2FJCO.2017.73.7585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paluch-Shimon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huober, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trédan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnica Jaliffe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourayou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leo, A.</span></span> <span> </span><span class="NLM_article-title">Monarch 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3638</span>– <span class="NLM_lpage">3646</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.75.6155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1200%2FJCO.2017.75.6155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28968163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFemt7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=3638-3646&author=M.+P.+Goetzauthor=M.+Toiauthor=M.+Camponeauthor=J.+Sohnauthor=S.+Paluch-Shimonauthor=J.+Huoberauthor=I.+H.+Parkauthor=O.+Tr%C3%A9danauthor=S.-C.+Chenauthor=L.+Mansoauthor=O.+C.+Freedmanauthor=G.+Garnica+Jaliffeauthor=T.+Forresterauthor=M.+Frenzelauthor=S.+Barrigaauthor=I.+C.+Smithauthor=N.+Bourayouauthor=A.+Di+Leo&title=Monarch+3%3A+Abemaciclib+as+Initial+Therapy+for+Advanced+Breast+Cancer&doi=10.1200%2FJCO.2017.75.6155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88aR"><div class="casContent"><span class="casTitleNuber">88a</span><div class="casTitle"><span class="NLM_cas:atitle">MONARCH 3: abemaciclib as initial therapy for advanced breast cancer</span></div><div class="casAuthors">Goetz, Matthew P.; Toi, Masakazu; Campone, Mario; Sohn, Joohyuk; Paluch-Shimon, Shani; Huober, Jens; Park, In Hae; Tredan, Olivier; Chen, Shin-Cheh; Manso, Luis; Freedman, Orit C.; Jaliffe, Georgina Garnica; Forrester, Tammy; Frenzel, Martin; Barriga, Susana; Smith, Ian C.; Bourayou, Nawel; Di Leo, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3638-3650</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-pos., human epidermal growth factor receptor 2 (HER2)-neg. advanced breast cancer previously treated with endocrine therapy.  Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-pos., HER2-neg. advanced breast cancer who had no prior systemic therapy in the advanced setting.  Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily.  The primary objective was investigator-assessed progression-free survival.  Secondary objectives included response evaluation and safety.  A planned interim anal. occurred after 189 events.  Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 mo in the placebo arm).  In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm (P = .004).  In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%).  Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%).  Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-pos., HER2-neg. advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKzv683888t7Vg90H21EOLACvtfcHk0lh7L_kIsqVnrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFemt7vF&md5=5695eb9bb7bd522a6cc85ea0a970bf93</span></div><a href="/servlet/linkout?suffix=cit88a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.75.6155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.75.6155%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DM.%2BP.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DPaluch-Shimon%26aufirst%3DS.%26aulast%3DHuober%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DI.%2BH.%26aulast%3DTr%25C3%25A9dan%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DS.-C.%26aulast%3DManso%26aufirst%3DL.%26aulast%3DFreedman%26aufirst%3DO.%2BC.%26aulast%3DGarnica%2BJaliffe%26aufirst%3DG.%26aulast%3DForrester%26aufirst%3DT.%26aulast%3DFrenzel%26aufirst%3DM.%26aulast%3DBarriga%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DI.%2BC.%26aulast%3DBourayou%26aufirst%3DN.%26aulast%3DDi%2BLeo%26aufirst%3DA.%26atitle%3DMonarch%25203%253A%2520Abemaciclib%2520as%2520Initial%2520Therapy%2520for%2520Advanced%2520Breast%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D3638%26epage%3D3646%26doi%3D10.1200%2FJCO.2017.75.6155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit88b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Laderian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 Inhibition as a Therapeutic Strategy in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2018.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1053%2Fj.seminoncol.2018.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29935901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCns7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=395-403&author=B.+Laderianauthor=T.+Fojo&title=Cdk4%2F6+Inhibition+as+a+Therapeutic+Strategy+in+Breast+Cancer%3A+Palbociclib%2C+Ribociclib%2C+and+Abemaciclib&doi=10.1053%2Fj.seminoncol.2018.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88bR"><div class="casContent"><span class="casTitleNuber">88b</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 Inhibition as a Therapeutic Strategy in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib</span></div><div class="casAuthors">Laderian, Bahar; Fojo, Tito</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">395-403</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">With 40,920 American women expected to die from breast cancer in 2018 and global health ests. that more than 508,000 women died in 2011 from this disease, the identification of novel therapeutic strategies for the treatment of breast cancer cannot be ignored.  A breakthrough class of cancer drugs that has emerged in recent years and has had an impact in the treatment of breast cancer are the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, with palbociclib the first in class to have received regulatory approval for breast cancer.  In this article we will compare and contrast three CDK4/6 inhibitors - palbociclib, ribociclib and abemaciclib - that have received regulatory approval for the treatment of metastatic breast cancer.  Ribociclib and abemaciclib developed after the success of palbociclib represent examples of "me-too" therapies increasingly being deployed in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThrkaFQi4NbVg90H21EOLACvtfcHk0lh7L_kIsqVnrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCns7rK&md5=9e8dd8a2354559a98c90178c12fdffd8</span></div><a href="/servlet/linkout?suffix=cit88b&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2018.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2018.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DLaderian%26aufirst%3DB.%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DCdk4%252F6%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520in%2520Breast%2520Cancer%253A%2520Palbociclib%252C%2520Ribociclib%252C%2520and%2520Abemaciclib%26jtitle%3DSemin.%2520Oncol.%26date%3D2017%26volume%3D44%26spage%3D395%26epage%3D403%26doi%3D10.1053%2Fj.seminoncol.2018.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. M.</span></span> <span> </span><span class="NLM_article-title">Combination of Anti-Human Vegfr2 Antibody and Abemaciclib for Treatment of Non-Small Cell Lung Cancer</span>. <span class="NLM_patent">WO 2015130540A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=E.+M.+Chan&title=Combination+of+Anti-Human+Vegfr2+Antibody+and+Abemaciclib+for+Treatment+of+Non-Small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DE.%2BM.%26atitle%3DCombination%2520of%2520Anti-Human%2520Vegfr2%2520Antibody%2520and%2520Abemaciclib%2520for%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0852-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0852-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29209955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFekurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=139-145&author=A.+Markhamauthor=S.+Dhillon&title=Acalabrutinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0852-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139-145</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Acerta Pharma is developing the Bruton's tyrosine kinase inhibitor acalabrutinib (Calquence) for the treatment of various haematol. and solid malignancies.  The drug has received accelerated approval from the US FDA for the treatment of mantle cell lymphoma based on the results of a phase II study, and phase III trials in mantle cell lymphoma and chronic lymphocytic leukemia are currently underway.  This article summarizes the milestones in the development of acalabrutinib leading to this first approval for mantle cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOeUJyNBrnP7Vg90H21EOLACvtfcHk0lh7L_kIsqVnrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFekurvF&md5=95ac3e46917e6e1b248a1a1da537f562</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0852-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0852-8%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DAcalabrutinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D139%26epage%3D145%26doi%3D10.1007%2Fs40265-017-0852-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krejsa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coss, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urie, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisseberth, W. C.</span></span> <span> </span><span class="NLM_article-title">Preclinical Evaluation of the Novel Btk Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0159607</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0159607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1371%2Fjournal.pone.0159607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27434128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVeks7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0159607&author=B.+K.+Harringtonauthor=H.+L.+Gardnerauthor=R.+Izumiauthor=A.+Hamdyauthor=W.+Rothbaumauthor=K.+R.+Coombesauthor=T.+Coveyauthor=A.+Kapteinauthor=M.+Gulrajaniauthor=B.+Van+Lithauthor=C.+Krejsaauthor=C.+C.+Cossauthor=D.+S.+Russellauthor=X.+Zhangauthor=B.+K.+Urieauthor=C.+A.+Londonauthor=J.+C.+Byrdauthor=A.+J.+Johnsonauthor=W.+C.+Kisseberth&title=Preclinical+Evaluation+of+the+Novel+Btk+Inhibitor+Acalabrutinib+in+Canine+Models+of+B-Cell+Non-Hodgkin+Lymphoma&doi=10.1371%2Fjournal.pone.0159607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-hodgkin lymphoma</span></div><div class="casAuthors">Harrington, Bonnie K.; Gardner, Heather L.; Izumi, Raquel; Hamdy, Ahmed; Rothbaum, Wayne; Coombes, Kevin R.; Covey, Todd; Kaptein, Allard; Gulrajani, Michael; Van Lith, Bart; Krejsa, Cecile; Coss, Christopher C.; Russell, Duncan S.; Zhang, Xiaoli; Urie, Bridget K.; London, Cheryl A.; Byrd, John C.; Johnson, Amy J.; Kisseberth, William C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0159607/1-e0159607/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib.  In this study, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy similar to human diffuse large B-cell lymphoma (DLBCL).  First, we demonstrated that acalabrutinib potently inhibited BTK activity and downstream effectors in CLBL1, a canine B-cell lymphoma cell line, and primary canine lymphoma cells.  Acalabrutinib also inhibited proliferation in CLBL1 cells.  Twenty dogs were enrolled in the clin. trial and treated with acalabrutinib at dosages of 2.5 to 20mg/kg every 12 or 24 h.  Acalabrutinib was generally well tolerated, with adverse events consisting primarily of grade 1 or 2 anorexia, wt. loss, vomiting, diarrhea and lethargy.  Overall response rate (ORR) was 25% (5/20) with a median progression free survival (PFS) of 22.5 days.  Clin. benefit was obsd. in 30% (6/20) of dogs.  These findings suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1K06NtKvNrrVg90H21EOLACvtfcHk0lgcPMYS8670DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVeks7vN&md5=6079330778c6c90593af4d7c99aada96</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0159607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0159607%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DB.%2BK.%26aulast%3DGardner%26aufirst%3DH.%2BL.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3DVan%2BLith%26aufirst%3DB.%26aulast%3DKrejsa%26aufirst%3DC.%26aulast%3DCoss%26aufirst%3DC.%2BC.%26aulast%3DRussell%26aufirst%3DD.%2BS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DUrie%26aufirst%3DB.%2BK.%26aulast%3DLondon%26aufirst%3DC.%2BA.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DKisseberth%26aufirst%3DW.%2BC.%26atitle%3DPreclinical%2520Evaluation%2520of%2520the%2520Novel%2520Btk%2520Inhibitor%2520Acalabrutinib%2520in%2520Canine%2520Models%2520of%2520B-Cell%2520Non-Hodgkin%2520Lymphoma%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0159607%26doi%3D10.1371%2Fjournal.pone.0159607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. S.</span>; <span class="NLM_string-name">Kumar, K. M.</span></span> <span> </span><span class="NLM_article-title">Amorphous Form of Acalabrutinib and Solid Dispersion Thereof</span>. <span class="NLM_patent">IN 201641037734A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+S.+Reddy&author=K.+M.+Kumar&title=Amorphous+Form+of+Acalabrutinib+and+Solid+Dispersion+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DP.%2BS.%26atitle%3DAmorphous%2520Form%2520of%2520Acalabrutinib%2520and%2520Solid%2520Dispersion%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit92b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">MacPhee, J. M.</span>; <span class="NLM_string-name">Neuman, L. L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Bruton’s Tyrosine Kinase Inhibitors and Succinate Forms Thereof</span>. <span class="NLM_patent">WO 2018017153A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+M.+MacPhee&author=L.+L.+Neuman&title=Preparation+of+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors+and+Succinate+Forms+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMacPhee%26aufirst%3DJ.%2BM.%26atitle%3DPreparation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%2520and%2520Succinate%2520Forms%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit92c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of Gdc-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+Gdc-0853%3A+A+Potent%2C+Selective%2C+and+Noncovalent+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+in+Early+Clinical+Development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92cR"><div class="casContent"><span class="casTitleNuber">92c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0lgcPMYS8670DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit92c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520Gdc-0853%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Noncovalent%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520in%2520Early%2520Clinical%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit92d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Allenamide as a Bioisostere of Acrylamide in the Design and Synthesis of Targeted Covalent Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1039/C7MD00571G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2FC7MD00571G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=30108918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFGns7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=244-253&author=D.+Chenauthor=D.+Guoauthor=Z.+Yanauthor=Y.+Zhao&title=Allenamide+as+a+Bioisostere+of+Acrylamide+in+the+Design+and+Synthesis+of+Targeted+Covalent+Inhibitors&doi=10.1039%2FC7MD00571G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92dR"><div class="casContent"><span class="casTitleNuber">92d</span><div class="casTitle"><span class="NLM_cas:atitle">Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors</span></div><div class="casAuthors">Chen, Deheng; Guo, Dexiang; Yan, Ziqin; Zhao, Yujun</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">244-253</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The success of acrylamide-contg. drugs in treating cancers has spurred a passion to search for acrylamide bioisosteres.  In our endeavour, we have identified that an allenamide group can be a reactive bioisostere of the acrylamide group.  In our development of allenamide-contg. compds., we found that the most potent compd., 14, inhibited the kinase activities of both T790M/L858R double mutant and wild type EGFR in a low nM range. 14 also inhibited the growth of NCI-H1975 lung cancer cells at IC50 = 33 nM, which is comparable to that of acrylamide-contg. osimertinib.  The western blot anal. showed that the phosphorylation of EGFR, AKT, and ERK1/2 was simultaneously inhibited in a dose-dependent manner when NCI-H1975 cells were treated with 14.  By measuring the conjugate addn. product formed by 14 and GSH, we obtained a reaction rate const. of 302.5 × 10-3 min-1, which is about 30-fold higher than that of osimertinib.  Taken together, our data suggest that the allenamide-contg. compds. inhibited EGFR kinases through covalent modifications.  Our study indicates that the allenamide group could serve as an alternative electrophilic warhead in the design of targeted covalent inhibitors, and this bioisostere replacement may have broad applications in medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65_4aYFEww7Vg90H21EOLACvtfcHk0lhDFj-fU1Ugow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFGns7rO&md5=919f67c6ee52d1996f0e5ccdfbe77279</span></div><a href="/servlet/linkout?suffix=cit92d&amp;dbid=16384&amp;doi=10.1039%2FC7MD00571G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00571G%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DAllenamide%2520as%2520a%2520Bioisostere%2520of%2520Acrylamide%2520in%2520the%2520Design%2520and%2520Synthesis%2520of%2520Targeted%2520Covalent%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26spage%3D244%26epage%3D253%26doi%3D10.1039%2FC7MD00571G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit92e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span> <span> </span><span class="NLM_article-title">Novel Synthetic Drugs Currently in Clinical Development for Chronic Lymphocytic Leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1384814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F13543784.2017.1384814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28942659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SktLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=1249-1265&author=P.+Robakauthor=T.+Robak&title=Novel+Synthetic+Drugs+Currently+in+Clinical+Development+for+Chronic+Lymphocytic+Leukemia&doi=10.1080%2F13543784.2017.1384814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92eR"><div class="casContent"><span class="casTitleNuber">92e</span><div class="casTitle"><span class="NLM_cas:atitle">Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia</span></div><div class="casAuthors">Robak, Pawel; Robak, Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1249-1265</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Over the last few years, several new synthetic drugs, particularly Bruton's tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K) and BCL-2 inhibitors have been developed and investigated in chronic lymphocytic leukemia (CLL).  This review highlights key aspects of BTK, PI3K and BCL-2 inhibitors that are currently at various stages of preclin. and clin. development in CLL.  A literature review of the MEDLINE database for articles in English concerning CLL, B-cell receptor, BCL-2 antagonists, BTK inhibitors and PI3K inhibitors, was conducted via PubMed.  Publications from 2000 through July 2017 were scrutinized.  The search terms used were acalabrutinib, ACP-196, BGB-3111, ONO-4059, GS-4059, duvelisib, IPI-145, TGR-1202, copanlisib, Bay 80-6946, buparlisib, BKM-120, BCL-2 inhibitors, venetoclax, ABT-263, navitoclax, CDK inhibitors, alvocidib, flavopiridol, dinaciclib, SCH 727,965, palbociclib, PD-0332991, in conjunction with CLL.  Conference proceedings from the previous five years of the ASH and EHA Annual Scientific Meetings were searched manually.  Addnl. relevant publications were obtained by reviewing the refs. from the chosen articles.: The use of new synthetic drugs is a promising strategy for the treatment of CLL.  Data from ongoing and future clin. trials will aid in better defining the status of new drugs in the treatment of CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTqQ_iFwdrrLVg90H21EOLACvtfcHk0lhDFj-fU1Ugow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SktLfI&md5=5b9ffa5b1ec3aa7c8b1691a76796cc92</span></div><a href="/servlet/linkout?suffix=cit92e&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1384814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1384814%26sid%3Dliteratum%253Aachs%26aulast%3DRobak%26aufirst%3DP.%26aulast%3DRobak%26aufirst%3DT.%26atitle%3DNovel%2520Synthetic%2520Drugs%2520Currently%2520in%2520Clinical%2520Development%2520for%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D1249%26epage%3D1265%26doi%3D10.1080%2F13543784.2017.1384814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit92f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B.</span>; <span class="NLM_string-name">Rothbaum, W.</span>; <span class="NLM_string-name">Barf, T.</span>; <span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 7,9-Dihydro-8h-Purin-8-One Derivatives as Bruton’s Tyrosine Kinase (Btk) Inhibitors and Therapeutic Combinations of an Interleukin-1 Receptor-Assocd. Kinase 4 (Irak4) Inhibitor and a Btk Inhibitor</span>. <span class="NLM_patent">US 20170035881A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=B.+Lannutti&author=W.+Rothbaum&author=T.+Barf&author=A.+Kaptein&title=Preparation+of+7%2C9-Dihydro-8h-Purin-8-One+Derivatives+as+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+Inhibitors+and+Therapeutic+Combinations+of+an+Interleukin-1+Receptor-Assocd.+Kinase+4+%28Irak4%29+Inhibitor+and+a+Btk+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLannutti%26aufirst%3DB.%26atitle%3DPreparation%2520of%25207%252C9-Dihydro-8h-Purin-8-One%2520Derivatives%2520as%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520Inhibitors%2520and%2520Therapeutic%2520Combinations%2520of%2520an%2520Interleukin-1%2520Receptor-Assocd.%2520Kinase%25204%2520%2528Irak4%2529%2520Inhibitor%2520and%2520a%2520Btk%2520Inhibitor%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit92g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Krejsa, C. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazopyrazines as Btk Inhibitors for the Treatment of Diseases</span>. <span class="NLM_patent">US 20170224688A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+M.+Krejsa&title=Preparation+of+Imidazopyrazines+as+Btk+Inhibitors+for+the+Treatment+of+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKrejsa%26aufirst%3DC.%2BM.%26atitle%3DPreparation%2520of%2520Imidazopyrazines%2520as%2520Btk%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Diseases%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit92h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compositions, Optionally Containing Fluorinated Pyrazolopyrimidine Bruton’s Tyrosine Kinase Inhibitors, for Treatment of Cancer and Autoimmune Diseases</span>. <span class="NLM_patent">WO 2017218844A2</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=W.+He&title=Pharmaceutical+Compositions%2C+Optionally+Containing+Fluorinated+Pyrazolopyrimidine+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%2C+for+Treatment+of+Cancer+and+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DW.%26atitle%3DPharmaceutical%2520Compositions%252C%2520Optionally%2520Containing%2520Fluorinated%2520Pyrazolopyrimidine%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%252C%2520for%2520Treatment%2520of%2520Cancer%2520and%2520Autoimmune%2520Diseases%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit92i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Phosphoryl-Substituted Diphenylpyrimidines (Pho-Dppys) as Potent Bruton’s Tyrosine Kinase (Btk) Inhibitors: Targeted Treatment of B Lymphoblastic Leukemia Cell Lines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.11.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2016.11.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27956037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyjur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=765-772&author=Y.+Geauthor=H.+Yangauthor=C.+Wangauthor=Q.+Mengauthor=L.+Liauthor=H.+Sunauthor=Y.+Zhenauthor=K.+Liuauthor=Y.+Liauthor=X.+Ma&title=Design+and+Synthesis+of+Phosphoryl-Substituted+Diphenylpyrimidines+%28Pho-Dppys%29+as+Potent+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+Inhibitors%3A+Targeted+Treatment+of+B+Lymphoblastic+Leukemia+Cell+Lines&doi=10.1016%2Fj.bmc.2016.11.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92iR"><div class="casContent"><span class="casTitleNuber">92i</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines</span></div><div class="casAuthors">Ge, Yang; Yang, Haijun; Wang, Changyuan; Meng, Qiang; Li, Lei; Sun, Huijun; Zhen, Yuhong; Liu, Kexin; Li, Yanxia; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">765-772</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A family of phosphoryl-substituted diphenylpyrimidine derivs. (Pho-DPPYs) were synthesized and biol. evaluated as potent BTK inhibitors in this study.  Compd. 7b was found to markedly inhibit BTK activity at concns. of 0.82 nmol/L, as well as to suppress the proliferations of B-cell leukemia cell lines (Ramos and Raji) expressing high levels of BTK at concns. of 3.17 μM and 6.69 μM.  Moreover, flow cytometry anal. results further indicated that 7b promoted cell apoptosis to a substantial degree.  In a word, compd. 7b is a promising BTK inhibitor for the treatment of B-cell lymphoblastic leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtgST7kwZKzbVg90H21EOLACvtfcHk0lhDFj-fU1Ugow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyjur7I&md5=1be63c64ac8f2ac19f9a6bb4146a6b15</span></div><a href="/servlet/linkout?suffix=cit92i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.11.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.11.054%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Phosphoryl-Substituted%2520Diphenylpyrimidines%2520%2528Pho-Dppys%2529%2520as%2520Potent%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520Inhibitors%253A%2520Targeted%2520Treatment%2520of%2520B%2520Lymphoblastic%2520Leukemia%2520Cell%2520Lines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D765%26epage%3D772%26doi%3D10.1016%2Fj.bmc.2016.11.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit92j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T. A.</span>; <span class="NLM_string-name">Jans, C. G. J. M.</span>; <span class="NLM_string-name">De Man, A. P. A.</span>; <span class="NLM_string-name">Oubrie, A. A.</span>; <span class="NLM_string-name">Raaijmakers, H. C. A.</span>; <span class="NLM_string-name">Rewinkel, J. B. M.</span>; <span class="NLM_string-name">Sterrenburg, J.-G.</span>; <span class="NLM_string-name">Wijkmans, J. C. H. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazopyrazinylbenzamide Derivatives and Analogs for Use as Btk Inhibitors</span>. <span class="NLM_patent">WO 2013010868A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=T.+A.+Barf&author=C.+G.+J.+M.+Jans&author=A.+P.+A.+De+Man&author=A.+A.+Oubrie&author=H.+C.+A.+Raaijmakers&author=J.+B.+M.+Rewinkel&author=J.-G.+Sterrenburg&author=J.+C.+H.+M.+Wijkmans&title=Preparation+of+Imidazopyrazinylbenzamide+Derivatives+and+Analogs+for+Use+as+Btk+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%2BA.%26atitle%3DPreparation%2520of%2520Imidazopyrazinylbenzamide%2520Derivatives%2520and%2520Analogs%2520for%2520Use%2520as%2520Btk%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mo, G.</span>; <span class="NLM_string-name">Zha, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Btk Inhibitor Acalabrutinib</span>. <span class="NLM_patent">CN 107522701A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Mo&author=X.+Zha&title=Preparation+of+Btk+Inhibitor+Acalabrutinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Btk%2520Inhibitor%2520Acalabrutinib%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit93b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Acalabrutinib</span>. <span class="NLM_patent">CN 107056786A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=X.+Xu&title=Process+for+the+Preparation+of+Acalabrutinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Acalabrutinib%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, B.</span>; <span class="NLM_string-name">Berree, F.</span></span> <span> </span><span class="NLM_article-title">Reactions Involving a Carbonyl Compound as Electropholic Component. Third Component Boronic Acid (Petasis Reaction)</span>. In  <i>Science of Synthesis, Multicomponent Reactions</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span>, Ed.; <span class="NLM_publisher-name">Georg Thieme Verlag</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2014</span>; Vol.  <span class="NLM_volume">1</span>, pp  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">259</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=219-259&author=B.+Carboni&author=F.+Berreeauthor=T.+Mueller&title=Science+of+Synthesis%2C+Multicomponent+Reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCarboni%26aufirst%3DB.%26atitle%3DReactions%2520Involving%2520a%2520Carbonyl%2520Compound%2520as%2520Electropholic%2520Component.%2520Third%2520Component%2520Boronic%2520Acid%2520%2528Petasis%2520Reaction%2529%26btitle%3DScience%2520of%2520Synthesis%252C%2520Multicomponent%2520Reactions%26aulast%3DMueller%26aufirst%3DT.%26pub%3DGeorg%2520Thieme%2520Verlag%26date%3D2014%26volume%3D1%26spage%3D219%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit94b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrera, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T. R.</span></span> <span> </span><span class="NLM_article-title">The Petasis Borono-Mannich Multicomponent Reaction</span>. <i>ACS Symp. Ser.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1236</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1021/bk-2016-1236.ch009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1236.ch009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1236&publication_year=2016&pages=275-311&author=C.+A.+Guerreraauthor=T.+R.+Ryder&title=The+Petasis+Borono-Mannich+Multicomponent+Reaction&doi=10.1021%2Fbk-2016-1236.ch009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94bR"><div class="casContent"><span class="casTitleNuber">94b</span><div class="casTitle"><span class="NLM_cas:atitle">The Petasis borono-Mannich multicomponent reaction</span></div><div class="casAuthors">Guerrera, Cessandra A.; Ryder, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Symposium Series</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1236</span>
        (<span class="NLM_cas:issue">Boron Reagents in Synthesis</span>),
    <span class="NLM_cas:pages">275-311</span>CODEN:
                <span class="NLM_cas:coden">ACSMC8</span>;
        ISSN:<span class="NLM_cas:issn">0097-6156</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Petasis borono-Mannich reaction is a multicomponent process that involves the addn. of an organoboronic acid to an imine or iminium ion formed by the condensation of an aldehyde and amine.  The initial report provided by Petasis in 1993 has attracted significant attention from the synthetic community and a no. of advances have been reported since the topic was last reviewed.  Recent highlights include new catalysts and reaction conditions, asym. variants, diversity-oriented approaches, and applications to the synthesis of natural products and other biol.-relevant targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1RUy-KhptYbVg90H21EOLACvtfcHk0li4uuGfdXiBjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKmt7w%253D&md5=c8f9fd1ef77e880bc0624738bebff37f</span></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1236.ch009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbk-2016-1236.ch009%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrera%26aufirst%3DC.%2BA.%26aulast%3DRyder%26aufirst%3DT.%2BR.%26atitle%3DThe%2520Petasis%2520Borono-Mannich%2520Multicomponent%2520Reaction%26jtitle%3DACS%2520Symp.%2520Ser.%26date%3D2016%26volume%3D1236%26spage%3D275%26epage%3D311%26doi%3D10.1021%2Fbk-2016-1236.ch009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit94c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Minbiole, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minbiole, K. P. C.</span></span> <span> </span><span class="NLM_article-title">The Petasis-Ferrier Rearrangement: Developments and Applications</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1038/ja.2015.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1038%2Fja.2015.136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=26732258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=213-219&author=E.+C.+Minbioleauthor=K.+P.+C.+Minbiole&title=The+Petasis-Ferrier+Rearrangement%3A+Developments+and+Applications&doi=10.1038%2Fja.2015.136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94cR"><div class="casContent"><span class="casTitleNuber">94c</span><div class="casTitle"><span class="NLM_cas:atitle">The Petasis-Ferrier rearrangement: developments and applications</span></div><div class="casAuthors">Minbiole, Emily C.; Minbiole, Kevin P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-219</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the mid-1990s, Petasis reexamd. a promising but infrequently used rearrangement strategy, the so-called Ferrier-type-II reaction, and provided it with a modern update.  Previously, Ferrier had developed a strategy where carbohydrate derivs. would undergo a fragmentation/aldol-type recombination sequence, generating a carbocycle, albeit under the promotion of stoichiometric mercury salts.  Petasis' new variant showed the promise to effectively and stereoselectively convert a range of cyclic vinyl acetals to useful tetrahydrofurans and tetrahydropyrans, using less toxic promoters.  Since these 1st reports, the Petasis-Ferrier rearrangement has represented a vibrant area of research and innovation for org. chemists.  With numerous applications in complex natural product total synthesis, the utility of the reaction has been resoundingly established.  Recent developments have extended the reaction to a broader synthetic context, allowing for in situ generation of rearrangement substrates and more liberal interpretation of what fragmentation/recombination reactions warrant the designation of a Petasis-Ferrier rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooiAhfOZyc6LVg90H21EOLACvtfcHk0li4uuGfdXiBjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslWjs78%253D&md5=e1b212eac291ee08ac8fd8381b22deaf</span></div><a href="/servlet/linkout?suffix=cit94c&amp;dbid=16384&amp;doi=10.1038%2Fja.2015.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2015.136%26sid%3Dliteratum%253Aachs%26aulast%3DMinbiole%26aufirst%3DE.%2BC.%26aulast%3DMinbiole%26aufirst%3DK.%2BP.%2BC.%26atitle%3DThe%2520Petasis-Ferrier%2520Rearrangement%253A%2520Developments%2520and%2520Applications%26jtitle%3DJ.%2520Antibiot.%26date%3D2016%26volume%3D69%26spage%3D213%26epage%3D219%26doi%3D10.1038%2Fja.2015.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luxami, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, K.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Development of Imidazo[1,2-a]Pyrazines: Synthesis, Reactivity and Their Biological Applications</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3525</span>– <span class="NLM_lpage">3555</span>, <span class="refDoi"> DOI: 10.1039/C4OB01380H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2FC4OB01380H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=25563506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2itL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=3525-3555&author=R.+Goelauthor=V.+Luxamiauthor=K.+Paul&title=Recent+Advances+in+Development+of+Imidazo%5B1%2C2-a%5DPyrazines%3A+Synthesis%2C+Reactivity+and+Their+Biological+Applications&doi=10.1039%2FC4OB01380H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in development of imidazo[1,2-a]pyrazines: synthesis, reactivity and their biological applications</span></div><div class="casAuthors">Goel, Richa; Luxami, Vijay; Paul, Kamaldeep</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3525-3555</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Imidazo[1,2-a]pyrazine acts as a versatile scaffold in org. synthesis and drug development.  This review article is an effort to compile the progress made in synthetic methods and to illustrate its reactivity and multifarious biol. activity.  This review is mainly based on the pattern and position of the substitution, and should help the scientific community to bring about future developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6DitVcY1CjbVg90H21EOLACvtfcHk0lg8jxG-k-NT0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2itL7O&md5=181649e259a4bf2205e76b552dafbe95</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1039%2FC4OB01380H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB01380H%26sid%3Dliteratum%253Aachs%26aulast%3DGoel%26aufirst%3DR.%26aulast%3DLuxami%26aufirst%3DV.%26aulast%3DPaul%26aufirst%3DK.%26atitle%3DRecent%2520Advances%2520in%2520Development%2520of%2520Imidazo%255B1%252C2-a%255DPyrazines%253A%2520Synthesis%252C%2520Reactivity%2520and%2520Their%2520Biological%2520Applications%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2015%26volume%3D13%26spage%3D3525%26epage%3D3555%26doi%3D10.1039%2FC4OB01380H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coutant, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janin, Y. L.</span></span> <span> </span><span class="NLM_article-title">Synthetic Routes to Coelenterazine and Other Imidazo[1,2-a]Pyrazin-3-One Luciferins: Essential Tools for Bioluminescence-Based Investigations</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">17158</span>– <span class="NLM_lpage">17171</span>, <span class="refDoi"> DOI: 10.1002/chem.201501531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fchem.201501531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=26403487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGkt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=17158-17171&author=E.+P.+Coutantauthor=Y.+L.+Janin&title=Synthetic+Routes+to+Coelenterazine+and+Other+Imidazo%5B1%2C2-a%5DPyrazin-3-One+Luciferins%3A+Essential+Tools+for+Bioluminescence-Based+Investigations&doi=10.1002%2Fchem.201501531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Routes to Coelenterazine and Other Imidazo[1,2-a]pyrazin-3-one Luciferins: Essential Tools for Bioluminescence-Based Investigations</span></div><div class="casAuthors">Coutant, Eloi P.; Janin, Yves L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">17158-17171</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  In the last few decades, bioluminescent systems based on the expression of a luciferase and the addn. of a luciferin to monitor the emission of light have become very important tools for biol. investigations.  A growing proportion of these systems use coelenterazine or analogs of imidazo[1,2-a]pyrazine luciferins along with photoproteins or luciferases from sea creatures such as Aequorea, Renilla, Gaussia or Oplophorus.  Central to the success of these tools are the synthetic pathways developed not only to prep. the naturally occurring luciferins, but also to design altered compds. that exhibit improved bioluminescence.  Current work is indeed focused on the design of systems exhibiting extended luminescence ("glow" systems) or red shifted wavelengths, as well as constructions better adapted to conditions in cells or in vivo.  This review describes the synthetic pathways used to prep. imidazo[1,2-a]pyrazine luciferins along with the research efforts aimed at prepg. analogs even better suited to the design of assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpECFLZXVqAwbVg90H21EOLACvtfcHk0lg8jxG-k-NT0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGkt7jO&md5=0758320d77611c5f9d74cc393262cd06</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2Fchem.201501531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201501531%26sid%3Dliteratum%253Aachs%26aulast%3DCoutant%26aufirst%3DE.%2BP.%26aulast%3DJanin%26aufirst%3DY.%2BL.%26atitle%3DSynthetic%2520Routes%2520to%2520Coelenterazine%2520and%2520Other%2520Imidazo%255B1%252C2-a%255DPyrazin-3-One%2520Luciferins%253A%2520Essential%2520Tools%2520for%2520Bioluminescence-Based%2520Investigations%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2015%26volume%3D21%26spage%3D17158%26epage%3D17171%26doi%3D10.1002%2Fchem.201501531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97a"><span><span class="NLM_label">(a) </span> <i>Brigatinib</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, April 28, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555841.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555841.htm</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Brigatinib%3B+U.S.+Food+and+Drug+Administration%2C+April+28%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Finformationondrugs%2Fapproveddrugs%2Fucm555841.htm+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DBrigatinib%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit97b"><span><span class="NLM_label">(b) </span> <i>Takeda Announces FDA Accelerated Approval of ALUNBRIG
(Brigatinib)</i>; <span class="NLM_publisher-name">Takeda</span>, April
28, <span class="NLM_year">2017</span>; <a href="https://www.takeda.com/newsroom/newsreleases/2017/alunbrig-fda-approval/" class="extLink">https://www.takeda.com/newsroom/newsreleases/2017/alunbrig-fda-approval/</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Takeda+Announces+FDA+Accelerated+Approval+of+ALUNBRIG%0A%28Brigatinib%29%3B+Takeda%2C+April%0A28%2C+2017%3B+https%3A%2F%2Fwww.takeda.com%2Fnewsroom%2Fnewsreleases%2F2017%2Falunbrig-fda-approval%2F+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DTakeda%2520Announces%2520FDA%2520Accelerated%2520Approval%2520of%2520ALUNBRIG%250A%2528Brigatinib%2529%26pub%3DTakeda%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Brigatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1131</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0776-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0776-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28597393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1131-1135&author=A.+Markham&title=Brigatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0776-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98aR"><div class="casContent"><span class="casTitleNuber">98a</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1131-1135</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Brigatinib (ALUNBRIG) is a small mol. antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company).  In Apr. 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-pos. metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants.  This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmCYwTukZCLVg90H21EOLACvtfcHk0lg8jxG-k-NT0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL&md5=c03f9d61e8e8fd4187d47ee207452f31</span></div><a href="/servlet/linkout?suffix=cit98a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0776-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0776-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBrigatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1131%26epage%3D1135%26doi%3D10.1007%2Fs40265-017-0776-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit98b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Spotlight on Brigatinib and Its Potential in the Treatment of Patients with Metastatic Alk-Positive Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Crizotinib</span>. <i>Lung Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S126507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2147%2FLCTT.S126507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVGmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=169-177&author=R.+K.+Jainauthor=H.+Chen&title=Spotlight+on+Brigatinib+and+Its+Potential+in+the+Treatment+of+Patients+with+Metastatic+Alk-Positive+Non-Small+Cell+Lung+Cancer+Who+Are+Resistant+or+Intolerant+to+Crizotinib&doi=10.2147%2FLCTT.S126507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98bR"><div class="casContent"><span class="casTitleNuber">98b</span><div class="casTitle"><span class="NLM_cas:atitle">Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib</span></div><div class="casAuthors">Jain, Rohit K.; Chen, Hongbin</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">In the last decade, there have been major therapeutic advances in the management of patients with anaplastic lymphoma kinase (ALK)-pos. non-small cell lung cancer.  Crizotinib was the first approved ALK inhibitor with significant benefits over chemotherapy.  However, patients inevitably develop disease progression esp. in central nervous system and acquire resistance to crizotinib.  Several next-generation ALK inhibitors have been developed to overcome these resistance mechanisms and have demonstrated clin. benefits in crizotinib-refractory non-small cell lung cancer including in central nervous system.  Brigatinib is a second-generation ALK inhibitor with high level of activity against ALK and several other targets.  It is active in vitro against many ALK kinase domain mutations including L1196M, E1210K, and G1202R which may mediate acquired resistance to other ALK inhibitors.  In Phase I/II and ALTA clin. studies, brigatinib has demonstrated substantial and durable responses and intracranial responses after progression on crizotinib.  It has acceptable safety profile, but early pulmonary toxicity has been obsd. prompting to pursue daily dosing of 180 mg (with lead-in).  Overall, 180 mg (with lead-in) has showed consistently better efficacy than 90 mg.  In this review, we will discuss in detail these two pivotal trials that led to the accelerated approval for brigatinib and its future directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx1r4oGHTe9LVg90H21EOLACvtfcHk0ljuFnP5hkIU3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVGmtb0%253D&md5=05bffdfb5c05ca7cf4c50d717b6d9a4b</span></div><a href="/servlet/linkout?suffix=cit98b&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S126507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S126507%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DSpotlight%2520on%2520Brigatinib%2520and%2520Its%2520Potential%2520in%2520the%2520Treatment%2520of%2520Patients%2520with%2520Metastatic%2520Alk-Positive%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Who%2520Are%2520Resistant%2520or%2520Intolerant%2520to%2520Crizotinib%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D169%26epage%3D177%26doi%3D10.2147%2FLCTT.S126507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (Ap26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28Ap26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0ljuFnP5hkIU3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528Ap26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, W.-S.</span>; <span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Thomas, R. M.</span>; <span class="NLM_string-name">Qi, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Kohlmann, A.</span>; <span class="NLM_string-name">Dalgarno, D. C.</span>; <span class="NLM_string-name">Romero, J. A. C.</span>; <span class="NLM_string-name">Zou, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Phosphorus Derivatives as Kinase Inhibitors</span>. <span class="NLM_patent">WO 2009143389A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=Y.+Wang&author=W.-S.+Huang&author=S.+Liu&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=J.+Qi&author=F.+Li&author=X.+Zhu&author=A.+Kohlmann&author=D.+C.+Dalgarno&author=J.+A.+C.+Romero&author=D.+Zou&title=Preparation+of+Phosphorus+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Phosphorus%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit100b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, W.-S.</span>; <span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Thomas, R. M.</span>; <span class="NLM_string-name">Qi, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Kohlmann, A.</span>; <span class="NLM_string-name">Dalgarno, D. C.</span>; <span class="NLM_string-name">Romero, J. A. C.</span>; <span class="NLM_string-name">Zou, D.</span></span> <span> </span><span class="NLM_article-title">Phosphorus Derivatives as Kinase Inhibitors</span>. <span class="NLM_patent">US 20130225528A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Wang&author=W.-S.+Huang&author=S.+Liu&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=J.+Qi&author=F.+Li&author=X.+Zhu&author=A.+Kohlmann&author=D.+C.+Dalgarno&author=J.+A.+C.+Romero&author=D.+Zou&title=Phosphorus+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPhosphorus%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit100c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, W.-S.</span>; <span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Thomas, R. M.</span>; <span class="NLM_string-name">Qi, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Kohlmann, A.</span>; <span class="NLM_string-name">Dalgarno, D. C.</span>; <span class="NLM_string-name">Romero, J. A. C.</span>; <span class="NLM_string-name">Zou, D.</span></span> <span> </span><span class="NLM_article-title">Phosphorus Derivatives as Kinase Inhibitors</span>. <span class="NLM_patent">US20130225527A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Wang&author=W.-S.+Huang&author=S.+Liu&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=J.+Qi&author=F.+Li&author=X.+Zhu&author=A.+Kohlmann&author=D.+C.+Dalgarno&author=J.+A.+C.+Romero&author=D.+Zou&title=Phosphorus+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPhosphorus%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit100d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, W.-S.</span>; <span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Thomas, R. M.</span>; <span class="NLM_string-name">Qi, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Kohlmann, A.</span>; <span class="NLM_string-name">Dalgarno, D. C.</span>; <span class="NLM_string-name">Romero, J. A. C.</span>; <span class="NLM_string-name">Zou, D.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Phosphine Oxide Derivatives as Kinase Inhibitors</span>. <span class="NLM_patent">US 20140066406A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Y.+Wang&author=W.-S.+Huang&author=S.+Liu&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=J.+Qi&author=F.+Li&author=X.+Zhu&author=A.+Kohlmann&author=D.+C.+Dalgarno&author=J.+A.+C.+Romero&author=D.+Zou&title=Heterocyclic+Phosphine+Oxide+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DHeterocyclic%2520Phosphine%2520Oxide%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit100e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozamus, L. W.</span>; <span class="NLM_string-name">Sharma, P.</span></span> <span> </span><span class="NLM_article-title">Crystalline Forms of 5-Chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine</span>. <span class="NLM_patent">WO2016065028A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+W.+Rozamus&author=P.+Sharma&title=Crystalline+Forms+of+5-Chloro-N4-%5B-2-%28dimethylphosphoryl%29phenyl%5D-N2-%7B2-methoxy-4-%5B4-%284-methylpiperazin-1-yl%29piperidin-1-yl%5Dpyrimidine-2%2C4-diamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRozamus%26aufirst%3DL.%2BW.%26atitle%3DCrystalline%2520Forms%2520of%25205-Chloro-N4-%255B-2-%2528dimethylphosphoryl%2529phenyl%255D-N2-%257B2-methoxy-4-%255B4-%25284-methylpiperazin-1-yl%2529piperidin-1-yl%255Dpyrimidine-2%252C4-diamine%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit100f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Methods for Inhibiting Cell Proliferation in Alk Kinase-Driven Cancers</span>. <span class="NLM_patent">US 9611283B1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Zhang&author=W.+C.+Shakespeare&author=V.+M.+Rivera&title=Methods+for+Inhibiting+Cell+Proliferation+in+Alk+Kinase-Driven+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DMethods%2520for%2520Inhibiting%2520Cell%2520Proliferation%2520in%2520Alk%2520Kinase-Driven%2520Cancers%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokol, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockland, R. A.</span></span> <span> </span><span class="NLM_article-title">Development of a Room Temperature Hirao Reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2008.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.tetlet.2008.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWjurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=457-459&author=M.+C.+Kohlerauthor=J.+G.+Sokolauthor=R.+A.+Stockland&title=Development+of+a+Room+Temperature+Hirao+Reaction&doi=10.1016%2Fj.tetlet.2008.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101aR"><div class="casContent"><span class="casTitleNuber">101a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a room temperature Hirao reaction</span></div><div class="casAuthors">Kohler, Mark C.; Sokol, Joseph G.; Stockland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-459</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Arylphosphonates, RC6H4P(O)(OEt)2 (R = 4-MeO, 4-Me, H, 4-NC, 4-C(O)Me, 4-OH, 4-Cl, 2-OMe, 4-NH2), were prepd. at 25° through the Pd-catalyzed coupling of aryl iodides, RC6H4I, with a Ag phosphonate, Ag[P(O)(OEt)2].  A wide range of aryl iodides were successfully employed including phenolic substrates as well as those contg. an ortho substituent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-q-sAv9Fi0rVg90H21EOLACvtfcHk0lj7JZXBtNuGjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWjurfF&md5=cc4c5b74c0f3dff0173c82232dcf50e1</span></div><a href="/servlet/linkout?suffix=cit101a&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2008.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2008.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DKohler%26aufirst%3DM.%2BC.%26aulast%3DSokol%26aufirst%3DJ.%2BG.%26aulast%3DStockland%26aufirst%3DR.%2BA.%26atitle%3DDevelopment%2520of%2520a%2520Room%2520Temperature%2520Hirao%2520Reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2009%26volume%3D50%26spage%3D457%26epage%3D459%26doi%3D10.1016%2Fj.tetlet.2008.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit101b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Belabassi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzghari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montchamp, J.-L.</span></span> <span> </span><span class="NLM_article-title">Revisiting the Hirao Cross-Coupling: Improved Synthesis of Aryl and Heteroaryl Phosphonates</span>. <i>J. Organomet. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>693</i></span>,  <span class="NLM_fpage">3171</span>– <span class="NLM_lpage">3178</span>, <span class="refDoi"> DOI: 10.1016/j.jorganchem.2008.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.jorganchem.2008.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=19156189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVyitr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=693&publication_year=2008&pages=3171-3178&author=Y.+Belabassiauthor=S.+Alzghariauthor=J.-L.+Montchamp&title=Revisiting+the+Hirao+Cross-Coupling%3A+Improved+Synthesis+of+Aryl+and+Heteroaryl+Phosphonates&doi=10.1016%2Fj.jorganchem.2008.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101bR"><div class="casContent"><span class="casTitleNuber">101b</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the Hirao cross-coupling: improved synthesis of aryl and heteroaryl phosphonates</span></div><div class="casAuthors">Belabassi, Yamina; Alzghari, Saeed; Montchamp, Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organometallic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">693</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3171-3178</span>CODEN:
                <span class="NLM_cas:coden">JORCAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The palladium-catalyzed cross-coupling of dialkylphosphite with arom. electrophiles (Hirao coupling) was re-investigated.  Some limitations in terms of palladium loadings and substrate reactivity are alleviated with the use of Pd(OAc)2 complexed to 1,1'-bis(diphenylphosphino)ferrocene (dppf) as a ligand.  Various aryl and heteroaryl halides are employed to deliver both known and novel substituted phosphonates.  The first examples of aryl chloride couplings are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6-tauPpJxZLVg90H21EOLACvtfcHk0lj7JZXBtNuGjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVyitr%252FJ&md5=2bbad04465690dbd0c37a42458030e34</span></div><a href="/servlet/linkout?suffix=cit101b&amp;dbid=16384&amp;doi=10.1016%2Fj.jorganchem.2008.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jorganchem.2008.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DBelabassi%26aufirst%3DY.%26aulast%3DAlzghari%26aufirst%3DS.%26aulast%3DMontchamp%26aufirst%3DJ.-L.%26atitle%3DRevisiting%2520the%2520Hirao%2520Cross-Coupling%253A%2520Improved%2520Synthesis%2520of%2520Aryl%2520and%2520Heteroaryl%2520Phosphonates%26jtitle%3DJ.%2520Organomet.%2520Chem.%26date%3D2008%26volume%3D693%26spage%3D3171%26epage%3D3178%26doi%3D10.1016%2Fj.jorganchem.2008.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit101c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hirao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masunaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohshiro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agawa, T.</span></span> <span> </span><span class="NLM_article-title">A Novel Synthesis of Dialkyl Arenephosphonates</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>1981</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1055/s-1981-29335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-1981-29335" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1981&publication_year=1981&pages=56-57&author=T.+Hiraoauthor=T.+Masunagaauthor=Y.+Ohshiroauthor=T.+Agawa&title=A+Novel+Synthesis+of+Dialkyl+Arenephosphonates&doi=10.1055%2Fs-1981-29335"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101c&amp;dbid=16384&amp;doi=10.1055%2Fs-1981-29335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1981-29335%26sid%3Dliteratum%253Aachs%26aulast%3DHirao%26aufirst%3DT.%26aulast%3DMasunaga%26aufirst%3DT.%26aulast%3DOhshiro%26aufirst%3DY.%26aulast%3DAgawa%26aufirst%3DT.%26atitle%3DA%2520Novel%2520Synthesis%2520of%2520Dialkyl%2520Arenephosphonates%26jtitle%3DSynthesis%26date%3D1981%26volume%3D1981%26spage%3D56%26epage%3D57%26doi%3D10.1055%2Fs-1981-29335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span> <i>FDA approves new treatment for adults with relapsed
follicular lymphoma</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, September 14, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576129.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576129.htm</a> (accessed November 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+approves+new+treatment+for+adults+with+relapsed%0Afollicular+lymphoma%3B+U.S.+Food+and+Drug+Administration%2C+September+14%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm576129.htm+%28accessed+November+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520approves%2520new%2520treatment%2520for%2520adults%2520with%2520relapsed%250Afollicular%2520lymphoma%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Copanlisib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2057</span>– <span class="NLM_lpage">2062</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0838-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0838-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29127587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSrsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2057-2062&author=A.+Markham&title=Copanlisib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0838-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Copanlisib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2057-2062</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Bayer are developing copanlisib (Aliqopa)-a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor-as a treatment for various haematol. and solid malignancies.  The US FDA has granted copanlisib accelerated approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies based on the results of a phase II trial.  Phase III trials are underway evaluating copanlisib as treatment for relapsed/refractory diffuse large B-cell lymphoma and in combination with rituximab or rituximab-based chemotherapy or std. immunochemotherapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma.  Phase I/II studies are underway in relapsed or refractory peripheral T-cell or NK/T-cell lymphoma, advanced cholangiocarcinoma, hormone receptor-pos. HER2-neg. stage I-IV breast cancer, HER2-pos. breast cancer and recurrent and/or metastatic head and neck squamous cell carcinomas harbouring a PI3KCA mutation/amplification and/or a PTEN loss.  This article summarizes the milestones in the development of copanlisib leading to this first approval for relapsed follicular lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe7-lxckqIRrVg90H21EOLACvtfcHk0lgHF-LM2lukZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSrsLfM&md5=574036e843f127a1dc40edc568e639dc</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0838-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0838-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DCopanlisib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D2057%26epage%3D2062%26doi%3D10.1007%2Fs40265-017-0838-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. G.</span>; <span class="NLM_string-name">Rubenbauer, P.</span>; <span class="NLM_string-name">Goetz, D.</span>; <span class="NLM_string-name">Grossbach, D.</span>; <span class="NLM_string-name">Mais, F. J.</span>; <span class="NLM_string-name">Schirmer, H.</span>; <span class="NLM_string-name">Stiehl, J.</span>; <span class="NLM_string-name">Lovis, K.</span>; <span class="NLM_string-name">Lender, A.</span>; <span class="NLM_string-name">Seyfried, M.</span>; <span class="NLM_string-name">Zweifel, T.</span>; <span class="NLM_string-name">Marty, M.</span>; <span class="NLM_string-name">Weingartner, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Copanlisib and Its Dihydrochloride Salt</span>. <span class="NLM_patent">WO 2016071435A2</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+G.+Peters&author=P.+Rubenbauer&author=D.+Goetz&author=D.+Grossbach&author=F.+J.+Mais&author=H.+Schirmer&author=J.+Stiehl&author=K.+Lovis&author=A.+Lender&author=M.+Seyfried&author=T.+Zweifel&author=M.+Marty&author=G.+Weingartner&title=Synthesis+of+Copanlisib+and+Its+Dihydrochloride+Salt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BG.%26atitle%3DSynthesis%2520of%2520Copanlisib%2520and%2520Its%2520Dihydrochloride%2520Salt%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit104b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Copanlisib</span> <span class="NLM_patent">CN 105130997A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Q.+Xu&title=Preparation+Method+of+Copanlisib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26atitle%3DPreparation%2520Method%2520of%2520Copanlisib%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roboz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekeres, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willekens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span> <span> </span><span class="NLM_article-title">Enasidenib in Mutant-Idh2 Relapsed or Refractory Acute Myeloid Leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-04-779405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1182%2Fblood-2017-04-779405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28588020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVSku7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=722-731&author=E.+M.+Steinauthor=C.+D.+DiNardoauthor=D.+A.+Pollyeaauthor=A.+T.+Fathiauthor=G.+J.+Robozauthor=J.+K.+Altmanauthor=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=R.+L.+Levineauthor=I.+W.+Flinnauthor=H.+M.+Kantarjianauthor=R.+Collinsauthor=M.+R.+Patelauthor=A.+E.+Frankelauthor=A.+Steinauthor=M.+A.+Sekeresauthor=R.+T.+Swordsauthor=B.+C.+Medeirosauthor=C.+Willekensauthor=P.+Vyasauthor=A.+Tosoliniauthor=Q.+Xuauthor=R.+D.+Knightauthor=K.+E.+Yenauthor=S.+Agrestaauthor=S.+de+Bottonauthor=M.+S.+Tallman&title=Enasidenib+in+Mutant-Idh2+Relapsed+or+Refractory+Acute+Myeloid+Leukemia&doi=10.1182%2Fblood-2017-04-779405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia</span></div><div class="casAuthors">Stein, Eytan M.; Di Nardo, Courtney D.; Pollyea, Daniel A.; Fathi, Amir T.; Roboz, Gail J.; Altman, Jessica K.; Stone, Richard M.; DeAngelo, Daniel J.; Levine, Ross L.; Flinn, Ian W.; Kantarjian, Hagop M.; Collins, Robert; Patel, Manish R.; Frankel, Arthur E.; Stein, Anthony; Sekeres, Mikkael A.; Swords, Ronan T.; Medeiros, Bruno C.; Willekens, Christophe; Vyas, Paresh; Tosolini, Alessandra; Xu, Qiang; Knight, Robert D.; Yen, Katharine E.; Agresta, Sam; de Botton, Stephane; Tallman, Martin S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-731</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML).  Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, leading to blocked cellular differentiation.  Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes.  This first-in-human, phase 1/2 study assessed the max. tolerated dose (MTD), pharmacokinetic and pharmacodynamic profiles, safety, and clin. activity of enasidenib in patients with mutant-IDH2 advanced myeloid malignancies.  We assessed safety outcomes for all patients (N=239) and clin. efficacy in the largest patient subgroup, those with relapsed or refractory AML (n=176), from the phase 1 dose-escalation and expansion phases of the study.  In the dose-escalation phase, an MTD was not reached at doses ranging from 50-650 mg daily.  Enasidenib 100 mg daily was selected for the expansion phase based on pharmacokinetic and pharmacodynamic profiles and demonstrated efficacy.  Grade 3-4 enasidenib-related adverse events included indirect hyperbilirubinemia (12%) and IDH-inhibitor-assocd. differentiation syndrome (IDH-DS; 7%).  Among patients with relapsed or refractory AML, overall response rate was 40.3%, with median response duration of 5.8 mo.  Responses were assocd. with cellular differentiation and maturation, typically without evidence of aplasia.  Median overall survival among relapsed/refractory patients was 9.3 mo, and for the 34 patients (19.3%) who attained complete remission was 19.7 mo.  Continuous daily enasidenib treatment was generally well-tolerated and induced hematol. responses in patients who had failed prior AML therapy.  Inducing differentiation of myeloblasts, not cytotoxicity, appears to drive the clin. efficacy of enasidenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm3133YTlQYrVg90H21EOLACvtfcHk0lgHF-LM2lukZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVSku7zP&md5=d934df7adacad5b02adddfdce812f225</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-04-779405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-04-779405%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3DDiNardo%26aufirst%3DC.%2BD.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFrankel%26aufirst%3DA.%2BE.%26aulast%3DStein%26aufirst%3DA.%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DWillekens%26aufirst%3DC.%26aulast%3DVyas%26aufirst%3DP.%26aulast%3DTosolini%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKnight%26aufirst%3DR.%2BD.%26aulast%3DYen%26aufirst%3DK.%2BE.%26aulast%3DAgresta%26aufirst%3DS.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26atitle%3DEnasidenib%2520in%2520Mutant-Idh2%2520Relapsed%2520or%2520Refractory%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D722%26epage%3D731%26doi%3D10.1182%2Fblood-2017-04-779405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coller, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedvat, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">The Common Feature of Leukemia-Associated Idh1 and Idh2Mutations Is a Neomorphic Enzyme Activity Converting Alpha-Ketoglutarate to 2-Hydroxyglutarate</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2010.01.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.ccr.2010.01.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=20171147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVWqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=225-234&author=P.+S.+Wardauthor=J.+Patelauthor=D.+R.+Wiseauthor=O.+Abdel-Wahabauthor=B.+D.+Bennettauthor=H.+A.+Collerauthor=J.+R.+Crossauthor=V.+R.+Fantinauthor=C.+V.+Hedvatauthor=A.+E.+Perlauthor=J.+D.+Rabinowitzauthor=M.+Carrollauthor=S.+M.+Suauthor=K.+A.+Sharpauthor=R.+L.+Levineauthor=C.+B.+Thompson&title=The+Common+Feature+of+Leukemia-Associated+Idh1+and+Idh2Mutations+Is+a+Neomorphic+Enzyme+Activity+Converting+Alpha-Ketoglutarate+to+2-Hydroxyglutarate&doi=10.1016%2Fj.ccr.2010.01.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate</span></div><div class="casAuthors">Ward, Patrick S.; Patel, Jay; Wise, David R.; Abdel-Wahab, Omar; Bennett, Bryson D.; Coller, Hilary A.; Cross, Justin R.; Fantin, Valeria R.; Hedvat, Cyrus V.; Perl, Alexander E.; Rabinowitz, Joshua D.; Carroll, Martin; Su, Shinsan M.; Sharp, Kim A.; Levine, Ross L.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-234</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The somatic mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) obsd. in gliomas can lead to the prodn. of 2-hydroxyglutarate (2HG).  Here, the authors report that tumor 2HG is elevated in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML).  Surprisingly, less than half of cases with elevated 2HG possessed IDH1 mutations.  The remaining cases with elevated 2HG had mutations in IDH2, the mitochondrial homolog of IDH1.  These data demonstrate that a shared feature of all cancer-assocd. IDH mutations is prodn. of the oncometabolite 2HG.  Furthermore, AML patients with IDH mutations display a significantly reduced no. of other well characterized AML-assocd. mutations and/or assocd. chromosomal abnormalities, potentially implicating IDH mutation in a distinct mechanism of AML pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppKH_IGRymibVg90H21EOLACvtfcHk0lgG4e7kLgdvxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVWqtLg%253D&md5=cf235f63ccd050ff3b121b94d3c49b9e</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.01.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.01.020%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DP.%2BS.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DWise%26aufirst%3DD.%2BR.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DBennett%26aufirst%3DB.%2BD.%26aulast%3DColler%26aufirst%3DH.%2BA.%26aulast%3DCross%26aufirst%3DJ.%2BR.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DHedvat%26aufirst%3DC.%2BV.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DS.%2BM.%26aulast%3DSharp%26aufirst%3DK.%2BA.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DThe%2520Common%2520Feature%2520of%2520Leukemia-Associated%2520Idh1%2520and%2520Idh2Mutations%2520Is%2520a%2520Neomorphic%2520Enzyme%2520Activity%2520Converting%2520Alpha-Ketoglutarate%2520to%25202-Hydroxyglutarate%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26spage%3D225%26epage%3D234%26doi%3D10.1016%2Fj.ccr.2010.01.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D.</span></span> <span> </span><span class="NLM_article-title">Enasidenib for the Treatment of Acute Myeloid Leukemia</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1080/17512433.2018.1477585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F17512433.2018.1477585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29770715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=755-760&author=J.+Duganauthor=D.+Pollyea&title=Enasidenib+for+the+Treatment+of+Acute+Myeloid+Leukemia&doi=10.1080%2F17512433.2018.1477585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Enasidenib for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Dugan, James; Pollyea, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">755-760</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: In August 2017, the United States Federal Drug Administration (FDA) approved enasidenib (Idhifa, Celgene/Agios) for adults with relapsed and refractory acute myelogenous leukemia (AML) with an IDH2 mutation.  Enasidenib targets cells with mutant copies of isocitrate dehydrogenase-2 (IDH2), inhibiting the oncometabolite 2-hydroxyglutarte (2-HG) formed by the mutant IDH2.: We review the studies leading to enasidenib's approval, as well as common side effects and safety issues experienced during the clin. trials.  There is a focus on the diagnosis and treatment of these side effects including differentiation syndrome.: We are experiencing a revolution in the understanding of the mechanism of AML.  A majority of the effort has been concd. on targeting gene mutations or pathway activations with precision therapeutics.  Enasidenib is beneficial in a patient population that previously had limited treatment options.  However, given the fact that enasidenib is a highly specific inhibitor of an early stable mutation, it is questionable whether a strategy of targeting a single mutation or pathway in relapsed AML will allow for better than the 20% complete remission (CR) rate obsd. with this therapy.  The proper role for single mutation targeting in AML needs to be carefully considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLh57HTR0seLVg90H21EOLACvtfcHk0lgG4e7kLgdvxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOrtLjI&md5=486b1abaa403ecc4b50b29516b06e3be</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1080%2F17512433.2018.1477585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17512433.2018.1477585%26sid%3Dliteratum%253Aachs%26aulast%3DDugan%26aufirst%3DJ.%26aulast%3DPollyea%26aufirst%3DD.%26atitle%3DEnasidenib%2520for%2520the%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D11%26spage%3D755%26epage%3D760%26doi%3D10.1080%2F17512433.2018.1477585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S. V.</span>; <span class="NLM_string-name">Gu, C.-H.</span>; <span class="NLM_string-name">Schenkein, D.</span>; <span class="NLM_string-name">Yang, H.</span>; <span class="NLM_string-name">Guo, L.</span>; <span class="NLM_string-name">Tang, Z.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Zhou, Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutically Active Compounds and Their Methods of Use</span>. <span class="NLM_patent">WO 2015017821A2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+V.+Agresta&author=C.-H.+Gu&author=D.+Schenkein&author=H.+Yang&author=L.+Guo&author=Z.+Tang&author=J.+Wang&author=Y.+Zhang&author=Y.+Zhou&title=Therapeutically+Active+Compounds+and+Their+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAgresta%26aufirst%3DS.%2BV.%26atitle%3DTherapeutically%2520Active%2520Compounds%2520and%2520Their%2520Methods%2520of%2520Use%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelljes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liedtke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goekbuget, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paccagnella, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandendries, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in Ino-Vate</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1722</span>– <span class="NLM_lpage">1732</span>, <span class="refDoi"> DOI: 10.1002/cncr.31249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fcncr.31249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29381191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1alsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=1722-1732&author=E.+J.+Jabbourauthor=D.+J.+DeAngeloauthor=M.+Stelljesauthor=W.+Stockauthor=M.+Liedtkeauthor=N.+Goekbugetauthor=S.+O%E2%80%99Brienauthor=T.+Wangauthor=M.+L.+Paccagnellaauthor=B.+Sleightauthor=E.+Vandendriesauthor=A.+S.+Advaniauthor=H.+M.+Kantarjian&title=Efficacy+and+Safety+Analysis+by+Age+Cohort+of+Inotuzumab+Ozogamicin+in+Patients+with+Relapsed+or+Refractory+Acute+Lymphoblastic+Leukemia+Enrolled+in+Ino-Vate&doi=10.1002%2Fcncr.31249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109aR"><div class="casContent"><span class="casTitleNuber">109a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE</span></div><div class="casAuthors">Jabbour, Elias J.; De Angelo, Daniel J.; Stelljes, Matthias; Stock, Wendy; Liedtke, Michaela; Goekbuget, Nicola; O'Brien, Susan; Wang, Tao; Paccagnella, M. Luisa; Sleight, Barbara; Vandendries, Erik; Advani, Anjali S.; Kantarjian, Hagop M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1722-1732</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial.  This subset anal. compared the efficacy and safety of InO in younger and older patients.  METHODS : Intent-to-treat analyses of morphol. responses and overall survival (OS) included 326 randomized patients, and safety assessments included 307 patients receiving 1 or more doses of the study treatment.  Of the 326 patients, 164 received InO at a starting dose of 1.8 mg/m2/cycle (0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15 of a 21- to 28-day cycle [≤6 cycles]); 60 patients were aged ≥55 years, and 104 were aged <55 years.  RESULTS : For older and younger patients, the median duration of InO therapy and the types and frequencies of adverse events of any grade were generally similar.  Although the remission rates, median duration of remission (DOR), and progression-free survival were similar with InO for those aged <55 years and those aged ≥55 years, OS was longer for younger patients (median, 8.6 vs 5.6 mo; hazard ratio, 0.610).  Among patients proceeding to hematopoietic stem cell transplantation after InO treatment (28% of older patients and 58% of younger patients), the incidence of veno-occlusive disease was greater in older patients (41% vs 17%).  The study database was not locked at the time of this anal.  CONCLUSIONS : InO was tolerable in older patients with relapsed/refractory ALL.  Although OS was longer for younger patients vs. older patients, InO demonstrated high response rates with similar DOR in the 2 age groups.  Cancer 2018;124:1722-32. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE9hrrEo-qSbVg90H21EOLACvtfcHk0lichgtJqCsOXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1alsL8%253D&md5=738bafcce6dcbc0515176c650264ba40</span></div><a href="/servlet/linkout?suffix=cit109a&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31249%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%2BJ.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStelljes%26aufirst%3DM.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DLiedtke%26aufirst%3DM.%26aulast%3DGoekbuget%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DPaccagnella%26aufirst%3DM.%2BL.%26aulast%3DSleight%26aufirst%3DB.%26aulast%3DVandendries%26aufirst%3DE.%26aulast%3DAdvani%26aufirst%3DA.%2BS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DEfficacy%2520and%2520Safety%2520Analysis%2520by%2520Age%2520Cohort%2520of%2520Inotuzumab%2520Ozogamicin%2520in%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Acute%2520Lymphoblastic%2520Leukemia%2520Enrolled%2520in%2520Ino-Vate%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26spage%3D1722%26epage%3D1732%26doi%3D10.1002%2Fcncr.31249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit109b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharyya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelleri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, D. I.</span></span> <span> </span><span class="NLM_article-title">Patient-Reported Outcomes from a Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2151</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi"> DOI: 10.1002/cncr.31317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fcncr.31317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29508899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1ajtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=2151-2160&author=H.+M.+Kantarjianauthor=Y.+Suauthor=E.+J.+Jabbourauthor=H.+Bhattacharyyaauthor=E.+Yanauthor=J.+C.+Cappelleriauthor=D.+I.+Marks&title=Patient-Reported+Outcomes+from+a+Phase+3+Randomized+Controlled+Trial+of+Inotuzumab+Ozogamicin+Versus+Standard+Therapy+for+Relapsed%2FRefractory+Acute+Lymphoblastic+Leukemia&doi=10.1002%2Fcncr.31317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109bR"><div class="casContent"><span class="casTitleNuber">109b</span><div class="casTitle"><span class="NLM_cas:atitle">Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia</span></div><div class="casAuthors">Kantarjian, Hagop M.; Su, Yun; Jabbour, Elias J.; Bhattacharyya, Helen; Yan, Eric; Cappelleri, Joseph C.; Marks, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2151-2160</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Inotuzumab ozogamicin (InO), an anti-CD22 antibody-calicheamicin conjugate, demonstrated superior clin. activity vs. std.-of-care (SOC) chemotherapies for relapsed/refractory B-cell acute lymphoblastic leukemia in the phase 3 randomized controlled INO-VATE trial.  The authors assessed patient-reported outcomes (PROs) from that study.  METHODS : Patients were randomized to receive either InO (1.8 mg/m2 per cycle for ≤6 cycles) or SOC (fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor, or ara-C plus mitoxantrone, or high-dose ara-C for ≤4 cycles) and completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the EuroQoL 5 Dimensions Questionnaires at baseline, on day 1 of each cycle, and at the end of treatment.  Treatment differences in PROs were assessed using longitudinal mixed-effects models with random intercepts and slopes.  RESULTS : Questionnaire completion rates in the InO (n = 164) and SOC (n = 162) arms were 85% and 65%, resp.  Baseline scores were similar between arms.  Patients who received InO reported better quality of life (QoL), functioning, and symptom scores (except for constipation and emotional functioning).  Least-squares mean (95% confidence interval [CI]) differences in phys., role, and social functioning and in appetite loss were significant (6.9 [95% CI, 1.4-12.3], 11.4 [95% CI, 3.2-19.5], 8.4 [95% CI, 0.7-16.1], and -8.7 [95% CI, -16.0 to -1.4], resp.; all P < .05) and had exceeded the minimally important difference of 5.  Mean treatment differences in favor of InO on the EuroQoL visual analog scale and the global health status/QoL, dyspnea, and fatigue scales reached or approached the minimally important difference of 5, although without statistical significance.  No dimensions were significantly worse with InO vs. SOC.  CONCLUSIONS : The current PRO data support the favorable benefit/risk ratio of InO for the treatment of relapsed/refractory acute lymphoblastic leukemia, with superior clin. efficacy and better QoL.  Cancer 2018;124:2151-60. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ1yd320kS2LVg90H21EOLACvtfcHk0lichgtJqCsOXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1ajtLo%253D&md5=4501ab64fb0a9d9a7df87516b7222677</span></div><a href="/servlet/linkout?suffix=cit109b&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31317%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DJabbour%26aufirst%3DE.%2BJ.%26aulast%3DBhattacharyya%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DE.%26aulast%3DCappelleri%26aufirst%3DJ.%2BC.%26aulast%3DMarks%26aufirst%3DD.%2BI.%26atitle%3DPatient-Reported%2520Outcomes%2520from%2520a%2520Phase%25203%2520Randomized%2520Controlled%2520Trial%2520of%2520Inotuzumab%2520Ozogamicin%2520Versus%2520Standard%2520Therapy%2520for%2520Relapsed%252FRefractory%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26spage%3D2151%26epage%3D2160%26doi%3D10.1002%2Fcncr.31317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiJoseph, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armellino, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boghaert, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridharan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorovits, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udata, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popplewell, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damle, N. K.</span></span> <span> </span><span class="NLM_article-title">Antibody-Targeted Chemotherapy with Cmc-544: A Cd22-Targeted Immunoconjugate of Calicheamicin for the Treatment of B-Lymphoid Malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1814</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-07-2466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1182%2Fblood-2003-07-2466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=14615373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVOhsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=1807-1814&author=J.+F.+DiJosephauthor=D.+C.+Armellinoauthor=E.+R.+Boghaertauthor=K.+Khandkeauthor=M.+M.+Dougherauthor=L.+Sridharanauthor=A.+Kunzauthor=P.+R.+Hamannauthor=B.+Gorovitsauthor=C.+Udataauthor=J.+K.+Moranauthor=A.+G.+Popplewellauthor=S.+Stephensauthor=P.+Frostauthor=N.+K.+Damle&title=Antibody-Targeted+Chemotherapy+with+Cmc-544%3A+A+Cd22-Targeted+Immunoconjugate+of+Calicheamicin+for+the+Treatment+of+B-Lymphoid+Malignancies&doi=10.1182%2Fblood-2003-07-2466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies</span></div><div class="casAuthors">DiJoseph, John F.; Armellino, Douglas C.; Boghaert, Erwin R.; Khandke, Kiran; Dougher, Maureen M.; Sridharan, Latha; Kunz, Arthur; Hamann, Philip R.; Gorovits, Boris; Udata, Chandrasekhar; Moran, Justin K.; Popplewell, Andrew G.; Stephens, Sue; Frost, Philip; Damle, Nitin K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1807-1814</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-γ-calicheamicin di-Me hydrazide [CalichDMH], a potent DNA-binding cytotoxic antitumor antibiotic) is a clin. validated therapeutic option for patients with acute myeloid leukemia (AML).  Here, we describe the preclin. profile of another immunoconjugate of CalichDMH, CMC-544, targeted to CD22 expressed by B-lymphoid malignancies.  CMC-544 comprises a humanized IgG4 anti-CD22 monoclonal antibody (mAb), G5/44, covalently linked to CalichDMH via an acid-labile 4-(4'-acetylphenoxy) butanoic acid (AcBut) linker.  Both CMC-544 and unconjugated G5/44 bound human CD22 with subnanomolar affinity.  CMC-544, but not unconjugated G5/44, exerted potent cytotoxicity against CD22+ B-cell lymphoma (BCL) cell lines (inhibitory concn. of 50%: 6-600 pM CalichDMH).  CMC-544 caused a potent inhibition of growth of small but established BCL xenografts leading to cures (therapeutic index > 10).  CMC-544 prevented the establishment of BCL xenografts and also caused regression of large BCLs (> 1.5 g tumor mass).  In contrast, unconjugated CalichDMH, unconjugated G5/44, and an isotype-matched control conjugate, CMA-676, were ineffective against these BCL xenografts.  Thus, CD22-targeted delivery of CalichDMH is a potent and effective preclin. therapeutic strategy for BCLs.  The strong antitumor profile of CMC-544 supports its clin. evaluation as a treatment option for B-lymphoid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxrcsoc82Fm7Vg90H21EOLACvtfcHk0lichgtJqCsOXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVOhsbc%253D&md5=0c225d0ce3e69b7c0dcfc21788cdc8a0</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-07-2466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-07-2466%26sid%3Dliteratum%253Aachs%26aulast%3DDiJoseph%26aufirst%3DJ.%2BF.%26aulast%3DArmellino%26aufirst%3DD.%2BC.%26aulast%3DBoghaert%26aufirst%3DE.%2BR.%26aulast%3DKhandke%26aufirst%3DK.%26aulast%3DDougher%26aufirst%3DM.%2BM.%26aulast%3DSridharan%26aufirst%3DL.%26aulast%3DKunz%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DGorovits%26aufirst%3DB.%26aulast%3DUdata%26aufirst%3DC.%26aulast%3DMoran%26aufirst%3DJ.%2BK.%26aulast%3DPopplewell%26aufirst%3DA.%2BG.%26aulast%3DStephens%26aufirst%3DS.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DDamle%26aufirst%3DN.%2BK.%26atitle%3DAntibody-Targeted%2520Chemotherapy%2520with%2520Cmc-544%253A%2520A%2520Cd22-Targeted%2520Immunoconjugate%2520of%2520Calicheamicin%2520for%2520the%2520Treatment%2520of%2520B-Lymphoid%2520Malignancies%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D1807%26epage%3D1814%26doi%3D10.1182%2Fblood-2003-07-2466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hinman, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durr, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span> <span> </span><span class="NLM_article-title">Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibiotics</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3336</span>– <span class="NLM_lpage">3342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=8324745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK3sXlvFGisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=3336-3342&author=L.+M.+Hinmanauthor=P.+R.+Hamannauthor=R.+Wallaceauthor=A.+T.+Menendezauthor=F.+E.+Durrauthor=J.+Upeslacis&title=Preparation+and+Characterization+of+Monoclonal+Antibody+Conjugates+of+the+Calicheamicins%3A+A+Novel+and+Potent+Family+of+Antitumor+Antibiotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111aR"><div class="casContent"><span class="casTitleNuber">111a</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics</span></div><div class="casAuthors">Hinman, Lois M.; Hamann, Philip R.; Wallace, Roslyn; Menendez, Ana T.; Durr, Frederick E.; Upeslacis, Janis</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3336-42</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The calicheamicin family of antitumor antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concns.  Their potency suggested that the calicheamicins would be excellent candidates for targeted delivery and a hydrazide prepd. from the most potent and abundant of the naturally occurring deriv., γ1I, was linked to oxidized sugars on CT-M-01, an internalizing anti-polyepithelial mucin antibody.  The conjugates retained the immunoreactivity of the unmodified antibody and were specifically cytotoxic toward antigen pos. tumor cells in vitro and in vivo.  Hydrazide analogs of less potent calicheamicin derivs. were also prepd. and conjugated to CT-M-01.  Comparison of the therapeutic efficacy of the conjugates against the MX-1 xenograft tumor implanted s.c. in nude mice showed that conjugates of derivs. missing the rhamnose, a sugar residue that is part of the DNA binding region of the drug, were not as promising as antitumor therapies.  However, conjugates of two derivs., α3I and N-acetyl-γ1I, in which the rhamnose residue is present but the amino sugar residue of the parent drug is either missing or modified, significantly inhibited tumor growth over a 4-fold dose range and produced long-term tumor-free survivors.  Sterically hindering Me groups adjacent to the disulfide in the linker further increased the therapeutic window of these potent conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Ey58uwD7ULVg90H21EOLACvtfcHk0lgcSKdH5Xtw8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvFGisLw%253D&md5=fcafd796345946fa29a62e3f12de3b7e</span></div><a href="/servlet/linkout?suffix=cit111a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHinman%26aufirst%3DL.%2BM.%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DWallace%26aufirst%3DR.%26aulast%3DMenendez%26aufirst%3DA.%2BT.%26aulast%3DDurr%26aufirst%3DF.%2BE.%26aulast%3DUpeslacis%26aufirst%3DJ.%26atitle%3DPreparation%2520and%2520Characterization%2520of%2520Monoclonal%2520Antibody%2520Conjugates%2520of%2520the%2520Calicheamicins%253A%2520A%2520Novel%2520and%2520Potent%2520Family%2520of%2520Antitumor%2520Antibiotics%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26spage%3D3336%26epage%3D3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit111b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ricart, A. D.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6417</span>– <span class="NLM_lpage">6427</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1158%2F1078-0432.CCR-11-0486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=22003069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSksrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6417-6427&author=A.+D.+Ricart&title=Antibody-Drug+Conjugates+of+Calicheamicin+Derivative%3A+Gemtuzumab+Ozogamicin+and+Inotuzumab+Ozogamicin&doi=10.1158%2F1078-0432.CCR-11-0486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111bR"><div class="casContent"><span class="casTitleNuber">111b</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin</span></div><div class="casAuthors">Ricart, Alejandro D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6417-6427</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently sensitive to cytotoxic agents.  CD33 and CD22 are specific markers of myeloid leukemias and B-cell malignancies, resp.  These endocytic receptors are ideal for an ADC strategy because they can effectively carry the cytotoxic payload into the cell.  Gemtuzumab ozogamicin (GO, Mylotarg) and inotuzumab ozogamicin consist of a deriv. of calicheamicin (a potent DNA-binding cytotoxic antibiotic) linked to a humanized monoclonal IgG4 antibody directed against CD33 or CD22, resp.  Both of these ADCs have a target-mediated pharmacokinetic disposition.  GO was the first drug to prove the ADC concept in the clinic, specifically in phase II studies that included substantial proportions of older patients with relapsed acute myeloid leukemia.  In contrast, in phase III studies, it has thus far failed to show clin. benefit in first-line treatment in combination with std. chemotherapy.  Inotuzumab ozogamicin has shown remarkable clin. activity in relapsed/refractory B-cell non-Hodgkin lymphoma, and it has started phase III evaluation.  The safety profile of these ADCs includes reversible myelosuppression (esp. neutropenia and thrombocytopenia), elevated hepatic transaminases, and hyperbilirubinemia.  There have been postmarketing reports of hepatotoxicity, esp. veno-occlusive disease, assocd. with GO.  The incidence is ∼2%, but patients who undergo hematopoietic stem cell transplantation have an increased risk.  As we steadily move toward the goal of personalized medicine, these kinds of agents will provide a unique opportunity to treat selected patient subpopulations based on the expression of their specific tumor targets.  Clin Cancer Res; 17(20); 6417-27.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXhh65029iwbVg90H21EOLACvtfcHk0lgcSKdH5Xtw8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSksrzF&md5=103b40cfe49632a86367414e0e97c011</span></div><a href="/servlet/linkout?suffix=cit111b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0486%26sid%3Dliteratum%253Aachs%26aulast%3DRicart%26aufirst%3DA.%2BD.%26atitle%3DAntibody-Drug%2520Conjugates%2520of%2520Calicheamicin%2520Derivative%253A%2520Gemtuzumab%2520Ozogamicin%2520and%2520Inotuzumab%2520Ozogamicin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6417%26epage%3D6427%26doi%3D10.1158%2F1078-0432.CCR-11-0486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, R. W.</span>; <span class="NLM_string-name">Letendre, L. J.</span>; <span class="NLM_string-name">Patel, V. B.</span>; <span class="NLM_string-name">Prashad, A. S.</span>; <span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Intermediates and Methods for Synthesizing Calicheamicin Derivatives</span>. <span class="NLM_patent">WO 2015063680</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+W.+Dugger&author=L.+J.+Letendre&author=V.+B.+Patel&author=A.+S.+Prashad&author=C.+Zhang&title=Intermediates+and+Methods+for+Synthesizing+Calicheamicin+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDugger%26aufirst%3DR.%2BW.%26atitle%3DIntermediates%2520and%2520Methods%2520for%2520Synthesizing%2520Calicheamicin%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maiese, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechevalier, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechevalier, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korshalla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenstein, M.</span></span> <span> </span><span class="NLM_article-title">Calicheamicins, a Novel Family of Antitumor Antibiotics: Taxonomy, Fermentation and Biological Properties</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.42.558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.7164%2Fantibiotics.42.558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=2722671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1SmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1989&pages=558-563&author=W.+M.+Maieseauthor=M.+P.+Lechevalierauthor=H.+A.+Lechevalierauthor=J.+Korshallaauthor=N.+Kuckauthor=A.+Fantiniauthor=M.+J.+Wildeyauthor=J.+Thomasauthor=M.+Greenstein&title=Calicheamicins%2C+a+Novel+Family+of+Antitumor+Antibiotics%3A+Taxonomy%2C+Fermentation+and+Biological+Properties&doi=10.7164%2Fantibiotics.42.558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113aR"><div class="casContent"><span class="casTitleNuber">113a</span><div class="casTitle"><span class="NLM_cas:atitle">Calicheamicins, a novel family of antitumor antibiotics:  taxonomy, fermentation and biological properties</span></div><div class="casAuthors">Maiese, W. M.; Lechevalier, M. P.; Lechevalier, H. A.; Korshalla, J.; Kuck, N.; Fantini, A.; Wildey, M. J.; Thomas, J.; Greenstein, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">558-63</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">A novel family of antitumor antibiotics, the calicheamicins, were isolated from the fermn. broth of Micromonospora echinospora subsp. calichensis.  These antibiotics exhibited significant activity against gram-pos. and gram-neg. bacteria in vitro.  Calicheamicin γ1I demonstrated antitumor activity against P388 leukemia and B16 melanoma in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA3VLMLNeUU7Vg90H21EOLACvtfcHk0lj3XYF2mYTsGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1SmurY%253D&md5=8944bd3a3bc333517c3ee816f01436bd</span></div><a href="/servlet/linkout?suffix=cit113a&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.42.558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.42.558%26sid%3Dliteratum%253Aachs%26aulast%3DMaiese%26aufirst%3DW.%2BM.%26aulast%3DLechevalier%26aufirst%3DM.%2BP.%26aulast%3DLechevalier%26aufirst%3DH.%2BA.%26aulast%3DKorshalla%26aufirst%3DJ.%26aulast%3DKuck%26aufirst%3DN.%26aulast%3DFantini%26aufirst%3DA.%26aulast%3DWildey%26aufirst%3DM.%2BJ.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DGreenstein%26aufirst%3DM.%26atitle%3DCalicheamicins%252C%2520a%2520Novel%2520Family%2520of%2520Antitumor%2520Antibiotics%253A%2520Taxonomy%252C%2520Fermentation%2520and%2520Biological%2520Properties%26jtitle%3DJ.%2520Antibiot.%26date%3D1989%26volume%3D42%26spage%3D558%26epage%3D563%26doi%3D10.7164%2Fantibiotics.42.558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit113b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. D.</span>; <span class="NLM_string-name">Greenstein, M.</span>; <span class="NLM_string-name">Labeda, D. P.</span>; <span class="NLM_string-name">Fantini, A. A.</span></span> <span> </span><span class="NLM_article-title">Fermentative Manufacture of Antitumor Antibiotics (Ll-E33288 Complex)</span>. <span class="NLM_patent">US 4970198</span>, <span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=M.+D.+Lee&author=M.+Greenstein&author=D.+P.+Labeda&author=A.+A.+Fantini&title=Fermentative+Manufacture+of+Antitumor+Antibiotics+%28Ll-E33288+Complex%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BD.%26atitle%3DFermentative%2520Manufacture%2520of%2520Antitumor%2520Antibiotics%2520%2528Ll-E33288%2520Complex%2529%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunne, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellestad, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGahren, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, D. B.</span></span> <span> </span><span class="NLM_article-title">Calicheamicins, a Novel Family of Antitumor Antibiotics. 4. Structure Elucidation of Calicheamicins B1br, Γ1br, A2i, A3i, B1i, Γ1i, and Δ1i</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1021/ja00029a030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00029a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK38Xkt1Kqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1992&pages=985-997&author=M.+D.+Leeauthor=T.+S.+Dunneauthor=C.+C.+Changauthor=M.+M.+Siegelauthor=G.+O.+Mortonauthor=G.+A.+Ellestadauthor=W.+J.+McGahrenauthor=D.+B.+Borders&title=Calicheamicins%2C+a+Novel+Family+of+Antitumor+Antibiotics.+4.+Structure+Elucidation+of+Calicheamicins+B1br%2C+%CE%931br%2C+A2i%2C+A3i%2C+B1i%2C+%CE%931i%2C+and+%CE%941i&doi=10.1021%2Fja00029a030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Calicheamicins, a novel family of antitumor antibiotics.  4.  Structure elucidation of calicheamicins β1Br, γ1Br, α2I, α3I, β1I, γ1I, and δ1I</span></div><div class="casAuthors">Lee, May D.; Dunne, Theresa S.; Chang, Conway C.; Siegel, Marshall M.; Morton, George O.; Ellestad, George A.; McGahren, William J.; Borders, Donald B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">985-97</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The details of the structural assignment of the potent antitumor antibiotic, calicheamicin γ1I (I; R = H; C55H74IN3O21S4), is reported.  Methanolysis studies on I (R = H) and N-acetylcalicheamicin γ1I (I; R = Ac; C57H76IN3O22S4) permitted the structural assignment of the glycosidic chain.  Details of the spectral anal. supporting the assignments of the 3-O-methyl-α-L-rhamnopyranoside (D-ring) and the Me 2,4-dideoxy-3-O-methyl-4-(N-acetyl-N-ethylamino)-α-L-xylopyranoside (E-ring) is reported.  The structure of calicheamicinone (II, C18H17NO5S3), contg. a bicyclo[7.3.1]tridec-9-ene-2,6-diyne system and a Me trisulfide, was elucidated by a series of chem. degrdn. studies, which included an unexpected free radical cycloaromatization reaction.  The presence of 4,6-dideoxy-4-(hydroxyamino)-β-D-glucopyranoside (A-ring) and its N-O glycosidic linkage to the thio sugar (ring-B) was ascertained by X-ray crystallog. of III (C36H40INO13S2), a degrdn. product of I (R = H).  The chem. structures of calicheamicins β1Br, γ1Br, α2I, α3I, β1I, and δ1I were assigned by correlating their 1H- and 13C-NMR data with that of I (R = H).  By tracking the biol. activities of the degrdn. products, the enediyne system of calicheamicinone was shown to be essential for the DNA-damaging abilities of the calicheamicins.  A mechanism whereby the enediyne could be triggered to cyclize via a 1,4-diyl, the putative DNA cleaving species, is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrokbMAgwMWr7Vg90H21EOLACvtfcHk0lj3XYF2mYTsGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xkt1Kqsbg%253D&md5=09da8d571f8783d2006999681bbc1318</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fja00029a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00029a030%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BD.%26aulast%3DDunne%26aufirst%3DT.%2BS.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DSiegel%26aufirst%3DM.%2BM.%26aulast%3DMorton%26aufirst%3DG.%2BO.%26aulast%3DEllestad%26aufirst%3DG.%2BA.%26aulast%3DMcGahren%26aufirst%3DW.%2BJ.%26aulast%3DBorders%26aufirst%3DD.%2BB.%26atitle%3DCalicheamicins%252C%2520a%2520Novel%2520Family%2520of%2520Antitumor%2520Antibiotics.%25204.%2520Structure%2520Elucidation%2520of%2520Calicheamicins%2520B1br%252C%2520%25CE%25931br%252C%2520A2i%252C%2520A3i%252C%2520B1i%252C%2520%25CE%25931i%252C%2520and%2520%25CE%25941i%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1992%26volume%3D114%26spage%3D985%26epage%3D997%26doi%3D10.1021%2Fja00029a030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunstmann, M. P.</span>; <span class="NLM_string-name">Hollander, I. J.</span>; <span class="NLM_string-name">Hamann, P.</span>; <span class="NLM_string-name">Kunz, A.</span></span> <span> </span><span class="NLM_article-title">Methods for the Preparation of Monomeric Calicheamicin Derivative/Carrier Conjugates</span>. <span class="NLM_patent">US 5714586</span>, <span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=M.+P.+Kunstmann&author=I.+J.+Hollander&author=P.+Hamann&author=A.+Kunz&title=Methods+for+the+Preparation+of+Monomeric+Calicheamicin+Derivative%2FCarrier+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKunstmann%26aufirst%3DM.%2BP.%26atitle%3DMethods%2520for%2520the%2520Preparation%2520of%2520Monomeric%2520Calicheamicin%2520Derivative%252FCarrier%2520Conjugates%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.
S.</span></span> <span> </span><span class="NLM_article-title">Midostaurin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0779-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0779-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28612232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1251-1259&author=E.%0AS.+Kim&title=Midostaurin%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0779-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116aR"><div class="casContent"><span class="casTitleNuber">116a</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1251-1259</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Midostaurin (Rydapt) is a multikinase inhibitor being developed by Novartis Pharmaceuticals.  In Apr. 2017, midostaurin was approved in the USA for the treatment of adult patients with newly diagnosed, FMS-like tyrosine kinase 3 (FLT3) mutation-pos. acute myeloid leukemia (AML) [in combination with std. cytarabine and daunorubicin induction, and cytarabine consolidation], or aggressive systemic mastocytosis (ASM), systemic mastocytosis with assocd. haematol. neoplasm (SM-AHN) or mast cell leukemia (MCL) [collectively known as advanced SM].  The article summarizes the milestones in the development of midostaurin leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNnPB8R_KAMrVg90H21EOLACvtfcHk0lj3XYF2mYTsGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrjO&md5=37f59dd537e4ed23475a117bec0e06d0</span></div><a href="/servlet/linkout?suffix=cit116a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0779-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0779-0%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DMidostaurin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1251%26epage%3D1259%26doi%3D10.1007%2Fs40265-017-0779-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit116b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b01126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b01126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOqurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=477-478&author=P.+W.+Manleyauthor=E.+Weisbergauthor=M.+Sattlerauthor=J.+D.+Griffin&title=Midostaurin%2C+a+Natural+Product-Derived+Kinase+Inhibitor+Recently+Approved+for+the+Treatment+of+Hematological+Malignancies&doi=10.1021%2Facs.biochem.7b01126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116bR"><div class="casContent"><span class="casTitleNuber">116b</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies</span></div><div class="casAuthors">Manley, Paul W.; Weisberg, Ellen; Sattler, Martin; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">477-478</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This brief article outlines the early design of midostaurin, the preclin. discovery of its activity against oncogenic FLT3, and its subsequent clin. development as a therapeutic agent for FLT3 mutant-pos. acute myeloid leukemia (AML) and several rare blood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVMHWjYVaxTLVg90H21EOLACvtfcHk0lioctHmeaAa6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOqurfP&md5=8f1c6a65ef0c3b8666fd7402fba3bbb2</span></div><a href="/servlet/linkout?suffix=cit116b&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b01126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b01126%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DMidostaurin%252C%2520a%2520Natural%2520Product-Derived%2520Kinase%2520Inhibitor%2520Recently%2520Approved%2520for%2520the%2520Treatment%2520of%2520Hematological%2520Malignancies%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D477%26epage%3D478%26doi%3D10.1021%2Facs.biochem.7b01126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasko, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span> <span> </span><span class="NLM_article-title">First Approved Kinase Inhibitor for Aml</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">981</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.cell.2017.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29149610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=981&author=J.+E.+J.+Raskoauthor=T.+P.+Hughes&title=First+Approved+Kinase+Inhibitor+for+Aml&doi=10.1016%2Fj.cell.2017.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">First Approved Kinase Inhibitor for AML</span></div><div class="casAuthors">Rasko, John E. J.; Hughes, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">981</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are assocd. with relapse and poor prognosis.  Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype.  To view this Bench to Bedside, open or download the PDF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOxSUYU6hN97Vg90H21EOLACvtfcHk0lioctHmeaAa6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vI&md5=4cb5f9bb62497756d222b62ccebe0dda</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRasko%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26atitle%3DFirst%2520Approved%2520Kinase%2520Inhibitor%2520for%2520Aml%26jtitle%3DCell%26date%3D2017%26volume%3D171%26spage%3D981%26doi%3D10.1016%2Fj.cell.2017.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span> <span> </span><span class="NLM_article-title">Midostaurin Treatment in Flt3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1080/17512433.2017.1387051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F17512433.2017.1387051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28960095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Chs7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=1177-1189&author=S.+Kayserauthor=M.+J.+Levisauthor=R.+F.+Schlenk&title=Midostaurin+Treatment+in+Flt3-Mutated+Acute+Myeloid+Leukemia+and+Systemic+Mastocytosis&doi=10.1080%2F17512433.2017.1387051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis</span></div><div class="casAuthors">Kayser, Sabine; Levis, Mark J.; Schlenk, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1177-1189</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : A no. of tyrosine kinase inhibitors (TKIs) have been developed that inhibit the constitutively activated kinase activity caused by activating tyrosine kinase mutations, such as FLT3 or KIT, thus interrupting signaling pathways.  Currently, midostaurin is the only approved TKI as monotherapy for aggressive systemic mastocytosis (SM), SM with assocd. hematol. neoplasm, or mast cell leukemia displaying a KIT mutation as well as in combination with std. intensive chemotherapy for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).  We provide a concise review of the pharmacol., tolerability and clin. efficacy of midostaurin and emerging new treatment options for ASM and FLT3-mutated AML.  Currently, midostaurin is the only approved TKI in aggressive SM, SM with assocd. hematol. neoplasm, or mast cell leukemia inducing responses including complete remissions.  With regard to AML, midostaurin is the first drug to receive regulatory approval in this indication in the molecularly defined subgroup of AML with FLT3 mutations.  By introduction of this new std. in AML with FLT3 mutations, the bare has been raised for future approvals of next generation FLT3 inhibitors which will be based increasingly on head to head comparisons with midostaurin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKGUTo4zG5eLVg90H21EOLACvtfcHk0lioctHmeaAa6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Chs7nN&md5=f2debaad0c5030cb58e67ca0b6d3b233</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1080%2F17512433.2017.1387051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17512433.2017.1387051%26sid%3Dliteratum%253Aachs%26aulast%3DKayser%26aufirst%3DS.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26atitle%3DMidostaurin%2520Treatment%2520in%2520Flt3-Mutated%2520Acute%2520Myeloid%2520Leukemia%2520and%2520Systemic%2520Mastocytosis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D10%26spage%3D1177%26epage%3D1189%26doi%3D10.1080%2F17512433.2017.1387051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, P.</span>; <span class="NLM_string-name">Koch, B.</span>; <span class="NLM_string-name">Mutz, M.</span></span> <span> </span><span class="NLM_article-title">Crystal Form of N-Benzoyl-staurosporine</span>. <span class="NLM_patent">US 8198435 B2</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.+Hoehn&author=B.+Koch&author=M.+Mutz&title=Crystal+Form+of+N-Benzoyl-staurosporine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoehn%26aufirst%3DP.%26atitle%3DCrystal%2520Form%2520of%2520N-Benzoyl-staurosporine%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awaya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asuma, R.</span></span> <span> </span><span class="NLM_article-title">A New Alkaloid Am-2282 of Streptomyces Origin. Taxonomy, Fermentation, Isolation and Preliminary Characterization</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.30.275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.7164%2Fantibiotics.30.275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=612708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaE2sXkt1Smsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1977&pages=275-282&author=S.+Omuraauthor=Y.+Iwaiauthor=A.+Hiranoauthor=A.+Nakagawaauthor=J.+Awayaauthor=H.+Tsuchiyaauthor=Y.+Takahashiauthor=R.+Asuma&title=A+New+Alkaloid+Am-2282+of+Streptomyces+Origin.+Taxonomy%2C+Fermentation%2C+Isolation+and+Preliminary+Characterization&doi=10.7164%2Fantibiotics.30.275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A new alkaloid AM-2282 of Streptomyces origin.  Taxonomy, fermentation, isolation and preliminary characterization</span></div><div class="casAuthors">Omura, Satoshi; Iwai, Yuzuru; Hirano, Atsushi; Nakagawa, Akira; Awaya, Juichi; Tsuchiya, Hisae; Takahashi, Yoko; Masuma, Rokurou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-82</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">A novel alkaloid, AM-2282 [62996-74-1], with high hypotensive activity, was isolated from Streptomyces strain AM-2282, for which the name S. staurosporens is proposed.  The substance was active against fungi and yeast but had no activity against bacteria.  The mol. formula is C28H26N4O3, and the i.p. LD50 of its hydrochloride in mice was 6.6 mg/kg.  Taxonomic features of the strain AM-2282, together with the fermn. isolation, and physicochem. and biol. properties of the new alkaloid are presented.  UV, IR, and 1H-NMR spectra are also given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjO4pjDwMWLrVg90H21EOLACvtfcHk0liqIryYP6txhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXkt1Smsbs%253D&md5=4f52ee08da1cba35345c971c313c7fc6</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.30.275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.30.275%26sid%3Dliteratum%253Aachs%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DA.%26aulast%3DAwaya%26aufirst%3DJ.%26aulast%3DTsuchiya%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DAsuma%26aufirst%3DR.%26atitle%3DA%2520New%2520Alkaloid%2520Am-2282%2520of%2520Streptomyces%2520Origin.%2520Taxonomy%252C%2520Fermentation%252C%2520Isolation%2520and%2520Preliminary%2520Characterization%26jtitle%3DJ.%2520Antibiot.%26date%3D1977%26volume%3D30%26spage%3D275%26epage%3D282%26doi%3D10.7164%2Fantibiotics.30.275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, D. R.</span>; <span class="NLM_string-name">Lam, K. S.</span>; <span class="NLM_string-name">Mattei, J. M.</span>; <span class="NLM_string-name">Hesler, G. A.</span></span> <span> </span><span class="NLM_article-title">Manufacture of Staurosporine with <i>Streptomyces Hygroscopicus</i></span>. <span class="NLM_patent">US 4973552</span>, <span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=D.+R.+Schroeder&author=K.+S.+Lam&author=J.+M.+Mattei&author=G.+A.+Hesler&title=Manufacture+of+Staurosporine+with+Streptomyces+Hygroscopicus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DD.%2BR.%26atitle%3DManufacture%2520of%2520Staurosporine%2520with%2520Streptomyces%2520Hygroscopicus%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit121b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span>; <span class="NLM_string-name">Zhou, B.</span>; <span class="NLM_string-name">Ding, W.</span></span> <span> </span><span class="NLM_article-title">Staurosporine Compound, Its Preparation Method and Application</span>. <span class="NLM_patent">CN 107446011</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Ma&author=B.+Zhou&author=W.+Ding&title=Staurosporine+Compound%2C+Its+Preparation+Method+and+Application"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DStaurosporine%2520Compound%252C%2520Its%2520Preparation%2520Method%2520and%2520Application%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit121c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, C.</span>; <span class="NLM_string-name">Zheng, D.</span>; <span class="NLM_string-name">Shen, S.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Liu, T.</span></span> <span> </span><span class="NLM_article-title"><i>Streptomyces Scabiei</i> Subsp. Xuchangensis, a Novel Streptomycete Isolate for Staurosporine Production and a Wheat Take-All Control Agent</span>.  <i>Int. J. Microbiol. Res.</i> <span class="NLM_year">2012</span>,  <span class="NLM_volume">4</span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">289</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Wen&author=D.+Zheng&author=S.+Shen&author=J.+Chen&author=W.+Liu&author=T.+Liu&title=Streptomyces+Scabiei+Subsp.+Xuchangensis%2C+a+Novel+Streptomycete+Isolate+for+Staurosporine+Production+and+a+Wheat+Take-All+Control+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DC.%26atitle%3DStreptomyces%2520Scabiei%2520Subsp.%2520Xuchangensis%252C%2520a%2520Novel%2520Streptomycete%2520Isolate%2520for%2520Staurosporine%2520Production%2520and%2520a%2520Wheat%2520Take-All%2520Control%2520Agent%26jtitle%3DInt.%2520J.%2520Microbiol.%2520Res.%26date%3D2012%26volume%3D4%26spage%3D282%26epage%3D289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit121d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span>; <span class="NLM_string-name">Iwai, Y.</span>; <span class="NLM_string-name">Hirano, A.</span></span> <span> </span><span class="NLM_article-title">Antibiotic Am-2282</span>. <span class="NLM_patent">JP 53073501</span>, <span class="NLM_year">1978</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1978&author=S.+Omura&author=Y.+Iwai&author=A.+Hirano&title=Antibiotic+Am-2282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOmura%26aufirst%3DS.%26atitle%3DAntibiotic%2520Am-2282%26date%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, P.</span>; <span class="NLM_string-name">Koch, B.</span>; <span class="NLM_string-name">Mutz, M.</span></span> <span> </span><span class="NLM_article-title">Process for Purifying Staurosporine</span>. <span class="NLM_patent">EP 2272850 B1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=P.+Hoehn&author=B.+Koch&author=M.+Mutz&title=Process+for+Purifying+Staurosporine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoehn%26aufirst%3DP.%26atitle%3DProcess%2520for%2520Purifying%2520Staurosporine%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri-Kordestani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balcazar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett-Ringgold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmby, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluetz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaver, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage Her2-Positive Breast Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3486</span>– <span class="NLM_lpage">3491</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-3628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1158%2F1078-0432.CCR-17-3628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29523624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3486-3491&author=H.+Singhauthor=A.+J.+Walkerauthor=L.+Amiri-Kordestaniauthor=J.+Chengauthor=S.+Tangauthor=P.+Balcazarauthor=K.+Barnett-Ringgoldauthor=T.+R.+Palmbyauthor=X.+Caoauthor=N.+Zhengauthor=Q.+Liuauthor=J.+Yuauthor=W.+F.+Pierceauthor=S.+R.+Danielsauthor=R.+Sridharaauthor=A.+Ibrahimauthor=P.+G.+Kluetzauthor=G.+M.+Blumenthalauthor=J.+A.+Beaverauthor=R.+Pazdur&title=U.S.+Food+and+Drug+Administration+Approval%3A+Neratinib+for+the+Extended+Adjuvant+Treatment+of+Early-Stage+Her2-Positive+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-17-3628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer</span></div><div class="casAuthors">Singh, Harpreet; Walker, Amanda J.; Amiri-Kordestani, Laleh; Cheng, Joyce; Tang, Shenghui; Balcazar, Pamela; Barnett-Ringgold, Kimberly; Palmby, Todd R.; Cao, Xianhua; Zheng, Nan; Liu, Qi; Yu, Jingyu; Pierce, William F.; Daniels, Selena R.; Sridhara, Rajeshwari; Ibrahim, Amna; Kluetz, Paul G.; Blumenthal, Gideon M.; Beaver, Julia A.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3486-3491</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On July 17, 2017, the FDA approved neratinib (NERLYNX; Puma Biotechnol., Inc.) for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.  Approval was based on data from ExteNET, a randomized, double-blind, placebo-controlled multicenter trial.  Women with early-stage HER2-pos. breast cancer and within 2 years of completing adjuvant trastuzumab were randomized to neratinib (n = 1,420) or placebo (n = 1,420) for 1 yr.  The primary endpoint was invasive disease-free survival (iDFS), defined as the time between randomization date to first occurrence of invasive recurrence (local/regional, ipsilateral, or contralateral breast cancer), distant recurrence, or death from any cause, with 2 years and 28 days of follow-up.  The trial showed a statistically significant treatment effect favoring neratinib with a stratified HR of 0.66 [95% confidence interval (CI), 0.49-0.90, P = 0.008].  The estd. iDFS rate at 2 years was 94.2% (95% CI, 92.6%-95.4%) in patients treated with neratinib vs. 91.9% (95% CI, 90.2%-93.2%) in those receiving placebo.  Diarrhea was the most common adverse event (AE), with a 40% incidence of grade 3 or 4 diarrhea, and represents the most common AE leading to treatment discontinuation.  Other frequent AEs (>10% incidence) were nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, and muscle spasms.  Other than diarrhea, neratinib is assocd. with a low incidence of severe AEs; toxicities are generally reversible and manageable with dose interruptions, dose redns., and/or std. medical care.  This article summarizes FDA decision-making and data supporting the neratinib approval.  Clin Cancer Res; 24(15); 3486-91. ©2018 AACR.  See related commentary by Unni et al., p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAEGUdXAjtGrVg90H21EOLACvtfcHk0liqIryYP6txhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtr3P&md5=3abbfe781f1386d6d057125a08c5bdac</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-3628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-3628%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DA.%2BJ.%26aulast%3DAmiri-Kordestani%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DBalcazar%26aufirst%3DP.%26aulast%3DBarnett-Ringgold%26aufirst%3DK.%26aulast%3DPalmby%26aufirst%3DT.%2BR.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DPierce%26aufirst%3DW.%2BF.%26aulast%3DDaniels%26aufirst%3DS.%2BR.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DKluetz%26aufirst%3DP.%2BG.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DBeaver%26aufirst%3DJ.%2BA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520Approval%253A%2520Neratinib%2520for%2520the%2520Extended%2520Adjuvant%2520Treatment%2520of%2520Early-Stage%2520Her2-Positive%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D3486%26epage%3D3491%26doi%3D10.1158%2F1078-0432.CCR-17-3628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek-Klumpers, E.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalak, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span> <span> </span><span class="NLM_article-title">Optimization of 6,7-Disubstituted-4-(Arylamino)Quinoline-3-Carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.%0AG.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-Disubstituted-4-%28Arylamino%29Quinoline-3-Carbonitriles+as+Orally+Active%2C+Irreversible+Inhibitors+of+Human+Epidermal+Growth+Factor+Receptor-2+Kinase+Activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1107-1131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles, e.g. I (R1 = H, Cl; R2 = PhCH2O, 1-imidazolyl, 2-furylmethoxy, etc.; R3 = Cl, CN, PhCH2O; R4 = Me, Et; R5 = Me, R6 = Me, HOCH2CH2; R5R6N = azetidinyl, piperidinyl, thiomorpholinyl, etc.) that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepd.  These compds. demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 pos. cells compared to the EGFR kinase inhibitor I [R1 = H; R2 = F; R3 = Cl; R4 = Et; R5 = R6 = Me; (EKB-569)].  Three synthetic routes were used to prep. these compds.  They were prepd. mostly by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsatd. acid chlorides or by amination of 4-chloro-6-(crotonamido)quinoline-3-carbonitriles with monocyclic or bicyclic anilines.  The third route was developed to prep. a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step.  It was shown that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase.  The importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramol. catalysis of the Michael addn. has also been demonstrated.  This, along with improved water soly., resulted in compds. with enhanced biol. properties.  The mol. modeling results consistent with the proposed mechanism of inhibition are presented.  Binding studies of one compd., I [R1 = H; R2 = 2-pyridylmethoxy; R3 = Cl; R4 = Et; R5 = R6 = Me; (HKI-272)] (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells.  Furthermore, it demonstrated excellent oral activity, esp. in HER-2 overexpressing xenografts.  Compd. HKI-272 was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0QL4-qQZCbVg90H21EOLACvtfcHk0lhRYL52wBHEHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D&md5=55f77e41bf920f738ae2750e7ca0eb22</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-Disubstituted-4-%2528Arylamino%2529Quinoline-3-Carbonitriles%2520as%2520Orally%2520Active%252C%2520Irreversible%2520Inhibitors%2520of%2520Human%2520Epidermal%2520Growth%2520Factor%2520Receptor-2%2520Kinase%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, W.</span>; <span class="NLM_string-name">Cheal, G.
K.</span>; <span class="NLM_string-name">Lunetta, J. F.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Substituted 3-Cyanoquinolines and Intermediates Thereof</span>. <span class="NLM_patent">WO 2006127207A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Chew&author=G.%0AK.+Cheal&author=J.+F.+Lunetta&title=Process+for+the+Preparation+of+Substituted+3-Cyanoquinolines+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DW.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Substituted%25203-Cyanoquinolines%2520and%2520Intermediates%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit125b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, W.</span>; <span class="NLM_string-name">Papamichelakis, M.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Substituted 3-Cyanoquinolines and Intermediates Thereof</span>. <span class="NLM_patent">WO 2006127205A2</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Chew&author=M.+Papamichelakis&title=Process+for+the+Preparation+of+Substituted+3-Cyanoquinolines+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DW.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Substituted%25203-Cyanoquinolines%2520and%2520Intermediates%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gontcharov, A.</span>; <span class="NLM_string-name">Eng, K. K.</span>; <span class="NLM_string-name">Sutherland, K.</span>; <span class="NLM_string-name">Sebastian, A.</span>; <span class="NLM_string-name">Yu, Q.</span>; <span class="NLM_string-name">Place, D. W.</span></span> <span> </span><span class="NLM_article-title">Improved Process for Preparation of Coupled Products from 4-Amino-3-cyanoquinolines Using Stabilized Intermediates</span>. <span class="NLM_patent">WO 2010048477A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+Gontcharov&author=K.+K.+Eng&author=K.+Sutherland&author=A.+Sebastian&author=Q.+Yu&author=D.+W.+Place&title=Improved+Process+for+Preparation+of+Coupled+Products+from+4-Amino-3-cyanoquinolines+Using+Stabilized+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGontcharov%26aufirst%3DA.%26atitle%3DImproved%2520Process%2520for%2520Preparation%2520of%2520Coupled%2520Products%2520from%25204-Amino-3-cyanoquinolines%2520Using%2520Stabilized%2520Intermediates%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span> <i>TESARO Announces U.S.
FDA Approval of ZEJULA (Niraparib) for Women
with Recurrent Ovarian Cancer</i>; <span class="NLM_publisher-name">TESARO</span>, March 27, <span class="NLM_year">2017</span>; <a href="http://ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-us-fda-approval-zejulatm-niraparib-women" class="extLink">http://ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-us-fda-approval-zejulatm-niraparib-women</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+TESARO+Announces+U.S.%0AFDA+Approval+of+ZEJULA+%28Niraparib%29+for+Women%0Awith+Recurrent+Ovarian+Cancer%3B+TESARO%2C+March+27%2C+2017%3B+http%3A%2F%2Fir.tesarobio.com%2Fnews-releases%2Fnews-release-details%2Ftesaro-announces-us-fda-approval-zejulatm-niraparib-women+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DTESARO%2520Announces%2520U.S.%250AFDA%2520Approval%2520of%2520ZEJULA%2520%2528Niraparib%2529%2520for%2520Women%250Awith%2520Recurrent%2520Ovarian%2520Cancer%26pub%3DTESARO%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Niraparib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0752-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0752-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28474297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1crkt12isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1029-1034&author=L.+J.+Scott&title=Niraparib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0752-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128aR"><div class="casContent"><span class="casTitleNuber">128a</span><div class="casTitle"><span class="NLM_cas:atitle">Niraparib: First Global Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1029-1034</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oral niraparib, a highly-selective, potent poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, is approved in the USA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.  It is also under regulatory review in the EU for use in maintenance treatment in patients with platinum-sensitive, recurrent epithelial ovarian cancer who are in response to platinum-based chemotherapy.  In the multinational, phase 3 NOVA trial in adult patients with platinum-sensitive, recurrent ovarian cancer, niraparib significantly prolonged median progression-free survival, irrespective of the presence or absence of a germline BRCA (gBRCA) mutation and irrespective of the presence or absence of homologous recombinant deficiency.  Niraparib is also in development for use in other solid tumours, including breast and prostate cancer.  This article summarizes the milestones in the development of niraparib leading to its first global approval for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgXAWLIQX9BrmQt-ICR3qNfW6udTcc2eavUD3-XtlFBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crkt12isQ%253D%253D&md5=3dd6187fab47616c093858f3e0cd8fba</span></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0752-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0752-y%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DNiraparib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1029%26epage%3D1034%26doi%3D10.1007%2Fs40265-017-0752-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit128b"><span><span class="NLM_label">(b) </span> <i>Zejula</i>; <span class="NLM_publisher-name">TESARO</span>, March <span class="NLM_year">2017</span>; <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf</a> (accessed November 18, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Zejula%3B+TESARO%2C+March+2017%3B+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F208447lbl.pdf+%28accessed+November+18%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DZejula%26pub%3DTESARO%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boueres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrigno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giomini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamartina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ontoria, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsale, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roscilli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3s)-Piperidin-3-Yl]Phenyl}-2h-Indazole-7-Carboxamide (Mk-4827): A Novel Oral Poly(Adp-Ribose)Polymerase (Parp) Inhibitor Efficacious in Brca-1 and −2 Mutant Tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7170</span>– <span class="NLM_lpage">7185</span>, <span class="refDoi"> DOI: 10.1021/jm901188v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtleisLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283s%29-Piperidin-3-Yl%5DPhenyl%7D-2h-Indazole-7-Carboxamide+%28Mk-4827%29%3A+A+Novel+Oral+Poly%28Adp-Ribose%29Polymerase+%28Parp%29+Inhibitor+Efficacious+in+Brca-1+and+%E2%88%922+Mutant+Tumors&doi=10.1021%2Fjm901188v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129aR"><div class="casContent"><span class="casTitleNuber">129a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors</span></div><div class="casAuthors">Jones, Philip; Altamura, Sergio; Boueres, Julia; Ferrigno, Federica; Fonsi, Massimiliano; Giomini, Claudia; Lamartina, Stefania; Monteagudo, Edith; Ontoria, Jesus M.; Orsale, Maria Vittoria; Palumbi, Maria Cecilia; Pesci, Silvia; Roscilli, Giuseppe; Scarpelli, Rita; Schultz-Fademrecht, Carsten; Toniatti, Carlo; Rowley, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7170-7185</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We disclose the development of a novel series of 2-phenyl-2H-indazole-7-carboxamides as poly(ADP-ribose)polymerase (PARP) 1 and 2 inhibitors.  This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells.  Extrahepatic oxidn. by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported.  These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clin. trials.  This compd. displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, resp., and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range.  MK-4827 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplFTodq58wELVg90H21EOLACvtfcHk0ljg5uZYpj9lQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtleisLjM&md5=ff6662626b95805aeece659fec25133c</span></div><a href="/servlet/linkout?suffix=cit129a&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283s%2529-Piperidin-3-Yl%255DPhenyl%257D-2h-Indazole-7-Carboxamide%2520%2528Mk-4827%2529%253A%2520A%2520Novel%2520Oral%2520Poly%2528Adp-Ribose%2529Polymerase%2520%2528Parp%2529%2520Inhibitor%2520Efficacious%2520in%2520Brca-1%2520and%2520%25E2%2588%25922%2520Mutant%2520Tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185%26doi%3D10.1021%2Fjm901188v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit129b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulger, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosjek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limanto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachert, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, K. M.</span></span> <span> </span><span class="NLM_article-title">Process Development of C–N Cross-Coupling and Enantioselective Biocatalytic Reactions for the Asymmetric Synthesis of Niraparib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1021/op400233z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op400233z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=215-227&author=C.+K.+Chungauthor=P.+G.+Bulgerauthor=B.+Kosjekauthor=K.+M.+Belykauthor=N.+Riveraauthor=M.+E.+Scottauthor=G.+R.+Humphreyauthor=J.+Limantoauthor=D.+C.+Bachertauthor=K.+M.+Emerson&title=Process+Development+of+C%E2%80%93N+Cross-Coupling+and+Enantioselective+Biocatalytic+Reactions+for+the+Asymmetric+Synthesis+of+Niraparib&doi=10.1021%2Fop400233z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129bR"><div class="casContent"><span class="casTitleNuber">129b</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development of C-N Cross-Coupling and Enantioselective Biocatalytic Reactions for the Asymmetric Synthesis of Niraparib</span></div><div class="casAuthors">Chung, Cheol K.; Bulger, Paul G.; Kosjek, Birgit; Belyk, Kevin M.; Rivera, Nelo; Scott, Mark E.; Humphrey, Guy R.; Limanto, John; Bachert, Donald C.; Emerson, Khateeta M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">215-227</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Process development of the synthesis of the orally active poly-(ADP-ribose)-polymerase inhibitor niraparib is described.  Two new asym. routes are reported, which converge on a high-yielding, regioselective, copper-catalyzed N-arylation of an indazole deriv. as the late-stage fragment coupling step.  Novel transaminase-mediated dynamic kinetic resolns. of racemic aldehyde surrogates provided enantioselective syntheses of the 3-aryl-piperidine coupling partner.  Conversion of the C-N cross-coupling product to the final API was achieved by deprotection and salt metathesis to isolate the desired cryst. salt form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4mNYQN5TMorVg90H21EOLACvtfcHk0lgI1kwNoh4vhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7fK&md5=ef37476ca5ed5201ce7a0790f80f91c1</span></div><a href="/servlet/linkout?suffix=cit129b&amp;dbid=16384&amp;doi=10.1021%2Fop400233z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop400233z%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BK.%26aulast%3DBulger%26aufirst%3DP.%2BG.%26aulast%3DKosjek%26aufirst%3DB.%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26aulast%3DRivera%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BE.%26aulast%3DHumphrey%26aufirst%3DG.%2BR.%26aulast%3DLimanto%26aufirst%3DJ.%26aulast%3DBachert%26aufirst%3DD.%2BC.%26aulast%3DEmerson%26aufirst%3DK.%2BM.%26atitle%3DProcess%2520Development%2520of%2520C%25E2%2580%2593N%2520Cross-Coupling%2520and%2520Enantioselective%2520Biocatalytic%2520Reactions%2520for%2520the%2520Asymmetric%2520Synthesis%2520of%2520Niraparib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D215%26epage%3D227%26doi%3D10.1021%2Fop400233z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit129c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, K. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmond, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzzio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajonz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span> <span> </span><span class="NLM_article-title">Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral Parp Inhibitor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1021/op2000783</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op2000783" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1agsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=831-840&author=D.+J.+Wallaceauthor=C.+A.+Baxterauthor=K.+J.+M.+Brandsauthor=N.+Bremeyerauthor=S.+E.+Brewerauthor=R.+Desmondauthor=K.+M.+Emersonauthor=J.+Foleyauthor=P.+Fernandezauthor=W.+Huauthor=S.+P.+Keenauthor=P.+Mullensauthor=D.+Muzzioauthor=P.+Sajonzauthor=L.+Tanauthor=R.+D.+Wilsonauthor=G.+Zhouauthor=G.+Zhou&title=Development+of+a+Fit-for-Purpose+Large-Scale+Synthesis+of+an+Oral+Parp+Inhibitor&doi=10.1021%2Fop2000783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129cR"><div class="casContent"><span class="casTitleNuber">129c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor</span></div><div class="casAuthors">Wallace, Debra J.; Baxter, Carl A.; Brands, Karel J. M.; Bremeyer, Nadine; Brewer, Sarah E.; Desmond, Richard; Emerson, Khateeta M.; Foley, Jennifer; Fernandez, Paul; Hu, Weifeng; Keen, Stephen P.; Mullens, Peter; Muzzio, Daniel; Sajonz, Peter; Tan, Lushi; Wilson, Robert D.; Zhou, George; Zhou, Guoyue</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">831-840</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compd. (1) a poly(ADP-ribose)polymerase (PARP) inhibitor has been made by a fit-for-purpose large-scale synthesis using either a classical resoln. or chiral chromatog. sepn.  The development and relative merits of each route are discussed, along with operational improvements and extensive safety evaluations of potentially hazardous reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2XhpQcEkvHbVg90H21EOLACvtfcHk0lgI1kwNoh4vhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1agsbs%253D&md5=226714068d18e45bb8c17b4a80e18102</span></div><a href="/servlet/linkout?suffix=cit129c&amp;dbid=16384&amp;doi=10.1021%2Fop2000783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop2000783%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DD.%2BJ.%26aulast%3DBaxter%26aufirst%3DC.%2BA.%26aulast%3DBrands%26aufirst%3DK.%2BJ.%2BM.%26aulast%3DBremeyer%26aufirst%3DN.%26aulast%3DBrewer%26aufirst%3DS.%2BE.%26aulast%3DDesmond%26aufirst%3DR.%26aulast%3DEmerson%26aufirst%3DK.%2BM.%26aulast%3DFoley%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DKeen%26aufirst%3DS.%2BP.%26aulast%3DMullens%26aufirst%3DP.%26aulast%3DMuzzio%26aufirst%3DD.%26aulast%3DSajonz%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWilson%26aufirst%3DR.%2BD.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DG.%26atitle%3DDevelopment%2520of%2520a%2520Fit-for-Purpose%2520Large-Scale%2520Synthesis%2520of%2520an%2520Oral%2520Parp%2520Inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2011%26volume%3D15%26spage%3D831%26epage%3D840%26doi%3D10.1021%2Fop2000783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit129d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Patent Review of Manufacturing Routes to Recently Approved Parp Inhibitors: Olaparib, Rucaparib, and Niraparib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00235</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00235" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1227-1244&author=D.+L.+Hughes&title=Patent+Review+of+Manufacturing+Routes+to+Recently+Approved+Parp+Inhibitors%3A+Olaparib%2C+Rucaparib%2C+and+Niraparib&doi=10.1021%2Facs.oprd.7b00235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129dR"><div class="casContent"><span class="casTitleNuber">129d</span><div class="casTitle"><span class="NLM_cas:atitle">Patent Review of Manufacturing Routes to Recently Approved PARP Inhibitors: Olaparib, Rucaparib, and Niraparib</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1227-1244</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Olaparib, rucaparib, and niraparib are three inhibitors of poly(ADP-ribose) polymerase (PARP) enzymes that have been recently approved for the treatment of ovarian cancer.  The current article reviews the patent and journal literature regarding synthetic routes and final forms of these PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5nRoIvG3Q6bVg90H21EOLACvtfcHk0lgI1kwNoh4vhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLnM&md5=890d4ba7694cdf6295d70a9ba41f219c</span></div><a href="/servlet/linkout?suffix=cit129d&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00235%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DPatent%2520Review%2520of%2520Manufacturing%2520Routes%2520to%2520Recently%2520Approved%2520Parp%2520Inhibitors%253A%2520Olaparib%252C%2520Rucaparib%252C%2520and%2520Niraparib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1227%26epage%3D1244%26doi%3D10.1021%2Facs.oprd.7b00235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit129e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Ontoria Ontoria, J. M.</span>; <span class="NLM_string-name">Scarpelli, R.</span>; <span class="NLM_string-name">Schultz-Fademrecht, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Piperidinylphenylindazolylcarboxamide for Use as Poly(ADP-ribose)polymerase Inhibitors</span>. <span class="NLM_patent">WO 2008084261A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Jones&author=J.+M.+Ontoria+Ontoria&author=R.+Scarpelli&author=C.+Schultz-Fademrecht&title=Preparation+of+Piperidinylphenylindazolylcarboxamide+for+Use+as+Poly%28ADP-ribose%29polymerase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3DPreparation%2520of%2520Piperidinylphenylindazolylcarboxamide%2520for%2520Use%2520as%2520Poly%2528ADP-ribose%2529polymerase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit129f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J. R.</span>; <span class="NLM_string-name">Wilson, R. D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pharmaceutically Acceptable Salts of (3S)-3-[4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl]piperidines as Inhibitors of Poly(ADP-ribose)polymerase (Parp)</span>. <span class="NLM_patent">WO 2009087381A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+R.+Foley&author=R.+D.+Wilson&title=Preparation+of+Pharmaceutically+Acceptable+Salts+of+%283S%29-3-%5B4-%5B7-%28Aminocarbonyl%29-2H-indazol-2-yl%5Dphenyl%5Dpiperidines+as+Inhibitors+of+Poly%28ADP-ribose%29polymerase+%28Parp%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFoley%26aufirst%3DJ.%2BR.%26atitle%3DPreparation%2520of%2520Pharmaceutically%2520Acceptable%2520Salts%2520of%2520%25283S%2529-3-%255B4-%255B7-%2528Aminocarbonyl%2529-2H-indazol-2-yl%255Dphenyl%255Dpiperidines%2520as%2520Inhibitors%2520of%2520Poly%2528ADP-ribose%2529polymerase%2520%2528Parp%2529%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit129g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. K.</span>; <span class="NLM_string-name">Scott, M. E.</span>; <span class="NLM_string-name">Bulger, P. G.</span>; <span class="NLM_string-name">Belyk, K. M.</span>; <span class="NLM_string-name">Limanto, J.</span>; <span class="NLM_string-name">Humphrey, G. R.</span></span> <span> </span><span class="NLM_article-title">Regioselective N-2 Arylation of Indazoles</span>. <span class="NLM_patent">WO 2014088983A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+K.+Chung&author=M.+E.+Scott&author=P.+G.+Bulger&author=K.+M.+Belyk&author=J.+Limanto&author=G.+R.+Humphrey&title=Regioselective+N-2+Arylation+of+Indazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BK.%26atitle%3DRegioselective%2520N-2%2520Arylation%2520of%2520Indazoles%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit129h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulger, P. G.</span>; <span class="NLM_string-name">Kosjek, B.</span>; <span class="NLM_string-name">Rivera, N.</span></span> <span> </span><span class="NLM_article-title">Biocatalytic Transamination Process</span>. <span class="NLM_patent">US 20160040201A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+Bulger&author=B.+Kosjek&author=N.+Rivera&title=Biocatalytic+Transamination+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBulger%26aufirst%3DP.%2BG.%26atitle%3DBiocatalytic%2520Transamination%2520Process%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Ribociclib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0742-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0742-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28417244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt12qtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=799-807&author=Y.+Y.+Syed&title=Ribociclib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0742-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Ribociclib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">799-807</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ribociclib is an oral, small-mol. inhibitor of cyclin-dependent kinase (CDK) 4 and 6 that is under development by Novartis for the treatment of cancer.  CDKs play an important role in cell cycle progression and cellular proliferation, and inhibition of these kinases with ribociclib results in G1 phase cell-cycle arrest.  Ribociclib, in combination with an aromatase inhibitor, was recently approved in the USA for the first-line treatment of advanced breast cancer and has been submitted for approval in the EU for this indication.  Ribociclib is undergoing further phase III investigations in breast cancer and is being evaluated in phase I or II trials for various solid tumor types and haematol. malignancies.  This article summarizes the milestones in the development of ribociclib leading to this first global approval for use as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-pos., human epidermal growth factor receptor 2-neg. advanced or metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwLNy3sAC4B7Vg90H21EOLACvtfcHk0lgEQ8ALuA9n9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt12qtL4%253D&md5=88e7fec84ca68c44a6b0895a95ca89ee</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0742-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0742-0%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DRibociclib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D799%26epage%3D807%26doi%3D10.1007%2Fs40265-017-0742-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Rebosini Intermediates and Methods for Their Preparation</span>. <span class="NLM_patent">CN 105037236B</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=X.+Xu&title=Rebosini+Intermediates+and+Methods+for+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26atitle%3DRebosini%2520Intermediates%2520and%2520Methods%2520for%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit131b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis Technology of Ribociclib</span>. <span class="NLM_patent">CN 106928236A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Chen&title=Synthesis+Technology+of+Ribociclib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSynthesis%2520Technology%2520of%2520Ribociclib%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit131c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Peddireddy, S. R.</span>; <span class="NLM_string-name">Kottur, M. K.</span>; <span class="NLM_string-name">Oruganti, S.</span>; <span class="NLM_string-name">Kandagatla, B.</span>; <span class="NLM_string-name">Das Gupta, S.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Ribociclib, Its Acid Addition Salts</span>. <span class="NLM_patent">WO 2018051280A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+R.+Peddireddy&author=M.+K.+Kottur&author=S.+Oruganti&author=B.+Kandagatla&author=S.+Das+Gupta&title=Process+for+Preparation+of+Ribociclib%2C+Its+Acid+Addition+Salts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPeddireddy%26aufirst%3DS.%2BR.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Ribociclib%252C%2520Its%2520Acid%2520Addition%2520Salts%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span> For an analogous
preparation of indoles, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Kempter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiewald, E.</span></span> <span> </span><span class="NLM_article-title">Heterocycles from Amino Ketones. VI. 1,2,3-Trisubstituted Indoles from N-Alkylated Aromatic Amino Ketones and α-Halo Diketones</span>. <i>J. Prakt. Chem. (Leipzig)</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1002/prac.19650280309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fprac.19650280309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaF2MXkt1equrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1965&pages=169-77&author=G.+Kempterauthor=E.+Schiewald&title=Heterocycles+from+Amino+Ketones.+VI.+1%2C2%2C3-Trisubstituted+Indoles+from+N-Alkylated+Aromatic+Amino+Ketones+and+%CE%B1-Halo+Diketones&doi=10.1002%2Fprac.19650280309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocycles from amino ketones. VI. 1,2,3-Trisubstituted indoles from N-alkylated aromatic amino ketones and α-halo diketones</span></div><div class="casAuthors">Kempter, Gerhard; Schiewald, Ekkehard</div><div class="citationInfo"><span class="NLM_cas:title">Journal fuer Praktische Chemie (Leipzig)</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">169-77</span>CODEN:
                <span class="NLM_cas:coden">JPCEAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-8383</span>.
    </div><div class="casAbstract">cf. CA 63, 1777h.  A soln. of 0.5 mole o-H2NC6H4COR in 500 ml. pyridine was mixed with 0.6 mole p-MeC6H4SO2Cl and refluxed for 90 min. to give the following o-(p-MeC6H4SO2NH)C6H4COR (I): R = Me, 45.3% yield, m. 147-8°; R = Ph, 60.5% yield, m. 127°.  To 0.2 mole I in 750 ml. PhMe was added 0.24 mole Na in 500 ml. MeOH, refluxed for 90 min., MeOH distd., and the residue treated with 0.4 mole R'2SO4 to give o(p-MeC6H4SO2NR')C6H4COR (II) (R, R', % yield, and m.p. given): Me, Me, 57, 114-15°; Me, Et, 54.6, 135-6°; Ph, Me, 79.4, 129°; Ph, Et, 66.1, 98.5-99°.  II (30 g.) was detosylated by heating with 600 ml. 70% H2SO4 at 105° and finally at 145° to give o-R'NHC6H4COR (III) (R, R', % yield, and b.p. or m.p. given): Me, Me, 77, b12 120-2° (m. 34-5°); Me, Et, 62.5, b10 125°; Ph, Me, 70, 69°; Ph, Et, 86.2, b1 158-60° (m. 35-6°).  A soln. of 0.01 mole III in 10-12 ml. EtOH was mixed with 1.68 g. NaHCO3 and 2.27 g. BrCH2COBz (IV) and warmed to 75-80° for 75 min. to give V (R, R', % yield, and m.p. given): Me, Me, 39.2, 104-5°; Me, Et, 20, 80°; Ph, Me, 29.6, 136°; Ph, Et, 26.8, 94-5°.  Treatment of PhNHR' (VI) with IV similarly (method A) or 0.02 mole VI with 0.01 mole IV in 10 ml. EtOH (method B) gave PhNR'CH2COBz [R', % yield (by method), and m.p. given]: Me, 51.3 (A), 55.3 (B), 125-8°; Et, 54.5 (A), 60.0 (B), 111°.  Similarly, VI and (BrCH2CO)2 gave (PhNR'CH2CO)2: R' = Me, 30.1% yield, m. 139-41° (EtOH); R' = Et, 27.8% yield, m. 62-4° (pert. ether).  Condensation of 1.39 g. V (R = R' = Me) with 0.54 g. o-phenylenediamine in EtOH gave 40% 2-phenyl-3-(1,3-dimethyl-2-indolyl)quinoxaline, m. 175-7° (EtOH).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8v4dLTSuA67Vg90H21EOLACvtfcHk0lgEQ8ALuA9n9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXkt1equrk%253D&md5=89fc4092bf4f87d334064406348199d0</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2Fprac.19650280309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprac.19650280309%26sid%3Dliteratum%253Aachs%26aulast%3DKempter%26aufirst%3DG.%26aulast%3DSchiewald%26aufirst%3DE.%26atitle%3DHeterocycles%2520from%2520Amino%2520Ketones.%2520VI.%25201%252C2%252C3-Trisubstituted%2520Indoles%2520from%2520N-Alkylated%2520Aromatic%2520Amino%2520Ketones%2520and%2520%25CE%25B1-Halo%2520Diketones%26jtitle%3DJ.%2520Prakt.%2520Chem.%2520%2528Leipzig%2529%26date%3D1965%26volume%3D28%26spage%3D169%26epage%3D77%26doi%3D10.1002%2Fprac.19650280309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Telotristat Ethyl: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0737-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0737-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28382568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Kmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=793-798&author=A.+Markham&title=Telotristat+Ethyl%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0737-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Telotristat Ethyl: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">793-798</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Telotristat Et (Xermelo) is a peripheral tryptophan hydroxylase (TPH) inhibitor that was developed by Lexicon Pharmaceuticals, Inc. for the treatment of carcinoid syndrome.  Many neuroendocrine tumors secrete serotonin (5-HT) into the blood stream, resulting in a no. of symptoms, notably diarrhoea.  Telotristat Et inhibits TPH, thereby reducing the prodn. of 5-HT.  In Feb. 2017, telotristat Et was approved in the USA for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.  This article summarizes the milestones in the development of telotristat Et leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriKbtJWiHZi7Vg90H21EOLACvtfcHk0ljtGaCr_vx8Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Kmtbs%253D&md5=b5846fcb80a1c72f74fdb898e69dafdd</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0737-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0737-x%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DTelotristat%2520Ethyl%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D793%26epage%3D798%26doi%3D10.1007%2Fs40265-017-0737-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulke, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoersch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, R. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombard-Bohas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grande, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapuerta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambrowicz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavel, M.</span></span> <span> </span><span class="NLM_article-title">Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.69.2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1200%2FJCO.2016.69.2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27918724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=14-23&author=M.+H.+Kulkeauthor=D.+Hoerschauthor=M.+E.+Caplinauthor=L.+B.+Anthonyauthor=E.+Bergslandauthor=K.+%C3%96bergauthor=S.+Welinauthor=R.+R.+P.+Warnerauthor=C.+Lombard-Bohasauthor=P.+L.+Kunzauthor=E.+Grandeauthor=J.+W.+Valleauthor=D.+Flemingauthor=P.+Lapuertaauthor=P.+Banksauthor=S.+Jacksonauthor=B.+Zambrowiczauthor=A.+T.+Sandsauthor=M.+Pavel&title=Telotristat+Ethyl%2C+a+Tryptophan+Hydroxylase+Inhibitor+for+the+Treatment+of+Carcinoid+Syndrome&doi=10.1200%2FJCO.2016.69.2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome</span></div><div class="casAuthors">Kulke, Matthew H.; Hoersch, Dieter; Caplin, Martyn E.; Anthony, Lowell B.; Bergsland, Emily; Oeberg, Kjell; Welin, Staffan; Warner, Richard R. P.; Lombard-Bohas, Catherine; Kunz, Pamela L.; Grande, Enrique; Valle, Juan W.; Fleming, Douglas; Lapuerta, Pablo; Banks, Phillip; Jackson, Shanna; Zambrowicz, Brian; Sands, Arthur T.; Pavel, Marianne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-28</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Preliminary studies suggested that telotristat Et, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome.  This placebo-controlled phase III study evaluated telotristat Et in this setting.  Patients and Methods: Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1:1:1) placebo, telotristat Et 250 mg, or telotristat Et 500 mg three times per day orally during a 12-wk double-blind treatment period.  The primary end point was change from baseline in BM frequency.  In an open-label extension, 115 patients subsequently received telotristat Et 500 mg.  Results: Estd. differences in BM frequency per day vs. placebo averaged over 12 wk were -0.81 for telotristat Et 250 mg (P < .001) and -0.69 for telotristat Et 500 mg (P < .001).  At week 12, mean BM frequency redns. per day for placebo, telotristat Et 250 mg, and telotristat Et 500 mg were -0.9, -1.7, and -2.1, resp.  Responses, predefined as a BM frequency redn. ≥ 30% from baseline for ≥ 50% of the double-blind treatment period, were obsd. in 20%, 44%, and 42% of patients given placebo, telotristat Et 250 mg, and telotristat Et 500 mg, resp.  Both telotristat Et dosages significantly reduced mean urinary 5-hydroxyindole acetic acid vs. placebo at week 12 (P < .001).  Mild nausea and asymptomatic increases in gamma-glutamyl transferase were obsd. in some patients receiving telotristat Et.  Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment.  Conclusion Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat Et was generally safe and well tolerated and resulted in significant redns. in BM frequency and urinary 5-hydroxyindole acetic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0pgTfmSZv3bVg90H21EOLACvtfcHk0ljtGaCr_vx8Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtLw%253D&md5=a6874fbdf793c9bfefc41fb73ce361ea</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.69.2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.69.2780%26sid%3Dliteratum%253Aachs%26aulast%3DKulke%26aufirst%3DM.%2BH.%26aulast%3DHoersch%26aufirst%3DD.%26aulast%3DCaplin%26aufirst%3DM.%2BE.%26aulast%3DAnthony%26aufirst%3DL.%2BB.%26aulast%3DBergsland%26aufirst%3DE.%26aulast%3D%25C3%2596berg%26aufirst%3DK.%26aulast%3DWelin%26aufirst%3DS.%26aulast%3DWarner%26aufirst%3DR.%2BR.%2BP.%26aulast%3DLombard-Bohas%26aufirst%3DC.%26aulast%3DKunz%26aufirst%3DP.%2BL.%26aulast%3DGrande%26aufirst%3DE.%26aulast%3DValle%26aufirst%3DJ.%2BW.%26aulast%3DFleming%26aufirst%3DD.%26aulast%3DLapuerta%26aufirst%3DP.%26aulast%3DBanks%26aufirst%3DP.%26aulast%3DJackson%26aufirst%3DS.%26aulast%3DZambrowicz%26aufirst%3DB.%26aulast%3DSands%26aufirst%3DA.%2BT.%26aulast%3DPavel%26aufirst%3DM.%26atitle%3DTelotristat%2520Ethyl%252C%2520a%2520Tryptophan%2520Hydroxylase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Carcinoid%2520Syndrome%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D14%26epage%3D23%26doi%3D10.1200%2FJCO.2016.69.2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span>; <span class="NLM_string-name">Burgoon, H. A.,  Jr.</span>; <span class="NLM_string-name">Iimura, S.</span>; <span class="NLM_string-name">Kanamarlapudi, R. C.</span>; <span class="NLM_string-name">Song, Q.</span>; <span class="NLM_string-name">Wu, W.</span>; <span class="NLM_string-name">Yan, J.</span>; <span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Methods of Preparing 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds</span>. <span class="NLM_patent">WO 2009029499A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+S.+Bednarz&author=H.+A.+Burgoon&author=S.+Iimura&author=R.+C.+Kanamarlapudi&author=Q.+Song&author=W.+Wu&author=J.+Yan&author=H.+Zhang&title=Methods+of+Preparing+4-Phenyl-6-%282%2C2%2C2-trifluoro-1-phenylethoxy%29pyrimidine-Based+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26atitle%3DMethods%2520of%2520Preparing%25204-Phenyl-6-%25282%252C2%252C2-trifluoro-1-phenylethoxy%2529pyrimidine-Based%2520Compounds%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span>; <span class="NLM_string-name">De Paul, S.</span>; <span class="NLM_string-name">Kanamarlapudi, R. C.</span>; <span class="NLM_string-name">Perlberg, A.</span>; <span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Solids Forms of (S)-Ethyl 2-Amino-3-(4-(2-amino-6-((<i>R</i>)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate</span>. <span class="NLM_patent">WO 2009042733A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+S.+Bednarz&author=S.+De+Paul&author=R.+C.+Kanamarlapudi&author=A.+Perlberg&author=H.+Zhang&title=Preparation+of+Solids+Forms+of+%28S%29-Ethyl+2-Amino-3-%284-%282-amino-6-%28%28R%29-1-%284-chloro-2-%283-methyl-1H-pyrazol-1-yl%29phenyl%29-2%2C2%2C2-trifluoroethoxy%29pyrimidin-4-yl%29phenyl%29propanoate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26atitle%3DPreparation%2520of%2520Solids%2520Forms%2520of%2520%2528S%2529-Ethyl%25202-Amino-3-%25284-%25282-amino-6-%2528%2528R%2529-1-%25284-chloro-2-%25283-methyl-1H-pyrazol-1-yl%2529phenyl%2529-2%252C2%252C2-trifluoroethoxy%2529pyrimidin-4-yl%2529phenyl%2529propanoate%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Devasagayaraj, A.</span>; <span class="NLM_string-name">Jin, H.</span>; <span class="NLM_string-name">Shi, Z.-C.</span>; <span class="NLM_string-name">Tunoori, A.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-[6-(2,2,2-Trifluoro-1-phenylethoxy)pyrimidin-4-yl]-(S)-phenylalanine Derivatives as Tryptophan Hydroxylase Inhibitors</span>. <span class="NLM_patent">WO 2008073933A2</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=A.+Devasagayaraj&author=H.+Jin&author=Z.-C.+Shi&author=A.+Tunoori&author=Y.+Wang&author=C.+Zhang&title=Preparation+of+4-%5B6-%282%2C2%2C2-Trifluoro-1-phenylethoxy%29pyrimidin-4-yl%5D-%28S%29-phenylalanine+Derivatives+as+Tryptophan+Hydroxylase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDevasagayaraj%26aufirst%3DA.%26atitle%3DPreparation%2520of%25204-%255B6-%25282%252C2%252C2-Trifluoro-1-phenylethoxy%2529pyrimidin-4-yl%255D-%2528S%2529-phenylalanine%2520Derivatives%2520as%2520Tryptophan%2520Hydroxylase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dewasajiayalayi, A.</span>; <span class="NLM_string-name">Jin, H.</span>; <span class="NLM_string-name">Shi, Z.</span>; <span class="NLM_string-name">Tunuli, A.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrimidine Derivatives as Tph1 Inhibitors</span>. <span class="NLM_patent">CN 101591332A</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Dewasajiayalayi&author=H.+Jin&author=Z.+Shi&author=A.+Tunuli&author=Y.+Wang&author=C.+Zhang&title=Preparation+of+Pyrimidine+Derivatives+as+Tph1+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewasajiayalayi%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520Derivatives%2520as%2520Tph1%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Zambrowicz, B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Multicyclic Amino Acid Derivative Tryptophan Hydroxylase Inhibitors and Methods of Using Them for Affecting Gastrointestinal Transit and Gastric Emptying</span>. <span class="NLM_patent">WO 2009014972A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=Q.+Liu&author=B.+Zambrowicz&title=Preparation+of+Multicyclic+Amino+Acid+Derivative+Tryptophan+Hydroxylase+Inhibitors+and+Methods+of+Using+Them+for+Affecting+Gastrointestinal+Transit+and+Gastric+Emptying"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520Multicyclic%2520Amino%2520Acid%2520Derivative%2520Tryptophan%2520Hydroxylase%2520Inhibitors%2520and%2520Methods%2520of%2520Using%2520Them%2520for%2520Affecting%2520Gastrointestinal%2520Transit%2520and%2520Gastric%2520Emptying%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Oravecz, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2-Amino-3-Arylpropanoic Acid and 2-Amino-3-Heterocyclylpropanoic Acid Derivatives as Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer</span>. <span class="NLM_patent">WO 2011056916A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=T.+Oravecz&title=Preparation+of+2-Amino-3-Arylpropanoic+Acid+and+2-Amino-3-Heterocyclylpropanoic+Acid+Derivatives+as+Tryptophan+Hydroxylase+Inhibitors+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOravecz%26aufirst%3DT.%26atitle%3DPreparation%2520of%25202-Amino-3-Arylpropanoic%2520Acid%2520and%25202-Amino-3-Heterocyclylpropanoic%2520Acid%2520Derivatives%2520as%2520Tryptophan%2520Hydroxylase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sands, A. T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Multicyclic Amino Acid Derivations as Potent and Selective Thp1 Inhibitors for Treating Metastatic Bone Disease</span>. <span class="NLM_patent">WO 2011100285A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+T.+Sands&title=Preparation+of+Multicyclic+Amino+Acid+Derivations+as+Potent+and+Selective+Thp1+Inhibitors+for+Treating+Metastatic+Bone+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSands%26aufirst%3DA.%2BT.%26atitle%3DPreparation%2520of%2520Multicyclic%2520Amino%2520Acid%2520Derivations%2520as%2520Potent%2520and%2520Selective%2520Thp1%2520Inhibitors%2520for%2520Treating%2520Metastatic%2520Bone%2520Disease%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.-C.</span>; <span class="NLM_string-name">Zhao, M. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-[6-(2,2,2-Trifluoro-1-phenylethoxy)pyrimidin-4-yl]-(S)-phenylalanine Derivative Tryptophan Hydroxylase Inhibitors for Treating Osteoporosis</span>. <span class="NLM_patent">WO 2010065333A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Z.-C.+Shi&author=M.+M.+Zhao&title=Preparation+of+4-%5B6-%282%2C2%2C2-Trifluoro-1-phenylethoxy%29pyrimidin-4-yl%5D-%28S%29-phenylalanine+Derivative+Tryptophan+Hydroxylase+Inhibitors+for+Treating+Osteoporosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.-C.%26atitle%3DPreparation%2520of%25204-%255B6-%25282%252C2%252C2-Trifluoro-1-phenylethoxy%2529pyrimidin-4-yl%255D-%2528S%2529-phenylalanine%2520Derivative%2520Tryptophan%2520Hydroxylase%2520Inhibitors%2520for%2520Treating%2520Osteoporosis%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136a"><span><span class="NLM_label">(a) </span> <a href="http://www.aveooncology.com/wp-content/uploads/2017/08/AVEO-EC-Tivozanib-Approval.pdf" class="extLink">http://www.aveooncology.com/wp-content/uploads/2017/08/AVEO-EC-Tivozanib-Approval.pdf</a> (accessed November 19, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+http%3A%2F%2Fwww.aveooncology.com%2Fwp-content%2Fuploads%2F2017%2F08%2FAVEO-EC-Tivozanib-Approval.pdf+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit136b"><span><span class="NLM_label">(b) </span> <i>AVEO Oncology Announces FOTIVDA
(tivozanib) Approved in the European Union for the Treatment of Advanced
Renal Cell Carcinoma</i>; <span class="NLM_publisher-name">AVEO Oncology</span>, August 28, <span class="NLM_year">2017</span>; <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004131/WC500229916.pdf" class="extLink">http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004131/WC500229916.pdf</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+AVEO+Oncology+Announces+FOTIVDA%0A%28tivozanib%29+Approved+in+the+European+Union+for+the+Treatment+of+Advanced%0ARenal+Cell+Carcinoma%3B+AVEO+Oncology%2C+August+28%2C+2017%3B+http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FSummary_of_opinion_-_Initial_authorisation%2Fhuman%2F004131%2FWC500229916.pdf+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DAVEO%2520Oncology%2520Announces%2520FOTIVDA%250A%2528tivozanib%2529%2520Approved%2520in%2520the%2520European%2520Union%2520for%2520the%2520Treatment%2520of%2520Advanced%250ARenal%2520Cell%2520Carcinoma%26pub%3DAVEO%2520Oncology%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jamil, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hathaway, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span> <span> </span><span class="NLM_article-title">Tivozanib: Status of Development</span>. <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1007/s11912-015-0451-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs11912-015-0451-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=25895472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC2MjmsFChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=24&author=M.+O.+Jamilauthor=A.+Hathawayauthor=A.+Mehta&title=Tivozanib%3A+Status+of+Development&doi=10.1007%2Fs11912-015-0451-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137aR"><div class="casContent"><span class="casTitleNuber">137a</span><div class="casTitle"><span class="NLM_cas:atitle">Tivozanib: status of development</span></div><div class="casAuthors">Jamil Muhammad Omer; Hathaway Amanda; Mehta Amitkumar</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tivozanib is a potent and highly specific orally available, tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGF) receptor-1, VEGF receptor-2, and VEGF receptor-3 at very low concentrations with a long half-life (4 days).  After its promising activity in xenograft and preclinical models, tivozanib was evaluated in early phase clinical trials in various solid tumors.  The phase III trial (TIVO-1) compared tivozanib with sorafenib in metastatic clear cell renal cell carcinoma (RCC).  Because of detrimental overall survival (OS), Oncology Drug Advisory Committee (ODAC) voted against its approval in RCC.  Tivozanib is also being evaluated in various other solid tumors like breast, gastrointestinal cancers, hepatocellular cancer, sarcomas, and gynecological cancer.  In BATON-CRC trial, low-serum neuropilin-1 (NRP-1) levels were associated with better progression-free survival (PFS) in patients treated with tivozanib.  The NRP-1 will be evaluated as a biomarker for tivozanib response in future clinical trials.  Ongoing clinical trial will further characterize activity of tivozanib in hepatocellular carcinoma, sarcomas, and gynecologic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0plewKHhQskPI-fCgwosgfW6udTcc2eauwZd0BmWKlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjmsFChsQ%253D%253D&md5=d3942d24a88da10edca55431823b651e</span></div><a href="/servlet/linkout?suffix=cit137a&amp;dbid=16384&amp;doi=10.1007%2Fs11912-015-0451-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-015-0451-3%26sid%3Dliteratum%253Aachs%26aulast%3DJamil%26aufirst%3DM.%2BO.%26aulast%3DHathaway%26aufirst%3DA.%26aulast%3DMehta%26aufirst%3DA.%26atitle%3DTivozanib%253A%2520Status%2520of%2520Development%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2015%26volume%3D17%26spage%3D24%26doi%3D10.1007%2Fs11912-015-0451-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit137b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Campas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, R.</span></span> <span> </span><span class="NLM_article-title">Tivozanib: Veger Tyrosine Kinase Inhibitor Angiogenesis Inhibitor Oncolytic</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1358/dof.2009.034.10.1417872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1358%2Fdof.2009.034.10.1417872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1WnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=793-796&author=C.+Campasauthor=J.+Bolosauthor=R.+Castaner&title=Tivozanib%3A+Veger+Tyrosine+Kinase+Inhibitor+Angiogenesis+Inhibitor+Oncolytic&doi=10.1358%2Fdof.2009.034.10.1417872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137bR"><div class="casContent"><span class="casTitleNuber">137b</span><div class="casTitle"><span class="NLM_cas:atitle">TIVOZANIB: VEGER tyrosine kinase inhibitor angiogenesis inhibitor oncolytic</span></div><div class="casAuthors">Campas, C.; Bolos, J.; Castaner, R.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">793-796</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Tivozanib is a novel oral quinoline urea deriv. with potent and selective activity against vascular endothelial growth factor (VEGFR) tyrosine kinase.  Preclin. data indicate that tivozanib blocks the proliferation and migration of endothelial cells in vitro, and suppresses angiogenesis and growth of human tumor xenografts in vivo.  Tivozanib has been shown to be safe and orally bioavailable when given to cancer patients.  Early clin. trials demonstrated inhibition of angiogenesis and tumor progression in several types of advanced solid tumors.  The compd. is under early clin. investigation for the treatment of renal cell carcinoma and non-small cell lung carcinoma, as well as in combination with other chemotherapies in breast, colorectal, and other gastrointestinal cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorlOz15aO1ZbVg90H21EOLACvtfcHk0ljnOGin0hmT3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1WnsLk%253D&md5=c6ca2b5f65472146d6d348ebbd4d62f2</span></div><a href="/servlet/linkout?suffix=cit137b&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.10.1417872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.10.1417872%26sid%3Dliteratum%253Aachs%26aulast%3DCampas%26aufirst%3DC.%26aulast%3DBolos%26aufirst%3DJ.%26aulast%3DCastaner%26aufirst%3DR.%26atitle%3DTivozanib%253A%2520Veger%2520Tyrosine%2520Kinase%2520Inhibitor%2520Angiogenesis%2520Inhibitor%2520Oncolytic%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D793%26epage%3D796%26doi%3D10.1358%2Fdof.2009.034.10.1417872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit137c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hepgur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorff, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, D. I.</span></span> <span> </span><span class="NLM_article-title">Tivozanib in the Treatment of Renal Cell Carcinoma</span>. <i>Biol.: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.2147/BTT.S32958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2147%2FBTT.S32958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=23788831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVanurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=139-148&author=M.+Hepgurauthor=S.+Sadeghiauthor=T.+B.+Dorffauthor=D.+I.+Quinn&title=Tivozanib+in+the+Treatment+of+Renal+Cell+Carcinoma&doi=10.2147%2FBTT.S32958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137cR"><div class="casContent"><span class="casTitleNuber">137c</span><div class="casTitle"><span class="NLM_cas:atitle">Tivozanib in the treatment of renal cell carcinoma</span></div><div class="casAuthors">Hepgur, Mehmet; Sadeghi, Sarmad; Dorff, Tanya B.; Quinn, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Biologics: Targets & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139-148</span>CODEN:
                <span class="NLM_cas:coden">BTTICT</span>;
        ISSN:<span class="NLM_cas:issn">1177-5491</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urol. malignancies and has been assocd. with poor responses to conventional cytotoxic chemotherapy.  Interferon-α and interleukin-2 were previously utilized in a limited no. of patients with good performance status due to toxicity and safety issues.  Over the last decade, through advances in the understanding of the biol. and pathol. of RCC, the important role of vascular endothelial growth factor (VEGF) in RCC has been identified.  Data from randomized trials have led to the approval of first-generation tyrosine kinase inhibitors (TKIs) sorafenib, sunitinib and pazopanib; however, these agents inhibit a wide variety of kinase targets and are assocd. with a range of adverse effects.  More recently, a new generation TKI, axitinib, has been approved by the US Food and Drug Administration.  Tivozanib is a novel TKI, which is a potent inhibitor of VEGF-1, VEGF-2, VEGF-3, c-kit and PDGR kinases, with a more restricted target spectrum.  Phase II and III studies have demonstrated significant activity and a favorable safety profile as an initial targeted treatment for advanced RCC.  This review examines the emerging data with tivozanib for the treatment of advanced RCC.  Preclin. investigations as well as Phase I, II and III data are examd.; data on the comparative benefits of tivozanib are reviewed.  Finally, we discuss the future potential of tivozanib in combination, biomarkers assocd. with tivozanib response and acquisition of resistance and nonkidney cancer indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0TzOgbrWMGrVg90H21EOLACvtfcHk0lgSO7aSRWBtAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVanurbN&md5=7fa8d758928d7c3d6774f081565b7f7f</span></div><a href="/servlet/linkout?suffix=cit137c&amp;dbid=16384&amp;doi=10.2147%2FBTT.S32958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBTT.S32958%26sid%3Dliteratum%253Aachs%26aulast%3DHepgur%26aufirst%3DM.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DDorff%26aufirst%3DT.%2BB.%26aulast%3DQuinn%26aufirst%3DD.%2BI.%26atitle%3DTivozanib%2520in%2520the%2520Treatment%2520of%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DBiol.%253A%2520Targets%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D139%26epage%3D148%26doi%3D10.2147%2FBTT.S32958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesovoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipatov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyulko, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alyasova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alekseev, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczylik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivoshik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strahs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteves, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenblit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span> <span> </span><span class="NLM_article-title">Tivozanib Versus Sorafenib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma: Results from a Phase Iii Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">3791</span>– <span class="NLM_lpage">3799</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.47.4940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1200%2FJCO.2012.47.4940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=24019545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWgtrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3791-3799&author=R.+J.+Motzerauthor=D.+Nosovauthor=T.+Eisenauthor=I.+Bondarenkoauthor=V.+Lesovoyauthor=O.+Lipatovauthor=P.+Tomczakauthor=O.+Lyulkoauthor=A.+Alyasovaauthor=M.+Harzaauthor=M.+Koganauthor=B.+Y.+Alekseevauthor=C.+N.+Sternbergauthor=C.+Szczylikauthor=D.+Cellaauthor=C.+Ivanescuauthor=A.+Krivoshikauthor=A.+Strahsauthor=B.+Estevesauthor=A.+Berkenblitauthor=T.+E.+Hutson&title=Tivozanib+Versus+Sorafenib+as+Initial+Targeted+Therapy+for+Patients+with+Metastatic+Renal+Cell+Carcinoma%3A+Results+from+a+Phase+Iii+Trial&doi=10.1200%2FJCO.2012.47.4940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial</span></div><div class="casAuthors">Motzer, Robert J.; Nosov, Dmitry; Eisen, Timothy; Bondarenko, Igor; Lesovoy, Vladimir; Lipatov, Oleg; Tomczak, Piotr; Lyulko, Oleksiy; Alyasova, Anna; Harza, Mihai; Kogan, Mikhail; Alekseev, Boris Y.; Sternberg, Cora N.; Szczylik, Cezary; Cella, David; Ivanescu, Cristina; Krivoshik, Andrew; Strahs, Andrew; Esteves, Brooke; Berkenblit, Anna; Hutson, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3791-3799</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3.  This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC).  Patients and Methods: Patients with metastatic RCC, with a clear cell component, prior nephrectomy, measurable disease, and 0 or 1 prior therapies for metastatic RCC were randomly assigned to tivozanib or sorafenib.  Prior VEGF-targeted therapy and mammalian target of rapamycin inhibitor were not permitted.  The primary end point was progression-free survival (PFS) by independent review.  Results: A total of 517 patients were randomly assigned to tivozanib (n = 260) or sorafenib (n = 257).  PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 mo; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042).  One hundred fifty-six patients (61%) who progressed on sorafenib crossed over to receive tivozanib.  The final overall survival (OS) anal. showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 mo; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105).  Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).  AEs more common with sorafenio than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).  Conclusion: Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlnE_Hp1TY6bVg90H21EOLACvtfcHk0lgSO7aSRWBtAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWgtrvK&md5=38cca075b6a432b228b7aaad9df1f595</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.47.4940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.47.4940%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DNosov%26aufirst%3DD.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DLesovoy%26aufirst%3DV.%26aulast%3DLipatov%26aufirst%3DO.%26aulast%3DTomczak%26aufirst%3DP.%26aulast%3DLyulko%26aufirst%3DO.%26aulast%3DAlyasova%26aufirst%3DA.%26aulast%3DHarza%26aufirst%3DM.%26aulast%3DKogan%26aufirst%3DM.%26aulast%3DAlekseev%26aufirst%3DB.%2BY.%26aulast%3DSternberg%26aufirst%3DC.%2BN.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DCella%26aufirst%3DD.%26aulast%3DIvanescu%26aufirst%3DC.%26aulast%3DKrivoshik%26aufirst%3DA.%26aulast%3DStrahs%26aufirst%3DA.%26aulast%3DEsteves%26aufirst%3DB.%26aulast%3DBerkenblit%26aufirst%3DA.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26atitle%3DTivozanib%2520Versus%2520Sorafenib%2520as%2520Initial%2520Targeted%2520Therapy%2520for%2520Patients%2520with%2520Metastatic%2520Renal%2520Cell%2520Carcinoma%253A%2520Results%2520from%2520a%2520Phase%2520Iii%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3791%26epage%3D3799%26doi%3D10.1200%2FJCO.2012.47.4940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Tivozanib</span>. <i>Chinese J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">544</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2013&pages=541-544&author=J.+Wangauthor=Y.+Wangauthor=Y.+Qin&title=Synthesis+of+Tivozanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520Tivozanib%26jtitle%3DChinese%2520J.%2520Pharm.%26date%3D2013%26volume%3D44%26spage%3D541%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit139b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Wu, J.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Method for Synthesizing Antitumor Targeting Drug Tivozanib</span>. <span class="NLM_patent">CN 102532116</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Liu&author=L.+Hu&author=J.+Wu&author=Z.+Zhang&author=J.+Liu&title=Method+for+Synthesizing+Antitumor+Targeting+Drug+Tivozanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26atitle%3DMethod%2520for%2520Synthesizing%2520Antitumor%2520Targeting%2520Drug%2520Tivozanib%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit139c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.-W.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Tivozanib Hydrochloride Monohydrate</span>. <i>Chin. J. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">29</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=26-29&author=Y.+Fuauthor=Q.-W.+Zhang&title=Synthesis+of+Tivozanib+Hydrochloride+Monohydrate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.-W.%26atitle%3DSynthesis%2520of%2520Tivozanib%2520Hydrochloride%2520Monohydrate%26jtitle%3DChin.%2520J.%2520New%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D26%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit139d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span>; <span class="NLM_string-name">Fang, Y.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Method for Synthesizing Tivozanib as Antitumor Drug Targeting Therapy</span>. <span class="NLM_patent">CN 104072492</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+Cai&author=Y.+Fang&author=Z.+Chen&author=L.+Zhang&title=Method+for+Synthesizing+Tivozanib+as+Antitumor+Drug+Targeting+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DJ.%26atitle%3DMethod%2520for%2520Synthesizing%2520Tivozanib%2520as%2520Antitumor%2520Drug%2520Targeting%2520Therapy%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span>; <span class="NLM_string-name">Yoshida, S.</span>; <span class="NLM_string-name">Yoshino, A.</span>; <span class="NLM_string-name">Nakajima, T.</span></span> <span> </span><span class="NLM_article-title">N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N′-(5-methyl-3-isoxazolyl)urea Salt Crystals</span>. <span class="NLM_patent">WO 2004035572</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=N.+Matsunaga&author=S.+Yoshida&author=A.+Yoshino&author=T.+Nakajima&title=N-%5B2-Chloro-4-%5B%286%2C7-dimethoxy-4-quinolyl%29oxy%5Dphenyl%5D-N%E2%80%B2-%285-methyl-3-isoxazolyl%29urea+Salt+Crystals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DN.%26atitle%3DN-%255B2-Chloro-4-%255B%25286%252C7-dimethoxy-4-quinolyl%2529oxy%255Dphenyl%255D-N%25E2%2580%25B2-%25285-methyl-3-isoxazolyl%2529urea%2520Salt%2520Crystals%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit140b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span>; <span class="NLM_string-name">Yoshida, S.</span>; <span class="NLM_string-name">Yoshino, A.</span>; <span class="NLM_string-name">Nakajima, T.</span></span> <span> </span><span class="NLM_article-title">N-[2-Chloro-4-[6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N′-5-methyl-3-isoxazolyl)urea Salt in Crystalline Form</span>. <span class="NLM_patent">US 7166722 B2</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+Matsunaga&author=S.+Yoshida&author=A.+Yoshino&author=T.+Nakajima&title=N-%5B2-Chloro-4-%5B6%2C7-dimethoxy-4-quinolyl%29oxy%5Dphenyl%5D-N%E2%80%B2-5-methyl-3-isoxazolyl%29urea+Salt+in+Crystalline+Form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DN.%26atitle%3DN-%255B2-Chloro-4-%255B6%252C7-dimethoxy-4-quinolyl%2529oxy%255Dphenyl%255D-N%25E2%2580%25B2-5-methyl-3-isoxazolyl%2529urea%2520Salt%2520in%2520Crystalline%2520Form%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohyama, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murooka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoe, T.</span></span> <span> </span><span class="NLM_article-title">Novel Potent Orally Active Selective Vegfr-2 Tyrosine Kinase Inhibitors: Synthesis, Structure-Activity Relationships, and Antitumor Activities of N-Phenyl-N′-{4-(4-Quinolyloxy)Phenyl}Ureas</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1359</span>– <span class="NLM_lpage">1366</span>, <span class="refDoi"> DOI: 10.1021/jm030427r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030427r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ygtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1359-1366&author=K.+Kuboauthor=T.+Shimizuauthor=S.-I.+Ohyamaauthor=H.+Murookaauthor=A.+Iwaiauthor=K.+Nakamuraauthor=K.+Hasegawaauthor=Y.+Kobayashiauthor=N.+Takahashiauthor=K.+Takahashiauthor=S.+Katoauthor=T.+Izawaauthor=T.+Isoe&title=Novel+Potent+Orally+Active+Selective+Vegfr-2+Tyrosine+Kinase+Inhibitors%3A+Synthesis%2C+Structure-Activity+Relationships%2C+and+Antitumor+Activities+of+N-Phenyl-N%E2%80%B2-%7B4-%284-Quinolyloxy%29Phenyl%7DUreas&doi=10.1021%2Fjm030427r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Structure-Activity Relationships, and Antitumor Activities of N-Phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas</span></div><div class="casAuthors">Kubo, Kazuo; Shimizu, Toshiyuki; Ohyama, Shin-Ichi; Murooka, Hideko; Iwai, Akemi; Nakamura, Kazuhide; Hasegawa, Kazumasa; Kobayashi, Yoshiko; Takahashi, Noriko; Takahashi, Kazumi; Kato, Shinichiro; Izawa, Toshio; Isoe, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1359-1366</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas were found to be a novel class of potent inhibitors for the vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase through synthetic modifications of a lead compd. and structure-activity relationship studies.  A representative compd. N-(2,4-difluorophenyl)-N'-4-[[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyl]urea, termed Ki8751, inhibited VEGFR-2 phosphorylation at an IC50 value of 0.90 nM, and also inhibited the PDGFR family members such as PDGFRα and c-Kit at 67 nM and 40 nM, resp.  However, Ki8751 did not have any inhibitory activity against other kinases such as EGFR, HGFR, InsulinR and others even at 10000 nM.  Ki8751 suppressed the growth of the VEGF-stimulated human umbilical vein endothelial cell (HUVEC) on a nanomolar level.  Ki8751 showed significant antitumor activity against five human tumor xenografts such as GL07 (glioma), St-4 (stomach carcinoma), LC6 (lung carcinoma), DLD-1 (colon carcinoma) and A375 (melanoma) in nude mice and also showed complete tumor growth inhibition with the LC-6 xenograft in nude rats following oral administration once a day for 14 days at 5 mg/kg without any body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbbFPBOSTo07Vg90H21EOLACvtfcHk0lgO0V60-YYcRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ygtrw%253D&md5=bdd440cf8de6044243dc19b23438e50a</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm030427r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030427r%26sid%3Dliteratum%253Aachs%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DOhyama%26aufirst%3DS.-I.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DS.%26aulast%3DIzawa%26aufirst%3DT.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DNovel%2520Potent%2520Orally%2520Active%2520Selective%2520Vegfr-2%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Synthesis%252C%2520Structure-Activity%2520Relationships%252C%2520and%2520Antitumor%2520Activities%2520of%2520N-Phenyl-N%25E2%2580%25B2-%257B4-%25284-Quinolyloxy%2529Phenyl%257DUreas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1359%26epage%3D1366%26doi%3D10.1021%2Fjm030427r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Impagnatiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirante, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquesroix, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, M. V. W.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin Analogues and Nitric Oxide Contribution in the Treatment of Ocular Hypertension and Glaucoma</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1079</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1111/bph.14328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1111%2Fbph.14328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29669171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSksrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=1079-1089&author=F.+Impagnatielloauthor=E.+Bastiaauthor=N.+Almiranteauthor=S.+Brambillaauthor=B.+Duquesroixauthor=A.+C.+Kotheauthor=M.+V.+W.+Bergamini&title=Prostaglandin+Analogues+and+Nitric+Oxide+Contribution+in+the+Treatment+of+Ocular+Hypertension+and+Glaucoma&doi=10.1111%2Fbph.14328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142aR"><div class="casContent"><span class="casTitleNuber">142a</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma</span></div><div class="casAuthors">Impagnatiello, Francesco; Bastia, Elena; Almirante, Nicoletta; Brambilla, Stefania; Duquesroix, Brigitte; Kothe, Angela C.; Bergamini, Michael V. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1079-1089</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  In patients with ocular hypertension or glaucoma, all treatments aim to lower intraocular pressure (IOP) by modulating aq. humor (AH) prodn. and/or uveoscleral and trabecular meshwork/Schlemm's canal AH drainage.  PG analogs are considered to be the 'gold std.' treatment and are the most frequently used IOP-lowering agents.  Recent data support an important role for NO in regulating IOP.  Thus, novel PG analogs carrying a NO-donating moiety were recently advanced.  Latanoprostene bunod (LBN) and NCX 470, NO-donating derivs. of latanoprost and bimatoprost, resp., are examples of such compds.  LBN ophthalmic soln., 0.024% (Vyzulta), showed greater IOP-lowering efficacy compared with that of Xalatan (latanoprost ophthalmic soln., 0.005%) or 0.5% timolol maleate in clin. settings.  NCX 470 was found to be more effective than bimatoprost in animal models of ocular hypertension and glaucoma.  Selective EP2 receptor agonists (i.e. taprenepag iso-Pr, omidenepag iso-Pr and aganepag isopropyl) and non-selective prostanoid receptor agonists (i.e. ONO-9054, sepetaprost isopropyl) that concomitantly stimulate FP and EP3 receptors have also been shown to hold promise as effective IOP-lowering agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrykVVGgiMxYbVg90H21EOLACvtfcHk0lgO0V60-YYcRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSksrzE&md5=6c342f008858bc8206eea2c038b8f840</span></div><a href="/servlet/linkout?suffix=cit142a&amp;dbid=16384&amp;doi=10.1111%2Fbph.14328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14328%26sid%3Dliteratum%253Aachs%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DBastia%26aufirst%3DE.%26aulast%3DAlmirante%26aufirst%3DN.%26aulast%3DBrambilla%26aufirst%3DS.%26aulast%3DDuquesroix%26aufirst%3DB.%26aulast%3DKothe%26aufirst%3DA.%2BC.%26aulast%3DBergamini%26aufirst%3DM.%2BV.%2BW.%26atitle%3DProstaglandin%2520Analogues%2520and%2520Nitric%2520Oxide%2520Contribution%2520in%2520the%2520Treatment%2520of%2520Ocular%2520Hypertension%2520and%2520Glaucoma%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3D1079%26epage%3D1089%26doi%3D10.1111%2Fbph.14328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit142b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, R.</span></span> <span> </span><span class="NLM_article-title">Latanoprostene Bunod, a Dual-Acting Nitric Oxide Donating Prostaglandin Analog for Lowering of Intraocular Pressure</span>. <i>US Ophthalmic Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.17925/USOR.2016.09.02.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.17925%2FUSOR.2016.09.02.80" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80-87&author=R.+N.+Weinrebauthor=T.+Realiniauthor=R.+Varma&title=Latanoprostene+Bunod%2C+a+Dual-Acting+Nitric+Oxide+Donating+Prostaglandin+Analog+for+Lowering+of+Intraocular+Pressure&doi=10.17925%2FUSOR.2016.09.02.80"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142b&amp;dbid=16384&amp;doi=10.17925%2FUSOR.2016.09.02.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17925%252FUSOR.2016.09.02.80%26sid%3Dliteratum%253Aachs%26aulast%3DWeinreb%26aufirst%3DR.%2BN.%26aulast%3DRealini%26aufirst%3DT.%26aulast%3DVarma%26aufirst%3DR.%26atitle%3DLatanoprostene%2520Bunod%252C%2520a%2520Dual-Acting%2520Nitric%2520Oxide%2520Donating%2520Prostaglandin%2520Analog%2520for%2520Lowering%2520of%2520Intraocular%2520Pressure%26jtitle%3DUS%2520Ophthalmic%2520Rev.%26date%3D2016%26volume%3D9%26spage%3D80%26epage%3D87%26doi%3D10.17925%2FUSOR.2016.09.02.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0914-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0914-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29761382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=773-780&author=S.+M.+Hoy&title=Latanoprostene+Bunod+Ophthalmic+Solution+0.024%25%3A+A+Review+in+Open-Angle+Glaucoma+and+Ocular+Hypertension&doi=10.1007%2Fs40265-018-0914-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">773-780</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Latanoprostene bunod ophthalmic soln. 0.024% (hereafter referred to as latanoprostene bunod 0.024%) [Vyzulta] is a nitric oxide (NO)-donating prostaglandin F2α analog approved in the USA for the redn. of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.  It is thought to lower IOP by increasing aq. humor outflow through the uveoscleral pathway (mediated by latanoprost acid) and increasing the facility of aq. humor outflow through the trabecular meshwork pathway (mediated by NO).  Results from two multinational, phase III studies (APOLLO and LUNAR) and a pooled anal. of these studies demonstrated the noninferiority of latanoprostene bunod 0.024% to timolol ophthalmic soln. 0.5% (hereafter referred to as timolol 0.5%) in terms of IOP-lowering efficacy over 3 mo in patients with OAG or ocular hypertension, with the superiority of latanoprostene bunod 0.024% over timolol 0.5% subsequently demonstrated in APOLLO and the pooled anal.  Moreover, there was no apparent loss of IOP-lowering effect in subsequent safety extension periods of up to 9 mo.  The IOP-lowering efficacy seen in APOLLO and LUNAR was confirmed in a phase III study (JUPITER) in Japanese patients, with IOP redns. obsd. early (week 4) and maintained over the longer-term (12 mo).  Latanoprostene bunod 0.024% was well tolerated over up to 12 mo in these studies, with most ocular treatment-emergent adverse events (TEAEs) being mild to moderate in severity.  Thus, current evidence indicates once-daily latanoprostene bunod 0.024% is an effective and well tolerated treatment option for the redn. of IOP in adults with OAG or ocular hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr26pnF0TbnBLVg90H21EOLACvtfcHk0lh8NYK8oNzqcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVCksb0%253D&md5=6d3a7bcdc17c510fdbf4d638f026241b</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0914-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0914-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DLatanoprostene%2520Bunod%2520Ophthalmic%2520Solution%25200.024%2525%253A%2520A%2520Review%2520in%2520Open-Angle%2520Glaucoma%2520and%2520Ocular%2520Hypertension%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D773%26epage%3D780%26doi%3D10.1007%2Fs40265-018-0914-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span>; <span class="NLM_string-name">Benedini, F.</span>; <span class="NLM_string-name">Chiroli, V.</span>; <span class="NLM_string-name">Del Soldato, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Prostaglandin Nitrooxy Derivatives for the Treatment of Glaucoma</span>. <span class="NLM_patent">WO 2005068421</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=E.+Ongini&author=F.+Benedini&author=V.+Chiroli&author=P.+Del+Soldato&title=Preparation+of+Prostaglandin+Nitrooxy+Derivatives+for+the+Treatment+of+Glaucoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOngini%26aufirst%3DE.%26atitle%3DPreparation%2520of%2520Prostaglandin%2520Nitrooxy%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Glaucoma%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Vittitow, J. L.</span>; <span class="NLM_string-name">Cavet, M. E.</span></span> <span> </span><span class="NLM_article-title">Nitric Oxide Releasing Prostaglandin Derivatives for Treating Normal Tension Glaucoma</span>. <span class="NLM_patent">WO 2018087092</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+L.+Vittitow&author=M.+E.+Cavet&title=Nitric+Oxide+Releasing+Prostaglandin+Derivatives+for+Treating+Normal+Tension+Glaucoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVittitow%26aufirst%3DJ.%2BL.%26atitle%3DNitric%2520Oxide%2520Releasing%2520Prostaglandin%2520Derivatives%2520for%2520Treating%2520Normal%2520Tension%2520Glaucoma%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Netarsudil Ophthalmic Solution 0.02%: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0877-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0877-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29453668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=389-396&author=S.+M.+Hoy&title=Netarsudil+Ophthalmic+Solution+0.02%25%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0877-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Netarsudil Ophthalmic Solution 0.02%: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-396</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Netarsudil ophthalmic soln. 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa] is a Rho-assocd. protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aq. humor outflow through the trabecular meshwork.  It has been developed by Aerie Pharmaceuticals and was recently approved in the USA for the redn. of elevated IOP in patients with open-angle glaucoma or ocular hypertension.  The recommended dosage is one drop in the affected eye(s) once daily in the evening.  Phase III development in the EU and phase II development in Japan are underway for this indication.  This article summarizes the milestones in the development of netarsudil 0.02% leading to this first approval for the redn. of elevated IOP in patients with open-angle glaucoma or ocular hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp80gV1sA_qmLVg90H21EOLACvtfcHk0lh8NYK8oNzqcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFOksbo%253D&md5=246f7b80c4a4d244e53c36ee42d3ae4b</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0877-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0877-7%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DNetarsudil%2520Ophthalmic%2520Solution%25200.02%2525%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D389%26epage%3D396%26doi%3D10.1007%2Fs40265-018-0877-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laethem, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deLong, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopczunski, C. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1089/jop.2017.0023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1089%2Fjop.2017.0023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28609185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=40-51&author=C.-W.+Linauthor=B.+Shermanauthor=L.+A.+Mooreauthor=C.+L.+Laethemauthor=D.-W.+Luauthor=P.+P.+Pattabiramanauthor=P.+V.+Raoauthor=M.+A.+deLongauthor=C.+C.+Kopczunski&title=Discovery+and+Preclinical+Development+of+Netarsudil%2C+a+Novel+Ocular+Hypotensive+Agent+for+the+Treatment+of+Glaucoma&doi=10.1089%2Fjop.2017.0023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma</span></div><div class="casAuthors">Lin, Cheng-Wen; Sherman, Bryan; Moore, Lori A.; Laethem, Carmen L.; Lu, Da-Wen; Pattabiraman, Padmanabhan P.; Rao, Ponugoti Vasantha; de Long, Mitchell A.; Kopczynski, Casey C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Purpose: Rho-assocd. protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aq. outflow through the trabecular meshwork (TM).  The preclin. characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clin. development, is presented herein.  Methods: The kinase inhibitory activity of netarsudil was compared to its esterase metabolite, netarsudil-M1, and 3 other ROCK inhibitors using a com. available kinase assay kit.  Disruption of actin stress fibers was measured in primary porcine TM cells and disruption of focal adhesions in transformed human TM (HTM) cells.  Induction of fibrosis markers after exposure to transforming growth factor-β2 (TGF-β2) was conducted in primary HTM cells.  Ocular hypotensive activity and tolerability of topical formulations were evaluated in normotensive Dutch Belted rabbits and Formosan Rock monkeys.  In vitro corneal metab. assays were conducted using dog, pig, rabbit, monkey, and human corneas.  In vivo ocular pharmacokinetics was studied in Dutch Belted rabbits.  Results: Netarsudil inhibited kinases ROCK1 and ROCK2 with a Ki of 1 nM each, disrupted actin stress fibers and focal adhesions in TM cells with IC50s of 79 and 16 nM, resp., and blocked the profibrotic effects of TGF-β2 in HTM cells.  Netarsudil produced large redns. in IOP in rabbits and monkeys that were sustained for at least 24 h after once daily dosing, with transient, mild hyperemia obsd. as the only adverse effect.  Conclusion: Netarsudil is a novel ROCK/NET inhibitor with high potency in biochem. and cell-based assays, an ability to produce large and durable IOP redns. in animal models, and favorable pharmacokinetic and ocular tolerability profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzAaB4ou88g7Vg90H21EOLACvtfcHk0lgaLQwod_DTlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCns7w%253D&md5=0aab049b2ff35df0ce0f03b33bb5f501</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1089%2Fjop.2017.0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjop.2017.0023%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DSherman%26aufirst%3DB.%26aulast%3DMoore%26aufirst%3DL.%2BA.%26aulast%3DLaethem%26aufirst%3DC.%2BL.%26aulast%3DLu%26aufirst%3DD.-W.%26aulast%3DPattabiraman%26aufirst%3DP.%2BP.%26aulast%3DRao%26aufirst%3DP.%2BV.%26aulast%3DdeLong%26aufirst%3DM.%2BA.%26aulast%3DKopczunski%26aufirst%3DC.%2BC.%26atitle%3DDiscovery%2520and%2520Preclinical%2520Development%2520of%2520Netarsudil%252C%2520a%2520Novel%2520Ocular%2520Hypotensive%2520Agent%2520for%2520the%2520Treatment%2520of%2520Glaucoma%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D34%26spage%3D40%26epage%3D51%26doi%3D10.1089%2Fjop.2017.0023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma</span>. <i>Yale J. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28356898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFaqur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2017&pages=111-118&author=L.+Luauthor=J.+C.+Tsaiauthor=J.+Liu&title=Novel+Pharmacologic+Candidates+for+Treatment+of+Primary+Open-Angle+Glaucoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Novel pharmacologic candidates for treatment of primary open-angle glaucoma</span></div><div class="casAuthors">Lu, Louise J.; Tsai, James C.; Liu, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Yale Journal of Biology and Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">YJBMAU</span>;
        ISSN:<span class="NLM_cas:issn">0044-0086</span>.
    
            (<span class="NLM_cas:orgname">Yale Journal of Biology and Medicine</span>)
        </div><div class="casAbstract">Primary open-angle glaucoma (OAG†) affects approx. 45 million people worldwide and more than 2.5 million people aged 40 years or older in the United States.  Pharmacol. treatment for glaucoma is directed towards lowering intraocular pressure (IOP) to slow disease progression and delay visual field loss.  Current medical treatment options for the lowering of IOP include the following classes of topical medications: beta-adrenergic antagonists, alpha-adrenergic agonists, cholinergic agonists, carbonic anhydrase inhibitors, and prostaglandin analogs.  Issues with existing drugs include failure to achieve target IOP with monotherapy, drug-related side effects, and low patient compliance with multiple daily administration of eye drops.  In recent years, the scientific and medical community has seen encouraging development of novel classes of drugs for primary OAG, the majority of which lower IOP by targeting the trabecular meshwork outflow pathway to increase aq. humor outflow.  Among the most promising new pharmacol. candidates are rho kinase inhibitors including ripasudil (K-115), netarsudil (AR13324), and AMA0076; adenosine receptor agonists including trabodenoson (INO-8875); and modified prostaglandin analogs including latanoprostene bunod (LBN, BOL-303259-X) and ONO-9054.  This study aims to systematically review and summarize the most recent developments in clin. trials for new pharmacol. options for the treatment of primary open-angle glaucoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouf3T6s73X_7Vg90H21EOLACvtfcHk0lgaLQwod_DTlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFaqur%252FP&md5=d53061d1832d623505fbe2ea7aaf7283</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DL.%26aulast%3DTsai%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DNovel%2520Pharmacologic%2520Candidates%2520for%2520Treatment%2520of%2520Primary%2520Open-Angle%2520Glaucoma%26jtitle%3DYale%2520J.%2520Biol.%2520Med.%26date%3D2017%26volume%3D90%26spage%3D111%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sturdivant, J. M.</span>; <span class="NLM_string-name">Delong, M. A.</span>; <span class="NLM_string-name">Chambournier, G.</span>; <span class="NLM_string-name">Pamment, M. G.</span>; <span class="NLM_string-name">Fedij, V.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Kinase Inhibitors and Intermediates Thereof</span>. <span class="NLM_patent">WO 2017086941A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+M.+Sturdivant&author=M.+A.+Delong&author=G.+Chambournier&author=M.+G.+Pamment&author=V.+Fedij&title=Process+for+the+Preparation+of+Kinase+Inhibitors+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSturdivant%26aufirst%3DJ.%2BM.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Kinase%2520Inhibitors%2520and%2520Intermediates%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e','cit2f','cit2g','cit2h','cit2i','cit2j','cit2k','cit2l','cit2m','cit2n','cit2o'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24a','cit24b','cit24c','cit24d','cit24e','cit24f'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27a','cit27b'],'ref28':['cit28a','cit28b'],'ref29':['cit29'],'ref30':['cit30a','cit30b'],'ref31':['cit31'],'ref32':['cit32a','cit32b'],'ref33':['cit33'],'ref34':['cit34a','cit34b'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37a','cit37b'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45a','cit45b'],'ref46':['cit46'],'ref47':['cit47a','cit47b'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51a','cit51b','cit51c','cit51d','cit51e'],'ref52':['cit52'],'ref53':['cit53a','cit53b'],'ref54':['cit54a','cit54b','cit54c'],'ref55':['cit55a','cit55b','cit55c'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58a','cit58b'],'ref59':['cit59a','cit59b'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68a','cit68b'],'ref69':['cit69a','cit69b'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77a','cit77b','cit77c'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80a','cit80b'],'ref81':['cit81'],'ref82':['cit82a','cit82b'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88a','cit88b'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92a','cit92b','cit92c','cit92d','cit92e','cit92f','cit92g','cit92h','cit92i','cit92j'],'ref93':['cit93a','cit93b'],'ref94':['cit94a','cit94b','cit94c'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97a','cit97b'],'ref98':['cit98a','cit98b'],'ref99':['cit99'],'ref100':['cit100a','cit100b','cit100c','cit100d','cit100e','cit100f'],'ref101':['cit101a','cit101b','cit101c'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104a','cit104b'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109a','cit109b'],'ref110':['cit110'],'ref111':['cit111a','cit111b'],'ref112':['cit112'],'ref113':['cit113a','cit113b'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116a','cit116b'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121a','cit121b','cit121c','cit121d'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125a','cit125b'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128a','cit128b'],'ref129':['cit129a','cit129b','cit129c','cit129d','cit129e','cit129f','cit129g','cit129h'],'ref130':['cit130'],'ref131':['cit131a','cit131b','cit131c'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135a','cit135b','cit135c','cit135d','cit135e','cit135f','cit135g','cit135h'],'ref136':['cit136a','cit136b'],'ref137':['cit137a','cit137b','cit137c'],'ref138':['cit138'],'ref139':['cit139a','cit139b','cit139c','cit139d'],'ref140':['cit140a','cit140b'],'ref141':['cit141'],'ref142':['cit142a','cit142b'],'ref143':['cit143'],'ref144':['cit144a','cit144b'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved during 2019. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3604-3657. <a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252Bduring%252B2019%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03022021%26date%3D30032021%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, Jacob C. DeForest, Peter D. Morse, Subham Mahapatra, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to New Drugs Approved during 2018. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10652-10704. <a href="https://doi.org/10.1021/acs.jmedchem.0c00345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252BNew%252BDrugs%252BApproved%252Bduring%252B2018%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D22052020%26date%3D27042020%26volume%3D63%26issue%3D19%26spage%3D10652%26epage%3D10704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chris De Savi, David L. Hughes, <span class="NLM_string-name hlFld-ContribAuthor">Lisbet Kvaerno</span>. </span><span class="cited-content_cbyCitation_article-title">Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (6)
                                     , 940-976. <a href="https://doi.org/10.1021/acs.oprd.0c00233" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00233%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DQuest%252Bfor%252Ba%252BCOVID-19%252BCure%252Bby%252BRepurposing%252BSmall-Molecule%252BDrugs%25253A%252BMechanism%252Bof%252BAction%25252C%252BClinical%252BDevelopment%25252C%252BSynthesis%252Bat%252BScale%25252C%252Band%252BOutlook%252Bfor%252BSupply%26aulast%3DDe%2BSavi%26aufirst%3DChris%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17052020%26date%3D08062020%26date%3D02062020%26volume%3D24%26issue%3D6%26spage%3D940%26epage%3D976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tomasz K. Olszewski, Michał Bieniek, <span class="NLM_string-name hlFld-ContribAuthor">Krzysztof Skowerski</span>. </span><span class="cited-content_cbyCitation_article-title">Ruthenium-Based Complexes Bearing Quaternary Ammonium Tags as Versatile Catalysts for Olefin Metathesis: From the Discovery to Practical Applications. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (2)
                                     , 125-145. <a href="https://doi.org/10.1021/acs.oprd.9b00483" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00483</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00483%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DRuthenium-Based%252BComplexes%252BBearing%252BQuaternary%252BAmmonium%252BTags%252Bas%252BVersatile%252BCatalysts%252Bfor%252BOlefin%252BMetathesis%25253A%252BFrom%252Bthe%252BDiscovery%252Bto%252BPractical%252BApplications%26aulast%3DOlszewski%26aufirst%3DTomasz%2BK.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D09112019%26date%3D04022020%26date%3D22012020%26volume%3D24%26issue%3D2%26spage%3D125%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepa R.  Parmar</span>, <span class="hlFld-ContribAuthor ">Jigar Y.  Soni</span>, <span class="hlFld-ContribAuthor ">Ramakrishna  Guduru</span>, <span class="hlFld-ContribAuthor ">Rahul H.  Rayani</span>, <span class="hlFld-ContribAuthor ">Rakesh V.  Kusurkar</span>, <span class="hlFld-ContribAuthor ">Anand G.  Vala</span>. </span><span class="cited-content_cbyCitation_article-title">Azetidines of pharmacological interest. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>22 </em><a href="https://doi.org/10.1002/ardp.202100062" title="DOI URL">https://doi.org/10.1002/ardp.202100062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202100062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202100062%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DAzetidines%252Bof%252Bpharmacological%252Binterest%26aulast%3DParmar%26aufirst%3DDeepa%2BR.%26date%3D2021%26date%3D2021%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossein  Mousavi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive survey upon diverse and prolific applications of chitosan-based catalytic systems in one-pot multi-component synthesis of heterocyclic rings. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>57 </em><a href="https://doi.org/10.1016/j.ijbiomac.2021.06.123" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2021.06.123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2021.06.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2021.06.123%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DA%252Bcomprehensive%252Bsurvey%252Bupon%252Bdiverse%252Band%252Bprolific%252Bapplications%252Bof%252Bchitosan-based%252Bcatalytic%252Bsystems%252Bin%252Bone-pot%252Bmulti-component%252Bsynthesis%252Bof%252Bheterocyclic%252Brings%26aulast%3DMousavi%26aufirst%3DHossein%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Krátký</span>, <span class="hlFld-ContribAuthor ">Klára  Konečná</span>, <span class="hlFld-ContribAuthor ">Kateřina  Brokešová</span>, <span class="hlFld-ContribAuthor ">Jana  Maixnerová</span>, <span class="hlFld-ContribAuthor ">František  Trejtnar</span>, <span class="hlFld-ContribAuthor ">Jarmila  Vinšová</span>. </span><span class="cited-content_cbyCitation_article-title">Optimizing the structure of (salicylideneamino)benzoic acids: Towards selective antifungal and anti-staphylococcal agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2021,</strong> <em>159 </em>, 105732. <a href="https://doi.org/10.1016/j.ejps.2021.105732" title="DOI URL">https://doi.org/10.1016/j.ejps.2021.105732</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2021.105732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2021.105732%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DOptimizing%252Bthe%252Bstructure%252Bof%252B%252528salicylideneamino%252529benzoic%252Bacids%25253A%252BTowards%252Bselective%252Bantifungal%252Band%252Banti-staphylococcal%252Bagents%26aulast%3DKr%25C3%25A1tk%25C3%25BD%26aufirst%3DMartin%26date%3D2021%26volume%3D159%26spage%3D105732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-Han  Yuan</span>, <span class="hlFld-ContribAuthor ">Sai-Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiao-Bing  Chen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113218. <a href="https://doi.org/10.1016/j.ejmech.2021.113218" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113218%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFDA-approved%252Bpyrimidine-fused%252Bbicyclic%252Bheterocycles%252Bfor%252Bcancer%252Btherapy%25253A%252BSynthesis%252Band%252Bclinical%252Bapplication%26aulast%3DWang%26aufirst%3DShuai%26date%3D2021%26volume%3D214%26spage%3D113218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garima  Tripathi</span>, <span class="hlFld-ContribAuthor ">Abhijeet  Kumar</span>, <span class="hlFld-ContribAuthor ">Sanchayita  Rajkhowa</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of biologically relevant heterocyclic skeletons under solvent-free condition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 421-459. <a href="https://doi.org/10.1016/B978-0-12-820586-0.00013-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-820586-0.00013-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820586-0.00013-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820586-0.00013-3%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Bof%252Bbiologically%252Brelevant%252Bheterocyclic%252Bskeletons%252Bunder%252Bsolvent-free%252Bcondition%26aulast%3DTripathi%26aufirst%3DGarima%26date%3D2021%26spage%3D421%26epage%3D459%26pub%3DElsevier%26atitle%3DGreen%252BSynthetic%252BApproaches%252Bfor%252BBiologically%252BRelevant%252BHeterocycles%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priyanka  Bose</span>, <span class="hlFld-ContribAuthor ">Anand K.  Agrahari</span>, <span class="hlFld-ContribAuthor ">Sumit K.  Singh</span>, <span class="hlFld-ContribAuthor ">Anoop S.  Singh</span>, <span class="hlFld-ContribAuthor ">Mangal S.  Yadav</span>, <span class="hlFld-ContribAuthor ">Sanchayita  Rajkhowa</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments on ionic liquids-mediated synthetic protocols for biologically relevant five- and six-membered heterocyclic skeletons. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 301-364. <a href="https://doi.org/10.1016/B978-0-12-820792-5.00015-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-820792-5.00015-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820792-5.00015-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820792-5.00015-9%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252Bdevelopments%252Bon%252Bionic%252Bliquids-mediated%252Bsynthetic%252Bprotocols%252Bfor%252Bbiologically%252Brelevant%252Bfive-%252Band%252Bsix-membered%252Bheterocyclic%252Bskeletons%26aulast%3DBose%26aufirst%3DPriyanka%26date%3D2021%26spage%3D301%26epage%3D364%26pub%3DElsevier%26atitle%3DGreen%252BSynthetic%252BApproaches%252Bfor%252BBiologically%252BRelevant%252BHeterocycles%26date%3D2021%26volume%3D1%25E2%2580%259315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katarzyna  Kaczanowska</span>, <span class="hlFld-ContribAuthor ">Bartosz  Trzaskowski</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Peszczyńska</span>, <span class="hlFld-ContribAuthor ">Andrzej  Tracz</span>, <span class="hlFld-ContribAuthor ">Rafał  Gawin</span>, <span class="hlFld-ContribAuthor ">Tomasz K.  Olszewski</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Skowerski</span>. </span><span class="cited-content_cbyCitation_article-title">Cross metathesis with acrylates:
              N
              ‐heterocyclic carbene (NHC)‐
              versus
              cyclic alkyl amino carbene (CAAC)‐based ruthenium catalysts, an unanticipated influence of the carbene type on efficiency and selectivity of the reaction. </span><span class="cited-content_cbyCitation_journal-name">ChemCatChem</span><span> <strong>2020,</strong> <em>12 </em>
                                    (24)
                                     , 6366-6374. <a href="https://doi.org/10.1002/cctc.202001268" title="DOI URL">https://doi.org/10.1002/cctc.202001268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cctc.202001268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcctc.202001268%26sid%3Dliteratum%253Aachs%26jtitle%3DChemCatChem%26atitle%3DCross%252Bmetathesis%252Bwith%252Bacrylates%25253A%252BN%252B%2525E2%252580%252590heterocyclic%252Bcarbene%252B%252528NHC%252529%2525E2%252580%252590%252Bversus%252Bcyclic%252Balkyl%252Bamino%252Bcarbene%252B%252528CAAC%252529%2525E2%252580%252590based%252Bruthenium%252Bcatalysts%25252C%252Ban%252Bunanticipated%252Binfluence%252Bof%252Bthe%252Bcarbene%252Btype%252Bon%252Befficiency%252Band%252Bselectivity%252Bof%252Bthe%252Breaction%26aulast%3DKaczanowska%26aufirst%3DKatarzyna%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D24%26spage%3D6366%26epage%3D6374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel  Genheden</span>, <span class="hlFld-ContribAuthor ">Amol  Thakkar</span>, <span class="hlFld-ContribAuthor ">Veronika  Chadimová</span>, <span class="hlFld-ContribAuthor ">Jean-Louis  Reymond</span>, <span class="hlFld-ContribAuthor ">Ola  Engkvist</span>, <span class="hlFld-ContribAuthor ">Esben  Bjerrum</span>. </span><span class="cited-content_cbyCitation_article-title">AiZynthFinder: a fast, robust and flexible open-source software for retrosynthetic planning. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cheminformatics</span><span> <strong>2020,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13321-020-00472-1" title="DOI URL">https://doi.org/10.1186/s13321-020-00472-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13321-020-00472-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13321-020-00472-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cheminformatics%26atitle%3DAiZynthFinder%25253A%252Ba%252Bfast%25252C%252Brobust%252Band%252Bflexible%252Bopen-source%252Bsoftware%252Bfor%252Bretrosynthetic%252Bplanning%26aulast%3DGenheden%26aufirst%3DSamuel%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingming  Dang</span>, <span class="hlFld-ContribAuthor ">Minhua  Liu</span>, <span class="hlFld-ContribAuthor ">Lu  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Ou</span>, <span class="hlFld-ContribAuthor ">Chuyun  Long</span>, <span class="hlFld-ContribAuthor ">Xingping  Liu</span>, <span class="hlFld-ContribAuthor ">Yeguo  Ren</span>, <span class="hlFld-ContribAuthor ">Ping  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingzhi  Huang</span>, <span class="hlFld-ContribAuthor ">Aiping  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and bioactivities of novel pyridazinone derivatives containing
              2‐phenylthiazole
              or oxazole skeletons. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2020,</strong> <em>57 </em>
                                    (11)
                                     , 4088-4098. <a href="https://doi.org/10.1002/jhet.4118" title="DOI URL">https://doi.org/10.1002/jhet.4118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.4118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.4118%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbioactivities%252Bof%252Bnovel%252Bpyridazinone%252Bderivatives%252Bcontaining%252B2%2525E2%252580%252590phenylthiazole%252Bor%252Boxazole%252Bskeletons%26aulast%3DDang%26aufirst%3DMingming%26date%3D2020%26date%3D2020%26volume%3D57%26issue%3D11%26spage%3D4088%26epage%3D4098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martina  Ferri</span>, <span class="hlFld-ContribAuthor ">Manuel  Alunno</span>, <span class="hlFld-ContribAuthor ">Francesco Antonio  Greco</span>, <span class="hlFld-ContribAuthor ">Andrea  Mammoli</span>, <span class="hlFld-ContribAuthor ">Giorgio  Saluti</span>, <span class="hlFld-ContribAuthor ">Andrea  Carotti</span>, <span class="hlFld-ContribAuthor ">Roccaldo  Sardella</span>, <span class="hlFld-ContribAuthor ">Antonio  Macchiarulo</span>, <span class="hlFld-ContribAuthor ">Emidio  Camaioni</span>, <span class="hlFld-ContribAuthor ">Paride  Liscio</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment based drug design and diversity-oriented synthesis of carboxylic acid isosteres. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (22)
                                     , 115731. <a href="https://doi.org/10.1016/j.bmc.2020.115731" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115731%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DFragment%252Bbased%252Bdrug%252Bdesign%252Band%252Bdiversity-oriented%252Bsynthesis%252Bof%252Bcarboxylic%252Bacid%252Bisosteres%26aulast%3DFerri%26aufirst%3DMartina%26date%3D2020%26volume%3D28%26issue%3D22%26spage%3D115731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tejas M.  Dhameliya</span>, <span class="hlFld-ContribAuthor ">Hiren A.  Donga</span>, <span class="hlFld-ContribAuthor ">Punit V.  Vaghela</span>, <span class="hlFld-ContribAuthor ">Bhoomi G.  Panchal</span>, <span class="hlFld-ContribAuthor ">Dipen K.  Sureja</span>, <span class="hlFld-ContribAuthor ">Kunjan B.  Bodiwala</span>, <span class="hlFld-ContribAuthor ">Mahesh T.  Chhabria</span>. </span><span class="cited-content_cbyCitation_article-title">A decennary update on applications of metal nanoparticles (MNPs) in the synthesis of nitrogen- and oxygen-containing heterocyclic scaffolds. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (54)
                                     , 32740-32820. <a href="https://doi.org/10.1039/D0RA02272A" title="DOI URL">https://doi.org/10.1039/D0RA02272A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA02272A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA02272A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Bdecennary%252Bupdate%252Bon%252Bapplications%252Bof%252Bmetal%252Bnanoparticles%252B%252528MNPs%252529%252Bin%252Bthe%252Bsynthesis%252Bof%252Bnitrogen-%252Band%252Boxygen-containing%252Bheterocyclic%252Bscaffolds%26aulast%3DDhameliya%26aufirst%3DTejas%2BM.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D54%26spage%3D32740%26epage%3D32820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Ji</span>, <span class="hlFld-ContribAuthor ">Weijin  Gu</span>, <span class="hlFld-ContribAuthor ">Ping  Liu</span>, <span class="hlFld-ContribAuthor ">Peipei  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Iron-mediated deuterium addition cascade cyano insertion/cyclization of
              N
              -arylacrylamides to access deuterium-labelled phenanthridines. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (31)
                                     , 6126-6133. <a href="https://doi.org/10.1039/D0OB01178A" title="DOI URL">https://doi.org/10.1039/D0OB01178A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB01178A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB01178A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DIron-mediated%252Bdeuterium%252Baddition%252Bcascade%252Bcyano%252Binsertion%25252Fcyclization%252Bof%252BN%252B-arylacrylamides%252Bto%252Baccess%252Bdeuterium-labelled%252Bphenanthridines%26aulast%3DJi%26aufirst%3DLei%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D31%26spage%3D6126%26epage%3D6133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Magdalena  Jawiczuk</span>, <span class="hlFld-ContribAuthor ">Anna  Marczyk</span>, <span class="hlFld-ContribAuthor ">Bartosz  Trzaskowski</span>. </span><span class="cited-content_cbyCitation_article-title">Decomposition of Ruthenium Olefin Metathesis Catalyst. </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2020,</strong> <em>10 </em>
                                    (8)
                                     , 887. <a href="https://doi.org/10.3390/catal10080887" title="DOI URL">https://doi.org/10.3390/catal10080887</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal10080887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal10080887%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DDecomposition%252Bof%252BRuthenium%252BOlefin%252BMetathesis%252BCatalyst%26aulast%3DJawiczuk%26aufirst%3DMagdalena%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D8%26spage%3D887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna V.  Listratova</span>, <span class="hlFld-ContribAuthor ">Najoua  Sbei</span>, <span class="hlFld-ContribAuthor ">Leonid G.  Voskressensky</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Electrosynthesis of
              N
              ,
              O
              -Heterocycles - Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (14)
                                     , 2012-2027. <a href="https://doi.org/10.1002/ejoc.201901635" title="DOI URL">https://doi.org/10.1002/ejoc.201901635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201901635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201901635%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCatalytic%252BElectrosynthesis%252Bof%252BN%252B%25252C%252BO%252B-Heterocycles%252B-%252BRecent%252BAdvances%26aulast%3DListratova%26aufirst%3DAnna%2BV.%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D14%26spage%3D2012%26epage%3D2027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nidhi  Mishra</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>, <span class="hlFld-ContribAuthor ">Richard R.  Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">Recent trends and challenges on carbohydrate-based molecular scaffolding: general consideration toward impact of carbohydrates in drug discovery and development. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-69. <a href="https://doi.org/10.1016/B978-0-12-816675-8.00001-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-816675-8.00001-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816675-8.00001-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816675-8.00001-4%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252Btrends%252Band%252Bchallenges%252Bon%252Bcarbohydrate-based%252Bmolecular%252Bscaffolding%25253A%252Bgeneral%252Bconsideration%252Btoward%252Bimpact%252Bof%252Bcarbohydrates%252Bin%252Bdrug%252Bdiscovery%252Band%252Bdevelopment%26aulast%3DMishra%26aufirst%3DNidhi%26date%3D2020%26spage%3D1%26epage%3D69%26pub%3DElsevier%26atitle%3DCarbohydrates%252Bin%252BDrug%252BDiscovery%252Band%252BDevelopment%26date%3D2020%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amol  Thakkar</span>, <span class="hlFld-ContribAuthor ">Thierry  Kogej</span>, <span class="hlFld-ContribAuthor ">Jean-Louis  Reymond</span>, <span class="hlFld-ContribAuthor ">Ola  Engkvist</span>, <span class="hlFld-ContribAuthor ">Esben Jannik  Bjerrum</span>. </span><span class="cited-content_cbyCitation_article-title">Datasets and their influence on the development of computer assisted synthesis planning tools in the pharmaceutical domain. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     , 154-168. <a href="https://doi.org/10.1039/C9SC04944D" title="DOI URL">https://doi.org/10.1039/C9SC04944D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC04944D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC04944D%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DDatasets%252Band%252Btheir%252Binfluence%252Bon%252Bthe%252Bdevelopment%252Bof%252Bcomputer%252Bassisted%252Bsynthesis%252Bplanning%252Btools%252Bin%252Bthe%252Bpharmaceutical%252Bdomain%26aulast%3DThakkar%26aufirst%3DAmol%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D154%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0065.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0001.jpeg" id="rightTab-gr60" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0002.jpeg" id="rightTab-GRAPHIC-d7e271-autogenerated" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0003.jpeg" id="rightTab-GRAPHIC-d7e272-autogenerated" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0004.jpeg" id="rightTab-GRAPHIC-d7e273-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 31 NCEs approved in 2017.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0001.jpeg jm-2019-00196t_0002.jpeg jm-2019-00196t_0003.jpeg jm-2019-00196t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Amenamevir (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benznidazole (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Delafloxacin Meglumine (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Delafloxacin Meglumine Ketoester Fragment <b>8</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Delafloxacin Meglumine Diaminopyridine <b>10</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Delafloxacin Meglumine Azetidine Fragment <b>13</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Elsulfavirine (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Glecaprevir Quinoxaline Subunit <b>34</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0014.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Glecaprevir Allyl Ether <b>38</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0015.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Preparation of Glecaprevir Cyclopropylamine <b>44</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0016.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Glecaprevir (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0017.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Pibrentasvir Pyrrolidine Core <b>54</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0018.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Pibrentasvir (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0019.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Preparation of Pibrentasvir Dimesylate <b>53</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0020.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Preparation of Letermovir Guanidine <b>74</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0021.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Letermovir (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0022.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Preparation of Letermovir Auxiliary <b>75</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0023.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Secnidazole (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0024.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Vaborbactam (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0025.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Preparation of Voxilaprevir Pyrrolidinol <b>95</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0026.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Preparation of Voxilaprevir Cyclopropyl Carbamate <b>100</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0027.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Preparation of Voxilaprevir Quinoxaline <b>105</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0028.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Voxilaprevir (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0005.jpeg" id="rightTab-gr61" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of (±)-tetrabenazine <b>118</b>, <i>R</i>,<i>R</i>,<i>R</i>-DHTBZ <b>119</b>, and valbenazine (<b>XII</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch24" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0029.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Deutetrabenazine (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch25" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0030.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Piperidone-Forming Reagent <b>115</b> for Deutetrabenazine (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch26" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0031.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Valbenazine (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch27" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0032.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Naldemedine (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch28" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0033.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Synthesis of Naldemedine Isocyanate Intermediate <b>123</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch29" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0034.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Betrixaban (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch30" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0035.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Amide <b>143</b> towards Ertugliflozin-<span class="smallcaps smallerCapital">l</span>-pyroglutamic Acid (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch31" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0036.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Synthesis of Ertugliflozin-<span class="smallcaps smallerCapital">l</span>-pyroglutamic Acid (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch32" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0037.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Benzyl Ether Intermediate <b>144</b> for Ertugliflozin-<span class="smallcaps smallerCapital">l</span>-pyroglutamic Acid</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch33" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0038.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Pemafibrate (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch34" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0039.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Pemafibrate Triflate <b>153</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch35" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0040.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Baricitinib Azetidine Sulfonamide <b>159</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch36" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0041.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 36. Synthesis of Baricitinib (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch37" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Scheme 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0042.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 37. Alternative Synthesis of Baricitinib (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch38" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0043.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 38. Synthesis of Abemaciclib Aminopyridine <b>170</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch39" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0044.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 39. Synthesis of Abemaciclib (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch40" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Scheme 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0045.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 40. Synthesis of Acalabrutinib (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch41" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0046.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 41. Synthesis of brigatinib (<b>XX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch42" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Scheme 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0047.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 42. Synthesis of Brigatinib Aniline <b>188</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch43" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Scheme 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0048.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 43. Synthesis of Copanlisib (<b>XXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch44" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Scheme 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0049.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 44. Synthesis of Enasidenib (<b>XXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch45" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Scheme 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0050.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 45. Synthesis of the Inotuzumab Ozogamicin Linker Fragment <b>218</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch46" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Scheme 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0051.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 46. Synthesis of Inotuzumab Ozogamicin (<b>XXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch47" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Scheme 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0052.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 47. Synthesis of Midostaurin (<b>XXIV</b>) from Staurosporine (<b>222</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch48" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Scheme 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0053.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 48. Synthesis of Neratinib Maleate (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch49" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Scheme 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0054.jpeg" id="rightTab-gr49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 49. Synthesis of Neratinib Anilino Side Chain <b>229</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch50" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Scheme 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0055.jpeg" id="rightTab-gr50" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 50. Synthesis of Niraparib Piperidinyl Aryl Bromide <b>244</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch51" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Scheme 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0056.jpeg" id="rightTab-gr51" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 51. Synthesis of Niraparib Tosylate Monohydrate (<b>XXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch52" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Scheme 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0057.jpeg" id="rightTab-gr52" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 52. Synthesis of Ribociclib (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch53" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Scheme 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0058.jpeg" id="rightTab-gr53" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 53. Synthesis of Ribociclib Bromooxylate <b>251</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch54" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Scheme 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0059.jpeg" id="rightTab-gr54" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 54. Synthesis of Telotristat Ethyl (<b>XXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch55" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Scheme 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0060.jpeg" id="rightTab-gr55" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 55. Preparation of Trifluoroalcohol Fragment <b>259</b> for Telotristat Ethyl</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch56" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Scheme 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0061.jpeg" id="rightTab-gr56" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 56. Synthesis of Tivozanib Hydrochloride (<b>XXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch57" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Scheme 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0062.jpeg" id="rightTab-gr57" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 57. Synthesis of Latanoprostene Vunod (<b>XXX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch58" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Scheme 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0063.jpeg" id="rightTab-gr58" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 58. Preparation of Netarsudil Oxazolidinone Fragment <b>282</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch59" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Scheme 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/medium/jm-2019-00196t_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0064.jpeg" id="rightTab-gr59" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 59. Synthesis of Netarsudil (<b>XXXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00196/20190815/images/large/jm-2019-00196t_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00196&amp;id=sch59"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i115">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81758" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81758" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 148 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raju, T. N. K.</span></span> <span> </span><span class="NLM_article-title">The Nobel Chronicles. 1988: James Whyte Black, (B 1924), Gertrude Elion (1918–99), and George H Hitchings (1905–98)</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1022</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)74775-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2FS0140-6736%2805%2974775-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10768469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=1022&author=T.+N.+K.+Raju&title=The+Nobel+Chronicles.+1988%3A+James+Whyte+Black%2C+%28B+1924%29%2C+Gertrude+Elion+%281918%E2%80%9399%29%2C+and+George+H+Hitchings+%281905%E2%80%9398%29&doi=10.1016%2FS0140-6736%2805%2974775-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span></div><div class="casAuthors">Raju T N</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9208</span>),
    <span class="NLM_cas:pages">1022</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTWLVzWjiD66qcneEtCi92fW6udTcc2ebfXdOsupaGMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D&md5=c89d64b40317d0d0cb4a76c1cceecb58</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974775-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974775-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DT.%2BN.%2BK.%26atitle%3DThe%2520Nobel%2520Chronicles.%25201988%253A%2520James%2520Whyte%2520Black%252C%2520%2528B%25201924%2529%252C%2520Gertrude%2520Elion%2520%25281918%25E2%2580%259399%2529%252C%2520and%2520George%2520H%2520Hitchings%2520%25281905%25E2%2580%259398%2529%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D1022%26doi%3D10.1016%2FS0140-6736%2805%2974775-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0lgFIXfzfkZ1tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0lgFIXfzfkZ1tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.-C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0lgFIXfzfkZ1tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0lisIywpjY27gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0lisIywpjY27gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0lisIywpjY27gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0lisIywpjY27gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2hR"><div class="casContent"><span class="casTitleNuber">2h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0lg0Gzn0v7ullQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0lg0Gzn0v7ullQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2jR"><div class="casContent"><span class="casTitleNuber">2j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0lg0Gzn0v7ullQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0ljINEPE6TrqMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2lR"><div class="casContent"><span class="casTitleNuber">2l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0ljINEPE6TrqMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2mR"><div class="casContent"><span class="casTitleNuber">2m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0ljINEPE6TrqMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6480</span>– <span class="NLM_lpage">6515</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6480-6515&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2015&doi=10.1021%2Facs.jmedchem.7b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2nR"><div class="casContent"><span class="casTitleNuber">2n</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2015</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K. -C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6480-6515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 29 new chem. entities (NCEs) that were approved for the first time in 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5OCn9h-Lu07Vg90H21EOLACvtfcHk0lg87NLtnY6hTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D&md5=b10c1f677c2f4a216b11a4c89e8b3683</span></div><a href="/servlet/linkout?suffix=cit2n&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6480%26epage%3D6515%26doi%3D10.1021%2Facs.jmedchem.7b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to New Drugs Approved During 2016</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7004</span>– <span class="NLM_lpage">7031</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2o&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7004-7031&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+New+Drugs+Approved+During+2016&doi=10.1021%2Facs.jmedchem.8b00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2oR"><div class="casContent"><span class="casTitleNuber">2o</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to New Drugs Approved During 2016</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7004-7031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review discusses the published syntheses of the nineteen new chem. entities approved for the first time by a governing body anywhere in the world in 2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr16l1kfs1KlbVg90H21EOLACvtfcHk0lg87NLtnY6hTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D&md5=183bbabe40dbfd7b7cfbcd94fd55f0d0</span></div><a href="/servlet/linkout?suffix=cit2o&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00260%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520New%2520Drugs%2520Approved%2520During%25202016%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7004%26epage%3D7031%26doi%3D10.1021%2Facs.jmedchem.8b00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graul, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, M.</span></span> <span> </span><span class="NLM_article-title">The Year’s New Drugs and Biologics 2018: Part I</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1358/dot.2018.54.1.2766396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1358%2Fdot.2018.54.1.2766396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktFGluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=35-84&author=A.+I.+Graulauthor=P.+Pinaauthor=M.+Stringer&title=The+Year%E2%80%99s+New+Drugs+and+Biologics+2018%3A+Part+I&doi=10.1358%2Fdot.2018.54.1.2766396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The year's new drugs and biologics 2017: Part I</span></div><div class="casAuthors">Graul A I; Pina P; Stringer M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-84</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">This review presents the 113 new drugs and biologics that were approved or launched for the first time globally in 2017.  Fifty-two new drugs and biologics reached their first markets worldwide in 2017.  Seven of the new launches were first-in-class agents, meaning the first drug with a novel mechanism of action to be approved and launched anywhere in the world.  In addition, 36 notable line extensions (i.e., new indications, new combinations and new formulations of previously marketed products) were introduced last year.  The remaining 25 products discussed in this article were approved for the first time during the year just passed, but had not yet been launched as of December 31, 2017.  The United States was the most active market for new drugs, and oncology was the most active therapeutic group.  Information on these new arrivals is covered in depth in part I of our annual review of the pharma and biotech industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDuiEw0Baa1AWRJ3OJdH_qfW6udTcc2eZU7BbZAlqRjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktFGluw%253D%253D&md5=9bfdac91095ed398ab8ae5561595699c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1358%2Fdot.2018.54.1.2766396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2018.54.1.2766396%26sid%3Dliteratum%253Aachs%26aulast%3DGraul%26aufirst%3DA.%2BI.%26aulast%3DPina%26aufirst%3DP.%26aulast%3DStringer%26aufirst%3DM.%26atitle%3DThe%2520Year%25E2%2580%2599s%2520New%2520Drugs%2520and%2520Biologics%25202018%253A%2520Part%2520I%26jtitle%3DDrugs%2520Today%26date%3D2018%26volume%3D54%26spage%3D35%26epage%3D84%26doi%3D10.1358%2Fdot.2018.54.1.2766396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span>For
a more detailed description of the medicinal chemistry strategy, preclinical
and clinical pharmacology of these drugs, see: <span> </span><span class="NLM_article-title">To Market, To Market—2017</span>. In  <i>2018
Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">ACS Division of Medicinal Chemistry</span>, <span class="NLM_year">2018</span>; Vol.  <span class="NLM_volume">53</span>, pp  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">693</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=587-693&author=J.+J.+Bronson&title=2018%0AMedicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTo%2520Market%252C%2520To%2520Market%25E2%2580%25942017%26btitle%3D2018%250AMedicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DACS%2520Division%2520of%2520Medicinal%2520Chemistry%26date%3D2018%26volume%3D53%26spage%3D587%26epage%3D693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, K.</span></span> <span> </span><span class="NLM_article-title">Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (Asp2151), in Rodents</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1007/s13318-018-0481-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs13318-018-0481-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29748821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVWmsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=693-706&author=Y.+Ohtsuauthor=Y.+Susakiauthor=K.+Noguchi&title=Absorption%2C+Distribution%2C+Metabolism%2C+and+Excretion+of+the+Novel+Helicase-Primase+Inhibitor%2C+Amenamevir+%28Asp2151%29%2C+in+Rodents&doi=10.1007%2Fs13318-018-0481-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents</span></div><div class="casAuthors">Ohtsu, Yoshiaki; Susaki, Yoko; Noguchi, Kiyoshi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">693-706</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">Background and Objectives: The helicase-primase inhibitor amenamevir (ASP2151) is a novel therapeutic agent which has been approved for the treatment of herpes zoster.  The present study examd. the pharmacokinetic profile of amenamevir in rodents and compared it with data from the literature of past and current established therapies (acyclovir and valaciclovir) to provide addnl. data to facilitate drug discovery and proper drug use.  Methods: In situ absorption, blood and plasma radioactivity concns., tissue distribution, and excretion were detd. using liq. scintillation counting.  Plasma amenamevir concns. were measured using a validated chromatog. method.  Chem. structures of in vivo metabolites were investigated using liq. chromatog.-mass spectrometry and NMR spectroscopy.  Results: Amenamevir, after single i.v. administration to mice, had an elimination half-life of 2 h.  Bioavailability was 40% after single oral administration.  In situ absorption data indicated that amenamevir is mainly absorbed in the small intestine.  The main component in mouse plasma was amenamevir, accounting for 87.9% of amenamevir-derived components.  Our results suggest that the main elimination pathway in mice is oxidative metab. at a Me group and a 1,2,3-trisubstituted benzene ring followed by biliary and fecal excretion.  Following oral administration of 14C-amenamevir to mice, 100.63% of the dose (10.06% in urine and 90.46% in feces) was excreted by 96 h post-dose.  Conclusions: The underlying mechanism of the improved pharmacokinetic profile of amenamevir was linked to an improved absorption ratio (not hepatic availability) compared to acyclovir, and qual. differences in elimination (slow metab. of amenamevir vs rapid urinary excretion of acyclovir/valaciclovir).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLaNJnfDGlkrVg90H21EOLACvtfcHk0linNLRGNQmHSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVWmsbzO&md5=3516e3d9aa2e0a7435f47e3d5c0b1286</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs13318-018-0481-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-018-0481-y%26sid%3Dliteratum%253Aachs%26aulast%3DOhtsu%26aufirst%3DY.%26aulast%3DSusaki%26aufirst%3DY.%26aulast%3DNoguchi%26aufirst%3DK.%26atitle%3DAbsorption%252C%2520Distribution%252C%2520Metabolism%252C%2520and%2520Excretion%2520of%2520the%2520Novel%2520Helicase-Primase%2520Inhibitor%252C%2520Amenamevir%2520%2528Asp2151%2529%252C%2520in%2520Rodents%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2018%26volume%3D43%26spage%3D693%26epage%3D706%26doi%3D10.1007%2Fs13318-018-0481-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusawake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keirns, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Adel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenendaal-van
de Meent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katashima, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2625</span>– <span class="NLM_lpage">2637</span>, <span class="refDoi"> DOI: 10.1007/s12325-017-0642-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs12325-017-0642-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29134426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSmsrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=2625-2637&author=T.+Kusawakeauthor=J.+J.+Keirnsauthor=D.+Kowalskiauthor=M.+den+Adelauthor=D.+Groenendaal-van%0Ade+Meentauthor=A.+Takadaauthor=Y.+Ohtsuauthor=M.+Katashima&title=Pharmacokinetics+and+Safety+of+Amenamevir+in+Healthy+Subjects%3A+Analysis+of+Four+Randomized+Phase+1+Studies&doi=10.1007%2Fs12325-017-0642-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies</span></div><div class="casAuthors">Kusawake, Tomohiro; Keirns, James J.; Kowalski, Donna; den Adel, Martin; Groenendaal-van de Meent, Dorien; Takada, Akitsugu; Ohtsu, Yoshiaki; Katashima, Masataka</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2625-2637</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Introduction: Amenamevir (ASP2151) is a nonnucleoside antiherpesvirus compd. available for the treatment of varicella-zoster virus infections.  In this article we summarize the findings of four phase 1 studies in healthy participants.  Methods: Four randomized phase 1 studies investigated the safety and pharmacokinetics of single and multiple doses of amenamevir, including the assessment of age group effect (nonelderly vs elderly), food effect, and the relative bioavailability of two formulations.  Amenamevir was administered orally at various doses as a single dose (5-2400 mg) or daily (300 or 600 mg/day) for 7 days.  Results: Following single and multiple oral doses, amenamevir demonstrated a less than dose proportional increase in the pharmacokinetic parameters area under the plasma drug concn. vs. time curve from time zero to infinity (AUCinf) and Cmax.  After single and multiple oral 300-mg doses of amenamevir, no apparent differences in pharmacokinetics were obsd. between nonelderly and elderly participants.  In contrast, with the amenamevir 600-mg dose both the area under the plasma drug concn. vs. time curve from time zero to 24 h and Cmax were slightly increased and renal clearance was decreased in elderly participants.  The pharmacokinetics of amenamevir was affected by food, with AUCinf increased by about 90%.  In the bioavailability study, AUCinf and Cmax were slightly lower following tablet vs. capsule administration (decreased by 14 and 12%, resp.), with relative bioavailability of 86%.  The different amenamevir doses and formulations were safe and well tolerated; no deaths or serious adverse events were reported.  Conclusion: Amenamevir had less than dose proportional pharmacokinetic characteristics.  Age may have an influence on amenamevir pharmacokinetics; however, the effect was considered minimal.  The pharmacokinetics of amenamevir were affected by food, with AUCinf almost doubling when amenamevir was administered with food.  The concn. vs. time profile of the tablet was slightly lower than that of the capsule; the relative bioavailability of the tablet vs. the capsule was 86%.  Amenamevir was safe and well tolerated in the dose range investigated.  Funding: Astellas Pharma.  Trial registration: ClinicalTrials.gov identifiers NCT02852876 (15L-CL-002) and NCT02796118 (15L-CL-003).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpziv1dPHTvMbVg90H21EOLACvtfcHk0linNLRGNQmHSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSmsrvF&md5=899c34c5e3bbb28c25fbe18980a015bd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0642-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0642-4%26sid%3Dliteratum%253Aachs%26aulast%3DKusawake%26aufirst%3DT.%26aulast%3DKeirns%26aufirst%3DJ.%2BJ.%26aulast%3DKowalski%26aufirst%3DD.%26aulast%3Dden%2BAdel%26aufirst%3DM.%26aulast%3DGroenendaal-van%2Bde%2BMeent%26aufirst%3DD.%26aulast%3DTakada%26aufirst%3DA.%26aulast%3DOhtsu%26aufirst%3DY.%26aulast%3DKatashima%26aufirst%3DM.%26atitle%3DPharmacokinetics%2520and%2520Safety%2520of%2520Amenamevir%2520in%2520Healthy%2520Subjects%253A%2520Analysis%2520of%2520Four%2520Randomized%2520Phase%25201%2520Studies%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26spage%3D2625%26epage%3D2637%26doi%3D10.1007%2Fs12325-017-0642-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span>; <span class="NLM_string-name">Sudo, K.</span></span> <span> </span><span class="NLM_article-title">Preventive or Therapeutic Agent for Herpesvirus-Related Disease</span>. <span class="NLM_patent">WO 2006082821A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=H.+Suzuki&author=K.+Sudo&title=Preventive+or+Therapeutic+Agent+for+Herpesvirus-Related+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DPreventive%2520or%2520Therapeutic%2520Agent%2520for%2520Herpesvirus-Related%2520Disease%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span>; <span class="NLM_string-name">Chono, K.</span>; <span class="NLM_string-name">Sudo, K.</span></span> <span> </span><span class="NLM_article-title">Agent for Prevention/Treatment of Disease Caused by Acyclovir-Resistant Herpesvirus</span>. <span class="NLM_patent">WO 2006082822A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=H.+Suzuki&author=K.+Chono&author=K.+Sudo&title=Agent+for+Prevention%2FTreatment+of+Disease+Caused+by+Acyclovir-Resistant+Herpesvirus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DAgent%2520for%2520Prevention%252FTreatment%2520of%2520Disease%2520Caused%2520by%2520Acyclovir-Resistant%2520Herpesvirus%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kontani, T.</span>; <span class="NLM_string-name">Miyata, J.</span>; <span class="NLM_string-name">Hamaguchi, W.</span>; <span class="NLM_string-name">Kawano, T.</span>; <span class="NLM_string-name">Kamikawa, A.</span>; <span class="NLM_string-name">Suzuki, H.</span>; <span class="NLM_string-name">Sudo, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of Tetrahydro-2H-thiopyran-4-carboxamides as Anti-Herpesvirus Agents</span>. <span class="NLM_patent">US 20050032855A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Kontani&author=J.+Miyata&author=W.+Hamaguchi&author=T.+Kawano&author=A.+Kamikawa&author=H.+Suzuki&author=K.+Sudo&title=Preparation+of+Tetrahydro-2H-thiopyran-4-carboxamides+as+Anti-Herpesvirus+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKontani%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Tetrahydro-2H-thiopyran-4-carboxamides%2520as%2520Anti-Herpesvirus%2520Agents%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span>; <span class="NLM_string-name">Salituro, F. G.</span>; <span class="NLM_string-name">Saunders, J. O.</span>; <span class="NLM_string-name">Travins, J.</span>; <span class="NLM_string-name">Yan, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Cycloalkylheteroarylacetylphenylaminophenylacetamide Derivatives and Analogs for Use as Antitumor Agents</span>. <span class="NLM_patent">WO 2012009678A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+Popovici-Muller&author=F.+G.+Salituro&author=J.+O.+Saunders&author=J.+Travins&author=S.+Yan&title=Preparation+of+Cycloalkylheteroarylacetylphenylaminophenylacetamide+Derivatives+and+Analogs+for+Use+as+Antitumor+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520Cycloalkylheteroarylacetylphenylaminophenylacetamide%2520Derivatives%2520and%2520Analogs%2520for%2520Use%2520as%2520Antitumor%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Zhou, H.</span>; <span class="NLM_string-name">Xie, J.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of 4-(1,2,4-Oxadiazole-3-yl)aniline</span>. <span class="NLM_patent">CN 108484522A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Zhen&author=J.+Chen&author=Z.+Zhang&author=H.+Zhou&author=J.+Xie&title=Preparation+Method+of+4-%281%2C2%2C4-Oxadiazole-3-yl%29aniline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhen%26aufirst%3DY.%26atitle%3DPreparation%2520Method%2520of%25204-%25281%252C2%252C4-Oxadiazole-3-yl%2529aniline%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span>Biocidal (2-Nitroimidazolyl)
Alkanoic Acids and Derivatives. <span class="NLM_patent">GB1138529</span>, <span class="NLM_year">1969</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Biocidal+%282-Nitroimidazolyl%29%0AAlkanoic+Acids+and+Derivatives.+GB1138529%2C+1969."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D1969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span> <i>FDA Approves First U.S. Treatment for Chagas Disease</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administraqtion</span>, August 29, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573942.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573942.htm</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+First+U.S.+Treatment+for+Chagas+Disease%3B+U.S.+Food+and+Drug+Administraqtion%2C+August+29%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm573942.htm+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520First%2520U.S.%2520Treatment%2520for%2520Chagas%2520Disease%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administraqtion%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajao, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passos-Silva, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Moura, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamber-Reis, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunrath-Lima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuma, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-da-Rocha, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, S. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza-Pinto, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Medeiros, M. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motta, M. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, S. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, C. R.</span></span> <span> </span><span class="NLM_article-title">Unveiling Benznidazoles Mechanism of Action through Overexpression of DNA Repair Proteins in Trypanosoma Cruzi</span>. <i>Environ. Mol. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1002/em.21839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fem.21839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=24347026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCjtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=309-321&author=M.+A.+Rajaoauthor=C.+Furtadoauthor=C.+L.+Alvesauthor=D.+G.+Passos-Silvaauthor=M.+B.+de+Mouraauthor=B.+L.+Schamber-Reisauthor=M.+Kunrath-Limaauthor=A.+A.+Zumaauthor=J.+P.+Vieira-da-Rochaauthor=J.+B.+F.+Garciaauthor=I.+C.+Mendesauthor=S.+D.+J.+Penaauthor=A.+M.+Macedoauthor=G.+R.+Francoauthor=N.+C.+de+Souza-Pintoauthor=M.+H.+G.+de+Medeirosauthor=A.+K.+Cruzauthor=M.+C.+M.+Mottaauthor=S.+M.+R.+Teixeiraauthor=C.+R.+Machado&title=Unveiling+Benznidazoles+Mechanism+of+Action+through+Overexpression+of+DNA+Repair+Proteins+in+Trypanosoma+Cruzi&doi=10.1002%2Fem.21839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Unveiling Benznidazoles mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi</span></div><div class="casAuthors">Rajao, Matheus Andrade; Furtado, Carolina; Alves, Ceres Luciana; Passos-Silva, Danielle Gomes; Moura, Michelle Barbi; Schamber-Reis, Bruno Luiz; Kunrath-Lima, Marianna; Zuma, Aline Araujo; Vieira-da-Rocha, Joao Pedro; Garcia, Juliana Borio Ferreira; Mendes, Isabela Cecilia; Pena, Sergio Danilo Junho; Macedo, Andrea Mara; Franco, Gloria Regina; Souza-Pinto, Nadja Cristhina; Medeiros, Marisa Helena Gennari; Cruz, Angela Kaysel; Motta, Maria Cristina Machado; Teixeira, Santuza Maria Ribeiro; Machado, Carlos Renato</div><div class="citationInfo"><span class="NLM_cas:title">Environmental and Molecular Mutagenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-321</span>CODEN:
                <span class="NLM_cas:coden">EMMUEG</span>;
        ISSN:<span class="NLM_cas:issn">0893-6692</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Benznidazole (BZ) is the most commonly used drug for the treatment of Chagas disease.  Although BZ is known to induce the formation of free radicals and electrophilic metabolites within the parasite Trypanosoma cruzi, its precise mechanisms of action are still elusive.  Here, the authors analyzed the survival of T. cruzi exposed to BZ using genetically modified parasites overexpressing different DNA repair proteins.  The authors' results indicate that BZ induces oxidn. mainly in the nucleotide pool, as heterologous expression of the nucleotide pyrophosphohydrolase MutT (but not overexpression of the glycosylase TcOgg1) increased drug resistance in the parasite.  In addn., electron microscopy indicated that BZ catalyzes the formation of double-stranded breaks in the parasite, as its genomic DNA undergoes extensive heterochromatin unpacking following exposure to the drug.  Furthermore, the overexpression of proteins involved in the recombination-mediated DNA repair increased resistance to BZ, reinforcing the idea that the drug causes double-stranded breaks.  The authors' results also show that the overexpression of mitochondrial DNA repair proteins increase parasite survival upon BZ exposure, indicating that the drug induces lesions in the mitochondrial DNA as well.  These findings suggest that BZ preferentially oxidizes the nucleotide pool, and the extensive incorporation of oxidized nucleotides during DNA replication leads to potentially lethal double-stranded DNA breaks in T. cruzi DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipqLqr5XxpbVg90H21EOLACvtfcHk0ljQAxoXZeakRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCjtr3L&md5=ebb14fc101937d18e805a687f6ba84a7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fem.21839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fem.21839%26sid%3Dliteratum%253Aachs%26aulast%3DRajao%26aufirst%3DM.%2BA.%26aulast%3DFurtado%26aufirst%3DC.%26aulast%3DAlves%26aufirst%3DC.%2BL.%26aulast%3DPassos-Silva%26aufirst%3DD.%2BG.%26aulast%3Dde%2BMoura%26aufirst%3DM.%2BB.%26aulast%3DSchamber-Reis%26aufirst%3DB.%2BL.%26aulast%3DKunrath-Lima%26aufirst%3DM.%26aulast%3DZuma%26aufirst%3DA.%2BA.%26aulast%3DVieira-da-Rocha%26aufirst%3DJ.%2BP.%26aulast%3DGarcia%26aufirst%3DJ.%2BB.%2BF.%26aulast%3DMendes%26aufirst%3DI.%2BC.%26aulast%3DPena%26aufirst%3DS.%2BD.%2BJ.%26aulast%3DMacedo%26aufirst%3DA.%2BM.%26aulast%3DFranco%26aufirst%3DG.%2BR.%26aulast%3Dde%2BSouza-Pinto%26aufirst%3DN.%2BC.%26aulast%3Dde%2BMedeiros%26aufirst%3DM.%2BH.%2BG.%26aulast%3DCruz%26aufirst%3DA.%2BK.%26aulast%3DMotta%26aufirst%3DM.%2BC.%2BM.%26aulast%3DTeixeira%26aufirst%3DS.%2BM.%2BR.%26aulast%3DMachado%26aufirst%3DC.%2BR.%26atitle%3DUnveiling%2520Benznidazoles%2520Mechanism%2520of%2520Action%2520through%2520Overexpression%2520of%2520DNA%2520Repair%2520Proteins%2520in%2520Trypanosoma%2520Cruzi%26jtitle%3DEnviron.%2520Mol.%2520Mutagen.%26date%3D2014%26volume%3D55%26spage%3D309%26epage%3D321%26doi%3D10.1002%2Fem.21839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watson, L.</span></span> <span> </span><span class="NLM_article-title">Making Benznidazole</span>. <span class="NLM_patent">WO 2017205622A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Watson&title=Making+Benznidazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DL.%26atitle%3DMaking%2520Benznidazole%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mealy, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, J.</span></span> <span> </span><span class="NLM_article-title">Abt-492: Quinolone Antibacterial</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1358/dof.2002.027.11.707859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1358%2Fdof.2002.027.11.707859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFelt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=1033-1038&author=N.+E.+Mealyauthor=J.+Castaner&title=Abt-492%3A+Quinolone+Antibacterial&doi=10.1358%2Fdof.2002.027.11.707859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-492: Quinolone antibacterial</span></div><div class="casAuthors">Mealy, N. E.; Castaner, J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1033-1038</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  ABT-492/WQ-3034 (I) is a novel fluoroquinolone that targets bacterial DNA topoisomerases and is undergoing clin. evaluation for the treatment of respiratory and urinary tract infections.  In numerous in vitro studies, the new antibiotic has demonstrated excellent, broad-spectrum antibacterial and bactericidal activity, with particularly good activity against respiratory tract pathogens.  ABT-492/WQ-3034 was generally more active than other quinolones and its spectrum included quinolone-sensitive and -resistant staphylococci and streptococci, vancomycin-sensitive and -resistant enterococci, anaerobic bacteria, Pseudomonas aeruginosa, Enterobacteriaceae, Legionella, mycobacteria and the causative organism of anthrax, Bacillus anthracis.  ABT-492/WQ-3034 has also been tested in rodent infection models, including systemic, respiratory tract and thigh infections.  The new fluoroquinolone proved to be generally at least as active as the ref. antibiotics following s.c. or p.o. administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNJbieb5vtsrVg90H21EOLACvtfcHk0ljQAxoXZeakRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFelt7w%253D&md5=dc0e65564bac4e6cda533b395a57bcd1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.11.707859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.11.707859%26sid%3Dliteratum%253Aachs%26aulast%3DMealy%26aufirst%3DN.%2BE.%26aulast%3DCastaner%26aufirst%3DJ.%26atitle%3DAbt-492%253A%2520Quinolone%2520Antibacterial%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D1033%26epage%3D1038%26doi%3D10.1358%2Fdof.2002.027.11.707859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Haight, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariman, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueffier, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willcox, D. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the Quinolone Abt-492: Crystallizations for Optimal Processing</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1021/op060054e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op060054e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt12mt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=751-756&author=A.+R.+Haightauthor=S.+Z.+Arimanauthor=D.+M.+Barnesauthor=N.+J.+Benzauthor=F.+X.+Gueffierauthor=R.+F.+Henryauthor=M.+C.+Hsuauthor=E.+C.+Leeauthor=L.+Morinauthor=K.+B.+Pearlauthor=M.+J.+Petersonauthor=D.+J.+Plataauthor=D.+R.+Willcox&title=Synthesis+of+the+Quinolone+Abt-492%3A+Crystallizations+for+Optimal+Processing&doi=10.1021%2Fop060054e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the Quinolone ABT-492: Crystallizations for Optimal Processing</span></div><div class="casAuthors">Haight, Anthony R.; Ariman, Sema Z.; Barnes, David M.; Benz, Nancy J.; Gueffier, Francoix X.; Henry, Rodger F.; Hsu, Margaret C.; Lee, Elaine C.; Morin, Larry; Pearl, Kurt B.; Peterson, Matthew J.; Plata, Daniel J.; Willcox, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">751-756</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ABT-492 was under development at Abbott Labs. as a quinolone antibiotic.  A convergent syntheses was utilized to prep. the compd. on a multi-kilogram scale.  Difficulties in isolation of intermediates were overcome by developing control of the phys. forms.  Examples of controlling the agglomeration, crystal habit, and polymorphism of intermediates and the API are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnTZJO1LdporVg90H21EOLACvtfcHk0lgd43uCLfyBkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt12mt7s%253D&md5=09459d3c4a8aa714dd311ff6d96ffa92</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Fop060054e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop060054e%26sid%3Dliteratum%253Aachs%26aulast%3DHaight%26aufirst%3DA.%2BR.%26aulast%3DAriman%26aufirst%3DS.%2BZ.%26aulast%3DBarnes%26aufirst%3DD.%2BM.%26aulast%3DBenz%26aufirst%3DN.%2BJ.%26aulast%3DGueffier%26aufirst%3DF.%2BX.%26aulast%3DHenry%26aufirst%3DR.%2BF.%26aulast%3DHsu%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DMorin%26aufirst%3DL.%26aulast%3DPearl%26aufirst%3DK.%2BB.%26aulast%3DPeterson%26aufirst%3DM.%2BJ.%26aulast%3DPlata%26aufirst%3DD.%2BJ.%26aulast%3DWillcox%26aufirst%3DD.%2BR.%26atitle%3DSynthesis%2520of%2520the%2520Quinolone%2520Abt-492%253A%2520Crystallizations%2520for%2520Optimal%2520Processing%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2006%26volume%3D10%26spage%3D751%26epage%3D756%26doi%3D10.1021%2Fop060054e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christesen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haight, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedrow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagaw, S.</span></span> <span> </span><span class="NLM_article-title">Chlorination at the 8-Position of a Functionalized Quinolone and the Synthesis of Quinolone Antibiotic Abt-492</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1021/op0600557</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op0600557" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVSiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=803-807&author=D.+M.+Barnesauthor=A.+C.+Christesenauthor=K.+M.+Engstromauthor=A.+R.+Haightauthor=M.+C.+Hsuauthor=E.+C.+Leeauthor=M.+J.+Petersonauthor=D.+J.+Plataauthor=P.+S.+Rajeauthor=E.+J.+Stonerauthor=J.+S.+Tedrowauthor=S.+Wagaw&title=Chlorination+at+the+8-Position+of+a+Functionalized+Quinolone+and+the+Synthesis+of+Quinolone+Antibiotic+Abt-492&doi=10.1021%2Fop0600557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Chlorination at the 8-Position of a Functionalized Quinolone and the Synthesis of Quinolone Antibiotic ABT-492</span></div><div class="casAuthors">Barnes, David M.; Christesen, Alan C.; Engstrom, Kenneth M.; Haight, Anthony R.; Hsu, Margaret C.; Lee, Elaine C.; Peterson, Matthew J.; Plata, Daniel J.; Raje, Prasad S.; Stoner, Eric J.; Tedrow, Jason S.; Wagaw, Seble</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">803-807</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The total synthesis of quinolone antibiotic ABT-492 (I) has been achieved in 67% yield over nine steps from 2,4,5-trifluorobenzoic acid.  The highlights of this synthesis include a novel chemoselective chlorination at the 8-position of a highly elaborated quinolone core.  In addn., a Lewis acid promoted cyclization reaction to form the quinolone heterocycle was developed which was incorporated into a one-pot, three-step cyclization/coupling/protection sequence that proceeds in 93% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphXtd9jRc3TLVg90H21EOLACvtfcHk0lgd43uCLfyBkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVSiu7c%253D&md5=d411e4afcaa965d5e389e253b511ea75</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fop0600557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0600557%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DD.%2BM.%26aulast%3DChristesen%26aufirst%3DA.%2BC.%26aulast%3DEngstrom%26aufirst%3DK.%2BM.%26aulast%3DHaight%26aufirst%3DA.%2BR.%26aulast%3DHsu%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DPeterson%26aufirst%3DM.%2BJ.%26aulast%3DPlata%26aufirst%3DD.%2BJ.%26aulast%3DRaje%26aufirst%3DP.%2BS.%26aulast%3DStoner%26aufirst%3DE.%2BJ.%26aulast%3DTedrow%26aufirst%3DJ.%2BS.%26aulast%3DWagaw%26aufirst%3DS.%26atitle%3DChlorination%2520at%2520the%25208-Position%2520of%2520a%2520Functionalized%2520Quinolone%2520and%2520the%2520Synthesis%2520of%2520Quinolone%2520Antibiotic%2520Abt-492%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2006%26volume%3D10%26spage%3D803%26epage%3D807%26doi%3D10.1021%2Fop0600557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Haight, A.</span>; <span class="NLM_string-name">Barnes, D.</span>; <span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of a 3-Quinolinecarboxylic Acid as an Antibacterial Agent</span>. <span class="NLM_patent">WO 2006015194</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=A.+Haight&author=D.+Barnes&author=G.+Zhang&title=Preparation+of+a+3-Quinolinecarboxylic+Acid+as+an+Antibacterial+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaight%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520a%25203-Quinolinecarboxylic%2520Acid%2520as%2520an%2520Antibacterial%2520Agent%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, J. P.</span>; <span class="NLM_string-name">Hirschfeld, D. R.</span>; <span class="NLM_string-name">Silva, T.</span>; <span class="NLM_string-name">Sweeney, Z. K.</span>; <span class="NLM_string-name">Vora, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Phenoxyphenylacetamides as Non-Nucleoside Reverse Transcriptase Inhibitors</span>. <span class="NLM_patent">US 20050239881A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+P.+Dunn&author=D.+R.+Hirschfeld&author=T.+Silva&author=Z.+K.+Sweeney&author=H.+Vora&title=Preparation+of+Phenoxyphenylacetamides+as+Non-Nucleoside+Reverse+Transcriptase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DJ.%2BP.%26atitle%3DPreparation%2520of%2520Phenoxyphenylacetamides%2520as%2520Non-Nucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span> <span> </span><span class="NLM_article-title">Elsulfavirine: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1811</span>– <span class="NLM_lpage">1816</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0820-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0820-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28940154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOitrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1811-1816&author=Z.+T.+Al-Salama&title=Elsulfavirine%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0820-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Elsulfavirine: First Global Approval</span></div><div class="casAuthors">Al-Salama, Zaina T.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1811-1816</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Elsulfavirine (Elpida) is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections.  It is the prodrug of the active compd. VM-1500A, a small mol. selective NNRTI, which prevents HIV replication.  In June 2017, elsulfavirine received its first global approval in Russia for the treatment of HIV-1 infections in combination with other antiretroviral medicines.  Other formulations of this drug are also being evaluated in preclin. and phase II studies for the treatment of HIV infections and/or pre-exposure and post-exposure prophylaxis.  This article summarizes the milestones in the development of elsulfavirine leading to this first approval in HIV-1 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWl64SuDGjZbVg90H21EOLACvtfcHk0lh1wX4C_0uihw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOitrnM&md5=f90acfd69a4867927c0cc287459e833f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0820-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0820-3%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26atitle%3DElsulfavirine%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1811%26epage%3D1816%26doi%3D10.1007%2Fs40265-017-0820-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J. P.</span>; <span class="NLM_string-name">Pang, F.</span>; <span class="NLM_string-name">Wong, M.</span>; <span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Polymorphs of Acyl Sulfonamides</span>. <span class="NLM_patent">US 20100063154A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+P.+Davidson&author=F.+Pang&author=M.+Wong&author=M.+Martin&title=Preparation+of+Polymorphs+of+Acyl+Sulfonamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DJ.%2BP.%26atitle%3DPreparation%2520of%2520Polymorphs%2520of%2520Acyl%2520Sulfonamides%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, L. E.</span>; <span class="NLM_string-name">Hegde, S.</span>; <span class="NLM_string-name">Kuo, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Stefanidis, D.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Concentrated Aqueous Micellar Solutions</span>. <span class="NLM_patent">WO 2009109476A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=L.+E.+Fisher&author=S.+Hegde&author=J.+Kuo&author=F.+Li&author=D.+Stefanidis&title=Process+for+Preparing+Concentrated+Aqueous+Micellar+Solutions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DL.%2BE.%26atitle%3DProcess%2520for%2520Preparing%2520Concentrated%2520Aqueous%2520Micellar%2520Solutions%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J. P.</span>; <span class="NLM_string-name">Pang, F.</span>; <span class="NLM_string-name">Wong, M.</span>; <span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Polymorphs of Acyl Sulfonamides</span>. <span class="NLM_patent">US 20100063154</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+P.+Davidson&author=F.+Pang&author=M.+Wong&author=M.+Martin&title=Preparation+of+Polymorphs+of+Acyl+Sulfonamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DJ.%2BP.%26atitle%3DPreparation%2520of%2520Polymorphs%2520of%2520Acyl%2520Sulfonamides%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Glecaprevir/Pibrentasvir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1804</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0817-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0817-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28929412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFant7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1797-1804&author=Y.+N.+Lamb&title=Glecaprevir%2FPibrentasvir%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0817-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Glecaprevir/Pibrentasvir: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1804</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; Maviret (EU); Mavyret (USA)] has been developed by AbbVie.  Oral glecaprevir/pibrentasvir 300 mg/120 mg (three 100 mg/40 mg tablets) taken once daily has been approved by the EMA for the treatment of all major genotypes (genotypes 1-6) of chronic HCV infection in adults.  It has also been approved by the US FDA for the treatment of adult patients with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis, and for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen contg. either an HCV NS5A inhibitor or an NS3/4A PI, but not both.  This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlCoM88PgfTLVg90H21EOLACvtfcHk0lh1wX4C_0uihw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFant7bM&md5=52dc993b2fafc0256e6cfc0d3461da9f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0817-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0817-y%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DGlecaprevir%252FPibrentasvir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1797%26epage%3D1804%26doi%3D10.1007%2Fs40265-017-0817-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Leuw, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, C.</span></span> <span> </span><span class="NLM_article-title">Protease Inhibitor Therapy for Hepatitis C Virus-Infection</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1454428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F14656566.2018.1454428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29595065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsF2gt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=577-587&author=P.+de%0ALeuwauthor=C.+Stephan&title=Protease+Inhibitor+Therapy+for+Hepatitis+C+Virus-Infection&doi=10.1080%2F14656566.2018.1454428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Protease inhibitor therapy for hepatitis C virus-infection</span></div><div class="casAuthors">de Leuw, P.; Stephan, C.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: The hepatitis C virus (HCV) has affected an estd. of 80 million individuals worldwide and is a strain on public health.  Around 25-30% of patients in Europe and the US who are infected with HIV are coinfected with HCV.  Prior to 2013, treatment modalities contg. an NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin improved sustained virol. response (SVR) rates.  However, rates of severe side effects were high.  Nowadays, oral direct-acting antiviral (DAA) combination therapy offers excellent treatment efficacy, safety and tolerability.: This review focuses on the current literature and clin. evidence and their impact regarding NS3/4A protease inhibitors.  The pitfalls encountered in treating HIV- and HBV-coinfected patients are also discussed.: In the era of DAA treatment, third-generation pan-genotypic NS3/4A protease inhibitors (mainly glecaprevir and voxilaprevir) show high antiviral activity and a genetic resistance barrier with cure rates of over 95% when combined with an NS5A inhibitor, irresp. of baseline resistance assocd. variants (RASs) being present.  These new key components of DAA combination therapy are impressive options to eradicate HCV in the so-called difficult-to-treat population (e.g. compensated cirrhosis, end-stage renal disease and patients who failed previous DAA treatment).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhRlnsjOpKi7Vg90H21EOLACvtfcHk0lgO1nCKjQiPMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsF2gt7k%253D&md5=2b1ffd31d392a62a846004cbf46efc34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1454428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1454428%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLeuw%26aufirst%3DP.%26aulast%3DStephan%26aufirst%3DC.%26atitle%3DProtease%2520Inhibitor%2520Therapy%2520for%2520Hepatitis%2520C%2520Virus-Infection%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D577%26epage%3D587%26doi%3D10.1080%2F14656566.2018.1454428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Or, Y. S.</span>; <span class="NLM_string-name">Ma, J.</span>; <span class="NLM_string-name">Wang, G.</span>; <span class="NLM_string-name">Long, J.</span>; <span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocycles, Especially Proline-Containing Cyclic Peptides, as Hepatitis C Virus (Hcv) Ns3-Ns4a Protease Inhibitors</span>. <span class="NLM_patent">US 20120070416A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Y.+S.+Or&author=J.+Ma&author=G.+Wang&author=J.+Long&author=B.+Wang&title=Preparation+of+Macrocycles%2C+Especially+Proline-Containing+Cyclic+Peptides%2C+as+Hepatitis+C+Virus+%28Hcv%29+Ns3-Ns4a+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOr%26aufirst%3DY.%2BS.%26atitle%3DPreparation%2520of%2520Macrocycles%252C%2520Especially%2520Proline-Containing%2520Cyclic%2520Peptides%252C%2520as%2520Hepatitis%2520C%2520Virus%2520%2528Hcv%2529%2520Ns3-Ns4a%2520Protease%2520Inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luche, J.-L.</span>; <span class="NLM_string-name">Sarandeses, L. A.</span></span> <span> </span><span class="NLM_article-title">Zinc-Mediated Barbier Reactions</span>. In  <i>Organozinc Reagents: A Practical Approach</i>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Knochel, P.</span>, <span class="NLM_string-name">Jones, P.</span></span>, Eds.; <span class="NLM_publisher-name">Oxford University Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1999</span>; pp  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">323</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=307-323&author=J.-L.+Luche&author=L.+A.+Sarandesesauthor=P.+Knochel&author=P.+Jones&title=Organozinc+Reagents%3A+A+Practical+Approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLuche%26aufirst%3DJ.-L.%26atitle%3DZinc-Mediated%2520Barbier%2520Reactions%26btitle%3DOrganozinc%2520Reagents%253A%2520A%2520Practical%2520Approach%26aulast%3DKnochel%26aufirst%3DP.%26pub%3DOxford%2520University%2520Press%26date%3D1999%26spage%3D307%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Green, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollinshead, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, M.</span></span> <span> </span><span class="NLM_article-title">Oxo Complexes of Ruthenium(Vi) and (Vii) as Organic Oxidants</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.1039/P19840000681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2FP19840000681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaL2cXkvV2ru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1984&pages=681-686&author=G.+Greenauthor=W.+P.+Griffithauthor=D.+M.+Hollinsheadauthor=S.+V.+Leyauthor=M.+Schroder&title=Oxo+Complexes+of+Ruthenium%28Vi%29+and+%28Vii%29+as+Organic+Oxidants&doi=10.1039%2FP19840000681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Oxo complexes of ruthenium(VI) and (VII) as organic oxidants</span></div><div class="casAuthors">Green, Graham; Griffith, William P.; Hollinshead, David M.; Ley, Steven V.; Schroder, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1:  Organic and Bio-Organic Chemistry (1972-1999)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">681-6</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    </div><div class="casAbstract">The oxidn. of alcs. by [RuO4]2- (I), [RuO4]- (II), trans-Ba[Ru(OH)2O3] (III), [RuO2Cl3]- (IV), and [RuO2(bpy)Cl2] (V; bpy = 2,2'-bipyridyl) was examd.  Both I and II oxidize primary alcs. to carboxylic acids and secondary alcs. to ketones.  IV ( as its Ph4P+ salt) and V cleanly oxidize a wide range of alcs. to aldehydes and ketones without attack on double bonds.  III functions as a heterogeneous oxidant in CH2Cl2, oxidizing only reactive alcs. to aldehydes.  I catalyzed the oxidn. of alcs. by S2O82-.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4AIaM0NUQz7Vg90H21EOLACvtfcHk0lgO1nCKjQiPMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvV2ru7o%253D&md5=cec8d0291a6c5e0bd67fb1fc47d2e773</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1039%2FP19840000681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FP19840000681%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DG.%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DHollinshead%26aufirst%3DD.%2BM.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DSchroder%26aufirst%3DM.%26atitle%3DOxo%2520Complexes%2520of%2520Ruthenium%2528Vi%2529%2520and%2520%2528Vii%2529%2520as%2520Organic%2520Oxidants%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1984%26spage%3D681%26epage%3D686%26doi%3D10.1039%2FP19840000681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolliffe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springhorn, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiffin, P. D.</span></span> <span> </span><span class="NLM_article-title">Oxidation of Activated Halides to Aldehydes and Ketones by N-Methylmorpholine N-Oxide</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1967</span>– <span class="NLM_lpage">1971</span>, <span class="refDoi"> DOI: 10.1080/00397919208021328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F00397919208021328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK38XkvV2qs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1992&pages=1967-1971&author=W.+P.+Griffithauthor=J.+M.+Jolliffeauthor=S.+V.+Leyauthor=K.+F.+Springhornauthor=P.+D.+Tiffin&title=Oxidation+of+Activated+Halides+to+Aldehydes+and+Ketones+by+N-Methylmorpholine+N-Oxide&doi=10.1080%2F00397919208021328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation of activated halides to aldehydes and ketones by N-methylmorpholine N-oxide</span></div><div class="casAuthors">Griffith, William P.; Jolliffe, Jenny M.; Ley, Steven V.; Springhorn, Karsten F.; Tiffin, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1967-71</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">N-methylmorpholine N-oxide (NMO) in acetonitrile soln. will oxidize activated primary halides to aldehydes and secondary halides to ketones in good yields at room temp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLhsYP3x4oqLVg90H21EOLACvtfcHk0lgHRbXUj3zBGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XkvV2qs7w%253D&md5=ea5dd42526b5dbe970d33f54e17bcb85</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1080%2F00397919208021328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919208021328%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DJolliffe%26aufirst%3DJ.%2BM.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DSpringhorn%26aufirst%3DK.%2BF.%26aulast%3DTiffin%26aufirst%3DP.%2BD.%26atitle%3DOxidation%2520of%2520Activated%2520Halides%2520to%2520Aldehydes%2520and%2520Ketones%2520by%2520N-Methylmorpholine%2520N-Oxide%26jtitle%3DSynth.%2520Commun.%26date%3D1992%26volume%3D22%26spage%3D1967%26epage%3D1971%26doi%3D10.1080%2F00397919208021328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolliffe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. J.</span></span> <span> </span><span class="NLM_article-title">A New Ruthenium(Vi) Oxidant: Preparation, X-Ray Crystal Structure, and Properties of (Ph4p)[Ruo2(Oac)Cl2]</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1039/c39900001219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fc39900001219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK3MXhs1GmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&pages=1219-1221&author=W.+P.+Griffithauthor=J.+M.+Jolliffeauthor=S.+V.+Leyauthor=D.+J.+Williams&title=A+New+Ruthenium%28Vi%29+Oxidant%3A+Preparation%2C+X-Ray+Crystal+Structure%2C+and+Properties+of+%28Ph4p%29%5BRuo2%28Oac%29Cl2%5D&doi=10.1039%2Fc39900001219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24cR"><div class="casContent"><span class="casTitleNuber">24c</span><div class="casTitle"><span class="NLM_cas:atitle">A new ruthenium(VI) oxidant:  preparation, x-ray crystal structure, and properties of (Ph4P)[RuO2(OAc)Cl2]</span></div><div class="casAuthors">Griffith, William P.; Jolliffe, Jennifer M.; Ley, Steven V.; Williams, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1219-21</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Ph4P[RuO2(OAc)Cl2] (I), and butyrato and propionato analogs, were prepd.  I was characterized by elemental anal., IR and Raman spectroscopies, and (as I.2HOAc) x-ray crystallog.  Crystals are monoclinic, space group Cc, a 16.823(4), b 7.725(2), c 20.576(5) Å, β 98.93(2)°, Z = 4, R = 0.050, and Rw = 0.047.  I has a quasi-trigonal bipyramidal (or alternatively, distorted octahedral) structure with a sym. bound acetato ligand and cis-dioxo ligands in the trigonal plane, and is an effective oxidant for halides, alcs., sulfides, and phosphines, functioning catalytically in the presence of N-methylmorpholine-N-oxide as cooxidant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9p7kW3LsC8bVg90H21EOLACvtfcHk0lgHRbXUj3zBGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhs1GmtA%253D%253D&md5=b0343b81e21c7e42d1282e558c698f54</span></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1039%2Fc39900001219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39900001219%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DJolliffe%26aufirst%3DJ.%2BM.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DWilliams%26aufirst%3DD.%2BJ.%26atitle%3DA%2520New%2520Ruthenium%2528Vi%2529%2520Oxidant%253A%2520Preparation%252C%2520X-Ray%2520Crystal%2520Structure%252C%2520and%2520Properties%2520of%2520%2528Ph4p%2529%255BRuo2%2528Oac%2529Cl2%255D%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1990%26spage%3D1219%26epage%3D1221%26doi%3D10.1039%2Fc39900001219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span> <span> </span><span class="NLM_article-title">TPAP: Tetra-N-Propylammonium Perruthenate, a Mild and Convenient Oxidant for Alcohols</span>. <i>Aldrichimica Acta</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1002/chin.199040362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fchin.199040362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK3MXotVKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1990&pages=13-19&author=W.+P.+Griffithauthor=S.+V.+Ley&title=TPAP%3A+Tetra-N-Propylammonium+Perruthenate%2C+a+Mild+and+Convenient+Oxidant+for+Alcohols&doi=10.1002%2Fchin.199040362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24dR"><div class="casContent"><span class="casTitleNuber">24d</span><div class="casTitle"><span class="NLM_cas:atitle">TRAP:  tetra-n-propylammonium perruthenate, a mild and convenient oxidant for alcohols</span></div><div class="casAuthors">Griffith, William P.; Ley, Steven V.</div><div class="citationInfo"><span class="NLM_cas:title">Aldrichimica Acta</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-19</span>CODEN:
                <span class="NLM_cas:coden">ALACBI</span>;
        ISSN:<span class="NLM_cas:issn">0002-5100</span>.
    </div><div class="casAbstract">A review with 19 refs. illustrating the use of the title compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqybUhLNpSCrLVg90H21EOLACvtfcHk0lgHRbXUj3zBGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXotVKmsw%253D%253D&md5=02c84ebd8229aafdb72b84a76b53aea9</span></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=10.1002%2Fchin.199040362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchin.199040362%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DLey%26aufirst%3DS.%2BV.%26atitle%3DTPAP%253A%2520Tetra-N-Propylammonium%2520Perruthenate%252C%2520a%2520Mild%2520and%2520Convenient%2520Oxidant%2520for%2520Alcohols%26jtitle%3DAldrichimica%2520Acta%26date%3D1990%26volume%3D23%26spage%3D13%26epage%3D19%26doi%3D10.1002%2Fchin.199040362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitcombe, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. D.</span></span> <span> </span><span class="NLM_article-title">Preparation and Use of Tetrabutylammonium Perruthenate (Tbap Reagent) and Tetrapropylammonium Perruthenate (Tpap Reagent) as New Catalytic Oxidants for Alcohols</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1627</span>, <span class="refDoi"> DOI: 10.1039/c39870001625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fc39870001625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaL1cXktlOhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=1625-1627&author=W.+P.+Griffithauthor=S.+V.+Leyauthor=G.+P.+Whitcombeauthor=A.+D.+White&title=Preparation+and+Use+of+Tetrabutylammonium+Perruthenate+%28Tbap+Reagent%29+and+Tetrapropylammonium+Perruthenate+%28Tpap+Reagent%29+as+New+Catalytic+Oxidants+for+Alcohols&doi=10.1039%2Fc39870001625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24eR"><div class="casContent"><span class="casTitleNuber">24e</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and use of tetrabutylammonium perruthenate (TBAP reagent) and tetrapropylammonium perruthenate (TPAP reagent) as new catalytic oxidants for alcohols</span></div><div class="casAuthors">Griffith, William P.; Ley, Steven V.; Whitcombe, Gwynne P.; White, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1625-7</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Bu4NRuO4 or Pr4NRuO4 in combination with N-methylmorpholine N-oxide are mild catalytic oxidants for the high yield conversion of alcs. to aldehyde and ketones and are competitive with more conventional reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxf2jCOWaVh7Vg90H21EOLACvtfcHk0lgTeNCbG7dSFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktlOhuro%253D&md5=19a661844cadf93bad8dc9ae9ba18477</span></div><a href="/servlet/linkout?suffix=cit24e&amp;dbid=16384&amp;doi=10.1039%2Fc39870001625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39870001625%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DWhitcombe%26aufirst%3DG.%2BP.%26aulast%3DWhite%26aufirst%3DA.%2BD.%26atitle%3DPreparation%2520and%2520Use%2520of%2520Tetrabutylammonium%2520Perruthenate%2520%2528Tbap%2520Reagent%2529%2520and%2520Tetrapropylammonium%2520Perruthenate%2520%2528Tpap%2520Reagent%2529%2520as%2520New%2520Catalytic%2520Oxidants%2520for%2520Alcohols%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1987%26spage%3D1625%26epage%3D1627%26doi%3D10.1039%2Fc39870001625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, S. P.</span></span> <span> </span><span class="NLM_article-title">Tetrapropylammonium Perruthenate, Pr4n+Ruo4-, Tpap: A Catalytic Oxidant for Organic Synthesis</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>1994</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1055/s-1994-25538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-1994-25538" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1994&publication_year=1994&pages=639-666&author=S.+V.+Leyauthor=J.+Normanauthor=W.+P.+Griffithauthor=S.+P.+Marsden&title=Tetrapropylammonium+Perruthenate%2C+Pr4n%2BRuo4-%2C+Tpap%3A+A+Catalytic+Oxidant+for+Organic+Synthesis&doi=10.1055%2Fs-1994-25538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24f&amp;dbid=16384&amp;doi=10.1055%2Fs-1994-25538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1994-25538%26sid%3Dliteratum%253Aachs%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DNorman%26aufirst%3DJ.%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DMarsden%26aufirst%3DS.%2BP.%26atitle%3DTetrapropylammonium%2520Perruthenate%252C%2520Pr4n%252BRuo4-%252C%2520Tpap%253A%2520A%2520Catalytic%2520Oxidant%2520for%2520Organic%2520Synthesis%26jtitle%3DSynthesis%26date%3D1994%26volume%3D1994%26spage%3D639%26epage%3D666%26doi%3D10.1055%2Fs-1994-25538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bjornson, K.</span>; <span class="NLM_string-name">Karki, K.
K.</span>; <span class="NLM_string-name">Link, J.
O.</span>; <span class="NLM_string-name">Pyun, H.-J.</span>; <span class="NLM_string-name">Schrier, A. J.</span>; <span class="NLM_string-name">Stevens, K. L.</span>; <span class="NLM_string-name">Taylor, J. G.</span>; <span class="NLM_string-name">Vivian, R. W.</span>; <span class="NLM_string-name">Zablocki, J.</span>; <span class="NLM_string-name">Zipfel, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocyclic and Bicyclic Derivatives of N-Prolyl-1-aminocyclopropanecarboxylic Acid Peptides as Inhibitors of Hepatitis C Virus</span>. <span class="NLM_patent">WO 2014145095A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+Bjornson&author=K.%0AK.+Karki&author=J.%0AO.+Link&author=H.-J.+Pyun&author=A.+J.+Schrier&author=K.+L.+Stevens&author=J.+G.+Taylor&author=R.+W.+Vivian&author=J.+Zablocki&author=S.+Zipfel&title=Preparation+of+Macrocyclic+and+Bicyclic+Derivatives+of+N-Prolyl-1-aminocyclopropanecarboxylic+Acid+Peptides+as+Inhibitors+of+Hepatitis+C+Virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBjornson%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Macrocyclic%2520and%2520Bicyclic%2520Derivatives%2520of%2520N-Prolyl-1-aminocyclopropanecarboxylic%2520Acid%2520Peptides%2520as%2520Inhibitors%2520of%2520Hepatitis%2520C%2520Virus%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, N. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furkert, D. P.</span></span> <span> </span><span class="NLM_article-title">Remarkable Influence of Cobalt Catalysis on Epoxide Ring-Opening with Sulfoxonium Ylides</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">3952</span>– <span class="NLM_lpage">3956</span>, <span class="refDoi"> DOI: 10.1055/s-0036-1588814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-0036-1588814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlyrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=3952-3956&author=M.+L.+Jamiesonauthor=N.+Z.+Brantauthor=M.+A.+Brimbleauthor=D.+P.+Furkert&title=Remarkable+Influence+of+Cobalt+Catalysis+on+Epoxide+Ring-Opening+with+Sulfoxonium+Ylides&doi=10.1055%2Fs-0036-1588814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Remarkable Influence of Cobalt Catalysis on Epoxide Ring-Opening with Sulfoxonium Ylides</span></div><div class="casAuthors">Jamieson, Megan L.; Brant, Nicola Z.; Brimble, Margaret A.; Furkert, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3952-3956</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Cobalt demonstrates a remarkable ability to catalytically divert the course of epoxide to oxetane ring expansion via reaction with a sulfoxonium ylide.  An expanded survey of transition-metal catalysts has confirmed that cobalt salts uniquely instead deliver homoallylic alc. products from epoxides, with retention of the original epoxide stereochem.  The reaction is an unusual example of cobalt-catalyzed epoxide ring-opening by a carbon nucleophile.  A tandem Corey-Chaykovsky/epoxide olefination sequence giving homoallylic alcs. from aldehydes is further demonstrated along with preliminary mechanistic anal.  This communication summarizes current understanding and ongoing studies into this intriguing new cobalt-mediated reactivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpodo_joTc5zLVg90H21EOLACvtfcHk0lidrZB_vrf8GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlyrtLY%253D&md5=7706b207f7896f2523d6ceb2745ad7af</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1055%2Fs-0036-1588814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0036-1588814%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DM.%2BL.%26aulast%3DBrant%26aufirst%3DN.%2BZ.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26aulast%3DFurkert%26aufirst%3DD.%2BP.%26atitle%3DRemarkable%2520Influence%2520of%2520Cobalt%2520Catalysis%2520on%2520Epoxide%2520Ring-Opening%2520with%2520Sulfoxonium%2520Ylides%26jtitle%3DSynthesis%26date%3D2017%26volume%3D49%26spage%3D3952%26epage%3D3956%26doi%3D10.1055%2Fs-0036-1588814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguloth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohapatra, D. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the Major Oxepane Segment of Zoapatanol</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1002/hlca.201200364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fhlca.201200364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls12rs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2013&pages=663-674&author=J.+S.+Yadavauthor=U.+Dashauthor=N.+Gugulothauthor=D.+K.+Mohapatra&title=Synthesis+of+the+Major+Oxepane+Segment+of+Zoapatanol&doi=10.1002%2Fhlca.201200364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the Major Oxepane Segment of Zoapatanol</span></div><div class="casAuthors">Yadav, Jhillu S.; Dash, Uttam; Guguloth, Nagesh; Mohapatra, Debendra K.</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">663-674</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta</span>)
        </div><div class="casAbstract">A linear synthesis of the major oxepane fragment (I) of zoapatanol, isolated from the leaves of Mexican zoapatle plant Montanoa tomentosa, is described from a known intermediate involving Sharpless asym. epoxidn., bis-epoxide opening reaction with Corey-Chaykovsky reagent, ring-closing metathesis reaction, and Horner-Wadsworth-Emmons olefination reaction as key steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqibindN9ROJ7Vg90H21EOLACvtfcHk0lidrZB_vrf8GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls12rs7w%253D&md5=29e50a456b976c6c769d600f55882023</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1002%2Fhlca.201200364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.201200364%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DJ.%2BS.%26aulast%3DDash%26aufirst%3DU.%26aulast%3DGuguloth%26aufirst%3DN.%26aulast%3DMohapatra%26aufirst%3DD.%2BK.%26atitle%3DSynthesis%2520of%2520the%2520Major%2520Oxepane%2520Segment%2520of%2520Zoapatanol%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2013%26volume%3D96%26spage%3D663%26epage%3D674%26doi%3D10.1002%2Fhlca.201200364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span>; <span class="NLM_string-name">Chen, L.</span>; <span class="NLM_string-name">Shan, Y.</span>; <span class="NLM_string-name">Luo, H.</span>; <span class="NLM_string-name">Liang, J.</span>; <span class="NLM_string-name">Huang, J.</span>; <span class="NLM_string-name">Xiong, J.</span>; <span class="NLM_string-name">Zhang, D.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Salts of a Macrocyclic Peptidomimetic as HCV Inhibitors</span>. <span class="NLM_patent">WO 2018028634A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Q.+Ren&author=L.+Chen&author=Y.+Shan&author=H.+Luo&author=J.+Liang&author=J.+Huang&author=J.+Xiong&author=D.+Zhang&author=Y.+Zhang&author=J.+Zhang&title=Preparation+of+Salts+of+a+Macrocyclic+Peptidomimetic+as+HCV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520Salts%2520of%2520a%2520Macrocyclic%2520Peptidomimetic%2520as%2520HCV%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Z.-Y. J.</span></span> <span> </span><span class="NLM_article-title">Highly Active Metathesis Catalysts Selective for Romp and Rcm Reactions</span>. <span class="NLM_patent">WO 2011079439A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Z.-Y.+J.+Zhan&title=Highly+Active+Metathesis+Catalysts+Selective+for+Romp+and+Rcm+Reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DZ.-Y.%2BJ.%26atitle%3DHighly%2520Active%2520Metathesis%2520Catalysts%2520Selective%2520for%2520Romp%2520and%2520Rcm%2520Reactions%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span>; <span class="NLM_string-name">Shepard, S.</span>; <span class="NLM_string-name">Li, Y.-L.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Liu, P.</span>; <span class="NLM_string-name">Meloni, D.</span>; <span class="NLM_string-name">Xia, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Azetidine and Cyclobutane Derivatives as Jak Inhibitors</span>. <span class="NLM_patent">WO 2009114512</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+D.+Rodgers&author=S.+Shepard&author=Y.-L.+Li&author=J.+Zhou&author=P.+Liu&author=D.+Meloni&author=M.+Xia&title=Preparation+of+Azetidine+and+Cyclobutane+Derivatives+as+Jak+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26atitle%3DPreparation%2520of%2520Azetidine%2520and%2520Cyclobutane%2520Derivatives%2520as%2520Jak%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobierski, M. E.</span>; <span class="NLM_string-name">Kopach, M. E.</span>; <span class="NLM_string-name">Martinelli, J. R.</span>; <span class="NLM_string-name">Varie, D. L.</span>; <span class="NLM_string-name">Wilson, T. M.</span></span> <span> </span><span class="NLM_article-title">Processes and Intermediates for the Preparation of {1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile</span>. <span class="NLM_patent">WO 2016205487</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+E.+Kobierski&author=M.+E.+Kopach&author=J.+R.+Martinelli&author=D.+L.+Varie&author=T.+M.+Wilson&title=Processes+and+Intermediates+for+the+Preparation+of+%7B1-%28Ethylsulfonyl%29-3-%5B4-%287H-pyrrolo%5B2%2C3-D%5Dpyrimidin-4-yl%29-1H-pyrazol-1-yl%5Dazetidin-3-yl%7Dacetonitrile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKobierski%26aufirst%3DM.%2BE.%26atitle%3DProcesses%2520and%2520Intermediates%2520for%2520the%2520Preparation%2520of%2520%257B1-%2528Ethylsulfonyl%2529-3-%255B4-%25287H-pyrrolo%255B2%252C3-D%255Dpyrimidin-4-yl%2529-1H-pyrazol-1-yl%255Dazetidin-3-yl%257Dacetonitrile%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevar, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kel'in, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulinkovich, O. G.</span></span> <span> </span><span class="NLM_article-title">One Step Preparation of 1,4-Diketones from Methyl Ketones and A-Bromomethyl Ketones in the Presence of Zncl2·T-Buoh·Et2nr as a Condensation Agent</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2000</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1055/s-2000-6418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-2000-6418" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2000&publication_year=2000&pages=1259-1262&author=N.+M.+Nevarauthor=A.+V.+Kel%27inauthor=O.+G.+Kulinkovich&title=One+Step+Preparation+of+1%2C4-Diketones+from+Methyl+Ketones+and+A-Bromomethyl+Ketones+in+the+Presence+of+Zncl2%C2%B7T-Buoh%C2%B7Et2nr+as+a+Condensation+Agent&doi=10.1055%2Fs-2000-6418"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-6418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-6418%26sid%3Dliteratum%253Aachs%26aulast%3DNevar%26aufirst%3DN.%2BM.%26aulast%3DKel%2527in%26aufirst%3DA.%2BV.%26aulast%3DKulinkovich%26aufirst%3DO.%2BG.%26atitle%3DOne%2520Step%2520Preparation%2520of%25201%252C4-Diketones%2520from%2520Methyl%2520Ketones%2520and%2520A-Bromomethyl%2520Ketones%2520in%2520the%2520Presence%2520of%2520Zncl2%25C2%25B7T-Buoh%25C2%25B7Et2nr%2520as%2520a%2520Condensation%2520Agent%26jtitle%3DSynthesis%26date%3D2000%26volume%3D2000%26spage%3D1259%26epage%3D1262%26doi%3D10.1055%2Fs-2000-6418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Periasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seenivasaperumal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. D.</span></span> <span> </span><span class="NLM_article-title">Convenient Procedures for the Asymmetric Reduction of 1,4-Diphenylbutane-1,4-Dione and Synthesis of 2,5-Diphenylpyrrolidine Derivatives</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2510</span>, <span class="refDoi"> DOI: 10.1055/s-2003-42447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-2003-42447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsV2htb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=2507-2510&author=M.+Periasamyauthor=M.+Seenivasaperumalauthor=V.+D.+Rao&title=Convenient+Procedures+for+the+Asymmetric+Reduction+of+1%2C4-Diphenylbutane-1%2C4-Dione+and+Synthesis+of+2%2C5-Diphenylpyrrolidine+Derivatives&doi=10.1055%2Fs-2003-42447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">Convenient procedures for the asymmetric reduction of 1,4-diphenylbutane-1,4-dione and synthesis of 2,5-diphenylpyrrolidine derivatives</span></div><div class="casAuthors">Periasamy, Mariappan; Seenivasaperumal, Muthu; Rao, Vutukuri Dharma</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2507-2510</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Asym. redn. of 1,4-diphenylbutane-1,4-dione was carried out using the reducing agents NaBH4, BH3·THF, and PhNEt2·BH3 in combination with the chiral reagents (S)-(-)-α,α-diphenyl-2-pyrrolidinemethanol or (S)-proline, in the presence of TMSCl or B(OMe)3 under various conditions to obtain the corresponding 1,4-diol I in good yield and high enantiomeric excess.  I was converted to various C2-sym. (2S,5S)-2,5-diphenylpyrrolidines II (R = Ph, PhCH2, 2-MeOC6H4, HOCH2CH2, Bu) via the corresponding dimesylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYep2mvYWKbVg90H21EOLACvtfcHk0lhfmILPajCG4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsV2htb8%253D&md5=f2d2121da2144ef04acb518b86dab373</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1055%2Fs-2003-42447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2003-42447%26sid%3Dliteratum%253Aachs%26aulast%3DPeriasamy%26aufirst%3DM.%26aulast%3DSeenivasaperumal%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DV.%2BD.%26atitle%3DConvenient%2520Procedures%2520for%2520the%2520Asymmetric%2520Reduction%2520of%25201%252C4-Diphenylbutane-1%252C4-Dione%2520and%2520Synthesis%2520of%25202%252C5-Diphenylpyrrolidine%2520Derivatives%26jtitle%3DSynthesis%26date%3D2003%26spage%3D2507%26epage%3D2510%26doi%3D10.1055%2Fs-2003-42447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span>; <span class="NLM_string-name">Meyer, M. P.</span></span> <span> </span><span class="NLM_article-title">The Corey–Bakshi–Shibata Reduction: Mechanistic and Synthetic Considerations—Bifunctional Lewis Base Catalysis with Dual Activation</span>. In  <i>Lewis Base Catalysis in Organic Synthesis</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedejs, E.</span>, <span class="NLM_string-name">Denmark, S. E.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">1, 2</span> and  <span class="NLM_volume">3</span>, pp  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">456</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2F9783527675142.ch11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=387-456&author=C.+J.+Helal&author=M.+P.+Meyerauthor=E.+Vedejs&author=S.+E.+Denmark&title=Lewis+Base+Catalysis+in+Organic+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1002%2F9783527675142.ch11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527675142.ch11%26sid%3Dliteratum%253Aachs%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520Corey%25E2%2580%2593Bakshi%25E2%2580%2593Shibata%2520Reduction%253A%2520Mechanistic%2520and%2520Synthetic%2520Considerations%25E2%2580%2594Bifunctional%2520Lewis%2520Base%2520Catalysis%2520with%2520Dual%2520Activation%26btitle%3DLewis%2520Base%2520Catalysis%2520in%2520Organic%2520Synthesis%26aulast%3DVedejs%26aufirst%3DE.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2016%26volume%3D1%252C%25202%26volume%3D3%26spage%3D387%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Letermovir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0860-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0860-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29288370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=147-152&author=E.+S.+Kim&title=Letermovir%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0860-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Letermovir: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-152</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Letermovir (Prevymis) is an orally or i.v. administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH.  Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropos. recipients of an allogeneic haematopoietic stem cell transplant (HSCT).  In addn., letermovir has received a pos. opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan.  This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropos. recipients of an allogeneic HSCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd17YxqIzKurVg90H21EOLACvtfcHk0lhfmILPajCG4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGrtQ%253D%253D&md5=f8119640200c6dcd24b78c6bf261b85e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0860-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0860-8%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DLetermovir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D147%26epage%3D152%26doi%3D10.1007%2Fs40265-017-0860-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goldner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewlett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettischer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruebsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lischka, P.</span></span> <span> </span><span class="NLM_article-title">The Novel Anticytomegalovirus Compound Aic246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">10884</span>– <span class="NLM_lpage">10893</span>, <span class="refDoi"> DOI: 10.1128/JVI.05265-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1128%2FJVI.05265-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=21752907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=10884-10893&author=T.+Goldnerauthor=G.+Hewlettauthor=N.+Ettischerauthor=H.+Ruebsamen-Schaeffauthor=H.+Zimmermannauthor=P.+Lischka&title=The+Novel+Anticytomegalovirus+Compound+Aic246+%28Letermovir%29+Inhibits+Human+Cytomegalovirus+Replication+through+a+Specific+Antiviral+Mechanism+That+Involves+the+Viral+Terminase&doi=10.1128%2FJVI.05265-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase</span></div><div class="casAuthors">Goldner, Thomas; Hewlett, Guy; Ettischer, Nicole; Ruebsamen-Schaeff, Helga; Zimmermann, Holger; Lschka, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10884-10893</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) remains the leading viral cause of birth defects and life-threatening disease in transplant recipients.  All approved antiviral drugs target the viral DNA polymerase and are assocd. with severe toxicity issues and the emergence of drug resistance.  Attempts to discover improved anti-HCMV drugs led to the identification of the small-mol.-wt. compd. AIC246 (Letermovir).  AIC246 exhibits outstanding anti-HCMV activity in vitro and in vivo and currently is undergoing a clin. phase IIb trial.  The initial mode-of-action studies suggested that the drug acts late in the HCMV replication cycle via a mechanism distinct from that of polymerase inhibitors.  Here, we extend our mode-of-action analyses and report that AIC246 blocks viral replication without inhibiting the synthesis of progeny HCMV DNA or viral proteins.  The genotyping of mutant viruses that escaped AIC246 inhibition uncovered distinct point mutations in the UL56 subunit of the viral terminase complex.  Marker transfer analyses confirmed that these mutations were sufficient to mediate AIC246 resistance.  The mapping of drug resistance to open reading frame UL56 suggests that viral DNA processing and/or packaging is targeted by AIC246.  In line with this, we demonstrate that AIC246 affects the formation of proper unit-length genomes from viral DNA concatemers and interferes with virion maturation.  However, since AIC246-resistant viruses do not exhibit cross-resistance to previously published terminase inhibitors, our data suggest that AIC246 interferes with HCMV DNA cleavage/packaging via a mol. mechanism that is distinct from that of other compd. classes known to target the viral terminase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswkV2gibRBbVg90H21EOLACvtfcHk0liJHuXSqFscdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsbzI&md5=63602456ebfb1cf9c2509d26d260487d</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1128%2FJVI.05265-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.05265-11%26sid%3Dliteratum%253Aachs%26aulast%3DGoldner%26aufirst%3DT.%26aulast%3DHewlett%26aufirst%3DG.%26aulast%3DEttischer%26aufirst%3DN.%26aulast%3DRuebsamen-Schaeff%26aufirst%3DH.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DLischka%26aufirst%3DP.%26atitle%3DThe%2520Novel%2520Anticytomegalovirus%2520Compound%2520Aic246%2520%2528Letermovir%2529%2520Inhibits%2520Human%2520Cytomegalovirus%2520Replication%2520through%2520a%2520Specific%2520Antiviral%2520Mechanism%2520That%2520Involves%2520the%2520Viral%2520Terminase%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D10884%26epage%3D10893%26doi%3D10.1128%2FJVI.05265-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lischka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewlett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruebsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Activities of the Novel Anticytomegalovirus Compound Aic246</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1297</span>, <span class="refDoi"> DOI: 10.1128/AAC.01596-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1128%2FAAC.01596-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=20047911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFWqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=1290-1297&author=P.+Lischkaauthor=G.+Hewlettauthor=T.+Wunbergauthor=J.+Baumeisterauthor=D.+Paulsenauthor=T.+Goldnerauthor=H.+Ruebsamen-Schaeffauthor=H.+Zimmermann&title=In+Vitro+and+in+Vivo+Activities+of+the+Novel+Anticytomegalovirus+Compound+Aic246&doi=10.1128%2FAAC.01596-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of the novel anti-cytomegalovirus compound AIC246</span></div><div class="casAuthors">Lischka, Peter; Hewlett, Guy; Wunberg, Tobias; Baumeister, Judith; Paulsen, Daniela; Goldner, Thomas; Ruebsamen-Schaeff, Helga; Zimmermann, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1290-1297</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) remains a serious threat for immunocompromised individuals, including transplant recipients and newborns.  To date, all drugs licensed for the treatment of HCMV infection and disease target the viral DNA polymerase.  Although these drugs are effective, several drawbacks are assocd. with their use, including toxicity and emergence of drug resistance.  Hence, new and improved antivirals with novel mol. targets are urgently needed.  Here we report on the antiviral properties of AIC246, a representative of a novel class of low-mol.-wt. compds. that is currently undergoing clin. phase II studies.  The anti-HCMV activity of AIC246 was evaluated in vitro and in vivo using various cell culture assays and an engineered mouse xenograft model.  In addn., antiviral properties of the drug were characterized in comparison to the current gold std. ganciclovir.  We demonstrate that AIC246 exhibits excellent in vitro inhibitory activity against HCMV lab. strains and clin. isolates, retains activity against ganciclovir-resistant viruses, is well tolerated in different cell types (median selectivity index, 18,000), and exerts a potent in vivo efficacy in a mouse xenograft model.  Moreover, we show that the antiviral block induced by AIC246 is reversible and the efficacy of the drug is not significantly affected by cell culture variations such as cell type or multiplicity of infection.  Finally, initial mode-of-action analyses reveal that AIC246 targets a process in the viral replication cycle that occurs later than DNA synthesis.  Thus, AIC246 acts via a mode of action that differs from that of polymerase inhibitors like ganciclovir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYctCp0_IZsrVg90H21EOLACvtfcHk0liJHuXSqFscdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFWqtro%253D&md5=5241b3ab03c28e9071c7e2ac7113d1c3</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1128%2FAAC.01596-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01596-09%26sid%3Dliteratum%253Aachs%26aulast%3DLischka%26aufirst%3DP.%26aulast%3DHewlett%26aufirst%3DG.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DBaumeister%26aufirst%3DJ.%26aulast%3DPaulsen%26aufirst%3DD.%26aulast%3DGoldner%26aufirst%3DT.%26aulast%3DRuebsamen-Schaeff%26aufirst%3DH.%26aulast%3DZimmermann%26aufirst%3DH.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Activities%2520of%2520the%2520Novel%2520Anticytomegalovirus%2520Compound%2520Aic246%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D1290%26epage%3D1297%26doi%3D10.1128%2FAAC.01596-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maffini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Festuccia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, B.</span></span> <span> </span><span class="NLM_article-title">Treatment of Cmv Infection after Allogeneic Hematopoietic Stem Cell Transplantation</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1080/17474086.2016.1174571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F17474086.2016.1174571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27043241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsValtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=585-596&author=E.+Maffiniauthor=L.+Giacconeauthor=M.+Festucciaauthor=L.+Brunelloauthor=A.+Buscaauthor=B.+Bruno&title=Treatment+of+Cmv+Infection+after+Allogeneic+Hematopoietic+Stem+Cell+Transplantation&doi=10.1080%2F17474086.2016.1174571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation</span></div><div class="casAuthors">Maffini, Enrico; Giaccone, Luisa; Festuccia, Moreno; Brunello, Lucia; Busca, Alessandro; Bruno, Benedetto</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">585-596</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Despite a remarkable redn. in the past decades, cytomegalovirus (CMV) disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients remains a feared complication, still assocd. with significant morbidity and mortality.  Today, first line treatment of CMV infection/reactivation is still based on dated antiviral compds. Ganciclovir (GCV), Foscarnet (FOS) and Cidofovir (CDF) with their burdensome wt. of side effects.  Maribavir (MBV), Letermovir (LMV) and Brincidofovir (BDF) are three new promising anti-CMV drugs without myelosuppressive properties or renal toxic effects that are under investigation in randomized phase II and III trials.  Adoptive T-cell therapy (ATCT) in CMV infection possesses a strong rationale, demonstrated by several proof of concept studies; its feasibility is currently under investigation by clin. trials.  ATCT from third-party and naive donors could meet the needs of HSCT recipients of seroneg. donors and cord blood grafts.  In selected patients such as recipients of T-cell depleted grafts, ATCT, based on CMV-specific host T-cells reconstitution kinetics, would be of value in the prophylactic and/or preemptive CMV treatment.  Vaccine-immunotherapy has the difficult task to reduce the incidence of CMV reactivation/infection in highly immunocompromised HSCT patients.  Newer notions on CMV biol. may represent the base to flush out the Troll of transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p3iqa8nYoLVg90H21EOLACvtfcHk0liJHuXSqFscdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsValtbc%253D&md5=6202b81031dab3e5909b610b72f7cc9c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F17474086.2016.1174571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2016.1174571%26sid%3Dliteratum%253Aachs%26aulast%3DMaffini%26aufirst%3DE.%26aulast%3DGiaccone%26aufirst%3DL.%26aulast%3DFestuccia%26aufirst%3DM.%26aulast%3DBrunello%26aufirst%3DL.%26aulast%3DBusca%26aufirst%3DA.%26aulast%3DBruno%26aufirst%3DB.%26atitle%3DTreatment%2520of%2520Cmv%2520Infection%2520after%2520Allogeneic%2520Hematopoietic%2520Stem%2520Cell%2520Transplantation%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2016%26volume%3D9%26spage%3D585%26epage%3D596%26doi%3D10.1080%2F17474086.2016.1174571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R.
F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmann, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoelben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornhauser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolling, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stobernack, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lischka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehninger, G.</span></span> <span> </span><span class="NLM_article-title">Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1789</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1309533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1056%2FNEJMoa1309533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=24806159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXot12jtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1781-1789&author=R.%0AF.+Chemalyauthor=A.+J.+Ullmannauthor=S.+Stoelbenauthor=M.+P.+Richardauthor=M.+Bornhauserauthor=C.+Grothauthor=H.+Einseleauthor=M.+Silvermanauthor=K.+M.+Mullaneauthor=J.+Brownauthor=H.+Nowakauthor=K.+Kollingauthor=H.+P.+Stobernackauthor=P.+Lischkaauthor=H.+Zimmermannauthor=H.+Rubsamen-Schaeffauthor=R.+E.+Champlinauthor=G.+Ehninger&title=Letermovir+for+Cytomegalovirus+Prophylaxis+in+Hematopoietic-Cell+Transplantation&doi=10.1056%2FNEJMoa1309533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation</span></div><div class="casAuthors">Chemaly, Roy F.; Ullmann, Andrew J.; Stoelben, Susanne; Richard, Marie Paule; Bornhauser, Martin; Groth, Christoph; Einsele, Hermann; Silverman, Margarida; Mullane, Kathleen M.; Brown, Janice; Nowak, Horst; Kolling, Katrin; Stobernack, Hans P.; Lischka, Peter; Zimmermann, Holger; Rubsamen-Schaeff, Helga; Champlin, Richard E.; Ehninger, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1781-1789</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Cytomegalovirus (CMV) infection is a leading cause of illness and death in patients who have undergone allogeneic hematopoietic-cell transplantation.  Available treatments are restricted by clin. significant toxic effects and drug resistance.  METHODS In this phase 2 study, we evaluated the effect of letermovir (also known as AIC246), a new anti-CMV drug with a novel mechanism of action, on the incidence and time to onset of prophylaxis failure in CMV-seropos. recipients of allogeneic hematopoietic-cell transplants from matched related or unrelated donors.  From March 2010 through Oct. 2011, we randomly assigned 131 transplant recipients in a 3:1 ratio to three sequential study cohorts according to a double-blind design.  Patients received oral letermovir (at a dose of 60, 120, or 240 mg per day, or matching placebo) for 12 wk after engraftment.  The primary end point was all-cause prophylaxis failure, defined as discontinuation of the study drug because of CMV antigen or DNA detection, end-organ disease, or any other cause.  Patients underwent weekly surveillance for CMV infection.  RESULTS The redn. in the incidence of all-cause prophylaxis failure was dose-dependent.  The incidence of prophylaxis failure with letermovir, as compared with placebo, was 48% vs. 64% at a daily letermovir dose of 60 mg (P = 0.32), 32% at a dose of 120 mg (P = 0.01), and 29% at a dose of 240 mg (P = 0.007).  Kaplan-Meier time-to-onset profiles for prophylaxis failure showed a significant difference in the comparison of letermovir at a dose of 240 mg per day with placebo (P = 0.002).  The safety profile of letermovir was similar to placebo, with no indication of hematol. toxicity or nephrotoxicity.  CONCLUSIONS Letermovir, as compared with placebo, was effective in reducing the incidence of CMV infection in recipients of allogeneic hematopoietic-cell transplants.  The highest dose (240 mg per day) had the greatest anti-CMV activity, with an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_0Nxh6vCjW7Vg90H21EOLACvtfcHk0lg8CL26-U8zog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXot12jtLc%253D&md5=bdba7e2d625d8713e7224584b2f3adaf</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1309533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1309533%26sid%3Dliteratum%253Aachs%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DUllmann%26aufirst%3DA.%2BJ.%26aulast%3DStoelben%26aufirst%3DS.%26aulast%3DRichard%26aufirst%3DM.%2BP.%26aulast%3DBornhauser%26aufirst%3DM.%26aulast%3DGroth%26aufirst%3DC.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DSilverman%26aufirst%3DM.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DNowak%26aufirst%3DH.%26aulast%3DKolling%26aufirst%3DK.%26aulast%3DStobernack%26aufirst%3DH.%2BP.%26aulast%3DLischka%26aufirst%3DP.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DRubsamen-Schaeff%26aufirst%3DH.%26aulast%3DChamplin%26aufirst%3DR.%2BE.%26aulast%3DEhninger%26aufirst%3DG.%26atitle%3DLetermovir%2520for%2520Cytomegalovirus%2520Prophylaxis%2520in%2520Hematopoietic-Cell%2520Transplantation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1781%26epage%3D1789%26doi%3D10.1056%2FNEJMoa1309533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljungman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadwal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmann, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snydman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNubile, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teal, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartsonis, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badshah, C.</span></span> <span> </span><span class="NLM_article-title">Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2433</span>– <span class="NLM_lpage">2444</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1056%2FNEJMoa1706640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29211658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2433-2444&author=F.+M.+Martyauthor=P.+Ljungmanauthor=R.+F.+Chemalyauthor=J.+Maertensauthor=S.+S.+Dadwalauthor=R.+F.+Duarteauthor=S.+Haiderauthor=A.+J.+Ullmannauthor=Y.+Katayamaauthor=J.+Brownauthor=K.+M.+Mullaneauthor=M.+Boeckhauthor=E.+A.+Blumbergauthor=H.+Einseleauthor=D.+R.+Snydmanauthor=Y.+Kandaauthor=M.+J.+DiNubileauthor=V.+L.+Tealauthor=H.+Wanauthor=Y.+Murataauthor=N.+A.+Kartsonisauthor=R.+Y.+Leavittauthor=C.+Badshah&title=Letermovir+Prophylaxis+for+Cytomegalovirus+in+Hematopoietic-Cell+Transplantation&doi=10.1056%2FNEJMoa1706640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation</span></div><div class="casAuthors">Marty, F. M.; Ljungman, P.; Chemaly, R. F.; Maertens, J.; Dadwal, S. S.; Duart, R. F.; Haider, S.; Ullmann, A. J.; Katayama, Y.; Brown, J.; Mullane, K. M.; Boeckh, M.; Blumberg, E. A.; Einsele, H.; Snydman, D. R.; Kanda, Y.; Di Nubile, M. J.; Teal, V. L.; Wan, H.; Murata, Y.; Kartsonis, N. A.; Leavitt, R. Y.; Badshah, C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2433-2444</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation.  Letermovir is an antiviral drug that inhibits the CMV-terminase complex. methods In this phase 3, double-blind trial, we randomly assigned CMV-seropos. transplant recipients, 18 years of age or older, in a 2:1 ratio to receive letermovir or placebo, administered orally or i.v., through week 14 after transplantation; randomization was stratified according to trial site and CMV disease risk.  Letermovir was administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine).  Patients in whom clin. significant CMV infection (CMV disease or CMV viremia leading to preemptive treatment) developed discontinued the trial regimen and received anti-CMV treatment.  The primary end point was the proportion of patients, among patients without detectable CMV DNA at randomization, who had clin. significant CMV infection through week 24 after transplantation.  Patients who discontinued the trial or had missing end-point data at week 24 were imputed as having a primary end-point event.  Patients were followed through week 48 after transplantation. results From June 2014 to March 2016, a total of 565 patients underwent randomization and received letermovir or placebo beginning a median of 9 days after transplantation.  Among 495 patients with undetectable CMV DNA at randomization, fewer patients in the letermovir group than in the placebo group had clin. significant CMV infection or were imputed as having a primary end-point event by week 24 after transplantation (122 of 325 patients [37.5%] vs. 103 of 170 [60.6%], P<0.001).  The frequency and severity of adverse events were similar in the two groups overall.  Vomiting was reported in 18.5% of the patients who received letermovir and in 13.5% of those who received placebo; edema in 14.5% and 9.4%, resp.; and atrial fibrillation or flutter in 4.6% and 1.0%, resp.  The rates of myelotoxic and nephrotoxic events were similar in the letermovir group and the placebo group.  All-cause mortality at week 48 after transplantation was 20.9% among letermovir recipients and 25.5% among placebo recipients. conclusions Letermovir prophylaxis resulted in a significantly lower risk of clin. significant CMV infection than placebo.  Adverse events with letermovir were mainly of low grade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZcGkNwE_sAbVg90H21EOLACvtfcHk0lg8CL26-U8zog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtLs%253D&md5=b474e8e6101f895a2b95bd4612e5954e</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706640%26sid%3Dliteratum%253Aachs%26aulast%3DMarty%26aufirst%3DF.%2BM.%26aulast%3DLjungman%26aufirst%3DP.%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DMaertens%26aufirst%3DJ.%26aulast%3DDadwal%26aufirst%3DS.%2BS.%26aulast%3DDuarte%26aufirst%3DR.%2BF.%26aulast%3DHaider%26aufirst%3DS.%26aulast%3DUllmann%26aufirst%3DA.%2BJ.%26aulast%3DKatayama%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DBoeckh%26aufirst%3DM.%26aulast%3DBlumberg%26aufirst%3DE.%2BA.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DSnydman%26aufirst%3DD.%2BR.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DDiNubile%26aufirst%3DM.%2BJ.%26aulast%3DTeal%26aufirst%3DV.%2BL.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DMurata%26aufirst%3DY.%26aulast%3DKartsonis%26aufirst%3DN.%2BA.%26aulast%3DLeavitt%26aufirst%3DR.%2BY.%26aulast%3DBadshah%26aufirst%3DC.%26atitle%3DLetermovir%2520Prophylaxis%2520for%2520Cytomegalovirus%2520in%2520Hematopoietic-Cell%2520Transplantation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D2433%26epage%3D2444%26doi%3D10.1056%2FNEJMoa1706640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzung, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschaen, D. M.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of Letermovir Using a Novel Phase-Transfer-Catalyzed Aza-Michael Reaction</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00076</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00076" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslOhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1097-1103&author=G.+R.+Humphreyauthor=S.+M.+Dalbyauthor=T.+Andreaniauthor=B.+Xiangauthor=M.+R.+Luzungauthor=Z.+J.+Songauthor=M.+Shevlinauthor=M.+Christensenauthor=K.+M.+Belykauthor=D.+M.+Tschaen&title=Asymmetric+Synthesis+of+Letermovir+Using+a+Novel+Phase-Transfer-Catalyzed+Aza-Michael+Reaction&doi=10.1021%2Facs.oprd.6b00076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Synthesis of Letermovir Using a Novel Phase-Transfer-Catalyzed Aza-Michael Reaction</span></div><div class="casAuthors">Humphrey, Guy R.; Dalby, Stephen M.; Andreani, Teresa; Xiang, Bangping; Luzung, Michael R.; Song, Zhiguo Jake; Shevlin, Michael; Christensen, Melodie; Belyk, Kevin M.; Tschaen, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1097-1103</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a concise asym. synthesis of the antiviral development candidate letermovir is reported, proceeding in >60% yield over a total of seven steps from com. available materials.  Key to the effectiveness of this process is a novel cinchonidine-based PTC-catalyzed aza-Michael reaction to configure the single stereocenter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSx6sMyAk_LVg90H21EOLACvtfcHk0lhABx-D20OHkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslOhs7g%253D&md5=b5ac61d9d4457c2a3dccefd78b0db80f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00076%26sid%3Dliteratum%253Aachs%26aulast%3DHumphrey%26aufirst%3DG.%2BR.%26aulast%3DDalby%26aufirst%3DS.%2BM.%26aulast%3DAndreani%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DLuzung%26aufirst%3DM.%2BR.%26aulast%3DSong%26aufirst%3DZ.%2BJ.%26aulast%3DShevlin%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26aulast%3DTschaen%26aufirst%3DD.%2BM.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520Letermovir%2520Using%2520a%2520Novel%2520Phase-Transfer-Catalyzed%2520Aza-Michael%2520Reaction%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1097%26epage%3D1103%26doi%3D10.1021%2Facs.oprd.6b00076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nyirjesy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwebke, J. R.</span></span> <span> </span><span class="NLM_article-title">Secnidazole: Next-Generation Antimicrobial Agent for Bacterial Vaginosis Treatment</span>. <i>Future Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.2217/fmb-2017-0270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2217%2Ffmb-2017-0270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29327947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVamur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=507-524&author=P.+Nyirjesyauthor=J.+R.+Schwebke&title=Secnidazole%3A+Next-Generation+Antimicrobial+Agent+for+Bacterial+Vaginosis+Treatment&doi=10.2217%2Ffmb-2017-0270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment</span></div><div class="casAuthors">Nyirjesy, Paul; Schwebke, Jane R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">507-524</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Secnidazole is a next-generation 5-nitroimidazole approved for more than three decades in Europe, Asia, South America and Africa and recently in the USA as a single-dose (2 g) treatment of bacterial vaginosis (BV).  Secnidazole is characterized by potent in vitro antimicrobial activity against BV-assocd. pathogens, as well as prolonged terminal elimination half-life and systemic exposure.  These characteristics form the basis of effective and safe treatment of BV with a 2-g single-dose secnidazole regimen, which was recently confirmed in double-blind, placebo-controlled clin. trials conducted in the USA.  The option to treat BV with single-dose secnidazole not only cures the primary infection but also may diminish risks of serious sequelae of untreated or undertreated infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0eIhix5Hck7Vg90H21EOLACvtfcHk0lhABx-D20OHkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVamur4%253D&md5=946d0e7a31c59499a112e6276b6ff24c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2217%2Ffmb-2017-0270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb-2017-0270%26sid%3Dliteratum%253Aachs%26aulast%3DNyirjesy%26aufirst%3DP.%26aulast%3DSchwebke%26aufirst%3DJ.%2BR.%26atitle%3DSecnidazole%253A%2520Next-Generation%2520Antimicrobial%2520Agent%2520for%2520Bacterial%2520Vaginosis%2520Treatment%26jtitle%3DFuture%2520Microbiol.%26date%3D2018%26volume%3D13%26spage%3D507%26epage%3D524%26doi%3D10.2217%2Ffmb-2017-0270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeanmart, C.</span>; <span class="NLM_string-name">Messer, M. N.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of 5-Nitroimidazole Derivatives</span>. <span class="NLM_patent">GB 1278758</span>, <span class="NLM_year">1972</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1972&author=C.+Jeanmart&author=M.+N.+Messer&title=Process+for+the+Preparation+of+5-Nitroimidazole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJeanmart%26aufirst%3DC.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%25205-Nitroimidazole%2520Derivatives%26date%3D1972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y. F.</span>; <span class="NLM_string-name">Yi, Z.
H.</span></span> <span> </span><span class="NLM_article-title">Method for Synthesizing Secnidazole and Secnidazole</span>. <span class="NLM_patent">CN 103772289</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Y.+F.+Zeng&author=Z.%0AH.+Yi&title=Method+for+Synthesizing+Secnidazole+and+Secnidazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DY.%2BF.%26atitle%3DMethod%2520for%2520Synthesizing%2520Secnidazole%2520and%2520Secnidazole%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avery, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, D. P.</span></span> <span> </span><span class="NLM_article-title">Investigational Drugs for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacteria</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1460354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F13543784.2018.1460354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29611447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlSmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=325-338&author=L.+M.+Averyauthor=D.+P.+Nicolau&title=Investigational+Drugs+for+the+Treatment+of+Infections+Caused+by+Multidrug-Resistant+Gram-Negative+Bacteria&doi=10.1080%2F13543784.2018.1460354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria</span></div><div class="casAuthors">Avery, Lindsay M.; Nicolau, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">325-338</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Infections caused by multidrug-resistant Gram-neg. bacteria (MDR-GNB) are assocd. with significant mortality and costs.  New drugs in development to combat these difficult-to-treat infections primarily target carbapenem-resistant Enterobacteriaceae, MDR Pseudomonas aeruginosa, and MDR Acinetobacter baumannii.: The authors summarize in vitro and in vivo efficacy studies, as well as available clin. trial findings, for new agents in development for treatment of infection caused by MDR-GNB.  Information regarding dosage regimens utilized in clin. trials and key pharmacokinetic and pharmacodynamic considerations are provided if available.  A summary of recently approved agents, delafloxacin and meropenem/vaborbactam, is also included.: The development of multiple novel agents to fight MDR-GNB is promising to help save the lives of patients who acquire infection, and judicious use of these agents is imperative once they come to market to prevent the development of resistance.  The other component paramount to this field of research is implementation of effective infection control policies and carbapenem-resistant Enterobacteriaceae (CRE) carrier screening protocols to mitigate the worldwide spread of MDR-GNB.  Further investigation of anti-infective synergistic combinations will also be important, as well as support for economic research to reveal the true cost-benefit of utilization of the new agents discussed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolNiho0hD-KLVg90H21EOLACvtfcHk0lhABx-D20OHkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlSmtLo%253D&md5=7d904dfaafedfbd9137568fd5a58faa9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1460354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1460354%26sid%3Dliteratum%253Aachs%26aulast%3DAvery%26aufirst%3DL.%2BM.%26aulast%3DNicolau%26aufirst%3DD.%2BP.%26atitle%3DInvestigational%2520Drugs%2520for%2520the%2520Treatment%2520of%2520Infections%2520Caused%2520by%2520Multidrug-Resistant%2520Gram-Negative%2520Bacteria%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26spage%3D325%26epage%3D338%26doi%3D10.1080%2F13543784.2018.1460354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loutit, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Cyclic Boronic Acid B-Lactamase Inhibitor (Rpx7009) with Utility Vs Class a Serine Carbapenemases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3682</span>– <span class="NLM_lpage">3692</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3682-3692&author=S.+J.+Heckerauthor=K.+R.+Reddyauthor=M.+Totrovauthor=G.+C.+Hirstauthor=O.+Lomovskayaauthor=D.+C.+Griffithauthor=P.+Kingauthor=R.+Tsivkovskiauthor=D.+Sunauthor=M.+Sabetauthor=Z.+Taraziauthor=M.+C.+Cliftonauthor=K.+Atkinsauthor=A.+Raymondauthor=K.+T.+Pottsauthor=J.+Abendrothauthor=S.+H.+Boyerauthor=J.+S.+Loutitauthor=E.+E.+Morganauthor=S.+Dursoauthor=M.+N.+Dudley&title=Discovery+of+a+Cyclic+Boronic+Acid+B-Lactamase+Inhibitor+%28Rpx7009%29+with+Utility+Vs+Class+a+Serine+Carbapenemases&doi=10.1021%2Facs.jmedchem.5b00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span></div><div class="casAuthors">Hecker, Scott J.; Reddy, K. Raja; Totrov, Maxim; Hirst, Gavin C.; Lomovskaya, Olga; Griffith, David C.; King, Paula; Tsivkovski, Ruslan; Sun, Dongxu; Sabet, Mojgan; Tarazi, Ziad; Clifton, Matthew C.; Atkins, Kateri; Raymond, Amy; Potts, Kristy T.; Abendroth, Jan; Boyer, Serge H.; Loutit, Jeffrey S.; Morgan, Elizabeth E.; Durso, Stephanie; Dudley, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3682-3692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing dissemination of carbapenemases in Gram-neg. bacteria has threatened the clin. usefulness of the β-lactam class of antimicrobials.  A program was initiated to discover a new series of serine β-lactamase inhibitors contg. a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials.  Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases.  Promising candidate mols. were synthesized and evaluated in biochem. and whole-cell assays.  Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases.  Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains.  Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXpE5YX_dRNLVg90H21EOLACvtfcHk0ljIL-f4Xg7_9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D&md5=965fbf2b42f2e1b38eccc3b23dfa374f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00127%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DSabet%26aufirst%3DM.%26aulast%3DTarazi%26aufirst%3DZ.%26aulast%3DClifton%26aufirst%3DM.%2BC.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DRaymond%26aufirst%3DA.%26aulast%3DPotts%26aufirst%3DK.%2BT.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DS.%2BH.%26aulast%3DLoutit%26aufirst%3DJ.%2BS.%26aulast%3DMorgan%26aufirst%3DE.%2BE.%26aulast%3DDurso%26aufirst%3DS.%26aulast%3DDudley%26aufirst%3DM.%2BN.%26atitle%3DDiscovery%2520of%2520a%2520Cyclic%2520Boronic%2520Acid%2520B-Lactamase%2520Inhibitor%2520%2528Rpx7009%2529%2520with%2520Utility%2520Vs%2520Class%2520a%2520Serine%2520Carbapenemases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3682%26epage%3D3692%26doi%3D10.1021%2Facs.jmedchem.5b00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenitsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagace-Wiens, P. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denisuik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoban, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-B-Lactamase Inhibitor Combinations</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0851-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0851-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29230684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKmu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=65-98&author=G.+G.+Zhanelauthor=C.+K.+Lawrenceauthor=H.+Adamauthor=F.+Schweizerauthor=S.+Zelenitskyauthor=M.+Zhanelauthor=P.+R.+S.+Lagace-Wiensauthor=A.+Walktyauthor=A.+Denisuikauthor=A.+Goldenauthor=A.+S.+Ginauthor=D.+J.+Hobanauthor=J.+P.+Lynchauthor=J.+A.+Karlowsky&title=Imipenem-Relebactam+and+Meropenem-Vaborbactam%3A+Two+Novel+Carbapenem-B-Lactamase+Inhibitor+Combinations&doi=10.1007%2Fs40265-017-0851-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations</span></div><div class="casAuthors">Zhanel, George G.; Lawrence, Courtney K.; Adam, Heather; Schweizer, Frank; Zelenitsky, Sheryl; Zhanel, Michael; Lagace-Wiens, Philippe R. S.; Walkty, Andrew; Denisuik, Andrew; Golden, Alyssa; Gin, Alfred S.; Hoban, Daryl J.; Lynch, Joseph P., III; Karlowsky, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-98</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-lactamase inhibitor that is structurally related to avibactam, differing by the addn. of a piperidine ring to the 2-position carbonyl group.  Vaborbactam (formerly known as RPX7009) is a non-β-lactam, cyclic, boronic acid-based, β-lactamase inhibitor.  The structure of vaborbactam is unlike any other currently marketed β-lactamase inhibitor.  Both inhibitors display activity against Ambler class A [including extended-spectrum β-lactamases (ESBLs), Klebsiella pneumoniae carbapenemases (KPCs)] and class C β-lactamases (AmpC).  Little is known about the potential for relebactam or vaborbactam to select for resistance; however, inactivation of the porin protein OmpK36 in K. pneumoniae has been reported to confer resistance to both imipenem-relebactam and meropenem-vaborbactam.  The addn. of relebactam significantly improves the activity of imipenem against most species of Enterobacteriaceae [by lowering the min. inhibitory concn. (MIC) by 2- to 128-fold] depending on the presence or absence of β-lactamase enzymes.  Against Pseudomonas aeruginosa, the addn. of relebactam also improves the activity of imipenem (MIC reduced eightfold).  Based on the data available, the addn. of relebactam does not improve the activity of imipenem against Acinetobacter baumannii, Stenotrophomonas maltophilia and most anaerobes.  Similar to imipenem-relebactam, the addn. of vaborbactam significantly (2- to > 1024-fold MIC redn.) improves the activity of meropenem against most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzymes.  Limited data suggest that the addn. of vaborbactam does not improve the activity of meropenem against A. baumannii, P. aeruginosa, or S. maltophilia.  The pharmacokinetics of both relebactam and vaborbactam are described by a two-compartment, linear model and do not appear to be altered by the co-administration of imipenem and meropenem, resp.  Relebactam's approx. vol. of distribution (Vd) and elimination half-life (t1/2) of ∼ 18 L and 1.2-2.1 h, resp., are similar to imipenem.  Likewise, vaborbactam's Vd and t1/2 of ∼ 18 L and 1.3-2.0 h, resp., are comparable to meropenem.  Like imipenem and meropenem, relebactam and vaborbactam are both primarily renally excreted, and clearance correlates with creatinine clearance.  In vitro and in vivo pharmacodynamic studies have reported bactericidal activity for imipenem-relebactam and meropenem-vaborbactam against various Gram-neg. β-lactamase-producing bacilli that are not inhibited by their resp. carbapenems alone.  These data also suggest that pharmacokinetic-pharmacodynamic parameters correlating with efficacy include time above the MIC for the carbapenems and overall exposure for their companion β-lactamase inhibitors.  Phase II clin. trials to date have reported that imipenem-relebactam is as effective as imipenem alone for treatment of complicated intra-abdominal infections and complicated urinary tract infections, including acute pyelonephritis.  Imipenem-relebactam is currently in two phase III clin. trials for the treatment of imipenem-resistant bacterial infections, as well as hospital-assocd. bacterial pneumonia (HABP) and ventilator-assocd. bacterial pneumonia (VABP).  A phase III clin. trial has reported superiority of meropenem-vaborbactam over piperacillin-tazobactam for the treatment of complicated urinary tract infections, including acute pyelonephritis.  Meropenem-vaborbactam has recently demonstrated higher clin. cure rates vs. best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE), as well as for HABP and VABP.  The safety and tolerability of imipenem-relebactam and meropenem-vaborbactam has been reported in various phase I pharmacokinetic studies and phase II and III clin. trials.  Both combinations appear to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.  In conclusion, relebactam and vaborbactam serve to broaden the spectrum of imipenem and meropenem, resp., against β-lactamase-producing Gram-neg. bacilli.  The exact roles for imipenem-relebactam and meropenem-vaborbactam will be defined by efficacy and safety data from further clin. trials.  Potential roles in therapy for these agents include the treatment of suspected or documented infections caused by resistant Gram-neg. bacilli-producing ESBL, KPC, and/or AmpC β-lactamases.  The usage of these agents in patients with CRE infections will likely become the std. of care.  Finally, increased activity of imipenem-relebactam against P. aeruginosa may be of clin. benefit to patients with suspected or documented P. aeruginosa infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYBXUqPtdemrVg90H21EOLACvtfcHk0ljIL-f4Xg7_9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKmu7bK&md5=a8506d493387208f8ac429057ca15a49</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0851-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0851-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DLawrence%26aufirst%3DC.%2BK.%26aulast%3DAdam%26aufirst%3DH.%26aulast%3DSchweizer%26aufirst%3DF.%26aulast%3DZelenitsky%26aufirst%3DS.%26aulast%3DZhanel%26aufirst%3DM.%26aulast%3DLagace-Wiens%26aufirst%3DP.%2BR.%2BS.%26aulast%3DWalkty%26aufirst%3DA.%26aulast%3DDenisuik%26aufirst%3DA.%26aulast%3DGolden%26aufirst%3DA.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DImipenem-Relebactam%2520and%2520Meropenem-Vaborbactam%253A%2520Two%2520Novel%2520Carbapenem-B-Lactamase%2520Inhibitor%2520Combinations%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D65%26epage%3D98%26doi%3D10.1007%2Fs40265-017-0851-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felfer, U.</span>; <span class="NLM_string-name">Stueckler, C.</span>; <span class="NLM_string-name">Steinhofer, S.</span>; <span class="NLM_string-name">Pelz, A.</span>; <span class="NLM_string-name">Hanacek, M.</span>; <span class="NLM_string-name">Pabst, T. H.</span>; <span class="NLM_string-name">Winkler, G.</span>; <span class="NLM_string-name">Poechlauer, P.</span>; <span class="NLM_string-name">Ritzen, B.</span>; <span class="NLM_string-name">Goldbach, M.</span></span> <span> </span><span class="NLM_article-title">Apparatus and Continuous Flow Process for Production of Boronic Acid Derivatives</span>. <span class="NLM_patent">WO 2016100043A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=U.+Felfer&author=C.+Stueckler&author=S.+Steinhofer&author=A.+Pelz&author=M.+Hanacek&author=T.+H.+Pabst&author=G.+Winkler&author=P.+Poechlauer&author=B.+Ritzen&author=M.+Goldbach&title=Apparatus+and+Continuous+Flow+Process+for+Production+of+Boronic+Acid+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFelfer%26aufirst%3DU.%26atitle%3DApparatus%2520and%2520Continuous%2520Flow%2520Process%2520for%2520Production%2520of%2520Boronic%2520Acid%2520Derivatives%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0895-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0895-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29546556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslGjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=577-587&author=Y.-A.+Heoauthor=E.+D.+Deeks&title=Sofosbuvir%2FVelpatasvir%2FVoxilaprevir%3A+A+Review+in+Chronic+Hepatitis+C&doi=10.1007%2Fs40265-018-0895-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C</span></div><div class="casAuthors">Heo, Young-A.; Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A fixed-dose combination of the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir, the HCV NS5A inhibitor velpatasvir and the HCV NS3/4A protease inhibitor voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir; Vosevi) is approved in the EU for the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in adults.  In the phase III POLARIS trials, in patients who had HCV genotype 1-6 infection with or without compensated cirrhosis, overall rates of sustained virol. response at 12 wk post-treatment (SVR12) with sofosbuvir/velpatasvir/voxilaprevir were high after 8 wk of treatment in direct-acting antiviral (DAA)-naive patients and 12 wk of treatment in DAA-experienced patients.  However, 8 wk of sofosbuvir/velpatasvir/voxilaprevir was inferior to 12 wk of sofosbuvir/velpatasvir in cirrhotic or non-cirrhotic DAA-naive patients with HCV genotype 1, 2, 4, 5 or 6 infection and non-cirrhotic DAA-naive patients with HCV genotype 3 infection, mostly due to an insufficient treatment period.  Sofosbuvir/velpatasvir/voxilaprevir was generally well tolerated, with most adverse events being of mild or moderate intensity.  The most common adverse events included headache, fatigue, nausea and diarrhoea.  In conclusion, sofosbuvir/velpatasvir/voxilaprevir is an important and effective option for the treatment of HCV genotype 1-6 infection in adults, esp. those who have previously failed a DAA therapy with or without an HCV NS5A inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpWFvjHRFxCLVg90H21EOLACvtfcHk0lgTwV1vP8EZnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslGjt7k%253D&md5=d4557e43a321ca3a9a30d996ac5f77ba</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0895-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0895-5%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DSofosbuvir%252FVelpatasvir%252FVoxilaprevir%253A%2520A%2520Review%2520in%2520Chronic%2520Hepatitis%2520C%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D577%26epage%3D587%26doi%3D10.1007%2Fs40265-018-0895-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grebely, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruneau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruggmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litwin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backmund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, G. J.</span></span> <span> </span><span class="NLM_article-title">Contradictory Advice for People Who Inject Drugs in the 2016 Easl Recommendations on Treatment of Hepatitis C</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2016.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.jhep.2016.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28167323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jslajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1101-1103&author=J.+Grebelyauthor=T.+Swanauthor=M.+Hickmanauthor=J.+Bruneauauthor=P.+Bruggmannauthor=O.+Dalgardauthor=A.+Litwinauthor=M.+Backmundauthor=G.+J.+Dore&title=Contradictory+Advice+for+People+Who+Inject+Drugs+in+the+2016+Easl+Recommendations+on+Treatment+of+Hepatitis+C&doi=10.1016%2Fj.jhep.2016.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C</span></div><div class="casAuthors">Grebely Jason; Swan Tracy; Hickman Matthew; Bruneau Julie; Bruggmann Philip; Dalgard Olav; Litwin Alain; Backmund Markus; Dore Gregory J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1101-1103</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRI8vVeL9xn7VQKX3ooHxWjfW6udTcc2eYrkBCMH458W7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jslajuw%253D%253D&md5=5d8a96950ca2668ce4b876ee56854bf3</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DGrebely%26aufirst%3DJ.%26aulast%3DSwan%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DBruneau%26aufirst%3DJ.%26aulast%3DBruggmann%26aufirst%3DP.%26aulast%3DDalgard%26aufirst%3DO.%26aulast%3DLitwin%26aufirst%3DA.%26aulast%3DBackmund%26aufirst%3DM.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26atitle%3DContradictory%2520Advice%2520for%2520People%2520Who%2520Inject%2520Drugs%2520in%2520the%25202016%2520Easl%2520Recommendations%2520on%2520Treatment%2520of%2520Hepatitis%2520C%26jtitle%3DJ.%2520Hepatol.%26date%3D2017%26volume%3D66%26spage%3D1101%26epage%3D1103%26doi%3D10.1016%2Fj.jhep.2016.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cagulada, A.</span>; <span class="NLM_string-name">Chan, J.</span>; <span class="NLM_string-name">Chan, L.</span>; <span class="NLM_string-name">Colby, D. A.</span>; <span class="NLM_string-name">Karki, K. K.</span>; <span class="NLM_string-name">Kato, D.</span>; <span class="NLM_string-name">Keaton, K. A.</span>; <span class="NLM_string-name">Kondapally, S.</span>; <span class="NLM_string-name">Levins, C.</span>; <span class="NLM_string-name">Littke, A.</span>; <span class="NLM_string-name">Martinez, R.</span>; <span class="NLM_string-name">Pcion, D.</span>; <span class="NLM_string-name">Reynolds, T.</span>; <span class="NLM_string-name">Ross, B.</span>; <span class="NLM_string-name">Sangi, M.</span>; <span class="NLM_string-name">Schrier, A. J.</span>; <span class="NLM_string-name">Seng, P.</span>; <span class="NLM_string-name">Siegel, D.</span>; <span class="NLM_string-name">Shapiro, N.</span>; <span class="NLM_string-name">Tang, D.</span>; <span class="NLM_string-name">Taylor, J. G.</span>; <span class="NLM_string-name">Tripp, J.</span>; <span class="NLM_string-name">Waltman, A. W.</span>; <span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis of an Antiviral N-(3-Ethyl)prolyl-1-aminocyclopropanecarboxylic Acid Peptide and New Routes to Its Difluoromethylaminocyclopropanecarboxylic Acid Intermediate</span>. <span class="NLM_patent">US 20150175626A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+Cagulada&author=J.+Chan&author=L.+Chan&author=D.+A.+Colby&author=K.+K.+Karki&author=D.+Kato&author=K.+A.+Keaton&author=S.+Kondapally&author=C.+Levins&author=A.+Littke&author=R.+Martinez&author=D.+Pcion&author=T.+Reynolds&author=B.+Ross&author=M.+Sangi&author=A.+J.+Schrier&author=P.+Seng&author=D.+Siegel&author=N.+Shapiro&author=D.+Tang&author=J.+G.+Taylor&author=J.+Tripp&author=A.+W.+Waltman&author=L.+Yu&title=Synthesis+of+an+Antiviral+N-%283-Ethyl%29prolyl-1-aminocyclopropanecarboxylic+Acid+Peptide+and+New+Routes+to+Its+Difluoromethylaminocyclopropanecarboxylic+Acid+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCagulada%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520an%2520Antiviral%2520N-%25283-Ethyl%2529prolyl-1-aminocyclopropanecarboxylic%2520Acid%2520Peptide%2520and%2520New%2520Routes%2520to%2520Its%2520Difluoromethylaminocyclopropanecarboxylic%2520Acid%2520Intermediate%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G.</span>; <span class="NLM_string-name">Bluemling, G. R.</span>; <span class="NLM_string-name">De La Rosa, A.</span>; <span class="NLM_string-name">Liotta, D. C.</span>; <span class="NLM_string-name">Kuiper, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Nucleotide and Nucleoside Therapeutic Compounds. and Uses Related Thereto as Antiviral Agents</span>. <span class="NLM_patent">WO 2017155923A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Painter&author=G.+R.+Bluemling&author=A.+De+La+Rosa&author=D.+C.+Liotta&author=D.+Kuiper&title=Preparation+of+Nucleotide+and+Nucleoside+Therapeutic+Compounds.+and+Uses+Related+Thereto+as+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPainter%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Nucleotide%2520and%2520Nucleoside%2520Therapeutic%2520Compounds.%2520and%2520Uses%2520Related%2520Thereto%2520as%2520Antiviral%2520Agents%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ene, D.</span></span> <span> </span><span class="NLM_article-title">Olefin Metathesis in Drug Discovery and Development-Examples from Recent Patent Literature</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1962</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1938-1962&author=D.+Hughesauthor=P.+Wheelerauthor=D.+Ene&title=Olefin+Metathesis+in+Drug+Discovery+and+Development-Examples+from+Recent+Patent+Literature&doi=10.1021%2Facs.oprd.7b00319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Olefin Metathesis in Drug Discovery and Development-Examples from Recent Patent Literature</span></div><div class="casAuthors">Hughes, David; Wheeler, Philip; Ene, Doina</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1938-1962</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review that summarizes applications of the metathesis reactions in drug discovery and development in the pharmaceutical industry disclosed in the patent literature from Jan. 2016 to August 2017.  The olefin metathesis reaction is finding increasing use in drug discovery and process chem., with a no. of applications now implemented at com. manufg. scale.  Catalyst improvements over the past decade have allowed use of the metathesis reaction with highly functionalized substrates, allowing chemists to access increasingly diverse chem. space, including most notably macrocycles, constrained small ring spirocycles, and fused-ring systems.  For scientists employed in the pharmaceutical industry, the patent literature is the primary avenue for communication of synthetic routes to drug candidates.  While most examples of the metathesis reaction in the patent literature offer only sketchy exptl. details and provide little context on reaction development, the wide scope of substrates within the pharmaceutical patent literature provides a true indication of reaction scope and functional group compatibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwS-l_9Wgak7Vg90H21EOLACvtfcHk0lgIy5YtkHaz5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsrbP&md5=8fcebbc4105e77751d56724d758535ac</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00319%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%26aulast%3DWheeler%26aufirst%3DP.%26aulast%3DEne%26aufirst%3DD.%26atitle%3DOlefin%2520Metathesis%2520in%2520Drug%2520Discovery%2520and%2520Development-Examples%2520from%2520Recent%2520Patent%2520Literature%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1938%26epage%3D1962%26doi%3D10.1021%2Facs.oprd.7b00319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Deutetrabenazine: A Review in Chorea Associated with Huntington’s Disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0831-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0831-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29080203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslejtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1857-1864&author=Y.-A.+Heoauthor=L.+J.+Scott&title=Deutetrabenazine%3A+A+Review+in+Chorea+Associated+with+Huntington%E2%80%99s+Disease&doi=10.1007%2Fs40265-017-0831-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease</span></div><div class="casAuthors">Heo, Young-A.; Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Oral deutetrabenazine (Austedo), a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) that is structurally related to tetrabenazine is approved for the treatment of chorea symptoms assocd. with Huntington's disease (HD).  In the pivotal 12-wk phase III FIRST-HD trial (n = 90), deutetrabenazine, at doses titrated for optimal chorea control and tolerability (maintenance dosage range 12-48 mg/day), was significantly more effective for controlling chorea in HD patients than placebo.  In the ongoing phase III ARC-HD trial, a preliminary anal. demonstrated that deutetrabenazine treatment was assocd. with improvements in chorea control at 54 wk in patients who had completed FIRST-HD (i.e. ≤ 66 wk' treatment; rollover cohort) or switched overnight from tetrabenazine to deutetrabenazine.  The tolerability profile of deutetrabenazine is similar to that of placebo, with most treatment-emergent adverse events of mild or moderate severity.  In both trials, with the exception of somnolence, individual neuropsychiatric adverse events typically occurred in < 7% of deutetrabenazine recipients; in FIRST-HD, there was no significant difference in the incidence of individual neuropsychiatric events between the deutetrabenazine and placebo groups.  The favorable pharmacokinetic (PK) profile of deutetrabenazine permits a lower dosage than tetrabenazine, thereby potentially improving the safety profile of deutetrabenazine vs. tetrabenazine, while maintaining its efficacy.  Long-term clin. experience will assist in fully defining the safety profile of deutetrabenazine.  Current evidence, albeit relatively limited, indicates that deutetrabenazine provides an effective and potentially better tolerated option than tetrabenazine for controlling chorea symptoms assocd. with HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosFkE2-piB3rVg90H21EOLACvtfcHk0lgIy5YtkHaz5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslejtLfL&md5=aa25bb171c0b5ccb5edca1dcea6cc425</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0831-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0831-0%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DDeutetrabenazine%253A%2520A%2520Review%2520in%2520Chorea%2520Associated%2520with%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1857%26epage%3D1864%26doi%3D10.1007%2Fs40265-017-0831-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">DeWitt, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Deuterated Drug Molecules: Focus on Fda-Approved Deutetrabenazine</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=472-473&author=S.+H.+DeWittauthor=B.+E.+Maryanoff&title=Deuterated+Drug+Molecules%3A+Focus+on+Fda-Approved+Deutetrabenazine&doi=10.1021%2Facs.biochem.7b00765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine</span></div><div class="casAuthors">DeWitt, Sheila H.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">472-473</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The approval of Austedo (deutetrabenazine) as a new chem. entity (NCE) via the 505(b)(2) regulatory pathway established an important milestone for the development and marketing of deuterated drugs.  Its notable introduction into clin. medicine could well be the harbinger of a new era for the utility of deuterium-substituted drug mols.  This point of view is further supported by the sizable collection of other deuterated mols. that are currently in clin. trials, some of which will hopefully emerge successful for the benefit of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQcRjVCOoN5bVg90H21EOLACvtfcHk0lgIy5YtkHaz5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL&md5=a1aecdd9f8b539b9e3988d8b135d881a</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00765%26sid%3Dliteratum%253Aachs%26aulast%3DDeWitt%26aufirst%3DS.%2BH.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DDeuterated%2520Drug%2520Molecules%253A%2520Focus%2520on%2520Fda-Approved%2520Deutetrabenazine%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D472%26epage%3D473%26doi%3D10.1021%2Facs.biochem.7b00765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reilmann, R.</span></span> <span> </span><span class="NLM_article-title">Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease</span>. <i>JAMA Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1406</span>, <span class="refDoi"> DOI: 10.1001/jamaneurol.2016.3916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1001%2Fjamaneurol.2016.3916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27749952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC2srhtlWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=1404-1406&author=R.+Reilmann&title=Deutetrabenazine-Not+a+Revolution+but+Welcome+Evolution+for+Treating+Chorea+in+Huntington+Disease&doi=10.1001%2Fjamaneurol.2016.3916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease</span></div><div class="casAuthors">Reilmann Ralf</div><div class="citationInfo"><span class="NLM_cas:title">JAMA neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1406</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx4xCzs0XGFQvupmecNw_lfW6udTcc2eYkNm8IAtEfTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srhtlWmsg%253D%253D&md5=d0b2b593b977dcdf3e71cde1cac2961b</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1001%2Fjamaneurol.2016.3916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaneurol.2016.3916%26sid%3Dliteratum%253Aachs%26aulast%3DReilmann%26aufirst%3DR.%26atitle%3DDeutetrabenazine-Not%2520a%2520Revolution%2520but%2520Welcome%2520Evolution%2520for%2520Treating%2520Chorea%2520in%2520Huntington%2520Disease%26jtitle%3DJAMA%2520Neurol.%26date%3D2016%26volume%3D73%26spage%3D1404%26epage%3D1406%26doi%3D10.1001%2Fjamaneurol.2016.3916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span> <span> </span><span class="NLM_article-title">Investigational Agents for the Management of Huntington’s Disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1270266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F13543784.2017.1270266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27927041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFWnur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=175-185&author=T.+Mueller&title=Investigational+Agents+for+the+Management+of+Huntington%E2%80%99s+Disease&doi=10.1080%2F13543784.2017.1270266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational agents for the management of Huntington's disease</span></div><div class="casAuthors">Mueller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-185</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: An inherited, chronic progressive, neurodegenerative disorder is Huntington's disease, characterized by motor, cognitive, and psychiatric symptoms.  Predictive genetic testing allows earlier diagnosis and identification of gene carriers for Huntington's disease.  These individuals are ideal candidates for testing of therapeutic interventions for disease modification.: According to queries in Pubmed, Embase and clin. register databases, research and clin. studies emerge on symptomatic and neuroprotective therapies in Huntington's disease.  This review discusses novel agents for symptomatic therapy and disease modification.  They are currently in phase I and II of drug development: There are promising, safe and well tolerated compds. for amelioration of motor and neuropsychiatric symptoms, but their efficacy still needs to be proven in clin. trials.  Deterioration of mutant huntington expression, antiapoptotic or cell death inhibition as disease modifying concepts was efficacious in models of Huntington's disease.  However, the risk for clin. trial failures is high not only due to ineffectiveness of the tested agent.  Neg. study outcomes may also result from design misconceptions, underestimation of the heterogeneity of Huntington's disease, too short study durations and too small study cohorts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNKNqKfMkAprVg90H21EOLACvtfcHk0lhj0vFVHYyqjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFWnur3M&md5=981868e57326b021902e0dae282a3b0b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1270266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1270266%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DT.%26atitle%3DInvestigational%2520Agents%2520for%2520the%2520Management%2520of%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D175%26epage%3D185%26doi%3D10.1080%2F13543784.2017.1270266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snively, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whaley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Shahed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claassen, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clouse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Hilaire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criswell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racette, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revilla, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucifora, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mary, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brashers-Krug, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinsky, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Factor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eglow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samii, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmail, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, W. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colcher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackmyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudesblatt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fafard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graffitti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojcieszek, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Faver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson-Perez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shprecher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blindauer, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farbman, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feigin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edicola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, E.</span></span> <span> </span><span class="NLM_article-title">Effect of Deutetrabenazine on Chorea among Patients with Huntington Disease. A Randomized Clinical Trial</span>. <i>JAMA, J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1001/jama.2016.8655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1001%2Fjama.2016.8655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27380342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2016&pages=40-50&author=S.+Frankauthor=C.+M.+Testaauthor=D.+Stamlerauthor=E.+Kaysonauthor=C.+Davisauthor=M.+C.+Edmondsonauthor=S.+Kinelauthor=B.+Leavittauthor=D.+Oakesauthor=C.+O%E2%80%99Neillauthor=C.+Vaughanauthor=J.+Goldsteinauthor=M.+Herzogauthor=V.+Snivelyauthor=J.+Whaleyauthor=C.+Wongauthor=G.+Suterauthor=J.+Jankovicauthor=J.+Jimenez-Shahedauthor=C.+Hunterauthor=D.+O.+Claassenauthor=O.+C.+Romanauthor=V.+Sungauthor=J.+Smithauthor=S.+Janickiauthor=R.+Clouseauthor=M.+Saint-Hilaireauthor=A.+Hohlerauthor=D.+Turpinauthor=R.+C.+Jamesauthor=R.+Rodriguezauthor=K.+Rizerauthor=K.+E.+Andersonauthor=H.+Hellerauthor=A.+Carlsonauthor=S.+Criswellauthor=B.+A.+Racetteauthor=F.+J.+Revillaauthor=F.+Nuciforaauthor=R.+L.+Margolisauthor=J.+O.+Maryauthor=T.+Mendisauthor=N.+Mendisauthor=C.+Singerauthor=M.+Quesadaauthor=J.+S.+Paulsenauthor=T.+Brashers-Krugauthor=A.+Millerauthor=J.+Kerrauthor=R.+M.+Dubinskyauthor=C.+Grayauthor=S.+A.+Factorauthor=E.+Sperinauthor=E.+Molhoauthor=M.+Eglowauthor=S.+Evansauthor=R.+Kumarauthor=C.+Reevesauthor=A.+Samiiauthor=S.+Chouinardauthor=M.+Belandauthor=B.+L.+Scottauthor=P.+T.+Hickeyauthor=S.+Esmailauthor=W.+L.+A.+Fungauthor=C.+Gibbonsauthor=L.+Qiauthor=A.+Colcherauthor=C.+Hackmyerauthor=A.+McGarryauthor=K.+Klosauthor=M.+Gudesblattauthor=L.+Fafardauthor=L.+Graffittiauthor=D.+P.+Schneiderauthor=R.+Dhallauthor=J.+M.+Wojcieszekauthor=K.+La+Faverauthor=A.+Dukerauthor=E.+Neefusauthor=H.+Wilson-Perezauthor=D.+Shprecherauthor=P.+Wallauthor=K.+A.+Blindauerauthor=L.+Wheelerauthor=J.+T.+Boydauthor=E.+Houstonauthor=E.+S.+Farbmanauthor=P.+Agarwalauthor=S.+W.+Eberlyauthor=A.+Wattsauthor=P.+N.+Tariotauthor=A.+Feiginauthor=S.+Evansauthor=C.+Beckauthor=C.+Ormeauthor=J.+Edicolaauthor=E.+Christopher&title=Effect+of+Deutetrabenazine+on+Chorea+among+Patients+with+Huntington+Disease.+A+Randomized+Clinical+Trial&doi=10.1001%2Fjama.2016.8655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of deutetrabenazine on chorea among patients with Huntington disease. A randomized clinical trial</span></div><div class="casAuthors">Frank, Samuel; Testa, Claudia M.; Stamler, David; Kayson, Elise; Davis, Charles; Edmondson, Mary C.; Kinel, Shari; Leavitt, Blair; Oakes, David; O'Neill, Christine; Vaughan, Christina; Goldstein, Jody; Herzog, Margaret; Snively, Victoria; Whaley, Jacquelyn; Wong, Cynthia; Suter, Greg; Jankovic, Joseph; Jimenez-Shahed, Joohi; Hunter, Christine; Claassen, Daniel O.; Roman, Olivia C.; Sung, Victor; Smith, Jenna; Janicki, Sarah; Clouse, Ronda; Saint-Hilaire, Marie; Hohler, Anna; Turpin, Denyse; James, Raymond C.; Rodriguez, Ramon; Rizer, Kyle; Anderson, Karen E.; Heller, Hope; Carlson, Alexis; Criswell, Susan; Racette, Brad A.; Revilla, Fredy J.; Nucifora, Frederick; Margolis, Russell L.; Mary, Jane Ong; Mendis, Tilak; Mendis, Neila; Singer, Carlos; Quesada, Monica; Paulsen, Jane S.; Brashers-Krug, Thomas; Miller, Amanda; Kerr, Jane; Dubinsky, Richard M.; Gray, Carolyn; Factor, Stewart A.; Sperin, Elaine; Molho, Eric; Eglow, Mary; Evans, Sharon; Kumar, Rajeev; Reeves, Christina; Samii, Ali; Chouinard, Sylvain; Beland, Monica; Scott, Burton L.; Hickey, Patrick T.; Esmail, Sherali; Fung, Wai Lun Alan; Gibbons, Clare; Qi, Lina; Colcher, Amy; Hackmyer, Cory; McGarry, Andrew; Klos, Kevin; Gudesblatt, Mark; Fafard, Lori; Graffitti, Laura; Schneider, Daniel P.; Dhall, Rohit; Wojcieszek, Joanne M.; La Faver, Kathrin; Duker, Andrew; Neefus, Erin; Wilson-Perez, Hilary; Shprecher, David; Wall, Paola; Blindauer, Karen A.; Wheeler, Lynn; Boyd, James T.; Houston, Emily; Farbman, Eric S.; Agarwal, Pinky; Eberly, Shirley W.; Watts, Arthur; Tariot, Pierre N.; Feigin, Andrew; Evans, Scott; Beck, Chris; Orme, Constance; Edicola, Jon; Christopher, Emily</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-50</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">IMPORTANCE: Deutetrabenazine is a novel mol. contg. deuterium, which attenuates CYP2D6 metab. and increases active metabolite half-lives and may therefore lead to stable systemic exposure while preserving key pharmacol. activity.  OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea assocd. with Huntington disease.  DESIGN, SETTING, AND PARTICIPANTS: Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea score of 8 or higher (range, 0-28; lower score indicates less chorea) were enrolled from August 2013 to August 2014 and randomized to receive deutetrabenazine (n = 45) or placebo (n = 45) in a double-blind fashion at 34 Huntington Study Group sites.  INTERVENTIONS: Deutetrabenazine or placebo was titrated to optimal dose level over 8 wk and maintained for 4 wk, followed by a 1-wk washout.  MAIN OUTCOMES AND MEASURES: Primary end point was the total maximal chorea score change from baseline (the av. of values from the screening and day-0 visits) to maintenance therapy (the av. of values from the week 9 and 12 visits) obtained by in-person visits.  This study was designed to detect a 2.7-unit treatment difference in scores.  The secondary end points, assessed hierarchically, were the proportion of patients who achieved treatment success on the Patient Global Impression of Change (PGIC) and on the Clin. Global Impression of Change (CGIC), the change in 36-Item Short Form- phys. functioning subscale score (SF-36), and the change in the Berg Balance Test.  RESULTS: Ninety patients with Huntington disease (mean age, 53.7 years;40women [44.4%]) were enrolled.  In the deutetrabenazine group, the mean total maximal chorea scores improved from 12.1 (95%CI, 11.2-12.9) to 7.7 (95%CI, 6.5-8.9), whereas in the placebo group, scores improved from 13.2 (95%CI,12.2-14.3)to11.3(95%CI,10.0-12.5);themeanbetween-group difference was -2.5 units (95%CI, -3.7 to -1.3) (P <.001).  Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%)in the placebo group (P =.002).  As measured by the CGIC, treatment success occurred in 19 patients (42%) in the deutetrabenazine group vs 6(13%)in the placebo group(P =.002).  In the deutetrabenazine group, the mean SF-36 phys. functioning subscale scores decreased from 47.5 (95%CI, 44.3-50.8) to 47.4(44.3-50.5),whereasin the placebo group, scores decreased from 43.2 (95%CI,40.2-46.3) to 39.9(95%CI, 36.2-43.6), for a treatment benefit of 4.3 (95%CI,0.4to8.3) (P =.03).  There was no difference between groups (mean difference of 1.0unit; 95%CI, -0.3 to 2.3; P =.14), for improvement in the Berg Balance Test, which improved by 2.2 units (95%CI, 1.3-3.1) in the deutetrabenazine group and by 1.3 units (95%CI,0.4-2.2) in the placebo group. Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety, and akathisia.  CONCLUSIONS AND RELEVANCE: Among patients with chorea assocd. with Huntington disease, the use of deutetrabenazine compared with placebo resulted in improved motor signs at 12 wk.  Further research is needed to assess the clin. importance of the effect size and to det. longer-term efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09cwKO054C7Vg90H21EOLACvtfcHk0ljE3w-GPfgOZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlu77M&md5=d1c5aebdb74a312c3f19c184e4789747</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1001%2Fjama.2016.8655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2016.8655%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DS.%26aulast%3DTesta%26aufirst%3DC.%2BM.%26aulast%3DStamler%26aufirst%3DD.%26aulast%3DKayson%26aufirst%3DE.%26aulast%3DDavis%26aufirst%3DC.%26aulast%3DEdmondson%26aufirst%3DM.%2BC.%26aulast%3DKinel%26aufirst%3DS.%26aulast%3DLeavitt%26aufirst%3DB.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DC.%26aulast%3DVaughan%26aufirst%3DC.%26aulast%3DGoldstein%26aufirst%3DJ.%26aulast%3DHerzog%26aufirst%3DM.%26aulast%3DSnively%26aufirst%3DV.%26aulast%3DWhaley%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DSuter%26aufirst%3DG.%26aulast%3DJankovic%26aufirst%3DJ.%26aulast%3DJimenez-Shahed%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DC.%26aulast%3DClaassen%26aufirst%3DD.%2BO.%26aulast%3DRoman%26aufirst%3DO.%2BC.%26aulast%3DSung%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DJanicki%26aufirst%3DS.%26aulast%3DClouse%26aufirst%3DR.%26aulast%3DSaint-Hilaire%26aufirst%3DM.%26aulast%3DHohler%26aufirst%3DA.%26aulast%3DTurpin%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DR.%2BC.%26aulast%3DRodriguez%26aufirst%3DR.%26aulast%3DRizer%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DHeller%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DA.%26aulast%3DCriswell%26aufirst%3DS.%26aulast%3DRacette%26aufirst%3DB.%2BA.%26aulast%3DRevilla%26aufirst%3DF.%2BJ.%26aulast%3DNucifora%26aufirst%3DF.%26aulast%3DMargolis%26aufirst%3DR.%2BL.%26aulast%3DMary%26aufirst%3DJ.%2BO.%26aulast%3DMendis%26aufirst%3DT.%26aulast%3DMendis%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DC.%26aulast%3DQuesada%26aufirst%3DM.%26aulast%3DPaulsen%26aufirst%3DJ.%2BS.%26aulast%3DBrashers-Krug%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DKerr%26aufirst%3DJ.%26aulast%3DDubinsky%26aufirst%3DR.%2BM.%26aulast%3DGray%26aufirst%3DC.%26aulast%3DFactor%26aufirst%3DS.%2BA.%26aulast%3DSperin%26aufirst%3DE.%26aulast%3DMolho%26aufirst%3DE.%26aulast%3DEglow%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DSamii%26aufirst%3DA.%26aulast%3DChouinard%26aufirst%3DS.%26aulast%3DBeland%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DB.%2BL.%26aulast%3DHickey%26aufirst%3DP.%2BT.%26aulast%3DEsmail%26aufirst%3DS.%26aulast%3DFung%26aufirst%3DW.%2BL.%2BA.%26aulast%3DGibbons%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DL.%26aulast%3DColcher%26aufirst%3DA.%26aulast%3DHackmyer%26aufirst%3DC.%26aulast%3DMcGarry%26aufirst%3DA.%26aulast%3DKlos%26aufirst%3DK.%26aulast%3DGudesblatt%26aufirst%3DM.%26aulast%3DFafard%26aufirst%3DL.%26aulast%3DGraffitti%26aufirst%3DL.%26aulast%3DSchneider%26aufirst%3DD.%2BP.%26aulast%3DDhall%26aufirst%3DR.%26aulast%3DWojcieszek%26aufirst%3DJ.%2BM.%26aulast%3DLa%2BFaver%26aufirst%3DK.%26aulast%3DDuker%26aufirst%3DA.%26aulast%3DNeefus%26aufirst%3DE.%26aulast%3DWilson-Perez%26aufirst%3DH.%26aulast%3DShprecher%26aufirst%3DD.%26aulast%3DWall%26aufirst%3DP.%26aulast%3DBlindauer%26aufirst%3DK.%2BA.%26aulast%3DWheeler%26aufirst%3DL.%26aulast%3DBoyd%26aufirst%3DJ.%2BT.%26aulast%3DHouston%26aufirst%3DE.%26aulast%3DFarbman%26aufirst%3DE.%2BS.%26aulast%3DAgarwal%26aufirst%3DP.%26aulast%3DEberly%26aufirst%3DS.%2BW.%26aulast%3DWatts%26aufirst%3DA.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DFeigin%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DBeck%26aufirst%3DC.%26aulast%3DOrme%26aufirst%3DC.%26aulast%3DEdicola%26aufirst%3DJ.%26aulast%3DChristopher%26aufirst%3DE.%26atitle%3DEffect%2520of%2520Deutetrabenazine%2520on%2520Chorea%2520among%2520Patients%2520with%2520Huntington%2520Disease.%2520A%2520Randomized%2520Clinical%2520Trial%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2016%26volume%3D316%26spage%3D40%26epage%3D50%26doi%3D10.1001%2Fjama.2016.8655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span> <span> </span><span class="NLM_article-title">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/jm4007998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3595-3611&author=T.+G.+Gant&title=Using+Deuterium+in+Drug+Discovery%3A+Leaving+the+Label+in+the+Drug&doi=10.1021%2Fjm4007998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span></div><div class="casAuthors">Gant, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Deuterium, the stable isotope of hydrogen, is known to medicinal chemists for its utility in mechanistic, spectroscopic, and tracer studies.  In fact, well-known applications utilizing deuterium exist within every subdiscipline in pharmaceutical discovery and development.  Recent emphasis on incorporation of deuterium into the active pharmaceutical ingredient has come about as a result of inquiries into the potential for substantial benefits of the deuterium kinetic isotope effect on the safety and disposition of the drug substance.  This Perspective traces the author's experience in reviving and expanding this potential utility, first suggested many decades prior by the discoverer of this, the simplest of all isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4z14tbfBfBbVg90H21EOLACvtfcHk0ljE3w-GPfgOZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ&md5=3818a1dba9be431098ad9dd941dababc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm4007998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007998%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DUsing%2520Deuterium%2520in%2520Drug%2520Discovery%253A%2520Leaving%2520the%2520Label%2520in%2520the%2520Drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3595%26epage%3D3611%26doi%3D10.1021%2Fjm4007998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span>; <span class="NLM_string-name">Shahbaz, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Deuterated Benzoquinolizidine Inhibitors of Vesicular Monoamine Transporter 2</span>. <span class="NLM_patent">WO 2010044981</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=T.+G.+Gant&author=M.+Shahbaz&title=Preparation+of+Deuterated+Benzoquinolizidine+Inhibitors+of+Vesicular+Monoamine+Transporter+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DPreparation%2520of%2520Deuterated%2520Benzoquinolizidine%2520Inhibitors%2520of%2520Vesicular%2520Monoamine%2520Transporter%25202%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit51b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzoquinolines as for Treatment of Abnormal Muscular Activity</span>. <span class="NLM_patent">WO 2015077520</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Shah&title=Preparation+of+Benzoquinolines+as+for+Treatment+of+Abnormal+Muscular+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DP.%26atitle%3DPreparation%2520of%2520Benzoquinolines%2520as%2520for%2520Treatment%2520of%2520Abnormal%2520Muscular%2520Activity%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit51c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Stamler, D.</span></span> <span> </span><span class="NLM_article-title">Benzoquinolines as Inhibitors of Vesicular Monoamine Transporter 2</span>. <span class="NLM_patent">WO 2015112707</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+Stamler&title=Benzoquinolines+as+Inhibitors+of+Vesicular+Monoamine+Transporter+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStamler%26aufirst%3DD.%26atitle%3DBenzoquinolines%2520as%2520Inhibitors%2520of%2520Vesicular%2520Monoamine%2520Transporter%25202%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit51d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span>; <span class="NLM_string-name">Saks, S.</span></span> <span> </span><span class="NLM_article-title">Benzoquinolines as Inhibitors of Vesicular Monoamine Transporter 2 and Their Preparation</span>. <span class="NLM_patent">WO 2015077521</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Shah&author=S.+Saks&title=Benzoquinolines+as+Inhibitors+of+Vesicular+Monoamine+Transporter+2+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DP.%26atitle%3DBenzoquinolines%2520as%2520Inhibitors%2520of%2520Vesicular%2520Monoamine%2520Transporter%25202%2520and%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit51e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Despande, T. N.</span>; <span class="NLM_string-name">Singare, D. T.</span>; <span class="NLM_string-name">Pawar, Y. D.</span>; <span class="NLM_string-name">Chavan, Y. A.</span>; <span class="NLM_string-name">Ray, P. C.</span>; <span class="NLM_string-name">Singh, G. P.</span></span> <span> </span><span class="NLM_article-title">Novel Process for the Preparation of Tetrabenazine and Deutetrabenazine</span>. <span class="NLM_patent">WO 2017182916</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=T.+N.+Despande&author=D.+T.+Singare&author=Y.+D.+Pawar&author=Y.+A.+Chavan&author=P.+C.+Ray&author=G.+P.+Singh&title=Novel+Process+for+the+Preparation+of+Tetrabenazine+and+Deutetrabenazine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDespande%26aufirst%3DT.%2BN.%26atitle%3DNovel%2520Process%2520for%2520the%2520Preparation%2520of%2520Tetrabenazine%2520and%2520Deutetrabenazine%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Methods of Manufacturing Benzoquinoline Compounds as Inhibitors of Vesicular Monoamine Transporter 2 (Vmat2)</span>. <span class="NLM_patent">US 20150152099A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+Zhang&title=Methods+of+Manufacturing+Benzoquinoline+Compounds+as+Inhibitors+of+Vesicular+Monoamine+Transporter+2+%28Vmat2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DMethods%2520of%2520Manufacturing%2520Benzoquinoline%2520Compounds%2520as%2520Inhibitors%2520of%2520Vesicular%2520Monoamine%2520Transporter%25202%2520%2528Vmat2%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Brossi, A.</span>, <span class="NLM_string-name">Schnider, O.</span>, <span class="NLM_string-name">Walter, M.</span></span> <span> </span><span class="NLM_article-title">Quinolizine Derivatives</span>. <span class="NLM_patent">US 2830993</span>, <span class="NLM_year">1958</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1958&author=A.+Brossi&author=O.+Schnider&author=M.+Walter&title=Quinolizine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrossi%26aufirst%3DA.%26atitle%3DQuinolizine%2520Derivatives%26date%3D1958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit53b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Brossi, A.</span></span> <span> </span><span class="NLM_article-title">Substituted 2-Oxobenzoquinolizines</span>. <span class="NLM_patent">US 3045021</span>, <span class="NLM_year">1962</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1962&author=A.+Brossi&title=Substituted+2-Oxobenzoquinolizines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrossi%26aufirst%3DA.%26atitle%3DSubstituted%25202-Oxobenzoquinolizines%26date%3D1962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Openshaw, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, N.</span></span> <span> </span><span class="NLM_article-title">The Synthesis of Emetine and Related Compounds. Iv. A New Synthesis of 3-Substituted 1,2,3,4,6,7-Hexahydro-9,10-Dimethoxy-2-Oxo-11bh-Benzo[A]Quinolizines</span>. <i>J. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1460</span>, <span class="refDoi"> DOI: 10.1039/jr9630001449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fjr9630001449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaF3sXlvF2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1963&pages=1449-1460&author=H.+T.+Openshawauthor=N.+Whittaker&title=The+Synthesis+of+Emetine+and+Related+Compounds.+Iv.+A+New+Synthesis+of+3-Substituted+1%2C2%2C3%2C4%2C6%2C7-Hexahydro-9%2C10-Dimethoxy-2-Oxo-11bh-Benzo%5BA%5DQuinolizines&doi=10.1039%2Fjr9630001449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54aR"><div class="casContent"><span class="casTitleNuber">54a</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis of emetine and related compounds. IV. A new synthesis of 3-substituted 1,2,3,4,6,7-hexahydro-9,10-dimethoxy-2-oxo-11bH-benzo[α]quinolizines</span></div><div class="casAuthors">Openshaw, H. T.; Whittaker, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society</span>
        (<span class="NLM_cas:date">1963</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1449-60</span>CODEN:
                <span class="NLM_cas:coden">JCSOA9</span>;
        ISSN:<span class="NLM_cas:issn">0368-1769</span>.
    </div><div class="casAbstract">cf. CA 56, 8765h.  The title compds. (I) are produced by spontaneous cyclization of the 2-(2-alkyl-3-oxobutyl)-3,4-dihydroisoquinolinium cations which arise either by the mercuric acetate dehydrogenation of the related tetrahydroisoquinolines, prepd. by a Mannich reaction, or more simply by amine interchange between 3,4-dihydroisoquinoline (II) and a quaternized Mannich base.  The procedure has also been applied to the synthesis of 9,10-methylenedioxy- and 9,10-unsubstituted analogs of I, and, less satisfactorily, to the related indoloquinolizines (III).  When II was treated with formaldehyde and a methyl ketone, I was not produced, but a more complex product, assigned structure IV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8iz6VJ8CcbVg90H21EOLACvtfcHk0lgjVa_jrXjp0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3sXlvF2hsw%253D%253D&md5=406a2b48886650a0cceac54d78c4cf73</span></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=10.1039%2Fjr9630001449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fjr9630001449%26sid%3Dliteratum%253Aachs%26aulast%3DOpenshaw%26aufirst%3DH.%2BT.%26aulast%3DWhittaker%26aufirst%3DN.%26atitle%3DThe%2520Synthesis%2520of%2520Emetine%2520and%2520Related%2520Compounds.%2520Iv.%2520A%2520New%2520Synthesis%2520of%25203-Substituted%25201%252C2%252C3%252C4%252C6%252C7-Hexahydro-9%252C10-Dimethoxy-2-Oxo-11bh-Benzo%255BA%255DQuinolizines%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1963%26spage%3D1449%26epage%3D1460%26doi%3D10.1039%2Fjr9630001449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit54b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Openshaw, H.
T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Emetine and Related Compounds. X. Synthesis of Emetine Analogs, Including C(3)-Dinoremetine and C(3)-Noremetine. Correlation of Structure with Amebicidal Activity</span>. <i>J. Chem. Soc. C</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1039/j39690000101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fj39690000101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaF1MXkslKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1969&pages=101-105&author=H.%0AT.+Openshawauthor=N.+C.+Robsonauthor=N.+Whittaker&title=Synthesis+of+Emetine+and+Related+Compounds.+X.+Synthesis+of+Emetine+Analogs%2C+Including+C%283%29-Dinoremetine+and+C%283%29-Noremetine.+Correlation+of+Structure+with+Amebicidal+Activity&doi=10.1039%2Fj39690000101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54bR"><div class="casContent"><span class="casTitleNuber">54b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of emetine and related compounds.  X.  Synthesis of emetine analogs, including C(3)-dinoremetine and C(3)-noremetine.  Correlation of structure with amebicidal activity</span></div><div class="casAuthors">Openshaw, Harry T.; Robson, N. C.; Whittaker, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society [Section] C:  Organic</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-5</span>CODEN:
                <span class="NLM_cas:coden">JSOOAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-4952</span>.
    </div><div class="casAbstract">The (±)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxybenzo[a]quinolizin-2-one [(±)-I] was converted into (±)-C(3)-dinoremetine (II) via an N-(3,4-dimethoxyphenethyl) amide which had the same relative configuration as emetine at C-11b and C-2.  3-Methyl deriv. of [(-)-I] obtained by asymmetric transformation of the racemic compd. was converted into (-)-C(3)-noremetine (III).  (-)-1',8a'-Secoemetine (IV) and the (-)-analogs were also prepd.  Only II, III, and IV showed appreciable amebicidal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpah4VzG-gGtbVg90H21EOLACvtfcHk0lgjVa_jrXjp0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkslKlsQ%253D%253D&md5=eaa452044183c57877d6f49b8b734999</span></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=10.1039%2Fj39690000101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fj39690000101%26sid%3Dliteratum%253Aachs%26aulast%3DOpenshaw%26aufirst%3DH.%2BT.%26aulast%3DRobson%26aufirst%3DN.%2BC.%26aulast%3DWhittaker%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520Emetine%2520and%2520Related%2520Compounds.%2520X.%2520Synthesis%2520of%2520Emetine%2520Analogs%252C%2520Including%2520C%25283%2529-Dinoremetine%2520and%2520C%25283%2529-Noremetine.%2520Correlation%2520of%2520Structure%2520with%2520Amebicidal%2520Activity%26jtitle%3DJ.%2520Chem.%2520Soc.%2520C%26date%3D1969%26spage%3D101%26epage%3D105%26doi%3D10.1039%2Fj39690000101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit54c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Emetine and Related Compounds. Vi. Improvements in the Synthesis of 3-Alkyl-1,3,4,6,7,11b-Hexahydro-9,10-Dimethoxybenzo[a]Quinolizin-2-Ones and 3-Alkyl-1,2,3,4,6,7,12,12b-Octahydroindolo[2,3-a]Quinolizin-2-Ones. Formation of Some Related Diazabicyclo[3.3.1]Nonanes</span>. <i>J. Chem. Soc. C</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1039/j39690000085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2Fj39690000085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaF1MXkslKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1969&pages=85-89&author=N.+Whittaker&title=Synthesis+of+Emetine+and+Related+Compounds.+Vi.+Improvements+in+the+Synthesis+of+3-Alkyl-1%2C3%2C4%2C6%2C7%2C11b-Hexahydro-9%2C10-Dimethoxybenzo%5Ba%5DQuinolizin-2-Ones+and+3-Alkyl-1%2C2%2C3%2C4%2C6%2C7%2C12%2C12b-Octahydroindolo%5B2%2C3-a%5DQuinolizin-2-Ones.+Formation+of+Some+Related+Diazabicyclo%5B3.3.1%5DNonanes&doi=10.1039%2Fj39690000085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54cR"><div class="casContent"><span class="casTitleNuber">54c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of emetine and related compounds.  VI.  Improvements in the synthesis of 3-alkyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxybenzo[a]quinolizin-2-ones and 3-alkyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-ones.  Formation of some related diazabicyclo[3.3.1]nonanes</span></div><div class="casAuthors">Whittaker, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society [Section] C:  Organic</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-9</span>CODEN:
                <span class="NLM_cas:coden">JSOOAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-4952</span>.
    </div><div class="casAbstract">A simplified procedure is reported for the almost quantitative conversion of 3,4-dihydro-6,7-di-methoxyisoquinoline (I) into benzo[a]quinolizines.  A byproduct formed in the prepn. of 1,3,4,6,7,11b-hexahydro-9,10-dimethoxybenzo[a]quinolizin-2-one is assigned the diisoquinopy-rimidine structure.  3,4-Dihydro-β-carboline condenses with Mannich bases in the presence of CO2 to give the indolo[2,3-a]quinolizines in good yield.  4-Dimethylamino-3-(dimethylaminomethyl)-2-butanone condenses with two mols. I to give 9,18-methanodiisoquino[2,1-a:1',2'-d][1,5]diazocine; similarly was prepd. the substituted 9,18-methanodiisoquino[2,1-a:2',1'-e]-[1,5]diazocine, together with a trace of a dipentacyclic ketone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7q6tHFtYe4LVg90H21EOLACvtfcHk0ljPIfLm8JqEEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkslKmuw%253D%253D&md5=43ff9e3bddc72eb532bd4fc8e536ac93</span></div><a href="/servlet/linkout?suffix=cit54c&amp;dbid=16384&amp;doi=10.1039%2Fj39690000085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fj39690000085%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520Emetine%2520and%2520Related%2520Compounds.%2520Vi.%2520Improvements%2520in%2520the%2520Synthesis%2520of%25203-Alkyl-1%252C3%252C4%252C6%252C7%252C11b-Hexahydro-9%252C10-Dimethoxybenzo%255Ba%255DQuinolizin-2-Ones%2520and%25203-Alkyl-1%252C2%252C3%252C4%252C6%252C7%252C12%252C12b-Octahydroindolo%255B2%252C3-a%255DQuinolizin-2-Ones.%2520Formation%2520of%2520Some%2520Related%2520Diazabicyclo%255B3.3.1%255DNonanes%26jtitle%3DJ.%2520Chem.%2520Soc.%2520C%26date%3D1969%26spage%3D85%26epage%3D89%26doi%3D10.1039%2Fj39690000085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">McGee, K.</span>; <span class="NLM_string-name">Li, B.-F.</span></span> <span> </span><span class="NLM_article-title">Synthetic Methods for Preparation of (S)-(2r,3r,11br)-3-Isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-Pyrido[2,1-a]isoquinolin-2-yl 2-Amino-3-methylbutanoate Di(4-methylbenzenesulfonate)</span>. <span class="NLM_patent">WO 2017112857</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+McGee&author=B.-F.+Li&title=Synthetic+Methods+for+Preparation+of+%28S%29-%282r%2C3r%2C11br%29-3-Isobutyl-9%2C10-dimethoxy-2%2C3%2C4%2C6%2C7%2C11b-hexahydro-1H-Pyrido%5B2%2C1-a%5Disoquinolin-2-yl+2-Amino-3-methylbutanoate+Di%284-methylbenzenesulfonate%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcGee%26aufirst%3DK.%26atitle%3DSynthetic%2520Methods%2520for%2520Preparation%2520of%2520%2528S%2529-%25282r%252C3r%252C11br%2529-3-Isobutyl-9%252C10-dimethoxy-2%252C3%252C4%252C6%252C7%252C11b-hexahydro-1H-Pyrido%255B2%252C1-a%255Disoquinolin-2-yl%25202-Amino-3-methylbutanoate%2520Di%25284-methylbenzenesulfonate%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit55b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span> <span> </span><span class="NLM_article-title">A Concise Synthesis of Tetrabenazine and Its Crystal Structure</span>. <i>Mol. Cryst. Liq. Cryst.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>557</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1080/15421406.2011.627764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F15421406.2011.627764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC38XksV2nt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=557&publication_year=2012&pages=39-49&author=C.+Liuauthor=Z.+Chenauthor=X.+Liauthor=J.+Tang&title=A+Concise+Synthesis+of+Tetrabenazine+and+Its+Crystal+Structure&doi=10.1080%2F15421406.2011.627764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55bR"><div class="casContent"><span class="casTitleNuber">55b</span><div class="casTitle"><span class="NLM_cas:atitle">A Concise Synthesis of Tetrabenazine and Its Crystal Structure</span></div><div class="casAuthors">Liu, Chunyi; Chen, Zhengping; Li, Xiaomin; Tang, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Crystals and Liquid Crystals</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">557</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-49</span>CODEN:
                <span class="NLM_cas:coden">MCLCD8</span>;
        ISSN:<span class="NLM_cas:issn">1542-1406</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The synthesis of the target compd. (Tetrabenazine) was achieved using 3-[(dimethylamino)methyl]-5-methyl-2-heptanone and 6,7-dimethoxy-3,4-dihydroisoquinoline hydrochloride as reactants.  This approach provides an efficient and concise way to the synthesis of the marketed drug Tetrabenazine.  A colorless single crystal of Tetrabenazine suitable for X-ray anal. was obtained from a satd. methanol soln.  The X-ray results showed that tetrabenazine consists of (3R,11bR)-enantiomer (I) [i.e., (3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one] and (3S,11bS)-enantiomer (II) [(3S,11bS)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one].  Two terminal Me groups are disordered in the (3R,11bR) enantiomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFdRBfJ_fnbbVg90H21EOLACvtfcHk0ljPIfLm8JqEEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksV2nt7k%253D&md5=4b7970ed498054204b9ec7e06a9003ef</span></div><a href="/servlet/linkout?suffix=cit55b&amp;dbid=16384&amp;doi=10.1080%2F15421406.2011.627764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15421406.2011.627764%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DA%2520Concise%2520Synthesis%2520of%2520Tetrabenazine%2520and%2520Its%2520Crystal%2520Structure%26jtitle%3DMol.%2520Cryst.%2520Liq.%2520Cryst.%26date%3D2012%26volume%3D557%26spage%3D39%26epage%3D49%26doi%3D10.1080%2F15421406.2011.627764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit55c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gano, K. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrido[2,1-a]isoquinoline Derivatives for Treating Hyperkinetic Disorders</span>. <span class="NLM_patent">WO 2008058261</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+W.+Gano&title=Preparation+of+Pyrido%5B2%2C1-a%5Disoquinoline+Derivatives+for+Treating+Hyperkinetic+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGano%26aufirst%3DK.%2BW.%26atitle%3DPreparation%2520of%2520Pyrido%255B2%252C1-a%255Disoquinoline%2520Derivatives%2520for%2520Treating%2520Hyperkinetic%2520Disorders%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilbourn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewett, D. M.</span></span> <span> </span><span class="NLM_article-title">Absolute Configuration of (+)-A-Dihydrotetrabenazine, an Active Metabolite of Tetrabenazine</span>. <i>Chirality</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1520-636X(1997)9:1<59::AID-CHIR11>3.0.CO;2-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2F%28SICI%291520-636X%281997%299%3A1%3C59%3A%3AAID-CHIR11%3E3.0.CO%3B2-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=9094204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK2sXit1aitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1997&pages=59-62&author=M.+R.+Kilbournauthor=L.+C.+Leeauthor=M.+J.+Heegauthor=D.+M.+Jewett&title=Absolute+Configuration+of+%28%2B%29-A-Dihydrotetrabenazine%2C+an+Active+Metabolite+of+Tetrabenazine&doi=10.1002%2F%28SICI%291520-636X%281997%299%3A1%3C59%3A%3AAID-CHIR11%3E3.0.CO%3B2-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Absolute configuration of (+)-α-dihydrotetrabenazine, an active metabolite of tetrabenazine</span></div><div class="casAuthors">Kilbourn, Michael R.; Lee, Lihsueh C.; Heeg, Mary J.; Jewett, Douglas M.</div><div class="citationInfo"><span class="NLM_cas:title">Chirality</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-62</span>CODEN:
                <span class="NLM_cas:coden">CHRLEP</span>;
        ISSN:<span class="NLM_cas:issn">0899-0042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss</span>)
        </div><div class="casAbstract">Chiral column liq. chromatog. and enantiospecific enzymic hydrolysis were utilized to sep. the enantiomers of α- and β-dihydrotetrabenazine and α-9-O-desmethyldihydrotetrabenazine, three benzo[a]quinolizines derived from the amine-depleting drug tetrabenazine.  An X-ray crystal structure anal. of (-)-α-9-O-desmethyldihydrotetrabenazine gave an abs. structure of that compd. as the 2S, 3S, 11bS isomer.  Therefore, (-)-α-dihydrotetrabenazine also has the 2S, 3S, 11bS abs. configuration.  (+)-α-Dihydrotetrabenazine, the single biol. active isomer from the metabolic redn. of tetrabenazine, thus has the abs. configuration of 2R, 3R, 11bR.  For further in vitro and in vivo studies of the vesicular monoamine transporter, it is now possible to use the single enantiomer of radiolabeled α-dihydrotetrabenazine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgn_jEbKw9U7Vg90H21EOLACvtfcHk0ljPIfLm8JqEEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1aitro%253D&md5=bf708fc279b4850a9191035a82323a99</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291520-636X%281997%299%3A1%3C59%3A%3AAID-CHIR11%3E3.0.CO%3B2-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291520-636X%25281997%25299%253A1%253C59%253A%253AAID-CHIR11%253E3.0.CO%253B2-P%26sid%3Dliteratum%253Aachs%26aulast%3DKilbourn%26aufirst%3DM.%2BR.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DHeeg%26aufirst%3DM.%2BJ.%26aulast%3DJewett%26aufirst%3DD.%2BM.%26atitle%3DAbsolute%2520Configuration%2520of%2520%2528%252B%2529-A-Dihydrotetrabenazine%252C%2520an%2520Active%2520Metabolite%2520of%2520Tetrabenazine%26jtitle%3DChirality%26date%3D1997%26volume%3D9%26spage%3D59%26epage%3D62%26doi%3D10.1002%2F%28SICI%291520-636X%281997%299%3A1%3C59%3A%3AAID-CHIR11%3E3.0.CO%3B2-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citrome, L.</span></span> <span> </span><span class="NLM_article-title">Valbenazine for Tardive Dyskinesia: A Systematic Review of the Efficacy and Safety Profile for This Newly Approved Novel Medication—What Is the Number Needed to Treat, Number Needed to Harm and Likelihood to Be Helped or Harmed?</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">e12964</span>, <span class="refDoi"> DOI: 10.1111/ijcp.12964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1111%2Fijcp.12964" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=e12964&author=L.+Citrome&title=Valbenazine+for+Tardive+Dyskinesia%3A+A+Systematic+Review+of+the+Efficacy+and+Safety+Profile+for+This+Newly+Approved+Novel+Medication%E2%80%94What+Is+the+Number+Needed+to+Treat%2C+Number+Needed+to+Harm+and+Likelihood+to+Be+Helped+or+Harmed%3F&doi=10.1111%2Fijcp.12964"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fijcp.12964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fijcp.12964%26sid%3Dliteratum%253Aachs%26aulast%3DCitrome%26aufirst%3DL.%26atitle%3DValbenazine%2520for%2520Tardive%2520Dyskinesia%253A%2520A%2520Systematic%2520Review%2520of%2520the%2520Efficacy%2520and%2520Safety%2520Profile%2520for%2520This%2520Newly%2520Approved%2520Novel%2520Medication%25E2%2580%2594What%2520Is%2520the%2520Number%2520Needed%2520to%2520Treat%252C%2520Number%2520Needed%2520to%2520Harm%2520and%2520Likelihood%2520to%2520Be%2520Helped%2520or%2520Harmed%253F%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2017%26volume%3D71%26spage%3De12964%26doi%3D10.1111%2Fijcp.12964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, D.</span></span> <span> </span><span class="NLM_article-title">Tardive Dyskinesia: Out of the Shadows</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2018.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.jns.2018.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29449008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1MritFOntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2018&pages=1-3&author=R.+A.+Hauserauthor=D.+Truong&title=Tardive+Dyskinesia%3A+Out+of+the+Shadows&doi=10.1016%2Fj.jns.2018.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58aR"><div class="casContent"><span class="casTitleNuber">58a</span><div class="casTitle"><span class="NLM_cas:atitle">Tardive dyskinesia: Out of the shadows</span></div><div class="casAuthors">Hauser Robert A; Truong Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the neurological sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The approvals of the first two medications, valbenazine and deutetrabenazine, to treat tardive dyskinesia have ushered in a new era in neuropsychiatric care.  Tardive syndromes are defined as delayed onset, persistent movement disorders or sensory phenomena that occur in association with exposure to dopamine receptor blocking agents (DRBAs).  Their underlying pathophysiology remains to be fully elucidated, but clinicians can conceptualize tardive syndromes as persistent dopamine supersensitivity states.  Tardive syndromes can potentially cause distress, disfigurement, embarrassment, and dysfunction, and are often permanent.  Therefore, practitioners who prescribe DRBAs should be aware of this potential, carefully assess the risk/benefit ratio when considering the use of these medications, and be sure that patients are appropriately informed.  Patients on DRBAs should be monitored for the development of tardive syndromes, including through the use of regularly scheduled Abnormal Involuntary Movement Scale (AIMS) (or similar) examinations.  Clinicians prescribing DRBAs should be familiar with the diagnosis and management of tardive syndromes, and be able to institute treatment or refer patients when treatment is appropriate.  Future research may focus on the potential benefit of earlier introduction of VMAT2 inhibitors to delay onset or progression of tardive syndromes.  More effective treatments are still needed, as are effective, well-tolerated antipsychotics that do not cause tardive syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQl20610aearWHOrQ6qeX-mfW6udTcc2ea80CjF6xOUZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MritFOntQ%253D%253D&md5=6d7a984c6854f8df5ae4e983b6afad49</span></div><a href="/servlet/linkout?suffix=cit58a&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2018.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2018.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DR.%2BA.%26aulast%3DTruong%26aufirst%3DD.%26atitle%3DTardive%2520Dyskinesia%253A%2520Out%2520of%2520the%2520Shadows%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2018%26volume%3D389%26spage%3D1%26epage%3D3%26doi%3D10.1016%2Fj.jns.2018.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit58b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankovic, J.</span></span> <span> </span><span class="NLM_article-title">Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0874-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0874-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29484607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=525-541&author=N.+Niemannauthor=J.+Jankovic&title=Treatment+of+Tardive+Dyskinesia%3A+A+General+Overview+with+Focus+on+the+Vesicular+Monoamine+Transporter+2+Inhibitors&doi=10.1007%2Fs40265-018-0874-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58bR"><div class="casContent"><span class="casTitleNuber">58b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors</span></div><div class="casAuthors">Niemann, Nicki; Jankovic, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-541</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Tardive dyskinesia (TD) encompasses the spectrum of iatrogenic hyperkinetic movement disorders following exposure to dopamine receptor-blocking agents (DRBAs).  Despite the advent of atypical or second- and third-generation antipsychotics with a presumably lower risk of complications, TD remains a persistent and challenging problem.  Prevention is the first step in mitigating the risk of TD, but early recognition, gradual withdrawal of offending medications, and appropriate treatment are also crit.  As TD is often a persistent and troublesome disorder, specific antidyskinetic therapies are often needed for symptomatic relief.  The vesicular monoamine transporter 2 (VMAT2) inhibitors, which include tetrabenazine, deutetrabenazine, and valbenazine, are considered the treatment of choice for most patients with TD.  Deutetrabenazine-a deuterated version of tetrabenazine-and valbenazine, the purified parent product of one of the main tetrabenazine metabolites, are novel VMAT2 inhibitors and the only drugs to receive approval from the US FDA for the treatment of TD.  VMAT2 inhibitors deplete presynaptic dopamine and reduce involuntary movements in many hyperkinetic movement disorders, particularly TD, Huntington disease, and Tourette syndrome.  The active metabolites of the VMAT2 inhibitors have high affinity for VMAT2 and minimal off-target binding.  Compared with tetrabenazine, deutetrabenazine and valbenazine have pharmacokinetic advantages that translate into less frequent dosing and better tolerability.  However, no head-to-head studies have compared the various VMAT2 inhibitors.  One of the major advantages of VMAT2 inhibitors over DRBAs, which are still being used by some clinicians in the treatment of some hyperkinetic disorders, including TD, is that they are not assocd. with the development of TD.  We also briefly discuss other treatment options for TD, including amantadine, clonazepam, Gingko biloba, zolpidem, botulinum toxin, and deep brain stimulation.  Treatment of TD and other drug-induced movement disorders must be individualized and based on the severity, phenomenol., potential side effects, and other factors discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKvcuWVWOIJrVg90H21EOLACvtfcHk0lgeSWsSHwBMjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKgurk%253D&md5=6865bade039dd5f6c3670a376de6160b</span></div><a href="/servlet/linkout?suffix=cit58b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0874-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0874-x%26sid%3Dliteratum%253Aachs%26aulast%3DNiemann%26aufirst%3DN.%26aulast%3DJankovic%26aufirst%3DJ.%26atitle%3DTreatment%2520of%2520Tardive%2520Dyskinesia%253A%2520A%2520General%2520Overview%2520with%2520Focus%2520on%2520the%2520Vesicular%2520Monoamine%2520Transporter%25202%2520Inhibitors%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D525%26epage%3D541%26doi%3D10.1007%2Fs40265-018-0874-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zai, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zai, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remington, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, J. L.</span></span> <span> </span><span class="NLM_article-title">Genetics of Tardive Dyskinesia: Promising Leads and Ways Forward</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2018.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.jns.2018.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29502799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGgtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2018&pages=28-34&author=C.+C.+Zaiauthor=M.+S.+Maesauthor=A.+K.+Tiwariauthor=G.+C.+Zaiauthor=G.+Remingtonauthor=J.+L.+Kennedy&title=Genetics+of+Tardive+Dyskinesia%3A+Promising+Leads+and+Ways+Forward&doi=10.1016%2Fj.jns.2018.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59aR"><div class="casContent"><span class="casTitleNuber">59a</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics of tardive dyskinesia: Promising leads and ways forward</span></div><div class="casAuthors">Zai, Clement C.; Maes, Miriam S.; Tiwari, Arun K.; Zai, Gwyneth C.; Remington, Gary; Kennedy, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">28-34</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tardive dyskinesia (TD) is a potentially irreversible and often debilitating movement disorder secondary to chronic use of dopamine receptor blocking medications.  Genetic factors have been implicated in the etiol. of TD.  We therefore have reviewed the most promising genes assocd. with TD, including DRD2, DRD3, VMAT2, HSPG2, HTR2A, HTR2C, and SOD2.  In addn., we present evidence supporting a role for these genes from preclin. models of TD.  The current understanding of the etiogenesis of TD is discussed in the light of the recent approvals of valbenazine and deutetrabenazine, VMAT2 inhibitors, for treating TD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWdvPQ0-XfM7Vg90H21EOLACvtfcHk0lg7rZIG8iudQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGgtb8%253D&md5=108bd106300c2fbcf96d8f02dc3c93e0</span></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2018.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2018.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DZai%26aufirst%3DC.%2BC.%26aulast%3DMaes%26aufirst%3DM.%2BS.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DZai%26aufirst%3DG.%2BC.%26aulast%3DRemington%26aufirst%3DG.%26aulast%3DKennedy%26aufirst%3DJ.%2BL.%26atitle%3DGenetics%2520of%2520Tardive%2520Dyskinesia%253A%2520Promising%2520Leads%2520and%2520Ways%2520Forward%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2018%26volume%3D389%26spage%3D28%26epage%3D34%26doi%3D10.1016%2Fj.jns.2018.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit59b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Skor, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozigian, H.</span></span> <span> </span><span class="NLM_article-title">Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine</span>. <i>Drugs R&amp;D</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1007/s40268-017-0202-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40268-017-0202-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28776237" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=449-459&author=H.+Skorauthor=E.+B.+Smithauthor=G.+Loewenauthor=C.+F.+O%E2%80%99Brienauthor=D.+E.+Grigoriadisauthor=H.+Bozigian&title=Differences+in+Dihydrotetrabenazine+Isomer+Concentrations+Following+Administration+of+Tetrabenazine+and+Valbenazine&doi=10.1007%2Fs40268-017-0202-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=10.1007%2Fs40268-017-0202-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40268-017-0202-z%26sid%3Dliteratum%253Aachs%26aulast%3DSkor%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DLoewen%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BF.%26aulast%3DGrigoriadis%26aufirst%3DD.%2BE.%26aulast%3DBozigian%26aufirst%3DH.%26atitle%3DDifferences%2520in%2520Dihydrotetrabenazine%2520Isomer%2520Concentrations%2520Following%2520Administration%2520of%2520Tetrabenazine%2520and%2520Valbenazine%26jtitle%3DDrugs%2520R%2526amp%253BD%26date%3D2017%26volume%3D17%26spage%3D449%26epage%3D459%26doi%3D10.1007%2Fs40268-017-0202-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harriott, N. D.</span>; <span class="NLM_string-name">Williams, J. P.</span>; <span class="NLM_string-name">Smith, E. B.</span>; <span class="NLM_string-name">Bozigian, H. P.</span>; <span class="NLM_string-name">Grigoriadis, D. E.</span></span> <span> </span><span class="NLM_article-title">Chapter Two—Vmat2 Inhibitors and the Path to Ingrezza (Valbenazine)</span>. In  <i>Progress in Medicinal Chemistry</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, D. R.</span>, <span class="NLM_string-name">Cox, B.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2018</span>; Vol.  <span class="NLM_volume">57</span>, pp  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">111</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=87-111&author=N.+D.+Harriott&author=J.+P.+Williams&author=E.+B.+Smith&author=H.+P.+Bozigian&author=D.+E.+Grigoriadisauthor=D.+R.+Witty&author=B.+Cox&title=Progress+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHarriott%26aufirst%3DN.%2BD.%26atitle%3DChapter%2520Two%25E2%2580%2594Vmat2%2520Inhibitors%2520and%2520the%2520Path%2520to%2520Ingrezza%2520%2528Valbenazine%2529%26btitle%3DProgress%2520in%2520Medicinal%2520Chemistry%26aulast%3DWitty%26aufirst%3DD.%2BR.%26pub%3DElsevier%26date%3D2018%26volume%3D57%26spage%3D87%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boldt, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggers, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phifer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brine, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehder, K. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (+)- and (−)-Tetrabenazine from the Resolution of A-Dihydrotetrabenazine</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">3574</span>– <span class="NLM_lpage">3585</span>, <span class="refDoi"> DOI: 10.1080/00397910902788125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F00397910902788125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2qs7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=3574-3585&author=K.+G.+Boldtauthor=M.+S.+Biggersauthor=S.+S.+Phiferauthor=G.+A.+Brineauthor=K.+S.+Rehder&title=Synthesis+of+%28%2B%29-+and+%28%E2%88%92%29-Tetrabenazine+from+the+Resolution+of+A-Dihydrotetrabenazine&doi=10.1080%2F00397910902788125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (+)- and (-)-tetrabenazine from the resolution of α-dihydrotetrabenazine</span></div><div class="casAuthors">Boldt, Karl G.; Biggers, Michael S.; Phifer, Sharnelle S.; Brine, George A.; Rehder, Ken S.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3574-3585</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">(±)-Tetrabenazine ((±)-I) was reduced with NaBH4 to (±)-α-dihydrotetrabenazine ((±)-II) and then resolved with di-4-toluoyl-L- and -D-tartrate to subsequently give (+)- and (-)-II.  The enantiomers were oxidized under Swern conditions to prep. samples of (+)- and (-)-I, which were optically pure by chiral HPLC anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTEb9wdKjbhrVg90H21EOLACvtfcHk0lg7rZIG8iudQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2qs7%252FE&md5=8ff1d09981dd945f8c19b08e0d047e23</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1080%2F00397910902788125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910902788125%26sid%3Dliteratum%253Aachs%26aulast%3DBoldt%26aufirst%3DK.%2BG.%26aulast%3DBiggers%26aufirst%3DM.%2BS.%26aulast%3DPhifer%26aufirst%3DS.%2BS.%26aulast%3DBrine%26aufirst%3DG.%2BA.%26aulast%3DRehder%26aufirst%3DK.%2BS.%26atitle%3DSynthesis%2520of%2520%2528%252B%2529-%2520and%2520%2528%25E2%2588%2592%2529-Tetrabenazine%2520from%2520the%2520Resolution%2520of%2520A-Dihydrotetrabenazine%26jtitle%3DSynth.%2520Commun.%26date%3D2009%26volume%3D39%26spage%3D3574%26epage%3D3585%26doi%3D10.1080%2F00397910902788125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mittelman, A.</span>; <span class="NLM_string-name">Shachan-Tov, S.</span>; <span class="NLM_string-name">Masarwa, A.</span>; <span class="NLM_string-name">Sella-Erez, R.</span>; <span class="NLM_string-name">Enav, J.</span>; <span class="NLM_string-name">Erlich, M.</span>; <span class="NLM_string-name">Machtey, V.</span>; <span class="NLM_string-name">Piran, M.</span>; <span class="NLM_string-name">Yarovoy, M.</span>; <span class="NLM_string-name">Azran, S.</span>; <span class="NLM_string-name">Kisin-Finfer, E.</span>; <span class="NLM_string-name">Nidam, T.</span></span> <span> </span><span class="NLM_article-title">Solid State Forms of Valbenazine</span>. <span class="NLM_patent">WO 2018067945A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Mittelman&author=S.+Shachan-Tov&author=A.+Masarwa&author=R.+Sella-Erez&author=J.+Enav&author=M.+Erlich&author=V.+Machtey&author=M.+Piran&author=M.+Yarovoy&author=S.+Azran&author=E.+Kisin-Finfer&author=T.+Nidam&title=Solid+State+Forms+of+Valbenazine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMittelman%26aufirst%3DA.%26atitle%3DSolid%2520State%2520Forms%2520of%2520Valbenazine%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gano, K. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrido[2,1-a]isoquinoline Derivatives for Treating Hyperkinetic Disorders</span>. <span class="NLM_patent">WO2008058261A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+W.+Gano&title=Preparation+of+Pyrido%5B2%2C1-a%5Disoquinoline+Derivatives+for+Treating+Hyperkinetic+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGano%26aufirst%3DK.%2BW.%26atitle%3DPreparation%2520of%2520Pyrido%255B2%252C1-a%255Disoquinoline%2520Derivatives%2520for%2520Treating%2520Hyperkinetic%2520Disorders%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Naldemedine: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0750-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0750-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28466424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1crjsFSmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=923-927&author=A.+Markham&title=Naldemedine%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0750-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Naldemedine: First Global Approval</span></div><div class="casAuthors">Markham Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">923-927</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Naldemedine (Symproic(®)) is an orally active μ-opioid receptor antagonist being developed by Shionogi & Co., Ltd. that has been approved in the USA and Japan for the treatment of opioid-induced constipation.  The drug inhibits peripheral μ-opioid receptors such as those present in the gastrointestinal tract and has minimal or no effect on central opioid activity.  This article summarizes the milestones in the development of naldemedine leading to its first global approval in the USA for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4GzOCvvzBrO98rul4nhSdfW6udTcc2ebX9YPW37bf9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjsFSmtg%253D%253D&md5=6af1127aa3c094af82bbb5617a4dfcf2</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0750-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0750-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DNaldemedine%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D923%26epage%3D927%26doi%3D10.1007%2Fs40265-017-0750-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stern, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, D. M.</span></span> <span> </span><span class="NLM_article-title">Spotlight on Naldemedine in the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Noncancer Pain: Design, Development, and Place in Therapy</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.2147/JPR.S141322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2147%2FJPR.S141322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29391826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKltLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=195-199&author=E.+K.+Sternauthor=D.+M.+Brenner&title=Spotlight+on+Naldemedine+in+the+Treatment+of+Opioid-Induced+Constipation+in+Adult+Patients+with+Chronic+Noncancer+Pain%3A+Design%2C+Development%2C+and+Place+in+Therapy&doi=10.2147%2FJPR.S141322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy</span></div><div class="casAuthors">Stern, Emily K.; Brenner, Darren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-199</span>CODEN:
                <span class="NLM_cas:coden">JPROEV</span>;
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Opioid-induced constipation (OIC) is an increasingly prevalent problem in the USA due to the growing use of opioids.  A novel class of therapeutics, the peripherally acting μ-opioid receptor antagonists (PAMORAs), has been developed to mitigate the deleterious effects of opioids in the gastrointestinal tract while maintaining central analgesia and minimizing opioid withdrawal.  This review aimed to summarize the literature on naldemedine, the third PAMORA to gain US Food and Drug Administration (FDA) approval for the treatment of OIC in adults with chronic noncancer pain-related syndromes.  Naldemedine has a chem. structure similar to naltrexone, an opioid receptor antagonist, with chem. modifications that limit its ability to cross the blood-brain barrier.  Naldemedine was evaluated in two Phase II and three Phase III clin. trials prior to gaining FDA approval.  In two pivotal identical Phase III trials, COMPOSE-I (NCT 01965158) and COMPOSE-II (NCT 01993940), patients receiving naldemedine were significantly more likely to respond when compared with placebo (COMPOSE-I: 47.6 vs 34.6%, P=0.002 and COMPOSE-II: 52.5 vs 33.6%, P<0.0001).  The most frequent adverse events were abdominal pain (8%) and diarrhea (7%) - rates similar to the other PAMORAs.  Based on the available data, naldemedine appears to be an effective and safe drug for the treatment of OIC in adults with chronic noncancer pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3a5L_7P8WQ7Vg90H21EOLACvtfcHk0lic1Hsgg-TbzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKltLvP&md5=0d15a9d564a22942aed2525a79d44d05</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2147%2FJPR.S141322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S141322%26sid%3Dliteratum%253Aachs%26aulast%3DStern%26aufirst%3DE.%2BK.%26aulast%3DBrenner%26aufirst%3DD.%2BM.%26atitle%3DSpotlight%2520on%2520Naldemedine%2520in%2520the%2520Treatment%2520of%2520Opioid-Induced%2520Constipation%2520in%2520Adult%2520Patients%2520with%2520Chronic%2520Noncancer%2520Pain%253A%2520Design%252C%2520Development%252C%2520and%2520Place%2520in%2520Therapy%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2018%26volume%3D11%26spage%3D195%26epage%3D199%26doi%3D10.2147%2FJPR.S141322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, Y.</span>; <span class="NLM_string-name">Noguchi, K.</span>; <span class="NLM_string-name">Inagaki, M.</span>; <span class="NLM_string-name">Morimoto, K.</span>; <span class="NLM_string-name">Haga, N.</span>; <span class="NLM_string-name">Oda, S.</span>; <span class="NLM_string-name">Omura, S.</span></span> <span> </span><span class="NLM_article-title">Crystal of 6,7-Unsaturated-7-carbamoyl Morphinan Derivative and Method for Producing the Same</span>. <span class="NLM_patent">US 9108975B2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Tamura&author=K.+Noguchi&author=M.+Inagaki&author=K.+Morimoto&author=N.+Haga&author=S.+Oda&author=S.+Omura&title=Crystal+of+6%2C7-Unsaturated-7-carbamoyl+Morphinan+Derivative+and+Method+for+Producing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DY.%26atitle%3DCrystal%2520of%25206%252C7-Unsaturated-7-carbamoyl%2520Morphinan%2520Derivative%2520and%2520Method%2520for%2520Producing%2520the%2520Same%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yee, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daaboul, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korjian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlKhalfan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerneis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhaber, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, C. M.</span></span> <span> </span><span class="NLM_article-title">Increased Benefit of Betrixaban among Patients with a History of Venous Thromboembolism: A Post-Hoc Analysis of the Apex Trial</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1007/s11239-017-1583-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs11239-017-1583-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29188425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1-8&author=M.+K.+Yeeauthor=T.+Nafeeauthor=Y.+Daaboulauthor=S.+Korjianauthor=F.+AlKhalfanauthor=M.+Kerneisauthor=C.+Wiestauthor=S.+Z.+Goldhaberauthor=A.+F.+Hernandezauthor=R.+D.+Hullauthor=A.+T.+Cohenauthor=R.+A.+Harringtonauthor=C.+M.+Gibson&title=Increased+Benefit+of+Betrixaban+among+Patients+with+a+History+of+Venous+Thromboembolism%3A+A+Post-Hoc+Analysis+of+the+Apex+Trial&doi=10.1007%2Fs11239-017-1583-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial</span></div><div class="casAuthors">Yee, Megan K.; Nafee, Tarek; Daaboul, Yazan; Korjian, Serge; Al Khalfan, Fahad; Kerneis, Mathieu; Wiest, Cara; Goldhaber, Samuel Z.; Hernandez, Adrian F.; Hull, Russell D.; Cohen, Alexander T.; Harrington, Robert A.; Gibson, C. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hospitalized acute medically ill patients with a history of venous thromboembolism (VTE) are at increased risk for recurrent VTE.  We characterized the efficacy and safety of betrixaban for prevention of recurrent VTE in these high risk patients.  The APEX trial randomized 7513 acutely ill hospitalized medical patients at risk for developing VTE to receive either betrixaban for 35-42 days or enoxaparin for 10 ± 4 days to prevent VTE.  This exploratory post-hoc anal. assessed the efficacy and safety of betrixaban vs. enoxaparin among subjects with and without prior VTE.  Time-to-multiple symptomatic VTE events was also calcd.  Approx. 8% of subjects in both arms had prior VTE, which was assocd. with a fourfold increase in adjusted risk of VTE [MV OR 4.03, 95% CI 3.06-5.30, p < 0.001].  Betrixaban reduced VTE compared with enoxaparin among subjects with prior VTE [32 (10.4%) vs. 55 (18.9%), RR 0.57, 95% CI 0.38-0.86, p = 0.006, ARR 8.5%, NNT 12] and without prior VTE [133 (3.9%) vs. 168 (4.9%), RR 0.79, 95% CI 0.64-0.99, p = 0.042, ARR 1.0%, NNT 100] (interaction p > 0.05).  Addnl., four subjects in the enoxaparin arm and one subject in the betrixaban arm experienced a recurrent VTE.  Compared with enoxaparin, betrixaban use was assocd. with redn. of recurrent VTE events through the active treatment period [36 vs. 57, HR 0.63, 95% CI 0.41-0.97, p = 0.045] and through the end of study [38 vs. 71, HR 0.54, 95% CI 0.36-0.81, p = 0.004].  Prior VTE is assocd. with a fourfold increase in the risk of VTE among hospitalized medically ill patients.  Only 12 such patients would need to be treated with betrixaban vs. enoxaparin to prevent an addnl. VTE endpoint.  Betrixaban reduced not only the first but also all recurrent VTE events in a time-to-any-event anal.  Trial registration: http://www.clinicaltrials.gov, Unique identifier: NCT01583218.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiFiuZS4tfhLVg90H21EOLACvtfcHk0lic1Hsgg-TbzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejsr%252FP&md5=5cae40f3e164559cc7b36f713e5f788f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs11239-017-1583-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-017-1583-0%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DM.%2BK.%26aulast%3DNafee%26aufirst%3DT.%26aulast%3DDaaboul%26aufirst%3DY.%26aulast%3DKorjian%26aufirst%3DS.%26aulast%3DAlKhalfan%26aufirst%3DF.%26aulast%3DKerneis%26aufirst%3DM.%26aulast%3DWiest%26aufirst%3DC.%26aulast%3DGoldhaber%26aufirst%3DS.%2BZ.%26aulast%3DHernandez%26aufirst%3DA.%2BF.%26aulast%3DHull%26aufirst%3DR.%2BD.%26aulast%3DCohen%26aufirst%3DA.%2BT.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26aulast%3DGibson%26aufirst%3DC.%2BM.%26atitle%3DIncreased%2520Benefit%2520of%2520Betrixaban%2520among%2520Patients%2520with%2520a%2520History%2520of%2520Venous%2520Thromboembolism%253A%2520A%2520Post-Hoc%2520Analysis%2520of%2520the%2520Apex%2520Trial%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2018%26volume%3D45%26spage%3D1%26epage%3D8%26doi%3D10.1007%2Fs11239-017-1583-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkart, T.</span></span> <span> </span><span class="NLM_article-title">Advances in Oral Anticoagulation Therapy – What’s in the Pipeline?</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2017.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.blre.2017.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28185693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1Ciu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=205-211&author=P.+S.+S.+Raoauthor=T.+Burkart&title=Advances+in+Oral+Anticoagulation+Therapy+%E2%80%93+What%E2%80%99s+in+the+Pipeline%3F&doi=10.1016%2Fj.blre.2017.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68aR"><div class="casContent"><span class="casTitleNuber">68a</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in oral anticoagulation therapy - What's in the pipeline?</span></div><div class="casAuthors">Rao, P. S. S.; Burkart, T.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-211</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Approx. 900,000 people are affected by some sort of venous thromboembolic (VTE) event every year in the United States.  VTE diagnosis used to mean treatment with medications that required routine lab monitoring for safety and efficacy.  Activated factor X (FXa) inhibition has emerged as a convenient pathway for management of VTE and currently three FXa inhibitors are available for anticoagulation management - rivaroxaban, apixaban, and edoxaban.  Continued development of medications utilizing this pathway may offer advantages via novel pharmacokinetic or pharmacodynamic properties that may minimize the adverse effects assocd. with traditional anticoagulant therapy.  This review summarizes the available information regarding pharmacokinetic, pharmacodynamic, and early safety and efficacy data for three factor Xa inhibitors being developed - darexaban, betrixaban and nokxaban.  The studies reviewed in this article suggests that three newer agents possess the potential for promise based on early phase I and II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKxaHqAjVZmbVg90H21EOLACvtfcHk0lg2EDvh0GNyTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1Ciu70%253D&md5=f506f70c09569727898309e3c0aecbca</span></div><a href="/servlet/linkout?suffix=cit68a&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2017.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2017.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DP.%2BS.%2BS.%26aulast%3DBurkart%26aufirst%3DT.%26atitle%3DAdvances%2520in%2520Oral%2520Anticoagulation%2520Therapy%2520%25E2%2580%2593%2520What%25E2%2580%2599s%2520in%2520the%2520Pipeline%253F%26jtitle%3DBlood%2520Rev.%26date%3D2017%26volume%3D31%26spage%3D205%26epage%3D211%26doi%3D10.1016%2Fj.blre.2017.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRemer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gums, J. G.</span></span> <span> </span><span class="NLM_article-title">Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1177/1060028018754383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1177%2F1060028018754383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29338293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt12ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2018&pages=554-561&author=S.+G.+Garlandauthor=C.+E.+DeRemerauthor=S.+M.+Smithauthor=J.+G.+Gums&title=Betrixaban%3A+A+New+Oral+Factor+Xa+Inhibitor+for+Extended+Venous+Thromboembolism+Prophylaxis+in+High-Risk+Hospitalized+Patients&doi=10.1177%2F1060028018754383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68bR"><div class="casContent"><span class="casTitleNuber">68b</span><div class="casTitle"><span class="NLM_cas:atitle">Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients</span></div><div class="casAuthors">Garland, Scott G.; De Remer, Christina E.; Smith, Steven M.; Gums, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">554-561</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., pharmacokinetics, efficacy, and safety of the factor Xa (FXa) inhibitor betrixaban for extended-duration prophylaxis of acute medically ill patients with venous thromboembolism (VTE) risk factors.  Data Sources: A MEDLINE/PubMed (Jan. 1990 to Oct. 2017) search was conducted using the following keywords: betrixaban, PRT054021, FXa inhibitor, novel oral anticoagulant, NOAC, direct oral anticoagulant, DOAC, and target specific oral anticoagulant, TSOAC.  Refs. of identified articles were searched by hand for addnl. relevant citations.  Study Selection and Data Extn.: We included English-language articles evaluating betrixaban pharmacol., pharmacokinetics, efficacy, or safety in human subjects for VTE prophylaxis.  Data Synthesis: Betrixaban is a FXa inhibitor that decreases prothrombinase activity and thrombin generation.  Betrixaban efficacy and safety has been compared with that of enoxaparin for prophylaxis of VTE in acutely ill medical patients.  In the APEX trial and substudies, extended-duration betrixaban was superior in efficacy to std.-duration enoxaparin in patients at high risk for VTE, including those with elevated D-dimer levels (≥2× upper limit of normal) and of older age (≥75 years).  Betrixaban is noninferior to enoxaparin in rates of major bleeding, but the former is assocd. with more clin. relevant nonmajor bleeding events.  Conclusion: Betrixaban is the first oral agent approved for extended-duration VTE prophylaxis in acutely ill hospitalized patients.  Extended-duration thromboprophylaxis with betrixaban reduces the risk of VTE compared with std.-duration thromboprophylaxis with enoxaparin but is assocd. with increased risk of bleeding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv8UZJFdksCrVg90H21EOLACvtfcHk0lg2EDvh0GNyTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt12ru7k%253D&md5=4e7e718093fdb2f2cbb1cdcfb7839112</span></div><a href="/servlet/linkout?suffix=cit68b&amp;dbid=16384&amp;doi=10.1177%2F1060028018754383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028018754383%26sid%3Dliteratum%253Aachs%26aulast%3DGarland%26aufirst%3DS.%2BG.%26aulast%3DDeRemer%26aufirst%3DC.%2BE.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DGums%26aufirst%3DJ.%2BG.%26atitle%3DBetrixaban%253A%2520A%2520New%2520Oral%2520Factor%2520Xa%2520Inhibitor%2520for%2520Extended%2520Venous%2520Thromboembolism%2520Prophylaxis%2520in%2520High-Risk%2520Hospitalized%2520Patients%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2018%26volume%3D52%26spage%3D554%26epage%3D561%26doi%3D10.1177%2F1060028018754383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Al Yami, M.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfayez, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsheikh, R.</span></span> <span> </span><span class="NLM_article-title">Direct Oral Anticoagulants for Extended-Duration Thromboprophylaxis in Hospitalized Medically Ill Patients: Are We There Yet?</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1007/s11239-017-1481-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs11239-017-1481-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28197755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVaqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=1-8&author=M.%0AS.+Al+Yamiauthor=O.+M.+Alfayezauthor=S.+M.+Kurdiauthor=R.+Alsheikh&title=Direct+Oral+Anticoagulants+for+Extended-Duration+Thromboprophylaxis+in+Hospitalized+Medically+Ill+Patients%3A+Are+We+There+Yet%3F&doi=10.1007%2Fs11239-017-1481-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69aR"><div class="casContent"><span class="casTitleNuber">69a</span><div class="casTitle"><span class="NLM_cas:atitle">Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?</span></div><div class="casAuthors">Al Yami, Majed S.; Alfayez, Osamah M.; Kurdi, Sawsan M.; Alsheikh, Razan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Despite a recommended 7-10 days of thromboprophylaxis, medically ill patients remain at increased risk of developing venous thromboembolism (VTE) after hospital discharge.  Here, we present a contemporary review on the efficacy and safety of extended-duration thromboprophylaxis with direct oral anticoagulants (DOACs) in hospitalized medically ill patients.  A search of publication and trial databases of controlled trials conducted from 2010 to 2016 using the key terms apixaban, rivaroxaban, and betrixaban showed three phase III trials that met our search criteria.  In the "ADOPT" trial, apixaban was not inferior to enoxaparin in preventing VTE events (relative risk [RR] of 0.87; 95% confidence interval [CI] 0.62-1.23; P = 0.44); however, major bleeding rate was significantly higher with apixaban (RR of 2.58; 95% CI 1.02-7.24; P = 0.04).  In the "MAGELLAN" trial, rivaroxaban was superior to enoxaparin in preventing VTE events (RR of 0.77; 95% CI 0.62-0.96; P = 0.02) but with higher clin. relevant bleeding rate (RR of 2.5; 95% CI 1.85-3.25; P < 0.001).  Finally, in the "APEX" trial, there were no differences between betrixaban and enoxaparin in preventing VTE events in patients with elevated D-dimer levels (RR of 0.81; 95% CI 0.65-1.00; P = 0.054) and no differences in major bleeding events in all patients (RR of 1.19; 95% CI 0.67-2.12; P = 0.55).  Compared with std.-duration thromboprophylaxis with enoxaparin, extended-duration thromboprophylaxis with DOACs in medically ill patients may provide an incremental benefit, although at the cost of increased bleeding events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplnxXCRi-BvrVg90H21EOLACvtfcHk0lhmH9OIkN5dqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVaqt74%253D&md5=a9e5e2906d598d17da002eb79f390844</span></div><a href="/servlet/linkout?suffix=cit69a&amp;dbid=16384&amp;doi=10.1007%2Fs11239-017-1481-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-017-1481-5%26sid%3Dliteratum%253Aachs%26aulast%3DAl%2BYami%26aufirst%3DM.%2BS.%26aulast%3DAlfayez%26aufirst%3DO.%2BM.%26aulast%3DKurdi%26aufirst%3DS.%2BM.%26aulast%3DAlsheikh%26aufirst%3DR.%26atitle%3DDirect%2520Oral%2520Anticoagulants%2520for%2520Extended-Duration%2520Thromboprophylaxis%2520in%2520Hospitalized%2520Medically%2520Ill%2520Patients%253A%2520Are%2520We%2520There%2520Yet%253F%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2017%26volume%3D44%26spage%3D1%26epage%3D8%26doi%3D10.1007%2Fs11239-017-1481-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit69b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douketis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz, J. I.</span></span> <span> </span><span class="NLM_article-title">Reversal Agents for Non-Vitamin K Antagonist Oral Anticoagulants</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2017.223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1038%2Fnrcardio.2017.223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29345686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=273-281&author=J.+H.+Levyauthor=J.+Douketisauthor=J.+I.+Weitz&title=Reversal+Agents+for+Non-Vitamin+K+Antagonist+Oral+Anticoagulants&doi=10.1038%2Fnrcardio.2017.223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69bR"><div class="casContent"><span class="casTitleNuber">69b</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal agents for non-vitamin K antagonist oral anticoagulants</span></div><div class="casAuthors">Levy, Jerrold H.; Douketis, James; Weitz, Jeffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">273-281</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit coagulation factor Xa.  Although clin. studies of NOACs were conducted without antidotes, patient outcomes with major bleeding when receiving NOACs were no worse than those in patients treated with a vitamin K antagonist.  Nonetheless, in patients with life-threatening bleeding or requiring urgent surgery, the capacity for rapid NOAC reversal is likely to increase patient safety.  Three NOAC reversal agents are in various stages of development: idarucizumab, a specific reversal agent for dabigatran; andexanet alfa, which reverses factor Xa inhibitors; and ciraparantag, which is purported to reverse all NOACs.  Idarucizumab is licensed in many countries, andexanet is under consideration by regulatory agencies, and ciraparantag is undergoing phase III evaluation.  In the absence of licensed reversal agents for the oral factor Xa inhibitors, prothrombin complex concs. are often used in patients taking these agents who present with life-threatening bleeding.  In this Review, we summarize the approved indications for the NOACs, outline how to measure their anticoagulant effects, describe the mechanism of action of the reversal strategies, assess the preclin. and clin. data supporting their use, provide guidance on potential indications for reversal, and offer a management approach for patients treated with NOACs who present with serious bleeding or require urgent surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQAKzCSQxfbVg90H21EOLACvtfcHk0lhmH9OIkN5dqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOju7g%253D&md5=9c75288fd177791f560d471f1014b84e</span></div><a href="/servlet/linkout?suffix=cit69b&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2017.223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2017.223%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DJ.%2BH.%26aulast%3DDouketis%26aufirst%3DJ.%26aulast%3DWeitz%26aufirst%3DJ.%2BI.%26atitle%3DReversal%2520Agents%2520for%2520Non-Vitamin%2520K%2520Antagonist%2520Oral%2520Anticoagulants%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2018%26volume%3D15%26spage%3D273%26epage%3D281%26doi%3D10.1038%2Fnrcardio.2017.223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probst, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolfrey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arfsten, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clizbe, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchaleelaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambing, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarborough, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Betrixaban (Prt054021), N-(5-Chloropyridin-2-Yl)-2-(4-(N,N-Dimethylcarbamimidoyl)Benzamido)-5-Methoxybenzamide, a Highly Potent, Selective, and Orally Efficacious Factor Xa Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2179</span>– <span class="NLM_lpage">2185</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.02.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmcl.2009.02.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=19297154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2179-2185&author=P.+Zhangauthor=W.+Huangauthor=L.+Wangauthor=L.+Baoauthor=Z.+J.+Jiaauthor=S.+M.+Bauerauthor=E.+A.+Goldmanauthor=G.+D.+Probstauthor=Y.+Songauthor=T.+Suauthor=J.+Fanauthor=Y.+Wuauthor=W.+Liauthor=J.+Woolfreyauthor=U.+Sinhaauthor=P.+W.+Wongauthor=S.+T.+Edwardsauthor=A.+E.+Arfstenauthor=L.+A.+Clizbeauthor=J.+Kanterauthor=A.+Pandeyauthor=G.+Parkauthor=A.+Hutchaleelahaauthor=J.+L.+Lambingauthor=S.+J.+Hollenbachauthor=R.+M.+Scarboroughauthor=B.-Y.+Zhu&title=Discovery+of+Betrixaban+%28Prt054021%29%2C+N-%285-Chloropyridin-2-Yl%29-2-%284-%28N%2CN-Dimethylcarbamimidoyl%29Benzamido%29-5-Methoxybenzamide%2C+a+Highly+Potent%2C+Selective%2C+and+Orally+Efficacious+Factor+Xa+Inhibitor&doi=10.1016%2Fj.bmcl.2009.02.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor</span></div><div class="casAuthors">Zhang, Penglie; Huang, Wenrong; Wang, Lingyan; Bao, Liang; Jia, Zhaozhong J.; Bauer, Shawn M.; Goldman, Erick A.; Probst, Gary D.; Song, Yonghong; Su, Ting; Fan, Jingmei; Wu, Yanhong; Li, Wenhao; Woolfrey, John; Sinha, Uma; Wong, Paul W.; Edwards, Susan T.; Arfsten, Ann E.; Clizbe, Lane A.; Kanter, James; Pandey, Anjali; Park, Gary; Hutchaleelaha, Athiwat; Lambing, Joseph L.; Hollenbach, Stanley J.; Scarborough, Robert M.; Zhu, Bing-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2179-2185</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Systematic SAR studies of in vitro factor Xa inhibitory activity around N-[(5-chloropyridin-2-yl)-2-(4-N,N-dimethylcarbamimidoyl)benzamido]benzamide were performed by modifying each of the three Ph rings.  A class of highly potent, selective, efficacious and orally bioavailable direct factor Xa inhibitors was discovered.  These compds. were screened in hERG binding assays to examine the effects of substitution groups on the hERG channel affinity.  From the leading compds., betrixaban (PRT054021) has been selected as the clin. candidate for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpd-1pBQ8QvLVg90H21EOLACvtfcHk0lhmH9OIkN5dqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjtr8%253D&md5=15697f13d2e0ab670db0a49135e3f6a1</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.02.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.02.111%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DJia%26aufirst%3DZ.%2BJ.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DGoldman%26aufirst%3DE.%2BA.%26aulast%3DProbst%26aufirst%3DG.%2BD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DT.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWoolfrey%26aufirst%3DJ.%26aulast%3DSinha%26aufirst%3DU.%26aulast%3DWong%26aufirst%3DP.%2BW.%26aulast%3DEdwards%26aufirst%3DS.%2BT.%26aulast%3DArfsten%26aufirst%3DA.%2BE.%26aulast%3DClizbe%26aufirst%3DL.%2BA.%26aulast%3DKanter%26aufirst%3DJ.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DHutchaleelaha%26aufirst%3DA.%26aulast%3DLambing%26aufirst%3DJ.%2BL.%26aulast%3DHollenbach%26aufirst%3DS.%2BJ.%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DDiscovery%2520of%2520Betrixaban%2520%2528Prt054021%2529%252C%2520N-%25285-Chloropyridin-2-Yl%2529-2-%25284-%2528N%252CN-Dimethylcarbamimidoyl%2529Benzamido%2529-5-Methoxybenzamide%252C%2520a%2520Highly%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520Factor%2520Xa%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2179%26epage%3D2185%26doi%3D10.1016%2Fj.bmcl.2009.02.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scarborough, R. M.</span>; <span class="NLM_string-name">Kanter, J. P.</span>; <span class="NLM_string-name">Sujino, K.</span>; <span class="NLM_string-name">Zuberi, S. S.</span></span> <span> </span><span class="NLM_article-title">Methods for Preparing Pharmaceutical Salts of a Factor Xa Inhibitor</span>. <span class="NLM_patent">WO 2008057972A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+M.+Scarborough&author=J.+P.+Kanter&author=K.+Sujino&author=S.+S.+Zuberi&title=Methods+for+Preparing+Pharmaceutical+Salts+of+a+Factor+Xa+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DMethods%2520for%2520Preparing%2520Pharmaceutical%2520Salts%2520of%2520a%2520Factor%2520Xa%2520Inhibitor%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span>; <span class="NLM_string-name">Leitao, E. P. T.</span>; <span class="NLM_string-name">Rato, J.</span>; <span class="NLM_string-name">Song, Z.
J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Betrixaban and Maleate Salt as Factor Xa Inhibitors</span>. <span class="NLM_patent">WO 2011084519A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Pandey&author=E.+P.+T.+Leitao&author=J.+Rato&author=Z.%0AJ.+Song&title=Process+for+Preparation+of+Betrixaban+and+Maleate+Salt+as+Factor+Xa+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Betrixaban%2520and%2520Maleate%2520Salt%2520as%2520Factor%2520Xa%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Ertugliflozin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0878-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0878-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29476348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=513-519&author=A.+Markham&title=Ertugliflozin%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0878-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Ertugliflozin: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">513-519</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ertugliflozin (Steglatro) is an orally active sodium glucose co-transporter type 2 inhibitor being developed by Merck and Pfizer as a treatment for type 2 diabetes mellitus (T2DM).  Ertugliflozin as monotherapy and in combination with various other antidiabetic drugs was assocd. with improvements in glycemic control and secondary outcome measures in the VERTIS phase III clin. trial program.  Ertugliflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet) and ertugliflozin and sitagliptin (Steglujan) have recently been approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.  These products have also received a pos. opinion from the EU Committee for Medicinal Products for Human Use (CHMP).  This article summarizes the milestones in the development of ertugliflozin leading to its first approval for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsUU0pdo7517Vg90H21EOLACvtfcHk0lglFM7twpucPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKns7g%253D&md5=f23e3b58816b270fcb9b473e35993f6f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0878-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0878-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DErtugliflozin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D513%26epage%3D519%26doi%3D10.1007%2Fs40265-018-0878-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span> <span> </span><span class="NLM_article-title">Sodium Glucose Co-Transporter-2 (Sglt2) Inhibitors: A Review of Their Basic and Clinical Pharmacology</span>. <i>Diabetes Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1007/s13300-014-0089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs13300-014-0089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=25424969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCgt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=355-366&author=S.+Kalra&title=Sodium+Glucose+Co-Transporter-2+%28Sglt2%29+Inhibitors%3A+A+Review+of+Their+Basic+and+Clinical+Pharmacology&doi=10.1007%2Fs13300-014-0089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology</span></div><div class="casAuthors">Kalra, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">DTIHAP</span>;
        ISSN:<span class="NLM_cas:issn">1869-6961</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">A review.  Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action.  This review describes the biochem. and physiol. underlying the use of SGLT2 inhibitors, and their clin. pharmacol., including mechanism of action and posol.  The pragmatic placement of these mols. in the existing OAD arena is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbe5yB6I3cm7Vg90H21EOLACvtfcHk0lglFM7twpucPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCgt7jI&md5=e3aa0a1431f783accef94b17fd8108e8</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1007%2Fs13300-014-0089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13300-014-0089-4%26sid%3Dliteratum%253Aachs%26aulast%3DKalra%26aufirst%3DS.%26atitle%3DSodium%2520Glucose%2520Co-Transporter-2%2520%2528Sglt2%2529%2520Inhibitors%253A%2520A%2520Review%2520of%2520Their%2520Basic%2520and%2520Clinical%2520Pharmacology%26jtitle%3DDiabetes%2520Ther.%26date%3D2014%26volume%3D5%26spage%3D355%26epage%3D366%26doi%3D10.1007%2Fs13300-014-0089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aguillón, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segretti, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Azevedo, H. F. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimaraes, C. R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, L. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Souza, R. O. M. A.</span></span> <span> </span><span class="NLM_article-title">Synthetic Strategies toward Sglt2 Inhibitors</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1artLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=467-488&author=A.+R.+Aguill%C3%B3nauthor=A.+Mascarelloauthor=N.+D.+Segrettiauthor=H.+F.+Z.+de+Azevedoauthor=C.+R.+W.+Guimaraesauthor=L.+S.+M.+Mirandaauthor=R.+O.+M.+A.+de%0ASouza&title=Synthetic+Strategies+toward+Sglt2+Inhibitors&doi=10.1021%2Facs.oprd.8b00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Strategies toward SGLT2 Inhibitors</span></div><div class="casAuthors">Aguillon, Anderson R.; Mascarello, Alessandra; Segretti, Natanael D.; de Azevedo, Hatylas F. Z.; Guimaraes, Cristiano R. W.; Miranda, Leandro S. M.; de Souza, Rodrigo O. M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-488</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with refs.  Gliflozins are an important class of prescription drugs used to treat type II diabetes.  They reduce blood sugar levels by targeting the sodium-glucose transport protein 2 (SGLT2) and consequently inhibit glucose reabsorption in the kidney.  There are currently several FDA-approved gliflozins as well as others in the pipeline to be launched in the next few years.  This review describes the synthetic strategies used for manufg. SGLT2 inhibitors on both bench and industrial scales.  Moreover, the drawbacks to the strategies and the improvements made to obtain selected gliflozins and their glucose derivs. over the years are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpfFZiYkkQlbVg90H21EOLACvtfcHk0lglFM7twpucPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1artLY%253D&md5=0294cd48b1ee220fbde82a0b4abce3ea</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00017%26sid%3Dliteratum%253Aachs%26aulast%3DAguill%25C3%25B3n%26aufirst%3DA.%2BR.%26aulast%3DMascarello%26aufirst%3DA.%26aulast%3DSegretti%26aufirst%3DN.%2BD.%26aulast%3Dde%2BAzevedo%26aufirst%3DH.%2BF.%2BZ.%26aulast%3DGuimaraes%26aufirst%3DC.%2BR.%2BW.%26aulast%3DMiranda%26aufirst%3DL.%2BS.%2BM.%26aulast%3Dde%2BSouza%26aufirst%3DR.%2BO.%2BM.%2BA.%26atitle%3DSynthetic%2520Strategies%2520toward%2520Sglt2%2520Inhibitors%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26spage%3D467%26epage%3D488%26doi%3D10.1021%2Facs.oprd.8b00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boustany-Kari, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klenotic, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leininger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaiyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobol, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuma, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugnait, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Clinical Candidate from the Structurally Unique Dioxa-Bicyclo[3.2.1]Octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2952</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1021/jm200049r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200049r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVCntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2952-60&author=V.+Mascittiauthor=T.+S.+Maurerauthor=R.+P.+Robinsonauthor=J.+Bianauthor=C.+M.+Boustany-Kariauthor=T.+Brandtauthor=B.+M.+Collmanauthor=A.+S.+Kalgutkarauthor=M.+K.+Klenoticauthor=M.+T.+Leiningerauthor=A.+Loweauthor=R.+J.+Maguireauthor=V.+M.+Mastersonauthor=Z.+Miaoauthor=E.+Mukaiyamaauthor=J.+D.+Patelauthor=J.+C.+Pettersenauthor=C.+Previlleauthor=B.+Samasauthor=L.+Sheauthor=Z.+Sobolauthor=C.+M.+Steppanauthor=B.+D.+Stevensauthor=B.+A.+Thumaauthor=M.+Tugnaitauthor=D.+Zengauthor=T.+Zhu&title=Discovery+of+a+Clinical+Candidate+from+the+Structurally+Unique+Dioxa-Bicyclo%5B3.2.1%5DOctane+Class+of+Sodium-Dependent+Glucose+Cotransporter+2+Inhibitors&doi=10.1021%2Fjm200049r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors</span></div><div class="casAuthors">Mascitti, Vincent; Maurer, Tristan S.; Robinson, Ralph P.; Bian, Jianwei; Boustany-Kari, Carine M.; Brandt, Thomas; Collman, Benjamin M.; Kalgutkar, Amit S.; Klenotic, Michelle K.; Leininger, Michael T.; Lowe, Andre; Maguire, Robert J.; Masterson, Victoria M.; Miao, Zhuang; Mukaiyama, Emi; Patel, Jigna D.; Pettersen, John C.; Preville, Cathy; Samas, Brian; She, Li; Sobol, Zhanna; Steppan, Claire M.; Stevens, Benjamin D.; Thuma, Benjamin A.; Tugnait, Meera; Zeng, Dongxiang; Zhu, Tong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2952-2960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-04971729 (I) belongs to a new class of potent and selective sodium-dependent glucose cotransporter 2 inhibitors incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system.  In this paper we present the design, synthesis, preclin. evaluation, and human dose predictions related to I.  This compd. demonstrated robust urinary glucose excretion in rats and an excellent preclin. safety profile.  It is currently in phase 2 clin. trials and is being evaluated for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoytwz0hHDVmrVg90H21EOLACvtfcHk0lipjyPa3psIBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVCntrY%253D&md5=80e156d19d3a6a87a61dca59cc1a0e99</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm200049r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200049r%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DBoustany-Kari%26aufirst%3DC.%2BM.%26aulast%3DBrandt%26aufirst%3DT.%26aulast%3DCollman%26aufirst%3DB.%2BM.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DKlenotic%26aufirst%3DM.%2BK.%26aulast%3DLeininger%26aufirst%3DM.%2BT.%26aulast%3DLowe%26aufirst%3DA.%26aulast%3DMaguire%26aufirst%3DR.%2BJ.%26aulast%3DMasterson%26aufirst%3DV.%2BM.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DMukaiyama%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DPettersen%26aufirst%3DJ.%2BC.%26aulast%3DPreville%26aufirst%3DC.%26aulast%3DSamas%26aufirst%3DB.%26aulast%3DShe%26aufirst%3DL.%26aulast%3DSobol%26aufirst%3DZ.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DThuma%26aufirst%3DB.%2BA.%26aulast%3DTugnait%26aufirst%3DM.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520Clinical%2520Candidate%2520from%2520the%2520Structurally%2520Unique%2520Dioxa-Bicyclo%255B3.2.1%255DOctane%2520Class%2520of%2520Sodium-Dependent%2520Glucose%2520Cotransporter%25202%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2952%26epage%3D60%26doi%3D10.1021%2Fjm200049r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span>; <span class="NLM_string-name">Collman, B. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol Derivatives as Antidiabetic Agents</span>. <span class="NLM_patent">WO 2010023594A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=V.+Mascitti&author=B.+M.+Collman&title=Preparation+of+Dioxa-bicyclo%5B3.2.1.%5Doctane-2%2C3%2C4-triol+Derivatives+as+Antidiabetic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26atitle%3DPreparation%2520of%2520Dioxa-bicyclo%255B3.2.1.%255Doctane-2%252C3%252C4-triol%2520Derivatives%2520as%2520Antidiabetic%2520Agents%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit77b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preville, C.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Synthesis of a Dioxa-Bicyclo[3.2.1]Octane Sglt2 Inhibitor</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2940</span>– <span class="NLM_lpage">2943</span>, <span class="refDoi"> DOI: 10.1021/ol100940w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol100940w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFyktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=2940-2943&author=V.+Mascittiauthor=C.+Preville&title=Stereoselective+Synthesis+of+a+Dioxa-Bicyclo%5B3.2.1%5DOctane+Sglt2+Inhibitor&doi=10.1021%2Fol100940w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77bR"><div class="casContent"><span class="casTitleNuber">77b</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective synthesis of a dioxa-bicyclo[3.2.1]octane SGLT2 inhibitor</span></div><div class="casAuthors">Mascitti, Vincent; Preville, Cathy</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2940-2943</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A promising class of SGLT2 inhibitors bearing a unique dioxa-bicyclo[3.2.1]octane motif I was recently disclosed.  An improved stereoselective synthesis providing efficient access to one of the most potent and selective compds. from this class is reported.  A one-pot deprotection/cyclization was used as the key step to form the dioxa-bicyclo[3.2.1]octane motif with full control of stereochem.  Using an appropriately substituted aryl group, the route enables the synthesis of any given compd. from the class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobDJBvQKnThrVg90H21EOLACvtfcHk0lipjyPa3psIBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFyktr0%253D&md5=e8106f180e5a652cd8a6d40c9a200419</span></div><a href="/servlet/linkout?suffix=cit77b&amp;dbid=16384&amp;doi=10.1021%2Fol100940w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol100940w%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DPreville%26aufirst%3DC.%26atitle%3DStereoselective%2520Synthesis%2520of%2520a%2520Dioxa-Bicyclo%255B3.2.1%255DOctane%2520Sglt2%2520Inhibitor%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D2940%26epage%3D2943%26doi%3D10.1021%2Fol100940w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit77c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulford, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagal, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Pierre, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuma, B.</span></span> <span> </span><span class="NLM_article-title">Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/op400289z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op400289z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=57-65&author=D.+Bernhardsonauthor=T.+A.+Brandtauthor=C.+A.+Hulfordauthor=R.+S.+Lehnerauthor=B.+R.+Prestonauthor=K.+Priceauthor=J.+F.+Sagalauthor=M.+J.+St.+Pierreauthor=P.+H.+Thompsonauthor=B.+Thuma&title=Development+of+an+Early-Phase+Bulk+Enabling+Route+to+Sodium-Dependent+Glucose+Cotransporter+2+Inhibitor+Ertugliflozin&doi=10.1021%2Fop400289z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77cR"><div class="casContent"><span class="casTitleNuber">77c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin</span></div><div class="casAuthors">Bernhardson, David; Brandt, Thomas A.; Hulford, Catherine A.; Lehner, Richard S.; Preston, Brian R.; Price, Kristin; Sagal, John F.; St. Pierre, Michael J.; Thompson, Peter H.; Thuma, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-65</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development and optimization of a scalable synthesis of sodium-dependent glucose cotransporter 2 inhibitor, ertugliflozin (I) , for the treatment of type-2 diabetes is described.  Highlights of the chem. are a concise, four-step synthesis of a structurally complex API from known intermediate II via persilylation-selective monodesilylation, primary alc. oxidn., aldol-crossed-Cannizzaro reaction, and solid-phase acid-catalyzed bicyclic ketal formation.  The final API was isolated as the L-pyroglutamic acid cocrystal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlgOpR9wfoBLVg90H21EOLACvtfcHk0lhKUAroedUpTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKjsg%253D%253D&md5=dfef0a029f4cd46ddd0c8179786a2042</span></div><a href="/servlet/linkout?suffix=cit77c&amp;dbid=16384&amp;doi=10.1021%2Fop400289z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop400289z%26sid%3Dliteratum%253Aachs%26aulast%3DBernhardson%26aufirst%3DD.%26aulast%3DBrandt%26aufirst%3DT.%2BA.%26aulast%3DHulford%26aufirst%3DC.%2BA.%26aulast%3DLehner%26aufirst%3DR.%2BS.%26aulast%3DPreston%26aufirst%3DB.%2BR.%26aulast%3DPrice%26aufirst%3DK.%26aulast%3DSagal%26aufirst%3DJ.%2BF.%26aulast%3DSt.%2BPierre%26aufirst%3DM.%2BJ.%26aulast%3DThompson%26aufirst%3DP.%2BH.%26aulast%3DThuma%26aufirst%3DB.%26atitle%3DDevelopment%2520of%2520an%2520Early-Phase%2520Bulk%2520Enabling%2520Route%2520to%2520Sodium-Dependent%2520Glucose%2520Cotransporter%25202%2520Inhibitor%2520Ertugliflozin%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D57%26epage%3D65%26doi%3D10.1021%2Fop400289z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenek, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljubicic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makowski, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustakis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Place, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salisbury, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanchina, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderplas, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weekly, R. M.</span></span> <span> </span><span class="NLM_article-title">Commercial Route Research and Development for Sglt2 Inhibitor Candidate Ertugliflozin</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1021/op4002802</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op4002802" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOnsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=66-81&author=P.+Bowlesauthor=S.+J.+Brenekauthor=S.+Caronauthor=N.+M.+Doauthor=M.+T.+Drexlerauthor=S.+Duanauthor=P.+Dub%C3%A9author=E.+C.+Hansenauthor=B.+P.+Jonesauthor=K.+N.+Jonesauthor=T.+A.+Ljubicicauthor=T.+W.+Makowskiauthor=J.+Mustakisauthor=J.+D.+Nelsonauthor=M.+Olivierauthor=Z.+Pengauthor=H.+H.+Perfectauthor=D.+W.+Placeauthor=J.+A.+Raganauthor=J.+J.+Salisburyauthor=C.+L.+Stanchinaauthor=B.+C.+Vanderplasauthor=M.+E.+Websterauthor=R.+M.+Weekly&title=Commercial+Route+Research+and+Development+for+Sglt2+Inhibitor+Candidate+Ertugliflozin&doi=10.1021%2Fop4002802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin</span></div><div class="casAuthors">Bowles, Paul; Brenek, Steven J.; Caron, Stephane; Do, Nga M.; Drexler, Michele T.; Duan, Shengquan; Dube, Pascal; Hansen, Eric C.; Jones, Brian P.; Jones, Kris N.; Ljubicic, Tomislav A.; Makowski, Teresa W.; Mustakis, Jason; Nelson, Jade D.; Olivier, Mark; Peng, Zhihui; Perfect, Hahdi H.; Place, David W.; Ragan, John A.; Salisbury, John J.; Stanchina, Corey L.; Vanderplas, Brian C.; Webster, Mark E.; Weekly, R. Matt</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-81</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical synthesis of SGLT2 inhibitor candidate ertugliflozin (1) has been developed for potential com. application.  The highly telescoped process involves only three intermediate isolations over a 12-step sequence.  The dioxa-bicyclo[3.2.1]-octane motif is prepd. from com. available 2,3,4,6-tetra-O-benzyl-D-glucose, with nucleophilic hydroxymethylation of a 5-ketogluconamide intermediate as a key step.  The aglycon moiety is introduced via aryl anion addn. to a methylpiperazine amide.  High chem. purity of the API is assured through isolation of the cryst. penultimate intermediate, tetraacetate 39.  A co-cryst. complex of the amorphous solid 1 with L-pyroglutamic acid has been prepd. in order to improve the phys. properties for manuf. and to ensure robust API quality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP6NFo2yUVILVg90H21EOLACvtfcHk0lhKUAroedUpTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOnsbbO&md5=bfbd79c5a79fd39dc6ad8f8081a56700</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fop4002802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop4002802%26sid%3Dliteratum%253Aachs%26aulast%3DBowles%26aufirst%3DP.%26aulast%3DBrenek%26aufirst%3DS.%2BJ.%26aulast%3DCaron%26aufirst%3DS.%26aulast%3DDo%26aufirst%3DN.%2BM.%26aulast%3DDrexler%26aufirst%3DM.%2BT.%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DDub%25C3%25A9%26aufirst%3DP.%26aulast%3DHansen%26aufirst%3DE.%2BC.%26aulast%3DJones%26aufirst%3DB.%2BP.%26aulast%3DJones%26aufirst%3DK.%2BN.%26aulast%3DLjubicic%26aufirst%3DT.%2BA.%26aulast%3DMakowski%26aufirst%3DT.%2BW.%26aulast%3DMustakis%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DJ.%2BD.%26aulast%3DOlivier%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DPerfect%26aufirst%3DH.%2BH.%26aulast%3DPlace%26aufirst%3DD.%2BW.%26aulast%3DRagan%26aufirst%3DJ.%2BA.%26aulast%3DSalisbury%26aufirst%3DJ.%2BJ.%26aulast%3DStanchina%26aufirst%3DC.%2BL.%26aulast%3DVanderplas%26aufirst%3DB.%2BC.%26aulast%3DWebster%26aufirst%3DM.%2BE.%26aulast%3DWeekly%26aufirst%3DR.%2BM.%26atitle%3DCommercial%2520Route%2520Research%2520and%2520Development%2520for%2520Sglt2%2520Inhibitor%2520Candidate%2520Ertugliflozin%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D66%26epage%3D81%26doi%3D10.1021%2Fop4002802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Pemafibrate: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1805</span>– <span class="NLM_lpage">1810</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0818-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0818-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28929345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFant7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1805-1810&author=H.+A.+Blair&title=Pemafibrate%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0818-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Pemafibrate: First Global Approval</span></div><div class="casAuthors">Blair, Hannah A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1805-1810</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Pemafibrate (Parmodia) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-α modulator (SPPARM).  It acts by binding to PPAR-α and regulating the expression of target genes that modulate lipid metab., thereby decreasing plasma triglyceride levels and increasing high-d. lipoprotein cholesterol levels.  Developed by Kowa Company, Ltd., oral pemafibrate has been approved in Japan for the treatment of hyperlipidemia (including familial hyperlipidemia).  This article summarizes the milestones in the development of pemafibrate leading to this first global approval for hyperlipidemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAtunrUMkTKLVg90H21EOLACvtfcHk0lhKUAroedUpTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFant7nL&md5=669b83e04a86005c951f2342451b696c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0818-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0818-x%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DPemafibrate%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1805%26epage%3D1810%26doi%3D10.1007%2Fs40265-017-0818-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokote, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suganami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of K-877, a Novel Selective Peroxisome Proliferator-Activated Receptor A Modulator (Spparmα), in Combination with Statin Treatment: Two Randomised, Double-Blind, Placebo-Controlled Clinical Trials in Patients with Dyslipidaemia</span>. <i>Atherosclerosis (Amsterdam, Neth.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.atherosclerosis.2017.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.atherosclerosis.2017.03.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFyrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=2017&pages=144-152&author=H.+Araiauthor=S.+Yamashitaauthor=K.+Yokoteauthor=E.+Arakiauthor=H.+Suganamiauthor=S.+Ishibashi&title=Efficacy+and+Safety+of+K-877%2C+a+Novel+Selective+Peroxisome+Proliferator-Activated+Receptor+A+Modulator+%28Spparm%CE%B1%29%2C+in+Combination+with+Statin+Treatment%3A+Two+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Clinical+Trials+in+Patients+with+Dyslipidaemia&doi=10.1016%2Fj.atherosclerosis.2017.03.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80aR"><div class="casContent"><span class="casTitleNuber">80a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia</span></div><div class="casAuthors">Arai, Hidenori; Yamashita, Shizuya; Yokote, Koutaro; Araki, Eiichi; Suganami, Hideki; Ishibashi, Shun</div><div class="citationInfo"><span class="NLM_cas:title">Atherosclerosis (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144-152</span>CODEN:
                <span class="NLM_cas:coden">ATHSBL</span>;
        ISSN:<span class="NLM_cas:issn">0021-9150</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Substantial residual cardiovascular risks remain despite intensive statin treatment.  Residual risks with high triglyceride and low high-d. lipoprotein cholesterol are not the primary targets of statins.  K-877 (pemafibrate) demonstrated robust efficacy on triglycerides and high-d. lipoprotein cholesterol and a good safety profile as a monotherapy.  The aim of these studies was to evaluate the efficacy and safety of K-877 add-on therapy to treat residual hypertriglyceridemia during statin treatment.  The objectives were investigated in two, multicentre, randomised, double-blind, placebo-controlled, parallel group comparison clin. trials: (A) K-877 0.1, 0.2, and 0.4 mg/day in combination with pitavastatin for 12 wk in 188 patients, (B) K-877 0.2 (fixed dose) and 0.2 (0.4) (conditional up-titrn.) mg/day in combination with any statin for 24 wk in 423 patients.  In both studies, we found a robust redn. in fasting triglyceride levels by approx. 50% in all combination therapy groups, which was significant compared to the statin-monotherapy (placebo) groups (p < 0.001).  High-performance liq. chromatog. anal. for lipoprotein subfractions revealed that atherogenic lipoprotein profiles were ameliorated by K-877 add-on therapy, i.e. small low-d. lipoproteins decreased whereas larger ones increased, and larger high-d. lipoproteins decreased whereas smaller ones increased.  The incidence rates of adverse events and adverse drug reactions in K-877 combination therapy groups were comparable to those in statin-monotherapy groups without any noteworthy event in both studies.  These results strongly support the favorable benefit-to-risk ratio of K-877 add-on therapy in combination with statin treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBX7qpzm9YrVg90H21EOLACvtfcHk0lgzEfDBIlZxeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFyrsr8%253D&md5=aaf3769f631e549dbc6225b130d2dd0e</span></div><a href="/servlet/linkout?suffix=cit80a&amp;dbid=16384&amp;doi=10.1016%2Fj.atherosclerosis.2017.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.atherosclerosis.2017.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DS.%26aulast%3DYokote%26aufirst%3DK.%26aulast%3DAraki%26aufirst%3DE.%26aulast%3DSuganami%26aufirst%3DH.%26aulast%3DIshibashi%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520K-877%252C%2520a%2520Novel%2520Selective%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520A%2520Modulator%2520%2528Spparm%25CE%25B1%2529%252C%2520in%2520Combination%2520with%2520Statin%2520Treatment%253A%2520Two%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Clinical%2520Trials%2520in%2520Patients%2520with%2520Dyslipidaemia%26jtitle%3DAtherosclerosis%2520%2528Amsterdam%252C%2520Neth.%2529%26date%3D2017%26volume%3D261%26spage%3D144%26epage%3D152%26doi%3D10.1016%2Fj.atherosclerosis.2017.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit80b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruchart, J.-C.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Highly Potent and Selective Human Peroxisome Proliferator-Activated Receptor A Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4689</span>– <span class="NLM_lpage">4693</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmcl.2007.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=17553678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFSiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4689-4693&author=Y.+Yamazakiauthor=K.+Abeauthor=T.+Tomaauthor=M.+Nishikawaauthor=H.+Ozawaauthor=A.+Okudaauthor=T.+Arakiauthor=S.+Odaauthor=K.+Inoueauthor=K.+Shibuyaauthor=B.+Staelsauthor=J.-C.+Fruchart&title=Design+and+Synthesis+of+Highly+Potent+and+Selective+Human+Peroxisome+Proliferator-Activated+Receptor+A+Agonists&doi=10.1016%2Fj.bmcl.2007.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80bR"><div class="casContent"><span class="casTitleNuber">80b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists</span></div><div class="casAuthors">Yamazaki, Yukiyoshi; Abe, Kazutoyo; Toma, Tsutomu; Nishikawa, Masahiro; Ozawa, Hidefumi; Okuda, Ayumu; Araki, Takaaki; Oda, Soichi; Inoue, Keisuke; Shibuya, Kimiyuki; Staels, Bart; Fruchart, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4689-4693</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aryloxyalkanoic acids substituted with aryloxyalkyl and benzoxazole-substituted aminoalkyl groups such as I are prepd. as human peroxisome proliferator-activated receptor α (PPAR-α) agonists for decreasing lipid levels; the binding of the compds. to PPAR-α, PPAR-δ, and PPA-γ and the decreases in liver wt. and triglyceride levels in rats upon administration of the sodium salts of three of the compds. are detd.  The racemate of I is prepd. and resolved by HPLC to provide I and its enantiomer; I inhibits PPAR-α with an EC50 value of 1 nM and approx. 1000-fold selectivity over PPAR-δ and PPAR-γ, while the sodium salt of I decreases triglyceride concns. in rats by approx. 49%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowBzT-9tjHnrVg90H21EOLACvtfcHk0lilg0LwDzUlCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFSiurg%253D&md5=212568f85768742693056e8f1fdce501</span></div><a href="/servlet/linkout?suffix=cit80b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DToma%26aufirst%3DT.%26aulast%3DNishikawa%26aufirst%3DM.%26aulast%3DOzawa%26aufirst%3DH.%26aulast%3DOkuda%26aufirst%3DA.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DS.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DShibuya%26aufirst%3DK.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DFruchart%26aufirst%3DJ.-C.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Highly%2520Potent%2520and%2520Selective%2520Human%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520A%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4689%26epage%3D4693%26doi%3D10.1016%2Fj.bmcl.2007.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takei, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arulmozhiraja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sladek, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokiwa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokiwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimano, H.</span></span> <span> </span><span class="NLM_article-title">Molecular Association Model of Pparα and Its New Specific and Efficient Ligand, Pemafibrate: Structural Basis for Spparmα</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>499</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.03.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bbrc.2018.03.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29567478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=499&publication_year=2018&pages=239-245&author=Y.+Yamamotoauthor=K.+Takeiauthor=S.+Arulmozhirajaauthor=V.+Sladekauthor=N.+Matsuoauthor=S.-i.+Hanauthor=T.+Matsuzakaauthor=M.+Sekiyaauthor=T.+Tokiwaauthor=M.+Shojiauthor=Y.+Shigetaauthor=Y.+Nakagawaauthor=H.+Tokiwaauthor=H.+Shimano&title=Molecular+Association+Model+of+Ppar%CE%B1+and+Its+New+Specific+and+Efficient+Ligand%2C+Pemafibrate%3A+Structural+Basis+for+Spparm%CE%B1&doi=10.1016%2Fj.bbrc.2018.03.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα</span></div><div class="casAuthors">Yamamoto, Yuta; Takei, Kenta; Arulmozhiraja, Sundaram; Sladek, Vladimir; Matsuo, Naoya; Han, Song-iee; Matsuzaka, Takashi; Sekiya, Motohiro; Tokiwa, Takaki; Shoji, Mitsuo; Shigeta, Yasuteru; Nakagawa, Yoshimi; Tokiwa, Hiroaki; Shimano, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">499</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-245</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Peroxisome proliferator-activated receptor-α (PPARα) is a ligand-activated transcription factor involved in the regulation of lipid homeostasis and improves hypertriglyceridemia.  Pemafibrate is a novel selective PPARα modulator (SPPARMα) that activates PPARα transcriptional activity.  Here, we computationally constructed the structure of the human PPARα in a complex with pemafibrate, along with that of hPPARα complexed with the classical fenofibrate, and studied their interactions quant. by using the first-principles calcns.-based fragment MO (FMO) method.  Comprehensive structural and protein-ligand binding elucidation along with the in vitro luciferase anal. let us to identify pemafibrate as a novel SPPARMα.  Unlike known fibrate ligands, which bind only with the arm I of the Y-shaped ligand binding pocket, the Y-shaped pemafibrate binds to the entire cavity region.  This lock and key nature causes enhanced induced fit in pemafibrate-ligated PPARα.  Importantly, this selective modulator allosterically changes PPARα conformation to form a brand-new interface, which in turn binds to PPARα co-activator, PGC-1α, resulting in the full activation of PPARα.  The structural basis for the potent effects of pemafibrate on PPARα transcriptional activity predicted by the in silico FMO methods was confirmed by in vitro luciferase assay for mutants.  The unique binding mode of pemafibrate reveals a new pattern of nuclear receptor ligand recognition and suggests a novel basis for ligand design, offering cues for improving the binding affinity and selectivity of ligand for better clin. consequences.  The findings explain the high affinity and efficacy of pemafibrate, which is expected to be in the clin. use soon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLVA8CZNSKTbVg90H21EOLACvtfcHk0lilg0LwDzUlCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOhs70%253D&md5=152c9cb80a81117a41c3bee909b11723</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.03.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.03.135%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DTakei%26aufirst%3DK.%26aulast%3DArulmozhiraja%26aufirst%3DS.%26aulast%3DSladek%26aufirst%3DV.%26aulast%3DMatsuo%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.-i.%26aulast%3DMatsuzaka%26aufirst%3DT.%26aulast%3DSekiya%26aufirst%3DM.%26aulast%3DTokiwa%26aufirst%3DT.%26aulast%3DShoji%26aufirst%3DM.%26aulast%3DShigeta%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DY.%26aulast%3DTokiwa%26aufirst%3DH.%26aulast%3DShimano%26aufirst%3DH.%26atitle%3DMolecular%2520Association%2520Model%2520of%2520Ppar%25CE%25B1%2520and%2520Its%2520New%2520Specific%2520and%2520Efficient%2520Ligand%252C%2520Pemafibrate%253A%2520Structural%2520Basis%2520for%2520Spparm%25CE%25B1%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D499%26spage%3D239%26epage%3D245%26doi%3D10.1016%2Fj.bbrc.2018.03.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, K.</span></span> <span> </span><span class="NLM_article-title">A Practical Synthesis of the Pparα Agonist, (R)-K-13675, Starting from (S)-2-Hydroxybutyrolactone</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">8155</span>– <span class="NLM_lpage">8158</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2008.06.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.tet.2008.06.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslensr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=8155-8158&author=Y.+Yamazakiauthor=T.+Arakiauthor=M.+Kouraauthor=K.+Shibuya&title=A+Practical+Synthesis+of+the+Ppar%CE%B1+Agonist%2C+%28R%29-K-13675%2C+Starting+from+%28S%29-2-Hydroxybutyrolactone&doi=10.1016%2Fj.tet.2008.06.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82aR"><div class="casContent"><span class="casTitleNuber">82a</span><div class="casTitle"><span class="NLM_cas:atitle">A practical synthesis of the PPARα agonist, (R)-K-13675, starting from (S)-2-hydroxybutyrolactone</span></div><div class="casAuthors">Yamazaki, Yukiyoshi; Araki, Takaaki; Koura, Minoru; Shibuya, Kimiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8155-8158</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A practical synthesis of optically pure PPARα agonist, (R)-K-13675, is described.  This process is based on the use of (S)-2-hydroxybutyrolactone, which can be transformed into the requisite Bu (S)-2-hydroxybutanoate in an efficient manner.  A key reaction is the etherification between the phenol and Bu (S)-2-trifluoromethanesulfonyloxybutanoate to give the Ph ether in excellent yield without loss of optical purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAPbfFv1MSfLVg90H21EOLACvtfcHk0lilg0LwDzUlCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslensr8%253D&md5=38e5140d3f23247fb7280629130d0abe</span></div><a href="/servlet/linkout?suffix=cit82a&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2008.06.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2008.06.049%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DKoura%26aufirst%3DM.%26aulast%3DShibuya%26aufirst%3DK.%26atitle%3DA%2520Practical%2520Synthesis%2520of%2520the%2520Ppar%25CE%25B1%2520Agonist%252C%2520%2528R%2529-K-13675%252C%2520Starting%2520from%2520%2528S%2529-2-Hydroxybutyrolactone%26jtitle%3DTetrahedron%26date%3D2008%26volume%3D64%26spage%3D8155%26epage%3D8158%26doi%3D10.1016%2Fj.tet.2008.06.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit82b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, K.</span></span> <span> </span><span class="NLM_article-title">Enantioselective Synthesis of the Pparα Agonist (R)-K-13675 Via (S)-2-Hydroxybutyrolactone</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2008</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1032123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-2008-1032123" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2008&publication_year=2008&pages=1017-1022&author=Y.+Yamazakiauthor=T.+Arakiauthor=M.+Kouraauthor=K.+Shibuya&title=Enantioselective+Synthesis+of+the+Ppar%CE%B1+Agonist+%28R%29-K-13675+Via+%28S%29-2-Hydroxybutyrolactone&doi=10.1055%2Fs-2008-1032123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82b&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1032123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1032123%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DKoura%26aufirst%3DM.%26aulast%3DShibuya%26aufirst%3DK.%26atitle%3DEnantioselective%2520Synthesis%2520of%2520the%2520Ppar%25CE%25B1%2520Agonist%2520%2528R%2529-K-13675%2520Via%2520%2528S%2529-2-Hydroxybutyrolactone%26jtitle%3DSynthesis%26date%3D2008%26volume%3D2008%26spage%3D1017%26epage%3D1022%26doi%3D10.1055%2Fs-2008-1032123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: A Review in Rheumatoid Arthritis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0908-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0908-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29687421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosFCrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=761-772&author=Z.+T.+Al-Salamaauthor=L.+J.+Scott&title=Baricitinib%3A+A+Review+in+Rheumatoid+Arthritis&doi=10.1007%2Fs40265-018-0908-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: A Review in Rheumatoid Arthritis</span></div><div class="casAuthors">Al-Salama, Zaina T.; Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Baricitinib (Olumiant) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA).  This novel, small mol. is approved for use as monotherapy, or in combination with methotrexate, for the treatment of adults with moderate to severe active RA who responded inadequately to or were intolerant of ≥ 1 DMARD.  In pivotal multinational trials, once-daily baricitinib 4 mg, with/without methotrexate (± another csDMARD), improved the signs and symptoms of RA, disease activity and phys. function in DMARD-naive patients and in patients with an inadequate response to methotrexate, csDMARDs or TNF inhibitors; baricitinib treatment also slowed structural joint damage in DMARD-naive patients and in those with an inadequate response to methotrexate and csDMARDs.  Baricitinib plus methotrexate was more effective than adalimumab plus methotrexate in patients with an inadequate response to methotrexate.  The onset of these benefits was generally rapid and sustained over time.  Baricitinib was generally well tolerated during up to 5.5 years' treatment; the most commonly reported adverse drug reactions were upper respiratory tract infections, increased LDL cholesterol, nausea and thrombocytosis.  Thus, once-daily baricitinib, as monotherapy or in combination with methotrexate, is an effective and generally well tolerated emerging treatment for patients with moderate to severe active RA who have responded inadequately to or are intolerant of ≥ 1 DMARD, and extends the options available for this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8sBLEBbET5bVg90H21EOLACvtfcHk0lh6gxBLl5wjcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosFCrs7k%253D&md5=df956988c6927dd96c7fe5e547919dd3</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0908-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0908-4%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DBaricitinib%253A%2520A%2520Review%2520in%2520Rheumatoid%2520Arthritis%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D761%26epage%3D772%26doi%3D10.1007%2Fs40265-018-0908-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">An Efficient Synthesis of Baricitinib</span>. <i>J. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.3184/174751916X14569294811333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.3184%2F174751916X14569294811333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVers77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=205-208&author=J.+Xuauthor=J.+Caiauthor=J.+Chenauthor=X.+Zongauthor=X.+Wuauthor=M.+Jiauthor=P.+Wang&title=An+Efficient+Synthesis+of+Baricitinib&doi=10.3184%2F174751916X14569294811333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of baricitinib</span></div><div class="casAuthors">Xu, Jiaojiao; Cai, Jin; Chen, Junding; Zong, Xi; Wu, Xuan; Ji, Min; Wang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-208</span>CODEN:
                <span class="NLM_cas:coden">JCROA4</span>;
        ISSN:<span class="NLM_cas:issn">1747-5198</span>.
    
            (<span class="NLM_cas:orgname">Science Reviews 2000 Ltd.</span>)
        </div><div class="casAbstract">A highly efficient method for the synthesis of baricitinib was developed.  The starting material tert-Bu 3-oxoazetidine-1-carboxylate was converted to intermediate 2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile via the Horner-Emmons reaction, deprotection of the N-Boc-group and a final sulfonamidation reaction.  Then the nucleophilic addn. reaction was carried out smoothly to afford the borate intermediate in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene under reflux.  Finally, the desired compd. baricitinib was obtained by the Suzuki coupling reaction of 4-chloro-7-H-pyrrolo[2,3-d]pyrimidine with the above borate intermediate.  All compds. were characterised by IR, MS, 1H NMR and 13C NMR.  The overall yield in this synthetic route was as high as 49%.  Moreover, this procedure was straightforward to carry out, had low cost and was suitable for industrial prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmrkAF79V4r7Vg90H21EOLACvtfcHk0lh6gxBLl5wjcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVers77F&md5=1028a8f75d586f7c99e984d187128efb</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.3184%2F174751916X14569294811333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3184%252F174751916X14569294811333%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZong%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DAn%2520Efficient%2520Synthesis%2520of%2520Baricitinib%26jtitle%3DJ.%2520Chem.%2520Res.%26date%3D2016%26volume%3D40%26spage%3D205%26epage%3D208%26doi%3D10.3184%2F174751916X14569294811333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shajahan-Haq, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, S. M.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 Inhibitors in Breast Cancer Therapy: Current Practice and Future Opportunities</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2018.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.pharmthera.2018.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29933034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFynu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2018&pages=65-73&author=F.+Lynceauthor=A.+N.+Shajahan-Haqauthor=S.+M.+Swain&title=Cdk4%2F6+Inhibitors+in+Breast+Cancer+Therapy%3A+Current+Practice+and+Future+Opportunities&doi=10.1016%2Fj.pharmthera.2018.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities</span></div><div class="casAuthors">Lynce, Filipa; Shajahan-Haq, Ayesha N.; Swain, Sandra M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Dysregulation of the cyclin dependent kinase pathway in luminal breast cancer creates a new therapeutic opportunity for estrogen receptor pos. breast cancer.  Initial pan-CDK inhibitors were assocd. with extensive toxicities but in recent years, the development of potent specific CDK inhibitors with favorable tolerability has driven renewed interests in this class of targeted therapies.  Palbociclib, ribociclib and abemaciclib are specific CDK4/6 inhibitors that have been approved by the U.S.  Food and Drug Administration for use in combination with endocrine therapy for women with advanced hormone receptor pos. breast cancer.  These three anticancer therapeutics were approved based on progression free survival benefit seen on phase III trials with the most common grade 3 treatment-related side effects being neutropenia, fatigue, nausea and diarrhea.  Except for estrogen receptor positivity, no biomarkers predictive of response to CDK4/6 inhibitors have been identified to date.  Based on mechanistic insights here described, CDK4/6 inhibitors are currently being explored in combination with other agents, including targeted therapies, immunotherapy and chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB4puZfFByuLVg90H21EOLACvtfcHk0lh6gxBLl5wjcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFynu7vN&md5=0f2e1c7c5577569da9066af98768dfb4</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DLynce%26aufirst%3DF.%26aulast%3DShajahan-Haq%26aufirst%3DA.%2BN.%26aulast%3DSwain%26aufirst%3DS.%2BM.%26atitle%3DCdk4%252F6%2520Inhibitors%2520in%2520Breast%2520Cancer%2520Therapy%253A%2520Current%2520Practice%2520and%2520Future%2520Opportunities%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D191%26spage%3D65%26epage%3D73%26doi%3D10.1016%2Fj.pharmthera.2018.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Effect of Abemaciclib (Ly2835219) on Enhancement of Chemotherapeutic Agents in Abcb1 and Abcg2 Overexpressing Cells in Vitro and in Vivo</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bcp.2016.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27816545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslyjsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=29-42&author=T.+Wuauthor=Z.+Chenauthor=K.+K.+W.+Toauthor=X.+Fangauthor=F.+Wangauthor=B.+Chengauthor=L.+Fu&title=Effect+of+Abemaciclib+%28Ly2835219%29+on+Enhancement+of+Chemotherapeutic+Agents+in+Abcb1+and+Abcg2+Overexpressing+Cells+in+Vitro+and+in+Vivo&doi=10.1016%2Fj.bcp.2016.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo</span></div><div class="casAuthors">Wu, Tong; Chen, Zhen; To, Kenneth K. W.; Fang, Xiaona; Wang, Fang; Cheng, Bin; Fu, Liwu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-42</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is the major obstacle of the success in cancer chemotherapy.  The overexpression of ATP-binding cassette (ABC) transporters, particularly ABCB1 and ABCG2, play a significant role in mediating MDR by pumping anticancer drugs out of cancer cells.  Abemaciclib (LY2835219) is an orally bioavailable CDK4/6 inhibitor under phase III clin. trials.  Here, we found that LY2835219 remarkably enhanced the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 over-expressing cancer cells in vitro and in vivo.  Furthermore, LY2835219 significantly increased the intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells.  Mechanistically, LY2835219 is likely a competitive inhibitor of ABCB1 and ABCG2 for its competition with [125I]-iodoarylazidoprazosin for photo affinity labeling of the transporters.  On the other hand, at the transporters-inhibiting concns., LY2835219 did not alter the expression level of ABCB1 and ABCG2, and the phosphorylation status of retinoblastoma (Rb) pathway in both parental and their resistant cells.  In conclusion, these findings revealed a novel role of LY2835219 in reversing ABCB1 or ABCG2-mediated MDR, which may be benefit to the patients with MDR cancer for combinational therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvdnLDHAGV7bVg90H21EOLACvtfcHk0liKZWxyj76nsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslyjsbvL&md5=3d6bd83fe2e6ece8660278efafe75e4c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DEffect%2520of%2520Abemaciclib%2520%2528Ly2835219%2529%2520on%2520Enhancement%2520of%2520Chemotherapeutic%2520Agents%2520in%2520Abcb1%2520and%2520Abcg2%2520Overexpressing%2520Cells%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D124%26spage%3D29%26epage%3D42%26doi%3D10.1016%2Fj.bcp.2016.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sledge, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pivot, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdaeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grischke, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourayou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart-Cussac, A.</span></span> <span> </span><span class="NLM_article-title">Monarch 2: Abemaciclib in Combination with Fulvestrant in Women with Hr+/Her2– Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2884</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.73.7585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1200%2FJCO.2017.73.7585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28580882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVemtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2875-2884&author=G.+W.+Sledgeauthor=M.+Toiauthor=P.+Nevenauthor=J.+Sohnauthor=K.+Inoueauthor=X.+Pivotauthor=O.+Burdaevaauthor=M.+Okeraauthor=N.+Masudaauthor=P.+A.+Kaufmanauthor=H.+Kohauthor=E.-M.+Grischkeauthor=M.+Frenzelauthor=Y.+Linauthor=S.+Barrigaauthor=I.+C.+Smithauthor=N.+Bourayouauthor=A.+Llombart-Cussac&title=Monarch+2%3A+Abemaciclib+in+Combination+with+Fulvestrant+in+Women+with+Hr%2B%2FHer2%E2%80%93+Advanced+Breast+Cancer+Who+Had+Progressed+While+Receiving+Endocrine+Therapy&doi=10.1200%2FJCO.2017.73.7585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy</span></div><div class="casAuthors">Sledge, George W., Jr.; Toi, Masakazu; Neven, Patrick; Sohn, Joohyuk; Inoue, Kenichi; Pivot, Xavier; Burdaeva, Olga; Okera, Meena; Masuda, Norikazu; Kaufman, Peter A.; Koh, Han; Grischke, Eva-Maria; Frenzel, Martin; Lin, Yong; Barriga, Susana; Smith, Ian C.; Bourayou, Nawel; Llombart-Cussac, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2875-2884</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose MONARCH 2 compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC).  Patients and Methods MONARCH 2 was a global, double-blind, phase III study of women with hormone receptor-pos. and human epidermal growth factor receptor 2-neg. ABC who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), ≤ 12 mo from the end of adjuvant ET, or while receiving first-line ET for metastatic disease.  Patients were randomly assigned 2:1 to receive abemaciclib or placebo (150 mg twice daily) on a continuous schedule and fulvestrant (500 mg, per label).  The primary end point was investigator-assessed progression-free survival (PFS), and key secondary end points included overall survival, objective response rate (ORR), duration of response, clin. benefit rate, quality of life, and safety.  Results Between August 2014 and Dec. 2015, 669 patients were randomly assigned to receive abemaciclib plus fulvestrant (n = 446) or placebo plus fulvestrant (n = 223).  Abemaciclib plus fulvestrant significantly extended PFS vs. fulvestrant alone (median, 16.4 v 9.3 mo; hazard ratio, 0.553; 95% CI, 0.449 to 0.681; P < .001).  In patients with measurable disease, abemaciclib plus fulvestrant achieved an ORR of 48.1% (95% CI, 42.6% to 53.6%) compared with 21.3% (95% CI, 15.1% to 27.6%) in the control arm.  The most common adverse events in the abemaciclib vs. placebo arms were diarrhea (86.4% v 24.7%), neutropenia (46.0% v 4.0%), nausea (45.1% v 22.9%), and fatigue (39.9% v 26.9%).  Conclusions Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-pos. and human epidermal growth factor receptor 2-neg. ABC who progressed while receiving ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv8MbtQF40ArVg90H21EOLACvtfcHk0liKZWxyj76nsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVemtrrO&md5=fd0fc00a4402aa089a88db1420ff9beb</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.73.7585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.73.7585%26sid%3Dliteratum%253Aachs%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DNeven%26aufirst%3DP.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DPivot%26aufirst%3DX.%26aulast%3DBurdaeva%26aufirst%3DO.%26aulast%3DOkera%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DKaufman%26aufirst%3DP.%2BA.%26aulast%3DKoh%26aufirst%3DH.%26aulast%3DGrischke%26aufirst%3DE.-M.%26aulast%3DFrenzel%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DBarriga%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DI.%2BC.%26aulast%3DBourayou%26aufirst%3DN.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26atitle%3DMonarch%25202%253A%2520Abemaciclib%2520in%2520Combination%2520with%2520Fulvestrant%2520in%2520Women%2520with%2520Hr%252B%252FHer2%25E2%2580%2593%2520Advanced%2520Breast%2520Cancer%2520Who%2520Had%2520Progressed%2520While%2520Receiving%2520Endocrine%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D2875%26epage%3D2884%26doi%3D10.1200%2FJCO.2017.73.7585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paluch-Shimon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huober, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trédan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnica Jaliffe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourayou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leo, A.</span></span> <span> </span><span class="NLM_article-title">Monarch 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3638</span>– <span class="NLM_lpage">3646</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.75.6155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1200%2FJCO.2017.75.6155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28968163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFemt7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=3638-3646&author=M.+P.+Goetzauthor=M.+Toiauthor=M.+Camponeauthor=J.+Sohnauthor=S.+Paluch-Shimonauthor=J.+Huoberauthor=I.+H.+Parkauthor=O.+Tr%C3%A9danauthor=S.-C.+Chenauthor=L.+Mansoauthor=O.+C.+Freedmanauthor=G.+Garnica+Jaliffeauthor=T.+Forresterauthor=M.+Frenzelauthor=S.+Barrigaauthor=I.+C.+Smithauthor=N.+Bourayouauthor=A.+Di+Leo&title=Monarch+3%3A+Abemaciclib+as+Initial+Therapy+for+Advanced+Breast+Cancer&doi=10.1200%2FJCO.2017.75.6155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88aR"><div class="casContent"><span class="casTitleNuber">88a</span><div class="casTitle"><span class="NLM_cas:atitle">MONARCH 3: abemaciclib as initial therapy for advanced breast cancer</span></div><div class="casAuthors">Goetz, Matthew P.; Toi, Masakazu; Campone, Mario; Sohn, Joohyuk; Paluch-Shimon, Shani; Huober, Jens; Park, In Hae; Tredan, Olivier; Chen, Shin-Cheh; Manso, Luis; Freedman, Orit C.; Jaliffe, Georgina Garnica; Forrester, Tammy; Frenzel, Martin; Barriga, Susana; Smith, Ian C.; Bourayou, Nawel; Di Leo, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3638-3650</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-pos., human epidermal growth factor receptor 2 (HER2)-neg. advanced breast cancer previously treated with endocrine therapy.  Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-pos., HER2-neg. advanced breast cancer who had no prior systemic therapy in the advanced setting.  Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily.  The primary objective was investigator-assessed progression-free survival.  Secondary objectives included response evaluation and safety.  A planned interim anal. occurred after 189 events.  Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 mo in the placebo arm).  In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm (P = .004).  In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%).  Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%).  Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-pos., HER2-neg. advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKzv683888t7Vg90H21EOLACvtfcHk0ljz7C6fFalEdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFemt7vF&md5=5695eb9bb7bd522a6cc85ea0a970bf93</span></div><a href="/servlet/linkout?suffix=cit88a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.75.6155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.75.6155%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DM.%2BP.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DPaluch-Shimon%26aufirst%3DS.%26aulast%3DHuober%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DI.%2BH.%26aulast%3DTr%25C3%25A9dan%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DS.-C.%26aulast%3DManso%26aufirst%3DL.%26aulast%3DFreedman%26aufirst%3DO.%2BC.%26aulast%3DGarnica%2BJaliffe%26aufirst%3DG.%26aulast%3DForrester%26aufirst%3DT.%26aulast%3DFrenzel%26aufirst%3DM.%26aulast%3DBarriga%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DI.%2BC.%26aulast%3DBourayou%26aufirst%3DN.%26aulast%3DDi%2BLeo%26aufirst%3DA.%26atitle%3DMonarch%25203%253A%2520Abemaciclib%2520as%2520Initial%2520Therapy%2520for%2520Advanced%2520Breast%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D3638%26epage%3D3646%26doi%3D10.1200%2FJCO.2017.75.6155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit88b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Laderian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 Inhibition as a Therapeutic Strategy in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2018.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1053%2Fj.seminoncol.2018.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29935901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCns7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=395-403&author=B.+Laderianauthor=T.+Fojo&title=Cdk4%2F6+Inhibition+as+a+Therapeutic+Strategy+in+Breast+Cancer%3A+Palbociclib%2C+Ribociclib%2C+and+Abemaciclib&doi=10.1053%2Fj.seminoncol.2018.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88bR"><div class="casContent"><span class="casTitleNuber">88b</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 Inhibition as a Therapeutic Strategy in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib</span></div><div class="casAuthors">Laderian, Bahar; Fojo, Tito</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">395-403</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">With 40,920 American women expected to die from breast cancer in 2018 and global health ests. that more than 508,000 women died in 2011 from this disease, the identification of novel therapeutic strategies for the treatment of breast cancer cannot be ignored.  A breakthrough class of cancer drugs that has emerged in recent years and has had an impact in the treatment of breast cancer are the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, with palbociclib the first in class to have received regulatory approval for breast cancer.  In this article we will compare and contrast three CDK4/6 inhibitors - palbociclib, ribociclib and abemaciclib - that have received regulatory approval for the treatment of metastatic breast cancer.  Ribociclib and abemaciclib developed after the success of palbociclib represent examples of "me-too" therapies increasingly being deployed in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThrkaFQi4NbVg90H21EOLACvtfcHk0ljz7C6fFalEdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCns7rK&md5=9e8dd8a2354559a98c90178c12fdffd8</span></div><a href="/servlet/linkout?suffix=cit88b&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2018.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2018.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DLaderian%26aufirst%3DB.%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DCdk4%252F6%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520in%2520Breast%2520Cancer%253A%2520Palbociclib%252C%2520Ribociclib%252C%2520and%2520Abemaciclib%26jtitle%3DSemin.%2520Oncol.%26date%3D2017%26volume%3D44%26spage%3D395%26epage%3D403%26doi%3D10.1053%2Fj.seminoncol.2018.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. M.</span></span> <span> </span><span class="NLM_article-title">Combination of Anti-Human Vegfr2 Antibody and Abemaciclib for Treatment of Non-Small Cell Lung Cancer</span>. <span class="NLM_patent">WO 2015130540A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=E.+M.+Chan&title=Combination+of+Anti-Human+Vegfr2+Antibody+and+Abemaciclib+for+Treatment+of+Non-Small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DE.%2BM.%26atitle%3DCombination%2520of%2520Anti-Human%2520Vegfr2%2520Antibody%2520and%2520Abemaciclib%2520for%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0852-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0852-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29209955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFekurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=139-145&author=A.+Markhamauthor=S.+Dhillon&title=Acalabrutinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0852-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139-145</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Acerta Pharma is developing the Bruton's tyrosine kinase inhibitor acalabrutinib (Calquence) for the treatment of various haematol. and solid malignancies.  The drug has received accelerated approval from the US FDA for the treatment of mantle cell lymphoma based on the results of a phase II study, and phase III trials in mantle cell lymphoma and chronic lymphocytic leukemia are currently underway.  This article summarizes the milestones in the development of acalabrutinib leading to this first approval for mantle cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOeUJyNBrnP7Vg90H21EOLACvtfcHk0ljz7C6fFalEdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFekurvF&md5=95ac3e46917e6e1b248a1a1da537f562</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0852-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0852-8%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DAcalabrutinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D139%26epage%3D145%26doi%3D10.1007%2Fs40265-017-0852-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krejsa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coss, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urie, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisseberth, W. C.</span></span> <span> </span><span class="NLM_article-title">Preclinical Evaluation of the Novel Btk Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0159607</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0159607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1371%2Fjournal.pone.0159607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27434128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVeks7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0159607&author=B.+K.+Harringtonauthor=H.+L.+Gardnerauthor=R.+Izumiauthor=A.+Hamdyauthor=W.+Rothbaumauthor=K.+R.+Coombesauthor=T.+Coveyauthor=A.+Kapteinauthor=M.+Gulrajaniauthor=B.+Van+Lithauthor=C.+Krejsaauthor=C.+C.+Cossauthor=D.+S.+Russellauthor=X.+Zhangauthor=B.+K.+Urieauthor=C.+A.+Londonauthor=J.+C.+Byrdauthor=A.+J.+Johnsonauthor=W.+C.+Kisseberth&title=Preclinical+Evaluation+of+the+Novel+Btk+Inhibitor+Acalabrutinib+in+Canine+Models+of+B-Cell+Non-Hodgkin+Lymphoma&doi=10.1371%2Fjournal.pone.0159607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-hodgkin lymphoma</span></div><div class="casAuthors">Harrington, Bonnie K.; Gardner, Heather L.; Izumi, Raquel; Hamdy, Ahmed; Rothbaum, Wayne; Coombes, Kevin R.; Covey, Todd; Kaptein, Allard; Gulrajani, Michael; Van Lith, Bart; Krejsa, Cecile; Coss, Christopher C.; Russell, Duncan S.; Zhang, Xiaoli; Urie, Bridget K.; London, Cheryl A.; Byrd, John C.; Johnson, Amy J.; Kisseberth, William C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0159607/1-e0159607/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib.  In this study, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy similar to human diffuse large B-cell lymphoma (DLBCL).  First, we demonstrated that acalabrutinib potently inhibited BTK activity and downstream effectors in CLBL1, a canine B-cell lymphoma cell line, and primary canine lymphoma cells.  Acalabrutinib also inhibited proliferation in CLBL1 cells.  Twenty dogs were enrolled in the clin. trial and treated with acalabrutinib at dosages of 2.5 to 20mg/kg every 12 or 24 h.  Acalabrutinib was generally well tolerated, with adverse events consisting primarily of grade 1 or 2 anorexia, wt. loss, vomiting, diarrhea and lethargy.  Overall response rate (ORR) was 25% (5/20) with a median progression free survival (PFS) of 22.5 days.  Clin. benefit was obsd. in 30% (6/20) of dogs.  These findings suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1K06NtKvNrrVg90H21EOLACvtfcHk0liXzYtCv121iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVeks7vN&md5=6079330778c6c90593af4d7c99aada96</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0159607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0159607%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DB.%2BK.%26aulast%3DGardner%26aufirst%3DH.%2BL.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3DVan%2BLith%26aufirst%3DB.%26aulast%3DKrejsa%26aufirst%3DC.%26aulast%3DCoss%26aufirst%3DC.%2BC.%26aulast%3DRussell%26aufirst%3DD.%2BS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DUrie%26aufirst%3DB.%2BK.%26aulast%3DLondon%26aufirst%3DC.%2BA.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DKisseberth%26aufirst%3DW.%2BC.%26atitle%3DPreclinical%2520Evaluation%2520of%2520the%2520Novel%2520Btk%2520Inhibitor%2520Acalabrutinib%2520in%2520Canine%2520Models%2520of%2520B-Cell%2520Non-Hodgkin%2520Lymphoma%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0159607%26doi%3D10.1371%2Fjournal.pone.0159607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. S.</span>; <span class="NLM_string-name">Kumar, K. M.</span></span> <span> </span><span class="NLM_article-title">Amorphous Form of Acalabrutinib and Solid Dispersion Thereof</span>. <span class="NLM_patent">IN 201641037734A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+S.+Reddy&author=K.+M.+Kumar&title=Amorphous+Form+of+Acalabrutinib+and+Solid+Dispersion+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DP.%2BS.%26atitle%3DAmorphous%2520Form%2520of%2520Acalabrutinib%2520and%2520Solid%2520Dispersion%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit92b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">MacPhee, J. M.</span>; <span class="NLM_string-name">Neuman, L. L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Bruton’s Tyrosine Kinase Inhibitors and Succinate Forms Thereof</span>. <span class="NLM_patent">WO 2018017153A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+M.+MacPhee&author=L.+L.+Neuman&title=Preparation+of+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors+and+Succinate+Forms+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMacPhee%26aufirst%3DJ.%2BM.%26atitle%3DPreparation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%2520and%2520Succinate%2520Forms%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit92c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of Gdc-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+Gdc-0853%3A+A+Potent%2C+Selective%2C+and+Noncovalent+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+in+Early+Clinical+Development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92cR"><div class="casContent"><span class="casTitleNuber">92c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0liXzYtCv121iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit92c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520Gdc-0853%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Noncovalent%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520in%2520Early%2520Clinical%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit92d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Allenamide as a Bioisostere of Acrylamide in the Design and Synthesis of Targeted Covalent Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1039/C7MD00571G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2FC7MD00571G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=30108918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFGns7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=244-253&author=D.+Chenauthor=D.+Guoauthor=Z.+Yanauthor=Y.+Zhao&title=Allenamide+as+a+Bioisostere+of+Acrylamide+in+the+Design+and+Synthesis+of+Targeted+Covalent+Inhibitors&doi=10.1039%2FC7MD00571G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92dR"><div class="casContent"><span class="casTitleNuber">92d</span><div class="casTitle"><span class="NLM_cas:atitle">Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors</span></div><div class="casAuthors">Chen, Deheng; Guo, Dexiang; Yan, Ziqin; Zhao, Yujun</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">244-253</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The success of acrylamide-contg. drugs in treating cancers has spurred a passion to search for acrylamide bioisosteres.  In our endeavour, we have identified that an allenamide group can be a reactive bioisostere of the acrylamide group.  In our development of allenamide-contg. compds., we found that the most potent compd., 14, inhibited the kinase activities of both T790M/L858R double mutant and wild type EGFR in a low nM range. 14 also inhibited the growth of NCI-H1975 lung cancer cells at IC50 = 33 nM, which is comparable to that of acrylamide-contg. osimertinib.  The western blot anal. showed that the phosphorylation of EGFR, AKT, and ERK1/2 was simultaneously inhibited in a dose-dependent manner when NCI-H1975 cells were treated with 14.  By measuring the conjugate addn. product formed by 14 and GSH, we obtained a reaction rate const. of 302.5 × 10-3 min-1, which is about 30-fold higher than that of osimertinib.  Taken together, our data suggest that the allenamide-contg. compds. inhibited EGFR kinases through covalent modifications.  Our study indicates that the allenamide group could serve as an alternative electrophilic warhead in the design of targeted covalent inhibitors, and this bioisostere replacement may have broad applications in medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65_4aYFEww7Vg90H21EOLACvtfcHk0lh5u7te777d8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFGns7rO&md5=919f67c6ee52d1996f0e5ccdfbe77279</span></div><a href="/servlet/linkout?suffix=cit92d&amp;dbid=16384&amp;doi=10.1039%2FC7MD00571G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00571G%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DAllenamide%2520as%2520a%2520Bioisostere%2520of%2520Acrylamide%2520in%2520the%2520Design%2520and%2520Synthesis%2520of%2520Targeted%2520Covalent%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26spage%3D244%26epage%3D253%26doi%3D10.1039%2FC7MD00571G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit92e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span> <span> </span><span class="NLM_article-title">Novel Synthetic Drugs Currently in Clinical Development for Chronic Lymphocytic Leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1384814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F13543784.2017.1384814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28942659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SktLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=1249-1265&author=P.+Robakauthor=T.+Robak&title=Novel+Synthetic+Drugs+Currently+in+Clinical+Development+for+Chronic+Lymphocytic+Leukemia&doi=10.1080%2F13543784.2017.1384814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92eR"><div class="casContent"><span class="casTitleNuber">92e</span><div class="casTitle"><span class="NLM_cas:atitle">Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia</span></div><div class="casAuthors">Robak, Pawel; Robak, Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1249-1265</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Over the last few years, several new synthetic drugs, particularly Bruton's tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K) and BCL-2 inhibitors have been developed and investigated in chronic lymphocytic leukemia (CLL).  This review highlights key aspects of BTK, PI3K and BCL-2 inhibitors that are currently at various stages of preclin. and clin. development in CLL.  A literature review of the MEDLINE database for articles in English concerning CLL, B-cell receptor, BCL-2 antagonists, BTK inhibitors and PI3K inhibitors, was conducted via PubMed.  Publications from 2000 through July 2017 were scrutinized.  The search terms used were acalabrutinib, ACP-196, BGB-3111, ONO-4059, GS-4059, duvelisib, IPI-145, TGR-1202, copanlisib, Bay 80-6946, buparlisib, BKM-120, BCL-2 inhibitors, venetoclax, ABT-263, navitoclax, CDK inhibitors, alvocidib, flavopiridol, dinaciclib, SCH 727,965, palbociclib, PD-0332991, in conjunction with CLL.  Conference proceedings from the previous five years of the ASH and EHA Annual Scientific Meetings were searched manually.  Addnl. relevant publications were obtained by reviewing the refs. from the chosen articles.: The use of new synthetic drugs is a promising strategy for the treatment of CLL.  Data from ongoing and future clin. trials will aid in better defining the status of new drugs in the treatment of CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTqQ_iFwdrrLVg90H21EOLACvtfcHk0lh5u7te777d8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SktLfI&md5=5b9ffa5b1ec3aa7c8b1691a76796cc92</span></div><a href="/servlet/linkout?suffix=cit92e&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1384814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1384814%26sid%3Dliteratum%253Aachs%26aulast%3DRobak%26aufirst%3DP.%26aulast%3DRobak%26aufirst%3DT.%26atitle%3DNovel%2520Synthetic%2520Drugs%2520Currently%2520in%2520Clinical%2520Development%2520for%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D1249%26epage%3D1265%26doi%3D10.1080%2F13543784.2017.1384814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit92f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B.</span>; <span class="NLM_string-name">Rothbaum, W.</span>; <span class="NLM_string-name">Barf, T.</span>; <span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 7,9-Dihydro-8h-Purin-8-One Derivatives as Bruton’s Tyrosine Kinase (Btk) Inhibitors and Therapeutic Combinations of an Interleukin-1 Receptor-Assocd. Kinase 4 (Irak4) Inhibitor and a Btk Inhibitor</span>. <span class="NLM_patent">US 20170035881A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=B.+Lannutti&author=W.+Rothbaum&author=T.+Barf&author=A.+Kaptein&title=Preparation+of+7%2C9-Dihydro-8h-Purin-8-One+Derivatives+as+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+Inhibitors+and+Therapeutic+Combinations+of+an+Interleukin-1+Receptor-Assocd.+Kinase+4+%28Irak4%29+Inhibitor+and+a+Btk+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLannutti%26aufirst%3DB.%26atitle%3DPreparation%2520of%25207%252C9-Dihydro-8h-Purin-8-One%2520Derivatives%2520as%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520Inhibitors%2520and%2520Therapeutic%2520Combinations%2520of%2520an%2520Interleukin-1%2520Receptor-Assocd.%2520Kinase%25204%2520%2528Irak4%2529%2520Inhibitor%2520and%2520a%2520Btk%2520Inhibitor%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit92g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Krejsa, C. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazopyrazines as Btk Inhibitors for the Treatment of Diseases</span>. <span class="NLM_patent">US 20170224688A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+M.+Krejsa&title=Preparation+of+Imidazopyrazines+as+Btk+Inhibitors+for+the+Treatment+of+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKrejsa%26aufirst%3DC.%2BM.%26atitle%3DPreparation%2520of%2520Imidazopyrazines%2520as%2520Btk%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Diseases%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit92h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compositions, Optionally Containing Fluorinated Pyrazolopyrimidine Bruton’s Tyrosine Kinase Inhibitors, for Treatment of Cancer and Autoimmune Diseases</span>. <span class="NLM_patent">WO 2017218844A2</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=W.+He&title=Pharmaceutical+Compositions%2C+Optionally+Containing+Fluorinated+Pyrazolopyrimidine+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%2C+for+Treatment+of+Cancer+and+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DW.%26atitle%3DPharmaceutical%2520Compositions%252C%2520Optionally%2520Containing%2520Fluorinated%2520Pyrazolopyrimidine%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%252C%2520for%2520Treatment%2520of%2520Cancer%2520and%2520Autoimmune%2520Diseases%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit92i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Phosphoryl-Substituted Diphenylpyrimidines (Pho-Dppys) as Potent Bruton’s Tyrosine Kinase (Btk) Inhibitors: Targeted Treatment of B Lymphoblastic Leukemia Cell Lines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.11.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.bmc.2016.11.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27956037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyjur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=765-772&author=Y.+Geauthor=H.+Yangauthor=C.+Wangauthor=Q.+Mengauthor=L.+Liauthor=H.+Sunauthor=Y.+Zhenauthor=K.+Liuauthor=Y.+Liauthor=X.+Ma&title=Design+and+Synthesis+of+Phosphoryl-Substituted+Diphenylpyrimidines+%28Pho-Dppys%29+as+Potent+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+Inhibitors%3A+Targeted+Treatment+of+B+Lymphoblastic+Leukemia+Cell+Lines&doi=10.1016%2Fj.bmc.2016.11.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92iR"><div class="casContent"><span class="casTitleNuber">92i</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines</span></div><div class="casAuthors">Ge, Yang; Yang, Haijun; Wang, Changyuan; Meng, Qiang; Li, Lei; Sun, Huijun; Zhen, Yuhong; Liu, Kexin; Li, Yanxia; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">765-772</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A family of phosphoryl-substituted diphenylpyrimidine derivs. (Pho-DPPYs) were synthesized and biol. evaluated as potent BTK inhibitors in this study.  Compd. 7b was found to markedly inhibit BTK activity at concns. of 0.82 nmol/L, as well as to suppress the proliferations of B-cell leukemia cell lines (Ramos and Raji) expressing high levels of BTK at concns. of 3.17 μM and 6.69 μM.  Moreover, flow cytometry anal. results further indicated that 7b promoted cell apoptosis to a substantial degree.  In a word, compd. 7b is a promising BTK inhibitor for the treatment of B-cell lymphoblastic leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtgST7kwZKzbVg90H21EOLACvtfcHk0lif--D9j3IUwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyjur7I&md5=1be63c64ac8f2ac19f9a6bb4146a6b15</span></div><a href="/servlet/linkout?suffix=cit92i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.11.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.11.054%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Phosphoryl-Substituted%2520Diphenylpyrimidines%2520%2528Pho-Dppys%2529%2520as%2520Potent%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520Inhibitors%253A%2520Targeted%2520Treatment%2520of%2520B%2520Lymphoblastic%2520Leukemia%2520Cell%2520Lines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D765%26epage%3D772%26doi%3D10.1016%2Fj.bmc.2016.11.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit92j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T. A.</span>; <span class="NLM_string-name">Jans, C. G. J. M.</span>; <span class="NLM_string-name">De Man, A. P. A.</span>; <span class="NLM_string-name">Oubrie, A. A.</span>; <span class="NLM_string-name">Raaijmakers, H. C. A.</span>; <span class="NLM_string-name">Rewinkel, J. B. M.</span>; <span class="NLM_string-name">Sterrenburg, J.-G.</span>; <span class="NLM_string-name">Wijkmans, J. C. H. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazopyrazinylbenzamide Derivatives and Analogs for Use as Btk Inhibitors</span>. <span class="NLM_patent">WO 2013010868A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=T.+A.+Barf&author=C.+G.+J.+M.+Jans&author=A.+P.+A.+De+Man&author=A.+A.+Oubrie&author=H.+C.+A.+Raaijmakers&author=J.+B.+M.+Rewinkel&author=J.-G.+Sterrenburg&author=J.+C.+H.+M.+Wijkmans&title=Preparation+of+Imidazopyrazinylbenzamide+Derivatives+and+Analogs+for+Use+as+Btk+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%2BA.%26atitle%3DPreparation%2520of%2520Imidazopyrazinylbenzamide%2520Derivatives%2520and%2520Analogs%2520for%2520Use%2520as%2520Btk%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mo, G.</span>; <span class="NLM_string-name">Zha, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Btk Inhibitor Acalabrutinib</span>. <span class="NLM_patent">CN 107522701A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Mo&author=X.+Zha&title=Preparation+of+Btk+Inhibitor+Acalabrutinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Btk%2520Inhibitor%2520Acalabrutinib%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit93b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Acalabrutinib</span>. <span class="NLM_patent">CN 107056786A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=X.+Xu&title=Process+for+the+Preparation+of+Acalabrutinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Acalabrutinib%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, B.</span>; <span class="NLM_string-name">Berree, F.</span></span> <span> </span><span class="NLM_article-title">Reactions Involving a Carbonyl Compound as Electropholic Component. Third Component Boronic Acid (Petasis Reaction)</span>. In  <i>Science of Synthesis, Multicomponent Reactions</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span>, Ed.; <span class="NLM_publisher-name">Georg Thieme Verlag</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2014</span>; Vol.  <span class="NLM_volume">1</span>, pp  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">259</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=219-259&author=B.+Carboni&author=F.+Berreeauthor=T.+Mueller&title=Science+of+Synthesis%2C+Multicomponent+Reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCarboni%26aufirst%3DB.%26atitle%3DReactions%2520Involving%2520a%2520Carbonyl%2520Compound%2520as%2520Electropholic%2520Component.%2520Third%2520Component%2520Boronic%2520Acid%2520%2528Petasis%2520Reaction%2529%26btitle%3DScience%2520of%2520Synthesis%252C%2520Multicomponent%2520Reactions%26aulast%3DMueller%26aufirst%3DT.%26pub%3DGeorg%2520Thieme%2520Verlag%26date%3D2014%26volume%3D1%26spage%3D219%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit94b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrera, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T. R.</span></span> <span> </span><span class="NLM_article-title">The Petasis Borono-Mannich Multicomponent Reaction</span>. <i>ACS Symp. Ser.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1236</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1021/bk-2016-1236.ch009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1236.ch009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1236&publication_year=2016&pages=275-311&author=C.+A.+Guerreraauthor=T.+R.+Ryder&title=The+Petasis+Borono-Mannich+Multicomponent+Reaction&doi=10.1021%2Fbk-2016-1236.ch009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94bR"><div class="casContent"><span class="casTitleNuber">94b</span><div class="casTitle"><span class="NLM_cas:atitle">The Petasis borono-Mannich multicomponent reaction</span></div><div class="casAuthors">Guerrera, Cessandra A.; Ryder, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Symposium Series</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1236</span>
        (<span class="NLM_cas:issue">Boron Reagents in Synthesis</span>),
    <span class="NLM_cas:pages">275-311</span>CODEN:
                <span class="NLM_cas:coden">ACSMC8</span>;
        ISSN:<span class="NLM_cas:issn">0097-6156</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Petasis borono-Mannich reaction is a multicomponent process that involves the addn. of an organoboronic acid to an imine or iminium ion formed by the condensation of an aldehyde and amine.  The initial report provided by Petasis in 1993 has attracted significant attention from the synthetic community and a no. of advances have been reported since the topic was last reviewed.  Recent highlights include new catalysts and reaction conditions, asym. variants, diversity-oriented approaches, and applications to the synthesis of natural products and other biol.-relevant targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1RUy-KhptYbVg90H21EOLACvtfcHk0lif--D9j3IUwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKmt7w%253D&md5=c8f9fd1ef77e880bc0624738bebff37f</span></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1236.ch009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbk-2016-1236.ch009%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrera%26aufirst%3DC.%2BA.%26aulast%3DRyder%26aufirst%3DT.%2BR.%26atitle%3DThe%2520Petasis%2520Borono-Mannich%2520Multicomponent%2520Reaction%26jtitle%3DACS%2520Symp.%2520Ser.%26date%3D2016%26volume%3D1236%26spage%3D275%26epage%3D311%26doi%3D10.1021%2Fbk-2016-1236.ch009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit94c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Minbiole, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minbiole, K. P. C.</span></span> <span> </span><span class="NLM_article-title">The Petasis-Ferrier Rearrangement: Developments and Applications</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1038/ja.2015.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1038%2Fja.2015.136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=26732258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=213-219&author=E.+C.+Minbioleauthor=K.+P.+C.+Minbiole&title=The+Petasis-Ferrier+Rearrangement%3A+Developments+and+Applications&doi=10.1038%2Fja.2015.136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94cR"><div class="casContent"><span class="casTitleNuber">94c</span><div class="casTitle"><span class="NLM_cas:atitle">The Petasis-Ferrier rearrangement: developments and applications</span></div><div class="casAuthors">Minbiole, Emily C.; Minbiole, Kevin P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-219</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the mid-1990s, Petasis reexamd. a promising but infrequently used rearrangement strategy, the so-called Ferrier-type-II reaction, and provided it with a modern update.  Previously, Ferrier had developed a strategy where carbohydrate derivs. would undergo a fragmentation/aldol-type recombination sequence, generating a carbocycle, albeit under the promotion of stoichiometric mercury salts.  Petasis' new variant showed the promise to effectively and stereoselectively convert a range of cyclic vinyl acetals to useful tetrahydrofurans and tetrahydropyrans, using less toxic promoters.  Since these 1st reports, the Petasis-Ferrier rearrangement has represented a vibrant area of research and innovation for org. chemists.  With numerous applications in complex natural product total synthesis, the utility of the reaction has been resoundingly established.  Recent developments have extended the reaction to a broader synthetic context, allowing for in situ generation of rearrangement substrates and more liberal interpretation of what fragmentation/recombination reactions warrant the designation of a Petasis-Ferrier rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooiAhfOZyc6LVg90H21EOLACvtfcHk0lgmcroZigdjyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslWjs78%253D&md5=e1b212eac291ee08ac8fd8381b22deaf</span></div><a href="/servlet/linkout?suffix=cit94c&amp;dbid=16384&amp;doi=10.1038%2Fja.2015.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2015.136%26sid%3Dliteratum%253Aachs%26aulast%3DMinbiole%26aufirst%3DE.%2BC.%26aulast%3DMinbiole%26aufirst%3DK.%2BP.%2BC.%26atitle%3DThe%2520Petasis-Ferrier%2520Rearrangement%253A%2520Developments%2520and%2520Applications%26jtitle%3DJ.%2520Antibiot.%26date%3D2016%26volume%3D69%26spage%3D213%26epage%3D219%26doi%3D10.1038%2Fja.2015.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luxami, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, K.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Development of Imidazo[1,2-a]Pyrazines: Synthesis, Reactivity and Their Biological Applications</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3525</span>– <span class="NLM_lpage">3555</span>, <span class="refDoi"> DOI: 10.1039/C4OB01380H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1039%2FC4OB01380H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=25563506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2itL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=3525-3555&author=R.+Goelauthor=V.+Luxamiauthor=K.+Paul&title=Recent+Advances+in+Development+of+Imidazo%5B1%2C2-a%5DPyrazines%3A+Synthesis%2C+Reactivity+and+Their+Biological+Applications&doi=10.1039%2FC4OB01380H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in development of imidazo[1,2-a]pyrazines: synthesis, reactivity and their biological applications</span></div><div class="casAuthors">Goel, Richa; Luxami, Vijay; Paul, Kamaldeep</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3525-3555</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Imidazo[1,2-a]pyrazine acts as a versatile scaffold in org. synthesis and drug development.  This review article is an effort to compile the progress made in synthetic methods and to illustrate its reactivity and multifarious biol. activity.  This review is mainly based on the pattern and position of the substitution, and should help the scientific community to bring about future developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6DitVcY1CjbVg90H21EOLACvtfcHk0lgmcroZigdjyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2itL7O&md5=181649e259a4bf2205e76b552dafbe95</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1039%2FC4OB01380H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB01380H%26sid%3Dliteratum%253Aachs%26aulast%3DGoel%26aufirst%3DR.%26aulast%3DLuxami%26aufirst%3DV.%26aulast%3DPaul%26aufirst%3DK.%26atitle%3DRecent%2520Advances%2520in%2520Development%2520of%2520Imidazo%255B1%252C2-a%255DPyrazines%253A%2520Synthesis%252C%2520Reactivity%2520and%2520Their%2520Biological%2520Applications%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2015%26volume%3D13%26spage%3D3525%26epage%3D3555%26doi%3D10.1039%2FC4OB01380H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coutant, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janin, Y. L.</span></span> <span> </span><span class="NLM_article-title">Synthetic Routes to Coelenterazine and Other Imidazo[1,2-a]Pyrazin-3-One Luciferins: Essential Tools for Bioluminescence-Based Investigations</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">17158</span>– <span class="NLM_lpage">17171</span>, <span class="refDoi"> DOI: 10.1002/chem.201501531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fchem.201501531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=26403487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGkt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=17158-17171&author=E.+P.+Coutantauthor=Y.+L.+Janin&title=Synthetic+Routes+to+Coelenterazine+and+Other+Imidazo%5B1%2C2-a%5DPyrazin-3-One+Luciferins%3A+Essential+Tools+for+Bioluminescence-Based+Investigations&doi=10.1002%2Fchem.201501531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Routes to Coelenterazine and Other Imidazo[1,2-a]pyrazin-3-one Luciferins: Essential Tools for Bioluminescence-Based Investigations</span></div><div class="casAuthors">Coutant, Eloi P.; Janin, Yves L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">17158-17171</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  In the last few decades, bioluminescent systems based on the expression of a luciferase and the addn. of a luciferin to monitor the emission of light have become very important tools for biol. investigations.  A growing proportion of these systems use coelenterazine or analogs of imidazo[1,2-a]pyrazine luciferins along with photoproteins or luciferases from sea creatures such as Aequorea, Renilla, Gaussia or Oplophorus.  Central to the success of these tools are the synthetic pathways developed not only to prep. the naturally occurring luciferins, but also to design altered compds. that exhibit improved bioluminescence.  Current work is indeed focused on the design of systems exhibiting extended luminescence ("glow" systems) or red shifted wavelengths, as well as constructions better adapted to conditions in cells or in vivo.  This review describes the synthetic pathways used to prep. imidazo[1,2-a]pyrazine luciferins along with the research efforts aimed at prepg. analogs even better suited to the design of assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpECFLZXVqAwbVg90H21EOLACvtfcHk0lgmcroZigdjyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGkt7jO&md5=0758320d77611c5f9d74cc393262cd06</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2Fchem.201501531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201501531%26sid%3Dliteratum%253Aachs%26aulast%3DCoutant%26aufirst%3DE.%2BP.%26aulast%3DJanin%26aufirst%3DY.%2BL.%26atitle%3DSynthetic%2520Routes%2520to%2520Coelenterazine%2520and%2520Other%2520Imidazo%255B1%252C2-a%255DPyrazin-3-One%2520Luciferins%253A%2520Essential%2520Tools%2520for%2520Bioluminescence-Based%2520Investigations%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2015%26volume%3D21%26spage%3D17158%26epage%3D17171%26doi%3D10.1002%2Fchem.201501531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97a"><span><span class="NLM_label">(a) </span> <i>Brigatinib</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, April 28, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555841.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555841.htm</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Brigatinib%3B+U.S.+Food+and+Drug+Administration%2C+April+28%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Finformationondrugs%2Fapproveddrugs%2Fucm555841.htm+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DBrigatinib%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit97b"><span><span class="NLM_label">(b) </span> <i>Takeda Announces FDA Accelerated Approval of ALUNBRIG
(Brigatinib)</i>; <span class="NLM_publisher-name">Takeda</span>, April
28, <span class="NLM_year">2017</span>; <a href="https://www.takeda.com/newsroom/newsreleases/2017/alunbrig-fda-approval/" class="extLink">https://www.takeda.com/newsroom/newsreleases/2017/alunbrig-fda-approval/</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Takeda+Announces+FDA+Accelerated+Approval+of+ALUNBRIG%0A%28Brigatinib%29%3B+Takeda%2C+April%0A28%2C+2017%3B+https%3A%2F%2Fwww.takeda.com%2Fnewsroom%2Fnewsreleases%2F2017%2Falunbrig-fda-approval%2F+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DTakeda%2520Announces%2520FDA%2520Accelerated%2520Approval%2520of%2520ALUNBRIG%250A%2528Brigatinib%2529%26pub%3DTakeda%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Brigatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1131</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0776-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0776-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28597393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1131-1135&author=A.+Markham&title=Brigatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0776-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98aR"><div class="casContent"><span class="casTitleNuber">98a</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1131-1135</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Brigatinib (ALUNBRIG) is a small mol. antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company).  In Apr. 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-pos. metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants.  This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmCYwTukZCLVg90H21EOLACvtfcHk0lgJHJki8LS_HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL&md5=c03f9d61e8e8fd4187d47ee207452f31</span></div><a href="/servlet/linkout?suffix=cit98a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0776-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0776-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBrigatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1131%26epage%3D1135%26doi%3D10.1007%2Fs40265-017-0776-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit98b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Spotlight on Brigatinib and Its Potential in the Treatment of Patients with Metastatic Alk-Positive Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Crizotinib</span>. <i>Lung Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S126507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2147%2FLCTT.S126507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVGmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=169-177&author=R.+K.+Jainauthor=H.+Chen&title=Spotlight+on+Brigatinib+and+Its+Potential+in+the+Treatment+of+Patients+with+Metastatic+Alk-Positive+Non-Small+Cell+Lung+Cancer+Who+Are+Resistant+or+Intolerant+to+Crizotinib&doi=10.2147%2FLCTT.S126507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98bR"><div class="casContent"><span class="casTitleNuber">98b</span><div class="casTitle"><span class="NLM_cas:atitle">Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib</span></div><div class="casAuthors">Jain, Rohit K.; Chen, Hongbin</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">In the last decade, there have been major therapeutic advances in the management of patients with anaplastic lymphoma kinase (ALK)-pos. non-small cell lung cancer.  Crizotinib was the first approved ALK inhibitor with significant benefits over chemotherapy.  However, patients inevitably develop disease progression esp. in central nervous system and acquire resistance to crizotinib.  Several next-generation ALK inhibitors have been developed to overcome these resistance mechanisms and have demonstrated clin. benefits in crizotinib-refractory non-small cell lung cancer including in central nervous system.  Brigatinib is a second-generation ALK inhibitor with high level of activity against ALK and several other targets.  It is active in vitro against many ALK kinase domain mutations including L1196M, E1210K, and G1202R which may mediate acquired resistance to other ALK inhibitors.  In Phase I/II and ALTA clin. studies, brigatinib has demonstrated substantial and durable responses and intracranial responses after progression on crizotinib.  It has acceptable safety profile, but early pulmonary toxicity has been obsd. prompting to pursue daily dosing of 180 mg (with lead-in).  Overall, 180 mg (with lead-in) has showed consistently better efficacy than 90 mg.  In this review, we will discuss in detail these two pivotal trials that led to the accelerated approval for brigatinib and its future directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx1r4oGHTe9LVg90H21EOLACvtfcHk0lgJHJki8LS_HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVGmtb0%253D&md5=05bffdfb5c05ca7cf4c50d717b6d9a4b</span></div><a href="/servlet/linkout?suffix=cit98b&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S126507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S126507%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DSpotlight%2520on%2520Brigatinib%2520and%2520Its%2520Potential%2520in%2520the%2520Treatment%2520of%2520Patients%2520with%2520Metastatic%2520Alk-Positive%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Who%2520Are%2520Resistant%2520or%2520Intolerant%2520to%2520Crizotinib%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D169%26epage%3D177%26doi%3D10.2147%2FLCTT.S126507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (Ap26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28Ap26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0ljafGR4L6wr6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528Ap26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, W.-S.</span>; <span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Thomas, R. M.</span>; <span class="NLM_string-name">Qi, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Kohlmann, A.</span>; <span class="NLM_string-name">Dalgarno, D. C.</span>; <span class="NLM_string-name">Romero, J. A. C.</span>; <span class="NLM_string-name">Zou, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Phosphorus Derivatives as Kinase Inhibitors</span>. <span class="NLM_patent">WO 2009143389A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=Y.+Wang&author=W.-S.+Huang&author=S.+Liu&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=J.+Qi&author=F.+Li&author=X.+Zhu&author=A.+Kohlmann&author=D.+C.+Dalgarno&author=J.+A.+C.+Romero&author=D.+Zou&title=Preparation+of+Phosphorus+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Phosphorus%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit100b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, W.-S.</span>; <span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Thomas, R. M.</span>; <span class="NLM_string-name">Qi, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Kohlmann, A.</span>; <span class="NLM_string-name">Dalgarno, D. C.</span>; <span class="NLM_string-name">Romero, J. A. C.</span>; <span class="NLM_string-name">Zou, D.</span></span> <span> </span><span class="NLM_article-title">Phosphorus Derivatives as Kinase Inhibitors</span>. <span class="NLM_patent">US 20130225528A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Wang&author=W.-S.+Huang&author=S.+Liu&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=J.+Qi&author=F.+Li&author=X.+Zhu&author=A.+Kohlmann&author=D.+C.+Dalgarno&author=J.+A.+C.+Romero&author=D.+Zou&title=Phosphorus+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPhosphorus%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit100c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, W.-S.</span>; <span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Thomas, R. M.</span>; <span class="NLM_string-name">Qi, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Kohlmann, A.</span>; <span class="NLM_string-name">Dalgarno, D. C.</span>; <span class="NLM_string-name">Romero, J. A. C.</span>; <span class="NLM_string-name">Zou, D.</span></span> <span> </span><span class="NLM_article-title">Phosphorus Derivatives as Kinase Inhibitors</span>. <span class="NLM_patent">US20130225527A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Wang&author=W.-S.+Huang&author=S.+Liu&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=J.+Qi&author=F.+Li&author=X.+Zhu&author=A.+Kohlmann&author=D.+C.+Dalgarno&author=J.+A.+C.+Romero&author=D.+Zou&title=Phosphorus+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPhosphorus%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit100d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, W.-S.</span>; <span class="NLM_string-name">Liu, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Thomas, R. M.</span>; <span class="NLM_string-name">Qi, J.</span>; <span class="NLM_string-name">Li, F.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Kohlmann, A.</span>; <span class="NLM_string-name">Dalgarno, D. C.</span>; <span class="NLM_string-name">Romero, J. A. C.</span>; <span class="NLM_string-name">Zou, D.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Phosphine Oxide Derivatives as Kinase Inhibitors</span>. <span class="NLM_patent">US 20140066406A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Y.+Wang&author=W.-S.+Huang&author=S.+Liu&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=J.+Qi&author=F.+Li&author=X.+Zhu&author=A.+Kohlmann&author=D.+C.+Dalgarno&author=J.+A.+C.+Romero&author=D.+Zou&title=Heterocyclic+Phosphine+Oxide+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DHeterocyclic%2520Phosphine%2520Oxide%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit100e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozamus, L. W.</span>; <span class="NLM_string-name">Sharma, P.</span></span> <span> </span><span class="NLM_article-title">Crystalline Forms of 5-Chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine</span>. <span class="NLM_patent">WO2016065028A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+W.+Rozamus&author=P.+Sharma&title=Crystalline+Forms+of+5-Chloro-N4-%5B-2-%28dimethylphosphoryl%29phenyl%5D-N2-%7B2-methoxy-4-%5B4-%284-methylpiperazin-1-yl%29piperidin-1-yl%5Dpyrimidine-2%2C4-diamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRozamus%26aufirst%3DL.%2BW.%26atitle%3DCrystalline%2520Forms%2520of%25205-Chloro-N4-%255B-2-%2528dimethylphosphoryl%2529phenyl%255D-N2-%257B2-methoxy-4-%255B4-%25284-methylpiperazin-1-yl%2529piperidin-1-yl%255Dpyrimidine-2%252C4-diamine%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit100f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span>; <span class="NLM_string-name">Shakespeare, W. C.</span>; <span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Methods for Inhibiting Cell Proliferation in Alk Kinase-Driven Cancers</span>. <span class="NLM_patent">US 9611283B1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Zhang&author=W.+C.+Shakespeare&author=V.+M.+Rivera&title=Methods+for+Inhibiting+Cell+Proliferation+in+Alk+Kinase-Driven+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DMethods%2520for%2520Inhibiting%2520Cell%2520Proliferation%2520in%2520Alk%2520Kinase-Driven%2520Cancers%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokol, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockland, R. A.</span></span> <span> </span><span class="NLM_article-title">Development of a Room Temperature Hirao Reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2008.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.tetlet.2008.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWjurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=457-459&author=M.+C.+Kohlerauthor=J.+G.+Sokolauthor=R.+A.+Stockland&title=Development+of+a+Room+Temperature+Hirao+Reaction&doi=10.1016%2Fj.tetlet.2008.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101aR"><div class="casContent"><span class="casTitleNuber">101a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a room temperature Hirao reaction</span></div><div class="casAuthors">Kohler, Mark C.; Sokol, Joseph G.; Stockland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-459</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Arylphosphonates, RC6H4P(O)(OEt)2 (R = 4-MeO, 4-Me, H, 4-NC, 4-C(O)Me, 4-OH, 4-Cl, 2-OMe, 4-NH2), were prepd. at 25° through the Pd-catalyzed coupling of aryl iodides, RC6H4I, with a Ag phosphonate, Ag[P(O)(OEt)2].  A wide range of aryl iodides were successfully employed including phenolic substrates as well as those contg. an ortho substituent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-q-sAv9Fi0rVg90H21EOLACvtfcHk0lgfq9KjS9quVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWjurfF&md5=cc4c5b74c0f3dff0173c82232dcf50e1</span></div><a href="/servlet/linkout?suffix=cit101a&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2008.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2008.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DKohler%26aufirst%3DM.%2BC.%26aulast%3DSokol%26aufirst%3DJ.%2BG.%26aulast%3DStockland%26aufirst%3DR.%2BA.%26atitle%3DDevelopment%2520of%2520a%2520Room%2520Temperature%2520Hirao%2520Reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2009%26volume%3D50%26spage%3D457%26epage%3D459%26doi%3D10.1016%2Fj.tetlet.2008.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit101b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Belabassi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzghari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montchamp, J.-L.</span></span> <span> </span><span class="NLM_article-title">Revisiting the Hirao Cross-Coupling: Improved Synthesis of Aryl and Heteroaryl Phosphonates</span>. <i>J. Organomet. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>693</i></span>,  <span class="NLM_fpage">3171</span>– <span class="NLM_lpage">3178</span>, <span class="refDoi"> DOI: 10.1016/j.jorganchem.2008.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.jorganchem.2008.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=19156189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVyitr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=693&publication_year=2008&pages=3171-3178&author=Y.+Belabassiauthor=S.+Alzghariauthor=J.-L.+Montchamp&title=Revisiting+the+Hirao+Cross-Coupling%3A+Improved+Synthesis+of+Aryl+and+Heteroaryl+Phosphonates&doi=10.1016%2Fj.jorganchem.2008.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101bR"><div class="casContent"><span class="casTitleNuber">101b</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the Hirao cross-coupling: improved synthesis of aryl and heteroaryl phosphonates</span></div><div class="casAuthors">Belabassi, Yamina; Alzghari, Saeed; Montchamp, Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organometallic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">693</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3171-3178</span>CODEN:
                <span class="NLM_cas:coden">JORCAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The palladium-catalyzed cross-coupling of dialkylphosphite with arom. electrophiles (Hirao coupling) was re-investigated.  Some limitations in terms of palladium loadings and substrate reactivity are alleviated with the use of Pd(OAc)2 complexed to 1,1'-bis(diphenylphosphino)ferrocene (dppf) as a ligand.  Various aryl and heteroaryl halides are employed to deliver both known and novel substituted phosphonates.  The first examples of aryl chloride couplings are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6-tauPpJxZLVg90H21EOLACvtfcHk0lgfq9KjS9quVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVyitr%252FJ&md5=2bbad04465690dbd0c37a42458030e34</span></div><a href="/servlet/linkout?suffix=cit101b&amp;dbid=16384&amp;doi=10.1016%2Fj.jorganchem.2008.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jorganchem.2008.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DBelabassi%26aufirst%3DY.%26aulast%3DAlzghari%26aufirst%3DS.%26aulast%3DMontchamp%26aufirst%3DJ.-L.%26atitle%3DRevisiting%2520the%2520Hirao%2520Cross-Coupling%253A%2520Improved%2520Synthesis%2520of%2520Aryl%2520and%2520Heteroaryl%2520Phosphonates%26jtitle%3DJ.%2520Organomet.%2520Chem.%26date%3D2008%26volume%3D693%26spage%3D3171%26epage%3D3178%26doi%3D10.1016%2Fj.jorganchem.2008.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit101c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hirao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masunaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohshiro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agawa, T.</span></span> <span> </span><span class="NLM_article-title">A Novel Synthesis of Dialkyl Arenephosphonates</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>1981</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1055/s-1981-29335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1055%2Fs-1981-29335" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1981&publication_year=1981&pages=56-57&author=T.+Hiraoauthor=T.+Masunagaauthor=Y.+Ohshiroauthor=T.+Agawa&title=A+Novel+Synthesis+of+Dialkyl+Arenephosphonates&doi=10.1055%2Fs-1981-29335"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101c&amp;dbid=16384&amp;doi=10.1055%2Fs-1981-29335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1981-29335%26sid%3Dliteratum%253Aachs%26aulast%3DHirao%26aufirst%3DT.%26aulast%3DMasunaga%26aufirst%3DT.%26aulast%3DOhshiro%26aufirst%3DY.%26aulast%3DAgawa%26aufirst%3DT.%26atitle%3DA%2520Novel%2520Synthesis%2520of%2520Dialkyl%2520Arenephosphonates%26jtitle%3DSynthesis%26date%3D1981%26volume%3D1981%26spage%3D56%26epage%3D57%26doi%3D10.1055%2Fs-1981-29335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span> <i>FDA approves new treatment for adults with relapsed
follicular lymphoma</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, September 14, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576129.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576129.htm</a> (accessed November 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+approves+new+treatment+for+adults+with+relapsed%0Afollicular+lymphoma%3B+U.S.+Food+and+Drug+Administration%2C+September+14%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm576129.htm+%28accessed+November+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520approves%2520new%2520treatment%2520for%2520adults%2520with%2520relapsed%250Afollicular%2520lymphoma%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Copanlisib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2057</span>– <span class="NLM_lpage">2062</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0838-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0838-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29127587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSrsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2057-2062&author=A.+Markham&title=Copanlisib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0838-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Copanlisib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2057-2062</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Bayer are developing copanlisib (Aliqopa)-a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor-as a treatment for various haematol. and solid malignancies.  The US FDA has granted copanlisib accelerated approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies based on the results of a phase II trial.  Phase III trials are underway evaluating copanlisib as treatment for relapsed/refractory diffuse large B-cell lymphoma and in combination with rituximab or rituximab-based chemotherapy or std. immunochemotherapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma.  Phase I/II studies are underway in relapsed or refractory peripheral T-cell or NK/T-cell lymphoma, advanced cholangiocarcinoma, hormone receptor-pos. HER2-neg. stage I-IV breast cancer, HER2-pos. breast cancer and recurrent and/or metastatic head and neck squamous cell carcinomas harbouring a PI3KCA mutation/amplification and/or a PTEN loss.  This article summarizes the milestones in the development of copanlisib leading to this first approval for relapsed follicular lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe7-lxckqIRrVg90H21EOLACvtfcHk0lgfq9KjS9quVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSrsLfM&md5=574036e843f127a1dc40edc568e639dc</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0838-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0838-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DCopanlisib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D2057%26epage%3D2062%26doi%3D10.1007%2Fs40265-017-0838-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. G.</span>; <span class="NLM_string-name">Rubenbauer, P.</span>; <span class="NLM_string-name">Goetz, D.</span>; <span class="NLM_string-name">Grossbach, D.</span>; <span class="NLM_string-name">Mais, F. J.</span>; <span class="NLM_string-name">Schirmer, H.</span>; <span class="NLM_string-name">Stiehl, J.</span>; <span class="NLM_string-name">Lovis, K.</span>; <span class="NLM_string-name">Lender, A.</span>; <span class="NLM_string-name">Seyfried, M.</span>; <span class="NLM_string-name">Zweifel, T.</span>; <span class="NLM_string-name">Marty, M.</span>; <span class="NLM_string-name">Weingartner, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Copanlisib and Its Dihydrochloride Salt</span>. <span class="NLM_patent">WO 2016071435A2</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+G.+Peters&author=P.+Rubenbauer&author=D.+Goetz&author=D.+Grossbach&author=F.+J.+Mais&author=H.+Schirmer&author=J.+Stiehl&author=K.+Lovis&author=A.+Lender&author=M.+Seyfried&author=T.+Zweifel&author=M.+Marty&author=G.+Weingartner&title=Synthesis+of+Copanlisib+and+Its+Dihydrochloride+Salt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BG.%26atitle%3DSynthesis%2520of%2520Copanlisib%2520and%2520Its%2520Dihydrochloride%2520Salt%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit104b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Copanlisib</span> <span class="NLM_patent">CN 105130997A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Q.+Xu&title=Preparation+Method+of+Copanlisib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26atitle%3DPreparation%2520Method%2520of%2520Copanlisib%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roboz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekeres, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willekens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span> <span> </span><span class="NLM_article-title">Enasidenib in Mutant-Idh2 Relapsed or Refractory Acute Myeloid Leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-04-779405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1182%2Fblood-2017-04-779405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28588020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVSku7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=722-731&author=E.+M.+Steinauthor=C.+D.+DiNardoauthor=D.+A.+Pollyeaauthor=A.+T.+Fathiauthor=G.+J.+Robozauthor=J.+K.+Altmanauthor=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=R.+L.+Levineauthor=I.+W.+Flinnauthor=H.+M.+Kantarjianauthor=R.+Collinsauthor=M.+R.+Patelauthor=A.+E.+Frankelauthor=A.+Steinauthor=M.+A.+Sekeresauthor=R.+T.+Swordsauthor=B.+C.+Medeirosauthor=C.+Willekensauthor=P.+Vyasauthor=A.+Tosoliniauthor=Q.+Xuauthor=R.+D.+Knightauthor=K.+E.+Yenauthor=S.+Agrestaauthor=S.+de+Bottonauthor=M.+S.+Tallman&title=Enasidenib+in+Mutant-Idh2+Relapsed+or+Refractory+Acute+Myeloid+Leukemia&doi=10.1182%2Fblood-2017-04-779405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia</span></div><div class="casAuthors">Stein, Eytan M.; Di Nardo, Courtney D.; Pollyea, Daniel A.; Fathi, Amir T.; Roboz, Gail J.; Altman, Jessica K.; Stone, Richard M.; DeAngelo, Daniel J.; Levine, Ross L.; Flinn, Ian W.; Kantarjian, Hagop M.; Collins, Robert; Patel, Manish R.; Frankel, Arthur E.; Stein, Anthony; Sekeres, Mikkael A.; Swords, Ronan T.; Medeiros, Bruno C.; Willekens, Christophe; Vyas, Paresh; Tosolini, Alessandra; Xu, Qiang; Knight, Robert D.; Yen, Katharine E.; Agresta, Sam; de Botton, Stephane; Tallman, Martin S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-731</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML).  Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, leading to blocked cellular differentiation.  Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes.  This first-in-human, phase 1/2 study assessed the max. tolerated dose (MTD), pharmacokinetic and pharmacodynamic profiles, safety, and clin. activity of enasidenib in patients with mutant-IDH2 advanced myeloid malignancies.  We assessed safety outcomes for all patients (N=239) and clin. efficacy in the largest patient subgroup, those with relapsed or refractory AML (n=176), from the phase 1 dose-escalation and expansion phases of the study.  In the dose-escalation phase, an MTD was not reached at doses ranging from 50-650 mg daily.  Enasidenib 100 mg daily was selected for the expansion phase based on pharmacokinetic and pharmacodynamic profiles and demonstrated efficacy.  Grade 3-4 enasidenib-related adverse events included indirect hyperbilirubinemia (12%) and IDH-inhibitor-assocd. differentiation syndrome (IDH-DS; 7%).  Among patients with relapsed or refractory AML, overall response rate was 40.3%, with median response duration of 5.8 mo.  Responses were assocd. with cellular differentiation and maturation, typically without evidence of aplasia.  Median overall survival among relapsed/refractory patients was 9.3 mo, and for the 34 patients (19.3%) who attained complete remission was 19.7 mo.  Continuous daily enasidenib treatment was generally well-tolerated and induced hematol. responses in patients who had failed prior AML therapy.  Inducing differentiation of myeloblasts, not cytotoxicity, appears to drive the clin. efficacy of enasidenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm3133YTlQYrVg90H21EOLACvtfcHk0lhAwjpuCC22UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVSku7zP&md5=d934df7adacad5b02adddfdce812f225</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-04-779405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-04-779405%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3DDiNardo%26aufirst%3DC.%2BD.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFrankel%26aufirst%3DA.%2BE.%26aulast%3DStein%26aufirst%3DA.%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DWillekens%26aufirst%3DC.%26aulast%3DVyas%26aufirst%3DP.%26aulast%3DTosolini%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKnight%26aufirst%3DR.%2BD.%26aulast%3DYen%26aufirst%3DK.%2BE.%26aulast%3DAgresta%26aufirst%3DS.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26atitle%3DEnasidenib%2520in%2520Mutant-Idh2%2520Relapsed%2520or%2520Refractory%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D722%26epage%3D731%26doi%3D10.1182%2Fblood-2017-04-779405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coller, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedvat, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">The Common Feature of Leukemia-Associated Idh1 and Idh2Mutations Is a Neomorphic Enzyme Activity Converting Alpha-Ketoglutarate to 2-Hydroxyglutarate</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2010.01.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.ccr.2010.01.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=20171147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVWqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=225-234&author=P.+S.+Wardauthor=J.+Patelauthor=D.+R.+Wiseauthor=O.+Abdel-Wahabauthor=B.+D.+Bennettauthor=H.+A.+Collerauthor=J.+R.+Crossauthor=V.+R.+Fantinauthor=C.+V.+Hedvatauthor=A.+E.+Perlauthor=J.+D.+Rabinowitzauthor=M.+Carrollauthor=S.+M.+Suauthor=K.+A.+Sharpauthor=R.+L.+Levineauthor=C.+B.+Thompson&title=The+Common+Feature+of+Leukemia-Associated+Idh1+and+Idh2Mutations+Is+a+Neomorphic+Enzyme+Activity+Converting+Alpha-Ketoglutarate+to+2-Hydroxyglutarate&doi=10.1016%2Fj.ccr.2010.01.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate</span></div><div class="casAuthors">Ward, Patrick S.; Patel, Jay; Wise, David R.; Abdel-Wahab, Omar; Bennett, Bryson D.; Coller, Hilary A.; Cross, Justin R.; Fantin, Valeria R.; Hedvat, Cyrus V.; Perl, Alexander E.; Rabinowitz, Joshua D.; Carroll, Martin; Su, Shinsan M.; Sharp, Kim A.; Levine, Ross L.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-234</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The somatic mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) obsd. in gliomas can lead to the prodn. of 2-hydroxyglutarate (2HG).  Here, the authors report that tumor 2HG is elevated in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML).  Surprisingly, less than half of cases with elevated 2HG possessed IDH1 mutations.  The remaining cases with elevated 2HG had mutations in IDH2, the mitochondrial homolog of IDH1.  These data demonstrate that a shared feature of all cancer-assocd. IDH mutations is prodn. of the oncometabolite 2HG.  Furthermore, AML patients with IDH mutations display a significantly reduced no. of other well characterized AML-assocd. mutations and/or assocd. chromosomal abnormalities, potentially implicating IDH mutation in a distinct mechanism of AML pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppKH_IGRymibVg90H21EOLACvtfcHk0lhAwjpuCC22UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVWqtLg%253D&md5=cf235f63ccd050ff3b121b94d3c49b9e</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.01.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.01.020%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DP.%2BS.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DWise%26aufirst%3DD.%2BR.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DBennett%26aufirst%3DB.%2BD.%26aulast%3DColler%26aufirst%3DH.%2BA.%26aulast%3DCross%26aufirst%3DJ.%2BR.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DHedvat%26aufirst%3DC.%2BV.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DS.%2BM.%26aulast%3DSharp%26aufirst%3DK.%2BA.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DThe%2520Common%2520Feature%2520of%2520Leukemia-Associated%2520Idh1%2520and%2520Idh2Mutations%2520Is%2520a%2520Neomorphic%2520Enzyme%2520Activity%2520Converting%2520Alpha-Ketoglutarate%2520to%25202-Hydroxyglutarate%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26spage%3D225%26epage%3D234%26doi%3D10.1016%2Fj.ccr.2010.01.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D.</span></span> <span> </span><span class="NLM_article-title">Enasidenib for the Treatment of Acute Myeloid Leukemia</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1080/17512433.2018.1477585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F17512433.2018.1477585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29770715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=755-760&author=J.+Duganauthor=D.+Pollyea&title=Enasidenib+for+the+Treatment+of+Acute+Myeloid+Leukemia&doi=10.1080%2F17512433.2018.1477585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Enasidenib for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Dugan, James; Pollyea, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">755-760</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: In August 2017, the United States Federal Drug Administration (FDA) approved enasidenib (Idhifa, Celgene/Agios) for adults with relapsed and refractory acute myelogenous leukemia (AML) with an IDH2 mutation.  Enasidenib targets cells with mutant copies of isocitrate dehydrogenase-2 (IDH2), inhibiting the oncometabolite 2-hydroxyglutarte (2-HG) formed by the mutant IDH2.: We review the studies leading to enasidenib's approval, as well as common side effects and safety issues experienced during the clin. trials.  There is a focus on the diagnosis and treatment of these side effects including differentiation syndrome.: We are experiencing a revolution in the understanding of the mechanism of AML.  A majority of the effort has been concd. on targeting gene mutations or pathway activations with precision therapeutics.  Enasidenib is beneficial in a patient population that previously had limited treatment options.  However, given the fact that enasidenib is a highly specific inhibitor of an early stable mutation, it is questionable whether a strategy of targeting a single mutation or pathway in relapsed AML will allow for better than the 20% complete remission (CR) rate obsd. with this therapy.  The proper role for single mutation targeting in AML needs to be carefully considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLh57HTR0seLVg90H21EOLACvtfcHk0liJJWQEE4FxxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOrtLjI&md5=486b1abaa403ecc4b50b29516b06e3be</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1080%2F17512433.2018.1477585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17512433.2018.1477585%26sid%3Dliteratum%253Aachs%26aulast%3DDugan%26aufirst%3DJ.%26aulast%3DPollyea%26aufirst%3DD.%26atitle%3DEnasidenib%2520for%2520the%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D11%26spage%3D755%26epage%3D760%26doi%3D10.1080%2F17512433.2018.1477585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S. V.</span>; <span class="NLM_string-name">Gu, C.-H.</span>; <span class="NLM_string-name">Schenkein, D.</span>; <span class="NLM_string-name">Yang, H.</span>; <span class="NLM_string-name">Guo, L.</span>; <span class="NLM_string-name">Tang, Z.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Zhou, Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutically Active Compounds and Their Methods of Use</span>. <span class="NLM_patent">WO 2015017821A2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+V.+Agresta&author=C.-H.+Gu&author=D.+Schenkein&author=H.+Yang&author=L.+Guo&author=Z.+Tang&author=J.+Wang&author=Y.+Zhang&author=Y.+Zhou&title=Therapeutically+Active+Compounds+and+Their+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAgresta%26aufirst%3DS.%2BV.%26atitle%3DTherapeutically%2520Active%2520Compounds%2520and%2520Their%2520Methods%2520of%2520Use%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelljes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liedtke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goekbuget, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paccagnella, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandendries, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in Ino-Vate</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1722</span>– <span class="NLM_lpage">1732</span>, <span class="refDoi"> DOI: 10.1002/cncr.31249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fcncr.31249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29381191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1alsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=1722-1732&author=E.+J.+Jabbourauthor=D.+J.+DeAngeloauthor=M.+Stelljesauthor=W.+Stockauthor=M.+Liedtkeauthor=N.+Goekbugetauthor=S.+O%E2%80%99Brienauthor=T.+Wangauthor=M.+L.+Paccagnellaauthor=B.+Sleightauthor=E.+Vandendriesauthor=A.+S.+Advaniauthor=H.+M.+Kantarjian&title=Efficacy+and+Safety+Analysis+by+Age+Cohort+of+Inotuzumab+Ozogamicin+in+Patients+with+Relapsed+or+Refractory+Acute+Lymphoblastic+Leukemia+Enrolled+in+Ino-Vate&doi=10.1002%2Fcncr.31249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109aR"><div class="casContent"><span class="casTitleNuber">109a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE</span></div><div class="casAuthors">Jabbour, Elias J.; De Angelo, Daniel J.; Stelljes, Matthias; Stock, Wendy; Liedtke, Michaela; Goekbuget, Nicola; O'Brien, Susan; Wang, Tao; Paccagnella, M. Luisa; Sleight, Barbara; Vandendries, Erik; Advani, Anjali S.; Kantarjian, Hagop M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1722-1732</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial.  This subset anal. compared the efficacy and safety of InO in younger and older patients.  METHODS : Intent-to-treat analyses of morphol. responses and overall survival (OS) included 326 randomized patients, and safety assessments included 307 patients receiving 1 or more doses of the study treatment.  Of the 326 patients, 164 received InO at a starting dose of 1.8 mg/m2/cycle (0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15 of a 21- to 28-day cycle [≤6 cycles]); 60 patients were aged ≥55 years, and 104 were aged <55 years.  RESULTS : For older and younger patients, the median duration of InO therapy and the types and frequencies of adverse events of any grade were generally similar.  Although the remission rates, median duration of remission (DOR), and progression-free survival were similar with InO for those aged <55 years and those aged ≥55 years, OS was longer for younger patients (median, 8.6 vs 5.6 mo; hazard ratio, 0.610).  Among patients proceeding to hematopoietic stem cell transplantation after InO treatment (28% of older patients and 58% of younger patients), the incidence of veno-occlusive disease was greater in older patients (41% vs 17%).  The study database was not locked at the time of this anal.  CONCLUSIONS : InO was tolerable in older patients with relapsed/refractory ALL.  Although OS was longer for younger patients vs. older patients, InO demonstrated high response rates with similar DOR in the 2 age groups.  Cancer 2018;124:1722-32. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE9hrrEo-qSbVg90H21EOLACvtfcHk0lhwnsy2yZwlKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1alsL8%253D&md5=738bafcce6dcbc0515176c650264ba40</span></div><a href="/servlet/linkout?suffix=cit109a&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31249%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%2BJ.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStelljes%26aufirst%3DM.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DLiedtke%26aufirst%3DM.%26aulast%3DGoekbuget%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DPaccagnella%26aufirst%3DM.%2BL.%26aulast%3DSleight%26aufirst%3DB.%26aulast%3DVandendries%26aufirst%3DE.%26aulast%3DAdvani%26aufirst%3DA.%2BS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DEfficacy%2520and%2520Safety%2520Analysis%2520by%2520Age%2520Cohort%2520of%2520Inotuzumab%2520Ozogamicin%2520in%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Acute%2520Lymphoblastic%2520Leukemia%2520Enrolled%2520in%2520Ino-Vate%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26spage%3D1722%26epage%3D1732%26doi%3D10.1002%2Fcncr.31249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit109b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharyya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelleri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, D. I.</span></span> <span> </span><span class="NLM_article-title">Patient-Reported Outcomes from a Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2151</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi"> DOI: 10.1002/cncr.31317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fcncr.31317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29508899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1ajtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=2151-2160&author=H.+M.+Kantarjianauthor=Y.+Suauthor=E.+J.+Jabbourauthor=H.+Bhattacharyyaauthor=E.+Yanauthor=J.+C.+Cappelleriauthor=D.+I.+Marks&title=Patient-Reported+Outcomes+from+a+Phase+3+Randomized+Controlled+Trial+of+Inotuzumab+Ozogamicin+Versus+Standard+Therapy+for+Relapsed%2FRefractory+Acute+Lymphoblastic+Leukemia&doi=10.1002%2Fcncr.31317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109bR"><div class="casContent"><span class="casTitleNuber">109b</span><div class="casTitle"><span class="NLM_cas:atitle">Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia</span></div><div class="casAuthors">Kantarjian, Hagop M.; Su, Yun; Jabbour, Elias J.; Bhattacharyya, Helen; Yan, Eric; Cappelleri, Joseph C.; Marks, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2151-2160</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Inotuzumab ozogamicin (InO), an anti-CD22 antibody-calicheamicin conjugate, demonstrated superior clin. activity vs. std.-of-care (SOC) chemotherapies for relapsed/refractory B-cell acute lymphoblastic leukemia in the phase 3 randomized controlled INO-VATE trial.  The authors assessed patient-reported outcomes (PROs) from that study.  METHODS : Patients were randomized to receive either InO (1.8 mg/m2 per cycle for ≤6 cycles) or SOC (fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor, or ara-C plus mitoxantrone, or high-dose ara-C for ≤4 cycles) and completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the EuroQoL 5 Dimensions Questionnaires at baseline, on day 1 of each cycle, and at the end of treatment.  Treatment differences in PROs were assessed using longitudinal mixed-effects models with random intercepts and slopes.  RESULTS : Questionnaire completion rates in the InO (n = 164) and SOC (n = 162) arms were 85% and 65%, resp.  Baseline scores were similar between arms.  Patients who received InO reported better quality of life (QoL), functioning, and symptom scores (except for constipation and emotional functioning).  Least-squares mean (95% confidence interval [CI]) differences in phys., role, and social functioning and in appetite loss were significant (6.9 [95% CI, 1.4-12.3], 11.4 [95% CI, 3.2-19.5], 8.4 [95% CI, 0.7-16.1], and -8.7 [95% CI, -16.0 to -1.4], resp.; all P < .05) and had exceeded the minimally important difference of 5.  Mean treatment differences in favor of InO on the EuroQoL visual analog scale and the global health status/QoL, dyspnea, and fatigue scales reached or approached the minimally important difference of 5, although without statistical significance.  No dimensions were significantly worse with InO vs. SOC.  CONCLUSIONS : The current PRO data support the favorable benefit/risk ratio of InO for the treatment of relapsed/refractory acute lymphoblastic leukemia, with superior clin. efficacy and better QoL.  Cancer 2018;124:2151-60. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ1yd320kS2LVg90H21EOLACvtfcHk0lhwnsy2yZwlKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1ajtLo%253D&md5=4501ab64fb0a9d9a7df87516b7222677</span></div><a href="/servlet/linkout?suffix=cit109b&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31317%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DJabbour%26aufirst%3DE.%2BJ.%26aulast%3DBhattacharyya%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DE.%26aulast%3DCappelleri%26aufirst%3DJ.%2BC.%26aulast%3DMarks%26aufirst%3DD.%2BI.%26atitle%3DPatient-Reported%2520Outcomes%2520from%2520a%2520Phase%25203%2520Randomized%2520Controlled%2520Trial%2520of%2520Inotuzumab%2520Ozogamicin%2520Versus%2520Standard%2520Therapy%2520for%2520Relapsed%252FRefractory%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26spage%3D2151%26epage%3D2160%26doi%3D10.1002%2Fcncr.31317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiJoseph, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armellino, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boghaert, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridharan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorovits, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udata, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popplewell, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damle, N. K.</span></span> <span> </span><span class="NLM_article-title">Antibody-Targeted Chemotherapy with Cmc-544: A Cd22-Targeted Immunoconjugate of Calicheamicin for the Treatment of B-Lymphoid Malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1814</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-07-2466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1182%2Fblood-2003-07-2466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=14615373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVOhsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=1807-1814&author=J.+F.+DiJosephauthor=D.+C.+Armellinoauthor=E.+R.+Boghaertauthor=K.+Khandkeauthor=M.+M.+Dougherauthor=L.+Sridharanauthor=A.+Kunzauthor=P.+R.+Hamannauthor=B.+Gorovitsauthor=C.+Udataauthor=J.+K.+Moranauthor=A.+G.+Popplewellauthor=S.+Stephensauthor=P.+Frostauthor=N.+K.+Damle&title=Antibody-Targeted+Chemotherapy+with+Cmc-544%3A+A+Cd22-Targeted+Immunoconjugate+of+Calicheamicin+for+the+Treatment+of+B-Lymphoid+Malignancies&doi=10.1182%2Fblood-2003-07-2466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies</span></div><div class="casAuthors">DiJoseph, John F.; Armellino, Douglas C.; Boghaert, Erwin R.; Khandke, Kiran; Dougher, Maureen M.; Sridharan, Latha; Kunz, Arthur; Hamann, Philip R.; Gorovits, Boris; Udata, Chandrasekhar; Moran, Justin K.; Popplewell, Andrew G.; Stephens, Sue; Frost, Philip; Damle, Nitin K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1807-1814</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-γ-calicheamicin di-Me hydrazide [CalichDMH], a potent DNA-binding cytotoxic antitumor antibiotic) is a clin. validated therapeutic option for patients with acute myeloid leukemia (AML).  Here, we describe the preclin. profile of another immunoconjugate of CalichDMH, CMC-544, targeted to CD22 expressed by B-lymphoid malignancies.  CMC-544 comprises a humanized IgG4 anti-CD22 monoclonal antibody (mAb), G5/44, covalently linked to CalichDMH via an acid-labile 4-(4'-acetylphenoxy) butanoic acid (AcBut) linker.  Both CMC-544 and unconjugated G5/44 bound human CD22 with subnanomolar affinity.  CMC-544, but not unconjugated G5/44, exerted potent cytotoxicity against CD22+ B-cell lymphoma (BCL) cell lines (inhibitory concn. of 50%: 6-600 pM CalichDMH).  CMC-544 caused a potent inhibition of growth of small but established BCL xenografts leading to cures (therapeutic index > 10).  CMC-544 prevented the establishment of BCL xenografts and also caused regression of large BCLs (> 1.5 g tumor mass).  In contrast, unconjugated CalichDMH, unconjugated G5/44, and an isotype-matched control conjugate, CMA-676, were ineffective against these BCL xenografts.  Thus, CD22-targeted delivery of CalichDMH is a potent and effective preclin. therapeutic strategy for BCLs.  The strong antitumor profile of CMC-544 supports its clin. evaluation as a treatment option for B-lymphoid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxrcsoc82Fm7Vg90H21EOLACvtfcHk0lj73VEH9AAtYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVOhsbc%253D&md5=0c225d0ce3e69b7c0dcfc21788cdc8a0</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-07-2466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-07-2466%26sid%3Dliteratum%253Aachs%26aulast%3DDiJoseph%26aufirst%3DJ.%2BF.%26aulast%3DArmellino%26aufirst%3DD.%2BC.%26aulast%3DBoghaert%26aufirst%3DE.%2BR.%26aulast%3DKhandke%26aufirst%3DK.%26aulast%3DDougher%26aufirst%3DM.%2BM.%26aulast%3DSridharan%26aufirst%3DL.%26aulast%3DKunz%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DGorovits%26aufirst%3DB.%26aulast%3DUdata%26aufirst%3DC.%26aulast%3DMoran%26aufirst%3DJ.%2BK.%26aulast%3DPopplewell%26aufirst%3DA.%2BG.%26aulast%3DStephens%26aufirst%3DS.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DDamle%26aufirst%3DN.%2BK.%26atitle%3DAntibody-Targeted%2520Chemotherapy%2520with%2520Cmc-544%253A%2520A%2520Cd22-Targeted%2520Immunoconjugate%2520of%2520Calicheamicin%2520for%2520the%2520Treatment%2520of%2520B-Lymphoid%2520Malignancies%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D1807%26epage%3D1814%26doi%3D10.1182%2Fblood-2003-07-2466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hinman, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durr, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span> <span> </span><span class="NLM_article-title">Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibiotics</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3336</span>– <span class="NLM_lpage">3342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=8324745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK3sXlvFGisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=3336-3342&author=L.+M.+Hinmanauthor=P.+R.+Hamannauthor=R.+Wallaceauthor=A.+T.+Menendezauthor=F.+E.+Durrauthor=J.+Upeslacis&title=Preparation+and+Characterization+of+Monoclonal+Antibody+Conjugates+of+the+Calicheamicins%3A+A+Novel+and+Potent+Family+of+Antitumor+Antibiotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111aR"><div class="casContent"><span class="casTitleNuber">111a</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics</span></div><div class="casAuthors">Hinman, Lois M.; Hamann, Philip R.; Wallace, Roslyn; Menendez, Ana T.; Durr, Frederick E.; Upeslacis, Janis</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3336-42</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The calicheamicin family of antitumor antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concns.  Their potency suggested that the calicheamicins would be excellent candidates for targeted delivery and a hydrazide prepd. from the most potent and abundant of the naturally occurring deriv., γ1I, was linked to oxidized sugars on CT-M-01, an internalizing anti-polyepithelial mucin antibody.  The conjugates retained the immunoreactivity of the unmodified antibody and were specifically cytotoxic toward antigen pos. tumor cells in vitro and in vivo.  Hydrazide analogs of less potent calicheamicin derivs. were also prepd. and conjugated to CT-M-01.  Comparison of the therapeutic efficacy of the conjugates against the MX-1 xenograft tumor implanted s.c. in nude mice showed that conjugates of derivs. missing the rhamnose, a sugar residue that is part of the DNA binding region of the drug, were not as promising as antitumor therapies.  However, conjugates of two derivs., α3I and N-acetyl-γ1I, in which the rhamnose residue is present but the amino sugar residue of the parent drug is either missing or modified, significantly inhibited tumor growth over a 4-fold dose range and produced long-term tumor-free survivors.  Sterically hindering Me groups adjacent to the disulfide in the linker further increased the therapeutic window of these potent conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Ey58uwD7ULVg90H21EOLACvtfcHk0lj73VEH9AAtYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvFGisLw%253D&md5=fcafd796345946fa29a62e3f12de3b7e</span></div><a href="/servlet/linkout?suffix=cit111a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHinman%26aufirst%3DL.%2BM.%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DWallace%26aufirst%3DR.%26aulast%3DMenendez%26aufirst%3DA.%2BT.%26aulast%3DDurr%26aufirst%3DF.%2BE.%26aulast%3DUpeslacis%26aufirst%3DJ.%26atitle%3DPreparation%2520and%2520Characterization%2520of%2520Monoclonal%2520Antibody%2520Conjugates%2520of%2520the%2520Calicheamicins%253A%2520A%2520Novel%2520and%2520Potent%2520Family%2520of%2520Antitumor%2520Antibiotics%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26spage%3D3336%26epage%3D3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit111b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ricart, A. D.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6417</span>– <span class="NLM_lpage">6427</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1158%2F1078-0432.CCR-11-0486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=22003069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSksrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6417-6427&author=A.+D.+Ricart&title=Antibody-Drug+Conjugates+of+Calicheamicin+Derivative%3A+Gemtuzumab+Ozogamicin+and+Inotuzumab+Ozogamicin&doi=10.1158%2F1078-0432.CCR-11-0486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111bR"><div class="casContent"><span class="casTitleNuber">111b</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin</span></div><div class="casAuthors">Ricart, Alejandro D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6417-6427</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently sensitive to cytotoxic agents.  CD33 and CD22 are specific markers of myeloid leukemias and B-cell malignancies, resp.  These endocytic receptors are ideal for an ADC strategy because they can effectively carry the cytotoxic payload into the cell.  Gemtuzumab ozogamicin (GO, Mylotarg) and inotuzumab ozogamicin consist of a deriv. of calicheamicin (a potent DNA-binding cytotoxic antibiotic) linked to a humanized monoclonal IgG4 antibody directed against CD33 or CD22, resp.  Both of these ADCs have a target-mediated pharmacokinetic disposition.  GO was the first drug to prove the ADC concept in the clinic, specifically in phase II studies that included substantial proportions of older patients with relapsed acute myeloid leukemia.  In contrast, in phase III studies, it has thus far failed to show clin. benefit in first-line treatment in combination with std. chemotherapy.  Inotuzumab ozogamicin has shown remarkable clin. activity in relapsed/refractory B-cell non-Hodgkin lymphoma, and it has started phase III evaluation.  The safety profile of these ADCs includes reversible myelosuppression (esp. neutropenia and thrombocytopenia), elevated hepatic transaminases, and hyperbilirubinemia.  There have been postmarketing reports of hepatotoxicity, esp. veno-occlusive disease, assocd. with GO.  The incidence is ∼2%, but patients who undergo hematopoietic stem cell transplantation have an increased risk.  As we steadily move toward the goal of personalized medicine, these kinds of agents will provide a unique opportunity to treat selected patient subpopulations based on the expression of their specific tumor targets.  Clin Cancer Res; 17(20); 6417-27.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXhh65029iwbVg90H21EOLACvtfcHk0ljfCNdi84MHaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSksrzF&md5=103b40cfe49632a86367414e0e97c011</span></div><a href="/servlet/linkout?suffix=cit111b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0486%26sid%3Dliteratum%253Aachs%26aulast%3DRicart%26aufirst%3DA.%2BD.%26atitle%3DAntibody-Drug%2520Conjugates%2520of%2520Calicheamicin%2520Derivative%253A%2520Gemtuzumab%2520Ozogamicin%2520and%2520Inotuzumab%2520Ozogamicin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6417%26epage%3D6427%26doi%3D10.1158%2F1078-0432.CCR-11-0486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, R. W.</span>; <span class="NLM_string-name">Letendre, L. J.</span>; <span class="NLM_string-name">Patel, V. B.</span>; <span class="NLM_string-name">Prashad, A. S.</span>; <span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Intermediates and Methods for Synthesizing Calicheamicin Derivatives</span>. <span class="NLM_patent">WO 2015063680</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+W.+Dugger&author=L.+J.+Letendre&author=V.+B.+Patel&author=A.+S.+Prashad&author=C.+Zhang&title=Intermediates+and+Methods+for+Synthesizing+Calicheamicin+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDugger%26aufirst%3DR.%2BW.%26atitle%3DIntermediates%2520and%2520Methods%2520for%2520Synthesizing%2520Calicheamicin%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maiese, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechevalier, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechevalier, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korshalla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenstein, M.</span></span> <span> </span><span class="NLM_article-title">Calicheamicins, a Novel Family of Antitumor Antibiotics: Taxonomy, Fermentation and Biological Properties</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.42.558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.7164%2Fantibiotics.42.558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=2722671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1SmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1989&pages=558-563&author=W.+M.+Maieseauthor=M.+P.+Lechevalierauthor=H.+A.+Lechevalierauthor=J.+Korshallaauthor=N.+Kuckauthor=A.+Fantiniauthor=M.+J.+Wildeyauthor=J.+Thomasauthor=M.+Greenstein&title=Calicheamicins%2C+a+Novel+Family+of+Antitumor+Antibiotics%3A+Taxonomy%2C+Fermentation+and+Biological+Properties&doi=10.7164%2Fantibiotics.42.558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113aR"><div class="casContent"><span class="casTitleNuber">113a</span><div class="casTitle"><span class="NLM_cas:atitle">Calicheamicins, a novel family of antitumor antibiotics:  taxonomy, fermentation and biological properties</span></div><div class="casAuthors">Maiese, W. M.; Lechevalier, M. P.; Lechevalier, H. A.; Korshalla, J.; Kuck, N.; Fantini, A.; Wildey, M. J.; Thomas, J.; Greenstein, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">558-63</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">A novel family of antitumor antibiotics, the calicheamicins, were isolated from the fermn. broth of Micromonospora echinospora subsp. calichensis.  These antibiotics exhibited significant activity against gram-pos. and gram-neg. bacteria in vitro.  Calicheamicin γ1I demonstrated antitumor activity against P388 leukemia and B16 melanoma in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA3VLMLNeUU7Vg90H21EOLACvtfcHk0ljfCNdi84MHaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1SmurY%253D&md5=8944bd3a3bc333517c3ee816f01436bd</span></div><a href="/servlet/linkout?suffix=cit113a&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.42.558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.42.558%26sid%3Dliteratum%253Aachs%26aulast%3DMaiese%26aufirst%3DW.%2BM.%26aulast%3DLechevalier%26aufirst%3DM.%2BP.%26aulast%3DLechevalier%26aufirst%3DH.%2BA.%26aulast%3DKorshalla%26aufirst%3DJ.%26aulast%3DKuck%26aufirst%3DN.%26aulast%3DFantini%26aufirst%3DA.%26aulast%3DWildey%26aufirst%3DM.%2BJ.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DGreenstein%26aufirst%3DM.%26atitle%3DCalicheamicins%252C%2520a%2520Novel%2520Family%2520of%2520Antitumor%2520Antibiotics%253A%2520Taxonomy%252C%2520Fermentation%2520and%2520Biological%2520Properties%26jtitle%3DJ.%2520Antibiot.%26date%3D1989%26volume%3D42%26spage%3D558%26epage%3D563%26doi%3D10.7164%2Fantibiotics.42.558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit113b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. D.</span>; <span class="NLM_string-name">Greenstein, M.</span>; <span class="NLM_string-name">Labeda, D. P.</span>; <span class="NLM_string-name">Fantini, A. A.</span></span> <span> </span><span class="NLM_article-title">Fermentative Manufacture of Antitumor Antibiotics (Ll-E33288 Complex)</span>. <span class="NLM_patent">US 4970198</span>, <span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=M.+D.+Lee&author=M.+Greenstein&author=D.+P.+Labeda&author=A.+A.+Fantini&title=Fermentative+Manufacture+of+Antitumor+Antibiotics+%28Ll-E33288+Complex%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BD.%26atitle%3DFermentative%2520Manufacture%2520of%2520Antitumor%2520Antibiotics%2520%2528Ll-E33288%2520Complex%2529%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunne, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellestad, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGahren, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, D. B.</span></span> <span> </span><span class="NLM_article-title">Calicheamicins, a Novel Family of Antitumor Antibiotics. 4. Structure Elucidation of Calicheamicins B1br, Γ1br, A2i, A3i, B1i, Γ1i, and Δ1i</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1021/ja00029a030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00029a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaK38Xkt1Kqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1992&pages=985-997&author=M.+D.+Leeauthor=T.+S.+Dunneauthor=C.+C.+Changauthor=M.+M.+Siegelauthor=G.+O.+Mortonauthor=G.+A.+Ellestadauthor=W.+J.+McGahrenauthor=D.+B.+Borders&title=Calicheamicins%2C+a+Novel+Family+of+Antitumor+Antibiotics.+4.+Structure+Elucidation+of+Calicheamicins+B1br%2C+%CE%931br%2C+A2i%2C+A3i%2C+B1i%2C+%CE%931i%2C+and+%CE%941i&doi=10.1021%2Fja00029a030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Calicheamicins, a novel family of antitumor antibiotics.  4.  Structure elucidation of calicheamicins β1Br, γ1Br, α2I, α3I, β1I, γ1I, and δ1I</span></div><div class="casAuthors">Lee, May D.; Dunne, Theresa S.; Chang, Conway C.; Siegel, Marshall M.; Morton, George O.; Ellestad, George A.; McGahren, William J.; Borders, Donald B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">985-97</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The details of the structural assignment of the potent antitumor antibiotic, calicheamicin γ1I (I; R = H; C55H74IN3O21S4), is reported.  Methanolysis studies on I (R = H) and N-acetylcalicheamicin γ1I (I; R = Ac; C57H76IN3O22S4) permitted the structural assignment of the glycosidic chain.  Details of the spectral anal. supporting the assignments of the 3-O-methyl-α-L-rhamnopyranoside (D-ring) and the Me 2,4-dideoxy-3-O-methyl-4-(N-acetyl-N-ethylamino)-α-L-xylopyranoside (E-ring) is reported.  The structure of calicheamicinone (II, C18H17NO5S3), contg. a bicyclo[7.3.1]tridec-9-ene-2,6-diyne system and a Me trisulfide, was elucidated by a series of chem. degrdn. studies, which included an unexpected free radical cycloaromatization reaction.  The presence of 4,6-dideoxy-4-(hydroxyamino)-β-D-glucopyranoside (A-ring) and its N-O glycosidic linkage to the thio sugar (ring-B) was ascertained by X-ray crystallog. of III (C36H40INO13S2), a degrdn. product of I (R = H).  The chem. structures of calicheamicins β1Br, γ1Br, α2I, α3I, β1I, and δ1I were assigned by correlating their 1H- and 13C-NMR data with that of I (R = H).  By tracking the biol. activities of the degrdn. products, the enediyne system of calicheamicinone was shown to be essential for the DNA-damaging abilities of the calicheamicins.  A mechanism whereby the enediyne could be triggered to cyclize via a 1,4-diyl, the putative DNA cleaving species, is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrokbMAgwMWr7Vg90H21EOLACvtfcHk0lgWMGTrq5HJdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xkt1Kqsbg%253D&md5=09da8d571f8783d2006999681bbc1318</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fja00029a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00029a030%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BD.%26aulast%3DDunne%26aufirst%3DT.%2BS.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DSiegel%26aufirst%3DM.%2BM.%26aulast%3DMorton%26aufirst%3DG.%2BO.%26aulast%3DEllestad%26aufirst%3DG.%2BA.%26aulast%3DMcGahren%26aufirst%3DW.%2BJ.%26aulast%3DBorders%26aufirst%3DD.%2BB.%26atitle%3DCalicheamicins%252C%2520a%2520Novel%2520Family%2520of%2520Antitumor%2520Antibiotics.%25204.%2520Structure%2520Elucidation%2520of%2520Calicheamicins%2520B1br%252C%2520%25CE%25931br%252C%2520A2i%252C%2520A3i%252C%2520B1i%252C%2520%25CE%25931i%252C%2520and%2520%25CE%25941i%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1992%26volume%3D114%26spage%3D985%26epage%3D997%26doi%3D10.1021%2Fja00029a030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunstmann, M. P.</span>; <span class="NLM_string-name">Hollander, I. J.</span>; <span class="NLM_string-name">Hamann, P.</span>; <span class="NLM_string-name">Kunz, A.</span></span> <span> </span><span class="NLM_article-title">Methods for the Preparation of Monomeric Calicheamicin Derivative/Carrier Conjugates</span>. <span class="NLM_patent">US 5714586</span>, <span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=M.+P.+Kunstmann&author=I.+J.+Hollander&author=P.+Hamann&author=A.+Kunz&title=Methods+for+the+Preparation+of+Monomeric+Calicheamicin+Derivative%2FCarrier+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKunstmann%26aufirst%3DM.%2BP.%26atitle%3DMethods%2520for%2520the%2520Preparation%2520of%2520Monomeric%2520Calicheamicin%2520Derivative%252FCarrier%2520Conjugates%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.
S.</span></span> <span> </span><span class="NLM_article-title">Midostaurin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0779-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0779-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28612232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1251-1259&author=E.%0AS.+Kim&title=Midostaurin%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0779-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116aR"><div class="casContent"><span class="casTitleNuber">116a</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1251-1259</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Midostaurin (Rydapt) is a multikinase inhibitor being developed by Novartis Pharmaceuticals.  In Apr. 2017, midostaurin was approved in the USA for the treatment of adult patients with newly diagnosed, FMS-like tyrosine kinase 3 (FLT3) mutation-pos. acute myeloid leukemia (AML) [in combination with std. cytarabine and daunorubicin induction, and cytarabine consolidation], or aggressive systemic mastocytosis (ASM), systemic mastocytosis with assocd. haematol. neoplasm (SM-AHN) or mast cell leukemia (MCL) [collectively known as advanced SM].  The article summarizes the milestones in the development of midostaurin leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNnPB8R_KAMrVg90H21EOLACvtfcHk0livEzVFQqYtoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrjO&md5=37f59dd537e4ed23475a117bec0e06d0</span></div><a href="/servlet/linkout?suffix=cit116a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0779-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0779-0%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DMidostaurin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1251%26epage%3D1259%26doi%3D10.1007%2Fs40265-017-0779-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit116b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b01126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b01126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOqurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=477-478&author=P.+W.+Manleyauthor=E.+Weisbergauthor=M.+Sattlerauthor=J.+D.+Griffin&title=Midostaurin%2C+a+Natural+Product-Derived+Kinase+Inhibitor+Recently+Approved+for+the+Treatment+of+Hematological+Malignancies&doi=10.1021%2Facs.biochem.7b01126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116bR"><div class="casContent"><span class="casTitleNuber">116b</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies</span></div><div class="casAuthors">Manley, Paul W.; Weisberg, Ellen; Sattler, Martin; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">477-478</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This brief article outlines the early design of midostaurin, the preclin. discovery of its activity against oncogenic FLT3, and its subsequent clin. development as a therapeutic agent for FLT3 mutant-pos. acute myeloid leukemia (AML) and several rare blood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVMHWjYVaxTLVg90H21EOLACvtfcHk0livEzVFQqYtoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOqurfP&md5=8f1c6a65ef0c3b8666fd7402fba3bbb2</span></div><a href="/servlet/linkout?suffix=cit116b&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b01126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b01126%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DMidostaurin%252C%2520a%2520Natural%2520Product-Derived%2520Kinase%2520Inhibitor%2520Recently%2520Approved%2520for%2520the%2520Treatment%2520of%2520Hematological%2520Malignancies%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D477%26epage%3D478%26doi%3D10.1021%2Facs.biochem.7b01126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasko, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span> <span> </span><span class="NLM_article-title">First Approved Kinase Inhibitor for Aml</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">981</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1016%2Fj.cell.2017.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29149610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=981&author=J.+E.+J.+Raskoauthor=T.+P.+Hughes&title=First+Approved+Kinase+Inhibitor+for+Aml&doi=10.1016%2Fj.cell.2017.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">First Approved Kinase Inhibitor for AML</span></div><div class="casAuthors">Rasko, John E. J.; Hughes, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">981</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are assocd. with relapse and poor prognosis.  Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype.  To view this Bench to Bedside, open or download the PDF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOxSUYU6hN97Vg90H21EOLACvtfcHk0lgVQHRMkpoGiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vI&md5=4cb5f9bb62497756d222b62ccebe0dda</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRasko%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26atitle%3DFirst%2520Approved%2520Kinase%2520Inhibitor%2520for%2520Aml%26jtitle%3DCell%26date%3D2017%26volume%3D171%26spage%3D981%26doi%3D10.1016%2Fj.cell.2017.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span> <span> </span><span class="NLM_article-title">Midostaurin Treatment in Flt3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1080/17512433.2017.1387051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1080%2F17512433.2017.1387051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28960095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Chs7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=1177-1189&author=S.+Kayserauthor=M.+J.+Levisauthor=R.+F.+Schlenk&title=Midostaurin+Treatment+in+Flt3-Mutated+Acute+Myeloid+Leukemia+and+Systemic+Mastocytosis&doi=10.1080%2F17512433.2017.1387051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis</span></div><div class="casAuthors">Kayser, Sabine; Levis, Mark J.; Schlenk, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1177-1189</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : A no. of tyrosine kinase inhibitors (TKIs) have been developed that inhibit the constitutively activated kinase activity caused by activating tyrosine kinase mutations, such as FLT3 or KIT, thus interrupting signaling pathways.  Currently, midostaurin is the only approved TKI as monotherapy for aggressive systemic mastocytosis (SM), SM with assocd. hematol. neoplasm, or mast cell leukemia displaying a KIT mutation as well as in combination with std. intensive chemotherapy for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).  We provide a concise review of the pharmacol., tolerability and clin. efficacy of midostaurin and emerging new treatment options for ASM and FLT3-mutated AML.  Currently, midostaurin is the only approved TKI in aggressive SM, SM with assocd. hematol. neoplasm, or mast cell leukemia inducing responses including complete remissions.  With regard to AML, midostaurin is the first drug to receive regulatory approval in this indication in the molecularly defined subgroup of AML with FLT3 mutations.  By introduction of this new std. in AML with FLT3 mutations, the bare has been raised for future approvals of next generation FLT3 inhibitors which will be based increasingly on head to head comparisons with midostaurin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKGUTo4zG5eLVg90H21EOLACvtfcHk0lgVQHRMkpoGiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Chs7nN&md5=f2debaad0c5030cb58e67ca0b6d3b233</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1080%2F17512433.2017.1387051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17512433.2017.1387051%26sid%3Dliteratum%253Aachs%26aulast%3DKayser%26aufirst%3DS.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26atitle%3DMidostaurin%2520Treatment%2520in%2520Flt3-Mutated%2520Acute%2520Myeloid%2520Leukemia%2520and%2520Systemic%2520Mastocytosis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D10%26spage%3D1177%26epage%3D1189%26doi%3D10.1080%2F17512433.2017.1387051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, P.</span>; <span class="NLM_string-name">Koch, B.</span>; <span class="NLM_string-name">Mutz, M.</span></span> <span> </span><span class="NLM_article-title">Crystal Form of N-Benzoyl-staurosporine</span>. <span class="NLM_patent">US 8198435 B2</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.+Hoehn&author=B.+Koch&author=M.+Mutz&title=Crystal+Form+of+N-Benzoyl-staurosporine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoehn%26aufirst%3DP.%26atitle%3DCrystal%2520Form%2520of%2520N-Benzoyl-staurosporine%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awaya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asuma, R.</span></span> <span> </span><span class="NLM_article-title">A New Alkaloid Am-2282 of Streptomyces Origin. Taxonomy, Fermentation, Isolation and Preliminary Characterization</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.30.275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.7164%2Fantibiotics.30.275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=612708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaE2sXkt1Smsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1977&pages=275-282&author=S.+Omuraauthor=Y.+Iwaiauthor=A.+Hiranoauthor=A.+Nakagawaauthor=J.+Awayaauthor=H.+Tsuchiyaauthor=Y.+Takahashiauthor=R.+Asuma&title=A+New+Alkaloid+Am-2282+of+Streptomyces+Origin.+Taxonomy%2C+Fermentation%2C+Isolation+and+Preliminary+Characterization&doi=10.7164%2Fantibiotics.30.275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A new alkaloid AM-2282 of Streptomyces origin.  Taxonomy, fermentation, isolation and preliminary characterization</span></div><div class="casAuthors">Omura, Satoshi; Iwai, Yuzuru; Hirano, Atsushi; Nakagawa, Akira; Awaya, Juichi; Tsuchiya, Hisae; Takahashi, Yoko; Masuma, Rokurou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-82</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">A novel alkaloid, AM-2282 [62996-74-1], with high hypotensive activity, was isolated from Streptomyces strain AM-2282, for which the name S. staurosporens is proposed.  The substance was active against fungi and yeast but had no activity against bacteria.  The mol. formula is C28H26N4O3, and the i.p. LD50 of its hydrochloride in mice was 6.6 mg/kg.  Taxonomic features of the strain AM-2282, together with the fermn. isolation, and physicochem. and biol. properties of the new alkaloid are presented.  UV, IR, and 1H-NMR spectra are also given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjO4pjDwMWLrVg90H21EOLACvtfcHk0lhC5DjivmBofQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXkt1Smsbs%253D&md5=4f52ee08da1cba35345c971c313c7fc6</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.30.275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.30.275%26sid%3Dliteratum%253Aachs%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DA.%26aulast%3DAwaya%26aufirst%3DJ.%26aulast%3DTsuchiya%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DAsuma%26aufirst%3DR.%26atitle%3DA%2520New%2520Alkaloid%2520Am-2282%2520of%2520Streptomyces%2520Origin.%2520Taxonomy%252C%2520Fermentation%252C%2520Isolation%2520and%2520Preliminary%2520Characterization%26jtitle%3DJ.%2520Antibiot.%26date%3D1977%26volume%3D30%26spage%3D275%26epage%3D282%26doi%3D10.7164%2Fantibiotics.30.275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, D. R.</span>; <span class="NLM_string-name">Lam, K. S.</span>; <span class="NLM_string-name">Mattei, J. M.</span>; <span class="NLM_string-name">Hesler, G. A.</span></span> <span> </span><span class="NLM_article-title">Manufacture of Staurosporine with <i>Streptomyces Hygroscopicus</i></span>. <span class="NLM_patent">US 4973552</span>, <span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=D.+R.+Schroeder&author=K.+S.+Lam&author=J.+M.+Mattei&author=G.+A.+Hesler&title=Manufacture+of+Staurosporine+with+Streptomyces+Hygroscopicus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DD.%2BR.%26atitle%3DManufacture%2520of%2520Staurosporine%2520with%2520Streptomyces%2520Hygroscopicus%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit121b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span>; <span class="NLM_string-name">Zhou, B.</span>; <span class="NLM_string-name">Ding, W.</span></span> <span> </span><span class="NLM_article-title">Staurosporine Compound, Its Preparation Method and Application</span>. <span class="NLM_patent">CN 107446011</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Ma&author=B.+Zhou&author=W.+Ding&title=Staurosporine+Compound%2C+Its+Preparation+Method+and+Application"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DStaurosporine%2520Compound%252C%2520Its%2520Preparation%2520Method%2520and%2520Application%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit121c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, C.</span>; <span class="NLM_string-name">Zheng, D.</span>; <span class="NLM_string-name">Shen, S.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Liu, T.</span></span> <span> </span><span class="NLM_article-title"><i>Streptomyces Scabiei</i> Subsp. Xuchangensis, a Novel Streptomycete Isolate for Staurosporine Production and a Wheat Take-All Control Agent</span>.  <i>Int. J. Microbiol. Res.</i> <span class="NLM_year">2012</span>,  <span class="NLM_volume">4</span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">289</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Wen&author=D.+Zheng&author=S.+Shen&author=J.+Chen&author=W.+Liu&author=T.+Liu&title=Streptomyces+Scabiei+Subsp.+Xuchangensis%2C+a+Novel+Streptomycete+Isolate+for+Staurosporine+Production+and+a+Wheat+Take-All+Control+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DC.%26atitle%3DStreptomyces%2520Scabiei%2520Subsp.%2520Xuchangensis%252C%2520a%2520Novel%2520Streptomycete%2520Isolate%2520for%2520Staurosporine%2520Production%2520and%2520a%2520Wheat%2520Take-All%2520Control%2520Agent%26jtitle%3DInt.%2520J.%2520Microbiol.%2520Res.%26date%3D2012%26volume%3D4%26spage%3D282%26epage%3D289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit121d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span>; <span class="NLM_string-name">Iwai, Y.</span>; <span class="NLM_string-name">Hirano, A.</span></span> <span> </span><span class="NLM_article-title">Antibiotic Am-2282</span>. <span class="NLM_patent">JP 53073501</span>, <span class="NLM_year">1978</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1978&author=S.+Omura&author=Y.+Iwai&author=A.+Hirano&title=Antibiotic+Am-2282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOmura%26aufirst%3DS.%26atitle%3DAntibiotic%2520Am-2282%26date%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, P.</span>; <span class="NLM_string-name">Koch, B.</span>; <span class="NLM_string-name">Mutz, M.</span></span> <span> </span><span class="NLM_article-title">Process for Purifying Staurosporine</span>. <span class="NLM_patent">EP 2272850 B1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=P.+Hoehn&author=B.+Koch&author=M.+Mutz&title=Process+for+Purifying+Staurosporine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoehn%26aufirst%3DP.%26atitle%3DProcess%2520for%2520Purifying%2520Staurosporine%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri-Kordestani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balcazar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett-Ringgold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmby, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluetz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaver, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage Her2-Positive Breast Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3486</span>– <span class="NLM_lpage">3491</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-3628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1158%2F1078-0432.CCR-17-3628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29523624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3486-3491&author=H.+Singhauthor=A.+J.+Walkerauthor=L.+Amiri-Kordestaniauthor=J.+Chengauthor=S.+Tangauthor=P.+Balcazarauthor=K.+Barnett-Ringgoldauthor=T.+R.+Palmbyauthor=X.+Caoauthor=N.+Zhengauthor=Q.+Liuauthor=J.+Yuauthor=W.+F.+Pierceauthor=S.+R.+Danielsauthor=R.+Sridharaauthor=A.+Ibrahimauthor=P.+G.+Kluetzauthor=G.+M.+Blumenthalauthor=J.+A.+Beaverauthor=R.+Pazdur&title=U.S.+Food+and+Drug+Administration+Approval%3A+Neratinib+for+the+Extended+Adjuvant+Treatment+of+Early-Stage+Her2-Positive+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-17-3628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer</span></div><div class="casAuthors">Singh, Harpreet; Walker, Amanda J.; Amiri-Kordestani, Laleh; Cheng, Joyce; Tang, Shenghui; Balcazar, Pamela; Barnett-Ringgold, Kimberly; Palmby, Todd R.; Cao, Xianhua; Zheng, Nan; Liu, Qi; Yu, Jingyu; Pierce, William F.; Daniels, Selena R.; Sridhara, Rajeshwari; Ibrahim, Amna; Kluetz, Paul G.; Blumenthal, Gideon M.; Beaver, Julia A.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3486-3491</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On July 17, 2017, the FDA approved neratinib (NERLYNX; Puma Biotechnol., Inc.) for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.  Approval was based on data from ExteNET, a randomized, double-blind, placebo-controlled multicenter trial.  Women with early-stage HER2-pos. breast cancer and within 2 years of completing adjuvant trastuzumab were randomized to neratinib (n = 1,420) or placebo (n = 1,420) for 1 yr.  The primary endpoint was invasive disease-free survival (iDFS), defined as the time between randomization date to first occurrence of invasive recurrence (local/regional, ipsilateral, or contralateral breast cancer), distant recurrence, or death from any cause, with 2 years and 28 days of follow-up.  The trial showed a statistically significant treatment effect favoring neratinib with a stratified HR of 0.66 [95% confidence interval (CI), 0.49-0.90, P = 0.008].  The estd. iDFS rate at 2 years was 94.2% (95% CI, 92.6%-95.4%) in patients treated with neratinib vs. 91.9% (95% CI, 90.2%-93.2%) in those receiving placebo.  Diarrhea was the most common adverse event (AE), with a 40% incidence of grade 3 or 4 diarrhea, and represents the most common AE leading to treatment discontinuation.  Other frequent AEs (>10% incidence) were nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, and muscle spasms.  Other than diarrhea, neratinib is assocd. with a low incidence of severe AEs; toxicities are generally reversible and manageable with dose interruptions, dose redns., and/or std. medical care.  This article summarizes FDA decision-making and data supporting the neratinib approval.  Clin Cancer Res; 24(15); 3486-91. ©2018 AACR.  See related commentary by Unni et al., p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAEGUdXAjtGrVg90H21EOLACvtfcHk0lh6khrbMTPDhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtr3P&md5=3abbfe781f1386d6d057125a08c5bdac</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-3628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-3628%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DA.%2BJ.%26aulast%3DAmiri-Kordestani%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DBalcazar%26aufirst%3DP.%26aulast%3DBarnett-Ringgold%26aufirst%3DK.%26aulast%3DPalmby%26aufirst%3DT.%2BR.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DPierce%26aufirst%3DW.%2BF.%26aulast%3DDaniels%26aufirst%3DS.%2BR.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DKluetz%26aufirst%3DP.%2BG.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DBeaver%26aufirst%3DJ.%2BA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520Approval%253A%2520Neratinib%2520for%2520the%2520Extended%2520Adjuvant%2520Treatment%2520of%2520Early-Stage%2520Her2-Positive%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D3486%26epage%3D3491%26doi%3D10.1158%2F1078-0432.CCR-17-3628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek-Klumpers, E.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalak, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span> <span> </span><span class="NLM_article-title">Optimization of 6,7-Disubstituted-4-(Arylamino)Quinoline-3-Carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.%0AG.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-Disubstituted-4-%28Arylamino%29Quinoline-3-Carbonitriles+as+Orally+Active%2C+Irreversible+Inhibitors+of+Human+Epidermal+Growth+Factor+Receptor-2+Kinase+Activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1107-1131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles, e.g. I (R1 = H, Cl; R2 = PhCH2O, 1-imidazolyl, 2-furylmethoxy, etc.; R3 = Cl, CN, PhCH2O; R4 = Me, Et; R5 = Me, R6 = Me, HOCH2CH2; R5R6N = azetidinyl, piperidinyl, thiomorpholinyl, etc.) that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepd.  These compds. demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 pos. cells compared to the EGFR kinase inhibitor I [R1 = H; R2 = F; R3 = Cl; R4 = Et; R5 = R6 = Me; (EKB-569)].  Three synthetic routes were used to prep. these compds.  They were prepd. mostly by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsatd. acid chlorides or by amination of 4-chloro-6-(crotonamido)quinoline-3-carbonitriles with monocyclic or bicyclic anilines.  The third route was developed to prep. a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step.  It was shown that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase.  The importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramol. catalysis of the Michael addn. has also been demonstrated.  This, along with improved water soly., resulted in compds. with enhanced biol. properties.  The mol. modeling results consistent with the proposed mechanism of inhibition are presented.  Binding studies of one compd., I [R1 = H; R2 = 2-pyridylmethoxy; R3 = Cl; R4 = Et; R5 = R6 = Me; (HKI-272)] (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells.  Furthermore, it demonstrated excellent oral activity, esp. in HER-2 overexpressing xenografts.  Compd. HKI-272 was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0QL4-qQZCbVg90H21EOLACvtfcHk0liLL8eQRgEtIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D&md5=55f77e41bf920f738ae2750e7ca0eb22</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-Disubstituted-4-%2528Arylamino%2529Quinoline-3-Carbonitriles%2520as%2520Orally%2520Active%252C%2520Irreversible%2520Inhibitors%2520of%2520Human%2520Epidermal%2520Growth%2520Factor%2520Receptor-2%2520Kinase%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, W.</span>; <span class="NLM_string-name">Cheal, G.
K.</span>; <span class="NLM_string-name">Lunetta, J. F.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Substituted 3-Cyanoquinolines and Intermediates Thereof</span>. <span class="NLM_patent">WO 2006127207A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Chew&author=G.%0AK.+Cheal&author=J.+F.+Lunetta&title=Process+for+the+Preparation+of+Substituted+3-Cyanoquinolines+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DW.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Substituted%25203-Cyanoquinolines%2520and%2520Intermediates%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit125b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, W.</span>; <span class="NLM_string-name">Papamichelakis, M.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Substituted 3-Cyanoquinolines and Intermediates Thereof</span>. <span class="NLM_patent">WO 2006127205A2</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Chew&author=M.+Papamichelakis&title=Process+for+the+Preparation+of+Substituted+3-Cyanoquinolines+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DW.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Substituted%25203-Cyanoquinolines%2520and%2520Intermediates%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gontcharov, A.</span>; <span class="NLM_string-name">Eng, K. K.</span>; <span class="NLM_string-name">Sutherland, K.</span>; <span class="NLM_string-name">Sebastian, A.</span>; <span class="NLM_string-name">Yu, Q.</span>; <span class="NLM_string-name">Place, D. W.</span></span> <span> </span><span class="NLM_article-title">Improved Process for Preparation of Coupled Products from 4-Amino-3-cyanoquinolines Using Stabilized Intermediates</span>. <span class="NLM_patent">WO 2010048477A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+Gontcharov&author=K.+K.+Eng&author=K.+Sutherland&author=A.+Sebastian&author=Q.+Yu&author=D.+W.+Place&title=Improved+Process+for+Preparation+of+Coupled+Products+from+4-Amino-3-cyanoquinolines+Using+Stabilized+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGontcharov%26aufirst%3DA.%26atitle%3DImproved%2520Process%2520for%2520Preparation%2520of%2520Coupled%2520Products%2520from%25204-Amino-3-cyanoquinolines%2520Using%2520Stabilized%2520Intermediates%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span> <i>TESARO Announces U.S.
FDA Approval of ZEJULA (Niraparib) for Women
with Recurrent Ovarian Cancer</i>; <span class="NLM_publisher-name">TESARO</span>, March 27, <span class="NLM_year">2017</span>; <a href="http://ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-us-fda-approval-zejulatm-niraparib-women" class="extLink">http://ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-us-fda-approval-zejulatm-niraparib-women</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+TESARO+Announces+U.S.%0AFDA+Approval+of+ZEJULA+%28Niraparib%29+for+Women%0Awith+Recurrent+Ovarian+Cancer%3B+TESARO%2C+March+27%2C+2017%3B+http%3A%2F%2Fir.tesarobio.com%2Fnews-releases%2Fnews-release-details%2Ftesaro-announces-us-fda-approval-zejulatm-niraparib-women+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DTESARO%2520Announces%2520U.S.%250AFDA%2520Approval%2520of%2520ZEJULA%2520%2528Niraparib%2529%2520for%2520Women%250Awith%2520Recurrent%2520Ovarian%2520Cancer%26pub%3DTESARO%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Niraparib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0752-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0752-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28474297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC1crkt12isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1029-1034&author=L.+J.+Scott&title=Niraparib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0752-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128aR"><div class="casContent"><span class="casTitleNuber">128a</span><div class="casTitle"><span class="NLM_cas:atitle">Niraparib: First Global Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1029-1034</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oral niraparib, a highly-selective, potent poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, is approved in the USA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.  It is also under regulatory review in the EU for use in maintenance treatment in patients with platinum-sensitive, recurrent epithelial ovarian cancer who are in response to platinum-based chemotherapy.  In the multinational, phase 3 NOVA trial in adult patients with platinum-sensitive, recurrent ovarian cancer, niraparib significantly prolonged median progression-free survival, irrespective of the presence or absence of a germline BRCA (gBRCA) mutation and irrespective of the presence or absence of homologous recombinant deficiency.  Niraparib is also in development for use in other solid tumours, including breast and prostate cancer.  This article summarizes the milestones in the development of niraparib leading to its first global approval for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgXAWLIQX9BrmQt-ICR3qNfW6udTcc2eakC6Nyu9pCprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crkt12isQ%253D%253D&md5=3dd6187fab47616c093858f3e0cd8fba</span></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0752-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0752-y%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DNiraparib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1029%26epage%3D1034%26doi%3D10.1007%2Fs40265-017-0752-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit128b"><span><span class="NLM_label">(b) </span> <i>Zejula</i>; <span class="NLM_publisher-name">TESARO</span>, March <span class="NLM_year">2017</span>; <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf</a> (accessed November 18, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Zejula%3B+TESARO%2C+March+2017%3B+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F208447lbl.pdf+%28accessed+November+18%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DZejula%26pub%3DTESARO%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boueres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrigno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giomini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamartina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ontoria, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsale, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roscilli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3s)-Piperidin-3-Yl]Phenyl}-2h-Indazole-7-Carboxamide (Mk-4827): A Novel Oral Poly(Adp-Ribose)Polymerase (Parp) Inhibitor Efficacious in Brca-1 and −2 Mutant Tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7170</span>– <span class="NLM_lpage">7185</span>, <span class="refDoi"> DOI: 10.1021/jm901188v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtleisLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283s%29-Piperidin-3-Yl%5DPhenyl%7D-2h-Indazole-7-Carboxamide+%28Mk-4827%29%3A+A+Novel+Oral+Poly%28Adp-Ribose%29Polymerase+%28Parp%29+Inhibitor+Efficacious+in+Brca-1+and+%E2%88%922+Mutant+Tumors&doi=10.1021%2Fjm901188v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129aR"><div class="casContent"><span class="casTitleNuber">129a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors</span></div><div class="casAuthors">Jones, Philip; Altamura, Sergio; Boueres, Julia; Ferrigno, Federica; Fonsi, Massimiliano; Giomini, Claudia; Lamartina, Stefania; Monteagudo, Edith; Ontoria, Jesus M.; Orsale, Maria Vittoria; Palumbi, Maria Cecilia; Pesci, Silvia; Roscilli, Giuseppe; Scarpelli, Rita; Schultz-Fademrecht, Carsten; Toniatti, Carlo; Rowley, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7170-7185</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We disclose the development of a novel series of 2-phenyl-2H-indazole-7-carboxamides as poly(ADP-ribose)polymerase (PARP) 1 and 2 inhibitors.  This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells.  Extrahepatic oxidn. by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported.  These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clin. trials.  This compd. displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, resp., and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range.  MK-4827 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplFTodq58wELVg90H21EOLACvtfcHk0lj1wcyS5kOADw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtleisLjM&md5=ff6662626b95805aeece659fec25133c</span></div><a href="/servlet/linkout?suffix=cit129a&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283s%2529-Piperidin-3-Yl%255DPhenyl%257D-2h-Indazole-7-Carboxamide%2520%2528Mk-4827%2529%253A%2520A%2520Novel%2520Oral%2520Poly%2528Adp-Ribose%2529Polymerase%2520%2528Parp%2529%2520Inhibitor%2520Efficacious%2520in%2520Brca-1%2520and%2520%25E2%2588%25922%2520Mutant%2520Tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185%26doi%3D10.1021%2Fjm901188v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit129b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulger, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosjek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limanto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachert, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, K. M.</span></span> <span> </span><span class="NLM_article-title">Process Development of C–N Cross-Coupling and Enantioselective Biocatalytic Reactions for the Asymmetric Synthesis of Niraparib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1021/op400233z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op400233z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=215-227&author=C.+K.+Chungauthor=P.+G.+Bulgerauthor=B.+Kosjekauthor=K.+M.+Belykauthor=N.+Riveraauthor=M.+E.+Scottauthor=G.+R.+Humphreyauthor=J.+Limantoauthor=D.+C.+Bachertauthor=K.+M.+Emerson&title=Process+Development+of+C%E2%80%93N+Cross-Coupling+and+Enantioselective+Biocatalytic+Reactions+for+the+Asymmetric+Synthesis+of+Niraparib&doi=10.1021%2Fop400233z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129bR"><div class="casContent"><span class="casTitleNuber">129b</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development of C-N Cross-Coupling and Enantioselective Biocatalytic Reactions for the Asymmetric Synthesis of Niraparib</span></div><div class="casAuthors">Chung, Cheol K.; Bulger, Paul G.; Kosjek, Birgit; Belyk, Kevin M.; Rivera, Nelo; Scott, Mark E.; Humphrey, Guy R.; Limanto, John; Bachert, Donald C.; Emerson, Khateeta M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">215-227</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Process development of the synthesis of the orally active poly-(ADP-ribose)-polymerase inhibitor niraparib is described.  Two new asym. routes are reported, which converge on a high-yielding, regioselective, copper-catalyzed N-arylation of an indazole deriv. as the late-stage fragment coupling step.  Novel transaminase-mediated dynamic kinetic resolns. of racemic aldehyde surrogates provided enantioselective syntheses of the 3-aryl-piperidine coupling partner.  Conversion of the C-N cross-coupling product to the final API was achieved by deprotection and salt metathesis to isolate the desired cryst. salt form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4mNYQN5TMorVg90H21EOLACvtfcHk0lj1wcyS5kOADw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7fK&md5=ef37476ca5ed5201ce7a0790f80f91c1</span></div><a href="/servlet/linkout?suffix=cit129b&amp;dbid=16384&amp;doi=10.1021%2Fop400233z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop400233z%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BK.%26aulast%3DBulger%26aufirst%3DP.%2BG.%26aulast%3DKosjek%26aufirst%3DB.%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26aulast%3DRivera%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BE.%26aulast%3DHumphrey%26aufirst%3DG.%2BR.%26aulast%3DLimanto%26aufirst%3DJ.%26aulast%3DBachert%26aufirst%3DD.%2BC.%26aulast%3DEmerson%26aufirst%3DK.%2BM.%26atitle%3DProcess%2520Development%2520of%2520C%25E2%2580%2593N%2520Cross-Coupling%2520and%2520Enantioselective%2520Biocatalytic%2520Reactions%2520for%2520the%2520Asymmetric%2520Synthesis%2520of%2520Niraparib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D215%26epage%3D227%26doi%3D10.1021%2Fop400233z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit129c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, K. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmond, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzzio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajonz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span> <span> </span><span class="NLM_article-title">Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral Parp Inhibitor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1021/op2000783</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op2000783" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1agsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=831-840&author=D.+J.+Wallaceauthor=C.+A.+Baxterauthor=K.+J.+M.+Brandsauthor=N.+Bremeyerauthor=S.+E.+Brewerauthor=R.+Desmondauthor=K.+M.+Emersonauthor=J.+Foleyauthor=P.+Fernandezauthor=W.+Huauthor=S.+P.+Keenauthor=P.+Mullensauthor=D.+Muzzioauthor=P.+Sajonzauthor=L.+Tanauthor=R.+D.+Wilsonauthor=G.+Zhouauthor=G.+Zhou&title=Development+of+a+Fit-for-Purpose+Large-Scale+Synthesis+of+an+Oral+Parp+Inhibitor&doi=10.1021%2Fop2000783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129cR"><div class="casContent"><span class="casTitleNuber">129c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor</span></div><div class="casAuthors">Wallace, Debra J.; Baxter, Carl A.; Brands, Karel J. M.; Bremeyer, Nadine; Brewer, Sarah E.; Desmond, Richard; Emerson, Khateeta M.; Foley, Jennifer; Fernandez, Paul; Hu, Weifeng; Keen, Stephen P.; Mullens, Peter; Muzzio, Daniel; Sajonz, Peter; Tan, Lushi; Wilson, Robert D.; Zhou, George; Zhou, Guoyue</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">831-840</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compd. (1) a poly(ADP-ribose)polymerase (PARP) inhibitor has been made by a fit-for-purpose large-scale synthesis using either a classical resoln. or chiral chromatog. sepn.  The development and relative merits of each route are discussed, along with operational improvements and extensive safety evaluations of potentially hazardous reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2XhpQcEkvHbVg90H21EOLACvtfcHk0liuHef709gmvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1agsbs%253D&md5=226714068d18e45bb8c17b4a80e18102</span></div><a href="/servlet/linkout?suffix=cit129c&amp;dbid=16384&amp;doi=10.1021%2Fop2000783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop2000783%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DD.%2BJ.%26aulast%3DBaxter%26aufirst%3DC.%2BA.%26aulast%3DBrands%26aufirst%3DK.%2BJ.%2BM.%26aulast%3DBremeyer%26aufirst%3DN.%26aulast%3DBrewer%26aufirst%3DS.%2BE.%26aulast%3DDesmond%26aufirst%3DR.%26aulast%3DEmerson%26aufirst%3DK.%2BM.%26aulast%3DFoley%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DKeen%26aufirst%3DS.%2BP.%26aulast%3DMullens%26aufirst%3DP.%26aulast%3DMuzzio%26aufirst%3DD.%26aulast%3DSajonz%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWilson%26aufirst%3DR.%2BD.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DG.%26atitle%3DDevelopment%2520of%2520a%2520Fit-for-Purpose%2520Large-Scale%2520Synthesis%2520of%2520an%2520Oral%2520Parp%2520Inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2011%26volume%3D15%26spage%3D831%26epage%3D840%26doi%3D10.1021%2Fop2000783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit129d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Patent Review of Manufacturing Routes to Recently Approved Parp Inhibitors: Olaparib, Rucaparib, and Niraparib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00235</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00235" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1227-1244&author=D.+L.+Hughes&title=Patent+Review+of+Manufacturing+Routes+to+Recently+Approved+Parp+Inhibitors%3A+Olaparib%2C+Rucaparib%2C+and+Niraparib&doi=10.1021%2Facs.oprd.7b00235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129dR"><div class="casContent"><span class="casTitleNuber">129d</span><div class="casTitle"><span class="NLM_cas:atitle">Patent Review of Manufacturing Routes to Recently Approved PARP Inhibitors: Olaparib, Rucaparib, and Niraparib</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1227-1244</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Olaparib, rucaparib, and niraparib are three inhibitors of poly(ADP-ribose) polymerase (PARP) enzymes that have been recently approved for the treatment of ovarian cancer.  The current article reviews the patent and journal literature regarding synthetic routes and final forms of these PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5nRoIvG3Q6bVg90H21EOLACvtfcHk0liuHef709gmvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLnM&md5=890d4ba7694cdf6295d70a9ba41f219c</span></div><a href="/servlet/linkout?suffix=cit129d&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00235%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DPatent%2520Review%2520of%2520Manufacturing%2520Routes%2520to%2520Recently%2520Approved%2520Parp%2520Inhibitors%253A%2520Olaparib%252C%2520Rucaparib%252C%2520and%2520Niraparib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1227%26epage%3D1244%26doi%3D10.1021%2Facs.oprd.7b00235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit129e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Ontoria Ontoria, J. M.</span>; <span class="NLM_string-name">Scarpelli, R.</span>; <span class="NLM_string-name">Schultz-Fademrecht, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Piperidinylphenylindazolylcarboxamide for Use as Poly(ADP-ribose)polymerase Inhibitors</span>. <span class="NLM_patent">WO 2008084261A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Jones&author=J.+M.+Ontoria+Ontoria&author=R.+Scarpelli&author=C.+Schultz-Fademrecht&title=Preparation+of+Piperidinylphenylindazolylcarboxamide+for+Use+as+Poly%28ADP-ribose%29polymerase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3DPreparation%2520of%2520Piperidinylphenylindazolylcarboxamide%2520for%2520Use%2520as%2520Poly%2528ADP-ribose%2529polymerase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit129f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J. R.</span>; <span class="NLM_string-name">Wilson, R. D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pharmaceutically Acceptable Salts of (3S)-3-[4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl]piperidines as Inhibitors of Poly(ADP-ribose)polymerase (Parp)</span>. <span class="NLM_patent">WO 2009087381A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+R.+Foley&author=R.+D.+Wilson&title=Preparation+of+Pharmaceutically+Acceptable+Salts+of+%283S%29-3-%5B4-%5B7-%28Aminocarbonyl%29-2H-indazol-2-yl%5Dphenyl%5Dpiperidines+as+Inhibitors+of+Poly%28ADP-ribose%29polymerase+%28Parp%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFoley%26aufirst%3DJ.%2BR.%26atitle%3DPreparation%2520of%2520Pharmaceutically%2520Acceptable%2520Salts%2520of%2520%25283S%2529-3-%255B4-%255B7-%2528Aminocarbonyl%2529-2H-indazol-2-yl%255Dphenyl%255Dpiperidines%2520as%2520Inhibitors%2520of%2520Poly%2528ADP-ribose%2529polymerase%2520%2528Parp%2529%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit129g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. K.</span>; <span class="NLM_string-name">Scott, M. E.</span>; <span class="NLM_string-name">Bulger, P. G.</span>; <span class="NLM_string-name">Belyk, K. M.</span>; <span class="NLM_string-name">Limanto, J.</span>; <span class="NLM_string-name">Humphrey, G. R.</span></span> <span> </span><span class="NLM_article-title">Regioselective N-2 Arylation of Indazoles</span>. <span class="NLM_patent">WO 2014088983A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+K.+Chung&author=M.+E.+Scott&author=P.+G.+Bulger&author=K.+M.+Belyk&author=J.+Limanto&author=G.+R.+Humphrey&title=Regioselective+N-2+Arylation+of+Indazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BK.%26atitle%3DRegioselective%2520N-2%2520Arylation%2520of%2520Indazoles%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit129h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulger, P. G.</span>; <span class="NLM_string-name">Kosjek, B.</span>; <span class="NLM_string-name">Rivera, N.</span></span> <span> </span><span class="NLM_article-title">Biocatalytic Transamination Process</span>. <span class="NLM_patent">US 20160040201A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+Bulger&author=B.+Kosjek&author=N.+Rivera&title=Biocatalytic+Transamination+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBulger%26aufirst%3DP.%2BG.%26atitle%3DBiocatalytic%2520Transamination%2520Process%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Ribociclib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0742-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0742-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28417244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt12qtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=799-807&author=Y.+Y.+Syed&title=Ribociclib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0742-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Ribociclib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">799-807</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ribociclib is an oral, small-mol. inhibitor of cyclin-dependent kinase (CDK) 4 and 6 that is under development by Novartis for the treatment of cancer.  CDKs play an important role in cell cycle progression and cellular proliferation, and inhibition of these kinases with ribociclib results in G1 phase cell-cycle arrest.  Ribociclib, in combination with an aromatase inhibitor, was recently approved in the USA for the first-line treatment of advanced breast cancer and has been submitted for approval in the EU for this indication.  Ribociclib is undergoing further phase III investigations in breast cancer and is being evaluated in phase I or II trials for various solid tumor types and haematol. malignancies.  This article summarizes the milestones in the development of ribociclib leading to this first global approval for use as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-pos., human epidermal growth factor receptor 2-neg. advanced or metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwLNy3sAC4B7Vg90H21EOLACvtfcHk0li_WXkd53e1MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt12qtL4%253D&md5=88e7fec84ca68c44a6b0895a95ca89ee</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0742-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0742-0%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DRibociclib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D799%26epage%3D807%26doi%3D10.1007%2Fs40265-017-0742-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Rebosini Intermediates and Methods for Their Preparation</span>. <span class="NLM_patent">CN 105037236B</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=X.+Xu&title=Rebosini+Intermediates+and+Methods+for+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26atitle%3DRebosini%2520Intermediates%2520and%2520Methods%2520for%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit131b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis Technology of Ribociclib</span>. <span class="NLM_patent">CN 106928236A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Chen&title=Synthesis+Technology+of+Ribociclib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSynthesis%2520Technology%2520of%2520Ribociclib%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit131c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Peddireddy, S. R.</span>; <span class="NLM_string-name">Kottur, M. K.</span>; <span class="NLM_string-name">Oruganti, S.</span>; <span class="NLM_string-name">Kandagatla, B.</span>; <span class="NLM_string-name">Das Gupta, S.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Ribociclib, Its Acid Addition Salts</span>. <span class="NLM_patent">WO 2018051280A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+R.+Peddireddy&author=M.+K.+Kottur&author=S.+Oruganti&author=B.+Kandagatla&author=S.+Das+Gupta&title=Process+for+Preparation+of+Ribociclib%2C+Its+Acid+Addition+Salts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPeddireddy%26aufirst%3DS.%2BR.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Ribociclib%252C%2520Its%2520Acid%2520Addition%2520Salts%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span> For an analogous
preparation of indoles, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Kempter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiewald, E.</span></span> <span> </span><span class="NLM_article-title">Heterocycles from Amino Ketones. VI. 1,2,3-Trisubstituted Indoles from N-Alkylated Aromatic Amino Ketones and α-Halo Diketones</span>. <i>J. Prakt. Chem. (Leipzig)</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1002/prac.19650280309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1002%2Fprac.19650280309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADyaF2MXkt1equrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1965&pages=169-77&author=G.+Kempterauthor=E.+Schiewald&title=Heterocycles+from+Amino+Ketones.+VI.+1%2C2%2C3-Trisubstituted+Indoles+from+N-Alkylated+Aromatic+Amino+Ketones+and+%CE%B1-Halo+Diketones&doi=10.1002%2Fprac.19650280309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocycles from amino ketones. VI. 1,2,3-Trisubstituted indoles from N-alkylated aromatic amino ketones and α-halo diketones</span></div><div class="casAuthors">Kempter, Gerhard; Schiewald, Ekkehard</div><div class="citationInfo"><span class="NLM_cas:title">Journal fuer Praktische Chemie (Leipzig)</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">169-77</span>CODEN:
                <span class="NLM_cas:coden">JPCEAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-8383</span>.
    </div><div class="casAbstract">cf. CA 63, 1777h.  A soln. of 0.5 mole o-H2NC6H4COR in 500 ml. pyridine was mixed with 0.6 mole p-MeC6H4SO2Cl and refluxed for 90 min. to give the following o-(p-MeC6H4SO2NH)C6H4COR (I): R = Me, 45.3% yield, m. 147-8°; R = Ph, 60.5% yield, m. 127°.  To 0.2 mole I in 750 ml. PhMe was added 0.24 mole Na in 500 ml. MeOH, refluxed for 90 min., MeOH distd., and the residue treated with 0.4 mole R'2SO4 to give o(p-MeC6H4SO2NR')C6H4COR (II) (R, R', % yield, and m.p. given): Me, Me, 57, 114-15°; Me, Et, 54.6, 135-6°; Ph, Me, 79.4, 129°; Ph, Et, 66.1, 98.5-99°.  II (30 g.) was detosylated by heating with 600 ml. 70% H2SO4 at 105° and finally at 145° to give o-R'NHC6H4COR (III) (R, R', % yield, and b.p. or m.p. given): Me, Me, 77, b12 120-2° (m. 34-5°); Me, Et, 62.5, b10 125°; Ph, Me, 70, 69°; Ph, Et, 86.2, b1 158-60° (m. 35-6°).  A soln. of 0.01 mole III in 10-12 ml. EtOH was mixed with 1.68 g. NaHCO3 and 2.27 g. BrCH2COBz (IV) and warmed to 75-80° for 75 min. to give V (R, R', % yield, and m.p. given): Me, Me, 39.2, 104-5°; Me, Et, 20, 80°; Ph, Me, 29.6, 136°; Ph, Et, 26.8, 94-5°.  Treatment of PhNHR' (VI) with IV similarly (method A) or 0.02 mole VI with 0.01 mole IV in 10 ml. EtOH (method B) gave PhNR'CH2COBz [R', % yield (by method), and m.p. given]: Me, 51.3 (A), 55.3 (B), 125-8°; Et, 54.5 (A), 60.0 (B), 111°.  Similarly, VI and (BrCH2CO)2 gave (PhNR'CH2CO)2: R' = Me, 30.1% yield, m. 139-41° (EtOH); R' = Et, 27.8% yield, m. 62-4° (pert. ether).  Condensation of 1.39 g. V (R = R' = Me) with 0.54 g. o-phenylenediamine in EtOH gave 40% 2-phenyl-3-(1,3-dimethyl-2-indolyl)quinoxaline, m. 175-7° (EtOH).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8v4dLTSuA67Vg90H21EOLACvtfcHk0ljmBgW8e2CYcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXkt1equrk%253D&md5=89fc4092bf4f87d334064406348199d0</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2Fprac.19650280309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprac.19650280309%26sid%3Dliteratum%253Aachs%26aulast%3DKempter%26aufirst%3DG.%26aulast%3DSchiewald%26aufirst%3DE.%26atitle%3DHeterocycles%2520from%2520Amino%2520Ketones.%2520VI.%25201%252C2%252C3-Trisubstituted%2520Indoles%2520from%2520N-Alkylated%2520Aromatic%2520Amino%2520Ketones%2520and%2520%25CE%25B1-Halo%2520Diketones%26jtitle%3DJ.%2520Prakt.%2520Chem.%2520%2528Leipzig%2529%26date%3D1965%26volume%3D28%26spage%3D169%26epage%3D77%26doi%3D10.1002%2Fprac.19650280309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Telotristat Ethyl: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0737-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-017-0737-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28382568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Kmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=793-798&author=A.+Markham&title=Telotristat+Ethyl%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0737-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Telotristat Ethyl: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">793-798</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Telotristat Et (Xermelo) is a peripheral tryptophan hydroxylase (TPH) inhibitor that was developed by Lexicon Pharmaceuticals, Inc. for the treatment of carcinoid syndrome.  Many neuroendocrine tumors secrete serotonin (5-HT) into the blood stream, resulting in a no. of symptoms, notably diarrhoea.  Telotristat Et inhibits TPH, thereby reducing the prodn. of 5-HT.  In Feb. 2017, telotristat Et was approved in the USA for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.  This article summarizes the milestones in the development of telotristat Et leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriKbtJWiHZi7Vg90H21EOLACvtfcHk0ljAm7xMb_Dthw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Kmtbs%253D&md5=b5846fcb80a1c72f74fdb898e69dafdd</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0737-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0737-x%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DTelotristat%2520Ethyl%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D793%26epage%3D798%26doi%3D10.1007%2Fs40265-017-0737-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulke, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoersch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, R. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombard-Bohas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grande, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapuerta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambrowicz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavel, M.</span></span> <span> </span><span class="NLM_article-title">Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.69.2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1200%2FJCO.2016.69.2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=27918724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=14-23&author=M.+H.+Kulkeauthor=D.+Hoerschauthor=M.+E.+Caplinauthor=L.+B.+Anthonyauthor=E.+Bergslandauthor=K.+%C3%96bergauthor=S.+Welinauthor=R.+R.+P.+Warnerauthor=C.+Lombard-Bohasauthor=P.+L.+Kunzauthor=E.+Grandeauthor=J.+W.+Valleauthor=D.+Flemingauthor=P.+Lapuertaauthor=P.+Banksauthor=S.+Jacksonauthor=B.+Zambrowiczauthor=A.+T.+Sandsauthor=M.+Pavel&title=Telotristat+Ethyl%2C+a+Tryptophan+Hydroxylase+Inhibitor+for+the+Treatment+of+Carcinoid+Syndrome&doi=10.1200%2FJCO.2016.69.2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome</span></div><div class="casAuthors">Kulke, Matthew H.; Hoersch, Dieter; Caplin, Martyn E.; Anthony, Lowell B.; Bergsland, Emily; Oeberg, Kjell; Welin, Staffan; Warner, Richard R. P.; Lombard-Bohas, Catherine; Kunz, Pamela L.; Grande, Enrique; Valle, Juan W.; Fleming, Douglas; Lapuerta, Pablo; Banks, Phillip; Jackson, Shanna; Zambrowicz, Brian; Sands, Arthur T.; Pavel, Marianne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-28</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Preliminary studies suggested that telotristat Et, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome.  This placebo-controlled phase III study evaluated telotristat Et in this setting.  Patients and Methods: Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1:1:1) placebo, telotristat Et 250 mg, or telotristat Et 500 mg three times per day orally during a 12-wk double-blind treatment period.  The primary end point was change from baseline in BM frequency.  In an open-label extension, 115 patients subsequently received telotristat Et 500 mg.  Results: Estd. differences in BM frequency per day vs. placebo averaged over 12 wk were -0.81 for telotristat Et 250 mg (P < .001) and -0.69 for telotristat Et 500 mg (P < .001).  At week 12, mean BM frequency redns. per day for placebo, telotristat Et 250 mg, and telotristat Et 500 mg were -0.9, -1.7, and -2.1, resp.  Responses, predefined as a BM frequency redn. ≥ 30% from baseline for ≥ 50% of the double-blind treatment period, were obsd. in 20%, 44%, and 42% of patients given placebo, telotristat Et 250 mg, and telotristat Et 500 mg, resp.  Both telotristat Et dosages significantly reduced mean urinary 5-hydroxyindole acetic acid vs. placebo at week 12 (P < .001).  Mild nausea and asymptomatic increases in gamma-glutamyl transferase were obsd. in some patients receiving telotristat Et.  Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment.  Conclusion Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat Et was generally safe and well tolerated and resulted in significant redns. in BM frequency and urinary 5-hydroxyindole acetic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0pgTfmSZv3bVg90H21EOLACvtfcHk0ljAm7xMb_Dthw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtLw%253D&md5=a6874fbdf793c9bfefc41fb73ce361ea</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.69.2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.69.2780%26sid%3Dliteratum%253Aachs%26aulast%3DKulke%26aufirst%3DM.%2BH.%26aulast%3DHoersch%26aufirst%3DD.%26aulast%3DCaplin%26aufirst%3DM.%2BE.%26aulast%3DAnthony%26aufirst%3DL.%2BB.%26aulast%3DBergsland%26aufirst%3DE.%26aulast%3D%25C3%2596berg%26aufirst%3DK.%26aulast%3DWelin%26aufirst%3DS.%26aulast%3DWarner%26aufirst%3DR.%2BR.%2BP.%26aulast%3DLombard-Bohas%26aufirst%3DC.%26aulast%3DKunz%26aufirst%3DP.%2BL.%26aulast%3DGrande%26aufirst%3DE.%26aulast%3DValle%26aufirst%3DJ.%2BW.%26aulast%3DFleming%26aufirst%3DD.%26aulast%3DLapuerta%26aufirst%3DP.%26aulast%3DBanks%26aufirst%3DP.%26aulast%3DJackson%26aufirst%3DS.%26aulast%3DZambrowicz%26aufirst%3DB.%26aulast%3DSands%26aufirst%3DA.%2BT.%26aulast%3DPavel%26aufirst%3DM.%26atitle%3DTelotristat%2520Ethyl%252C%2520a%2520Tryptophan%2520Hydroxylase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Carcinoid%2520Syndrome%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D14%26epage%3D23%26doi%3D10.1200%2FJCO.2016.69.2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span>; <span class="NLM_string-name">Burgoon, H. A.,  Jr.</span>; <span class="NLM_string-name">Iimura, S.</span>; <span class="NLM_string-name">Kanamarlapudi, R. C.</span>; <span class="NLM_string-name">Song, Q.</span>; <span class="NLM_string-name">Wu, W.</span>; <span class="NLM_string-name">Yan, J.</span>; <span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Methods of Preparing 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds</span>. <span class="NLM_patent">WO 2009029499A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+S.+Bednarz&author=H.+A.+Burgoon&author=S.+Iimura&author=R.+C.+Kanamarlapudi&author=Q.+Song&author=W.+Wu&author=J.+Yan&author=H.+Zhang&title=Methods+of+Preparing+4-Phenyl-6-%282%2C2%2C2-trifluoro-1-phenylethoxy%29pyrimidine-Based+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26atitle%3DMethods%2520of%2520Preparing%25204-Phenyl-6-%25282%252C2%252C2-trifluoro-1-phenylethoxy%2529pyrimidine-Based%2520Compounds%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span>; <span class="NLM_string-name">De Paul, S.</span>; <span class="NLM_string-name">Kanamarlapudi, R. C.</span>; <span class="NLM_string-name">Perlberg, A.</span>; <span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Solids Forms of (S)-Ethyl 2-Amino-3-(4-(2-amino-6-((<i>R</i>)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate</span>. <span class="NLM_patent">WO 2009042733A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+S.+Bednarz&author=S.+De+Paul&author=R.+C.+Kanamarlapudi&author=A.+Perlberg&author=H.+Zhang&title=Preparation+of+Solids+Forms+of+%28S%29-Ethyl+2-Amino-3-%284-%282-amino-6-%28%28R%29-1-%284-chloro-2-%283-methyl-1H-pyrazol-1-yl%29phenyl%29-2%2C2%2C2-trifluoroethoxy%29pyrimidin-4-yl%29phenyl%29propanoate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26atitle%3DPreparation%2520of%2520Solids%2520Forms%2520of%2520%2528S%2529-Ethyl%25202-Amino-3-%25284-%25282-amino-6-%2528%2528R%2529-1-%25284-chloro-2-%25283-methyl-1H-pyrazol-1-yl%2529phenyl%2529-2%252C2%252C2-trifluoroethoxy%2529pyrimidin-4-yl%2529phenyl%2529propanoate%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Devasagayaraj, A.</span>; <span class="NLM_string-name">Jin, H.</span>; <span class="NLM_string-name">Shi, Z.-C.</span>; <span class="NLM_string-name">Tunoori, A.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-[6-(2,2,2-Trifluoro-1-phenylethoxy)pyrimidin-4-yl]-(S)-phenylalanine Derivatives as Tryptophan Hydroxylase Inhibitors</span>. <span class="NLM_patent">WO 2008073933A2</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=A.+Devasagayaraj&author=H.+Jin&author=Z.-C.+Shi&author=A.+Tunoori&author=Y.+Wang&author=C.+Zhang&title=Preparation+of+4-%5B6-%282%2C2%2C2-Trifluoro-1-phenylethoxy%29pyrimidin-4-yl%5D-%28S%29-phenylalanine+Derivatives+as+Tryptophan+Hydroxylase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDevasagayaraj%26aufirst%3DA.%26atitle%3DPreparation%2520of%25204-%255B6-%25282%252C2%252C2-Trifluoro-1-phenylethoxy%2529pyrimidin-4-yl%255D-%2528S%2529-phenylalanine%2520Derivatives%2520as%2520Tryptophan%2520Hydroxylase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dewasajiayalayi, A.</span>; <span class="NLM_string-name">Jin, H.</span>; <span class="NLM_string-name">Shi, Z.</span>; <span class="NLM_string-name">Tunuli, A.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrimidine Derivatives as Tph1 Inhibitors</span>. <span class="NLM_patent">CN 101591332A</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Dewasajiayalayi&author=H.+Jin&author=Z.+Shi&author=A.+Tunuli&author=Y.+Wang&author=C.+Zhang&title=Preparation+of+Pyrimidine+Derivatives+as+Tph1+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDewasajiayalayi%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520Derivatives%2520as%2520Tph1%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Zambrowicz, B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Multicyclic Amino Acid Derivative Tryptophan Hydroxylase Inhibitors and Methods of Using Them for Affecting Gastrointestinal Transit and Gastric Emptying</span>. <span class="NLM_patent">WO 2009014972A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=Q.+Liu&author=B.+Zambrowicz&title=Preparation+of+Multicyclic+Amino+Acid+Derivative+Tryptophan+Hydroxylase+Inhibitors+and+Methods+of+Using+Them+for+Affecting+Gastrointestinal+Transit+and+Gastric+Emptying"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520Multicyclic%2520Amino%2520Acid%2520Derivative%2520Tryptophan%2520Hydroxylase%2520Inhibitors%2520and%2520Methods%2520of%2520Using%2520Them%2520for%2520Affecting%2520Gastrointestinal%2520Transit%2520and%2520Gastric%2520Emptying%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Oravecz, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2-Amino-3-Arylpropanoic Acid and 2-Amino-3-Heterocyclylpropanoic Acid Derivatives as Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer</span>. <span class="NLM_patent">WO 2011056916A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=T.+Oravecz&title=Preparation+of+2-Amino-3-Arylpropanoic+Acid+and+2-Amino-3-Heterocyclylpropanoic+Acid+Derivatives+as+Tryptophan+Hydroxylase+Inhibitors+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOravecz%26aufirst%3DT.%26atitle%3DPreparation%2520of%25202-Amino-3-Arylpropanoic%2520Acid%2520and%25202-Amino-3-Heterocyclylpropanoic%2520Acid%2520Derivatives%2520as%2520Tryptophan%2520Hydroxylase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sands, A. T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Multicyclic Amino Acid Derivations as Potent and Selective Thp1 Inhibitors for Treating Metastatic Bone Disease</span>. <span class="NLM_patent">WO 2011100285A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+T.+Sands&title=Preparation+of+Multicyclic+Amino+Acid+Derivations+as+Potent+and+Selective+Thp1+Inhibitors+for+Treating+Metastatic+Bone+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSands%26aufirst%3DA.%2BT.%26atitle%3DPreparation%2520of%2520Multicyclic%2520Amino%2520Acid%2520Derivations%2520as%2520Potent%2520and%2520Selective%2520Thp1%2520Inhibitors%2520for%2520Treating%2520Metastatic%2520Bone%2520Disease%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.-C.</span>; <span class="NLM_string-name">Zhao, M. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-[6-(2,2,2-Trifluoro-1-phenylethoxy)pyrimidin-4-yl]-(S)-phenylalanine Derivative Tryptophan Hydroxylase Inhibitors for Treating Osteoporosis</span>. <span class="NLM_patent">WO 2010065333A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Z.-C.+Shi&author=M.+M.+Zhao&title=Preparation+of+4-%5B6-%282%2C2%2C2-Trifluoro-1-phenylethoxy%29pyrimidin-4-yl%5D-%28S%29-phenylalanine+Derivative+Tryptophan+Hydroxylase+Inhibitors+for+Treating+Osteoporosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.-C.%26atitle%3DPreparation%2520of%25204-%255B6-%25282%252C2%252C2-Trifluoro-1-phenylethoxy%2529pyrimidin-4-yl%255D-%2528S%2529-phenylalanine%2520Derivative%2520Tryptophan%2520Hydroxylase%2520Inhibitors%2520for%2520Treating%2520Osteoporosis%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136a"><span><span class="NLM_label">(a) </span> <a href="http://www.aveooncology.com/wp-content/uploads/2017/08/AVEO-EC-Tivozanib-Approval.pdf" class="extLink">http://www.aveooncology.com/wp-content/uploads/2017/08/AVEO-EC-Tivozanib-Approval.pdf</a> (accessed November 19, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+http%3A%2F%2Fwww.aveooncology.com%2Fwp-content%2Fuploads%2F2017%2F08%2FAVEO-EC-Tivozanib-Approval.pdf+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit136b"><span><span class="NLM_label">(b) </span> <i>AVEO Oncology Announces FOTIVDA
(tivozanib) Approved in the European Union for the Treatment of Advanced
Renal Cell Carcinoma</i>; <span class="NLM_publisher-name">AVEO Oncology</span>, August 28, <span class="NLM_year">2017</span>; <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004131/WC500229916.pdf" class="extLink">http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004131/WC500229916.pdf</a> (accessed November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+AVEO+Oncology+Announces+FOTIVDA%0A%28tivozanib%29+Approved+in+the+European+Union+for+the+Treatment+of+Advanced%0ARenal+Cell+Carcinoma%3B+AVEO+Oncology%2C+August+28%2C+2017%3B+http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FSummary_of_opinion_-_Initial_authorisation%2Fhuman%2F004131%2FWC500229916.pdf+%28accessed+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DAVEO%2520Oncology%2520Announces%2520FOTIVDA%250A%2528tivozanib%2529%2520Approved%2520in%2520the%2520European%2520Union%2520for%2520the%2520Treatment%2520of%2520Advanced%250ARenal%2520Cell%2520Carcinoma%26pub%3DAVEO%2520Oncology%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jamil, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hathaway, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span> <span> </span><span class="NLM_article-title">Tivozanib: Status of Development</span>. <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1007/s11912-015-0451-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs11912-015-0451-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=25895472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A280%3ADC%252BC2MjmsFChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=24&author=M.+O.+Jamilauthor=A.+Hathawayauthor=A.+Mehta&title=Tivozanib%3A+Status+of+Development&doi=10.1007%2Fs11912-015-0451-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137aR"><div class="casContent"><span class="casTitleNuber">137a</span><div class="casTitle"><span class="NLM_cas:atitle">Tivozanib: status of development</span></div><div class="casAuthors">Jamil Muhammad Omer; Hathaway Amanda; Mehta Amitkumar</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tivozanib is a potent and highly specific orally available, tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGF) receptor-1, VEGF receptor-2, and VEGF receptor-3 at very low concentrations with a long half-life (4 days).  After its promising activity in xenograft and preclinical models, tivozanib was evaluated in early phase clinical trials in various solid tumors.  The phase III trial (TIVO-1) compared tivozanib with sorafenib in metastatic clear cell renal cell carcinoma (RCC).  Because of detrimental overall survival (OS), Oncology Drug Advisory Committee (ODAC) voted against its approval in RCC.  Tivozanib is also being evaluated in various other solid tumors like breast, gastrointestinal cancers, hepatocellular cancer, sarcomas, and gynecological cancer.  In BATON-CRC trial, low-serum neuropilin-1 (NRP-1) levels were associated with better progression-free survival (PFS) in patients treated with tivozanib.  The NRP-1 will be evaluated as a biomarker for tivozanib response in future clinical trials.  Ongoing clinical trial will further characterize activity of tivozanib in hepatocellular carcinoma, sarcomas, and gynecologic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0plewKHhQskPI-fCgwosgfW6udTcc2ea-AFkyEmj7sbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjmsFChsQ%253D%253D&md5=d3942d24a88da10edca55431823b651e</span></div><a href="/servlet/linkout?suffix=cit137a&amp;dbid=16384&amp;doi=10.1007%2Fs11912-015-0451-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-015-0451-3%26sid%3Dliteratum%253Aachs%26aulast%3DJamil%26aufirst%3DM.%2BO.%26aulast%3DHathaway%26aufirst%3DA.%26aulast%3DMehta%26aufirst%3DA.%26atitle%3DTivozanib%253A%2520Status%2520of%2520Development%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2015%26volume%3D17%26spage%3D24%26doi%3D10.1007%2Fs11912-015-0451-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit137b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Campas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, R.</span></span> <span> </span><span class="NLM_article-title">Tivozanib: Veger Tyrosine Kinase Inhibitor Angiogenesis Inhibitor Oncolytic</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1358/dof.2009.034.10.1417872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1358%2Fdof.2009.034.10.1417872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1WnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=793-796&author=C.+Campasauthor=J.+Bolosauthor=R.+Castaner&title=Tivozanib%3A+Veger+Tyrosine+Kinase+Inhibitor+Angiogenesis+Inhibitor+Oncolytic&doi=10.1358%2Fdof.2009.034.10.1417872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137bR"><div class="casContent"><span class="casTitleNuber">137b</span><div class="casTitle"><span class="NLM_cas:atitle">TIVOZANIB: VEGER tyrosine kinase inhibitor angiogenesis inhibitor oncolytic</span></div><div class="casAuthors">Campas, C.; Bolos, J.; Castaner, R.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">793-796</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Tivozanib is a novel oral quinoline urea deriv. with potent and selective activity against vascular endothelial growth factor (VEGFR) tyrosine kinase.  Preclin. data indicate that tivozanib blocks the proliferation and migration of endothelial cells in vitro, and suppresses angiogenesis and growth of human tumor xenografts in vivo.  Tivozanib has been shown to be safe and orally bioavailable when given to cancer patients.  Early clin. trials demonstrated inhibition of angiogenesis and tumor progression in several types of advanced solid tumors.  The compd. is under early clin. investigation for the treatment of renal cell carcinoma and non-small cell lung carcinoma, as well as in combination with other chemotherapies in breast, colorectal, and other gastrointestinal cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorlOz15aO1ZbVg90H21EOLACvtfcHk0lieHZhy_K_1mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1WnsLk%253D&md5=c6ca2b5f65472146d6d348ebbd4d62f2</span></div><a href="/servlet/linkout?suffix=cit137b&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.10.1417872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.10.1417872%26sid%3Dliteratum%253Aachs%26aulast%3DCampas%26aufirst%3DC.%26aulast%3DBolos%26aufirst%3DJ.%26aulast%3DCastaner%26aufirst%3DR.%26atitle%3DTivozanib%253A%2520Veger%2520Tyrosine%2520Kinase%2520Inhibitor%2520Angiogenesis%2520Inhibitor%2520Oncolytic%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D793%26epage%3D796%26doi%3D10.1358%2Fdof.2009.034.10.1417872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit137c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hepgur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorff, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, D. I.</span></span> <span> </span><span class="NLM_article-title">Tivozanib in the Treatment of Renal Cell Carcinoma</span>. <i>Biol.: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.2147/BTT.S32958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.2147%2FBTT.S32958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=23788831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVanurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=139-148&author=M.+Hepgurauthor=S.+Sadeghiauthor=T.+B.+Dorffauthor=D.+I.+Quinn&title=Tivozanib+in+the+Treatment+of+Renal+Cell+Carcinoma&doi=10.2147%2FBTT.S32958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137cR"><div class="casContent"><span class="casTitleNuber">137c</span><div class="casTitle"><span class="NLM_cas:atitle">Tivozanib in the treatment of renal cell carcinoma</span></div><div class="casAuthors">Hepgur, Mehmet; Sadeghi, Sarmad; Dorff, Tanya B.; Quinn, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Biologics: Targets & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139-148</span>CODEN:
                <span class="NLM_cas:coden">BTTICT</span>;
        ISSN:<span class="NLM_cas:issn">1177-5491</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urol. malignancies and has been assocd. with poor responses to conventional cytotoxic chemotherapy.  Interferon-α and interleukin-2 were previously utilized in a limited no. of patients with good performance status due to toxicity and safety issues.  Over the last decade, through advances in the understanding of the biol. and pathol. of RCC, the important role of vascular endothelial growth factor (VEGF) in RCC has been identified.  Data from randomized trials have led to the approval of first-generation tyrosine kinase inhibitors (TKIs) sorafenib, sunitinib and pazopanib; however, these agents inhibit a wide variety of kinase targets and are assocd. with a range of adverse effects.  More recently, a new generation TKI, axitinib, has been approved by the US Food and Drug Administration.  Tivozanib is a novel TKI, which is a potent inhibitor of VEGF-1, VEGF-2, VEGF-3, c-kit and PDGR kinases, with a more restricted target spectrum.  Phase II and III studies have demonstrated significant activity and a favorable safety profile as an initial targeted treatment for advanced RCC.  This review examines the emerging data with tivozanib for the treatment of advanced RCC.  Preclin. investigations as well as Phase I, II and III data are examd.; data on the comparative benefits of tivozanib are reviewed.  Finally, we discuss the future potential of tivozanib in combination, biomarkers assocd. with tivozanib response and acquisition of resistance and nonkidney cancer indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0TzOgbrWMGrVg90H21EOLACvtfcHk0lj6R3MnEHC7dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVanurbN&md5=7fa8d758928d7c3d6774f081565b7f7f</span></div><a href="/servlet/linkout?suffix=cit137c&amp;dbid=16384&amp;doi=10.2147%2FBTT.S32958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBTT.S32958%26sid%3Dliteratum%253Aachs%26aulast%3DHepgur%26aufirst%3DM.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DDorff%26aufirst%3DT.%2BB.%26aulast%3DQuinn%26aufirst%3DD.%2BI.%26atitle%3DTivozanib%2520in%2520the%2520Treatment%2520of%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DBiol.%253A%2520Targets%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D139%26epage%3D148%26doi%3D10.2147%2FBTT.S32958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesovoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipatov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyulko, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alyasova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alekseev, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczylik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivoshik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strahs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteves, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenblit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span> <span> </span><span class="NLM_article-title">Tivozanib Versus Sorafenib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma: Results from a Phase Iii Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">3791</span>– <span class="NLM_lpage">3799</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.47.4940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1200%2FJCO.2012.47.4940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=24019545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWgtrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3791-3799&author=R.+J.+Motzerauthor=D.+Nosovauthor=T.+Eisenauthor=I.+Bondarenkoauthor=V.+Lesovoyauthor=O.+Lipatovauthor=P.+Tomczakauthor=O.+Lyulkoauthor=A.+Alyasovaauthor=M.+Harzaauthor=M.+Koganauthor=B.+Y.+Alekseevauthor=C.+N.+Sternbergauthor=C.+Szczylikauthor=D.+Cellaauthor=C.+Ivanescuauthor=A.+Krivoshikauthor=A.+Strahsauthor=B.+Estevesauthor=A.+Berkenblitauthor=T.+E.+Hutson&title=Tivozanib+Versus+Sorafenib+as+Initial+Targeted+Therapy+for+Patients+with+Metastatic+Renal+Cell+Carcinoma%3A+Results+from+a+Phase+Iii+Trial&doi=10.1200%2FJCO.2012.47.4940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial</span></div><div class="casAuthors">Motzer, Robert J.; Nosov, Dmitry; Eisen, Timothy; Bondarenko, Igor; Lesovoy, Vladimir; Lipatov, Oleg; Tomczak, Piotr; Lyulko, Oleksiy; Alyasova, Anna; Harza, Mihai; Kogan, Mikhail; Alekseev, Boris Y.; Sternberg, Cora N.; Szczylik, Cezary; Cella, David; Ivanescu, Cristina; Krivoshik, Andrew; Strahs, Andrew; Esteves, Brooke; Berkenblit, Anna; Hutson, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3791-3799</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3.  This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC).  Patients and Methods: Patients with metastatic RCC, with a clear cell component, prior nephrectomy, measurable disease, and 0 or 1 prior therapies for metastatic RCC were randomly assigned to tivozanib or sorafenib.  Prior VEGF-targeted therapy and mammalian target of rapamycin inhibitor were not permitted.  The primary end point was progression-free survival (PFS) by independent review.  Results: A total of 517 patients were randomly assigned to tivozanib (n = 260) or sorafenib (n = 257).  PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 mo; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042).  One hundred fifty-six patients (61%) who progressed on sorafenib crossed over to receive tivozanib.  The final overall survival (OS) anal. showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 mo; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105).  Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).  AEs more common with sorafenio than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).  Conclusion: Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlnE_Hp1TY6bVg90H21EOLACvtfcHk0lj6R3MnEHC7dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWgtrvK&md5=38cca075b6a432b228b7aaad9df1f595</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.47.4940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.47.4940%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DNosov%26aufirst%3DD.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DLesovoy%26aufirst%3DV.%26aulast%3DLipatov%26aufirst%3DO.%26aulast%3DTomczak%26aufirst%3DP.%26aulast%3DLyulko%26aufirst%3DO.%26aulast%3DAlyasova%26aufirst%3DA.%26aulast%3DHarza%26aufirst%3DM.%26aulast%3DKogan%26aufirst%3DM.%26aulast%3DAlekseev%26aufirst%3DB.%2BY.%26aulast%3DSternberg%26aufirst%3DC.%2BN.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DCella%26aufirst%3DD.%26aulast%3DIvanescu%26aufirst%3DC.%26aulast%3DKrivoshik%26aufirst%3DA.%26aulast%3DStrahs%26aufirst%3DA.%26aulast%3DEsteves%26aufirst%3DB.%26aulast%3DBerkenblit%26aufirst%3DA.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26atitle%3DTivozanib%2520Versus%2520Sorafenib%2520as%2520Initial%2520Targeted%2520Therapy%2520for%2520Patients%2520with%2520Metastatic%2520Renal%2520Cell%2520Carcinoma%253A%2520Results%2520from%2520a%2520Phase%2520Iii%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3791%26epage%3D3799%26doi%3D10.1200%2FJCO.2012.47.4940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Tivozanib</span>. <i>Chinese J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">544</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2013&pages=541-544&author=J.+Wangauthor=Y.+Wangauthor=Y.+Qin&title=Synthesis+of+Tivozanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520Tivozanib%26jtitle%3DChinese%2520J.%2520Pharm.%26date%3D2013%26volume%3D44%26spage%3D541%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit139b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Wu, J.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Method for Synthesizing Antitumor Targeting Drug Tivozanib</span>. <span class="NLM_patent">CN 102532116</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Liu&author=L.+Hu&author=J.+Wu&author=Z.+Zhang&author=J.+Liu&title=Method+for+Synthesizing+Antitumor+Targeting+Drug+Tivozanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26atitle%3DMethod%2520for%2520Synthesizing%2520Antitumor%2520Targeting%2520Drug%2520Tivozanib%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit139c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.-W.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Tivozanib Hydrochloride Monohydrate</span>. <i>Chin. J. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">29</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=26-29&author=Y.+Fuauthor=Q.-W.+Zhang&title=Synthesis+of+Tivozanib+Hydrochloride+Monohydrate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.-W.%26atitle%3DSynthesis%2520of%2520Tivozanib%2520Hydrochloride%2520Monohydrate%26jtitle%3DChin.%2520J.%2520New%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D26%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit139d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span>; <span class="NLM_string-name">Fang, Y.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Method for Synthesizing Tivozanib as Antitumor Drug Targeting Therapy</span>. <span class="NLM_patent">CN 104072492</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+Cai&author=Y.+Fang&author=Z.+Chen&author=L.+Zhang&title=Method+for+Synthesizing+Tivozanib+as+Antitumor+Drug+Targeting+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DJ.%26atitle%3DMethod%2520for%2520Synthesizing%2520Tivozanib%2520as%2520Antitumor%2520Drug%2520Targeting%2520Therapy%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span>; <span class="NLM_string-name">Yoshida, S.</span>; <span class="NLM_string-name">Yoshino, A.</span>; <span class="NLM_string-name">Nakajima, T.</span></span> <span> </span><span class="NLM_article-title">N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N′-(5-methyl-3-isoxazolyl)urea Salt Crystals</span>. <span class="NLM_patent">WO 2004035572</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=N.+Matsunaga&author=S.+Yoshida&author=A.+Yoshino&author=T.+Nakajima&title=N-%5B2-Chloro-4-%5B%286%2C7-dimethoxy-4-quinolyl%29oxy%5Dphenyl%5D-N%E2%80%B2-%285-methyl-3-isoxazolyl%29urea+Salt+Crystals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DN.%26atitle%3DN-%255B2-Chloro-4-%255B%25286%252C7-dimethoxy-4-quinolyl%2529oxy%255Dphenyl%255D-N%25E2%2580%25B2-%25285-methyl-3-isoxazolyl%2529urea%2520Salt%2520Crystals%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit140b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span>; <span class="NLM_string-name">Yoshida, S.</span>; <span class="NLM_string-name">Yoshino, A.</span>; <span class="NLM_string-name">Nakajima, T.</span></span> <span> </span><span class="NLM_article-title">N-[2-Chloro-4-[6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N′-5-methyl-3-isoxazolyl)urea Salt in Crystalline Form</span>. <span class="NLM_patent">US 7166722 B2</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+Matsunaga&author=S.+Yoshida&author=A.+Yoshino&author=T.+Nakajima&title=N-%5B2-Chloro-4-%5B6%2C7-dimethoxy-4-quinolyl%29oxy%5Dphenyl%5D-N%E2%80%B2-5-methyl-3-isoxazolyl%29urea+Salt+in+Crystalline+Form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DN.%26atitle%3DN-%255B2-Chloro-4-%255B6%252C7-dimethoxy-4-quinolyl%2529oxy%255Dphenyl%255D-N%25E2%2580%25B2-5-methyl-3-isoxazolyl%2529urea%2520Salt%2520in%2520Crystalline%2520Form%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohyama, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murooka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoe, T.</span></span> <span> </span><span class="NLM_article-title">Novel Potent Orally Active Selective Vegfr-2 Tyrosine Kinase Inhibitors: Synthesis, Structure-Activity Relationships, and Antitumor Activities of N-Phenyl-N′-{4-(4-Quinolyloxy)Phenyl}Ureas</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1359</span>– <span class="NLM_lpage">1366</span>, <span class="refDoi"> DOI: 10.1021/jm030427r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030427r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ygtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1359-1366&author=K.+Kuboauthor=T.+Shimizuauthor=S.-I.+Ohyamaauthor=H.+Murookaauthor=A.+Iwaiauthor=K.+Nakamuraauthor=K.+Hasegawaauthor=Y.+Kobayashiauthor=N.+Takahashiauthor=K.+Takahashiauthor=S.+Katoauthor=T.+Izawaauthor=T.+Isoe&title=Novel+Potent+Orally+Active+Selective+Vegfr-2+Tyrosine+Kinase+Inhibitors%3A+Synthesis%2C+Structure-Activity+Relationships%2C+and+Antitumor+Activities+of+N-Phenyl-N%E2%80%B2-%7B4-%284-Quinolyloxy%29Phenyl%7DUreas&doi=10.1021%2Fjm030427r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Structure-Activity Relationships, and Antitumor Activities of N-Phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas</span></div><div class="casAuthors">Kubo, Kazuo; Shimizu, Toshiyuki; Ohyama, Shin-Ichi; Murooka, Hideko; Iwai, Akemi; Nakamura, Kazuhide; Hasegawa, Kazumasa; Kobayashi, Yoshiko; Takahashi, Noriko; Takahashi, Kazumi; Kato, Shinichiro; Izawa, Toshio; Isoe, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1359-1366</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas were found to be a novel class of potent inhibitors for the vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase through synthetic modifications of a lead compd. and structure-activity relationship studies.  A representative compd. N-(2,4-difluorophenyl)-N'-4-[[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyl]urea, termed Ki8751, inhibited VEGFR-2 phosphorylation at an IC50 value of 0.90 nM, and also inhibited the PDGFR family members such as PDGFRα and c-Kit at 67 nM and 40 nM, resp.  However, Ki8751 did not have any inhibitory activity against other kinases such as EGFR, HGFR, InsulinR and others even at 10000 nM.  Ki8751 suppressed the growth of the VEGF-stimulated human umbilical vein endothelial cell (HUVEC) on a nanomolar level.  Ki8751 showed significant antitumor activity against five human tumor xenografts such as GL07 (glioma), St-4 (stomach carcinoma), LC6 (lung carcinoma), DLD-1 (colon carcinoma) and A375 (melanoma) in nude mice and also showed complete tumor growth inhibition with the LC-6 xenograft in nude rats following oral administration once a day for 14 days at 5 mg/kg without any body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbbFPBOSTo07Vg90H21EOLACvtfcHk0lisJnu3SNEQtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ygtrw%253D&md5=bdd440cf8de6044243dc19b23438e50a</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm030427r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030427r%26sid%3Dliteratum%253Aachs%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DOhyama%26aufirst%3DS.-I.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DS.%26aulast%3DIzawa%26aufirst%3DT.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DNovel%2520Potent%2520Orally%2520Active%2520Selective%2520Vegfr-2%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Synthesis%252C%2520Structure-Activity%2520Relationships%252C%2520and%2520Antitumor%2520Activities%2520of%2520N-Phenyl-N%25E2%2580%25B2-%257B4-%25284-Quinolyloxy%2529Phenyl%257DUreas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1359%26epage%3D1366%26doi%3D10.1021%2Fjm030427r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Impagnatiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirante, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquesroix, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, M. V. W.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin Analogues and Nitric Oxide Contribution in the Treatment of Ocular Hypertension and Glaucoma</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1079</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1111/bph.14328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1111%2Fbph.14328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29669171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSksrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=1079-1089&author=F.+Impagnatielloauthor=E.+Bastiaauthor=N.+Almiranteauthor=S.+Brambillaauthor=B.+Duquesroixauthor=A.+C.+Kotheauthor=M.+V.+W.+Bergamini&title=Prostaglandin+Analogues+and+Nitric+Oxide+Contribution+in+the+Treatment+of+Ocular+Hypertension+and+Glaucoma&doi=10.1111%2Fbph.14328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142aR"><div class="casContent"><span class="casTitleNuber">142a</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma</span></div><div class="casAuthors">Impagnatiello, Francesco; Bastia, Elena; Almirante, Nicoletta; Brambilla, Stefania; Duquesroix, Brigitte; Kothe, Angela C.; Bergamini, Michael V. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1079-1089</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  In patients with ocular hypertension or glaucoma, all treatments aim to lower intraocular pressure (IOP) by modulating aq. humor (AH) prodn. and/or uveoscleral and trabecular meshwork/Schlemm's canal AH drainage.  PG analogs are considered to be the 'gold std.' treatment and are the most frequently used IOP-lowering agents.  Recent data support an important role for NO in regulating IOP.  Thus, novel PG analogs carrying a NO-donating moiety were recently advanced.  Latanoprostene bunod (LBN) and NCX 470, NO-donating derivs. of latanoprost and bimatoprost, resp., are examples of such compds.  LBN ophthalmic soln., 0.024% (Vyzulta), showed greater IOP-lowering efficacy compared with that of Xalatan (latanoprost ophthalmic soln., 0.005%) or 0.5% timolol maleate in clin. settings.  NCX 470 was found to be more effective than bimatoprost in animal models of ocular hypertension and glaucoma.  Selective EP2 receptor agonists (i.e. taprenepag iso-Pr, omidenepag iso-Pr and aganepag isopropyl) and non-selective prostanoid receptor agonists (i.e. ONO-9054, sepetaprost isopropyl) that concomitantly stimulate FP and EP3 receptors have also been shown to hold promise as effective IOP-lowering agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrykVVGgiMxYbVg90H21EOLACvtfcHk0lisJnu3SNEQtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSksrzE&md5=6c342f008858bc8206eea2c038b8f840</span></div><a href="/servlet/linkout?suffix=cit142a&amp;dbid=16384&amp;doi=10.1111%2Fbph.14328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14328%26sid%3Dliteratum%253Aachs%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DBastia%26aufirst%3DE.%26aulast%3DAlmirante%26aufirst%3DN.%26aulast%3DBrambilla%26aufirst%3DS.%26aulast%3DDuquesroix%26aufirst%3DB.%26aulast%3DKothe%26aufirst%3DA.%2BC.%26aulast%3DBergamini%26aufirst%3DM.%2BV.%2BW.%26atitle%3DProstaglandin%2520Analogues%2520and%2520Nitric%2520Oxide%2520Contribution%2520in%2520the%2520Treatment%2520of%2520Ocular%2520Hypertension%2520and%2520Glaucoma%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3D1079%26epage%3D1089%26doi%3D10.1111%2Fbph.14328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit142b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, R.</span></span> <span> </span><span class="NLM_article-title">Latanoprostene Bunod, a Dual-Acting Nitric Oxide Donating Prostaglandin Analog for Lowering of Intraocular Pressure</span>. <i>US Ophthalmic Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.17925/USOR.2016.09.02.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.17925%2FUSOR.2016.09.02.80" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80-87&author=R.+N.+Weinrebauthor=T.+Realiniauthor=R.+Varma&title=Latanoprostene+Bunod%2C+a+Dual-Acting+Nitric+Oxide+Donating+Prostaglandin+Analog+for+Lowering+of+Intraocular+Pressure&doi=10.17925%2FUSOR.2016.09.02.80"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142b&amp;dbid=16384&amp;doi=10.17925%2FUSOR.2016.09.02.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17925%252FUSOR.2016.09.02.80%26sid%3Dliteratum%253Aachs%26aulast%3DWeinreb%26aufirst%3DR.%2BN.%26aulast%3DRealini%26aufirst%3DT.%26aulast%3DVarma%26aufirst%3DR.%26atitle%3DLatanoprostene%2520Bunod%252C%2520a%2520Dual-Acting%2520Nitric%2520Oxide%2520Donating%2520Prostaglandin%2520Analog%2520for%2520Lowering%2520of%2520Intraocular%2520Pressure%26jtitle%3DUS%2520Ophthalmic%2520Rev.%26date%3D2016%26volume%3D9%26spage%3D80%26epage%3D87%26doi%3D10.17925%2FUSOR.2016.09.02.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0914-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0914-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29761382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=773-780&author=S.+M.+Hoy&title=Latanoprostene+Bunod+Ophthalmic+Solution+0.024%25%3A+A+Review+in+Open-Angle+Glaucoma+and+Ocular+Hypertension&doi=10.1007%2Fs40265-018-0914-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">773-780</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Latanoprostene bunod ophthalmic soln. 0.024% (hereafter referred to as latanoprostene bunod 0.024%) [Vyzulta] is a nitric oxide (NO)-donating prostaglandin F2α analog approved in the USA for the redn. of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.  It is thought to lower IOP by increasing aq. humor outflow through the uveoscleral pathway (mediated by latanoprost acid) and increasing the facility of aq. humor outflow through the trabecular meshwork pathway (mediated by NO).  Results from two multinational, phase III studies (APOLLO and LUNAR) and a pooled anal. of these studies demonstrated the noninferiority of latanoprostene bunod 0.024% to timolol ophthalmic soln. 0.5% (hereafter referred to as timolol 0.5%) in terms of IOP-lowering efficacy over 3 mo in patients with OAG or ocular hypertension, with the superiority of latanoprostene bunod 0.024% over timolol 0.5% subsequently demonstrated in APOLLO and the pooled anal.  Moreover, there was no apparent loss of IOP-lowering effect in subsequent safety extension periods of up to 9 mo.  The IOP-lowering efficacy seen in APOLLO and LUNAR was confirmed in a phase III study (JUPITER) in Japanese patients, with IOP redns. obsd. early (week 4) and maintained over the longer-term (12 mo).  Latanoprostene bunod 0.024% was well tolerated over up to 12 mo in these studies, with most ocular treatment-emergent adverse events (TEAEs) being mild to moderate in severity.  Thus, current evidence indicates once-daily latanoprostene bunod 0.024% is an effective and well tolerated treatment option for the redn. of IOP in adults with OAG or ocular hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr26pnF0TbnBLVg90H21EOLACvtfcHk0ljNyernFHG2QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVCksb0%253D&md5=6d3a7bcdc17c510fdbf4d638f026241b</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0914-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0914-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DLatanoprostene%2520Bunod%2520Ophthalmic%2520Solution%25200.024%2525%253A%2520A%2520Review%2520in%2520Open-Angle%2520Glaucoma%2520and%2520Ocular%2520Hypertension%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D773%26epage%3D780%26doi%3D10.1007%2Fs40265-018-0914-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span>; <span class="NLM_string-name">Benedini, F.</span>; <span class="NLM_string-name">Chiroli, V.</span>; <span class="NLM_string-name">Del Soldato, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Prostaglandin Nitrooxy Derivatives for the Treatment of Glaucoma</span>. <span class="NLM_patent">WO 2005068421</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=E.+Ongini&author=F.+Benedini&author=V.+Chiroli&author=P.+Del+Soldato&title=Preparation+of+Prostaglandin+Nitrooxy+Derivatives+for+the+Treatment+of+Glaucoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOngini%26aufirst%3DE.%26atitle%3DPreparation%2520of%2520Prostaglandin%2520Nitrooxy%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Glaucoma%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Vittitow, J. L.</span>; <span class="NLM_string-name">Cavet, M. E.</span></span> <span> </span><span class="NLM_article-title">Nitric Oxide Releasing Prostaglandin Derivatives for Treating Normal Tension Glaucoma</span>. <span class="NLM_patent">WO 2018087092</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+L.+Vittitow&author=M.+E.+Cavet&title=Nitric+Oxide+Releasing+Prostaglandin+Derivatives+for+Treating+Normal+Tension+Glaucoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVittitow%26aufirst%3DJ.%2BL.%26atitle%3DNitric%2520Oxide%2520Releasing%2520Prostaglandin%2520Derivatives%2520for%2520Treating%2520Normal%2520Tension%2520Glaucoma%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Netarsudil Ophthalmic Solution 0.02%: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0877-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1007%2Fs40265-018-0877-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=29453668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=389-396&author=S.+M.+Hoy&title=Netarsudil+Ophthalmic+Solution+0.02%25%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0877-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Netarsudil Ophthalmic Solution 0.02%: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-396</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Netarsudil ophthalmic soln. 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa] is a Rho-assocd. protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aq. humor outflow through the trabecular meshwork.  It has been developed by Aerie Pharmaceuticals and was recently approved in the USA for the redn. of elevated IOP in patients with open-angle glaucoma or ocular hypertension.  The recommended dosage is one drop in the affected eye(s) once daily in the evening.  Phase III development in the EU and phase II development in Japan are underway for this indication.  This article summarizes the milestones in the development of netarsudil 0.02% leading to this first approval for the redn. of elevated IOP in patients with open-angle glaucoma or ocular hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp80gV1sA_qmLVg90H21EOLACvtfcHk0lhUcLPE-PJbUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFOksbo%253D&md5=246f7b80c4a4d244e53c36ee42d3ae4b</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0877-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0877-7%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DNetarsudil%2520Ophthalmic%2520Solution%25200.02%2525%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D389%26epage%3D396%26doi%3D10.1007%2Fs40265-018-0877-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laethem, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deLong, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopczunski, C. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1089/jop.2017.0023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=10.1089%2Fjop.2017.0023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28609185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=40-51&author=C.-W.+Linauthor=B.+Shermanauthor=L.+A.+Mooreauthor=C.+L.+Laethemauthor=D.-W.+Luauthor=P.+P.+Pattabiramanauthor=P.+V.+Raoauthor=M.+A.+deLongauthor=C.+C.+Kopczunski&title=Discovery+and+Preclinical+Development+of+Netarsudil%2C+a+Novel+Ocular+Hypotensive+Agent+for+the+Treatment+of+Glaucoma&doi=10.1089%2Fjop.2017.0023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma</span></div><div class="casAuthors">Lin, Cheng-Wen; Sherman, Bryan; Moore, Lori A.; Laethem, Carmen L.; Lu, Da-Wen; Pattabiraman, Padmanabhan P.; Rao, Ponugoti Vasantha; de Long, Mitchell A.; Kopczynski, Casey C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Purpose: Rho-assocd. protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aq. outflow through the trabecular meshwork (TM).  The preclin. characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clin. development, is presented herein.  Methods: The kinase inhibitory activity of netarsudil was compared to its esterase metabolite, netarsudil-M1, and 3 other ROCK inhibitors using a com. available kinase assay kit.  Disruption of actin stress fibers was measured in primary porcine TM cells and disruption of focal adhesions in transformed human TM (HTM) cells.  Induction of fibrosis markers after exposure to transforming growth factor-β2 (TGF-β2) was conducted in primary HTM cells.  Ocular hypotensive activity and tolerability of topical formulations were evaluated in normotensive Dutch Belted rabbits and Formosan Rock monkeys.  In vitro corneal metab. assays were conducted using dog, pig, rabbit, monkey, and human corneas.  In vivo ocular pharmacokinetics was studied in Dutch Belted rabbits.  Results: Netarsudil inhibited kinases ROCK1 and ROCK2 with a Ki of 1 nM each, disrupted actin stress fibers and focal adhesions in TM cells with IC50s of 79 and 16 nM, resp., and blocked the profibrotic effects of TGF-β2 in HTM cells.  Netarsudil produced large redns. in IOP in rabbits and monkeys that were sustained for at least 24 h after once daily dosing, with transient, mild hyperemia obsd. as the only adverse effect.  Conclusion: Netarsudil is a novel ROCK/NET inhibitor with high potency in biochem. and cell-based assays, an ability to produce large and durable IOP redns. in animal models, and favorable pharmacokinetic and ocular tolerability profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzAaB4ou88g7Vg90H21EOLACvtfcHk0lhUcLPE-PJbUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCns7w%253D&md5=0aab049b2ff35df0ce0f03b33bb5f501</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1089%2Fjop.2017.0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjop.2017.0023%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DSherman%26aufirst%3DB.%26aulast%3DMoore%26aufirst%3DL.%2BA.%26aulast%3DLaethem%26aufirst%3DC.%2BL.%26aulast%3DLu%26aufirst%3DD.-W.%26aulast%3DPattabiraman%26aufirst%3DP.%2BP.%26aulast%3DRao%26aufirst%3DP.%2BV.%26aulast%3DdeLong%26aufirst%3DM.%2BA.%26aulast%3DKopczunski%26aufirst%3DC.%2BC.%26atitle%3DDiscovery%2520and%2520Preclinical%2520Development%2520of%2520Netarsudil%252C%2520a%2520Novel%2520Ocular%2520Hypotensive%2520Agent%2520for%2520the%2520Treatment%2520of%2520Glaucoma%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D34%26spage%3D40%26epage%3D51%26doi%3D10.1089%2Fjop.2017.0023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma</span>. <i>Yale J. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=28356898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFaqur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2017&pages=111-118&author=L.+Luauthor=J.+C.+Tsaiauthor=J.+Liu&title=Novel+Pharmacologic+Candidates+for+Treatment+of+Primary+Open-Angle+Glaucoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Novel pharmacologic candidates for treatment of primary open-angle glaucoma</span></div><div class="casAuthors">Lu, Louise J.; Tsai, James C.; Liu, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Yale Journal of Biology and Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">YJBMAU</span>;
        ISSN:<span class="NLM_cas:issn">0044-0086</span>.
    
            (<span class="NLM_cas:orgname">Yale Journal of Biology and Medicine</span>)
        </div><div class="casAbstract">Primary open-angle glaucoma (OAG†) affects approx. 45 million people worldwide and more than 2.5 million people aged 40 years or older in the United States.  Pharmacol. treatment for glaucoma is directed towards lowering intraocular pressure (IOP) to slow disease progression and delay visual field loss.  Current medical treatment options for the lowering of IOP include the following classes of topical medications: beta-adrenergic antagonists, alpha-adrenergic agonists, cholinergic agonists, carbonic anhydrase inhibitors, and prostaglandin analogs.  Issues with existing drugs include failure to achieve target IOP with monotherapy, drug-related side effects, and low patient compliance with multiple daily administration of eye drops.  In recent years, the scientific and medical community has seen encouraging development of novel classes of drugs for primary OAG, the majority of which lower IOP by targeting the trabecular meshwork outflow pathway to increase aq. humor outflow.  Among the most promising new pharmacol. candidates are rho kinase inhibitors including ripasudil (K-115), netarsudil (AR13324), and AMA0076; adenosine receptor agonists including trabodenoson (INO-8875); and modified prostaglandin analogs including latanoprostene bunod (LBN, BOL-303259-X) and ONO-9054.  This study aims to systematically review and summarize the most recent developments in clin. trials for new pharmacol. options for the treatment of primary open-angle glaucoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouf3T6s73X_7Vg90H21EOLACvtfcHk0lhMAovOeeZQig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFaqur%252FP&md5=d53061d1832d623505fbe2ea7aaf7283</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DL.%26aulast%3DTsai%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DNovel%2520Pharmacologic%2520Candidates%2520for%2520Treatment%2520of%2520Primary%2520Open-Angle%2520Glaucoma%26jtitle%3DYale%2520J.%2520Biol.%2520Med.%26date%3D2017%26volume%3D90%26spage%3D111%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sturdivant, J. M.</span>; <span class="NLM_string-name">Delong, M. A.</span>; <span class="NLM_string-name">Chambournier, G.</span>; <span class="NLM_string-name">Pamment, M. G.</span>; <span class="NLM_string-name">Fedij, V.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Kinase Inhibitors and Intermediates Thereof</span>. <span class="NLM_patent">WO 2017086941A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+M.+Sturdivant&author=M.+A.+Delong&author=G.+Chambournier&author=M.+G.+Pamment&author=V.+Fedij&title=Process+for+the+Preparation+of+Kinase+Inhibitors+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSturdivant%26aufirst%3DJ.%2BM.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Kinase%2520Inhibitors%2520and%2520Intermediates%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00196%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-16%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00196" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                11MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ae3190ae43c58","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
